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A range of C-N bond forming reactions using hydroxylamine-derived N-O donors have been 
developed. Initial studies focused on the development of a dearomatising amination reaction 
of phenols and naphthols. Whilst attempts at developing C-N bond forming dearomatisation 
reactions of N-acyloxysulfonamides and N-acyloxycarbamates were largely unsuccessful, 
further studies identified an effective transition metal-free protocol for dearomatising 
aminations of N-tosyloxycarbamates. Under acidic conditions, in situ Boc-deprotection of 
N-tosyloxycarbamate derivatives occurs to generate an electrophilic nitrogen source that can 
trigger dearomatisation via nucleophilic attack of a pendant arene. Through the dearomative 
cyclisation of phenol- and naphthol-substituted N-tosyloxycarbamates, spirocyclic pyrrolidines 
were obtained in good to excellent yield. Mechanistic experiments suggest the reaction 
proceeds via an SEAr-like mechanism. Annulative derivatisations of the dearomatised products 
provides access to complex natural product-like scaffolds. Preliminary studies demonstrated 
the feasibility of an asymmetric variant of the dearomatising amination reaction. 
Additionally, a metal-free aziridination of alkenes using the previously developed N-O donors 
was demonstrated. The stereospecific aziridination of di-, tri- and tetrasubstituted alkenes was 
achieved to form azabicyclo[3.1.0]hexane and azabicyclo[4.1.0]heptane motifs. Computational 
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Chapter 1 - Introduction 
1.1 The importance of nitrogen-containing compounds 
Nitrogen is prevalent in many biologically active compounds and pharmaceuticals. Of the top 
100 best-selling small molecule drugs in 2018 90% contain at least one nitrogen atom.1 Many 
of these compounds contain aryl-substituted amines such as anilines, but chiral N-heterocycles 
including pyrrolidines and piperidines are also well represented. The frequency of nitrogen in 
natural products and pharmaceutical agents makes efficient and versatile carbon-nitrogen bond 
forming reactions highly valuable.  
 
Figure 1 Examples of pharmaceuticals1 and natural products2-5 containing nitrogen. 
Classically, C-N bonds are formed by either SN2 attack of a nucleophilic amine derivative on 
an electrophilic carbon or by reductive amination;6 however, these approaches are limited in 
their effectiveness due to possible problems of regioselectivity and the  potential for over 
alkylation of nitrogen. More recently, metal-promoted C-N cross-coupling reactions have 
emerged as powerful approaches for the formation of C(sp2)-N bonds. The palladium-catalysed 
cross-coupling of nucleophilic amines with aryl halides (Buchwald-Hartwig amination)7-9 and 
the copper-mediated oxidative coupling of amines with arylboronic acids (Chan-Lam-type 
coupling)10-12 are two of the most effective and reliable methods for the synthesis of 
aryl-nitrogen bonds. 




An alternative, umpolung strategy for C-N bond formation is electrophilic amination13-17 which 
employs an electrophilic nitrogen source (R2N
+) and a nucleophile such as an organometallic 
reagent. Although in the past this approach has received little attention, over the last 10 years 
or so it has become an effective means for the construction of C(sp2)-N and C(sp3)-N bonds. A 
range of aminating reagents for electrophilic amination have been developed, many of which 
contain a nitrogen bonded to a more electron-withdrawing atom such as oxygen or a halide. 
Commonly used electrophilic nitrogen reagents include O-substituted hydroxylamines, 
N-haloamines, oxaziridines and oxime esters (Figure 2). A brief overview of some of the key 
advances in the field of electrophilic amination is given below. In particular, examples of C-N 
bond forming reactions that utilise O-substituted hydroxylamines and oxime esters as 
electrophilic nitrogen sources will be highlighted.  
 
Figure 2 Common electrophilic aminating reagents. 
1.2 Electrophilic amination reactions of O-substituted hydroxylamines 
Due to their versatility O-substituted hydroxylamine derivatives such as 
2,4-dinitrophenylhydroxylamine (DPH) and hydroxylamine-O-sulfonic acid (HOSA) have 
emerged as effective reagents for the preparation of C-N bonds by electrophilic amination. 
Generally, these and other related reagents can be accessed using straightforward synthetic 
methods from cheap and available precursors. For this reason, O-substituted hydroxylamines 
have received attention in transition metal-catalysed electrophilic aminations as well as a 
number of metal-free electrophilic amination protocols.I  
1.2.1 Amination of organoboron reagents 
Many different organometallic species have been reported as nucleophiles in electrophilic 
amination reactions but, organoboron reagents are amongst the most common. The amination 
of organoboron reagents using hydroxylamine-O-sulfonic acid was first reported by Brown and 
co-workers for the synthesis of primary amines.18,19 Using enantioenriched borinate esters 1 a 
range of chiral primary amines 2 were generated in good yields (Scheme 1).20 
 
I An overview of relevant electrophilic amination approaches to dearomative C-N bond formations and for alkene 
aziridinations is given in Chapter 2 and Chapter 3 respectively. 





Scheme 1 Synthesis of chiral amines from enantioenriched borinate esters.20 
More recently a number of transition metal-catalysed electrophilic amination reactions of 
organoboron derivatives have been developed; typically, these approaches involve the use of 
copper catalysts. In 2012, Miura and Hirano reported a mild procedure for the 
copper(I)-catalysed coupling of arylboronic esters 3 with O-benzoylhydroxylamines for the 
synthesis of arylamines 4 (Scheme 2).21  
 
Scheme 2 Copper-catalysed amination of organoboronic esters with O-benzoylhydroxylamines.21  




The reaction was proposed to proceed by the mechanism illustrated in Scheme 2. Following 
reduction of Cu(II) and ligand exchange with LiOt-Bu, the reactive CuOt-Bu species is 
generated. Transmetalation with boronate 3 forms monoarylcopper species 5 which then reacts 
with a second equivalent of boronate 3 to generate the more reactive diarylcuprate 6. Reaction 
with O-benzoylhydroxylamine forms the arylamine product 4 and regenerates the 
monoarylcopper species 5 to complete the catalytic cycle. Using this approach, a variety of 
secondary amines underwent arylation in good to excellent yields. The reaction tolerates a 
variety of functional groups including halides, aldehydes, ketones and esters. A modified 
version of this transformation was later reported by Lalic and co-workers.22 This approach 
utilised a combination of a wider bite-angle ligand, Xantphos and a non-coordinating solvent, 
iso-octane to achieve a more efficient amination of arylboronic esters (Scheme 3). Of particular 
note was the compatibility of bulky hydroxylamines 7 which enabled the synthesis of highly 
congested tertiary anilines 8.  
 
Scheme 3 Copper-catalysed amination of organoboronic esters with O-benzoylhydroxylamines.22 
In 2012 Kürti and Falck reported a transition metal-free electrophilic amination of arylboronic 
acids for the synthesis of primary aromatic amines (Scheme 4).23 The authors demonstrated 
that heating arylboronic acids 9 with O-2,4-dinitrophenylhydroxylamine (DPH) as a 
stoichiometric aminating agent afforded the desired primary anilines 10 in good to excellent 
yields.II The reaction is proposed to proceed via formation of intermediate 11 which 
subsequently undergoes facile 1,2-aryl migration to generate intermediate 12 aided by the 
strongly electron-withdrawing nature of the dinitrophenyl group. The desired aniline is 
obtained following subsequent hydrolysis of 12. The reaction tolerates a variety of functional 
groups and in particular provides a means of accessing halogenated primary anilines that are 
otherwise difficult to prepare by transition metal-catalysed amination. Electron-rich 
arylboronic acids were effective substrates for this transformation whilst electron-deficient 
arylboronic acids were generally less reactive requiring longer reaction times. More recently, 
 
II Two examples of transition metal-free electrophilic amination of arylboronic acids24 and arylboroxines had 
previously been reported;25 however, these required harsh reaction conditions (>130 oC). 




it has been shown that related hydroxylamine reagents such as hydroxylamine-O-sulfonic 
acid26 can also facilitate this transformation. 
 
Scheme 4 Transition metal-free amination of arylboronic acids using 
O-2,4-dinitrophenylhydroxylamine.23 
A related transition metal-free approach for the amination of boronic acids with 
N-alkylhydroxylamines was recently reported by Niu and co-workers (Scheme 5).27 Using 
N-alkylhydroxylamines 13 in the presence of trichloroacetonitrile the conversion of aryl- and 
alkylboronic acids to the corresponding secondary amines 14 was achieved. The authors 
proposed that the reaction proceeds via activated intermediate 15, which acts as the aminating 
agent in this transformation.III 
 
Scheme 5 Amination of aryl- and alkylboronic acids using N-benzylhydroxylamine 13.27 
 
III When 15 was reacted with phenylboronic acid the corresponding aniline was obtained in high yield. 




1.2.2 Amination of organozinc and Grignard reagents 
In addition to electrophilic amination reactions of organoboronic acids, electrophilic 
aminations of other organometallic reagents have also been reported. In 2004 Johnson and 
co-workers pioneered an approach for electrophilic amination of organozinc reagents 16 using 
O-acylhydroxylamines and Cu(OTf)2 (Scheme 6).
28-30 The reaction is compatible with a variety 
of functional groups and both primary and secondary amines are tolerated.IV This methodology 
was later expanded to include electrophilic aminations of Grignard reagents.32  
 
Scheme 6 Copper-catalysed amination of organozinc and Grignard reagents with 
O-acylhydroxylamines.29,30,32  
1.2.3 Aryl C-H amination of O-substituted hydroxylamines 
The application of hydroxylamine-derived electrophilic nitrogen sources has also been 
extended to the direct amination of aryl C-H bonds. Although regioselectivity can be a problem 
these reactions have the advantage of negating the requirement for stoichiometric 
organometallic reagents. In 2016 Falck and co-workers reported an efficient protocol for direct 
aryl C-H amination of arenes 17 using N-methyl-O-tosylhydroxylamine (TsONHMe) and 
Rh2(esp)2 (Scheme 7a).
33 The reaction is compatible with a wide variety of functional groups 
including halide, hydroxyl, ether, silyl and carbonyl groups and also tolerates potentially 
sensitive groups, such as benzylic, tertiary and α-keto hydrogens. Epoxides and acetals, 
however, are not tolerated and were cleaved under the reaction conditions. Many electron-rich 
arenes underwent efficient amination, but arenes with only electron withdrawing groups such 
as CF3 and CN groups were unreactive. A key facet of the reaction is the release of a 
 
IV The same group later reported that Ni(PPh3)2Cl2 was also an effective catalyst for this transformation.31 




stoichiometric amount of tosic acid which protonates the arylamine product 18 and prevents 
inhibition of the rhodium catalyst. For the mechanism of this transformation the authors 
propose that initial reaction of the dirhodium catalyst with TsONHMe generates electrophilic 
intermediate 19 (Scheme 7b). This intermediate exists in an equilibrium with 
rhodium-nitrenoid species 20; however, the weakly basic nature of the tosylate anion results in 
the equilibrium lying in favour of 19. Intermediate 19 undergoes intermolecular aryl C-H 
amination with arenes to generate the corresponding arylamine 18. An alternative mechanism 
involving a C-H activation pathway was disfavoured based on deuterium labelling studies. 
 
Scheme 7 (a) Rhodium-catalysed aryl C-H amination. (b) Proposed mechanism for 
rhodium-catalysed aryl C-H amination.33  




As part of the same study the authors reported an intramolecular version of this 
transformation.33 For this approach the aminating functionality was introduced in an efficient 
manner by Mitsunobu alkylation of BocNHOTs with the corresponding alcohol. Through the 
addition of TFA (200 mol%) to the reaction conditions, in situ cleavage of the N-Boc group of 
21 reveals the activated aminating agent for aryl C-H amination. This protocol enabled the 
formation of a range of fused aza-bicycles 22 in good to excellent yields (Scheme 8). The same 
group later reported a copper(II)-catalysed aryl C-H amination using HOSA as the electrophilic 
nitrogen source.34  
 
Scheme 8 Rhodium-catalysed intramolecular aryl C-H amination.33 
More recently Jiao and co-workers reported a related iron-catalysed approach to unprotected 
aryl amines by direct aryl amination.35 Using O-(p-nitrobenzoyl)hydroxylammonium salt 23 
and FeBr2 a variety of arenes were converted to the corresponding anilines 24 in good to 
excellent yield (Scheme 9a). The reaction tolerates a wide variety of functional groups and was 
effective for the late state amination of several bioactive compounds. The reaction is proposed 
to proceed by the mechanism shown in Scheme 9b. An outer-sphere single-electron transfer 
from FeBr2 to 23 initiates N-O bond cleavage forming N-centred radical intermediate 25. C-N 
bond formation occurs between 25 and the arene generating radical intermediate 26. This 
intermediate is then oxidised by iron(III) in a single-electron transfer process to form cationic 
intermediate 27 which is subsequently deprotonated to the desired aryl amine product.  





Scheme 9 (a) Iron(II)-catalysed electrophilic aryl amination. (b) Proposed mechanism of 
iron(II)-catalysed aryl amination.35 
A related protocol for direct aryl C-H amination was reported by Morandi and co-workers using 
methanesulfonylhydroxylammonium salt 28 and FeSO4 (Scheme 10).
36 This approach enabled 
the synthesis of primary anilines from a variety of arenes. Heteroarenes such as 
dihydrobenzofuran and indole also underwent efficient amination. A variety of functional 
groups on the arene were tolerated including hydroxy, halo and amino groups.V 
 
Scheme 10 Iron(II)-catalysed aryl amination with 28.36 
 
V Recently Ritter and co-workers reported an improved procedure for direct aryl C-H amination using 28 that 
enabled the amination of electron-poor arenes; previously this was a limitation of this approach.37 




A further example of direct aryl C-H amination using electrophilic nitrogen reagents was 
recently reported by Wang and co-workers. The authors demonstrated a direct and selective 
amidation of indoles 29 to 3-aminoindoles 31 using N-[(benzenesulfonyl)oxy]amides 30 in 
combination with ZnCl2 (Scheme 11a).
38 The reaction was compatible with a variety of 
electron-rich indoles but was less efficient with electron-poor indoles. In addition to indoles 
this approach was also effective for the amidation of pyrroles. The use of ZnCl2 was shown to 
be crucial for selective reaction at the C3-position. In the absence of ZnCl2, the aminal product 
32 was formed as the major product through alkylation of the indole nitrogen (Scheme 11b). 
 
Scheme 11 (a) Selective 3-amidation of indoles 29 using N-[(benzenesulfonyl)oxy]amides 30. 
(b) Formation of aminal 32 in the absence of ZnCl2.
38 
1.3 Electrophilic amination reactions of oxime esters  
1.3.1 The Narasaka-Heck reaction 
In 1999 Narasaka and co-workers pioneered the use of O-pentafluorobenzoyl oxime esters as 
electrophilic nitrogen sources in palladium(0)-catalysed cyclisations to generate substituted 
pyrroles.39,40 Exposure of γ,δ-unsaturated pentafluorobenzoyl oxime ester 33 to 10 mol% 
Pd(PPh3)4 afforded pyrrole 34 in 81% yield (Scheme 12). The reaction was proposed to proceed 
via oxidative addition of palladium(0) into the N-O bond of the oxime ester generating 
imino-palladium(II) intermediate 35. From this intermediate, migratory insertion of the alkene 
into the Pd-N bond occurs and following β-hydride elimination and alkene isomerisation the 
desired pyrrole product is obtained. With many of the key steps being analogous to the 




conventional Mizoroki-Heck reaction,41 the transformation has become known as the 
‘Narasaka-Heck reaction’. Evidence for the mechanism was provided by the groups of 
Hartwig42 and Stahl,43 who have characterised imino-palladium(II) intermediates related to 35 
using crystallography.  
 
Scheme 12 Palladium(0)-catalysed cyclisation of oxime esters (Narasaka-Heck reaction).39  
1.3.2 Synthesis of chiral heterocycles via aza-Heck reactions 
Whilst the Narasaka-Heck reaction is an effective means of generating new C(sp2)-N bonds, 
the importance of C(sp3)-N bonds in natural products and pharmaceuticals has inspired 
previous work in the Bower group aimed at developing aza-Heck reactions to form C(sp3)-N 
bonds, allowing access to chiral products.44 Prior to this there were only a few examples of 
aza-Heck reactions in which a C(sp3)-N bond is retained in the product. One of these examples 
came from the work of Narasaka who observed that cyclisation of oxime ester 36 afforded a 
mixture of pyrrole 38 and dihydropyrrole 39 (Scheme 13). This mixture of products arises 
because alkyl-palladium(II) intermediate 37 can undergo β-hydride elimination in two different 
directions. Elimination of Ha generates pyrrole 38 (after isomerisation), whilst elimination of 
Hb affords dihydropyrrole 39. 
 





Scheme 13 Competitive formation of dihydropyrrole 39 in the Narasaka-Heck cyclisation of 36.39 
Chiral N-heterocycles have also been generated through cascade Narasaka-Heck reactions of 
oxime esters (Scheme 14).45, 46 In these transformations, oxime ester 40 undergoes oxidative 
addition with Pd(0) to form imino-palladium(II) intermediate 41, which subsequently 
undergoes cyclisation to alkyl-palladium(II) intermediate 42. The lack of any β-hydrogens 
prevents β-hydride elimination from this intermediate which instead undergoes 1,2-insertion 
with the second alkene to generate alkyl-palladium(II) intermediate 43. At this point β-hydride 
occurs to generate spirocyclic imine 44.VI  
 
Scheme 14 Synthesis of spirocyclic imines through a cascade Narasaka-Heck reaction.45 
 
VI The use of molecular sieves was required to obtain high yields.  




1.3.3 Work at Bristol: aza-Heck reactions to access chiral heterocycles 
Due to the lack of a general method for the synthesis of chiral N-heterocycles by aza-Heck 
reactions, work has been carried out at Bristol aimed at developing aza-Heck reactions to form 
C(sp3)-N bonds. A number of novel classes of aza-Heck reactions which access dihydropyrrole 
products have been developed. The first of these strategies involved the cyclisation of oxime 
esters onto cyclic alkenes (Scheme 15).47 A variety of oxime esters 45 with aryl, alkyl or 
heteroaryl substituents underwent aza-Heck cyclisation to the corresponding cis-fused bicycles 
46 in good to excellent yields. In addition, cyclic alkenes with a range of ring sizes from 5 to 7 
were effective. Important to the success of this transformation is the use of electron-deficient 
phosphine ligands, with P(3,5-(CF3)2C6H3)3 being particularly effective. This is consistent with 
a study by Hartwig which has shown that alkene migratory insertion into a Pd-N bond is 
facilitated by bulky and/or electron-deficient ligands.48 The selectivity for the formation of 
dihydropyrrole product 46 is rationalised due to Hb in 47 not being available for syn-β-hydride 
elimination.  
 
Scheme 15 Aza-Heck cyclisation of oxime esters with cyclic alkenes.47 
The scope of aza-Heck reactions which access chiral products was further expanded to the use 
of 1,1-49 and 1,2-disubstituted50 alkenes as substrates (Scheme 16).  A range of 1,1- and 
1,2-disubstituted alkenes 48 cyclised to afford dihydropyrrole products 49 in good yields. For 
1,1-disubstituted alkenes (R2 ≠ H) only one hydrogen is available for β-hydride elimination 
which removes any selectivity issues. For 1,2-disubstituted alkenes (R = H) the β-hydride 
elimination step could lead to either the dihydropyrrole or pyrrole product; however, selectivity 




for the dihydropyrrole product was achieved by activating Ha in 50 by incorporating an aryl 
substituent in the R3 position.  
 
Scheme 16 Synthesis of dihydropyrroles by aza-Heck cyclisations of 1,1-disubstituted49and 
1,2-disubstituted alkenes.50 
An enantioselective aza-Heck cyclisation for the preparation of enantiopure dihydropyrroles 
51 was developed using SPINOL-derived ligand 52 (Scheme 17).51 This ligand promoted 
highly enantioselective cyclisations of oxime esters 48, containing 1,1-disubstituted alkenes, 
allowing for the efficient preparation of sterically congested tetrasubstituted C-N stereocentres.  
 
Scheme 17 Palladium(0)-catalysed enantioselective aza-Heck cyclisations.51 
One of the major limitations of the Narasaka-Heck reaction is that successful cyclisations 
typically require a large substituent α to nitrogen and as such aldoximes 53 are generally not 
suitable substrates. In the case of aldoximes the small size of hydrogen means that formation 




of the reactive (Z)-imino-palladium(II) intermediate 54b is not enforced with the 
(E)-imino-palladium(II) intermediate 54a being more sterically favourable (Scheme 18). As 
intermediate 54a is unreactive the rate of aza-Heck cyclisation is reduced and unproductive 
β-hydride elimination from 54a can occur to generate nitrile 55.VII  
 
Scheme 18 Aldoxime esters are ineffective substrates in aza-Heck cyclisations.44 
To overcome this limitation a new class of N-O donors for aza-Heck reactions was sought and 
to this end N-(pentafluorobenzoyloxy)sulfonamides 56 were identified as being suitable 
substrates (Scheme 19).52 This approach has a number of advantages over previous aza-Heck 
reactions. Firstly, substitution in the α-position is not required as β-hydride elimination from 
the resulting aza-palladium(II) intermediate 57 is slow due to the formation of a less 
thermodynamically stable imine 58 and thus the aza-Heck pathway dominates. Another benefit 
of this approach is that the substrates can be easily prepared by Mitsunobu reaction of the 
corresponding alcohol 59 with an N-(pentafluorobenzoyloxy)sulfonamide reagent allowing for 
an effective approach to transforming homoallylic alcohols to chiral pyrrolidines 60. The 
synthesis of bicyclic nitrogen heterocycles such as 61 which make up the core structure of 
natural products like cocaine was also possible using this methodology.VIII  
 
VII Alternatively, this could form by Beckmann rearrangement of oxime ester 53. 
VIII This approach has since been adapted to the cyclisation of N-acyloxycarbamates.53 





Scheme 19 Aza-Heck cyclisations of N-(pentafluorobenzoyloxy)sulfonamides.52 
1.3.4 Aza-Heck reactions of O-phenyl hydroxamates 
A related aza-Heck cyclisation of O-phenylhydroxamates 62 was reported by Watson and 
co-workers to afford 5-membered lactams 63 (Scheme 20).54 The reaction was compatible with 
a wide range of alkenes including tetrasubstituted alkenes which had not previously been 
successful in aza-Heck reactions. Although not confirmed the reaction is proposed to proceed 
by an aza-Heck mechanism. This methodology has also been extended to the synthesis of cyclic 
ureas.55 





Scheme 20 Aza-Heck cyclisations of O-phenylhydroxamates.54 
1.4 Project objectives 
The dearomative amination of aromatic compounds has emerged as a powerful means of 
converting simple ‘flat molecules’ into highly functionalised 3-dimensional products. Over the 
past few decades in the field of drug development there has been an over-reliance on 
well-established metal-catalysed sp2-sp2 cross coupling reactions such as the Suzuki 
cross-coupling.56 This has contributed to drug libraries consisting of ‘flatter’ compounds 
containing multiple aromatic rings.57 However, the increasing need to produce more effective 
drug candidates is seeing a new focus towards the synthesis of more 3-dimensional, saturated 
compounds which are recognised as more likely to be successful drug candidates than ‘flatter’ 
aromatic based compounds.58 The development of new and efficient dearomative processes to 
access complex scaffolds is therefore of significant value. 
In previous work carried out at Bristol, aza-Heck reactions to access chiral N-heterocycles from 
pentafluorobenzoyl oxime esters47,49-51 and N-acyloxysulfonamides52 have been developed. 
These reactions proceed via formation of an electrophilic imino- or amino-palladium(II) 
intermediate such as 64 or 57 (Scheme 21a). It was envisaged that intermediates of this type 
may be exploited to trigger other C-N bond forming reactions such as dearomatisation reactions 
as outlined in Scheme 21b. It was proposed that amino-palladium(II) intermediate 66 generated 
via oxidative addition of palladium(0) into the N-O bond of hydroxylamine-derived 65 would 
induce nucleophilic attack of a pendent arene ring. Reductive elimination from the resulting 
palladacycle 67 would then afford the dearomatised spirocycle 68 and regenerate palladium(0) 
to complete the catalytic cycle.  





Scheme 21 (a) Previous work in Bristol: palladium(0)-catalysed aza-Heck reactions.47,52 
(b) Proposed palladium(0)-catalysed dearomatising amination reaction. 
Although there appears to be no direct precedent for the use of amino-palladium(II) 
intermediates like 66 in C-N bond forming dearomatisations, related palladium(0)-catalysed 
C-C bond forming dearomatisations have been reported. In 2011 Buchwald and co-workers 
developed a palladium(0)-catalysed arylative dearomatisation of phenols 69 to generate 
spirocyclohexadienones 70 (Scheme 22a).59 This process involves generation of an 
aryl-palladium(II) intermediate 71 via oxidative addition of palladium(0) into the aryl-halide 
bond, followed by nucleophilic attack of the tethered phenol onto the palladium(II) centre. The 
resulting spirocyclic palladacycle 72 then undergoes reductive elimination to form the desired 
spirocyclic product. The use of a chiral phosphine ligand 73 enabled an asymmetric variant of 
this reaction to be developed with high levels of enantioselectivity. A related 
palladium-catalysed arylative dearomatisation approach was used by You and co-workers for 
the synthesis of the spirocyclic core of the Erythrina alkaloids. Good enantioselectivity for the 
synthesis of spirocycle 74 was achieved using chiral P-N ligand 75 (Scheme 22b).60 





Scheme 22 (a) Palladium(0)-catalysed arylative dearomatisation reaction.59 
(b) Palladium(0)-catalysed arylative dearomatisation for the synthesis of the erythrinane skeleton.60 




Chapter 2 - Electrophilic nitrogen-promoted 
dearomatising amination reactions 
2.1 Introduction 
Before presenting the results in this chapter on the development of an electrophilic 
nitrogen-enabled dearomatising amination reaction, a brief survey of relevant literature relating 
to C-N bond forming dearomatisation reactions will be given. In particular, methods that 
harness the use of electrophilic nitrogen sources will be discussed; however, a conceptually 
distinct, oxidative amination approach pioneered by Ciufolini, in which nucleophilic nitrogen 
sources are used, will also be highlighted. 
2.1.1 Electrophilic nitrogen-promoted dearomatising amination reactions 
In 1984 Kikugawa61 and Glover62 independently reported the conversion of 
N-chloro-N-methoxyamides 76 into lactams 77 by electrophilic aromatic substitution 
(Scheme 23). These transformations invoked the intermediacy of N-methoxynitrenium ions 78, 
which were generated by treatment of 76 with silver salts in TFA or benzene. These highly 
electrophilic species induced cyclisation with the pendent arene to generate lactam products. 
Efficient cyclisation via a nitrenium ion was attributed primarily to the stabilising effect of the 
oxygen lone pair of the N-alkoxy group through electron donation, which enables the nitrenium 
ion to be long-lived enough to undergo cyclisation.IX As expected, based on an electrophilic 
aromatic substitution mechanism, cyclisation proceeded efficiently with electron-donating or 
mildly electron-withdrawing substituents on the arene; however, strongly 
electron-withdrawing groups resulted in low yields.  
 
Scheme 23 Nitrenium ion-induced aryl amination of N-chloro-N-alkoxyamides.61 
 
IX This was supported by MNDO molecular orbital calculations. 




Both Kikugawa63 and Glover64 expanded the application of nitrenium ion-induced cyclisations 
to the synthesis of spirolactams through a dearomative transformation (Scheme 24). Using 
N-chloro-N-methoxyamides 79 with pendent ortho- or para-methoxyphenyl groups, the 
generation of spirolactams 80 was achieved through intramolecular ipso-attack of the resulting 
nitrenium ion intermediate. The electron-donating methoxy group increases electron density at 
the ipso-position leading to cyclisation to intermediate 81 which then undergoes hydrolysis to 
the spirodienone compound. By using this approach, Kikugawa demonstrated the synthesis of 
a variety of spirolactams, including β-, γ- and δ-lactams 80a-c.63 The synthesis of spirocyclic 
oxazetidines 82a-b was also possible by this method, whilst spirocyclisation also occurred with 
a para-chloro substituent in place of a methoxy group to give 83 in good yield. 
 
Scheme 24 Synthesis of spirodienones by nitrenium ion-induced cyclisation.63 
These ‘first generation’ nitrenium ion-induced dearomative cyclisations relied on the 
generation of nitrenium ions from N-chloro-N-alkoxyamides. These were in turn prepared by 
reaction of the corresponding N-alkoxyamides with t-BuOCl. However, the use of t-BuOCl is 
not ideal due to environmental factors and so an improved route to N-alkoxynitrenium ions was 
developed by Kikugawa, which involved the direct oxidation of N-alkoxyamides with 
hypervalent iodine reagents such as [bis(trifluoroacetoxy)iodo]benzene (PIFA).65 Using this 
improved protocol, Wardrop and co-workers harnessed the reactivity of nitrenium ion 




intermediates in a number of natural product syntheses. In a series of reports, nitrenium 
ion-induced C-N bond forming dearomatisations of phenol derivatives were used as key steps 
in the total syntheses of (-)-TAN1251A,66 (±)-adalinine,67 (+)-Kishi lactam,68 (-)-dysibetaine69 
and (±)-desmethylamino FR901483 (Scheme 25).70 In each case the reactive nitrenium ion 84 
was generated from the corresponding N-methoxyamide using PIFA before undergoing 
dearomative cyclisation. This work highlights the scope of dearomatising amination reactions 
for accessing a wide range of natural products. 
 
Scheme 25 Application of nitrenium ion-induced spirocyclisation in natural product synthesis.66-70 
As part of the same group’s studies into dearomative cyclisations, stereoselective 
spirocyclisations of α- and β-substituted 3-(methoxyphenyl) propiohydroxamates were 
reported.71,72 Until this point substrates used in spirocyclic cyclisations to afford 
hexa-2,5-dienones typically contained an arene with a plane of symmetry and as such led to 
the formation of a non-stereogenic centre. However, if the arene is instead substituted in a way 
that breaks the symmetry, then the π-faces become enantio-/diastereotopic and a new 
stereogenic centre is formed upon spirocyclisation. Wardrop and co-workers harnessed this to 
carry out spirocyclisations with high levels of diastereoselectivity. For example, reaction of 
α-substituted N-methoxyamide 85 with PIFA afforded the spirocycle with complete 
stereoselectivity for the anti-product 87a (Scheme 26).71 The selective formation of the 
anti-product was rationalised by the preference of the reaction to proceed via transition state 




86a. Cyclisation via transition state 86b, which leads to the syn-product 87b, is disfavoured 
due to unfavourable steric interactions between the benzyl substituent on the side chain and the 
methoxy substituent on the aromatic ring. This transformation was also extended to 6-ring 
cyclisations: N-methoxyamide 88 was converted to δ-lactam 89 in high yield and excellent 
diastereoselectivity.72 
 
Scheme 26 Nitrenium ion-induced diastereoselective spirocyclisations.71,72 
The nitrenium ion intermediates described thus far rely on electron-donating N-alkoxy groups 
for stabilisation; however, other stabilised nitrenium ion-induced cyclisations have also been 
explored. In 2003 Kikugawa and co-workers reported the use of 
N-phthalimido-N-acylnitrenium ions as a new class of electrophilic intermediates. These were 
used to carry out electrophilic aromatic substitutions as well as dearomative spirocyclisations.73 
Treatment of N-acylaminophthalimide 90, containing a para-methoxy group, with PIFA in 
TFE afforded spirocycle 91 in 77% yield (Scheme 27a). In addition to a para-methoxy 
substituent, substrates containing halogen substituents, such as chloro- or fluoro-groups in the 
para position (92a and 92b), also underwent efficient spirocyclisation. Whilst the reaction of 
unsubstituted phenyl substrate 93 with PIFA in HFIP led to the expected benzannulated product 
94, when TFE was used as the solvent the unexpected formation of spirocyclic product 95 was 
also observed (Scheme 27b). The formation of 95 can be attributed to the attack of the 




nitrenium ion formed from 93 on the ipso-carbon followed by trapping with a molecule of 
solvent.  
 
Scheme 27 (a) Spirocyclisation of para-substituted N-acylaminophthalimides. (b) Effect of solvent on 
the cyclisation of unsubstituted phenyl system 93.73 
A related electrophilic amination of aromatic compounds was reported in 1994 by Prabhakar 
and co-workers; this approach harnessed the electrophilicity of azodicarbonyl compounds 
97.74,75 These highly electrophilic species were generated by oxidation of the corresponding 
bishydrazide 96 and underwent Lewis acid-promoted cyclisation with pendent arenes to 
generate N-substituted amino dihydrocarbostyrils 98 or spiro-γ-lactams 99 depending on the 
nature of substitution on the aryl ring (Scheme 28). Other N-heterocycles were also accessed 
by this method, including oxindoles 100, benzazepinones 101, benzazocinones 102, 
benzimidazolones 103 and benoxazinones 104. However, a limitation of this reaction is that it 
is restricted to the cyclisation of highly electron rich arenes. 





Scheme 28 Intramolecular electrophilic amination of azodicarbonyls.74,75 
It is also pertinent to highlight several recent reports of transition metal-catalysed 
dearomatising amination reactions using electrophilic nitrogen sources, these were published 
after the studies presented in this chapter were completed. These examples rely on the 
generation of metal-nitrenoids which act as the reactive electrophile. 
You and co-workers developed an efficient rhodium-catalysed intermolecular aminative 
dearomatisation of 2-naphthols to generate a variety of unprotected α-amino-β-naphthalenones 
105 (Scheme 29).76 In this transformation O-2,4-dinitrophenylhydroxylamine (DPH) was utilised 
as the aminating agent; however, the application of DPH is limited by its high price and safety 
concerns and so the authors subsequently reported a procedure where DPH was replaced with 
the safer electrophilic nitrogen source hydroxylamine-O-sulfonic acid (Scheme 29).77  
 
Scheme 29 Rhodium-catalysed dearomative amination of naphthols.76,77 




Wang and co-workers reported a copper-catalysed dearomative amination of phenols with 
O-benzoylhydroxylamines (Scheme 30). In this transformation C-N bond formation occurs 
exclusively at the ortho-position to afford aminocyclohexa-2,4-dienones 106 under very mild 
conditions.78 To rationalise the observed ortho-selectivity the authors proposed a mechanism 
as shown in Scheme 30. Oxidative addition of the amine electrophile with a copper(I)-phenol 
species generates amino-copper(III) complex 107. This species may equilibrate to the 
corresponding N-centred radical/copper(II) complex 108, and then either 107 or 108 may 
undergo C-N bond formation by an inner-sphere pseudo-five-membered cyclic transition state. 
The reaction tolerates a wide variety of cyclic O-benzoylhydroxylamines, such as morpholines, 
piperidines and piperazines. 
 
Scheme 30 Copper-catalysed dearomative amination of phenols.78 
Two more related reports of metal-nitrenoid-induced C-N bond forming dearomatisation of 
phenols have also very recently been reported by Chang79 and Shibasaki.80 Chang and 
co-workers reported an approach to spirolactams via an iridium-nitrenoid intermediate 110 
which was generated from dioxazolones 109 (Scheme 31).79 Using this method, a variety of 
unprotected five-membered spirolactams 111 were accessed in excellent yields and the scope 
was also extended to the more challenging synthesis of a four membered spirolactam 112. 





Scheme 31 Iridium-catalysed intramolecular dearomatising amination.79 
Shibasaki and co-workers reported a rhodium-nitrenoid-promoted dearomatising amination of 
O-acylhydroxylamines 113 to access spirocycles 114 (Scheme 32).80 The reaction is proposed 
to proceed via the formation of a rhodium-nitrenoid species 115 with concomitant cleavage of 
the N-O bond. The advantage of this transformation is that by using cyclic isoxazolidin-5-ones 
as substrates the oxygen leaving group is retained, eliminating by-product waste. 





Scheme 32 Rhodium-catalysed dearomative amination of O-acylhydroxylamines.80 
2.1.2 Oxidative dearomative amination reactions 
The dearomative amination reactions described thus far rely on generating an electrophilic 
nitrogen source which reacts with a nucleophilic arene. Dearomative transformations which 
harness the more common nucleophilicity of nitrogen are also well-established. Ciufolini and 
co-workers have pioneered an ‘oxidative amidation’ approach for the conversion of phenols 
into spirodienones. Mechanistically, these reactions proceed via initial oxidation of the phenol 
ring to generate an electrophilic intermediate, which is then intercepted by a suitable 
nucleophilic nitrogen source. Typically, hypervalent iodine reagents such as DIB or PIFA serve 
as the external oxidant as these reagents are known to be effective oxidants for the oxidation 
of phenols and other arenes.81-84 
In 1998 Ciufolini and co-workers demonstrated that oxazolinesX 116 cyclise upon treatment 
with (diacetoxyiodo)benzene (DIB) in TFE or HFIP to the corresponding spirolactams 117 
(Scheme 33).85 The spirolactam products showed a strong propensity to cyclise to oxazines 118 
upon chromatographic purification. This reactivity was suppressed by in situ O-acetylation of 
the crude spirolactam products and a range of spirolactams 119a-d were obtained in modest 
yields via this two-step process (Scheme 34a). The reaction is believed to proceed via 
 
X Earlier work by Kita had demonstrated that amides were ineffective as substrates for this transformation due to 
a preference for reaction through oxygen to form spirolactones.81 




DIB-mediated oxidation of the phenol to generate electrophile 120 which is intercepted by the 
oxazoline nitrogen to afford intermediate 121. The iminium ion of 121 is then captured by 
another nucleophile present in the reaction mixture, such as an acetate ion or solvent molecule 
and the resulting intermediate affords the desired spirolactam product upon aqueous work-up.  
 
Scheme 33 Oxidative amidation of phenolic oxazolines.85 
For the cyclisation of oxaziridine 116d, containing a carbamate functional group, a low yield 
of 22% was obtained (Scheme 34a). This poor result was rationalised as being due to 
competition between the oxazoline nitrogen and the carbonyl oxygen of the carbamate group 
for interception of the electrophile. Reaction via the carbonyl leads to formation of an unstable 
intermediate 122 which unravels to a variety of side products (Scheme 34b). As such, a 
limitation of this approach is the unsuitability of substrates containing nucleophilic 
functionality which may compete with the oxazoline for capture of the electrophile. 




Scheme 34 (a) Oxidative amidation of phenolic oxazolines. (b) Competitive reactive pathways of 
oxazoline 116d.85 
Whilst secondary amines are generally incompatible as substrates for oxidative aminations of 
this typeXI there are several instances in the literature of secondary amines undergoing 
successful oxidative cyclisation to form spiropyrrolidines; in these cases, the transformation 
represents a key step in a natural product synthesis. In 2000 Sorensen and co-workers reported 
a synthesis of FR901483, a fungal-derived natural product with potent immunosuppressant 
properties.86 For the construction of the core azaspiro[4.5]decane motif the authors performed 
an oxidative amination of the tyrosine-derived compound 123 (Scheme 35). Using PhI(OAc)2 
in HFIP, the desired spirocyclic product 124 was obtained in good yield and subsequently 
transformed into the natural product. A related transformation was reported by Honda as a key 
step in the formal synthesis of the alkaloid natural product (-)-TAN1251A (Scheme 35).87 
Reaction of compound 125 under the same reaction conditions as used by Sorensen gave the 
desired spirocyclic amine 126 in 69% yield. Initially, the authors had attempted to convert 125 
into the spirocompound 126 via formation of a nitrenium ion; however, attempted chlorination 
of 125 with NCS, followed by treatment with silver oxide failed to deliver the desired 
 
XI This is believed to be due to the formation of acid in reactions involving DIB which protonates the amine 
suppressing its nucleophilicity. 




product.XII In both of these examples, successful oxidative cyclisation of these secondary 
amines is possibly due to inductive effects of the neighbouring functionality which decreases 
the basicity of the amines sufficiently that they remain unprotonated during the reaction and so 
are able to intercept the electrophilic intermediate. 
 
Scheme 35 Oxidative amination of secondary amines for the synthesis of natural products.86 87 
Whilst oxidative amidations are effective for constructing spirocyclic pyrrolidines, attempts to 
perform more challenging 6-ring cyclisations to form spirocyclic piperidines have met with 
less success. Ciufolini and co-workers reported the oxidative cyclisation of oxazoline 127 to 
afford spiropiperidine 128, but the reaction was low yielding (Scheme 36). Higher yields were 
obtained with more conformationally restricted substrates such as 129; however, this 
transformation remains a challenge.88 
 
 
XII This is likely due to the formation of an unstable nitrenium ion. 





Scheme 36 Formation of piperidines by oxidative amidation of oxazolines.88 
A significant improvement in the area of oxidative amidation chemistry emerged when 
Ciufolini and co-workers reported the oxidative dearomative cyclisation of sulfonamides. A 
series of sulfonamides 130 were cyclised with PhI(OAc)2 in HFIP to afford the spirocyclic 
sulfonamide products 131 with much greater efficiency than that obtained with previous 
systems (Scheme 37a).89 The choice of solvent was crucial to obtaining high yields as when 
TFE was used competition between the sulfonamide nitrogen and the solvent for capture of the 
electrophile was observed. In addition to the reaction being effective for a variety of 
sulfonamides, phosphonamide 132 cyclised to spirocycle 133 in excellent yield 
(Scheme 37b).88 
 
Scheme 37 (a) Oxidative amidation of phenolic sulfonamides.89 (b) Oxidative amidation of a 
phosphonamide.88 




Oxidative cyclisation of ortho-sulfonamides, where nucleophilic attack occurs ortho to the 
phenol OH were also successfully demonstrated by Ciufolini and co-workers, although these 
reactions were generally less efficient than for para-phenol substrates. By coupling oxidative 
cyclisation of allylic sulfonamide 134 with a Diels-Alder reaction tetracycle 135 was obtained 
in good yield (Scheme 38a).90 In addition to the dearomatisation of phenols, the scope of the 
reaction was also extended to the oxidative amidation of naphthols. Upon exposure to 
PhI(OAc)2 a variety of 1-naphthols 136a-d cyclised efficiently to the corresponding spirocyclic 
compounds 137a-d (Scheme 38b).91,XIII 
 
Scheme 38 (a) Tandem oxidative amidation/Diels-Alder reaction of ortho-sulfonamide 134.90 
(b) Oxidative amidation of naphthols.91 
All the previous examples of oxidative cyclisation involve intramolecular reactions; however, 
precedence for an intermolecular oxidative amidation of phenols was set by Kita in 1996 who 
during the attempted oxidative cyclisation of 138 observed the competing formation of 
amidation product 140 in addition to the desired alkylated product 139 (Scheme 39).92 This 
product likely arises by a Ritter-type reaction following initial trapping of the electrophile by 
a molecule of acetonitrile. 
 
XIII No product was observed from the cyclisation of 1-naphthol 136d; the authors attributed this to the instability 
of the corresponding product 137d. 





Scheme 39 Observation of side product 140, a product of intermolecular oxidative amidation.92 
Inspired by this result, Ciufolini developed an efficient intermolecular oxidative amidation of 
phenols to the corresponding dearomatised products 141a-e using PhI(OAc)2 in a 1:1 mixture 
of MeCN and HFIP (Scheme 40a).93 The reaction proved compatible with a variety of 
functional groups including esters, nitriles, halides, sulfonamides and protected alcohols. 
Through treatment of compound 141e with NaH, cyclisation to the spirocyclic piperidine 142 
was achieved, allowing for an effective approach to the synthesis of spirocyclic piperidines 
(Scheme 40b). 
 
Scheme 40 (a) Intermolecular oxidative amidation of phenols. (b) Application to the synthesis of 
spirocyclic piperidines.93 
 




2.2 Studies towards a palladium-catalysed dearomatising amination 
reaction  
2.2.1 Initial results 
It was envisaged that the proposed dearomatising amination protocol discussed in Chapter 1 
(Scheme 41) would represent (a) a mild, catalytic alternative to traditional dearomative 
amination approaches and (b) offer a number of additional advantages. Classical nitrenium 
ion-induced dearomatising amination reactions, whilst effective, are limited in scope, as 
typically only spirolactams with specific electron-donating N-protecting groups can be formed. 
Another advantage of the proposed approach is the lack of a requirement for oxidative 
conditions as the N-O bond acts as a mild internal oxidant. In the dearomatising amination 
approach pioneered by Ciufolini and co-workers stoichiometric amounts of external oxidants 
are required.85,89,91,93-96 The strongly oxidising conditions renders oxidisable functional groups 
incompatible and it can lead to competing oxidation processes involving the electron-rich 
arene.  
 
Scheme 41 Proposed palladium(0)-catalysed dearomative amination. 
In order to examine the feasibility of the proposed dearomative transformation, phenolic 
substrate 148 was prepared. During the course of developing a dearomative amination of 
indoles (Section 2.3) Xiaofeng Ma (University of Bristol) demonstrated that the preactivated 
amino-reagent TsNHOFBz can participate in a Mitsunobu reaction to afford sulfonamide 144 
in one step from alcohol 143 (Scheme 42a).97 TsNHOFBz is itself readily prepared by an amide 




coupling reaction of TsNHOH and FBzOH. For the synthesis of 148 via Mitsunobu reaction, 
alcohol 146 was prepared in two steps from carboxylic acid 145 (Scheme 42b). To avoid 
potential competing side reactions during the Mitsunobu reaction, alcohol 146 was prepared 
with the phenol group protected as the silyl ether. Mitsunobu alkylation of TsNHOFBz with 
alcohol 146 afforded 147 in 56% yield. The final step was deprotection of 147 and this was 
performed using 1 M HCl to provide substrate 148 in excellent yield. 
 
Scheme 42 (a) Synthesis of sulfonamide 144 by Mitsunobu reaction.97 (b) Synthesis of substrate 148. 
With substrate 148 in hand, the dearomatising amination reaction was investigated. When 148 
was subjected to conditions previously identified as effective for aza-Heck cyclisations of 
N-acyloxysulfonamides52 [Pd2(dba)3 (2.5 mol%), P(3,5-(CF3)2(C6H3)3 (12.5 mol%), Et3N 
(25 mol%), n-BuCN, 110 oC] the desired dearomatised product 149 was not observed 
(Scheme 43). Instead the major product isolated was sulfonamide 150 which was generated in 
34% yield. Sulfonamide 150, the product of reduction of the N-O bond of 148 probably occurs 
by protodepalladation. This most likely involves heterolytic cleavage of the Pd-N bond of 151, 
formed by oxidative addition of Pd(0) into the N-O bond, followed by protonation of the 
ensuing nitrogen anion 152. It is possible that these events could occur the other way around, 
with protonation of nitrogen preceding heterolytic cleavage. Alternatively, it is known that 
under certain palladium-catalysed conditions nitrogen-centred radicals are generated98 and as 




such 151 could potentially undergo homolytic cleavage to form a nitrogen-centred radical 
followed by hydrogen atom abstraction. 
 
Scheme 43 Attempted palladium(0)-catalysed dearomatising amination of  substrate 148. 
In light of this disappointing result further studies into the dearomative amination of substrate 
148 were carried out (Table 1). The effects of changing the base and the use of different ligands 
were investigated; however, in all case no desired product was observed. The effect of 
temperature was also studied but increasing the temperature to 140 oC also failed to yield any 
desired reactivity. In the absence of base (Table 1 entry 5) a significant amount of starting 
material was recovered (40%) in addition to protodepalladation product 150 (27%). A series of 
bidentate ligands was also examined; however, these failed to induce any desired reactivity 
(Table 17, appendix). 
 
Table 1 Attempted palladium(0)-catalysed dearomatising amination of substrate 148. 




As the OFBz leaving group was unsuccessful in the dearomatising amination reaction other 
leaving groups were examined. Substrate 153 containing an OBz group was prepared in good 
yield via Mitsunobu reaction from 146 and TsNHOBz (Scheme 43a). When 153 was subjected 
to the reaction conditions no dearomatised product was observed (Scheme 44b). As for 
substrate 148 the major product that was isolated was the protodepalladation product 150, in 
addition to a significant portion of recovered starting material (51%). 
 
Scheme 44 (a) Synthesis of substrate 153. (b) Attempted dearomatisation of substrate 153. 
For substrate 153 different bases were also investigated. When 153 was reacted with the 
inorganic base K2CO3 (25 mol%) no dearomatised product was observed. Once again, the 
protodepalladation product 150 was observed, albeit in a reduced yield of 9%; however, under 
these conditions nitriles 154 and 155 were also isolated in 12% and 10% yields respectively 
(Scheme 45a). The yields of these products were significantly improved by increasing the 
loading of K2CO3 to 150 mol% (Scheme 45b). In contrast, in the absence of base, 154 and 155 
were not observed and only protodepalladation product 150 was formed in 14% yield (in 
addition to the recovery of 63% starting material) (Scheme 45c). 





Scheme 45 (a) Observation of side products 154 and 155 in the attempted dearomatising amination 
of substrate 153 using 25 mol% K2CO3. (b) Increased formation of 154 and 155 using 150 mol% 
K2CO3. (c) In the absence of base products 154 and 155 were not observed. 
Nitriles 154 and 155 likely result from elimination of BzOH and the tosyl group from 153, 
although the order of elimination is unclear (Scheme 46). It is known that O-acylaldoximines 
can be converted to nitriles when exposed to palladium(0).47 This is proposed to occur by 
Beckmann rearrangement. Alternatively, elimination of BzOH could precede elimination of 
the tosyl group and this could involve either a β-hydride elimination from intermediate 151 or 
an E2 elimination mechanism. However, 154 and 155 were still observed when 153 was heated 
with K2CO3 in n-BuCN in the absence of palladium, which implies palladium is not involved 
in this transformation. It is possible that following elimination of BzOH, the resulting imine 
157 could undergo hydrolysis, to generate aldehyde 158 and TsNH2.
XIV However, neither of 
these products were identified in the crude reaction mixture. There is literature precedence for 
 
XIV 158 could also potentially arise from hydrolysis of 156. 




the conversion of N-tosylhydroxylamines to nitriles under basic conditions; however, an exact 
mechanism was not proposed.99 
 
Scheme 46 Possible mechanisms for the formation of nitriles 154 and 155. 
With no successful dearomatisation having occurred so far, the effect of the protecting group 
on nitrogen was examined next. The Cbz group was chosen as it is also electron-withdrawing 
but has the added benefit of being easier to remove than the tosyl group thereby improving its 
synthetic utility. Substrate 159 was prepared in the same manner as sulfonamide 148 but using 
instead CbzNHOFBz in the Mitsunobu reaction (Scheme 47a). Unfortunately, when 159 was 
subjected to the dearomatisation reaction conditions no cyclised product 160 was observed 
(Scheme 47b).  





Scheme 47 (a) Synthesis of substrate 159. (b) Attempted dearomatisation of N-Cbz substrate 159. 
2.2.2 Studies towards a dearomatising amination reaction of naphthols and 
pyrroles 
With phenol derivatives proving unsuccessful in the dearomative cyclisation other potentially 
more reactive arenes were investigated, beginning with pyrrole substrate 164 (Scheme 48). The 
synthesis of 164 began from 2-pyrrole aldehyde which was reacted with stabilised ylide 161 to 
give unsaturated ester 162. Hydrogenation followed by reduction with LiAlH4 generated 
alcohol 163 which then underwent Mitsunobu reaction with TsNHOFBz to give substrate 164 
in a low yield of 33%. Substrate 164 was subjected to the original reaction conditions which 
were investigated for the phenol substrate; however, no dearomatised product 165 was 
observed. 
 
Scheme 48 Synthesis and attempted dearomatisation of substrate 164. 




Dearomatisation of naphthols were also investigated. 2-Naphthol-derived substrate 169 was 
targeted, as a convenient route to its synthesis had already been identified (Scheme 49a). The 
synthesis began with the formation of lactone 166 by Friedel-Crafts alkylation of 2-naphthol 
and acrylic acid followed by spontaneous lactonisation. Lactone hydrolysis followed by TBS 
protection of the phenol hydroxyl group gave 167. To obtain alcohol 168 reduction of the 
carboxylic acid of 167 was required. A low yield was initially obtained for this step using 
LiAlH4 as the reductant, with deprotection of the TBS-protected phenol also occurring. 
However, by converting the carboxylic acid into an anhydride followed by reduction with the 
milder reducing agent NaBH4, 168 was generated in high yield. Substrate 169 was then 
prepared by Mitsunobu reaction followed by TBS deprotection. When 169 was subjected to 
the following conditions: [Pd2(dba)3 (5 mol%), 5-nitro-1,10-phenanthroline (20 mol%), K3PO4 
(200 mol%) in n-BuCN (0.05 M) at 120 oC] spirocycle 170 was generated in 22% yield 
(Scheme 49b). Despite this promising result, further optimisation of this reaction was 
abandoned in favour of alternative more successful avenues which will be discussed in the 
remainder of this chapter.  
 
Scheme 49 (a) Synthesis of substrate 169. (b) Dearomatisation of substrate 169. 
2.2.3 Studies towards a dearomatising amination reaction under oxidative 
conditions 
As the dearomative amination reactions discussed above, where the amino-palladium(II) 
intermediate is accessed from an electrophile nitrogen source through oxidative addition of 




palladium(0) into the N-O bond, were proving generally unsuccessful, alternative avenues were 
explored. Another well-established approach to palladium-catalysed C-N bond formation is the 
aza-Wacker reaction, which involves the oxidative amination of alkenes with nitrogen 
nucleophiles.100-102 This approach has been used to carry out intramolecular couplings of 
alkenes with sulfonamides to generate pyrrolidine derivatives.103,104 In many cases, the reaction 
is believed to proceed through an amino-palladium(II) intermediate which is accessed through 
ligand displacement at the metal centre by the amine nucleophile.105,106 It was therefore 
proposed that reaction of sulfonamide 150 with a palladium(II) source would result in ligand 
exchange to give amino-palladium(II) intermediate 151 which could then undergo dearomative 
amination (Scheme 50). Reductive elimination from 171 would give the dearomatised product 
149 and palladium(0) which would then require re-oxidation to palladium(II) with an external 
oxidant to re-enter the catalytic cycle. Although this approach was not considered ideal due to 
the requirement for oxidative conditions, it was nevertheless investigated due to the ease of 
preparation of the required substrate 150. 
 
Scheme 50 Proposed oxidative dearomatising amination.  
To this end substrate 150 was prepared by Mitsunobu alkylation of TsNHBoc with alcohol 146 
(Scheme 51). The resulting N-Boc compound 172 then underwent global deprotection using 
concentrated HCl to afford the NH compound 150.XV  
 
XV Substrate 150 could not be prepared directly by Mitsunobu reaction of TsNH2 as primary sulfonamides do not 
undergo Mitsunobu reactions.107 





Scheme 51 Synthesis of sulfonamide 150. 
With sulfonamide 150 in hand, it was subjected to typical aza-Wacker conditions:102 [Pd(OAc)2 
(5 mol%), pyridine (10 mol%), NaOAc (200 mol%) in PhMe (0.1 M) at 80 oC] under a balloon 
of oxygen. After stirring overnight, no desired dearomatised product 149 was observed and 
only starting material was recovered (Table 2 entry 1). A variety of bases (Table 2 entries 3-5) 
and solvents were examined (Table 2 entries 6-9); however, no reaction occurred under any of 
the conditions trialled. 
 
Table 2 Attempted oxidative dearomatising amination of substrate 150. 
Although not an amination reaction, attempted oxidative dearomative cyclisation was also 
attempted with 173 as this would give rise to spirocycles such as 174 (Table 3).XVI When 173 
was examined in the oxidative dearomative cyclisation using a variety of bases no spirocyclic 
product was identified. The only product, other than recovered starting material, that was 
obtained was aldehyde 158, formed by oxidation of 173 presumably via β-hydride elimination 
from 175 (Scheme 52). 
 
XVI Conditions for this reaction were based on a report by Lin and co-workers who developed a protocol for 
palladium-catalysed intramolecular oxidative dearomatisation of indoles using phenol nucleophiles.108 





Table 3 Attempted oxidative dearomatisation of substrate 173. Yields were determined by 1H NMR 
spectroscopic analysis of the crude reaction mixture versus 1,3,5-trimethyoxybenzene as an internal 
standard. 
 
Scheme 52 Proposed formation of aldehyde 158 by β-hydride elimination. 
2.3 Acid-promoted dearomatising amination reactions of N-Boc 
hydroxylamines  
The contents of this section have been communicated: Farndon, J, J.; Ma, X.; Bower, J. F.; 
J. Am. Chem. Soc. 2017, 139, 14005-14008. Parts of this section have been reproduced from 
this publication. 
2.3.1 Introduction 
Whilst the studies presented so far in this chapter were being carried out Falck and co-workers 
reported the dirhodium-catalysed arene amination of O-(sulfonyl)hydroxylamines 
(Scheme 53a).33 The mildness and efficiency of this protocol in combination with there being 
no precedence for its use in dearomatising amination made the development of a dearomatising 
cyclisation based on this approach a worthwhile endeavour (Scheme 53b). It was envisaged 
that this approach may succeed where attempted palladium-catalysed C-N bond forming 
dearomatisation of N-acyloxysulfonamides had proved ineffective. This approach would also 




have a further benefit of allowing the direct preparation of unprotected nitrogen ring systems; 
this is something that is not generally possible using traditional approaches to C-N bond 
forming dearomatisations that harness the electrophilicity of nitrenium ions61-65,71,73,109,110 or 
by the oxidative amidation approach pioneered by Ciufolini and co-workers.85,89-91,93,94 
 
Scheme 53 (a) Rhodium-catalysed intramolecular aryl C-H amination.33(b) Proposed 
rhodium-catalysed dearomatising amination. 
2.3.2 Reaction discovery 
In order to explore a rhodium-catalysed dearomatising amination reaction of 
N-tosyloxycarbamates, phenol substrate 177 was synthesised (Scheme 54a). Using the 
Mitsunobu conditions developed by Falck and co-workers,33 N-tosyloxycarbamate 176 was 
generated in 93% yield from alcohol 146. Deprotection of the silyl ether of 176 was then 
required. Initial attempts using TBAF in THF resulted in poor yields of the desired phenol 177 
most likely due to the basic nature of TBAF and the ease with which the tosylate group can 
eliminate. The poor yield of this deprotection step was ameliorated by the addition of acetic 
acid to the TBAF solution to counteract its basicity, and substrate 177 was generated in 
60% yield using this modified approach. 





Scheme 54 (a) Synthesis of substrate 177. (b) Rhodium-catalysed cyclisation of substrate 177. 
With substrate 177 in hand, the dearomatising amination reaction was investigated. Using the 
optimised conditions as reported by Falck and co-workers33 [Rh2(esp)2 (2 mol%), TFA 
(200 mol%) in TFE (0.1 M) at 0 oC to room temperature] efficient cyclisation was observed to 
give the dearomatised product 178 in 88% yield (Scheme 54b).XVII  
During reaction optimisation, it was discovered unexpectedly that the rhodium catalyst is not 
necessary for this reaction as when 177 was subjected to TFA in TFE, in the absence of 
rhodium, 178 was still obtained in 77% yield (Scheme 55). Spirocycle 178 was isolated as its 
TsOH salt upon completion of the reaction by removal of the solvent and other volatiles under 
reduced pressure. Purification was then carried out by flash column chromatography using 
Et3N-washed silica to release the free base of 178. As the free base, 178 is relatively unstable 
and so it was re-acidified with TFA to form the TFA salt for characterisation. In its protonated 
form 178 is more resistant to polymerisation and other decomposition pathways and as such 
this purification procedure was used in most cases, when necessary, during the investigation of 
substrate scope. Having established that the rhodium catalyst is not required for this reaction, 
with only a relatively minor reduction in yield observed in its absence, this metal-free approach 
was investigated further. 
 
XVII The yield was determined by 1H NMR analysis versus 1,3,5-trimethoxybenzene as an internal standard. 





Scheme 55 Metal-free dearomative cyclisation of substrate 177. 
2.3.3 Reaction optimisation 
Attempts at further reaction optimisation commenced with a solvent screen, the results of 
which highlighted the importance of TFE as the solvent for this transformation. Polar protic 
solvents similar to TFE, such as MeOH, EtOH and i-PrOH were investigated but failed to 
produce any desired reactivity (Table 4, entries 1-3). Less polar solvents such as THF, EtOAc 
and 1,4-dioxane were also unsuccessful (Table 4, entries 4-6). By contrast the aprotic and 
relatively non-polar solvents PhMe and CH2Cl2 produced 178 in modest yields of 40% and 
41% respectively (Table 4, entries 7, 8). Some reactivity was also observed with MeCN as 
solvent, as 178 was obtained in 8% yield (Table 4 entry 9). A brief investigation into reaction 
concentration failed to give any improvement in yield with 0.1 M appearing to be the optimal 
concentration.XVIII 
 
Table 4 Solvent screen for the dearomatising amination of 178. Yields were determined by 1H NMR 
analysis of the crude reaction mixture versus 1,3,5-trimethoxybenzene as an internal standard. 
 
XVIII The use of distilled TFA and TFE was also investigated; however, comparable yields were obtained with or 
without distillation. 




The temperature of the reaction was next examined. Increasing the temperature to 40 oC had 
no effect on the yield of dearomatised product formed with 178 generated in 78% yield 
(Table 5, entry 1). However, at this higher temperature the reaction was complete in a slightly 
reduced time of 15 hours (versus 24 hours at room temperature). At 60 oC the reaction time 
was further reduced but this also led to a slight reduction in yield (Table 5, entry 2). A further 
increase in temperature to 80 oC led to a significant reduction in yield to 44% (Table 5, entry 3) 
likely due to the thermal degradation of the starting material or product at this temperature.  
 
Table 5 The effect of temperature on the dearomatisation of substrate 177. Yields were determined by 
1H NMR analysis of the crude reaction mixture versus 1,3,5-trimethoxybenzene as an internal 
standard. 
2.3.4 Tandem desilylation-dearomatisation reaction 
Due to the presence of acid in the reaction conditions the possibility of in situ deprotection of 
the silyl ether was investigated as this would negate the additional deprotection step during 
substrate synthesis. TBS-protected phenol 176 was subjected to the dearomatisation conditions 
and dearomatised product 178 was formed in a reduced yield of 60% (Scheme 56). By 
increasing the loading of TFA to 300 mol% an improvement in yield to 83% was observed 
meaning that the reaction could be carried out with similar levels of efficiency as when the free 
phenol was used. However, for the purposes of investigating the substrate scope of this 
dearomative cyclisation, reactions were performed on O-TBS cleaved substrates. 
 
Scheme 56 Dearomatising amination of TBS-protected substrate 176. 




2.3.5 Dearomatising amination of para-phenol systems: substitution on the 
phenyl ring 
With optimal conditions in hand, the substrate scope of the dearomatising amination reaction 
was examined, beginning with substitution on the phenol ring. To this end substrate 182 
containing a dimethyl-substituted phenol was synthesised (Scheme 57a). The synthesis began 
with a Wittig reaction of the commercially available benzaldehyde 179. The resulting 
unsaturated ester 180 was transformed into alcohol 181 via a three-step sequence, beginning 
with Pd/C-catalysed alkene hydrogenation with concurrent removal of the benzyl group. 
Reprotection of the phenol as the silyl ether and finally reduction of the ester with LiAlH4 gave 
alcohol 181. Mitsunobu reaction with BocNHOTs, followed by deprotection of the silyl ether 
with TBAF:AcOH completed the synthesis of substrate 182, with each step occurring in high 
yield. When substrate 182 was subjected to the dearomatisation conditions product 183 was 
obtained in 85% yield (Scheme 57b). Spirocycle 183 exhibited improved stability over the 
parent product 178 and could be isolated as its free base. This is likely a result of the methyl 
substituents providing sufficient steric shielding of the sensitive unsaturated dienone group 
which otherwise would be highly susceptible to nucleophilic attack from another molecule of 
183 leading to potential polymerisation pathways. As a result of its stability 183 was 
crystallised and its structure confirmed by X-ray crystallography. 
  
Scheme 57 (a) Synthesis of substrate 182. (b) Dearomative amination of substrate 182. 




The effect of the electronics of the phenol ring on the effectiveness of the dearomatisation 
reaction was next examined. A series of substrates with electron-donating or 
electron-withdrawing substituents on the phenol ring were prepared. Substrate 186 containing 
a highly electron-rich methoxy-substituted phenol was prepared (Scheme 58). The synthesis 
began with Knoevenagel condensation between vanillin and malonic acid to give carboxylic 
acid 184. In a similar sequence to the previous substrate, hydrogenation, protection of the 
phenol group and reduction with LiAlH4 followed. From the resulting alcohol 185, substrate 
186 was synthesised by Mitsunobu reaction and deprotection of the silyl ether. 
 
Scheme 58 Synthesis of substrate 186. 
Next substrate 190 containing a bromo-substituted phenol was prepared. The synthesis began 
by bromination of phenol 187 with bromine in AcOH (Scheme 59). Following protection of 
the phenol hydroxyl group with TBSCl, the ester of 188 was reduced to alcohol 189 in 
preparation for the Mitsunobu reaction. The use of LiAlH4 (75 mol%) at -15 
oC proved effective 
for generating alcohol 189 in 87% yield without reduction of the aryl bromide. 189 was then 
converted to 190 by Mitsunobu reaction and O-TBS deprotection. 





Scheme 59 Synthesis of substrate 190. 
The introduction of a bromide handle allowed for further derivatives to be synthesised using 
metal-catalysed cross-coupling chemistry. Intermediates 192 and 193 were prepared by 
palladium-catalysed Suzuki cross-coupling of bromo-phenol 191 and the corresponding 
phenyl- and cyclopropylboronic acids (Scheme 60). After a series of optimisations, the 
cross-coupled products 192 and 193 were obtained in high yields. From these esters, substrates 
194 and 195 were accessed using the same general approach as used for previous substrates. 
 
Scheme 60 Synthesis of substrates 194 and 195. 
With substrates 186, 190, 194 and 195 in hand, they were employed in the dearomatisation 
reaction (Scheme 61). Although dearomatisation was accomplished in each case the yields 
produced were lower than for the unsubstituted parent substrate. The methoxy-substituted 




example 186 was particular poor yielding producing the desired product 196 in only 27% yield. 
In addition, the product proved too unstable to isolate by column chromatography and as such 
its yield was determined by 1H NMR analysis of the crude material versus an internal standard. 
Improved yields of 53%, 51% and 43% were observed for the bromo-, phenyl- and 
cyclopropyl-substituted spirocycles 198, 200 and 202 respectively; however, these were still 
considerably less than the yield of 77% observed for the unsubstituted system 178. For these 
systems the low yields can be attributed to the competitive formation of tetrahydroquinoline 
side products in addition to the desired spirocyclic targets. This was most apparent for 
methoxy-substituted system 186, which cyclised to give the tetrahydroquinoline product 197 
in 62% yield in addition to the 27% yield of dearomatised product 196 (Scheme 61). The 
phenyl- and cyclopropyl-substituted systems were more selective for formation of the 
spirocyclic products (200 and 202) but still formed the tetrahydroquinoline products 201 and 
203 in yields of 35% and 34% respectively. For the bromo-substituted system only a small 
amount of tetrahydroquinoline product 199 was formed in addition to spirocycle 198. 
 
Scheme 61 Competitive aryl C-H amination observed in the dearomatising amination of substrates 
186, 190, 194 and 195. aYield determined by 1H NMR analysis of the crude reaction mixture versus 
1,3,5-trimethoxybenzene as an internal standard. bCompounds were isolated as the TFA salt. 




The tetrahydroquinoline products most likely form due to activation of the position para to the 
substituent resulting in a competing C-H amination pathway. No reaction via activation of the 
position ortho to the substituents was observed, most likely due to steric factors. The methoxy 
group is strongly activating which is reflected in the significant amount of tetrahydroquinoline 
197 observed. The phenyl and cyclopropyl groups, whilst still electron-donating are less 
activating than the hydroxyl group and as such the selectivity is in favour of the spirocyclic 
products.  
 
Scheme 62 (a) Formation of 203 by either a direct aryl C-H amination or 
dearomatisation/rearrangement pathway. (b) Control reaction to confirm a direct aryl C-H amination 
pathway. 
Whilst the formation of the tetrahydroquinoline products can be rationalised by a direct aryl 
C-H amination pathway, these ring systems can also arise by initial spirocyclisation followed 
by C-N bond migration (Scheme 62a). It is well established that under acidic conditions 
spirodienones can undergo dienone-phenol rearrangement processes to generate the more 
stable phenol product.111 In their reports on intramolecular electrophilic C-H amination 
Glover,64 Kikugawa63,112 and Cherest113 have all described dienone-phenol rearrangements of 
similar aza-spirocyclic compounds.XIX To ascertain whether or not the tetrahydroquinoline 
 
XIX Several related transformations that generate tetrahydroquinoline products via iridium-79 or 
rhodium-nitrenoid80 intermediates propose a mechanistic pathway involving initial spirocyclisation followed by 
C-C bond migration. 




products were formed from the spirocyclic intermediates, spirocycle 202 was re-subjected to 
the standard reaction conditions but was returned unchanged and formation of 
tetrahydroquinoline 203 was not observed (Scheme 62b). This result confirms that 
tetrahydroquinoline 203 is formed via a direct aryl C-H amination pathway rather than by 
rearrangement of spirocycle 202 through a dienone-phenol rearrangement. In other cases, 
formation of a tetrahydroquinoline via a dienone-phenol rearrangement was observed and this 
is described in Section 2.3.15. 
In order to remove the issue of selectivity, substrate 204 containing a meta-methoxy-substituent 
was synthesised (Scheme 63). In this case, both of the electron-donating substituents should 
serve to activate the position para to the hydroxyl group. Indeed, when substrate 204 was 
subjected to the dearomatisation reaction spirocycle 205 was formed as the sole product in 
74% yield. 
 
Scheme 63 Synthesis and dearomatising amination of substrate 204. 
2.3.6 Dearomatising amination of para-phenols with substitution α to nitrogen 
Next the reaction scope study was expanded to investigate the effects of substitution on the 
carbon tether, beginning with substitution α to nitrogen. To this end, substrate 209 was prepared 
(Scheme 64). Carboxylic acid 206 was converted to Weinreb amide 207 by reaction with 
N,O-dimethylhydroxylamine hydrochloride. Following addition of MeMgBr and reduction of 
the resulting ketone with NaBH4, alcohol 208 was obtained and converted to substrate 209 by 
Mitsunobu reaction and TBS deprotection. When 209 was subjected to the dearomatising 
amination reaction conditions spirocycle 210 was obtained in 58% yield (Scheme 64). The 
reduction in yield is possibly due to increased steric effects around the reactive nitrogen centre 




due to the introduction of an adjacent methyl group. As such the rate of reaction is slower 
allowing for potential competing decomposition of the substrate to occur. 
 
Scheme 64 Synthesis and dearomatising amination of substrate 209. 
2.3.7 Dearomatising amination of para-phenols with substitution γ to nitrogen 
Attention then turned to substrates containing substitution on the carbon tether γ to nitrogen. 
To this end, unsaturated ester 211 was synthesised by Wittig reaction of 
4-hydroxybenzaldehyde, followed by protection of the phenol hydroxyl group (Scheme 65a). 
Reaction of 211 with EtMgBr at -20 oC in the presence of CuI led to successful 1,4-addition to 
afford ester 212 in 86% yield. Reduction of the ester of 212 with LiAlH4, followed by 
Mitsunobu reaction and deprotection completed the synthesise of substrate 213. Under the 
dearomatising amination reaction conditions substrate 213 cyclised to spirocycle 214 in 
69% yield (Scheme 65b). This improvement in yield over the α-substituted system is likely due 
to the ethyl substituent being further away from the reactive nitrogen centre and as such is less 
of a steric hinderance to reactivity. 





Scheme 65 (a) Synthesis of substrate 213. (b) Dearomatising amination of substrate 213. 
2.3.8 Dearomatising amination of ortho-phenols 
Up until this point, all the systems examined have involved formation of the C-N bond para to 
the phenol hydroxyl group. In order to expand the reaction scope, dearomatisations of 
ortho-substituted phenols were next investigated. Substrate 217 was prepared from 
commercially available carboxylic acid 215 (Scheme 66a). After protection of the phenol 
hydroxyl group, reduction of the carboxylic acid to alcohol 216 was achieved using NaBH4 via 
formation of an anhydride. Following the general Mitsunobu reaction and silyl ether 
deprotection strategy, substrate 217 was obtained in good yield. The dearomative cyclisation 
of 217 was disappointing with 218 obtained in only 33% yield (Scheme 66b). The low yield 
can be attributed to poor stability of the dearomatised product.XX 218 could not be isolated 
following flash column chromatography and as such the yield was determined by 1H NMR 
analysis versus 1,3,5-trimethoxybenzene as an internal standard. To enable isolation and 
characterisation of the dearomatised product the crude reaction mixture was treated with acyl 
chloride and Et3N to provide amide 219 in 14% yield from substrate 217. 
 
XX Lower yields were generally obtained for ortho-cyclisations in the oxidative amidation reactions reported by 
Ciufolini.95 





Scheme 66 (a) Synthesis of substrate 217. (b) Dearomatising amination of substrate 217. 
In order to achieve a more satisfactory yield of dearomatisation from an ortho-phenol substrate, 
substrate 221 containing a methyl-substituted phenol was prepared (Scheme 67). It was 
proposed that the methyl group would provide a degree of steric shielding to the highly reactive 
dienone and as a result it would make the product more stable. The synthesis of substrate 221 
began from 6-methylcoumarin. Alkene hydrogenation followed by lactone hydrolysis and 
protection of the resulting phenol hydroxyl group afforded carboxylic acid 220. The synthesis 
of substrate 221 was completed by reduction of the carboxylic acid, followed by Mitsunobu 
reaction and deprotection of the phenol hydroxyl group. Substrate 221 cyclised efficiently to 
give spirocycle 222 in 91% yield (Scheme 67). Due to the high conversion of this substrate and 
the lack of side products, 222 was isolated in sufficient purity without the need for further 
purification. Upon completion of the reaction, the solvent and any other volatile components 
were removed by concentration in vacuo and 222 was obtained as the TsOH salt. 
 
Scheme 67 Synthesis and dearomatising amination of substrate 221. 




Methoxy-substituted substrate 223, which was prepared in a similar manner as substrate 221, 
was also examined (Scheme 68). When subjected to the dearomatisation conditions, substrate 
223 cyclised to the dearomatised product 224 in 78% yield. In this case the dearomatised 
product was purified by flash column chromatography and 224 was obtained as the TFA salt 
upon re-acidification. 
 
Scheme 68 Synthesis and dearomatising amination of substrate 223. 
2.3.9 Dearomatising amination of naphthols 
To expand the scope of the dearomatisation process a further class of nucleophilic arene, 
naphthols, was investigated. Para-substituted naphthol 225XXI cyclised under the standard 
dearomatisation conditions to form spirocycle 226 (Scheme 69); however, the yield was 
disappointing as 226 was isolated in only 30% yield. The exact explanation for the low yield 
is unclear: starting material 225 was fully consumed and no side products could be isolated. 
Significant decomposition of the starting material or product must therefore have occurred. 
 
Scheme 69 Dearomatising amination of substrate 225. 
To extend further the scope of naphthol systems, ortho-naphthol substrate 227 derived from 
2-naphthol was prepared. Substrate 227 was synthesised from alcohol 168 (which was prepared 
as described in section 2.2.2). Mitsunobu reaction of alcohol 168 with BocNHOTs followed 
by deprotection of the phenol hydroxyl group with 1:1 TBAF:AcOH completed the synthesis 
 
XXI This was prepared by Xiaofeng Ma (University of Bristol) and hence is not detailed in the experimental section. 




(Scheme 70a). With 227 in hand, it was subjected to the dearomatisation conditions and the 
spirocyclic product 228 was obtained in 78% yield (Scheme 70b). Unlike many of the previous 
examples described, spirocycle 228 proved sufficiently stable for isolation and characterisation 
as the free base without needing to be converted to the TFA salt.  
 
Scheme 70 (a) Synthesis of substrate 227. (b) Dearomatising amination of substrate 227. 
Alcohol 231 for the synthesis of 1-naphthol-derived substrate 232 was prepared following a 
reported procedure (Scheme 71a).91 Alkylation of 1-naphthol gave allyl ether 229 which upon 
heating underwent Claisen rearrangement to give 230 after TBS protection of the phenol. 230 
was then converted to alcohol 231 via a hydroboration-oxidation sequence. Mitsunobu 
reaction, followed by TBS deprotection afforded 232. For the dearomatisation reaction a small 
amount of CH2Cl2 was required as a co-solvent due to the poor solubility of substrate 232 in 
TFE. When subjected to these modified conditions spirocycle 233 was obtained in 38% yield 
(Scheme 71b).  
 
Scheme 71 (a) Synthesis of substrate 232. (b) Dearomatising amination of substrate 232. 




Substitution on the phenol ring was next investigated. Starting from 
7-methoxynaphthalen-2-ol, substrate 234 was synthesised using the same strategy as for the 
unsubstituted naphthol system 227. When subjected to the standard dearomatisation conditions, 
the dearomatised product 235 was generated in 76% yield (Scheme 72).  
 
Scheme 72 Synthesis and dearomatising amination of substrate 234. 
2.3.10 Dearomatising amination of naphthols with substitution α to nitrogen 
The effect of substitution adjacent to the nitrogen on the carbon tether for naphthol systems 
was next investigated. Substrate 236 was prepared using the same general approach as for the 
phenol equivalent (Scheme 73a). When substrate 236 was subjected to the dearomatising 
amination conditions spirocycle 237 was obtained in 54% yield (Scheme 73b). 237 was formed 
as an approximately 1.5:1 mixture of diastereomers indicating a lack of diastereocontrol in this 
reaction. The structure of 237 was confirmed by X-ray crystallography. In this case substitution 
α to nitrogen had a fairly negligible effect on the yield. 





Scheme 73 (a) Synthesis of substrate 236. (b) Dearomatising amination of substrate 236. 
2.3.11 Dearomatising amination of naphthols with substitution γ to nitrogen 
Next substitution γ to nitrogen was investigated for naphthol systems. As such, substrate 241 
containing a phenyl substituent in the γ-position was prepared (Scheme 74a). 2-Naphthol was 
alkylated with cinnamyl bromide to generate allyl ether 238 which upon heating, underwent 
Claisen rearrangement; this was followed by protection of the resulting phenol hydroxyl group 
to give allyl substituted naphthol 239. Alcohol 240 was then accessed via a 
hydroboration-oxidation strategy as used previously, and further transformed to substrate 241 
via Mitsunobu reaction. Under the conditions of the dearomatisation reaction, substrate 241 
cyclised to spirocycle 242 in 72% yield and as a 1:1 mixture of diastereomers (Scheme 74b).  





Scheme 74 (a) Synthesis of substrate 241. (b) Dearomatising amination of substrate 241. 
2.3.12 Attempted cyclisation to form 4-membered rings 
Having established that the dearomatisation reaction is effective for cyclisation to generate 
pyrrolidines, the synthesis of other ring sizes was investigated. If successful this would allow 
the preparation of other important classes of N-heterocycles such as azetidines and piperidines, 
the latter in particular are well represented in pharmaceuticals and natural products. Using the 
same general synthesis strategy as for the synthesis of 5-membered ring substrates, 
4-membered ring substrate 244 was generated in four steps from carboxylic acid 243 
(Scheme 75). When substrate 244 was subjected to the dearomatising amination conditions, 
azetidine 245 was not observed. Full consumption of starting material occurred, and no 
identifiable products were isolated from the reaction mixture. Cyclisation to form 4-membered 
rings is much slower than for 5-membered rings and as such it is possible that the substrate 
decomposes before cyclisation can occur.114 It is also possible that the azetidine product is 
formed but is too unstable due to the high ring strain and as such decomposes under the reaction 
conditions.  





Scheme 75 Synthesis and attempted dearomatising amination of substrate 244. 
2.3.13 Attempted cyclisation to form 6-membered rings 
Following the unsuccessful attempt to carry out cyclisations to form 4-membered rings, the 
analogous 6-exo cyclisation was investigated (Scheme 76). Due to the significantly reduced 
ring strain present in piperidine rings compared to azetidines this was expected to be a more 
feasible transformation; however, when substrate 246 was subjected to the amination reaction 
conditions, none of the desired dearomatised product 247 was observed and no significant 
products could be isolated following flash column chromatography. The piperidine product 
247 formed would not be expected to be unstable compared to the pyrrolidine equivalent, as 
such it is likely that the slower rate at which 6-membered rings form compared to 5-membered 
rings results in competing decomposition of the starting material before cyclisation can occur. 
 
Scheme 76 Synthesis and attempted dearomatising amination of substrate 246. 
 
 




2.3.14 Mechanistic investigations 
A proposed mechanism for C-N bond forming dearomatisation is presented in Scheme 77. The 
reaction begins with TFA-promoted Boc-deprotection of 177 which releases O-tosyl 
hydroxylammonium intermediate 248. This electrophilic nitrogen species then induces 
nucleophilic attack of the tethered arene nucleophile in an SEAr-type reaction with the release 
of TsOH. In this proposed mechanism the nitrogen of intermediate 248 is protonated during 
the C-N bond forming step as this alleviates electronic repulsion that would otherwise exist 
between the incoming arene nucleophile and the nitrogen lone pair of the hydroxylamine; 
however, it is also possible that the neutral species acts as the reactive intermediate. 
 
Scheme 77 Proposed mechanism for the dearomatising amination reaction. 
Although there appears to be no direct precedent for this type of nucleophilic attack of an arene 
onto an electrophilic N(sp3)-centre, a related mechanism involving attack onto a C(sp3)-centre 
has been invoked in C-C bond forming dearomatisations. Both Winstein and Baird115 and 
Masamune116 have reported base-promoted dearomatisations of phenol derivatives in which an 
intramolecular nucleophilic attack of a phenol onto an C(sp3)-sulfonate is invoked 
(Scheme 78a). In addition, intramolecular nucleophilic substitution at an N(sp3)-centre of 
hydroxylamines derivatives 249 has been reported by Sheradsky and Yusupova for the 
synthesis of pyrrolidines 250 (Scheme 78b).117 This transformation involves generation of an 
enolate which subsequently undergoes intramolecular cyclisation onto the nitrogen of a 
tethered N-diphenylphosphinyloxy derivative with expulsion of diphenylphosphinate. 





Scheme 78 (a) Dearomatisation via SEAr-type attack on C-(sp
3) centres.115,116 (b) Intramolecular 
nucleophilic substitution at N-(sp3) centre of hydroxylamine derivatives.117 
To gain more insight into the reaction mechanism, substrate 251 containing a methyl carbamate 
group was prepared (Scheme 79). The methyl carbamate of substrate 251 possesses similar 
electronic properties to the tert-butyl carbamate but is not cleaved under acidic conditions. 
When 251 was subjected to the reaction conditions, cyclisation to 252 did not occur and the 
starting material was recovered unchanged. This result implies that the mechanism proceeds 
via formation of an N-H hydroxylamine intermediate in which Boc deprotection occurs prior 
to the cyclisation event. 
 
Scheme 79 Attempted dearomatising amination of N-methylcarbamate 251. 
Based on the precedent for many traditional C-N bond forming dearomatisation reactions of 
substrates containing N-O bonds to proceed via formation of a nitrenium ion, reaction via 
nitrenium ion intermediate 253 is an alternative possibility (Scheme 80a). Classical approaches 
towards intramolecular electrophilic aryl C-H amination and C-N bond forming 
dearomatisation reported by Kikugawa,61,63,65,73,109 Glover62,64 and others71,110 invoke the 
intermediacy of nitrenium ions. However, in these examples stabilised nitrenium ions such as 




N-alkoxy-N-acylnitrenium ions or N-phthalimido-N-acylnitrenium ions are generated in which 
the nitrenium ion is stabilised by delocalisation of the positive charge onto the neighbouring 
alkoxy or Nphth group (Scheme 80b). Moreover, the presence of a carbonyl group adjacent to 
the nitrenium ion is required; this is likely to prevent elimination. 
 
Scheme 80 (a) Possible mechanism for the formation of 178 via an alkylnitrenium ion. (b) Classical 
electrophilic dearomatising aminations that invoke stabilised N-alkoxynitrenium ions. 
On the other hand, efficient cyclisations of unstabilised nitrenium ions are unknown. In 
circumstances where unstabilised nitrenium ions have been invoked they typically undergo 
isomerisation such as 1,2-alkyl or -hydride shifts.118-120,XXII Therefore, although dearomative 
cyclisation via formation of an alkylnitrenium ion cannot be definitively ruled out, this option 
is unlikely because such species would not be sufficiently stable and long-lived to undergo 
efficient cyclisation with the pendent arene.XXIII 
Another mechanistic possibility is that the reaction proceeds through a radical-based pathway. 
This would involve homolytic cleavage of the N-O bond to generate protonated aminyl radical 
254, followed by radical cyclisation with the pendent arene (Scheme 81a). In this case, reaction 
would likely occur through a protonated aminyl radical as these are known to be more reactive 
than the corresponding neutral aminyl radical.124 Intramolecular cyclisations of aminyl radicals 
onto aromatic rings have been previously invoked; however, in these cases the aminyl radicals 
are generated from N-chloroamines and require photochemical or strongly acidic conditions 
(Scheme 81b).125,126  
 
XXII The intermediacy of unstabilised nitrenium ions in these transformations is a source of debate.121,122 
XXIII An extensive computational study into the stability of nitrenium ions, including alkylnitrenium ions has been 
carried out by Falvey.123 





Scheme 81 (a) Potential dearomatisation via a radical pathway. (b) Intramolecular cyclisation of an 
aminyl radical.125,126 
To rule out a radical pathway, a series of experiments was conducted. When the 
dearomatisation of 177 was performed in the presence of 2,2,6,6-tetramethyl-1-piperidinyloxy 
(TEMPO), no TEMPO trapped product was observed. The addition of either TEMPO or BHT 
did have an inhibitory effect on the reaction, resulting in lower conversion of starting material; 
however, this was largely negated using slightly elevated temperatures (Table 6, entries 2-6). 
Moreover, when the dearomatisation of 177 was performed in the absence of light spirocycle 
178 was still generated in 78% yield, excluding the possibility of light-initiated N-O bond 
homolysis.XXIV 
 
Table 6 Dearomatising amination reaction of 177 in the presence of BHT or TEMPO. Yields were 
determined by 1H NMR analysis of the crude reaction mixture versus 1,3,5-trimethoxybenzene as an 
internal standard. 
 
XXIV Computation results presented in Chapter 3 suggest that N-O bond homolysis under these reaction conditions 
is disfavoured on energetic grounds. 




To investigate further the possibility of the reaction proceeding via formation of an N-centred 
radical, alkenyl system 255 was prepared (Scheme 82a). It is well-established that aminyl 
radicals will undergo fast 5-exo cyclisation onto alkenes,127 this would generate pyrrolidine 
256. When 255 was subjected to the reaction conditions with and without the addition of the 
hydrogen atom donor, 1,4-cyclohexadiene (CHD), pyrrolidine 256 was not observed.  
 
Scheme 82 (a) Potential 5-exo cyclisation of an aminyl radical intermediate. (b) Attempted radical 
cyclisation of substrate 255. 
Due to the lack of precedence for efficient cyclisations of unstabilised nitrenium ions, and with 
mechanistic work providing no clear evidence of a radical cyclisation, an SEAr-like mechanism 
as shown in scheme 77, involving direct SN2 attack of the arene nucleophile on an activated 
hydroxylammonium, is favoured at this current time. 
2.3.15 Aza-dienone phenol rearrangement 
During optimisation, it was shown that the dearomative cyclisation can be performed using 
fewer equivalents of TFA, although a higher temperature was used to increase the rate of 
reaction. Using TFA (15 mol%) in TFE (0.07 M) at 60 oC, 177 cyclised to spirocycle 178 in 
79% yield (Scheme 83a). When these conditions were applied to tosyloxycarbamate 213, 
spirocycle 214 was not observed and instead tetrahydroquinoline 257 was generated in 77% 
yield (Scheme 83b). Analysis of the product using nOe analysis confirmed the structure of 257 
in which skeletal rearrangement has occurred. As such, unlike the tetrahydroquinoline side 
products observed with other systems (section 2.3.5) which were generated via direct aryl-CH 




amination, this reaction must proceed via a mechanistically distinct pathway involving skeletal 
rearrangement.  
 
Scheme 83 (a) Dearomatising amination of substrate 177 using a catalytic amount of TFA. (b) 
Observation of tetrahydroquinoline 257 in the dearomatising amination reaction of substrate 213. 
The formation of 257 likely proceeds via initial spirocyclisation to 214 which then undergoes 
a thermally promoted aza-dienone-phenol rearrangement to tetrahydroquinoline 257 
(Scheme 84). Migration of the C-C bond is favoured over migration of the C-N bond as the 
carbocation formed is stabilised through resonance with the lone pair of the adjacent nitrogen. 
As a result of the lower equivalents of acid, the amine is not fully protonated and so can use its 
lone pair to assist C-C bond migration. This rationalises why no dienone-phenol rearrangement 
was observed for reaction of 213 under standard conditions (200 mol% TFA at room 
temperature). The presence of the ethyl substituent in this substrate is also key to observing 
this reaction pathway as no dienone-phenol rearrangement was observed for 
tosyloxycarbamate 177 under the same reaction conditions. This can be rationalised due to the 
increased migratory aptitude of the migrating C-C bond as a result of the +I inductive effect of 
the ethyl substituent.  
 





Scheme 84 Proposed formation of tetrahydroquinoline 257 by a dienone-phenol rearrangement. 
2.3.16 Annulative derivatisations of the spirocyclic pyrrolidine products 
The spirocyclic pyrrolidine products generated from the dearomatising cyclisations described 
thus far provide many opportunities for further functionalisation. One obvious avenue for 
derivatisation was to exploit 1,4-addition addition of nucleophiles onto one of the 
diastereotopic alkenes of the cyclohexadienone ring of 178. This approach would enable the 
creation of a tetrasubstituted nitrogen-bearing stereogenic carbon centre. Such carbon centres 
are generally difficult to access in a stereoselective manner. Through protection of the 
pyrrolidine nitrogen with appropriate functionality which can then acts as a nucleophile it was 
considered feasible to access tricyclic ring systems containing a nitrogen-bearing spirocyclic 
carbon centre (Scheme 85a). Related structural motifs are present in a number of alkaloid 
natural products including cylindricine C,128,129 polycitorol A130 and lepadiformine.2,131-133 The 
functionalisation of spirocyclic pyrrolidines similar to those presented in this chapter have been 
studied by Ciufolini and co-workers as a key step in the synthesis of cyclindricine C.134 The 
authors demonstrated that treatment of N-mesyl protected spirocycle 258, which was prepared 
by oxidative amination, with KHMDS at -100 oC generated tricycle compound 260 as a 7:1 
mixture of diastereomers (Scheme 85b). The diastereoselectivity observed in the cyclisation 
was rationalised by the steric demands of the O-protecting group favouring reaction via 259a 
over the alternative conformer 259b in which it clashes with the N-sulfonyl group. 





Scheme 85 (a) Strategy for annulative derivatisations. (b) Derivatisation of spirocyclohexadienones 
through intramolecular 1,4-addition.134 
To investigate derivatisations of the spirocyclohexadienones generated by dearomatisation of 
N-tosyloxycarbamtes, 214 was acylated using phenylacetylchloride (Scheme 86). It was 
envisaged that upon addition of an appropriate base this would set up a 1,4-addition onto the 
dienone ring via formation of an enolate. The TFA salt of spirocycle 214 was reacted with 
phenylacetyl chloride (120 mol%) in the presence of Et3N (400 mol%) at 0 
oC to generate 
amide 261 in 22% yield. Further increasing the equivalents of phenylacetyl chloride to 
400 mol% effected a slight increase in yield to 33% but any further increase of this reagent had 
a negligible effect. After further optimisation, it was identified that K3PO4 (400 mol%) in THF 
at 0 oC to room temperature enabled the efficient synthesis of amide 261 in 79% yield.  





Scheme 86 Optimisation of the acylation of spirocycle 214. 
Pleasingly when exposed to LHMDS (150 mol%) amide 261 underwent cyclisation to generate 
tricyclic amide 262 in 56% yield and 3:1 d.r. (Scheme 87). The reaction proceeds via formation 
of a lithium enolate which then undergoes conjugate addition onto one of the double bonds of 
the dienone. The relative stereochemistry of the major diastereomer was confirmed by X-ray 
crystallography whilst that of the minor diastereomer was assigned using nOe analysis. 262 
contains 4 contiguous stereocentres, 3 of which are formed with high diastereocontrol during 
the conjugate addition step. Control of the stereochemistry of the benzylic carbon centre is 
likely a result of epimerisation of the relatively acidic C3 proton to give the more 
thermodynamically stable isomer. 
 
Scheme 87 Synthesis of 262 by intramolecular 1,4-addition of 261. The stereochemistry of the minor 
diastereomer of 262  was determined by nOe. 




The same transformation was also performed with spirocycle 178 (Scheme 88). Following 
acylation, the lithium enolate of 263 cyclised efficiently to give tricycle 264 in 67% yield and 
as a single diastereomer.  
 
Scheme 88 Synthesis of tricycle 264 from spirocycle 178. 
Using a similar approach, the generation of tricyclic ureas were also explored. When spirocycle 
214 was reacted with benzyl isocyanate (200 mol%) and Et3N (400 mol%) in CH2Cl2 urea 265 
was generated in 59% yield (Scheme 89). Treatment with LHMDS then promoted 
intramolecular 1,4-addition of the urea NH onto the enone to give N-benzyl protected tricycle 
266 in 93% yield and 3:1 d.r. Spirocycle 214 was also acylated with phenyl isocyanate. In this 
case the increased acidity of the N-phenyl urea versus the N-benzyl urea meant that Et3N was 
sufficient to effect cyclisation, and tricycle 267 was generated in 75% yield and 4:1 d.r. directly 
from spirocycle 214. 
 
Scheme 89 Synthesis of tricyclic ureas by annulative derivatisations of 214. 
Similar derivatisation processes were also carried out on ortho-cyclised spirocycle 222 
(Scheme 90). Following the dearomatisation reaction the crude reaction mixture containing 
spirocycle 222 was treated with phenylacetyl chloride using the optimised reaction conditions 
to generate amide 268 in 81% yield. When 268 was reacted with LHMDS, 1,2-addition onto 
the carbonyl of the dienone was observed to give tricycle 269 in 67% yield (Scheme 90a). The 




structure and relative stereochemistry were confirmed by single crystal X-ray diffraction. In 
contrast, when spirocycle 222 was treated with phenyl isocyanate, 1,6-addition occurred to 
afford tricycle 270 as a single diastereomer (Scheme 90b).  
 
Scheme 90 (a) Synthesis of tricycle 269 from spirocycle 222. (b) Synthesis of tricyclic urea 270 from 
spirocycle 222. 
2.4 Base-promoted dearomatising amination reaction 
The contents of this section have been communicated: Ma, X.; Farndon, J, J.; Young, T.; Fey, 
N.; Bower, J. F.; Angew. Chem. Int. Ed. 2017, 56, 14531-14535. Parts of this section have been 
reproduced from this publication. 
The results in this section were obtained by Xiaofeng Ma and hence are not detailed in the 
experimental section. 
2.4.1 Initial results 
In tandem with the development of the acid-promoted dearomatising amination of phenols and 
naphthols presented so far in this chapter, other classes of dearomatising aminations were also 
investigated. To this end, a base-promoted, metal-free C-N bond forming dearomatisation of 
indoles was developed. It was discovered by Xiaofeng Ma that sulfonamide 144, which was 
prepared via Mitsunobu alkylation of TsNHOFBz with alcohol 143, could undergo C-N bond 
forming dearomatisation under mild, basic conditions [K2HPO4 (15 mol%) in n-BuCN at 
140 oC] to provide spirocycle 271 in 44% yield (Scheme 91). To improve the efficiency of this 




process OTs substrate 272 was prepared. Following optimisation of the reaction conditions the 
desired dearomative transformation was achieved using a milder set of reaction conditions 
[K2CO3 (200 mol%) in TFE at 80 
oC] to generate spirocycle 271 in 75% yield. The milder 
conditions possible for the OTs substrate 272 can be rationalised by the leaving group ability 
of pentafluorobenzoate versus tosylate (pKa values in H2O at 25 
oC: FBzOH 1.75, TsOH 0.7).135 
TsOH is over 10 times more acidic than that of FBzOH reflecting the higher stability of the 
tosylate anion, which makes reaction of 272 relatively more facile. As this reaction proceeds 
under basic conditions it represents a complementary approach to the dearomatisation reaction 
presented previously in this chapter, and in this approach the protecting group on nitrogen is 
retained. Whilst C-N bond forming dearomatisations of indoles to provide spirocyclic 
pyrrolidines of this type have not previously been reported, Nishikawa and Isobe have reported 
a related dearomatisation of indoles to form spirocyclic-β-lactams using O-sulfonyl-
hydroxylamine derivatives.136 
 
Scheme 91 Base-promoted dearomatising amination of indole substrates 144 and 272. 
2.4.2 Scope of the N-protecting groupXXV 
The dearomative aminations of indole substrates containing a wide range of N-protecting 
groups were examined (Scheme 92). These were all prepared by Mitsunobu alkylation of the 
corresponding amino reagent with alcohol 143. In general, both the OFBz and OTs substrates 
were prepared and examined using the optimised conditions developed for each class of 
substrate. The reaction demonstrated good protecting group tolerance. In addition to 
sulfonamide based systems, including N-Mbs (Mbs = p-methoxybenzenesulfonyl) system 
273a, a variety of carbamate-based systems were also effective. By this approach spirocyclic 
 
XXV The results in this section were carried out by Xiaofeng Ma (University of Bristol). 




products 273b-e containing benzyl, methyl, tert-butyl and allylcarbamates could also be 
accessed relatively efficiently. The higher reactivity of OTs systems was generally reflected in 
higher yields, with the exception of N-Cbz system 273b where cyclisation of the OFBz 
precursor was more efficient. The explanation for the higher efficiency of the OFBz system in 
this case is unclear; however, in general OFBz precursors were more stable than the OTs 
counterparts. 
 
Scheme 92 Scope of protecting group in the base promoted dearomatising amination of indoles. 
2.4.3 Scope of base-promoted dearomatisation of indolesXXVI 
Following on from investigating the scope of the protecting group, the scope of the indole part 
was evaluated. A variety of substrates with substitution on the indole ring underwent 
dearomatisation to provide spirocycles 274a-h in excellent yields (Scheme 93). The reaction 
tolerates a variety of both electron-donating and electron-withdrawing groups although in the 
case of electron-withdrawing halogen-substituted systems 274c-f lower yields were generally 
observed. 
 
XXVI The results in this section were carried out by Xiaofeng Ma (University of Bristol). 





Scheme 93 Scope of substitution on the indole ring in the base-promoted dearomatising reaction. 
Substitution on the pyrrolidine ring was also investigated (Scheme 94). Modest 
diastereocontrol was observed for system 275a with a C3-substituted methyl group; however, 
high levels of diastereocontrol were observed for systems with a methyl group in the C2 or C4 
positions, 275b and 275c.  As expected, improved levels of diastereocontrol were observed for 
systems 275d and 275e with bulkier substituents on the pyrrolidine ring.  
 
Scheme 94 Scope of substitution on the pyrrolidine ring in the dearomatising amination reaction. 




2.4.5 Scope of base-promoted dearomatisation of phenols and naphtholsXXVII 
The scope of this base-promoted dearomatisation reaction was then extended to the cyclisation 
of para-phenols and para-naphthols (Scheme 95). N-Boc-protected systems 276a-e were 
accessed in excellent yields. In addition, the base-promoted dearomatising amination 
conditions were also successfully applied to the reaction of ortho-phenols and ortho-naphthols 
(Scheme 96, 277a-c). In general, these conditions could be applied to a wide variety of 
functionalised phenols and naphthols with similarly levels of efficiency observed in most cases. 
 
Scheme 95 Scope of base-promoted dearomatising amination of para-phenols and para-naphthols. 
aThe reaction was carried out at 60 oC. 
 
Scheme 96 Scope of base-promoted dearomatising amination of ortho-phenols and ortho-naphthols. 
aThe reaction was carried out at 60 oC. 
 
 
XXVII The results in this section were carried out by Xiaofeng Ma (University of Bristol). 




2.4.6 Derivatisations of the dearomatisation productsXXVIII 
A number of derivatisations of the dearomatised products were carried out (Scheme 97). 
Reduction of the imine moiety of 275e with NaBH4 occurred smoothly to afford indoline 278 
in quantitative yield. In addition, imine 275e was alkylated with allyl-Grignard reagent to 
provide 279 in 78% yield and 6:1 d.r. with addition occurring primarily from the face opposite 
to the N-Boc group. Conjugate addition of vinyl-cuprate reagent to 276e also occurred 
diastereoselectively to afford 280 in 77% yield and 5:1 d.r. 
 
Scheme 97 Derivatisations of the dearomatisation products. 
2.4.7 Mechanistic studiesXXIX 
Based on a series of computational and practical experiments, a proposed mechanism for this 
reaction is presented in Scheme 98. The proposed mechanism is very similar to that of the 
acid-promoted reaction, in that dearomative cyclisation occurs by direct nucleophilic attack of 
the arene onto the electrophilic nitrogen centre in an SN2-like manner. However, in this case, 
the mild base present (K2CO3 or K2HPO4) likely increases the nucleophilicity of the aromatic 
unit by deprotonation either prior to or during the dearomatisation process. In the absence of 
base minimal conversion is observed, whilst hindered organic bases such as 
2,6-di-tert-butylpyridine are ineffective. This suggests that the base is not merely required to 
sequester the TsOH or FBzOH by-products and is likely required to increase the nucleophilicity 
 
XXVIII The results in this section were carried out by Xiaofeng Ma (University of Bristol). 
XXIX The results in this section were carried out by Xiaofeng Ma (University of Bristol). 




of the arene. For the OFBz systems catalytic quantities of base can be used as the 
pentafluorobenzoate leaving group undergoes facile protodecarboxylation to afford 
pentafluorobenzene and CO2 with regeneration of the base.
137,XXX  
 
Scheme 98 Proposed mechanism for the base-promoted dearomatising amination reaction. 
As with the acid-promoted dearomative amination reaction, a series of experiments were 
performed to rule out the potential of dearomatisation via a radical-based pathway 
(Scheme 99a,b). The cyclisation of 281 was not affected by the presence of TEMPO or BHT 
and the dearomatisation product 273b was obtained in comparable yields to the reaction 
without the addition of either additive (Scheme 99a). In addition, the behaviour of alkenyl 
systems 282 and 283 was examined; however, when 282 and 283 were subjected to the 
optimised dearomatisation conditions (in the presence or absence of 1,4-cyclohexadiene) 
pyrrolidine 284 was not observed (Scheme 99b). This implies that an aminyl radical 
intermediate is not generated as this would be expected to undergo 5-exo cyclisation onto the 
pendent alkene.127 
To further support the proposed mechanism a cross-over experiment was performed in which 
substrate 285 was subjected to the dearomatisation conditions in the presence of NH carbamate 
286 (Scheme 99c). Dearomative cyclisation of 285 was observed in a similar yield to the 
reaction without 286 whilst 273d, the product of cyclisation of 286 was not observed. This 
confirms that the N-O bond acts as an internal oxidant during the reaction and is not effective 
as an external oxidant.  
 
 
XXX The presence of pentafluorobenzene was confirmed by GCMS analysis of the crude reaction mixture. 





Scheme 99 (a) Base-promoted dearomatising amination of substrate 281 in the presence of TEMPO 
or BHT. (b) Attempted radical cyclisation of substrates 282 and 283. (c) Base-promoted 
dearomatising amination of substrate 285 in the presence of 286. 
Density functional theory (DFT) calculations were also performed to assess the viability of the 
proposed SN2-like mechanism.
XXXI For the purposes of the study the calculations were 
performed using tosyloxycarbamate substrate 251 which experimentally undergoes efficient 
dearomative cyclisation to 252 in 93% yield (Scheme 100a). When the dearomatisation of 251 
was modelled for an SN2-like mechanism, the predicted free energy barrier (ΔG
‡
solv) is 
25.1 kcal mol-1 (Scheme 100b). The magnitude of this energy barrier is consistent with the 
reaction time required for complete conversion under the reaction conditions.   
 
XXXI Computational studies were carried out by Tom Young with guidance from Dr Natalie Fey (University of 
Bristol). 
 





Scheme 100 (a) Base-promoted dearomatising amination of N-methylcarbamate 251. (b) Reaction 
profile for the proposed SN2 mechanism. 
2.5 Studies towards an enantioselective dearomatising amination 
reaction 
2.5.1 Introduction 
The dearomatising amination reactions discussed so far allow access to complex 
N-heterocycles. Due to the importance of nitrogen heterocycles in nature particularly those 
with defined stereocentres adjacent to nitrogen, enantioselective dearomatising amination 
reactions are highly desirable and so the development of an asymmetric reaction was 
investigated. 
 





Scheme 101 (a) Proposed enantioselective dearomatising amination of naphthols. (b) Natural 
products and therapeutic agents containing α-amino,β-naphthalenone core. 
The enantioselective ortho-dearomative amination of naphthols was investigated as this would 
enable the formation of α-amino,β-naphthalenone structures containing a tetrasubstituted 
stereogenic centre (Scheme 101a). These types of motifs are important components of many 
biologically active natural products and therapeutic agents, including a hepatitis C virus 
polymerase inhibitor (Scheme 101b).138 Also despite the importance of this motif only a few 
examples of asymmetric aminative dearomatisations to access these structures have been 
reported. These approaches typically employ azodicarboxylates as a source of electrophilic 
nitrogen which are activated by either Brønsted or Lewis acids (Scheme 102). You and 
co-workers reported an asymmetric dearomatising amination reaction of β-naphthols using 
chiral phosphoric acids as catalysts.139 The reaction could be performed with loadings as low 
as 0.1 mol% and e.e’s up to 96% were achieved using (R)-SPINOL-derived phosphoric acid 
287. Enantioselective dearomatising aminations of naphthols using azodicarboxylates were 
also reported by the Luan group.140 A catalyst system comprising of Sc(OTf)3 and a chiral 
pybox ligand 288 (Scheme 102) allowed for the generation of α-substituted 2-naphthols with 
excellent enantioselectivities of up to 98%. A related process was also developed by Feng and 
co-workers using a combination of Sc(OTf)3 and a chiral N,N-dioxide ligand 289 to affect the 
dearomative amination of naphthols with high levels of enantioselectivity (Scheme 102).141 
 





Scheme 102 Previous examples of enantioselective dearomatising amination of β-naphthols using 
azodicarboxylates.139-141 
For the development of an enantioselective dearomatisation reaction of naphthols, the use of 
Cinchona alkaloid-derived phase transfer catalysts (PTC) was investigated. These quaternary 
ammonium salts were first employed as chiral phase transfer catalysts by the Merck research 
group in 1984 (Scheme 103a). Using N-p-trifluoromethylbenzylcinchonium bromide 290 as 
catalyst enantioselective methylation of phenylindanone was achieved to generate the product 
291 in 92% e.e.142 Similar Cinchona-derived phase transfer catalysts were used by O’Donnell 
and co-workers for the enantioselective alkylation of N-(diphenylmethylene)glycine tert-butyl 
ester 292.143-145 The resulting alkylated product 293 was then hydrolysed to allow access to the 
corresponding amino acid. The origin of enantioselectivity in this reaction can be explained as 
shown in Scheme 103b by thinking of the quaternary ammonium salt 294 as an imaginary 
tetrahedron composed of the four carbons attached to the quaternary nitrogen. The enolate of 
292 forms an ionic complex with the ammonium cation of the PTC. However, the cinchona 
PTC provides steric shielding that inhibits the approach of the enolate to three faces of the 
tetrahedron leaving only one face open to form the ionic complex. Once the ionic complex is 
formed, one face of the enolate is blocked by the quinoline ring of the PTC forcing the PhCH2Br 
electrophile to approach from the other face leading to high enantioselectivity. The commercial 




availability and relatively low cost of many of these Cinchona PTC make them attractive 
catalysts for developing a variety of asymmetric reactions.  
Cinchona alkaloids have been reported as effective catalysts for the enantioselective 
α-amination of carbonyl compounds,146-149 whilst there have been several examples reported 
of their use in enantioselective alkylative and aminative dearomatisations.150-152 As such, the 
use of Cinchona PTC to achieve an enantioselective dearomatising amination reaction was 
envisaged to be a feasible route to explore. XXXII 
Scheme 103 (a) Enantioselective methylation of phenylindanone using Cinchona-derived 
PTC.142(b) Enantioselective alkylation using Cinchona-derived PTC.143-145 
2.5.2 Preliminary results 
To examine the potential for an enantioselective dearomatising amination reaction, N-Boc 
protected naphthol 227 was investigated with five different commercially available Cinchona 
alkaloid-derived chiral phase transfer catalysts (Scheme 104). Using Cs2CO3 (200 mol%) in 
PhMe at 30 oC only minor enantioselectivity was observed in most cases with 295 producing 
the highest level of asymmetric induction to afford 277b in 22% e.e. In contrast, for 290 no 
enantioselectivity was observed. The reactions were run at a lower temperature of 30 oC (versus 
 
XXXII Four common Cinchona alkaloid-derived catalysts were examined by Luan; however, only minor 
enantioselectivity was observed.140 




the optimised conditions developed for the racemic base-promoted dearomatisation reaction) 
with the view that this would lead to improved enantioselectivity. However, as a result, the 
conversion to product was quite low which is reflected in the generally low yields achieved 
even after performing the reactions for 48 hours.  
  
Scheme 104 Enantioselective dearomatising amination of substrate 227. 
To explore this enantioselective reaction further, the choice of N-protecting group was 
examined. N-Cbz protected naphthol 299 was prepared in the same manner as for the N-Boc 
substrate with the rationale that the slightly larger protecting group (Cbz versus Boc) may 
translate into higher levels of enantioselectivity. 299 was then examined using the same five 
chiral phase transfer catalysts (Scheme 105). Under the same reaction conditions, the N-Cbz 
naphthol proved more reactive resulting in higher yields of dearomatised product 170. This 
also coincided with generally much higher levels of enantioselectivity. The best result was 
obtained with 298 which gave the spirocyclic product in 62% yield and 54% e.e. This result 
shows that enantioselective dearomatising amination of naphthols using phase transfer 
catalysts is feasible and with further optimisation satisfactory levels of enantioselectivity might 




be obtainable. Unfortunately, due to time constraints further optimisation of this 
enantioselective dearomatisation could not be carried out; however, additional investigations 
into this project will likely be carried out by other members of the group. 
  
Scheme 105 Enantioselective dearomatising amination of substrate 299. 
2.6 Conclusions 
The development of transition metal-free dearomative C-N bond forming cyclisations of 
hydroxylamines for the synthesis of spirocyclic pyrrolidines has been discussed. Under acidic 
conditions, in situ deprotection of OTs activated N-Boc hydroxylamines generates a potent 
electrophilic aminating agent for the dearomative amination of phenols and naphthols. This 
approach provides a metal-free alternative to metal-nitrenoid-promoted amination reactions. In 
a complementary approach, mild, basic conditions were also shown to be effective for C-N 
bond forming dearomatisation of the same OTs activated hydroxylamines as well as OFBz 
activated hydroxylamines. This protocol offers unprecedented scope versus traditional 
dearomatising amination approaches, encompassing indoles, phenols and naphthols as the 
nucleophile as well as tolerating a range of N-protecting groups. Another benefit over many 




traditional approaches is the lack of requirement for oxidising conditions as the N-O bond acts 
as a mild internal oxidant which avoids any competing oxidation processes involving the arene. 
The spirocyclic pyrrolidine products presented in this Chapter are recognised as privileged 
scaffolds in drug discovery and are commonly found in the core structures of many natural 
products, such as cyclindricine C128,129 and lepadiformine.2,131-133 Preliminary studies towards 
an enantioselective dearomatising amination of β-naphthols using Cinchona alkaloid-derived 
chiral phase transfer catalysts were carried out, and moderate levels of enantioselectivity were 
obtained.  




Chapter 3 - Alkene aziridinations of N-Boc 
hydroxylamines 
The contents of this chapter have been communicated: Farndon, J. J.; Young, T. A.; Bower, J. 
F.; J. Am. Chem. Soc. 2018, 140, 17846-17850. Parts of this chapter have been reproduced 
from this publication. 
3.1 Introduction 
Following the successful development of a dearomatising amination reaction involving 
N-tosyloxycarbamates under mild, metal-free conditions, it became clear that other classes of 
C-N bond forming reaction that utilised electrophilic nitrogen sources may be amenable to this 
approach. As similar N-O donors have been effectively applied in alkene aziridination 
reactions, this area was deemed worthy of investigation. Before presenting the studies in this 
chapter related to the development of an alkene aziridination reaction of N-Boc 
hydroxylamines; it is pertinent to give a brief survey of the chemical literature relating to alkene 
aziridinations; in particular, methods that involve the addition of nitrenes or metal-nitrenoids 
to alkenes will be discussed.  
In 1967 Kwart and Khan reported the first metal-catalysed nitrogen atom transfer process for 
the synthesis of aziridines (Scheme 106).153 When heated with copper powder in cyclohexene 
the authors observed the decomposition of benzenesulfonyl azide. Amongst the decomposition 
products obtained was aziridine 300 which was proposed to form via addition of a nitrene or 
nitrenoid intermediate to cyclohexene.  
 
Scheme 106 Copper powder-promoted alkene aziridination of benzenesulfonyl azide.153 
Since this initial report, metal-catalysed addition of nitrenes to alkenes has become one of the 
most common approaches to the synthesis of aziridines. A variety of nitrene sources have been 
utilised in such reactions include aryl azides, sulfonyl azides, halo amines, imino iodinanes, 




and tosyloxycarbamates. In addition, a variety of transition-metal catalysts, usually in 
combination with ligands such as porphyrins, bis(oxazolines) and diimines, have been 
reported.154 A general mechanism for metal nitrene-promoted aziridination is shown in 
Scheme 107. Whilst there remains some uncertainties in the mechanism, it is generally believed 
that aziridination can proceed via a singlet or triplet nitrene (301a and 301b respectively) and 
that reaction via a singlet nitrene species occurs stereospecifically, with retention of the 
alkene’s stereochemistry, whilst triplet species do not react stereospecifically.XXXIII It should 
be noted, however, that experiments on the stereospecificity of aziridinations are often 
substrate dependent.154 
 
Scheme 107 Proposed mechanistic pathways for metal nitrene-mediated aziridination.155 
One of the most widely used nitrene sources for alkene aziridination are 
sulfonyliminoiodinanes, such as N-(p-tolylsulfonyl)imino)phenyliodinane (PhI=NTs). These 
reactive nitrogen sources are easily generated from the corresponding sulfonyl amides. In a 
series of reports by Mansuy and co-workers, iron(II) or manganese(II)-porphyrin complexes 
were employed to catalyse the transfer of nitrogen to alkenes using PhI=NTs.156,157 Many other 
groups have subsequently reported transition metal-catalysed aziridinations of alkenes using 
PhI=NTs as a nitrene precursor. In 1991 Evans reported that low valent copper catalysts could 
promote aziridinations of styrenes and aliphatic alkenes.158,159 The use of CuOTf in 
combination with chiral 4,4’-disubstituted bis(oxazolines) ligand 302 enabled the first 
asymmetric copper-catalysed nitrene transfer to alkenes to generate N-tosyl aziridines in up to 
97 % e.e. (Scheme 108a).160 A related asymmetric copper(I)-catalysed aziridination was 
reported by Jacobsen and co-workers using chiral diamine-based ligand 303 (Scheme 108b).161 
Poor enantioselectivity was achieved using trans-alkenes; however, cis-alkenes were generally 
 
XXXIIIA recent report on the stereospecific aziridination of alkenes was proposed to proceed via a triplet 
copper-nitrene intermediate.155  




more effective substrates. Stereospecific aziridination of 6-cyano-2,2-dimethylchromene 304 
was achieved to afford aziridine 305 in >98% e.e. Investigation into the mechanism of 
(diimine)copper(I)-catalysed aziridination provided evidence to support reaction via a discrete 
copper(III)-nitrene intermediate 306.162 Copper-catalysed aziridinations of alkenes have also 
been  reported by Andersson using p-NO2C6H4SO2N=IPh (PhI=NNs) as the nitrene source.
163 
As well as being a more efficient for alkene aziridination than the more commonly used nitrene 
source, PhI=NTs, the p-nitroarylsulfonamide products can be cleaved more easily to the NH 
products than the corresponding p-tosylsulfonamides.  
 
Scheme 108 (a) Enantioselective copper-catalysed aziridination of alkenes using bis(oxazolines) 
ligand 302.160 (b) Enantioselective copper-catalysed alkene aziridination using diimine ligand 
303.161,162 
A number of other groups have reported metal-catalysed alkene aziridinations using a variety 
of transition metals including manganese,164,165 silver,166 or ruthenium.167 Müller and 
co-workers demonstrated that Rh2(OAc)4 can effectively promote the aziridination of alkenes 
using PhI=NNs as the nitrene source.168,169 The reaction proceeds stereospecifically with alkyl-




substituted alkenes; however, loss of stereospecificity was observed with aryl-disubstituted 
alkenes. 
The previous examples utilise iminoiodinanes as nitrene sources; however, other aziridination 
protocols have since been developed in which the nitrene source is generated in situ by 
oxidation of amine derivatives such as sulfonamides or sulfamates with hypervalent iodine 
reagents. In 2002 Che and co-workers reported a rhodium(II)-catalysed intramolecular 
aziridination of unsaturated sulfonamides 307 using PhI(OAc)2 as the oxidant (Scheme 109).
170 
The corresponding bicyclic aziridine products 308 were obtained in generally excellent yields. 
An asymmetric variant of the reaction was later developed, using a chiral 
dirhodium(II)-complex 309 to afford the aziridine products with good levels of 
enantioselectivity (up to 76%).171  
 
Scheme 109 Rhodium-catalysed intramolecular aziridination of sulfonamides.170,171 
Du Bois and co-workers demonstrated the use of sulfamate esters as nitrogen donors in the 
aziridination of alkenes.172 In the presence of Rh2(oct)4 and PhI(OAc)2 as the oxidant, highly 
diastereoselective intramolecular aziridinations of alkenes 310 were achieved and a variety of 
bicyclic sulfamate esters 312 were obtained in good to excellent yields (Scheme 110). XXXIV 
The observed stereoselectivity is consistent with the reaction proceeding through a chair-like 
transition state 311 that minimises gauche and A1,3-type interactions.  
 
XXXIV The aziridination is stereospecific with respect to the alkene geometry. 





Scheme 110 Intramolecular alkene aziridination using sulfamate esters.172  
This approach was also applied in an intermolecular process. Aziridination of a variety of 
alkenes to the corresponding aziridines 314a-d was achieved using a trichloroethoxysulfonyl 
(Tces) protected amine 313 which can be cleavage under mild reductive conditions (e.g. Zn).173 
Aziridination occurs stereospecifically as demonstrated by cis- and trans-β-methylstyrene 
which underwent aziridination to afford aziridines 314a and 314b respectively as single 
diastereomers. (Scheme 111). 
 
Scheme 111 Intermolecular alkene aziridination using sulfamate esters.173 
Other nitrene sources that have been employed in metal-catalysed alkene aziridination are 
sulfonyloxycarbamates. Lebel and co-workers reported that rhodium or copper catalysts could 
promote the intermolecular aziridination of styrenes with tosyloxycarbamate 315 leading to 
aziridines 317 in good yields (Scheme 112).174,175 Using a chiral bis(oxazoline) ligand 316 an 
enantioselective aziridination of styrenes was achieved.176  





Scheme 112 Copper-catalysed intermolecular alkene aziridination with N-tosyloxycarbamate 315.176 
Lebel and co-workers also reported a copper or rhodium-catalysed intramolecular aziridination 
of N-tosyloxycarbamates 318 to generate bicyclic carbamates 319 in good to excellent yields 
(Scheme 113).174,177 Aliphatic and aromatic (E)-disubstituted alkenes were shown to react 
stereospecifically to produce the corresponding trans-aziridines as single diastereomers. 
However, the aziridination of (Z)-disubstituted alkene 320 led to a mixture of cis- and 
trans-aziridines 321a and 321b. Based on this observation, the authors proposed a stepwise 
mechanism involving generation of a triplet nitrene intermediate. 
 
Scheme 113 Copper-catalysed alkene aziridination with N-tosyloxycarbamates.174,177 
Many of the methods developed for the metal-catalysed transfer of nitrenes to alkenes are 
limited to the formation of aziridines bearing strongly electron-withdrawing N-protecting 
groups. Removal of these protecting groups is often difficult, requiring harsh conditions that 
can often result in undesired ring-opening of the aziridine ring. Methods of alkene aziridination 




to access unprotected NH aziridines are less prevalent but are potentially more synthetically 
useful.  
In 2012 Wang and co-workers reported an approach for the synthesis of NH aziridines 323 
from α,β-unsaturated ketones 322 using DPH as a nitrogen source in combination with 
N-methylmorpholine and NaOH (Scheme 114).178 The reaction was proposed to proceed by 
reaction of N-methylmorpholine with DPH to generate a hydrazinium salt 324. This is then 
deprotonated by NaOH to form aminimide 325, which then undergoes a conjugate addition on 
to the α,β-unsaturated ketone 322 followed by cyclisation to afford the aziridine product. 
Whilst effective for the synthesis of NH aziridines, this reaction is limited in scope to the 
aziridination of α,β-unsaturated ketones. 
 
Scheme 114 Aziridination of α,β-unsaturated ketones with O-(2,4-dinitrophenyl)-hydroxylamine.178 
A more efficient and general protocol for stereospecific alkene aziridination that affords 
unprotected NH aziridines was reported by Falck and co-workers.179 The authors demonstrated 
that Rh2(esp)2 in combination with DPH can effect the aziridination of a wide variety of 
alkenes, including tetrasubstituted alkenes, under mild reaction conditions (Scheme 115). From 
experimental observations and computational studies, a mechanism was proposed that involves 
generation of a triplet rhodium-NH-nitrenoid species 326. This undergoes reaction with an 
alkene, followed by intersystem crossing to form diradical intermediate 327 from which the 
aziridine product is generated. As stereospecific aziridination was observed, it was rationalised 




that the diradical intermediate 327 undergoes C-N bond formation without C-C bond 
isomerisation. The use of N-alkyl-DPH derivatives allowed for the generation of N-alkylated 
aziridines. 
 
Scheme 115 Synthesis of N-H and N-alkyl aziridines by rhodium-catalysed alkene aziridination.179 
aO-(2,4-dinitrophenyl)-N-methylhydroxylamine (140 mol%) was used. 
Despite its effectiveness, DPH is impractical for large scale purposes and so an improved 
protocol was subsequently developed by Kürti and co-workers using HOSA as the aminating 
agent in combination with a mild base (Scheme 116).180 This aziridination procedure gave 
comparable or improved yields of aziridination of N-H or N-alkyl aziridination than the 
procedure developed by Falck and co-workers but was much more practical and safer for large 
scale reactions. 





Scheme 116 Rhodium-catalysed alkene aziridination using hydroxylamine-O-sulfonic acid or N-
methyl hydroxylamine-O-sulfonic acid.180  
Whilst metal-nitrenoid-promoted aziridinations of alkenes are well-established, a number of 
transition metal-free alkene aziridinations have also been developed. These typically employ 
amine derivatives in the presence of an oxidant such as Pb(OAc)4 or hypervalent iodine 
reagents. 
In 1967 Nagata and co-workers demonstrated that treatment of primary amine 328 with 
stoichiometric Pb(OAc)4 yielded the bridged aziridine compound 329 (Scheme 117).
181 
Cyclisation to 329 was also achieved but with less efficiency using N-chlorosuccinimide or 
HgO as the oxidant. Pb(OAc)4-mediated alkene aziridination protocols have since been 
demonstrated by a number of groups for the synthesis of similar bridged aziridine 
structures.182,183  
 
Scheme 117 Pb(OAc)4-promoted aziridination of 329.
181 
A number of groups have reported methods for alkene aziridination using N-aminophthalimide 
330 (or N-aminoquinazolinones) as the nitrogen source. These are oxidised in situ to generate 
the active aziridination agent 331 (Scheme 118). Pioneering work was carried out by Atkinson 
and co-workers using Pb(OAc)4 as the oxidant.
184-190 This method promoted the stereospecific 
aziridination of a range of alkenes with varying electronic properties including styrenes and 




α,β-unsaturated esters. To account for the stereospecificity of the reaction the authors proposed 
a concerted mechanism of aziridination analogous to epoxidation of alkenes with peroxyacids 
(Scheme 118). Related Pb(OAc)4-mediated alkene aziridinations for the synthesis of 
N-phthalimidoaziridines were reported by the Vederas191 and Chen192 groups. The obvious 
downside to these methods is the requirement for stoichiometric quantities of toxic lead-based 
reagents. 
 
Scheme 118 Proposed mechanism for alkene aziridination using N-aminophthalimide.154 
The groups of Che193 and Yudin194 reported alkene aziridinations using N-aminophthalimide 
330 and PhI(OAc)2 as the oxidant. A milder approach to alkene aziridination was developed 
by Yudin which bypassed the need for stoichiometric oxidants through the use of 
electrochemical conditions.195 A related mild alkene aziridination approach was reported by 
Che and co-workers which used N-aminophthalimide 330 in combination with aryl iodide 332 
and m-CPBA to generate the active aziridination agent 333 (Scheme 119).196  





Scheme 119 Hypervalent iodine-mediated aziridination of alkenes with N-aminophthalimide 330.196 
A further example of a metal-free approach to alkene aziridination was reported by Sharpless 
and co-workers.197 They demonstrated a bromine-catalysed procedure for the synthesis of 
N-sulfonyl aziridines using Chloramine-T (TsNClNa) as a cheap and practical nitrogen source 
(Scheme 120). The reaction was proposed to proceed via formation of bromonium ion 334 
which is opened by TsNCl- to generate intermediate 335. Cleavage of the N-Cl group generates 
nitrogen anion 336 which subsequently cyclises to the aziridine product. A variety of alkenes 
underwent aziridination in good yields with allylic alcohols being particularly effective 
substrates. A related approach for alkene aziridination was reported by Zhdankin and 
co-workers. This approach used TBAI to promote alkene aziridination via the formation of an 
iodonium intermediate.198  





Scheme 120 Bromine-catalysed aziridination of alkenes with Chloramine-T.197 
It is also pertinent to highlight the work of Cόrdova and co-workers who reported an 
enantioselective organocatalytic aziridination of α,β-unsaturated aldehydes employing N-acyl 
hydroxycarbamates as “nitrene” equivalents (Scheme 121).199,200 The use of a chiral 
pyrrolidine-derived catalyst 337 enabled the generation of a variety of 2-formylaziridines 338 
in good yields and with excellent levels of enantioselectivity (up to 99% e.e.). In the proposed 
mechanism unsaturated iminium ion 339 is generated and acts as a conjugate addition acceptor 
for the hydroxycarbamate. Asymmetry is induced by the shielding of one face of the chiral 
iminium intermediate by the bulky groups of the amine catalyst leading to stereoselective attack 
of the nucleophilic N-acyl hydroxycarbamate. The resulting enamine 340 then undergoes ring 
closure onto the now electrophilic nitrogen of the hydroxycarbamate with release of acetic acid. 
Hydrolysis of iminium 341 then affords the aziridine product. Hamada and co-workers reported 
a related enantioselective organocatalysed aziridination of α,β-unsaturated aldehydes using 
N-sulfonyloxycarbamates,201 whilst Melchiorre extended this strategy to the aziridination of 
α,β-unsaturated ketones.202 





Scheme 121 Organocatalysed aziridination of α,β-unsaturated aldehydes.199 
3.2 Development of an intramolecular aziridination of N-Boc 
hydroxylamines 
3.2.1 Initial results and reaction optimisation 
To investigate the potential of carrying out an intramolecular aziridination of N-Boc 
hydroxylamines, phenyl-substituted alkene 345 was synthesised (Scheme 122a). Wittig 
reaction of benzaldehyde with phosphonium bromide 342 afforded carboxylic acid 343 which 
was subsequently reduced with LiAlH4 to alcohol 344. Substrate 345 was then obtained by 
Mitsunobu reaction with BocNHOTs. 345 was subjected to the acid-promoted dearomatising 
amination conditions [TFA (200 mol%) in TFE (0.1 M)] and bicyclic aziridine 346 was 
obtained in 76% yield and as a single diastereomer (Scheme 122b). Following this pleasing 
result further optimisation was carried out. 





Scheme 122 (a) Synthesis of substrate 345. (b) Intramolecular aziridination of substrate 345. 
A brief solvent screen commenced with common alcohols such as EtOH and MeOH; however, 
no reactivity was observed in these solvents (Table 7, entries 1-2). Other solvents such as THF, 
1,4-dioxane, DMF and MeCN were also ineffective (Table 7, entries 3-6). In contrast, when 
the reaction was run in PhMe or CH2Cl2 appreciable quantities of aziridine 346 was observed 
(32% and 40% respectively) (Table 7, entries 7-8). The solvent screen highlights the 
importance of TFE as solvent for this reaction. Another fluorinated solvent 
α,α,α-trifluorotoluene was examined; however, under these conditions 346 was obtained in 
only 26% yield. (Table 7, entry 9). 
 
Table 7 Solvent screen for the aziridination of substrate 345. Yields were determined by 1H NMR 
analysis of the crude reaction mixture versus 1,4-dinitrobenzene as an internal standard. 
At this stage a number of different hydroxylamine-derived activating groups were examined. 
When substrate 347 containing an OBz group was subjected to the standard reaction conditions, 




no aziridination occurred (Scheme 123b). In contrast, substrate 349 containing an OMs group 
cyclised effectively to aziridine 346 in a slightly reduced yield versus the OTs-substrate.  
 
Scheme 123 (a) Synthesis of substrates 347 and 348 by Mitsunobu reaction. (b) Attempted 
intramolecular aziridination of substrates 347 and 348.  
3.2.2 Aziridination of a (Z)-alkene 
With conditions in hand, the scope of the reaction was investigated. As a starting point the 
stereospecificity of the reaction was first examined. To this end (Z)-345, the (Z)-alkene isomer 
of substrate 345 was prepared. The synthesis began with a Sonogashira reaction of iodobenzene 
and 4-pentyn-1-ol (Scheme 124a). The resulting alkyne 349 was hydrogenated to the (Z)-alkene 
using Lindlar catalyst (poisoned with quinoline to prevent over-reduction). Alcohol (Z)-344 
was then converted to (Z)-345 by Mitsunobu reaction. (Z)-345 was subjected to the standard 
aziridination conditions to provide aziridine 350 in 78% yield (Scheme 124b). The formation 
of the other diastereomer 346 was not observed. The relative stereochemistry of 350 was 
supported by NMR analysis of the coupling constant of the benzylic C2 proton which couples 
to the adjacent C3 proton with a coupling constant value of 7.8 Hz. This value is in line with 
typically observed values for cis-vicinal coupling of protons in aziridine rings.203 In comparison 
for 346 the corresponding C2-C3 trans-coupling has a value of 2.7 Hz.  





Scheme 124 (a) Synthesis of substrate (Z)-345. (b) Intramolecular aziridination of substrate (Z)-345. 
Yield was obtained by 1H NMR analysis versus 1,4-dinitrobenzene as an internal standard. 
3.2.3 Aziridination of 1,2-disubstituted alkenes 
To investigate further the scope of the aziridination process a series of 1,2-disubstituted alkenes 
353a-d were prepared (Scheme 125). These substrates were accessed using the same general 
synthetic sequence which was used to prepare the parent substrate 345. Wittig reaction of 
phosphonium bromide 342 with the corresponding aldehydes gave carboxylic acids 351a-d in 
good yields.XXXV Reduction of the carboxylic acids to the alcohols 352a-d with LiAlH4 and 
Mitsunobu reaction with BocNHOTs completed the synthesis of substrates 353a-d.  
 
Scheme 125 Synthesis of substrates 353a-d.  
 
XXXV For carboxylic acids 351a-d a mixture of (E/Z)-alkene isomers were obtained; these were separated by 
column chromatography. 




With substrates 353a-d in hand, they were subjected to the aziridination conditions. Substrates 
353a-c cyclised effectively to generate the corresponding aziridine products 354a-c with 
comparable levels of efficiency. (Scheme 126a). Aziridine 354c was obtained as a crystalline 
solid and as such its structure and relative stereochemistry was confirmed by single crystal 
X-ray diffraction. For naphthol system 353d cyclisation to aziridine 354d occurred in a slightly 
lower yield of 58%. Here, in addition to the aziridine product, aminoether 355 was isolated in 
20% yield. (Scheme 126b).  
 
Scheme 126 (a) Intramolecular aziridination of substrates 353a-c. (b) Formation of aminoether 355 
in the intramolecular aziridination of 353d. 
To extend the scope of the reaction beyond that of aryl-substituted alkenes, alkyl-substituted 
alkene substrates 357 and 360 and acyl-substituted alkene substrate 361 were prepared 
(Scheme 127). n-Butyl-substituted alkene 357 was prepared from alcohol 356 by Mitsunobu 
reaction.XXXVI Alcohols 358 and 359 were prepared in one step from pent-4-en-1-ol by alkene 
cross-metathesis using Hoveyda-Grubbs second generation catalyst and subsequently 
converted into substrates 360 and 361 by Mitsunobu reaction. 
 
XXXVI Alcohol 356 was prepared by Ian Hazelden (University of Bristol) and hence is not detailed in the 
experimental section. 





Scheme 127 (a) Synthesis of substrate 357 by Mitsunobu reaction. (b) Synthesis of substrates 360 and 
361. 
When subjected to the standard reaction conditions, substrates 357 and 360 cyclised 
successfully to the corresponding aziridine products 362 and 363 in 55% and 62% yields 
respectively (Scheme 128). Interestingly, when substrate 361 was subjected to the aziridination 
conditions the desired aziridine product 364 was not observed despite consumption of the 
starting material. As the alkene in substrate 361 is unreactive (presumably due to being 
electron-deficient) the starting material is instead likely consumed by other degradation 
pathways, although no identifiable products could be isolated. This result highlights a 
limitation of this reaction as electron-deficient alkenes are seemingly incompatible with the 
aziridination process. 
 
Scheme 128 Intramolecular aziridination of alkyl and acyl-substituted alkenes. 
To explore further the scope of functionality that is tolerated in the aziridination reaction 
substrate 366 containing an unprotected alcohol was prepared (Scheme 129a). 366 was 
synthesised by deprotection of tert-butyldiphenylsilyl (TBDPS)-protected alcohol 365 using 




TBAF.XXXVII Unfortunately, when 366 was subjected to the aziridination conditions the desired 
aziridine product 368 could not be isolated (Scheme 129b). The TBDPS-protected alcohol 365 
was also examined and, in this case, the desired aziridine product 369 was formed in a low 
yield of 24%. To define further the scope of reaction substrate 367 containing a benzoyl group 
was synthesised by reaction of alcohol 366 with BzCl (Scheme 129a). When 367 was exposed 
to the aziridination conditions, aziridine 370 was formed in 78% yield (Scheme 129b). These 
results highlight that although free alcohols are not tolerated in the aziridination process, 
bicyclic aziridine products that incorporate an alcohol functionality can be accessed through 
the use of a compatible protecting group. 
 
Scheme 129 (a) Synthesis of substrates 365-367. (b) Aziridination of substrates 365-367. 
The effect of substitution on the carbon tether was examined next. To this end, substrate 375 
containing a cyclopropyl group in the α-position (with respect to nitrogen) was synthesised 
(Scheme 120a). The synthesis began with alkylation of cyclopropyl-β-ketoester 371 with 
cinnamyl bromide. The resulting β-ketoester 372 then underwent decarboxylation and this was 
followed by reduction of the ketone moiety of 373 with NaBH4. 375 was then accessed by 
 
XXXVII TBDPS-protected alcohol 365 was prepared by Xiaofeng Ma (University of Bristol) and hence is not 
detailed in the experimental. 




Mitsunobu reaction of alcohol 374.XXXVIII 375 underwent aziridination to generate aziridine 
376 in 57% yield and as a single diastereomer (Scheme 130b). The relative stereochemistry of 
376 was assigned using 1H NMR nOe analysis. An nOe was observed between the C7 proton 
of the cyclopropyl group and the C2 proton suggesting a cis relationship. The relationship 
between C3 and the phenyl group was also confirmed by nOe. 
 
Scheme 130 (a) Synthesis of substrate 375. (b) Intramolecular aziridination of substrate 375. 
Substitution in the γ-position of the carbon tether was next examined. To this end substrate 381 
containing an n-propyl group was prepared (Scheme 131a). The synthesis began with Grignard 
addition of PhMgCl onto α,β-unsaturated aldehyde 377. The resulting allylic alcohol 378 was 
then converted to ester 379 by Johnson-Claisen rearrangement before reduction to alcohol 380 
with LiAlH4. Mitsunobu reaction of alcohol 380 completed the synthesis. When substrate 381 
was subjected to the aziridination conditions, aziridine 382 was formed in 69% yield and 10:1 
d.r. (Scheme 131b). The relative stereochemistry of the major isomer was assigned by 1H NMR 
nOe analysis. An nOe was observed between the C2 and C4 protons suggesting a cis 
relationship between these two protons. These results highlight that with substitution on the 
carbon tether highly diastereoselective aziridinations can be achieved, allowing access to 
highly substituted bicyclic ring systems. 
 
XXXVIII In general, secondary alcohols underwent less efficient Mitsunobu reactions with BocNHOTs than primary 
alcohols.  





Scheme 131 (a) Synthesis of substrate 381. (b) Intramolecular aziridination of substrate 381. 
3.2.4 Aziridination of 1,1-disubstituted alkenes 
To expand the scope of aziridination of disubstituted alkenes, the reaction of 1,1-disubstituted 
alkene 388 was examined (Scheme 132). For the synthesis of 388, aldehyde 383 was converted 
to α,β-unsaturated aldehyde 384 via Mannich reaction (Scheme 132a). The aldehyde was then 
reduced using NaBH4 and the resulting alcohol 385 was converted to ester 386 by 
Johnson-Claisen rearrangement. Reduction with LiAlH4 completed the synthesis of alcohol 
387 which was then converted to substrate 388 by Mitsunobu reaction. When substrate 388 
was trialled in the aziridination reaction, aziridine 389 was generated in 80% yield 
(Scheme 132b). 
 





Scheme 132 (a) Synthesis of substrate 388. (b) Intramolecular aziridination of substrate 388. 
3.2.5 Aziridination of trisubstituted alkenes 
Having explored the scope of the reaction of 1,1- and 1,2-disubstituted alkenes, the 
aziridination of trisubstituted alkenes was next examined. As a starting point trisubstituted 
alkene substrate 392 was targeted (Scheme 133). This was prepared from methacrolein 390 via 
1,2-addition of PhMgCl, followed by Johnson-Claisen rearrangement of the resulting allylic 
alcohol 391. Reduction with LiAlH4, followed by Mitsunobu reaction completed the synthesis 
of substrate 392. When employed in the aziridination reaction, 392 cyclised efficiently to 
generate aziridine 393 in 81% yield. This result shows that even hindered alkenes are suitable 
for the aziridination process, which in turn enables access to interesting and challenging 
heterobicyclic ring systems. 
 
Scheme 133 Synthesis and intramolecular aziridination of substrate 392. 




To investigate further the scope of trisubstituted alkenes in the aziridination reaction a series 
of other substrates were prepared (Scheme 134). Alcohols 394a-c were all accessed from 
aldehyde 384 by 1,2-addition of the appropriate organometallic reagent followed by 
Johnson-Claisen rearrangement and LiAlH4 reduction (Scheme 134a). Alcohol 394d, 
containing a furan group was also prepared by a similar route. Substrates 395a-d where then 
synthesised from the corresponding alcohols 394a-d by Mitsunobu reaction (Scheme 134b). 
 
Scheme 134 (a) Synthesis of alcohols 394a-d. (b) Synthesis of substrates 395a-d by Mitsunobu 
reaction. 
With substrates 395a-c in hand, they were examined in the aziridination reaction. All cyclised 
efficiently to provide the corresponding aziridines 396a-c in excellent yields (Scheme 135). 
Substrate 395d also cyclised to the corresponding aziridine 396d; however, the yield was much 
lower at 48%. The low yield in the case of the furan-substituted system is likely due to the 
susceptibility of furans to acid-promoted decomposition through ring opening pathways.  





Scheme 135 Intramolecular aziridination of substrates 395a-d. 
Several other trisubstituted alkenes 397a-dXXXIX containing a variety of functionality were also 
examined in the aziridination reaction. 397a-d underwent efficient cyclisation to the 
corresponding aziridine products 398a-d (Scheme 136). Substrate 397a is noteworthy in that 
it contains a skipped diene which was well tolerated in the reaction as aziridine 398a was 
obtained in 81% yield and no acid-promoted isomerisation was observed. Substrate 397c, 
containing an O-TBS protected phenol, was also compatible with the reaction conditions and 
cyclised to aziridine 398c in 67% yield with the O-TBS protected phenol remaining intact. 
Where possible the relative stereochemistry of the aziridine products was confirmed by nOe 
analysis. 
 
Scheme 136 Intramolecular aziridination of substrates 397a-d. 
3.2.6 Aziridination of tetrasubstituted alkenes 
Having established that di- and trisubstituted alkenes undergo efficient aziridination the 
possibility of extending the scope of the reaction to tetrasubstituted alkenes was examined. To 
 
XXXIX Substrates 397a-d were prepared by Xiaofeng Ma (University of Bristol) and hence are not detailed in the 
experimental section. 




this end gem-dimethyl-substituted alkene substrate 401 was prepared (Scheme 137a). The route 
to 401 began from diethyl benzyl malonate which was converted to allylic alcohol 399 in three 
steps. The required alcohol 400 for Mitsunobu reaction was then prepared via Johnson-Claisen 
rearrangement followed by LiAlH4 reduction. When subjected to the standard reaction 
conditions 401 cyclised efficiently to give aziridine 402 in 90% yield (Scheme 137b).  
 
Scheme 137 (a) Synthesis of tetrasubstituted alkene 401. (b) Intramolecular aziridination of substrate 
401. 
3.2.7 Cyclisation to form azabicyclo[4.1.0]heptanes 
Having established that the aziridination protocol is effective for constructing 
azabicyclo[3.1.0]hexane ring systems, the possibility of performing aziridinations to access 
other ring systems such as azabicyclo[4.1.0]heptanes were investigated. To this end, 
phenyl-substituted alkene 405 was targeted as a suitable substrate (Scheme 138). The synthesis 
began from 5-hexyn-1-ol which underwent Sonogashira coupling with iodobenzene to generate 
403 in excellent yield. Reduction of the alkyne of 403 with LiAlH4 in refluxing THF afforded 
alcohol 404 which was then converted to substrate 405 by Mitsunobu reaction. When 405 was 
subjected to the aziridination reaction conditions cyclisation to aziridine 406 occurred in 
44% yield (Scheme 138).  





Scheme 138 Synthesis and intramolecular aziridination of substrate 405. 
In order to achieve a more efficient aziridination other 6-ring substrates were prepared. 
Substrate 408 was targeted as a suitable substrate as it was hypothesised that introducing a 
conformational bias in the form of an arene group in the carbon tether may improve the rate of 
cyclisation and thus lead to an improved yield of aziridination (Scheme 139). Substrate 408 
was prepared from alcohol 407 by Mitsunobu reaction.XL Unfortunately, when 408 was 
subjected to the standard aziridination reaction conditions, aziridine 413 was obtained in only 
26% yield. 
 
Scheme 139 Synthesis and intramolecular aziridination of substrate 408. 
Substrate 413 containing an arene linker in the carbon tether but one carbon atom further away 
from the tosyloxycarbamate group (versus 408) was also synthesised (Scheme 140). The 
synthesis of 413 began with a Sonogashira coupling of alcohol 410 and 1-hexyne to give alkyne 
411.XLI Reduction of the alkyne was performed using LiAlH4 in refluxing diglyme to afford 
alcohol 412 which was then converted to substrate 413 by Mitsunobu reaction. 413 underwent 
efficient aziridination under the standard conditions to give aziridine 414 in 60% yield. This 
result represented a significant improvement over the previous 6-ring cyclisation substrates 
trialled (Scheme 140). 
 
XL Alcohol 407 was prepared by Ian Hazelden (University of Bristol) and hence is not detailed in the experimental 
section. 
XLI Attempted optimisation of this reaction was carried out; however, no improvement in yield was achieved. 





Scheme 140 Synthesis and intramolecular aziridination of substrate 413. 
To extend further the scope of this 6-ring cyclisation, substrates 418 and 419 containing a 
sulfonamide in the tether were prepared as successful aziridination of these substrates would 
provide access to piperazines. Alcohols 416 and 417 were prepared by alkylation of 
sulfonamide 415 with the appropriate allyl bromide (Scheme 141). Alcohols 416 and 417 were 
then converted to substrates 418 and 419 by Mitsunobu reactions, although low yields of 
products were obtained.XLII 
 
Scheme 141 Synthesis of substrates 418 and 419. 
When subjected to the standard reaction conditions substrates 418 and 419 cyclised to the 
corresponding aziridines 420 and 421 in 51% and 64% yields respectively (Scheme 142). The 
effective cyclisation of substrate 419 highlights that aziridination of cyclic alkenes can be 
performed using this approach. 
 
XLII The low yields were largely due to issues with purification of the Mitsunobu products. 





Scheme 142 Intramolecular aziridination of substrates 418 and 419. 
To extend the scope of heteroatoms that are compatible with this reaction, substrate 422 
containing an ether group in the carbon tether was synthesised (Scheme 143). Unfortunately, 
when 422 was subjected to the aziridination reaction conditions the desired aziridine product 
423 was not observed. It is likely that due to the electron-withdrawing nature of the ether group 
the alkene is insufficiently reactive to undergo cyclisation. This is consistent with earlier results 
which have shown that electron-rich alkenes are more effective substrates.  
 
Scheme 143 Synthesis and attempted aziridination of substrate 422. 
Two final trisubstituted alkene substrates 424 and 425 were prepared and examined in the 
aziridination reaction (Scheme 144).XLIII When subjected to the standard reaction conditions, 
substrates 424 and 425 cyclised to the desired aziridine products 426 and 427 in 52% and 
40% yields respectively. 
 
 
XLIII These substrates were prepared by Xiaofeng Ma (University of Bristol) and hence are not detailed in the 
experimental. 





Scheme 144 Intramolecular aziridination of substrates 424 and 425. 
3.2.8 Mechanistic studies 
Based on the observed diastereospecificity of this reaction, as demonstrated by the aziridination 
of the (E)- and (Z)-isomers of 345 leading to different diastereomers of product, a mechanism 
of aziridination is proposed as shown in Scheme 145. Following TFA promoted N-Boc 
deprotection of 345, alkene aziridination proceeds via a concerted mechanism in which both 
new C-N bonds are formed simultaneously. Mechanistically, this could be rationalised by the 
formation and subsequent capture of a nitrenium ion (Scheme 145, path a) or by an 
aza-Prilezhaev type mechanism (path b).XLIV 
 
Scheme 145 Plausible mechanisms of concerted alkene aziridination. Based on available evidence an 
aza-Prilezhaev-type mechanism (path b) is favoured.  
To gain more of an insight into the mechanism of the aziridination reaction a series of 
computational studies were carried out.XLV The results imply that the transition state for a 
 
XLIV This would resemble the aza-Prilezhaev type alkene aziridination of N-aminophthalimides proposed by 
Atkinson.184-188  
XLV All computational studies were carried out by Tom Young with guidance from Natalie Fey (University of 
Bristol). 




concerted aza-Prilezhaev-type mechanism is thermally accessible under the reaction conditions 
(ΔG‡solv = 22.0 kcal mol
-1) and strongly resembles the spiro “butterfly” transition state involved 





Figure 3 Reaction profile for aziridination of 345 via an aza-Prilezhaev-type mechanism. Solvated 
Gibbs free energies are quoted at PBE0/6-311++G(2d,p)//PBE0-D3BJ/6-31+G(d), SMD (TFE). Free 
energy contributions have been calculated at 298 K. 
As the reaction is under acidic conditions, the effect of N-protonation following 
Boc-deprotection was also examined. For the purposes of these studies a model system 428, 
containing a methyl-substituted alkene and a mesylate leaving group was used 
(Scheme 146).XLVI The results suggest that the protonated form 429 affords a considerably 
higher energy barrier to aziridination than the neutral form (22.3 kcal mol-1 versus 
14.7 kcal mol-1).  The effect of complexation of a molecule of MsOH on the transition state 
stability was also examined, as this would potentially help to stabilise the developing negative 
charge (Scheme 146). However, the Gibbs free energy barrier of the transition state with a 
complexed MsOH molecule is predicted to be higher than without MsOH (ΔG‡solv = 22.4 
kcal mol-1 versus 14.7 kcal mol-1). This difference is likely to be due to the loss of entropy 
which occurs upon formation of the highly ordered H-bonded transition state 430. 
 
XLVIThe reaction energies are expected to differ somewhat between the actual systems and the model system. 





Scheme 146 (a) Comparison of aziridination via a protonated or non-protonated species. 
(b) Aziridination of 428 assisted by MsOH complexation. 
Reaction via the formation and subsequent capture of a nitrenium ion 431 was also examined; 
however, computational results imply that this is unfeasible due to the high-energy barrier to 
mesylate dissociation (Scheme 147). Moreover, in the event of the formation of a nitrenium 
ion, proton loss to afford an iminium ion 432 is expected to occur. The computational results 
in combination with the lack of any precedence in the literature for an efficient alkene 
aziridination via formation of an unstabilised nitrenium ion suggests that a reaction pathway of 
this type is unlikely.XLVII 
 
Scheme 147 Predicted reactivity of unstabilised nitrenium ion 431. 
 
XLVII Zhdankin and co-workers have reported an alkene aziridination that is proposed to proceed via a stabilised 
nitrenium ion.198 




An alternative radical-based mechanism involving initial N-O bond homolysis was also 
considered and examined computationally. The results suggest that this type of mechanism is 
also unlikely as homolysis of the N-O bond of 433 under the reaction conditions is energetically 
inaccessible (ΔG‡solv = 32.8 kcal mol
-1) (Scheme 148). Therefore, based on the computational 
studies and experimental observations an aza-Prilezhaev-type mechanism is favoured for this 
reaction. However, reaction via formation and capture of a nitrenium or a radical based 
mechanism cannot be entirely discounted. 
 
Scheme 148 N-O bond homolysis of 433 is energetically inaccessible under the reaction conditions. 
3.2.9 Alkene aminofunctionalisations 
As discussed in section 3.2.3 (Scheme 126b), when naphthyl-substituted alkene 353d was 
subjected to the aziridination reaction conditions the formation of 1,2-aminoether product 355 
was observed in 20% yield, in addition to aziridine product 354d. When substrates 434 and 
437, containing highly stabilising para-methoxyphenyl or 2-thienyl substituents were 
subjected to the aziridination conditions, the expected aziridine products 435 and 438 were not 
observed (Scheme 149a). Instead 1,2-aminoetherification products 436 and 439 were formed 
exclusively in 57% and 31% yield respectively, and with good levels of diastereocontrol.XLVIII 
The stereochemistry of the major diastereomer of 436 was confirmed by single crystal X-ray 
diffraction following conversion of 436 to N-nosyl derivative 440 and subsequent 
recrystallisation (Scheme 149b). The stereochemistry of 355 and 439 were then assigned by 
comparison to 436. 
 
XLVIII 1,2-Aminoetherification products were only observed with these highly electron-rich alkenes. 





Scheme 149 (a) Formation of 1,2-aminoetherification products in the aziridination of substrates 
353d, 434 and 437. (b) Derivatisation of 436 for relative stereochemical assignment. 
This formation of 1,2-aminoetherifcation products is consistent with an SN1 mechanism in 
which acid-promoted ionisation of the initially formed aziridine generates a carbocation 441 
which is subsequently captured by a molecule of solvent (Scheme 150, path a).XLIX, L This 
process is likely facilitated by the electron-rich aryl unit which helps to stabilise the adjacent 
carbocation. Alternatively, it is possible that the aminoether products could also form by an 
alternative pathway (Scheme 150, path b) that does not proceed through the formation of an 
aziridine intermediate and instead leads directly to the key benzylic carbocation. 
 
XLIX The stereochemistry of the product in which apparent ring-opening occurs with retention, is inconsistent with 
ring-opening of the aziridine via an SN2 mechanism. 
L 354d was stirred overnight in TFE with the addition of TFA/TsOH, and 1,2-aminoetherification product 355 
was obtained in 10% yield. 





Scheme 150 Plausible mechanisms for formation of 1,2-aminoetherification products. 
In an attempt to suppress this ring opening reaction and obtain the aziridine products, 
aziridination of substrate 434 was performed in CH2Cl2 and PhMe as these non-nucleophilic 
solvents should not undergo ring-opening of the aziridine product. However, in these solvents 
aziridine product 435 could not be isolated (Table 8, entries 1-2). Similarly, no aziridine 
product was observed in HFIP, a comparable solvent to TFE but less nucleophilic (Table 8, 
entry 3). It is most likely that due to its sensitive nature any aziridine formed undergoes 
decomposition (possibly through polymerisation) under the reaction conditions.  
 
Table 8 Attempted optimisation of the intramolecular aziridination of substrate 434. 
The in situ trapping of intermediates with TFE prompted investigations into the use of other 
alcohol-based nucleophiles to expand the scope of 1,2-aminoetherification products that can 
be obtained. Following optimisation and the use of HFIP as solvent, substrate 442 was 
converted to 1,2-aminoether 443 in the presence of benzyl alcohol with good levels of 
diastereocontrol (Scheme 151). The stereochemistry of 443 was confirmed by X-ray 
crystallography following derivatisation to compound 444 which showed that ring opening has 
occurred with retention of stereochemistry. 






Scheme 151 1,2-Aminoetherification reaction of substrate 442 with BnOH. The reaction occurs with 
retention of stereochemistry. 
With the aziridination/ionisation sequence providing access to 1,2-aminoetherificiation 
products the protocol was adapted to other classes of 1,2-aminodifunctionalisations. Under 
optimised aziridination conditions, trimethoxybenzene functioned as an external nucleophile 
to enable the conversion of alkene 345 to 1,2-aminoarylation product 445 in 50% yield and as 
a single diastereomer (Scheme 152). The relative stereochemistry of 445 was confirmed by 
reaction with NsCl to generate 446 as a crystalline solid from which an X-ray crystal structure 
was obtained. From the X-ray crystal structure, ring opening has occurred by inversion. 
 
Scheme 152 1,2-Aminoarylation of substrate 345. The reaction occurs with inversion of 
stereochemistry. 




3.2.10 Further derivatisations 
To expand the scope of diversification a series of further derivatisations of the aziridine 
products was carried out. Ring-opening of aziridine 346 was achieved using TMSN3 and a 
catalytic amount of TfOH to afford 1,2-amino-azide compound 447 in good yield and with 
high stereoselectivity (Scheme 153a). Aziridine 393 was subjected to hydrogenative C-N bond 
reduction using Pd/C and H2 to generate pyrrolidine 448 in excellent yield (Scheme 153b).
206 
This transformation represents a formal hydroamination of alkene 392. 
 
Scheme 153 (a) Trapping of aziridine 346 with TMSN3. (b) Hydrogenative C-N bond reduction of 
aziridine 392. 
3.2.11 Ring expansion of azabicyclo[3.1.0]hexanes to piperidines 
One of the major limitations of the dearomatising amination reaction was its inability to afford 
6-membered (piperidine ring) products, with the reaction seemingly restricted to the formation 
of spirocyclic pyrrolidines. Piperidines are important and prevalent structures in natural 
products, making them attractive targets for synthesis;207 as such, a further class of 
derivatisations involving ring expansion of azabicyclo[3.1.0]hexanes to piperidines was 
investigated. In the chemical literature bicyclic aziridinium ions that resemble the aziridine 
products obtained in this chapter have been invoked as intermediates in the ring expansion of 
pyrrolidines to piperidines.208-214,LI Of particular note is the work of Cossy and co-workers who 
have demonstrated that fluorinating reagents such as diethylaminosulfur trifluoride (DAST) 
can induce ring expansion of prolinols to 3-fluoropiperidines via an aziridinium intermediate 
(Scheme 154).210 For example, through treatment with DAST, N-benzyl prolinol 449 was 
converted to 3-fluoropiperidine 450 and 2-(fluoromethyl)pyrrolidine 451 in a ratio of 1.3:1 in 
favour of the piperidine product. The transformation is under kinetic control and the selectivity 
 
LI Related ring expansions of azepanes,215 azocanes,215 piperazines,215 morpholines,215 indolines215 and ring 
expansions to access azepanones216 have also been reported. 




of the rearrangement is improved when the nitrogen atom of the prolinol is protected with a 
bulky group. Exclusive formation of the piperidine product 454 was achieved with prolinol 452 
containing a quaternary centre at C3. The selective attack of fluoride at the C3 position of 
substituted prolinols can be rationalised due to a lengthening/weakening of the C3-N bond in 
aziridinium intermediate 453. The presence of the quaternary centre at C3 results in the 
stabilisation of a partial positive charge at C3 and thus the fluoride attacks the more 
electrophilic C3 carbon to give the ring expanded product. 
 
Scheme 154 DAST-induced ring expansion of prolinols to piperidines.210  
It was envisaged that the bicyclic aziridine products obtained by the methods used in this 
chapter could be acylated to form an aziridinium ion which would then undergo ring expansion 
with an appropriate nucleophile. To this end, aziridine 389 was reacted with 2-phenylacetyl 
fluoride (150 mol%) in THF at 0 oC and the desired 3-fluoropiperidine product 457 was formed 
exclusively in 59% yield (Scheme 155a). The pyrrolidine product 458 formed by attack of the 
fluoride at C2 of 456 was not observed. This method proved amenable to other nucleophiles; 
piperidines 459 and 460 were generated in good yields from aziridine 389 by reaction with 
ethyl chloroformate and acetic anhydride respectively (Scheme 155b). Selectivity for 
formation of the piperidine product was confirmed by single crystal X-ray diffraction of 459.  





Scheme 155 (a) Formation of 3-fluoropiperidine 457 by ring expansion of aziridine 389. (b) Ring 
expansions of aziridine 389 using other nucleophiles. 
3.3 Studies towards an intermolecular aziridination reaction 
3.3.1 Preliminary results 
Following on from the development of an intramolecular aziridination procedure for the 
synthesis of aza-bicyclic structures, the potential to carry out an intermolecular aziridination 
was explored. As a starting point, the aziridination of styrene with BocNHOTs as the aminating 
agent was investigated. Unfortunately, aziridination of styrene under the following reaction 
conditions [BocNHOTs (150 mol%), TFA (200 mol%) in TFE (0.4 M)] failed to produce any 
of the desired aziridine 461 (Scheme 156). 
 
Scheme 156 Attempted intermolecular aziridination of styrene. 
A brief survey of other alkenes identified trans-β-methylstyrene as a potentially suitable 
alkene; aziridination of trans-β-methylstyrene afforded aziridine 462 in 6% yield (Table 9, 
entry 3). Attempts at optimising this result by varying the concentration of the reaction failed 
to have a significant effect on the yield although increasing the concentration to 0.5 M did 




increase the yield to 12% (Table 9, entry 4). The yields were determined by 1H NMR analysis 
of the crude reaction mixture with the addition of an internal standard as attempts to isolate 
aziridine 462 by flash column chromatography were unsuccessful.  
 
Table 9 Effect of concentration on the intermolecular aziridination of trans-β-methylstyrene. 
The use of an N-substituted aminating reagent in the reaction was investigated as this would 
give rise to N-alkylated aziridines. N-Methyl substituted aminating agent 463 was prepared in 
two steps from commercially available N-methyl hydroxylamine hydrochloride (Scheme 157).  
 
Scheme 157 Synthesis of N-methyl amino-reagent 463. 
Using the previous best conditions [200 mol% TFA in TFE (0.5 M)] cis-β-methylstyrene 
underwent aziridination to afford the desired aziridine product 464 in 15% yield (Table 10 
entry 1) which was improved to 21% by increasing the reaction time (48 h versus 42 h) 
(Table 10, entry 2). Unfortunately, further attempts at reaction optimisation failed to improve 
the yield further. Increasing the loading of alkene to 10 equivalents resulted in 464 being 
obtained in 15% yield, whilst increasing the equivalents of TFA had no effect on the yield of 
reaction (Table 10, entries 3 and 4). As previously observed a concentration of 0.5 M appears 
to be optimal with lower and higher concentrations both giving lower yields (Table 10 entries 
5 and 6). In addition, changing the solvent to HFIP gave no improvement to the yield, whilst 
no product was observed in CH2Cl2 (Table 10, entry 7 and 8). The use of a lower amount of 
TFA (15mol%) was also ineffective (Table 10, entry 9). 
 





Table 10 Attempted optimisation of the intermolecular aziridination of cis-β-methylstyrene. aReaction 
time was 42 h. b100 mol% of amine used, 1000 mol% of alkene used. 
In an attempt to improve the reactivity, a range of different activated N-methyl hydroxylamine 
reagents were prepared and examined in the aziridination reaction. As for reagent 463, 
compounds 465a-f were synthesised from tert-butyl hydroxy(methyl)carbamate by coupling 
with the appropriate sulfonyl chloride or anhydride (Scheme 158).  
 
Scheme 158 Synthesis of N-methylhydroxylamine aminating reagents 465a-f. 
With the reagents in hand, they were examined in the aziridination reaction. As shown in Table 
11, methylsulfonyl and mesitylsulfonyl systems 465a and 465b were less effective in the 
aziridination reaction than the tosyl system (17% and 9% respectively versus 21% for the tosyl) 
(Table 11, entries 1 and 2). However, both the 4-nitrophenyl and 2,4-dinitrophenyl systems 
465c and 465d were more effective, providing aziridine 464 in 35% and 38% yields 
respectively (Table 11, entries 3 and 4). Optimal reactivity was observed with the 
chloromethanesulfonyl system 465e which gave the desired aziridine 464 in 42% yield 
(Table 11, entry 5). After synthesising the trifluoromethane system 465f, and on the basis that 




it was likely to be unstable to column chromatography it was used immediately in the 
aziridination reaction without purification, and aziridine 464 was obtained in 7% yield 
(Table 11, entry 6). Presumably this low yield can be attributed to hydrolysis of 465f, before 
aziridination can occur. 
 
Table 11 Effect of the leaving group on the intramolecular aziridination of cis-β-methylstyrene. 
Upon repeating the aziridination of cis-β-methylstyrene using 465e as the aminating reagent a 
3:1 mixture of the cis- and trans-aziridine isomers was obtained. As these are only preliminary 
results a full mechanistic study of the intermolecular aziridination was not performed, as such 
it is not clear if the mechanism is analogous to that which was proposed for the intramolecular 
reaction or if a different mechanism is in operation. If the mechanism is the same as the 
intramolecular aziridination (i.e. concerted C-N bond formation) loss of stereospecificity could 
be due to isomerisation of the alkene or the aziridine product under the acidic reaction 
conditions; however, this is unconfirmed.  




Aziridination of trans-β-methylstyrene was also examined using 465e. When subjected to the 
optimised conditions, trans-aziridine 466 was obtained in 32% yield and as a single 
diastereomer. The cis-aziridine isomer 464 was not observed (Scheme 159). 
 
Scheme 159 Intermolecular aziridination of trans-β-methylstyrene. 
Due to the disappointing results obtained for intermolecular aziridination a number of other 
approaches for generating activated hydroxylamines in situ were investigated. Teoc-protected 
hydroxylamine reagent 467 was prepared and aziridination of trans-β-methylstyrene was 
attempted using the following conditions [TBAF (200 mol%) in TFE (0.25 M)]. Unfortunately, 
the desired aziridine product 466 was not observed (Scheme 160). 
 
Scheme 160 Attempted intermolecular aziridination of trans-β-methylstyrene with Teoc-activated 
hydroxylamines. 
Attempts to access an activated hydroxylamine such as 465f in situ from tert-butyl 
hydroxy(methyl)carbamate was also carried out. To this end tert-butyl 
hydroxy(methyl)carbamate was treated with trifluoromethanesulfonic anhydride in TFE before 
addition of trans-β-methylstyrene (Scheme 161). Unfortunately, the desired aziridine product 
466 was not observed. An attempt to generate activated hydroxylamine 468 using 
N,N′-dicyclohexylcarbodiimide was also performed; however, this also failed to induce 
aziridination of trans-β-methylstyrene. 
 





Scheme 161 Attempted in situ generation of activated hydroxylamines for intramolecular 
aziridination. 
3.4 Conclusions 
The development of a novel transition metal-free aziridination of N-tosyloxycarbamates was 
successfully achieved. Excellent yields were generally observed with substrates containing 
di- and trisubstituted alkenes and the methodology is also compatible with tetrasubstituted 
alkenes, allowing for the synthesis of highly congested N-heterocycles. One of the limitations 
of the dearomative amination reactions presented in the previous chapter is that 6-exo 
cyclisations to afford piperidine products were unsuccessful. However, through this 
aziridination protocol 6-ring cyclisations to afford azabicyclo[4.1.0]heptanes were possible 
although lower yields were generally observed versus 5-ring cyclisations. Access to 
6-membered piperidine structures was also obtained by ring expansion of the 
azabicyclo[3.1.0]hexanes products using suitable nucleophiles. Extension of the aziridination 
protocol to a metal-free intermolecular reaction was attempted; however, only modest yields 
of aziridines were obtained. 
3.5 Preliminary studies for future work 
Having established an intramolecular aziridination protocol to access azabicyclo[3.1.0]hexane 
and azabicyclo[4.1.0]heptane motifs, the application to the formation of other aza-bicyclic ring 
structures such as azabicyclo[1.1.0]butanes was investigated. Very few methods exist for 
accessing such intermediates,217-219 but one of the most effective methods was reported by 
Nagao and co-workers in which 1-azabicyclo[1.1.0]butane 471 is accessed in a two-step 
procedure from allylamine 469, via cyclisation of 2,3-dibromopropylamine 470.220,221 For this 
transformation the use of a strong organolithium base is required. A number of groups 
including Nagoa,222 Baran223,224 and Gianatassio225 have demonstrated that 




1-azabicyclo[1.1.0]butane intermediates 471 can be intercepted with a variety of nucleophiles 
to prepare functionalised azetidines.226-228 
The lack of effective methods for generating azabicyclo[1.1.0]butane intermediates spurred us 
to investigate if alkenyl substrates such as 472 could undergo the same intramolecular 
aziridination process as observed for the formation of azabicyclo[3.1.0]hexane and 
azabicyclo[4.1.0]heptane systems, but instead lead to intermediate 473 which could be 
functionalised by ring-opening with an appropriate nucleophile. This could allow access to 
azetidine 474 or aziridine 475 products depending on the regioselectivity of the attack of the 
nucleophile. (Scheme 162). If successful, this approach would represent a mild alternative to 
traditional methods and negate the need for a strong base. Preliminary results towards 
harnessing the reactivity of strained azabicyclobutane intermediates are given below.  
 
Scheme 162 (a) Synthesis and reactions of azabicyclo[1.1.0]butanes.220,223-225 (b) General strategy for 
harnessing the reactivity of strained aza-bicyclobutane intermediates. 
The investigation began by preparing substrate 476 which was synthesised by Mitsunobu 
reaction of cinnamyl alcohol (Scheme 163). Upon treatment with TFA (200 mol%) in TFE, 
476 cyclised to the corresponding aziridine in 34% yield and as a 9:1 mixture of diastereomers. 
To improve stability and to help with isolation of the product the aziridine was isolated as 
sulfonamide 477 by in situ protection with MsCl. 
 





Scheme 163 Synthesis and aziridination of substrate 476. 
In an attempt to improve reactivity trisubstituted alkene 480 was prepared (Scheme 164a). The 
synthesis began with a Horner-Wadsworth-Emmons reaction to generate unsaturated ester 478 
predominantly as the (E)-alkene isomer; however, the (E)- and (Z)-alkene isomers were 
separated by flash column chromatography. 478 was then reduced to allylic alcohol 479 before 
Mitsunobu reaction afforded the desired substrate 480 in good yield. When 480 was reacted 
using the aziridination conditions [TFA (200 mol%), TFE (0.1 M) at room temperature] 
aziridine 481 was obtained in 51% yield and as an 8:1 mixture of diastereomers (Scheme 164b). 
Attempts at optimising this reaction were performed (Table 18, appendix); however, no 
significant improvement was observed. 
 
Scheme 164 (a) Synthesis of substrate 480. (b) Aziridination of substrate 480. 
The (Z)-alkene isomer of 480 was also subjected to the aziridination conditions. Aziridine 481 
was obtained in 55% yield and approximately 5:1 d.r. (Scheme 165). Although the relative 
stereochemistry of the major diastereomer of 481 was not confirmed, reaction of both (E)- and 
(Z)-481 led to formation of the same major diastereomer. This result suggests that nucleophilic 




attack of the alcohol occurs via an SN1 mechanism which implies the formation of a benzylic 
carbocation, either directly or from an azabicyclobutane intermediate. 
 
Scheme 165 Aziridination of (Z)-480. 
To investigate further the scope of this reaction a series of substrates with substitution in the 
para position of the phenyl group were synthesised. 4-Methyl- and 4-bromophenyl substrates 
483 and 485 were synthesised using the same strategy as for the parent substrate (Scheme 166). 
The synthesis of 4-methoxyphenyl substrate 487 was also attempted; however, Mitsunobu 
reaction of alcohol 486 was unsuccessful (Scheme 167). The 4-methyl- and 4-bromophenyl 
substrates 483 and 485 were both obtained as a 5:1 and 3:1 mixture of (E/Z)-isomers 
respectively and were subjected to the aziridination conditions as isomeric mixtures.  
 
Scheme 166 (a) Synthesis of substrate 483. (b) Synthesis of substrate 485. 





Scheme 167 Attempted synthesis of substrate 487. 
When 485 was examined in the aziridination reaction, aziridine 489 was formed in 34% yield 
and as a 5:1 mixture of diastereomers (Scheme 168). A slightly improved result was obtained 
for 4-bromo-phenyl substrate 483 which underwent aziridination to afford aziridine 488 in 45% 
yield and 6:1 d.r. 
 
Scheme 168 Aziridination of substrates 483 and 485. 
It was envisaged that cyclisation of 490 would generate an 1-azabicyclo[2.1.0]pentane 
intermediate 491 that could undergo either ring-opening to generate an azetidine 492, or ring 
expansion to form pyrrolidine 493 (Scheme 169a). Substrate 497 was synthesised in three steps 
from cyclopropyl ketone 494 (Scheme 169b). Addition of PhMgBr generated alcohol 495 
which then under acidic conditions underwent ring opening of the cyclopropane to afford 
homoallylic alcohol 496. Alcohol 496 was then converted to substrate 497 by Mitsunobu 
reaction.  





Scheme 169 (a) Potential ring-opening of azetidine intermediate 491. (b) Synthesis of substrate 497. 
When substrate 497 was subjected to the aziridination reaction conditions neither azetidine 498 
or pyrrolidine 499 were formed and the only observed product was amino-ketone 500 which 
was isolated in 45% yield (Scheme 170a). A proposed mechanism for the formation of 500 is 
given in Scheme 170b. Substrate 497 undergoes acid-promoted cyclisation to generate 
pyrrolidine intermediate 501. From intermediate 501, 1,2-shift of the phenyl group can occur 
with loss of TsOH to generate aniline 502. Hydrolysis of the iminium ion 503 then occurs to 
generate amino-ketone 500. 





Scheme 170 (a) Observation of an amino ketone side-product 500 in the cyclisation of 497. 
(b) Proposed mechanism for formation of 500. 
In summary, preliminary results have been carried out into the use of azabicyclobutanes as 
reactive intermediates for the generation of nitrogen heterocycles. Thus far the use of TFE as 
a nucleophilic solvent has enable the synthesis of highly substituted aziridine products. 
Although mechanistic studies have not been performed, preliminary experimental results 
suggest that a benzylic cation is formed either directly from the substrate or via formation of 
an azabicyclobutane intermediate. The benzylic cation is then capture by a molecule of TFE 
by an SN1 pathway to provide the 1,2-aminoether products. Further studies, including reaction 
optimisation and scope study will likely be carried out by other members of the group. 
 




Chapter 4 - Other classes of electrophilic 
nitrogen-promoted aminations 
4.1 Studies towards an intramolecular aryl C-H amination 
4.1.1 Introduction 
In this chapter the results of an investigation into two additional classes of amination reaction 
involving the use of hydroxylamine-derived electrophilic nitrogen sources are presented. The 
first is an intramolecular aryl C-H amination reaction to afford benzannulated products, whilst 
the second transformation involves the conversion of sulfoxides to sulfoximines. Before 
discussing the results in this section relating to the development of an intramolecular aryl C-H 
amination reaction of N-Boc hydroxylamines, a brief overview of the chemical literature 
relating to aryl aminations is given below. 
As highlighted in Chapter 2 several groups have harnessed the reactivity of stabilised nitrenium 
ions for the synthesis of lactams by electrophilic aromatic substitution.61-65,73 Typically, these 
highly reactive intermediates are accessed from N-alkoxyamides by either (a) conversion to an 
N-chloro-N-alkoxyamide followed by activation with silver salts or (b) by direct oxidation 
using a hypervalent iodine reagent. However, the effectiveness of these approaches is limited 
by the requirement for specific electron-donating N-protecting groups. A related synthesis of 
N-substituted amino dihydrocarbostyrils by Lewis acid-promoted cyclisation of azodicarbonyl 
compounds was reported by Prabhakar and co-workers.74,75  
 
Scheme 171 (a) Synthesis of benzo-fused lactams by nitrenium ion-promoted aryl amination.61-65,73 
(b) Electrophilic aryl amination using azodicarbonyls.74,75 




A more general approach for the synthesis of arylamines by direct aryl C-H amination was 
reported by Falck and co-workers.33 The authors demonstrated that 
N-methyl-O-tosylhydroxylamine and other related O-substituted hydroxylamines in 
combination with Rh2(esp)2 can effect intermolecular aryl C-H amination of a variety of arenes 
to afford unprotected arylamine products (Scheme 172). Based on mechanistic studies the 
reaction is proposed to procced via an SEAr mechanism from electrophilic intermediate 19. 
This approach was also adapted to enable an intramolecular amination which allowed access 
to benzannulated products. In a later report the authors demonstrated that copper(II)-species 
also serve as effective catalysts for aryl amination using HOSA as the aminating agent.34 
 
Scheme 172 Rhodium-catalysed aryl C-H amination using hydroxylamine-derived reagents.33 
Whilst Falck and co-workers demonstrated aryl C-H aminations with compelling evidence for 
an SEAr mechanism, Chang and co-workers recently reported a related iridium-catalysed 
synthesis of six-membered heterocycles by a mechanistically distinct pathway.79 When 
attempting to carry out an aryl amidation of dioxazolone 504 the authors found that the 
expected δ-lactam product 505 was not formed. Instead the major product identified was the 
isomeric δ-lactam 506 in which a skeletal rearrangement had occurred. This suggested a 
different mode of reaction to the conventional SEAr pathway was operative. To rationalise the 
observed regioselectivity the authors proposed a mechanism as shown in Scheme 173. Upon 
generation of iridium-nitrenoid intermediate 507, spirocyclisation at the ipso-carbon generates 
spiro-amido intermediate 508. To generate the observed lactam 506, C-C bond migration of 
508 followed by rearomatisation is proposed to occur. Evidence for the proposed mechanism 
was also provided by a series of DFT calculations. For other substrates such as 509, cyclisation 




occurred to provide lactam products 510 and 511 without skeletal rearrangement. In these 
cases, the authors were unable to distinguish whether a direct SEAr or spirocyclisation/C-N 
bond migration is operative.  
 
Scheme 173 Iridium-catalysed arene amidation of dioxazolones.79 
A related rhodium-catalysed electrophilic amination of isoxazolidin-5-ones 512 was reported 
by Shibasaki and co-workers; this enabled the synthesis of benzo-fused lactams 513 and 514.80 
Following investigation of Hammett analysis and kinetic isotopes effects a mechanistic 
pathway involving spirocyclisation to 515 followed by skeletal rearrangement was proposed. 
 





Scheme 174 Rhodium-catalysed arene amination of isoxazolidin-5-ones.80 
4.1.2 Initial results 
As described previously, during the development of an acid-promoted dearomative amination 
of phenolic tosyloxycarbamates, competing aryl C-H amination was observed for substrates 
containing additional activating substituents on the aromatic ring (section 2.3.5). In light of 
this, a scope study of aryl C-H amination reaction was undertaken. To this end, a range of 
phenyl tosyloxycarbamates 517a-d, with varying electron properties of the aryl ring were 
synthesised (Scheme 175). The substrates were prepared by Mitsunobu reaction of the 
corresponding alcohols 516a-d with the preactivated reagent BocNHOTs to generate 517a-d 
in excellent yields. 
 
 Scheme 175 Synthesis of substituted phenyl tosyloxycarbamates 517a-d.  
With the substrates in hand, they were subjected to the reaction conditions [200 mol% TFA in 
0.1 M TFE] and the results are presented in Scheme 176. For unsubstituted phenyl-system 517a 
cyclisation under these conditions was relatively efficient and the tetrahydroquinoline product 
518a was formed in 65% yield. Improved reactivity was observed for the more electron-rich 
methoxy-phenyl-substituted 517b which cyclised to 518b in 80% yield. In contrast, the 
presence of moderately electron-withdrawing substituents on the aromatic ring resulted in a 
complete shutdown of the reaction, as exemplified by the Br-substituted system 517c from 
which none of the desired product 518c was isolated. The reaction also failed with substrate 




517d containing a CF3-substituted phenyl group. From these results, it is evident that the 
reaction is very dependent on the electronic properties of the arene and requires a sufficiently 
electron-rich arene for efficient cyclisation to occur. It should be noted that in Falck and 
co-workers report on rhodium-catalysed intramolecular amination the conditions are much less 
dependent on the electronic properties of the arene with high yields observed even with 
electron-poor substrates such as 517c and 517d.33  
 
Scheme 176 Intramolecular amination of substituted arenes. 
4.1.3 Further studies towards an intramolecular aryl C-H amination reaction 
The following results in this section (3.1.2) were obtained by an MSci student Jacob Burley 
and hence are not detailed in the experimental section. 
To further investigate a transition metal-free intramolecular aryl C-H amination reaction the 
nature of the hydroxylamine-derived activating group was examined. To this end, a series of 
hydroxylamine substrates 519a-c, each containing a different activated hydroxylamine group 
were synthesised and subjected to the standard reaction conditions (Table 12). An excellent 
yield was obtained using the OMs substrate 519a which cyclised to 518b with a comparable 
level of efficiency to the OTs substrate 517b. Significantly lower yields were observed with 
OBz and OFBz substrates 519b and 519c which were converted to 518b in 52% and 42% yields 
respectively. As none of these leaving groups had performed significantly more effectively 
than substrate 517b, the OTs group was chosen for further evaluation of the reaction scope. 
 





Table 12 Effect of the leaving group on the intramolecular aryl C-H amination reaction. 
With an effective leaving group in hand, a further evaluation of the scope with regard to 
substitution on the aryl ring and carbon tether was performed. As mention previously 
electron-poor arenes were ineffective as substrates in the reaction and therefore electron-poor 
arenes were generally avoided. Following Mitsunobu reactions with the corresponding 
alcohols, substrates 520a-d were obtained in high yield and examined in the aryl amination 
reaction (Scheme 177). Cyclisation of 520a, containing a methyl group in the meta-position, 
cyclised effectively to 521a although only a moderate yield of 48% was obtained. A similar 
level of efficiency was observed for naphthyl substrate 520b which cyclised to 
tetrahydroquinoline 521b in 49% yield. The reaction tolerates substitution at the γ-position of 
the carbon tether, as exemplified by substrate 520c which cyclised to 521c in 81% yield. On 
the other hand, substitution at the α-position was not tolerated. Attempted cyclisation of 520d 
containing a methyl group α to nitrogen was unsuccessful and the only isolated product was 
ketone 522 which formed in 68% yield (Scheme 177).  
 
Scheme 177 Further evaluation of the scope of aryl C-H amination: substitution on the arene and 
carbon tether.  




Ketone 522 likely forms by Boc deprotection of 520d to generate intermediate 523 which 
undergoes 1,2-migration with expulsion of TsOH (Scheme 178). The resulting iminium ion 
524 is then hydrolysed, possibly upon work up to form the corresponding ketone product. In 
the presence of a rhodium catalyst substrate 520d undergoes efficient cyclisation to form 
tetrahydroquinoline 521d;33 however, in its absence it is likely that the rate of cyclisation is 
slower than this side reaction and so formation of ketone 522 is favoured. LII 
 
Scheme 178 Proposed mechanism for formation of ketone 522. 
To extend the scope further, the use of heteroatoms in the tether was investigated. Substrate 
525a containing an ether group and substrate 525b containing an amine group in the tether 
were synthesised and subjected to the standard reaction conditions (Scheme 179). 
Unfortunately, both 525a and 525b failed to undergo the desired cyclisation. The generation 
of other ring sizes was next examined. 5- and 7-ring substrates 525c and 525d were synthesised 
and subjected to the aryl C-H amination reaction; however, both substrates proved ineffective. 
The failure of substrate 525d to undergo cyclisation is perhaps not surprising due to the slower 
rate at which 7-exo cyclisations occur versus 6-exo cyclisations; however, the failure of 
substrate 525c is surprising. The formation of 5-membered rings is usually very facile 
compared to 6-ring cyclisations.  
 
LII The increased sterics around the nitrogen likely slows down the rate of cyclisation. 





Scheme 179 Attempted aryl C-H amination of substrates 525a-d. 
Two additional substrates, aniline-derived 527 and benzothiophene-derived 528 were also 
examined in the aryl C-H amination reaction; however, both 527 and 528 failed to generate the 
desired cyclised products 529 and 530 (Scheme 180). In the case of the aniline substrate 527 
this is most likely due to protonation of the aniline nitrogen under the acidic conditions 
converting the amine from an electron donating to an electron withdrawing group and, hence 
impeding reactivity. 
 
Scheme 180 Attempted aryl C-H aminations of substrates 527 and 528. 
When the aryl C-H amination reaction was performed using lower loading of TFA (15 mol%) 
successful cyclisation was observed with substrates 520a and 520c; in the case of the former 
improved efficiency was observed versus the reaction under the standard conditions 
(Scheme 181a). Dimethyl aniline substrate 527 was also examined using these modified 
conditions; however, the desired tetrahydroquinoline product 529 was not obtained 
(Scheme 181b). Instead the fully unsaturated quinoline product 531 was isolated in 22% yield. 
The mechanism for the formation of 531 is unclear; however, it is likely that upon formation 
of tetrahydroquinoline 529 the N-O bond of a second equivalent of substrate acts as an external 
oxidant to oxidise 529 at least as far as the dihydroquinoline which may then be further oxidised 
to quinoline 531 by exposure to air.229  





Scheme 181 (a) Aryl C-H amination of substrates 520, 527 under modified conditions. 
(b) Observation of quinoline side-product 531 in the cyclisation of substrate 527. 
4.2 Studies towards a sulfoxide imination reaction for the synthesis of 
sulfoximines 
The results of brief studies towards an intermolecular imination of sulfoxides to generate 
sulfoximines are described below. As with the previously described amination reactions the 
approach relies upon the generation of an electrophilic amino-reagent through the in situ 
activation of N-Boc-hydroxylamine reagents. 
4.2.1 Introduction 
In recent years sulfoximines have emerged as a valuable class of compounds, particularly in 
the area of medicinal chemistry, due to their versatile chemical properties and interesting 
bioactivities.230,231 The sulfoximine group has a number of desirable physiochemical properties 
including high metabolic stability, such as stability to hydrolysis, and has both hydrogen bond 
acceptor and donor capabilities. Following the discovery of the first sulfoximine, methionine 
sulfoximine,232 a number of bioactive sulfoximine-containing compounds have been reported. 
These include sulfoxaflor,233 a commercially available insecticide and BAY1000394, a 
cyclin-dependent kinase inhibitor developed by Bayer, which is currently undergoing clinical 
trials (Scheme 182a).234 As well as their use in medicinal chemistry sulfoximines have also 




found application as chiral auxiliaries,235-238 as ligands for asymmetric catalysis239-242 and as 
directing groups for C-H functionalisation (Scheme 182b).243-246 As such, the development of 
novel synthetic routes to access sulfoximines is a valuable area of research.247 Access to 
unprotected sulfoximines containing a ‘free’ NH-group is particularly desirable as this offers 
potential to introduce further diversity. The functionalisation of NH-sulfoximines by 
arylation,248 alkylation,249 cyanation250 and thioetherification251 reactions have all been 
reported. 
 
Scheme 182 (a) Biological relevant sulfoximines.232-234 (b) Applications of sulfoximines.240,243 
Over the last few decades many methodologies for the synthesis of NH-sulfoximines have been 
reported. Most approaches involve the transfer of nitrogen to sulfoxides, which are in turn 
accessed by oxidation of the corresponding sulfide (Scheme 183). In most cases a protected 
N-group is introduced and therefore an additional deprotection step is required to access the 
NH-sulfoximine.LIII  
 
LIII An alternative approach to the synthesis of sulfoximines involves initial nitrogen transfer to a sulfilimine 
followed by an oxidation step.252 





Scheme 183 Strategies for synthesising sulfoximines from sulfides. 
Early methods for the preparation of NH-sulfoximines involved the metal-free imination of 
sulfoxides; however, these methods require harsh reaction conditions and toxic or explosive 
reagents such as a combination of NaN3 and sulfuric acid.
253-256 Other early methods employed 
O-mesitylene sulfonylhydroxylamine (MSH) as the aminating agent257-260 (Scheme 184a); 
however, the synthetic utility of this approach is limited by the use of MSH261 which is unstable 
and has to be prepared directly before use.  
In 1998 Müller and co-workers262 reported a copper-catalysed imination of sulfoxides with 
PhI=NTs as the nitrogen source. Since then a number of transition metal-catalysed approaches 
for the synthesis of sulfonamide protected sulfoximines have been reported 
(Scheme 184b).263,264 In particular, it is worth highlighting the work of Tye and co-workers 
who reported the transfer of nosyl-protected amines to sulfoxides to generate sulfoximines, 
which were then cleaved to the free N-H under mild conditions.265 Other transition 
metal-catalysed approaches to the synthesis of sulfoximines involved the generation of the 
active nitrogen source by in situ oxidation of an appropriate amine derivative. For example, 
Bolm and co-workers reported a rhodium-catalysed synthesis of sulfoximines using 
iminoiodinanes generated from the oxidation of amides in the presence of PhI(OAc)2; this 
approach enables the transfer of easily cleaved N-acyl groups to sulfoxides.266,LIV A related 
rhodium-catalysed approach to sulfoximines was reported by Bull and co-workers and enabled 
the generation of carbamate-protected sulfoximines, which were deprotected to the free N-H 
sulfoximine under acidic conditions. (Scheme 184b).269,LV  
 
LIV Fe267 and Ag268 catalysed methodologies have also been reported. 
LV Boc-protected sulfoximines have also been prepared from Boc-azides in the presence of an 
iron(II)-catalyst.270,271 





Scheme 184 (a) Traditional “meta-free” approaches to accessing NH-sulfoximines.253-260 
(b) Transition metal-catalysed synthesis and subsequent cleavage of N-protected sulfoximines.262-269 
Whilst these transformations are very effective at generating protected sulfoximines, to access 
the NH-sulfoximine an additional deprotection step is required. A transition metal-catalysed 
method for the direct synthesis of NH-sulfoximines was reported by Richards and Ge using 
DPH as the nitrogen source and Rh2(esp)2 as the catalyst (Scheme 185).
272 This approach is 
compatible with sulfoxides containing alkyl, aryl, allyl and heterocyclic groups and in general 
the sulfoximines were obtained in good to excellent yields. 
 
Scheme 185 Rhodium-catalysed synthesis of NH-sulfoximines.272 
As the use of transition metal catalysts such as rhodium can be expensive on large scale and 
presents toxicological issues when used in the late-stage preparation of pharmaceuticals, a 
number of metal-free approaches to sulfoximines have been developed. Several groups have 
reported metal-free syntheses of protected sulfoximines by the metal-free transfer of amines to 




sulfoxides in the presence of an oxidant such as PhI(OAc)2 or NCS (Scheme 186).
194,273,274 A 
very mild approach to the synthesis of sulfoximines was reported by Yudin and co-workers 
who developed an electrochemical approach to sulfoximines using Phth-NH2 as the iminating 
agent; this method avoids the use of transition metals and stoichiometric oxidants.275 
 
Scheme 186 Selected examples of metal-free imination of sulfoxides.273-275 
As with most transition-metal catalysed approaches, the majority of metal-free methods for the 
synthesis of sulfoximines generate protected sulfoximines. To address this issue Bull and 
co-workers reported a metal-free approach to N-H sulfoximines using ammonium carbonate as 
the nitrogen source in combination with PhI(OAc)2 (Scheme 187a).
276 Based on mechanistic 
studies the authors proposed that the ammonium carbonate provides a source of ammonia 
which reacts with PhI(OAc)2 to form iminoiodinane 532 or iodonitrene 533, either of which 
may act as the reactive nitrogen electrophile. The reaction showed excellent compatibility with 
a variety of functional groups including alkenes, alkynes, alkyl amines, phenols, esters, 
aldehydes and nitriles. Extension of the methodology to the direct synthesis of sulfoximines 
from the corresponding sulfides was also possible, providing an efficient route to sulfoximines 
under very mild reaction conditions (Scheme 187b).277,LVI 
 
LVI A flow process based on this approach was recently developed by Luisi.278 





Scheme 187 (a) A metal-free synthesis of N-H sulfoximines by sulfoxide imination.276 (b) A direct 
synthesis of NH-sulfoximines from sulfides.277 
4.2.2 Initial results and optimisation 
With the view to investigating a metal and oxidant-free synthesis of sulfoximines the feasibility 
of using the preactivated hydroxylamine reagent BocNHOTs for the amination of sulfoxides 
was examined. Methyl phenyl sulfoxide 534a was chosen as substrate for initial investigation. 
When subjected to the reaction conditions [BocNHOTs (150 mol%), TFA (200 mol%) in TFE 
(0.1 M)] 534a was converted to sulfoximine 535a in 50% yield (Scheme 188). 
 
Scheme 188 Initial attempted imination of sulfoxide 534. 
To improve the efficiency of this reaction a series of optimisations were carried out beginning 
with studying the effect of concentration. Lowering the concentration to 0.05 M had no effect 
on the yield of sulfoximine 535a (Table 13, entry 1); however, when the yield was increased 
to 0.2 M a slight improvement to 57% yield was observed (Table 13, entry 2). The yield 




continued to increase as the concentration was increased until an optimal yield was obtained at 
a concentration of 1.0 M. (Table 13, entry 5). At higher concentrations the poor solubility of 
BocNHOTs in TFE was an issue.  
 
Table 13 The effect of concentration on the imination of sulfoxide 534a. 
A solvent screen was performed, and the results are summarised in Table 14. As observed for 
the dearomative amination reaction, effective imination was observed in CH2Cl2 and PhMe 
(Table 13, entries 1 and 2). In this case, however, reaction in these solvents performed with 
similar levels of efficiency versus the reaction in TFE. A moderate yield of 51% was also 
achieved in MeCN (Table 14, entry 3). However, polar protic solvents such as MeOH, i-PrOH 
and EtOH did not lead to successful imination (Table 14, entries 4-5). Other common solvents 
such as Et2O, THF, acetone and EtOAc were also ineffective for this reaction (Table 14, entries 
7-10). 
 
Table 14 Solvent screen for the imination of sulfoxides 534a. 




Finally, the effect of temperature was evaluated. At a higher temperature of 40 oC a reduction 
in yield to 62% was observed (Table 15, entry 2). At 60 oC a further decrease in yield to 48% 
occurred. (Table 15, entry 3).  
 
Table 15 The effect of temperature on the imination of sulfoxide 534a in TFE. 
As the reaction occurs with a similar level of efficiency in PhMe as in TFE, and due to the 
lower cost of PhMe, further optimisation was also performed in PhMe. In this solvent 
increasing the temperature to 40 oC also led to a reduction in yield to 55% (Table 16, entry 3). 
However, a slight increase in yield to 75% was obtained by performing the reaction at 30 oC 
(Table 16, entry 2).LVII  
 
Table 16 The effect of temperature on the imination of sulfoxide 534a in PhMe. 
4.2.2.2 Substrate scope 
With two optimised conditions in hand, the scope of the reaction was investigated. Sulfoxides 
534b-e were synthesised from the corresponding sulfides using FeCl3/H5IO6 (Scheme 189).
279 
The required sulfoxides 534b-e were obtained in good to excellent yields. 
 
LVII Increasing the loading of BocNHOTs and TFA had a detrimental effect on the yield as did increasing or 
decreasing the reaction time. 





Scheme 189 Synthesis of sulfoxides 534b-e. 
A range of sulfoxides were subjected to the optimised reaction conditions and the results are 
summarised in Scheme 190. Moderate yields were obtained for diphenyl and dibenzyl 
substituted sulfoxides 534f and 534b which in TFE afforded the sulfoximine products 535f and 
535b in 58% and 53% respectively. The reaction was more efficient with 
para-methoxyphenyl-substituted 534c which was converted to sulfoximine 535c in 70% yield. 
In contrast, sulfoxides 534d and 534e both performed poorly in the reaction. The low yields 
are likely due to a reduction in nucleophilicity of the sulfoxide due to the presence of the 
electron-withdrawing chloro- and ester groups. The reactions were also performed using the 
conditions optimised for reaction in PhMe. In general, with the exception of sulfoxide 534f, 
comparable yields were obtained versus reaction in TFE.  
 
Scheme 190 Amination of sulfoxides 534a-f. 





The application of metal-free amination reactions using activated N-Boc hydroxylamines has 
been applied to aryl C-H aminations. Electron-rich arenes undergo efficient cyclisation to 
afford unprotected tetrahydroquinolines. Unfortunately, the scope of this methodology is 
limited as many arenes failed to undergo efficient amination. In particular, electron-deficient 
arenes are incompatible with this reaction.  
N-Boc hydroxylamines have also been applied to the synthesis of sulfoximines by sulfoxide 
imination. Unlike many of the approaches in the literature to sulfoximines this methodology 
allows efficient access to unprotected NH-sulfoximines allowing for further functionalisation. 
Although this approach benefits from the lack of a requirement for a transition metal catalyst 
or the need for an external oxidant, the poor reactivity of electron-deficient sulfoxides is a 
limitation of this approach.  




Chapter 5 - Overall summary and conclusions 
In summary, the main focus of this thesis is the development of C-N bond forming reactions 
of electrophilic N-tosyloxycarbamates and related N-O donors. In Chapter 2 the development 
of a dearomatising amination reaction that affords unprotected nitrogen-containing spirocyclic 
ring systems was described (Scheme 191a). This approach builds upon the work of Falck and 
co-workers who developed intramolecular aryl C-H amination processes triggered by 
rhodium-nitrenoids, that are generated from activated hydroxylamines.33 These activated 
species are themselves accessed by in situ deprotection of N-Boc precursors which are easily 
prepared by Mitsunobu reaction. For the dearomative cyclisation of phenols and naphthols 
hydroxylammonium intermediates of this kind are sufficiently reactive for C-N bond formation 
to occur effectively in the absence of a transition metal catalyst. Upon treatment with 
trifluoroacetic acid in 2,2,2-trifluoroethanol, a potent electrophilic aminating agent is formed 
that reacts with pendant arenes in a SEAr-like process to generate the dearomatised product.  
 
Scheme 191 (a) C-N bond forming dearomatising amination and aryl C-H amination. (b) Annulative 
derivatisations of the dearomatised products. 
In addition to dearomatisations, this method can promote aryl C-H aminations of sufficiently 
electron-rich arenes, under the same metal-free conditions, to access tetrahydroquinoline 
structures (section 4.1). As these processes allow for the direct preparation of unprotected 
nitrogen ring systems, further manipulations can be achieved by direct reaction at nitrogen to 
access complex, natural product-like structures (Scheme 191b).  




A related base-promoted dearomatising amination reaction of indoles, phenols and naphthols 
was developed in tandem by another member of the group, Xiaofeng Ma. This represents a 
complimentary approach to the formation of spirocyclic pyrrolidine products in which the 
N-protecting group is maintained in the product. Preliminary results suggest that the 
development of an enantioselective reaction based on this approach is feasible. In the presence 
of chiral phase transfer catalyst 298, naphthol 299 cyclised to spirocycle 170 in 54% e.e. 
(Scheme 192). 
 
Scheme 192 Preliminary result in the development of an enantioselective dearomatising amination 
reaction. 
The application of N-Boc protected hydroxylamines in metal-free C-N bond forming reactions 
was further expanded to the synthesis of aziridines (section 3.2). Hydroxylamine-derived 
substrates containing a pendent alkene underwent stereospecific intramolecular aziridination 
to generate novel aza-bicyclic ring systems (Scheme 193a). Based on a combination of 
experimental observations and computational studies, aziridination is believed to occur by a 
concerted mechanism resembling an aza-variant of a Prilezhaev reaction. This protocol exhibits 
good substrate scope and is effective for the aziridination of di-, tri- and tetrasubstituted 
alkenes. The same alkenyl substrates can also undergo 1,2-alkene-difunctionalisations, when a 
suitable external nucleophile is present, to generate highly functionalised pyrrolidine and 
piperidine structures (Scheme 193b). 





Scheme 193 (a) Intramolecular aziridination reaction. (b) Alkene 1,2-difunctionalisations. 
Further work has shown that N-Boc hydroxylamine reagents also undergo metal-free imination 
of sulfoxides to generate NH-sulfoximines. There a very few methods in the literature for the 
direct synthesis of NH-sulfoximines from sulfoxides, with most methods generating a 
N-protected sulfoximine which must then be deprotected requiring an extra synthetic step. A 
range of NH-sulfoximines were generated using this approach in moderate to excellent yields. 




Chapter 6 - Experimental 
6.1 General Experimental Details 
Starting materials were purchased from commercial sources (Acros, Aldrich, Alfa Aesar, 
Fluorochem and Strem) and used without further purification unless otherwise stated. 
Anhydrous 2,2,2-trifluoroethanol was obtained by drying over 4Ȧ molecular sieves while other 
anhydrous solvents were obtained by distillation using standard procedures or by passage 
through drying columns supplied by Anhydrous Engineering Ltd. The removal of solvents 
in vacuo was achieved using both a Büchi rotary evaporator (bath temperatures up to 45 °C) at 
a pressure of either 15 mmHg (diaphragm pump) or 0.1 mmHg (oil pump), as appropriate, and 
a high vacuum line at room temperature. Reactions requiring anhydrous conditions were run 
under a dry atmosphere of nitrogen or argon; glassware was either flame dried immediately 
prior to use or placed in an oven (200 °C) for at least 2 hours and allowed to cool either in a 
desiccator or under an atmosphere of nitrogen or argon; liquid reagents, solutions or solvents 
were added via syringe through rubber septa. Flash column chromatography was performed 
using silica gel (Aldrich 40-63 μm, 230-400 mesh). Thin layer chromatography was performed 
using aluminium backed 60F254 silica plates. Visualisation was achieved by UV fluorescence 
or a basic KMnO4 solution and heat. Proton nuclear magnetic resonance were recorded on a 
Varian or Jeol spectrometer at 400 MHz or 500 MHz while 13C NMR spectra were recorded at 
100 MHz. 19F NMR spectra were recorded at 283 MHz. Chemical shifts (δ) are given in parts 
per million (ppm) and referenced to the appropriate residual solvent peak.  Peaks are described 
as singlets (s), doublets (d), triplets (t), quartets (q), quintets (qn), sextet (sex), multiplets (m) 
and broad (br). Coupling constants (J) are quoted to the nearest 0.5 Hz. Assignments of 
1H NMR and 13C NMR signals were made, where possible, using COSY, HSQC, HMBC and 
NOE experiments. Mixtures of isomers which could not be separated (e.g. diastereomers and/or 
rotamers) have been characterized together and are referred to as A and B. Numbering systems 
for NMR signal assignments are specified on the structure and are not related to those used for 
the compound names.  In situ yields were determined by integration of the 1H NMR of the 
crude material employing 1,3,5-trimethoxybenzene or 1,4-dinitrobenzene as internal standard. 
Mass spectra were obtained by the University of Bristol mass spectrometry service using a 
Bruker Daltonics FT-ICR-MS Apex 4e 7.0T FT-MS. Infrared spectra were recorded on a 
Perkin Elmer Spectrum Two FTIR spectrometer as either neat films or solids. Abbreviations 
used are: w (weak), m (medium), s (strong) and br (broad). Melting points were determined 




using a Reichert melting point table and temperature controller and are uncorrected. Chiral SFC 
was performed on an Agilent 1260 Infinity SFC Control Module system equipped with a 
quaternary pump, diode array detector and column thermostat under the conditions specified. 
Enantiomeric excess was determined by integration of chromatogram peaks. 
  




6.2 General procedures 
General procedure A for TBS protection of phenol 
To a solution of alcohol (1.0 equivalent) in DMF (approx. 2mL/mmol) at 0 o C was added 
imidazole (3.3 equivalents) and tert-butyldimethylsilyl chloride (2.2 equivalents). The reaction 
was stirred at room temperature and monitored by TLC. Upon completion, the reaction was 
quenched by addition of H2O and the organic phase extracted with hexane, dried over Na2SO4 
and concentrated in vacuo. To the crude reaction mixture was added MeOH (1 mL/mmol), 
THF (1 mL/mmol) and aqueous K2CO3 (2.0 equivalents) After stirring for 12 hours the reaction 
was quenched with 1 M HCl at 0 o C (until pH approx. 3). The mixture was extracted with Et2O 
(3 × 20 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude reaction mixture 
was purified by flash column chromatography. 
General procedure B for reduction of carboxylic acid/ester to alcohol using LiAlH4 
To a solution of carboxylic acid/ester (1.0 equivalents) in anhydrous THF or Et2O (approx. 
5 mL/mmol) at 0 oC was added LiAlH4 (equivalents specified) dropwise. The reaction was 
stirred at room temperature and monitored by TLC. Upon completion, the reaction mixture was 
cooled to 0 o C before addition of water (1 mL/g of LiAlH4), 15% aqueous NaOH 
(1 mL/g LiAlH4) and a final portion of water (3 mL/g of LiAlH4). The mixture was filtered 
through Celite® and washed with CH2Cl2. The phases were separated, and the aqueous phase 
extracted with CH2Cl2 (2 × 10 mL). The combined organic extracts were dried over Na2SO4, 
filtered and concentrated in vacuo to afford the crude product which was purified by flash 
column chromatography. 
General procedure C for the preparation of N-acyloxysulfonamides by Mitsunobu 
alkylation employing DEAD or DIAD 
To a solution of alcohol (1.0 equivalent), hydroxylamine-derived nucleophile (1.5 equivalents), 
and PPh3 (2.0 equivalents) in anhydrous PhMe/THF (3:1, 8 mL/mmol) at 0
 oC was added a 
solution of DEAD or DIAD (2.0 equivalents) in anhydrous PhMe (2 mL/mmol) dropwise. The 
reaction mixture was stirred at room temperature until completion by TLC analysis and the 
crude product was purified by flash column chromatography. 
General procedure D for the removal of silyl protecting group with HCl 
To a solution of silyl ether (1 equivalents) in MeOH (25 mL/mmol) and THF (25 mL/mmol) 
at 0 oC was added 1 M HCl (amount specified). The reaction was stirred at room temperature 




overnight until completion by TLC analysis. The reaction mixture was diluted with EtOAc 
(20 mL) and washed with saturated aqueous NaHCO3 (10 mL) and brine (10 mL), dried over 
MgSO4, filtered and concentrated in vacuo. 
General procedure E for alkene hydrogenation with Pd/C 
A solution of alkene (1.0 equivalent) in MeOH or EtOH or EtOAc (approx. 5 mL/mmol) was 
purged with argon before the addition of 10 wt. % Pd/C (5-10 mol%). The flask was fitted with 
a balloon of hydrogen and stirred at room temperature overnight and monitored by TLC. Upon 
completion, the reaction mixture was filtered over a bed of Celite® washing with the 
appropriate solvent and concentrated in vacuo to afford the product 
General procedure F for reduction of carboxylic acids to alcohols via anhydride 
To a solution of carboxylic acid (1.0 equivalent) and triethylamine (1.0 equivalent) in THF (10 
mL/mmol) at -5 oC was added a solution of ethyl chloroformate (1.0 equivalent) in THF 
(1 mL/mmol) dropwise maintaining a temperature below 0 oC. The reaction was stirred at the 
same temperature for 1 hour and filtered to remove the white precipitate that formed, washing 
with THF (10 mL). The filtrate was added dropwise to a solution of NaBH4 (2.5 equivalents) 
in H2O (approx. 2 mL/mmol) at -5 
oC. The reaction was stirred at room temperature overnight 
and monitored by TLC. Upon completion, the reaction was acidified to approx. pH 3 with 
1 M HCl. The layers were separated, and the aqueous layer extracted with Et2O (3 × 10 mL). 
The combined organic extracts were washed with aqueous 1 M NaOH (10 mL) and H2O 
(10 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude product was purified 
by flash column chromatography. 
General procedure G for preparation of Boc-protected hydroxylamine derivatives by 
Mitsunobu alkylation33 
Diisopropyl azodicarboxylate (1.2 equivalents) was added at 0 oC to a stirring solution of 
triphenylphosphine (1.2 equivalents) in anhydrous THF (approx. 2mL/mmol) under a nitrogen 
atmosphere. After 30 minutes stirring at this temperature a solution of alcohol (1.0 equivalent) 
and amine nucleophile (1.2 equivalents) in anhydrous THF (approx. 2mL/mmol) were added. 
The reaction was stirred at 0 o C for 1 hour after which it was stirred at room temperature and 
monitored by TLC. Upon completion, the reaction mixture was concentrated in vacuo and 
purified by flash column chromatography.  
 




General procedure H for the removal of silyl protecting group with TBAF/AcOH 
To a solution of silyl ether (1.0 equivalent) in THF (approx. 20mL/mmol) at 0 oC was added a 
solution of 1:1 TBAF/AcOH (equivalents specified, 0.1 M in THF). The reaction mixture was 
stirred at room temperature and monitored by TLC. Upon completion, the reaction mixture was 
quenched with water (10 mL), extracted with EtOAc (2 × 10 mL), washed with saturated 
aqueous NaHCO3 (10 mL) and brine (10 mL), dried over Na2SO4, filtered and the concentrated 
in vacuo. The crude product was purified by flash column chromatography. 
General procedure I for intramolecular dearomatising amination  
To a stirring solution of Boc-protected amino substrate (1.0 equivalent) in anhydrous 
2,2,2,-trifluoroethanol (0.1 M) at 0 oC was added trifluoroacetic acid (2.0 equivalents). After 
stirring for 2 hours at 0 oC the reaction was warmed to room temperature and monitored by 
TLC. Upon completion, the reaction mixture was concentrated in vacuo and purified by flash 
column chromatography, with a small amount of Et3N (<1%) added to the appropriate eluent. 
In cases where the product was unstable the TFA salt was obtained by re-acidification with 
TFA. 
General procedure J for formation of unsaturated esters by Wittig reaction  
Aldehyde (1.0 equivalent) and methyl 2-(triphenyl-phosphaneylidene) acetate or ethyl 
2-(triphenyl-phosphaneylidene) acetate (1.5 equivalents) in CH2Cl2 (approx. 1 mL/mmol) were 
stirred at room temperature overnight and monitored by TLC. Upon completion, the reaction 
mixture was concentrated in vacuo and purified by flash column chromatography. 
General Procedure K for preparation of Weinreb amides from Carboxylic acids 
To a solution of carboxylic acid (1.0 equivalent) in anhydrous CH2Cl2 under nitrogen at 0 
oC 
was added N,O-dimethylhydroxylamine hydrochloride (1.4 equivalents), Et3N (1.4 
equivalents), 4-dimethylaminopyridine (1.4 equivalents), and N,N’-dicyclohexylcarbodiimide 
(1.4 eq.). The solution was stirred at room temperature overnight and then filtered through 
Celite, eluting with EtOAc. The filtrate was washed sequentially with 1 M HCl (10 mL) and 
saturated aqueous NaHCO3 (10 mL). The combined organic extracts were dried over MgSO4, 
filtered and concentrated in vacuo. The crude product was purified by flash column 
chromatography. 
 




General procedure L for the acylation of spirocyclic pyrrolidines with phenylacetyl 
chloride 
A solution of spirocyclic pyrrolidine (1.0 equivalent) in anhydrous THF (5 mL/mmol) under 
an atmosphere of nitrogen was cooled to 0 oC and phenylacetyl chloride (2.0 equivalents) and 
K3PO4 (4.0 equivalents) were added. The reaction was warmed to room temperature and stirred 
overnight and monitored by TLC. Upon completion, the reaction was quenched with water 
(1 mL) and extracted with EtOAc (3 × 2 mL). The combined organic extracts were dried over 
Na2SO4, filtered and concentrated in vacuo. The crude product was purified by flash column 
chromatography. 
General procedure M for the synthesis of tricyclic amides using LiHMDS 
To a solution of amide (1.0 equivalent) in anhydrous THF (1 mL) at -78 oC and under an 
atmosphere of nitrogen was added lithium bis(trimethylsilyl)amide (1.5 equivalents). The 
reaction was stirred at this temperature for the time stated. Upon completion, the reaction 
mixture was warmed to 0 oC and quenched with saturated aqueous NH4Cl (0.3 mL) and 
extracted with EtOAc (3 × 5 mL). The combined organic extracts were washed with brine 
(5 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product 
was purified by flash column chromatography. 
General procedure N for the synthesis of tricyclic urea compounds 
A solution of spirocyclic pyrrolidine (1.0 equivalent) in anhydrous CH2Cl2 (0.2 M) was cooled 
to 0 oC and phenyl isocyanate (2.0 equivalents) and Et3N (4.0 equivalents) were added. The 
reaction was stirred at this temperature for 2 hours before warming to room temperature and 
stirring overnight, monitoring by TLC. Upon completion, the reaction mixture was quenched 
with saturated aqueous NH4Cl (1 mL) and extracted with EtOAc (3 × 5 mL). The combined 
organic extracts were washed with brine (5 mL), dried over Na2SO4, filtered and concentrated 
in vacuo. 
General procedure O for enantioselective dearomatising amination  
A flame-dried resealable tube, fitted with a magnetic stirrer, was charged with cyclisation 
substrate (1.0 equivalent) phase-transfer catalyst (10 mol%) and Cs2CO3 (2.0 equivalents). The 
tube was fitted with a rubber septum and purged with nitrogen before solvent was added by 
syringe. The tube was sealed and heated at the specified time for 48 hours. The reaction mixture 




was cooled to room temperature and concentrated in vacuo. The crude product was purified by 
flash column chromatography. 
General procedure P for intramolecular aziridination 
A flame dried re-sealable tube was charged with alkene (1.0 equivalent) and fitted with a rubber 
septum. The tube was purged with nitrogen before anhydrous TFE (0.1 M) and TFA (2.0 
equivalents) were added via syringe. The tube was sealed and stirred at room temperature for 
the time noted. Upon completion the reaction mixture was concentrated in vacuo and the crude 
mixture was purified by flash column chromatography with addition of Et3N (1-2 drops) to the 
eluent to afford the pure product.  
General procedure Q for Johnson-Claisen rearrangement  
A solution of propionic acid (0.2 equivalents) in triethyl orthoacetate (10.0 equivalents) was 
heated at 110 °C for 1 hour. After this time allylic alcohol (1.0 equivalent) was added and the 
reaction mixture was heated at reflux overnight. Upon cooling to room temperature, the 
reaction mixture was concentrated in vacuo to afford the crude product which was purified by 
flash column chromatography. 
General procedure R for alkylation of sulfonamides with allylic bromides 
To a solution of sulfonamide (1.0 equivalent) and K2CO3 (1.5 equivalents) in acetone 
(2 mL/mmol) was added allylic bromide (1.5 equivalents) and the reaction was stirred at room 
temperature overnight. Upon completion the reaction was concentrated in vacuo and purified 
by flash column chromatography. 
General procedure S for formation of piperidines by ring expansion of aziridines 
To a solution of aziridine (1.0 equivalent) in anhydrous THF (1 M) was added the appropriate 
acid halide or anhydride (equivalents specified) and the reaction was stirred at 0 oC or room 
temperature. Upon completion the reaction was concentrated in vacuo and purified by flash 
column chromatography. 
General procedure T for the synthesis of N-methyl tert-butyl carbamate reagents  
To a solution of tert-butyl hydroxy(methyl)carbamate (1.0 equivalent) and sulfonyl chloride 
(1.05 equivalents) in Et2O (4 mL/mmol) at 0 
oC was added Et3N (1.05 equivalent). The reaction 
was warmed to room temperature and stirred overnight. The reaction mixture was filtered 




through Celite®, washing with Et2O and concentrated in vacuo. The crude product was purified 
by flash column chromatography.  
General procedure U for intermolecular aziridination 
 A flame dried resealable tube was charged with tert-butyl (((chloromethyl)sulfonyl)oxy) 
(methyl)carbamate (1.2 equivalents) and fitted with a rubber septum. The tube was purged with 
nitrogen before addition of alkene (1.0 equivalent), TFE (0.5 M) and TFA (2.0 equivalents). 
The tube was sealed and stirred at room temperature for the stated time before being 
concentrated in vacuo and purified by flash column chromatography. 
General procedure V for formation of unsaturated esters by Horner-Wadsworth-
Emmons reaction 
To a suspension of NaH (60 w.t.% in mineral oil, 1.5 equivalents) in anhydrous THF 
(5 mL/mmol) at 0 oC was added phosphonoacetate reagent (1.5 equivalents) dropwise. The 
reaction was stirred at this temperature until gas evolution had ceased at which point a solution 
of aldehyde (1.0 equivalent) in THF (0.5 mL/mmol) was added. The reaction was stirred at 
room temperature overnight. The reaction was quenched with saturated aqueous NH4Cl 
(40 mL), extracted with EtOAc (20 mL) and the organic phase washed with brine (20 mL), 
dried, filtered and concentrated. The crude product was purified by flash column 
chromatography. 
General procedure W for formation of aziridines by 1,2-alkene difunctionalisations 
A flame dried re-sealable tube was charged with alkene (1.0 equivalent) and fitted with a rubber 
septum. The tube was purged with nitrogen before anhydrous TFE (0.1 M) and TFA (2.0 
equivalents) were added via syringe. The tube was sealed and stirred at room temperature for 
the time noted. Upon completion the reaction mixture was concentrated in vacuo and the crude 
mixture was purified by flash column chromatography with addition of Et3N (1-2 drops) to the 
eluent to afford the pure product.  
General procedure X for intramolecular aryl C-H amination 
To a stirring solution of Boc-protected amino substrate (1.0 equivalent) in anhydrous 
2,2,2,-trifluoroethanol (0.1 M) at 0 oC was added trifluoroacetic acid (2.0 equivalents). After 
stirring for 2 hours at 0 oC the reaction was warmed to room temperature and monitored by 




TLC. Upon completion, the reaction mixture was concentrated in vacuo and purified by flash 
column chromatography, with a small amount of Et3N (<1%) added to the appropriate eluent.  
General procedure Y synthesis of sulfoximines by amination of sulfoxides 
To a flame-dried reaction tube was added sulfoxide (1.0 equivalent) and amino reagent (1.5 
equivalents). The tube was fitted with a suba seal and flushed with nitrogen. TFE or PhMe 
(1 M) was added via syringe followed by TFA (2.0 equivalents) and the reaction was stirred at 
the stated temperature and monitored by TLC. Upon completion the reaction was diluted with 
CH2Cl2 (5 mL) and washed with saturated aqueous Na2CO3 (5 mL) and the phases were 
separated, and the aqueous phase extracted with CH2Cl2 (2 × 5 mL). The combined organic 
phases were washed with brine (5 mL), dried over Na2SO4, filtered and concentrated in vacuo 
before purification by flash column chromatography.  
General procedure Z oxidation of sulfides to sulfoxides279 
To a solution of sulfide (1.0 equivalent) in MeCN (1mL/mmol) was added FeCl3 (3 mol%). 
The reaction was stirred for 5 minutes before the addition of H5IO6 (1.1 equivalents). After 
stirring at room temperature, the reaction until complete by TLC, the reaction was quenched 
with saturated aqueous Na2S2O3 (4 mL/mmol) and extracted with CH2Cl2 (4 × 4 mL/mmol) 
and the combined organic extracts were dried over Na2SO4, filtered and concentrated in vacuo. 
Purification by flash column chromatography afford the desired sulfoxide. 
  




6.3 Experimental procedure for the studies in Chapter 2 
N-Hydroxy-4-methylbenzenesulfonamide 
 
This compound was prepared according to a literature procedure.280 
To a solution of hydroxylamine hydrochloride (10.4 g, 150 mmol) in MeOH (45 mL) and water 
(30 mL) was added MgO (5.1 g, 129 mmol). The reaction mixture was stirred at room 
temperature for 10 minutes before addition of a solution of TsCl (12.4 g, 65 mmol) in THF 
(450 mL) followed by another portion of MgO (2.6 g, 64.5 mmol). The reaction mixture was 
stirred for 1 hour before being filtered and concentrated in vacuo. Purification by flash column 
chromatography (40% EtOAc:hexane) afforded the title compound (7.6 g, 62%) as a colourless 
crystalline solid; 1H NMR (400 MHz, CDCl3) δ 7.84 (2H, d, J = 8.5 Hz), 7.37 (2H, d, J = 8.5 
Hz), 6.65 (1H, s), 6.05 (1H, d, J = 4.0 Hz), 2.46 (3H, s). 
The spectroscopic properties were consistent with the data available in the literature.281 
 
N-Tosyl-O-pentafluorobenzoyl hydroxylamine  
 
To a suspension of N-tosylhydroxylamine (2.80 g, 14.4 mmol) and pentafluorobenzoic acid 
(3.05 g, 14.4 mmol) in CH2Cl2 (130 mL) at 0 
oC was added a solution of 
N-N’-dicyclohexylcarbodiimide (3.30 g, 16.0 mmol) in CH2Cl2 (130 mL) dropwise. The 
resulting mixture was stirred at 0 oC overnight before filtration to remove the white precipitate. 
The filtrate was concentrated in vacuo and the crude mixture was purified by flash column 
chromatography (20% EtOAc:hexane) to give the title compound (3.48 g, 63%) as a colourless 
solid; νmax / cm
-1 (solid) 3187 (br), 1777 (s), 1653 (s), 1597 (m), 1501 (s), 1170 (s); 1H NMR 
(400 MHz, CDCl3) δ 9.00 (1H, br s, NH), 7.87 (2H, d, J = 8.5 Hz, Ts ArCH), 7.37 (2H, d, 
J = 8.5 Hz, Ts ArCH), 2.46 (3H, s, Ts CH3); 
13C NMR (101 MHz, CDCl3) δ 157.9 (
FBz C=O), 
146.2 (Ts ArC), 132.0 (Ts ArC), 130.0 (2 × Ts ArCH), 128.9 (2 × Ts ArCH), 21.8 (Ts CH3). 
The aromatic 13C signals corresponding to the pentafluorobenzoyl group could not be resolved 
due to their weak intensity. 19F NMR (377 MHz, CDCl3) δ -134.7– -134.8 (2F, m), -144.1 (1F, 
tt, J = 21.0, 6.5 Hz), -158.6 – -158.8 (2F, m). 
The spectroscopic properties were consistent with the data available in the literature.52 








General procedure A: Carboxylic acid 145 (8.30 g, 50.0 mmol), tert-butyldimethylsilyl 
chloride (16.5 g, 110.0 mmol) and imidazole (11.25 g, 165.0 mmol) in DMF (100 mL) were 
employed. Purification by flash column chromatography (25% EtOAc:hexane) afforded 206 
(10.8 g, 77%) as a colourless solid; m.p.: 69-71 oC (EtOAc:hexane); Rf = 0.2 (20% 
EtOAc:hexane);  νmax / cm
-1 (solid) 2926 (m), 2882 (m), 2855 (m), 1714 (s), 1509 (s), 1249 (s), 
1213 (s); 1H NMR (400 MHz, CDCl3) δ 10.30 (1H, br s, CO2H), 7.06 (2H, d, J = 8.5 Hz, 
ArCH), 6.77 (2H, d, J = 8.5 Hz, ArCH), 2.89 (2H, t, J = 7.5 Hz, C3-H2), 2.65 (2H, t, J = 7.5 
Hz, C2-H2), 0.99 (9H, s, TBS (CH3)3), 0.19 (6H, s, TBS Si(CH3)2); 
13C NMR (101 MHz, 
CDCl3) δ 179.4 (C1), 154.2 (ArC), 133.0 (ArC), 129.3 (2 × ArCH), 120.2 (2 × ArCH), 36.1 
(C2), 30.0 (C3), 25.8 (TBS (CH3)3), 18.3 (TBS SiC(CH3)3), -4.3 (TBS Si(CH3)2); HRMS (ESI
+) 
Calculated for C15H25O3Si: 281.1567. Found [M+H]





General procedure B: 3-(4-((tert-Butyldimethylsilyl)oxy)phenyl)propanoic acid (1.40 g, 
5.0 mmol) and 2.0 equivalents of LiAlH4 (1M in THF) in anhydrous Et2O were employed. 
Purification by flash column chromatography (25% EtOAc:hexane) afforded 146 (990 mg, 
74%) as a colourless oil Rf = 0.6 (33% EtOAc:hexane); νmax / cm
-1 (film) 3339 (br), 2929 (s), 
2885 (s), 2858 (s), 1609 (m), 1508 (s), 1250 (s); 1H NMR (400 MHz, CDCl3) δ 7.04 (2H, d, 
J = 8.0 Hz), 6.75 (2H, d, J = 8.0 Hz), 3.64 – 3.68 (2H, m), 2.64 (2H, t, J = 7.5 Hz), 1.86 (2H, 




m), 1.35 (1H, br s), 0.98 (9H, s), 0.18 (6H, s); 13C NMR (101 MHz, CDCl3) δ 153.7, 134.4, 
129.2, 119.9, 62.3, 34.4, 31.2, 25.7, 18.2, -4.4.  





General Procedure C: Alcohol 146 (790 mg, 3.00 mmol), DEAD (0.94 mL, 6.0 mmol), 
TsNHOFBz (1.71 g, 4.50 mmol), and PPh3 (1.57 g, 6.00 mmol) in anhydrous PhMe:THF (5:1, 
38 mL) were employed. The reaction mixture was stirred at room temperature until completion 
by TLC analysis. The reaction mixture was concentrated in vacuo and purified by flash column 
chromatography (gradient, eluent: 4 – 15% EtOAc:hexane) to afford 147 (1.05 g, 56%) as an 
off-white solid; m.p.: 99-100 oC (Et2O:hexane); νmax / cm
-1 (solid) 2929 (m), 2857 (m), 1787 
(s), 1744 (s), 1508 (s), 1252 (s), 1168 (s); 1H NMR (400 MHz, CDCl3) δ 7.78 (2H, d, J = 8.5 
Hz, Ts ArCH), 7.37 (2H, d, J = 8.0 Hz, Ts ArCH), 7.00 (2H, d, J = 8.5 Hz, C5-H), 6.74 (2H, 
d, J = 8.5 Hz, C6-H), 3.21 (2H, br s, C1-H2), 2.71 (2H, t, J = 7.5 Hz, C3-H2), 2.46 (3H, s, Ts, 
CH3), 1.83 (2H, app. quint, J = 7.0 Hz, C2-H2), 0.97 (9H, s, TBS (CH3)3), 0.18 (6H, s, TBS 
Si(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 156.4 (O
FBz C=O), 153.9 (C7), 145.8 (Ts ArC), 
133.4 (Ts ArC), 130.0 (C4), 129.9 (2 × Ts ArCH), 129.6 (C5), 129.4 (2 × Ts ArCH), 119.9 
(C6)  51.9 (C1), 31.6 (C3), 28.6 (C2), 25.7 (TBS (CH3)3), 21.7 (Ts CH3), 18.2 (TBS 
SiC(CH3)3), -4.5 (TBS Si(CH3)2). The aromatic 
13C signals corresponding to the 
pentafluorobenzoyl group could not be resolved due to their weak intensity. 19F NMR (377 
MHz, CDCl3) -135.8 – -135.9 (2F, m), -145.9 (1F, tt, J = 21.0, 5.0 Hz), -158.9 – -159.0 (2F, 












General procedure D: N-acyloxysulfonamide 147 (150 mg, 0.24 mmol) and 1 M HCl (1.5 
mL) in MeOH (5 mL) and THF (5 mL) were employed. The reaction was stirred at room 
temperature overnight until completion by TLC analysis. The crude product was purified by 
flash column chromatography (20% EtOAc:hexane) to afford 148 (115 mg, 93%) as a 
colourless solid; m.p.: 139-141 oC (EtOAc:hexane); νmax / cm
-1 (solid) 3506 (m), 2970 (m), 
2901 (m), 1791 (s), 1517 (s), 1500 (s), 1361 (s), 1165 (s); 1H NMR (400 MHz, CDCl3) δ 7.78 
(2H, d, J = 8.0 Hz, Ts ArCH), 7.37 (2H, d, J = 8.0 Hz, Ts ArCH), 7.03 (2H, d, J = 8.0 Hz, 
C5-H), 6.74 (2H, d, J = 8.0 Hz, C6-H), 4.64 (1H, s, OH), 3.20 (2H, br s, C1-H2), 2.73 (2H, t, J 
= 7.5 Hz, C3-H2) 2.46 (3H, s, Ts CH3), 1.82 (2H, app. quint, J = 7.0 Hz, C2-H2); 
13C NMR 
(101 MHz, CDCl3) δ 153.9 (C7), 145.9 ( Ts ArC), 133.0 (Ts ArC), 130.0 (C4), 129.9 (2 × Ts 
ArCH), 129.8 (2 × Ts ArCH), 129.7 (C5), 115.4 (C6) 51.9 (C1), 31.6 (C3), 28.7 (C2), 21.8 (Ts 
CH3). The aromatic 
13C signals corresponding to the pentafluorobenzoyl group could not be 
resolved due to their weak intensity. 19F NMR (377 MHz, CDCl3) δ -135.9 (2F, m), -145.9 (1F, 







To a stirred solution of TsNHOH (1.87 g, 10.0 mmol) in EtOAc (50 mL) at -5 oC was added 
Et3N (1.37 mL, 9.90 mmol) dropwise. After 5 minutes benzyl chloride (1.14 mL, 9.90 mmol) 
was added dropwise over 15 minutes. After complete addition, the solution was warmed to 
room temperature and left to stir for 1.5 hours. After addition of water (25 mL) the layers were 
separated, and the aqueous phase extracted with EtOAc (3 × 30 mL). The combined organic 




extracts were washed with brine (20 mL), dried over MgSO4 and concentrated in vacuo. The 
resulting colourless solid (2.81 g, 97%) was used without any further purification; 1H NMR 
(400 MHz, CDCl3) δ 9.24 (1H, br s, NH), 7.91 (2H, dd, J = 8.5, 1.0 Hz, ArCH), 7.83 (2H, d, J 
= 8.5 Hz, Ts ArCH), 7.63 (1H, tt, J = 7.5, 1.0 Hz, ArCH), 7.45 (2H, dd, J = 8.0, 7.5 Hz, ArCH), 
7.27 (2H, d, J = 8.5 Hz, Ts ArCH), 2.39 (3H, s, Ts CH3); 
13C NMR (101 MHz, CDCl3) δ 164.9, 
145.7, 134.6, 132.3, 129.9, 129.6, 128.8, 128.7, 125.7, 21.7 (Ts CH3); HRMS (ESI
+) Calculated 






General procedure C: Alcohol 146 (532 mg, 2.00 mmol), DIAD (0.63 mL, 4.0 mmol), 
TsNHOBz (870 mg, 3.00 mmol) and PPh3 (1.05 g, 4.00 mmol) in anhydrous PhMe:THF (5:1, 
24 mL) were employed. The reaction mixture was stirred at room temperature until completion 
by TLC analysis. The reaction mixture was concentrated in vacuo and purified by flash column 
chromatography (gradient, eluent: 10 – 20% EtOAc:hexane) to afford the title compound (805 
mg, 74%) as a colourless solid; m.p.: 105-107 oC (Et2O:hexane); νmax / cm
-1 (solid) 2954 (m), 
2928 (m), 2900 (m), 2855 (m), 1767 (s), 1236 (s), 1168 (s); 1H NMR (400 MHz, CDCl3) δ 7.96 
(2H, m, ArCH), 7.80 (2H, d, J = 8.5 Hz, Ts ArCH), 7.62 (1H, t, J = 7.5 Hz, ArCH), 7.50 – 7.44 
(2H, m, ArCH), 7.38 (2H, d, J = 8.5 Hz, Ts ArCH), 6.99 (2H, d, J = 8.5 Hz, C5-H), 6.71 (2H, 
d, J = 8.5 Hz, C6-H), 3.25 (2H, br s, C1-H2), 2.71 (2H, t, J = 7.5 Hz, C3-H2), 2.48 (3H, s, Ts 
CH3), 1.82 (2H, app. qn, J = 7.5 Hz, C2-H2), 0.97 (9H, s, TBS (CH3)3), 0.17 (6H, s, TBS 
Si(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 163.5 (OBz C=O), 153.8 (ArC), 145.4 (ArC), 133.9 
(ArC), 133.7 (ArC), 130.4 (ArC), 129.9 (ArCH), 129.8 (ArCH), 129.5 (ArCH), 129.4 (ArCH), 
128.7 (ArCH), 127.3 (ArCH), 119.9 (ArCH), 52.0 (C1), 31.8 (C3), 28.6 (C2), 25.7 (TBS 
(CH3)3), 21.7 (Ts CH3), 18.2 (TBS SiC(CH3)3), -4.5 (TBS Si(CH3)2); HRMS (ESI
+) Calculated 










General procedure D: N-(Benzoyloxy)-N-(3-(4-((tert-butyldimethylsilyl)oxy)phenyl)propyl) 
-4-methylbenzenesulfonamide (534 mg, 1.00 mmol) was employed using 1 M HCl (7 mL). 
The crude product was purified by flash column chromatography (20% EtOAc:hexane) to 
afford 153 (410 g, 96%) as a colourless solid; m.p.: 148-149 oC (Et2O:hexane); νmax / cm
-1 
(solid) 3432 (br), 2932 (m), 1770 (s), 1236 (s), 1167 (s); 1H NMR (400 MHz, CDCl3) δ 7.98 – 
7.94 (2H, m, ArCH), 7.80 (2H, d, J = 8.5 Hz, Ts ArCH), 7.65 – 7.60 (1H, m, ArCH), 7.49 – 
7.44 (2H, m, ArCH), 7.38 (2H, d, J = 8.5 Hz, Ts ArCH), 7.02 (2H, d, J = 8.5 Hz, C5-H), 6.72 
(2H, d, J = 8.5 Hz, C6-H), 4.86 (1H, br s, OH), 3.25 (2H, br s, C1-H2), 2.71 (2H, t, J = 7.5 Hz, 
C3-H2), 2.47 (3H, s, Ts CH3), 1.81 (2H, app. qn, J = 7.5 Hz, C2-H2); 
13C NMR (101 MHz, 
CDCl3) δ 163.6 (OBz C=O), 153.8 (ArC), 145.5 (ArC), 133.9 (ArC), 133.1 (ArC), 130.3 (ArC), 
129.9 (ArCH), 129.8 (ArCH), 129.7 (ArCH), 129.5 (ArCH), 128.7 (ArCH), 127.3 (ArCH), 
115.2 (ArCH), 51.9 (C1), 31.7 (C3), 28.7 (C2), 21.7 (Ts CH3);  HRMS (ESI
+) Calculated for 
C23H23NNaO5S: 448.1189. Found [M+Na]
+ : 448.1181. 
3-(4-Hydroxyphenyl)propanenitrile (154), 4-(2-Cyanoethyl)phenyl benzoate (155) and 
N-(3-(4-Hydroxyphenyl)propyl)-4-methylbenzenesulfonamide (150) 
 
A flame-dried resealable tube, fitter with a magnetic stirrer, was charged with 
N-acyloxysulfonamide 153 (63.8 mg, 0.15 mmol), K2CO3 (31.1 mg, 0.225 mmol), Pd2(dba)3 
(3.43 mg, 3.75 µmol) and P(3,5-(CF3)2C6H3)3 (12.6 mg, 0.019 mmol). The tube was fitted with 
a rubber septum and purged with nitrogen before n-BuCN (1.5 mL) was added via syringe. The 
tube was sealed and heated at 110 oC for 24 hours. The reaction was cooled to room 




temperature, filtered through a pad of Celite® and concentrated in vacuo. Purification by flash 
column chromatography afforded the title compounds. 
Data for 154: νmax / cm
-1 (film) 3379 (br), 2931 (m), 2251 (m), 1515 (s); 1H NMR (400 MHz, 
CDCl3) δ 7.03 – 7.01 (2H, m), 6.79 (2H, d, J = 8.5 Hz), 5.15 (1H, br s), 2.89 (2H, t, J = 7.5 Hz), 
2.58 (2H, t, J = 7.5 Hz). 
The spectroscopic properties were consistent with the data available in the literature.283 
Data for 155: νmax / cm
-1 (film) 2918 (m), 2849 (m), 2242 (m), 1727 (s), 1508 (s); 1H NMR 
(400 MHz, CDCl3) δ 8.24 – 8.16 (2H, m, ArCH), 7.68 – 7.60 (1H, m, ArCH), 7.52 (2H, t, J = 
7.5 Hz, ArCH), 7.30 (2H, d, J = 8.5 Hz, C5-H), 7.23 – 7.14 (2H, m, C6-H), 3.00 (2H, t, J = 7.5 
Hz, C3-H2), 2.65 (2H, t, J = 7.5 Hz, C2-H2); 
13C NMR (101 MHz, CDCl3) δ 165.3 (C8), 150.2 
(C7), 135.8 (C4), 133.8 (ArCH), 130.3 (ArCH), 129.5 (C5), 128.8 (ArCH), 122.3 (C6), 119.1 
(C1), 31.2 (C3), 19.5 (C2). 
Data for 150: 1H NMR (400 MHz, CDCl3) δ 7.70 (2H, d, J = 8.5 Hz), 7.29 (2H, d, J = 8.5 Hz), 
6.93 (2H, d, J = 8.5 Hz), 6.71 (2H, d, J = 8.5 Hz), 2.99 – 2.90 (2H, m), 2.53 – 2.49 (2H, m), 
2.42 (3H, s), 1.72 (2H, p, J = 7.0 Hz); 13C NMR (101 MHz, CDCl3) δ 152.1, 143.6, 136.3, 
132.9, 129.9, 129.6, 127.8, 115.5, 42.8, 32.0, 31.5, 21.7. 





A solution of hydroxylamine hydrochloride (10.4 g, 150 mmol) and K2CO3 (20.7 g, 150 mmol) 
in Et2O (50 mL) and water (50 mL) was stirred at room temperature for 1 hour then cooled to 
0 oC before the addition of CbzCl (17.0 g, 100 mmol). The reaction was stirred at room 
temperature for 6 hours then the reaction was filtered, and the phases were separated. The 
aqueous phase was extracted with Et2O (2 × 100 mL) and the combined organic extracts were 
dried over Na2SO4 and concentrated in vacuo to afford the title compound (12.3 g, 74%) as a 
colourless crystalline solid; 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.30 (5H, m), 5.16 (2H, s); 
13C NMR (101 MHz, CDCl3) δ 159.2, 135.5, 128.8, 128.7, 128.5, 68.0. 












To a suspension of benzyl hydroxycarbamate (4.20 g, 25.0 mmol) and pentafluorobenzoic acid 
(5.30 g, 25.0 mmol) in CH2Cl2 (235 mL) at 0 
oC was added a solution of N-N’-
dicyclohexylcarbodiimide (5.70 g, 27.5 mmol) in CH2Cl2 (235 mL) dropwise. The resulting 
mixture was stirred at 0 oC overnight before filtration to remove the white precipitate. The 
filtrate was concentrated in vacuo and the crude mixture was purified by flash column 
chromatography (20% EtOAc:hexane) to give the title compound (5.6 g, 64%) as a colourless 
solid; νmax / cm
-1 (solid) 3237 (s, br), 2971 (m), 2987 (m), 2901 (m), 1779 (m), 1755 (s), 1494 
(s); 1H NMR (400 MHz, CDCl3) δ 8.35 (1H, br s), 7.37 (5H, s), 5.26 (2H, s); 
13C NMR (101 
MHz, CDCl3) δ 155.7, 134.6, 128.8, 128.7, 128.4, 69.0. The aromatic 
13C signals 
corresponding to the pentafluorobenzoyl group could not be resolved due to their weak 
intensity. 





General procedure C: Alcohol 146 (798 mg, 3.00 mmol), DIAD (0.88 mL, 4.5 mmol), 
CbzNHOFBz (1.35 g, 3.90 mmol) and PPh3 (1.17 g, 4.5 mmol) in anhydrous PhMe:THF (5:1, 
32 mL) were employed. The reaction was stirred at room temperature overnight until 
completion by TLC analysis. The reaction mixture was concentrated in vacuo and purified by 
flash column chromatography (20% EtOAc:hexane) to afford the title compound (736 mg, 
41%) as a colourless solid; m.p.: 55-57 oC (EtOAc:hexane); 1H NMR (400 MHz, CDCl3) δ 
7.36 – 7.32 (5H, m, ArCH), 7.00 (2H, d, J = 8.5 Hz, ArCH), 6.73 (2H, d, J = 8.5 Hz, ArCH), 
5.21 (2H, s, Cbz CH2), 3.76 (2H, t, J = 7.0 Hz, C1-H2), 2.63 (2H, t, J = 7.5 Hz, C3-H2), 1.93 
(2H, app. qn, J = 7.5 Hz, C2-H2), 0.98 (9H, s, TBS (CH3)3), 0.18 (6H, s, TBS Si(CH3)2); 




13C NMR (101 MHz, CDCl3) δ 157.3 (C=O), 155.4 (C=O), 153.8 (ArC), 135.2 (ArC), 133.5 
(ArC), 129.2 (ArCH), 128.6 (ArCH), 128.5 (ArCH), 128.1 (ArCH), 120.0 (ArCH), 68.8 (Cbz 
CH2), 50.7 (C1), 31.7 (C3), 28.7 (C2), 25.7 (TBS (CH3)3), 18.2 (TBS SiC(CH3)3), -4.5 (TBS 
Si(CH3)2). The aromatic 
13C signals corresponding to the pentafluorobenzoyl group could not 




General procedure D: N-(Pentafluorobenzoyloxy)3-(4-((tert-butyldimethylsilyl)oxy)phenyl) 
propyl) benzylcarbamate (720 mg, 1.21 mmol) and 1 M HCl (7.5 mL) in MeOH (25 mL) and 
THF (25 mL) were employed. The crude product was purified by flash column chromatography 
(20% EtOAc:hexane) to afford 159 (516 mg, 86%) as a colourless solid; νmax / cm
-1 (solid) 3362 
(br), 1776 (s), 1698 (s), 1495 (s); 1H NMR (400 MHz, CDCl3) δ 7.37 – 7.32 (5H, m, ArCH), 
7.02 (2H, d, J = 8.5 Hz, C5-H), 6.72 (2H, d, J = 8.5 Hz, C6-H), 5.22 (2H, s, Cbz CH2), 4.62 
(1H, s, OH), 3.76 (2H, t, J = 7.0 Hz, C1-H2), 2.63 (2H, t, J = 7.0 Hz, C3-H2), 1.92 (2H, app. 
qn, J = 7.0 Hz, C2-H2); 
13C NMR (101 MHz, CDCl3) δ 157.3 (C=O), 155.5 (C=O), 153.9 (C7), 
135.1 (ArC), 133.0 (ArC), 129.4 (ArCH), 128.6 (ArCH), 128.5 (ArCH), 128.1 (ArCH), 115.2 
(C6), 68.8 (Cbz CH2), 50.6 (C1), 31.6 (C3), 28.7 (C2). The aromatic 
13C signals corresponding 
to the pentafluorobenzoyl group could not be resolved due to their weak intensity. HRMS 
(ESI+) Calculated for C24H18F5NNaO5: 518.0997. Found [M+Na]
+: 518.0997. 
Methyl (E) 3-(1H-pyrrol-2-yl)acrylate (162) 
 
 
1H-Pyrrole-2-carboxaldehyde (1.25 g, 13.1 mmol) and methyl(triphenylphosphornaylidene) 
acetate 161 (4.61 g, 13.8 mmol) were heated at 45 oC in toluene (125 mL) until completion by 
TLC analysis (18 hours). The reaction was cooled to room temperature and concentrated in 
vacuo. Purification by flash column chromatography (20% EtOAc:hexane) afforded 162 




(1.60 g, 80%) as a colourless solid; 1H NMR (400 MHz, CDCl3) δ 8.62 (1H, br s), 7.56 (1H, d, 
J = 16.0 Hz), 6.94 – 6.92 (1H, m), 6.58 – 6.56 (1H, m), 6.30 – 6.27 (1H, m), 5.99 (1H, d, J = 
16.0 Hz), 3.78 (3H, s); 13C NMR (101 MHz, CDCl3) δ 168.0, 134.3, 128.3, 122.4, 114.5, 111.0, 
110.8, 51.6.  




General procedure E: The preceding ester 162 (3.02 g, 20 mmol) and 10 wt.% Pd/C in MeOH 
(150 mL) were employed. The reaction was stirred at room temperature under a hydrogen 
atmosphere until completion by TLC analysis (20 hours). The crude mixture was filtered over 
a bed of Celite® washed with MeOH (50 mL) and the solvent was removed in vacuo to afford 
the title compound (3.01 g, 100%) as a yellow oil, which required no further purification; 
1H NMR (400 MHz, CDCl3) δ 8.55 (1H, br s), 6.69 – 6.67 (1H, m), 6.13 – 6.10 (1H, m), 5.94 
– 5.93 (1H, m), 3.71 (3H, s), 2.93 (2H, t, J = 7.0 Hz), 2.66 (2H, t, J = 7.0 Hz); 13C NMR (101 
MHz, CDCl3) δ 174.5, 130.9, 116.8, 108.0, 105.5, 51.8, 34.3, 22.6.  




General procedure B: Methyl 3-(1H-pyrrol-2-yl)propanoate (2.92 g, 19.1 mmol) and 1.5 
equivalents of LiAlH4 (1 M in THF) in anhydrous Et2O (100 mL) were employed. The crude 
product was purified by flash column chromatography (33% EtOAc:hexane) to afford 163 
(2.05 g, 87%) as a yellow oil; 1H NMR (400 MHz, CDCl3) δ 8.46 (1H, br s), 6.69 – 6.67 (1H, 
m), 6.14 – 6.12 (1H, m), 5.93 – 5.92 (1H, m), 3.68 (2H, t, J = 6.0 Hz), 2.71 (2H, t, J = 7.5 Hz), 
2.55 (1H, br s), 1.91 – 1.84 (2H, m); 13C NMR (101 MHz, CDCl3) δ 131.9, 116.5, 108.1, 105.0, 
62.1, 32.3, 24.1.  
The spectroscopic properties were consistent with the data available in the literature.286 
 







General procedure C: The preceding alcohol 163 (380 mg, 3.00 mmol), DIAD (1.18 mL, 6.0 
mmol), PPh3 (1.57 g, 6.00 mmol), and TsNHO
FBz (1.71 g, 4.50 mmol) in anhydrous 
PhMe:THF (5:1, 32 mL) were employed. The reaction mixture was stirred at room temperature 
until completion by TLC analysis. The reaction mixture was concentrated in vacuo and purified 
by flash column chromatography to afford 164 (410 mg, 33%) as a brown solid; νmax / cm
-1 
(solid) 3358 (m, br), 2974 (m), 2901 (m), 1788 (s), 1502 (s), 1168 (s); 1H NMR (400 MHz, 
CDCl3) δ  8.30 (1H, br s, NH), 7.78 (2H, d, J = 8.0 Hz, Ts ArCH), 7.38 (2H, d, J = 8.0 Hz, Ts 
ArCH), 6.71 – 6.69 (1H, m, C7-H), 6.14 – 6.12 (1H, m, C6-H), 5.93 – 5.90 (1H, m, C5), 3.20 
(2H, br s, C1-H2), 2.88 (2H, t, J = 7.0 Hz, C3-H2), 2.47 (3H, s, Ts CH3), 1.82 (2H, app. qn, J = 
6.5 Hz, C2-H2); 
13C NMR (101 MHz, CDCl3) δ 146.2 (Ts ArC), 131.0 (C4), 130.1 (2 × Ts 
ArCH), 130.0 (Ts ArC), 129.7 (2 × Ts ArCH), 116.8 (C7), 108.5 (C6), 105.6 (C5), 52.0 (C1), 
27.5 (C2), 24.1 (C3), 21.8 (Ts CH3). HRMS (ESI
+) Calculated for C21H18F5N2O4S: 489.0902. 
Found [M+H]+: 489.0909. 
1,2-Dihydro-3H-benzo[f]chromen-3-one (166) 
 
The compound was prepared according to a literature procedure.287  
To a solution of 2-naphthol (4.33 g, 30.0 mmol) and Amberlyst 15® (3.0 g) in toluene (80 mL) 
was added acrylic acid (4.32 g, 60.0 mmol) and the suspension was heated at reflux for 48 
hours. After cooling to room temperature, the mixture was filtered over Celite® and the filtrate 
was concentrated in vacuo. Purification by flash column chromatography (5% EtOAc:hexane) 
afforded 166 (4.49 g, 76%) as a yellow solid; 1H NMR (400 MHz, CDCl3) δ 7.90 – 7.84 (2H, 
m), 7.76 (2H, d, J = 9.0 Hz), 7.58 (1H, app. t, J = 7.5 Hz), 7.47 (1H, app. t, J = 7.5 Hz), 7.26 – 
7.21 (2H, m), 3.35 (2H, t, J = 7.5 Hz), 2.91 (2H, t, J = 7.5 Hz); 13C NMR (101 MHz, CDCl3) δ 
168.3, 149.6, 131.1, 130.8, 128.9, 128.7, 127.1, 125.1, 122.8, 117.4, 115.5, 28.6, 19.9. 
The spectroscopic properties were consistent with the data available in the literature.287 




3-(2-((tert-Butyldimethylsilyl)oxy)naphthalen-1-yl)propanoic acid (167) 
 
To a solution of the preceding lactone 166 (7.90 g, 37.0 mmol) in THF (200 mL) was added 
aqueous 1 M LiOH (125 mL). After stirring at room temperature overnight the pH was acidified 
to approx. 3 with 1 M HCl. The product was extracted with EtOAc (50 mL), dried over Na2SO4, 
filtered and concentrated in vacuo. The crude product was dissolved in DMF (20 mL) and 
tert-butyldimethylsilyl chloride (12.2 g, 81.4 mmol) and imidazole (8.30 g, 122.1 mmol) were 
added at 0 o C. After being stirred at room temperature overnight the reaction was quenched by 
addition of H2O and the product was extracted with hexane, dried over MgSO4, filtered and 
concentrated in vacuo. To the crude product in MeOH (30 mL) and THF (30 mL) was added 
aqueous K2CO3 (74.0 mmol, 10.2 g in 100 mL H2O). After stirring for 5 hours the reaction was 
quenched with aqueous 1 M HCl (100 mL) at 0 oC. The mixture was extracted with Et2O, dried 
over Na2SO4, filtered and concentrated in vacuo. Purification by flash column chromatography 
(20% EtOAc:hexane) afforded 167 (8.10 g, 66%) as a pale yellow solid; m.p.: 94-96 oC 
(EtOAc:hexane); Rf = 0.3 (33% EtOAc:hexane); νmax / cm
-1 (solid) 2957 (m), 2928 (m), 2900 
(m), 2857 (m), 1699 (s); 1H NMR (400 MHz, CDCl3) δ 7.97 (1H, d, J = 8.5 Hz, ArCH), 7.79 
(1H, d, J = 8.0 Hz, ArCH), 7.65 (1H, d, J = 8.5 Hz, ArCH), 7.51 (1H, t, J = 8.0 Hz, ArCH), 
7.36 (1H, t, J = 7.5 Hz, ArCH), 7.11 (1H, d, J = 9.0 Hz, ArCH), 3.43 (2H, t, J = 8.5 Hz, C2-H2), 
2.67 (2H, t, J = 8.5 Hz, C3-H2), 1.08 (9H, s, TBS (CH3)3), 0.31 (6H, s, TBS Si(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 179.3 (C=O), 150.8 (ArC), 133.0 (ArC), 129.5 (ArC), 128.6 
(ArCH), 127.9 (ArCH), 126.5 (ArCH), 123.4 (ArCH), 123.1 (ArC), 122.8 (ArCH), 120.2 
(ArCH), 33.9 (C1), 25.8 (TBS (CH3)3), 21.0 (C2), 18.3 (TBS SiC(CH3)3), 3.9 (TBS Si(CH3)2); 





General procedure F: The preceding carboxylic acid 167 (1.65 g, 5.00 mmol), Et3N (0.70 
mL, 5.00 mmol), ethyl chloroformate (540 mg, 5.00 mmol) and NaBH4 (470 mg, 12.5 mmol) 




in THF (50 mL) and H2O (20 mL) were employed. Purification by flash column 
chromatography (20% EtOAc:hexane) afforded 168 (1.19 g, 75%) as a colourless oil; Rf = 0.6 
(33% EtOAc:hexane); νmax / cm
-1 (film) 3336 (m, br), 2953 (m), 2929 (m), 2882 (m), 2857 (m), 
1622 (m), 1594 (m), 1465 (m), 1264 (m), 1241 (s), 1H NMR (400 MHz, CDCl3) δ 8.00 (1H, d, 
J = 8.0 Hz), 7.79 (1H, d, J = 8.5 Hz), 7.63 (1H, d, J = 8.5 Hz), 7.48 (1H, t, J = 8.0 Hz), 7.35 
(1H, t, J = 7.0 Hz), 7.12 (1H, d, J = 9.0 Hz), 3.63 (2H, t, J = 6.0 Hz), 3.20 (2H, t, J = 6.5 Hz), 
2.53 (1H, br s), 1.95 (2H, qn, J = 7.5 Hz), 1.10 (9H, s), 0.31 (6H, s); 13C NMR (101 MHz, 
CDCl3) δ 150.6, 133.4, 129.9, 128.6, 127.4, 126.3, 124.7, 123.6, 123.5, 120.6, 62.2, 32.5, 26.0, 
21.5, 18.5, -3.8.  





General procedure C: The preceding alcohol 168 (633 mg, 2.0 mmol), DIAD (0.82 mL, 4.2 
mmol), PPh3 (1.10 g, 4.2 mmol) and CbzNHO
FBz (1.52 g, 4.2 mmol) in anhydrous PhMe:THF 
(5:1, 24 mL) were employed. Purification by flash column chromatography (10% 
EtOAc:hexane) afforded the title compound (194.2 mg, 15%) as a colourless, viscous oil; νmax 
/ cm-1 (film) 2931 (m), 2858 (m), 1782 (s), 1730 (s), 1498 (s), 1169 (s); 1H NMR (400 MHz, 
CDCl3) δ 7.89 (1H, d, J = 8.5 Hz, ArCH), 7.75 (1H, d, J = 8.0 Hz, ArCH), 7.60 (1H, d, J = 9.0 
Hz, ArCH), 7.42 (1H, ddd, J = 8.5, 6.5, 1.5 Hz, ArCH), 7.37 – 7.26 (6H, m, ArCH), 7.06 (1H, 
d, J = 9.0 Hz, ArCH), 5.20 (s, 2H, Cbz, CH2), 3.86 (2H, t, J = 7.5 Hz, C1-H2), 3.21 – 2.93 (2H, 
m, C3-H2), 1.98 (2H, app. qn, J = 7.5 Hz, C2-H2), 1.01 (9H, s, SiC(CH3)3), 0.24 (6H, s, 
Si(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 155.6 (Cbz, C=O), 150.7 (ArC), 135.3 (ArC), 133.3 
(ArC), 129.6 (ArC), 128.7 (ArCH), 128.6 (ArCH), 128.6 (ArCH), 128.2 (ArCH), 127.6 
(ArCH), 126.4 (ArCH), 124.2 (ArC), 123.4 (ArCH), 123.2 (ArCH), 120.4 (ArCH), 68.9 (Cbz, 
CH2), 51.5 (C1), 27.2 (C2), 25.9 (SiC(CH3)3), 22.8 (C3), 18.4 (SiC(CH3)3), -3.8 (Si(CH3)2). 
The 13C signals corresponding to the pentafluorobenzoyl group could not be resolved due to 
their weak intensity. 19F NMR (377 MHz, CDCl3) δ -135.4 – -135.7 (2F, m), -144.8 – -146.6 
(1F, m), -157.8 – -160.3 (2F, m). HRMS (ESI+) Calculated for C34H35F5NO5Si: 660.2199. 
Found [M+H]+: 660.2204. 




Benzyl (3-(2-hydroxynaphthalen-1-yl)propyl)((perfluorobenzoyl)oxy)carbamate (169) 
 
General procedure D: Benzyl (3-(2-((tert-butyldimethylsilyl)oxy)naphthalen-1-yl)propyl) 
((perfluorobenzoyl)oxy)carbamate (279 mg, 0.41 mmol) and 1 M HCl (2.5 mL) in MeOH (10 
mL) and THF (8 mL) were employed. Purification by flash column chromatography (20% 
EtOAc:Hex) afforded 169 (59 mg, 26%) as a colourless solid; m.p.: 129-131 oC 
(EtOAc:hexane); νmax / cm
-1 (solid) 3312 (br), 2966 (m), 1782 (s), 1698 (s), 1496 (s), 1278 (s), 
1172 (s); 1H NMR (400 MHz, CDCl3) δ 7.87 (1H, d, J = 8.5 Hz, ArCH), 7.75 (1H, dd, J = 8.0, 
1.5 Hz, ArCH), 7.61 (1H, d, J = 9.0 Hz, ArCH), 7.45 (1H, ddd, J = 8.5, 6.5, 1.5 Hz, ArCH), 
7.38 – 7.27 (6H, m, ArCH), 7.05 (1H, d, J = 9.0 Hz, ArCH), 5.80 (1H, s, OH), 5.22 (2H, s, Cbz 
CH2), 3.83 (2H, t, J = 6.5 Hz, C1-H2), 3.16 (2H, t, J = 7.5 Hz, C3-H2), 2.12 – 1.88 (2H, m, 
C2-H2); 
13C NMR (101 MHz, CDCl3) δ 158.1 (
FBz C=O), 156.0 (Cbz C=O), 151.3 (ArC), 
135.1 (ArC), 133.2 (ArC), 129.5 (ArC), 128.8 (ArCH), 128.7 (ArCH), 128.7 (ArCH), 128.3 
(ArCH), 128.2 (ArCH), 126.6 (ArCH), 123.2 (ArCH), 122.7 (ArCH), 118.3 (ArCH), 118.0 
(ArC), 69.2 (Cbz CH2), 50.9 (C1), 26.7 (C2), 21.8 (C3). The aromatic 
13C signals 
corresponding to the pentafluorobenzoyl group could not be resolved due to their weak 
intensity.  HRMS (ESI+) Calculated for C28H20F5NNaO5: 568.1154. Found [M+Na]
+: 568.1152. 
Benzyl 2-oxo-2H-spiro[naphthalene-1,2'-pyrrolidine]-1'-carboxylate (170) 
 
A flame-dried resealable tube, fitter with a magnetic stirrer, was charged with 
N-acyloxysulfonamide 169 (40.9 mg, 0.075 mmol), K3PO4 (31.8 mg, 0.150 mmol), Pd2(dba)3 
(3.43 mg, 3.75 µmol) and 5-nitro-1,10-phenanthroline (3.37 mg, 0.015 mmol). The tube was 
fitted with a rubber septum and purged with nitrogen before n-BuCN (1.5 mL) was added via 
syringe. The tube was sealed and heated at 120 oC for 66 hours. The reaction was cooled to 
room temperature and purified by flash column chromatography (20% EtOAc:hexane) to 
afford 170 (5.6 mg, 22%) as a colourless oil. This compound exists as an approximately 3:2 




mixture of rotamers A and B; νmax / cm
-1 (film) 2953 (m), 1700 (s), 1671 (s), 1404 (s), 1350 (s); 
1H NMR (400 MHz, CDCl3) δ 7.44 (0.4H, d, J = 10.0 Hz, B: C7-H), 7.38 – 7.24 (7H, m, A: 
C7-H, A and B: ArCH), 7.17 – 7.09 (0.6H, m, A: ArCH), 7.07 – 7.03 (1H, m, A and B: ArCH), 
6.80 (1H, d, J = 7.0 Hz, A and B: ArCH), 6.22 (0.4H, d, J = 10.0 Hz, B: C6-H), 6.07 (0.6H, d, 
J = 10.0 Hz, A: C6-H), 5.07 (0.4H, d, J = 12.5 Hz, B: C9-H), 5.03 (0.4H, d, J = 12.5 Hz, B: 
C9-H’), 4.91 (0.6H, d, J = 12.5 Hz, A: C9-H), 4.68 (0.6H, d, J = 12.5 Hz, A: C9-H’), 4.07 – 
3.97 (1H, m, A and B: C1-H), 3.92 – 3.82 (1H, m, A and B: C1-H’), 2.40 – 2.29 (1H, m, A and 
B: C3-H), 2.20 – 2.07 (1H, m, A and B: C2-H), 2.05 – 1.89 (2H, m, A and B: C2-H’ and C3-H’); 
13C NMR (101 MHz, CDCl3) δ 
13C NMR (101 MHz, CDCl3) δ 200.4 (B: C5), 200.3 (A: C5), 
154.3 (B: C8), 154.0 (A: C8), 146.6 (A: ArC), 145.8 (B: ArC), 145.3 (B: C7), 145.0 (A: C7), 
136.8 (ArC), 136.2 (ArC), 130.6 (ArCH), 130.5 (ArCH), 129.7 (ArCH), 129.6 (ArCH), 129.5 
(B: ArC), 129.3 (A: ArC), 128.6 (ArCH), 128.0 (ArCH), 127.9 (ArCH), 127.6 (ArCH), 127.5 
(ArCH), 127.4 (ArCH), 127.2 (ArCH), 125.0 (ArCH), 124.7 (ArCH), 124.4 (B: C6), 124.1 (A: 
C6), 72.3 (B: C4), 72.0 (A: C4), 67.2 (B: C9), 66.9 (A: C9), 49.7 (A or B: C1), 49.2 (A or B: 
C1), 42.8 (A or B: C3), 41.8 (A or B: C3), 22.7 (A or B: C2), 21.7 (A or B: C2); HRMS (ESI+) 
Calculated for C21H19NNaO3: 356.1257. Found [M+Na]
+: 356.1241. 
 
tert-Butyl (3-(4-((tert-butyldimethylsilyl)oxy)phenyl)propyl)(tosyl)carbamate (172) 
 
General procedure C: Alcohol 146 (532 mg, 2.00 mmol), DIAD (0.63 mL, 4.0 mmol), 
TsNHBoc (813 mg, 3.00 mmol) and PPh3 (1.05 g, 4.00 mmol) in anhydrous PhMe:THF (5:1, 
24 mL) were employed. The reaction mixture was stirred at room temperature overnight until 
completion by TLC analysis. The reaction was concentrated in vacuo and purified by flash 
column chromatography (10% EtOAc:hexane) to afford 172 (920 mg, 89%) as a colourless 
solid; m.p.: 106-107 oC (EtOAc:hexane); νmax / cm
-1 (solid) 2981 (m), 2960 (m), 2934 (m), 
2901 (m), 2862 (m), 1715 (s), 1509 (m); 1H NMR (400 MHz, CDCl3) δ 7.77 (2H, d, J = 8.5 
Hz, Ts ArCH), 7.29 (2H, d, J = 8.5 Hz, Ts ArCH), 7.06 (2H, d, J = 8.5 Hz, C5-H), 6.76 (2H, 
d, J = 8.5 Hz, C6-H), 3.86 – 3.82 (2H, m, C1-H2), 2.63 – 2.58 (2H, m, C3-H2), 2.43 (3H, s, Ts 
CH3), 2.05 (2H, app. qn, J = 8.0 Hz, C2-H2), 1.32 (9H, s, Boc (CH3)3), 0.98 (9H, s, TBS 




(CH3)3), 0.18 (6H, s, TBS Si(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 153.8 (Boc C=O), 150.9 
(C7), 144.0 (Ts ArC), 137.5 (Ts ArC), 133.8 (C4), 129.2 (2 × Ts ArCH), 129.1 (2 × Ts ArCH), 
127.8 (C5), 119.9 (C6), 84.0 (Boc C(CH3)3), 46.9 (C1), 32.2 (C3), 31.9 (C2), 27.9 (Boc 
(CH3)3), 25.7 (TBS (CH3)3), 21.6 (Ts CH3), 18.2 (TBS C(CH3)3), -4.4 (TBS Si(CH3)2). HRMS 




To a solution of the preceding N-tosylcarbamate 172 (620 mg, 1.2 mmol) in EtOAc (60 mL) at 
0 oC was added concentrated HCl (6 mL). The reaction was stirred at room temperature until 
completion by TLC analysis (20 hours). To the crude reaction mixture was added Et2O (30 
mL) and the solution was washed with saturated aqueous NaHCO3 (20 mL) and water (10 mL). 
The organic extracts were dried over MgSO4, filtered and concentrated in vacuo. Purification 
by flash column chromatography (33% EtOAc:hexane) afforded 150 (300 mg, 83%) as a 
colourless solid; νmax / cm
-1 (solid) 3317 (m, br), 3269 (m, br), 2976 (m), 2937 (m), 1514 (m), 
1140 (s); 1H NMR (400 MHz, CDCl3) δ 7.72 (2H, d, J = 8.5 Hz), 7.30 (2H, d, J = 8.0 Hz), 6.94 
(2H, d, J = 8.5 Hz), 6.72 (2H, d, J = 8.5 Hz), 4.73 (1H, s), 4.36 (1H, t, J = 6.0 Hz), 2.94 (2H, 
q, J = 6.5 Hz), 2.52 (2H, t, J = 7.5 Hz), 2.42 (3H, s), 1.73 (2H, app. qn, J = 7.0 Hz); 13C NMR 
(CDCl3, 101 MHz) δ 153.8, 143.4, 136.9, 132.9, 129.7, 129.4, 127.0, 115.2, 42.6, 31.8, 31.3, 
21.5.  













General procedure B: Carboxylic acid 145 (3.32 g, 20 mmol) and 1.0 equivalent of LiAlH4 
(2M in THF, 10 mL, 20 mmol) in anhydrous Et2O (100 mL) were employed. Purification by 
flash column chromatography (50% EtOAc:hexane) afforded 173 (784 mg, 26%) as a 
colourless solid; m.p.: 49-51 oC (EtOAc:hexane) [lit: 52-53 oC288]; 1H NMR (400 MHz, CDCl3) 
δ 7.05 (2H, d, J = 8.5 Hz), 6.75 (2H, d, J = 8.5 Hz), 5.20 (1H, br s), 3.68 (2H, t, J = 6.5 Hz), 
2.64 (2H, t, J = 7.5 Hz), 1.91 – 1.82 (2H, m), 1.45 (1H, br s); 13C NMR (101 MHz, CDCl3) δ 
154.0, 133.9, 129.6, 115.4, 62.5, 34.5, 31.3. 




A flame-dried resealable tube, fitted with a magnetic stirrer, was charged with alcohol 173 
(22.8 mg, 0.15 mmol), Pd(OAc)2 (3.4 mg, 10 mol%) and 4,5-diazafluoren-9-one (5.5 mg, 20 
mol%). The tube was fitted with a rubber septum and purged with nitrogen before 1,4-dioxane 
(1.5 mL) was added by syringe. The reaction tube was fitted with a balloon of oxygen and 
heated at 80 oC for 18 hours. The reaction mixture was filtered through Celite® and washed 
with EtOAc. The yield of 158 (41%) was determined by 1H NMR analysis using 
1,2-dinitrobenzene as internal standard; 1H NMR (400 MHz, CDCl3) δ 7.06 (2H, d, J = 8.5 
Hz), 6.76 (2H, d, J = 8.5 Hz), 2.89 (2H, t, J = 7.5 Hz), 2.77 – 2.72 (2H, m). 












The title compound was prepared according to a literature procedure.291  
The spectroscopic properties were consistent with the data available in the literature.291 
 
tert-Butyl (3-(4-((tert-butyldimethylsilyl)oxy)phenyl)propyl)(tosyloxy)carbamate (176)  
 
 
General procedure G: Alcohol 146 (0.79 g, 3.00 mmol), PPh3 (0.94 g, 3.60 mmol), DIAD 
(0.71 mL, 3.60 mmol) and BocNHOTs (1.03 g, 3.60 mmol) in THF (12 mL) were employed. 
Purification by flash column chromatography (10% EtOAc:hexane) afforded 176 (1.49 g, 93%) 
as a pale yellow oil; Rf = 0.5 (20% EtOAc:hexane); νmax / cm
-1 (film) 2955 (m), 2930 (m), 2858 
(m), 1753 (m), 1720 (s), 1509 (s), 1382 (s), 1368 (s), 1251 (s), 1178 (s), 1154 (s); 1H NMR 
(400 MHz, CDCl3) δ 7.84 (2H, d, J = 8.5 Hz, Ts ArCH), 7.33 (2H, d, J = 8.5 Hz, Ts ArCH), 
7.00 (2H, d, J = 8.5 Hz, C5-H), 6.74 (2H, d, J = 8.5 Hz, C6-H), 3.60 (2H, br s, C1-H2), 2.52 
(2H, t, J = 8.0 Hz, C3-H2), 2.45 (3H, s, Ts CH3), 1.95 – 1.85 (2H, m, C2-H2), 1.22 (9H, s, Boc 
(CH3)3), 0.98 (9H, s, TBS (CH3)3), 0.18 (6H, s, TBS (CH3)2); 
13C NMR (101 MHz, CDCl3) δ 
155.5 (Boc C=O), 153.8 (C7), 145.6 (Ts ArC), 133.7 (C4), 131.3 (Ts ArC), 129.6 (2 × Ts 
ArCH), 129.5 (2 × Ts ArCH), 129.1 (C5), 120.0 (C6), 83.2 (Boc C(CH3)3), 52.6 (C1), 32.0 
(C3), 27.6 (Boc (CH3)3), 27.5 (C2), 25.7 (TBS (CH3)3), 21.7 (Ts CH3), 18.2 (TBS SiC(CH3)3), 
-4.4 (TBS Si(CH3)2); HRMS (ESI









tert-Butyl (3-(4-hydroxyphenyl)propyl)(tosyloxy)carbamate (177) 
 
General procedure H: The preceding N-tosyloxycarbamate 176 (0.69 g, 1.28 mmol) and 1:1 
TBAF:HOAc solution (0.1 M in THF, 1.28 mmol) in THF (20 mL) were employed. 
Purification by flash column chromatography (20% EtOAc:hexane) afforded 177 (0.35 g, 60%) 
as a colourless solid; m.p.: 63-65 oC (EtOAc:hexane); Rf = 0.2 (20% EtOAc:hexane); νmax / 
cm-1 (solid) 3426 (m, br), 2982 (m), 2934 (m), 1721 (s), 1515 (s), 1369 (s), 1191 (s), 1177 (s), 
1152 (s); 1H NMR (400 MHz, CDCl3) δ 7.83 (2H, d, J = 8.5 Hz, Ts ArCH), 7.32 (2H, d, J = 
8.5 Hz, Ts ArCH), 6.98 (2H, d, J = 8.5 Hz, C5-H), 6.75 (2H, d, J = 8.5 Hz, C6-H), 5.75 (1H, 
br s, OH), 3.60 (2H, br s, C1-H2), 2.50 (2H, t, J = 8.0 Hz, C3-H2), 2.44 (3H, s, Ts CH3), 1.97 – 
1.80 (2H, m, C2-H2), 1.23 (9H, s, Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) δ 155.7 (Boc 
C=O), 154.1 (C7), 145.9 (Ts ArC), 132.8 (C4), 131.0 (Ts ArC), 129.6 (2 × Ts ArCH), 129.5 
(2 × Ts ArCH), 129.3 (C5), 115.3 (C6), 83.6 (Boc C(CH3)3), 52.6 (C1), 31.9 (C3), 27.7 (C2), 
27.6 (Boc (CH3)3), 21.7 (Ts, CH3); HRMS (ESI
+) Calculated for C21H27NNaO6S: 444.1451. 
Found [M+Na]+: 444.1434. 
 
1-Azaspiro[4.5]deca-6,9-dien-8-one trifluoroacetate (178) 
 
General procedure I: The preceding N-tosyloxycarbamate 177 (60.7 mg, 0.14 mmol) and 
TFA (22 μL, 0.28 mmol) in TFE (1.4 mL) were stirred at room temperature for 24 hours. 
Purification of the product by flash column chromatography (EtOAc) afforded 178 (29.0 mg, 
77%) as a yellow solid; m.p.: 100-102 oC (EtOAc:hexane); Rf = 0.1 (5% MeOH:CH2Cl2); νmax 
/ cm-1 (solid) 1651 (s), 1633 (s), 1426 (m), 1400 (m), 1192 (s), 1175 (s), 1130 (s); 1H NMR 
(400 MHz, CD3OD) δ 7.11 (2H, d, J = 10.5 Hz, C5-H), 6.43 (2H, d, J = 10.5 Hz, C6-H), 3.64 




(2H, t, J = 7.5 Hz, C1-H2), 2.42 – 2.34 (2H, m, C2-H2), 2.30 – 2.25 (2H, m, C3-H2). The signals 
corresponding to the NH2 were not observed. 
13C NMR (101 MHz, CD3OD) δ 185.3 (C7), 
144.5 (C5), 131.7 (C6), 64.5 (C4), 46.6 (C1), 37.8 (C3), 24.8 (C2). The signals corresponding 
to the trifluoroacetate group could not be resolved due to their weak intensity. HRMS (ESI+) 
Calculated for C9H12NO: 150.0913. Found [M+H]
+: 150.0908. 
Methyl (E)-3-(4-(benzyloxy)-3,5-dimethylphenyl)acrylate (180) 
 
General procedure J: 4-(Benzyloxy)-3,5-dimethylbenzaldehyde 179 (2.40 g, 10.0 mmol) and 
methyl 2-(triphenyl-phosphaneylidene) acetate (5.00 g, 15.0 mmol) in CH2Cl2 (15 mL) were 
employed. Purification by flash column chromatography (gradient, eluent: 10 – 20% 
EtOAc:hexane) afforded 180 (2.85 g, 96%) as a colourless oil; Rf = 0.6 (20% EtOAc:hexane); 
νmax / cm
-1 (film) 1713 (s), 1632 (m), 1434 (m), 1265 (s), 1143 (s); 1H NMR (400 MHz, CDCl3) 
δ 7.63 (1H, d, J = 16.0 Hz, C3-H), 7.50 – 7.46 (2H, m, ArCH), 7.46 – 7.33 (3H, m, ArCH), 
7.23 (2H, s, C5-H), 6.36 (1H, d, J = 16.0 Hz, C2-H), 4.83 (2H, s, OCH2), 3.81 (3H, s, OCH3), 
2.32 (6H, s, C7-H3); 
13C NMR (101 MHz, CDCl3) δ 167.7 (C1), 157.9 (C8), 144.8 (C3), 137.4 
(ArC), 131.9 (C6), 130.2 (C4), 129.0 (C5), 128.7 (2 × ArCH), 128.2 (ArCH), 127.9 (2 × ArCH), 
116.6 (C2), 74.2 (OCH2), 51.7 (OCH3), 16.6 (C7); HRMS (ESI
+) Calculated for C19H20NaO3: 




General procedure E: The preceding α,β-unsaturated ester 180 (2.37 g, 8.00 mmol) and 10 
wt.% Pd/C (10 mol%) in MeOH (50 mL) were employed to afford the title compound (1.66 g, 
99%) as a colourless solid, which was used without further purification; m.p.: 66-68 oC 
(EtOAc:hexane); Rf = 0.4 (20 % EtOAc:hexane); νmax / cm
-1 (solid) 3492 (br), 2952 (m), 2928 




(m), 1723 (s), 1277 (s), 1174 (s), 1151 (s); 1H NMR (400 MHz, CDCl3) δ 6.81 (2H, s, C5-H), 
4.55 (1H, br s, OH), 3.67 (3H, s, OCH3), 2.82 (2H, t, J = 8.0 Hz, C3-H2), 2.58 (2H, t, J = 8.0 
Hz, C2-H2), 2.22 (6H, s, C7-H3); 
13C NMR (101 MHz, CDCl3) 173.7 (C1), 150.7 (C8), 132.2 
(C4), 128.5 (ArCH), 123.2 (ArCH), 51.7 (OCH3), 36.3 (C2), 30.3 (C3), 16.0 (C7); HRMS 
(ESI+) Calculated for C12H16NaO3: 231.0992. Found [M+Na]
+: 231.1002.  
 
Methyl 3-(4-((tert-butyldimethylsilyl)oxy)-3,5-dimethylphenyl)propanoate  
 
To a solution of methyl 3-(4-hydroxy-3,5-dimethylphenyl)propanoate (1.33 g, 6.00 mmol) in 
CH2Cl2 (10 mL) and DMF (12 mL) was added tert-butyldimethylsilyl chloride (1.8 g, 12.0 
mmol) and imidazole (820 mg, 12.0 mmol) at 0 oC. The reaction was stirred at room 
temperature overnight and quenched with H2O (50 mL) and the organic phase extracted with 
CH2Cl2 (3 × 15 mL), washed with brine (15 mL), dried over MgSO4, filtered and concentrated 
in vacuo. Purification by flash column chromatography (10% EtOAc:hexane) afforded the title 
compound (1.22 g, 63%) as a colourless oil; Rf = 0.6 (25% EtOAc:hexane); νmax / cm
-1 (film) 
2953 (m), 2930 (m), 1740 (s), 1484 (m), 1473 (m), 1253 (s), 1228 (s), 1153 (s); 1H NMR (400 
MHz, CDCl3) δ 6.79 (2H, s, C5-H), 3.67 (3H, s, OCH3), 2.81 (2H, t, J = 8.0 Hz, C3-H2), 2.58 
(2H, t, J = 8.0 Hz, C2-H2), 2.18 (6H, s, C7-H3), 1.03 (9H, s, TBS (CH3)3), 0.18 (6H, s, TBS 
(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 173.7 (C1), 150.6 (C8), 133.1 (C4), 128.6 (C5), 128.6 
(C6), 51.7 (OCH3), 36.2 (C2), 30.3 (C3), 26.3 (TBS (CH3)3), 18.9 (TBS C(CH3)3), 18.0 (C7), 
-2.8 (TBS Si(CH3)2); HRMS (ESI














General procedure B: Methyl 3-(4-((tert-butyldimethylsilyl)oxy)-3,5-dimethylphenyl) 
propanoate (960 mg, 3.0 mmol) and 2.0 equivalents of LiAlH4 (1 M in THF) in anhydrous Et2O 
were employed. The crude product was filtered through a plug of silica and washed with EtOAc 
to afford 181 (690 mg, 80%) as a pale yellow oil; Rf = 0.2 (25% EtOAc:hexane); νmax / cm
-1 
(film) 3345 (br m), 2929 (m), 2858 (m), 1483 (s), 1472 (s), 1252 (s), 1227 (s), 1152 (s); 
1H NMR (400 MHz, CDCl3) δ 6.79 (2H, s), 3.66 (2H, t, J = 6.5 Hz), 2.57 (2H, t, J = 7.5 Hz), 
2.18 (6H, s), 1.89 – 1.81 (2H, m), 1.29 (1H, br s), 1.03 (9H, s), 0.18 (6H, s); 13C NMR (101 
MHz, CDCl3) δ 150.1, 134.2, 128.6, 128.3, 62.5, 34.3, 31.2, 26.1, 18.7, 17.8, -3.0.  





General procedure G: The preceding alcohol 181 (530 mg, 1.80 mmol), PPh3 (580 mg, 2.20 
mmol), DIAD (0.43 mL, 2.20 mmol) and BocNHOTs (630 mg, 2.20 mmol) in anhydrous THF 
(8 mL) were employed. Purification by flash column chromatography (10% EtOAc:hexane) 
afforded the title compound (880 mg, 87%) as a colourless oil; Rf = 0.55 (20% EtOAc:hexane); 
νmax / cm
-1 (film) 2955 (m), 2930 (m), 1722 (s), 1473 (m), 1483 (m), 1383 (s), 1369 (s), 1230 
(s), 1191 (s), 1179 (s), 1154 (s); 1H NMR (400 MHz, CDCl3) δ 7.84 (2H, d, J = 8.5 Hz, Ts 
ArCH), 7.32 (2H, d, J = 8.5 Hz, Ts ArCH), 6.75 (2H, s, C5-H), 3.61 (2H, br s, C1-H2), 2.46 – 
2.42 (5H, m, overlapping C3-H2 and Ts CH3), 2.18 (6H, s, C7-H3) 1.93 – 1.81 (2H, m, C2-H2), 
1.21 (9H, s, Boc (CH3)3), 1.03 (9H, s, TBS (CH3)3), 0.17 (6H, s, TBS Si(CH3)2); 
13C NMR 
(101 MHz, CDCl3) δ 155.6 (Boc C=O), 150.4 (C8), 145.7 (Ts ArC), 133.7 (C4), 131.4 (Ts 




ArC), 129.8 (2 × Ts ArCH), 129.6 (2 × Ts ArCH), 128.7 (C5), 128.5 (C6), 83.2 (Boc C(CH3)3), 
52.9 (C1), 32.1 (C3), 27.8 (C2), 27.7 (Boc (CH3)3), 26.3 (TBS (CH3)3), 21.9 (Ts CH3), 18.9 
(TBS C(CH3)3), 18.0 (C7), -2.8 (TBS (CH3)2); HRMS (ESI
+) Calculated for C29H45NNaO6SSi: 
586.2629. Found [M+Na]+: 586.2648. 
 
tert-Butyl (3-(4-hydroxy-3,5-dimethylphenyl)propyl)(tosyloxy)carbamate (182) 
 
General procedure H: tert-Butyl (3-(4-((tert-butyldimethylsilyl)oxy)-3,5-dimethylphenyl) 
propyl)(tosyloxy)carbamate (450 mg, 0.80 mmol) and 1:1 TBAF:HOAc solution (0.1 M in 
THF, 0.88 mmol) in THF (16 mL) were employed. Purification by flash column 
chromatography (gradient, eluent: 20 – 33% EtOAc:hexane) afforded 182 (310 mg, 87%) as a 
colourless, viscous oil; Rf = 0.3 (20% EtOAc:hexane); νmax / cm
-1 (film) 3530 (br m), 2979 (m), 
2930 (m), 1721 (s), 1597 (m), 1489 (m), 1370 (s), 1192 (s), 1177 (s), 1152 (s); 1H NMR (400 
MHz, CDCl3) δ 7.84 (2H, d, J = 8.5 Hz, Ts ArCH), 7.32 (2H, d, J = 8.5 Hz, Ts ArCH), 6.77 
(2H, s, C5-H), 4.49 (1H, s, OH), 3.62 (2H, br s, C1-H2), 2.44 (5H, m, overlapping C3-H2 and 
Ts CH3), 2.21 (6H, s, C7-H3), 1.93 – 1.85 (2H, m, C2-H2), 1.20 (9H, s, Boc (CH3)3); 
13C NMR 
(101 MHz, CDCl3) δ 155.6 (Boc C=O), 150.5 (C8), 145.8 (Ts ArC), 132.8 (C4), 131.4 (Ts 
ArC), 129.8 (2 × Ts ArCH), 129.6 (2 × Ts ArCH), 128.5 (C5), 123.0 (C6), 83.3 (Boc C(CH3)3), 
52.8 (C1), 32.1 (C3), 27.9 (C2), 27.7 (Boc (CH3)3), 21.8 (Ts CH3), 16.0 (C7); HRMS (ESI
+) 














General procedure I: The preceding N-tosyloxycarbamate 182 (89.8 mg, 0.20 mmol) and 
TFA (31.0 μL, 0.40 mmol) in TFE (2 mL) were employed. After stirring at room temperature 
for 22 hours, purification by flash column chromatography (EtOAc) afforded 183 (30.0 mg, 
85%) as a pale yellow/orange solid; m.p.: 110-113 oC (EtOAc:hexane); Rf = 0.1 (EtOAc); νmax 
/ cm-1 (film)  3318 (m), 2970 (m), 2946 (m), 2917 (m), 2882 (m), 1664 (s), 1623 (s), 1369 (m), 
1222 (m); 1H NMR (400 MHz, CDCl3) δ 6.60 (2H, s, C5-H), 3.19 (2H, t, J = 7.0 Hz, C1-H2), 
2.04 – 1.96 (2H, m, C2-H2), 1.87 – 1.84 (9H, m, overlapping C3-H2, C7-H3 and NH); 
13C NMR 
(101 MHz, CDCl3) δ 187.2 (C8), 147.7 (C5), 132.7 (C6), 60.4 (C4), 46.1 (C1), 36.7 (C3), 25.5 
(C2), 16.0 (C7); HRMS (ESI+) Calculated for C11H16NO: 178.1226. Found [M+H]
+: 178.1228.  
  









(E)-3-(4-Hydroxy-3-methoxyphenyl)acrylic acid (184) 
 
Vanillin (3.04 g, 20.0 mmol) and malonic acid (2.30 g, 22.0 mmol) were added to a solution of 
aniline (0.22 mL, 2.36 mmol) and pyridine (2.43 mL, 30.0 mmol) in toluene (5 mL). The 
solution was stirred at reflux for 2 hours. The mixture was cooled to room temperature and 
neutralised with an aqueous 25% solution of K2CO3 (12 mL) followed by careful addition of 
concentrated HCl (until pH = 3). The resulting precipitate was filtered and washed with ice 
cold H2O (10 mL) to afford 184 (3.0 g, 77%) as a yellow solid which was used without further 
purification; Rf = 0.5 (33% EtOAc:hexane); 
1H NMR (440 MHz, CD3OD) δ 7.60 (1H, d, J = 
16.0 Hz), 7.18 (1H, d, J = 2.0 Hz), 7.07 (1H, dd, J = 8.0, 2.0 Hz), 6.81 (1H, d, J = 8.0 Hz), 6.31 
(1H, d, J = 16.0 Hz), 3.90 (3H, s); 13C NMR (101 MHz, CD3OD) δ 171.0, 150.5, 149.4, 146.9, 
127.8, 123.9, 116.5, 115.9, 111.7, 56.4.  




General procedure E: The preceding carboxylic acid 184 (1.94 g, 10.0 mmol) and 10 wt.% 
Pd/C (5 mol%) in 5:1 EtOAc:MeOH (60 mL) were employed. Purification by flash column 
chromatography (50% EtOAc:hexane) afforded the title compound (1.66 g, 80 %) as a yellow 
oil; Rf = 0.4 (33% EtOAc:hexane); 
1H NMR (400 MHz, CDCl3) δ 6.83 (1H, d, J = 8.0 Hz), 
6.72 – 6.66 (2H, m), 5.57 (1H, s), 3.86 (3H, s), 3.67 (3H, s), 2.88 (2H, t, J = 8.0 Hz), 2.60 (2H, 
t, J = 8.0 Hz); 13C NMR (101 MHz, CDCl3) δ 173.5, 146.4, 144.1, 132.5, 120.9, 114.5, 111.0, 
55.9, 51.7, 36.2, 30.7.  
The spectroscopic properties were consistent with the data available in the literature.294 




Methyl 3-(4-((tert-butyldimethylsilyl)oxy)-3-methoxyphenyl)propanoate  
 
Methyl 3-(4-hydroxy-3-methoxyphenyl)propanoate (1.55 g, 7.40 mmol), tert-butyl dimethyl 
silyl chloride (1.34 g, 8.90 mmol) and imidazole (650 mg, 9.60 mmol) in 2.5:1 CH2Cl2:DMF 
(35 mL) were stirred at room temperature overnight and monitored by TLC. Upon completion, 
the reaction was quenched by addition of H2O (50 mL), extracted with CH2Cl2 (3 × 20 mL), 
washed with brine (20 mL), dried over MgSO4, filtered and concentrated in vacuo. Purification 
by flash column chromatography (gradient, eluent: 20 – 33% EtOAc:hexane) afforded the title 
compound (1.85 g, 77%) as a pale yellow oil; Rf = 0.7 (33% EtOAc:hexane); νmax / cm
-1 (film) 
2952 (m), 2930 (m), 2857 (m), 1738 (s), 1512 (s);  1H NMR (400 MHz, CDCl3) δ 6.74 (1H, d, 
J = 8.0 Hz, C6-H), 6.67 (1H, d, J = 2.0 Hz, C9-H), 6.62 (1H, dd, J = 8.0 Hz, 2.0 Hz, C5-H), 
3.77 (3H, s, C10-H3), 3.65 (3H, s, CO2CH3), 2.87 (2H, t, J = 7.5 Hz, C3-H2), 2.59 (2H, t, J = 
7.5 Hz, C2-H2), 0.98 (9H, s, TBS (CH3)3), 0.13 (6H, s, TBS Si(CH3)2); 
13C NMR (101 MHz, 
CDCl3) δ 173.5 (C1), 150.9 (C8), 143.5 (C7), 134.1 (C4), 120.9 (C6), 120.4 (C5) 112.5 (C9), 
55.5 (C10), 51.6 (CO2CH3), 36.1 (C2), 30.8 (C3), 25.8 (TBS (CH3)3), 18.5 (TBS SiC(CH3)3), 
-4.6 (TBS Si(CH3)2). HRMS (ESI






General procedure B: Methyl 3-(4-((tert-butyldimethylsilyl)oxy)-3-methoxyphenyl) 
propanoate (1.71 g, 5.00 mmol) and 2.0 equivalents of LiAlH4 (1.0 M in THF) in anhydrous 
Et2O (25 mL) were employed to afford 185 (1.34 g, 90%) as a pale yellow oil which was used 
without further purification; Rf = 0.3 (33% EtOAc:hexane); νmax / cm
-1 (film) 3357 (m br), 2930 




(m), 2885 (m), 2857 (m), 1511 (s); 1H NMR (400 MHz, CDCl3) δ 6.74 (1H, d, J = 8.0 Hz, 
C6-H), 6.67 (1H, d, J = 2.0 Hz, C9-H), 6.62 (1H, dd, J = 8.0, 2.0 Hz, C5-H), 3.78 (3H, s, 
C10-H3), 3.65 (2H, t, J = 6.5 Hz, C1-H2), 2.63 (2H, t, J = 7.5 Hz, C3-H2), 1.89 – 1.82 (2H, m, 
C2-H2), 0.98 (9H, s, TBS (CH3)3), 0.13 (6H, s, TBS Si(CH3)2); 
13C NMR (101 MHz, CDCl3) 
δ 150.8 (C8), 143.2 (C7), 135.3 (C5), 120.8 (C6), 120.5 (C5), 112.6 (C9), 62.5 (C1), 55.6 
(C10), 34.4 (C2), 31.9 (C3), 25.8 (TBS (CH3)3), 18.5 (TBS SiC(CH3)3), -4.6, (TBS Si(CH3)2). 






General procedure G: The preceding alcohol 185 (590 mg, 2.00 mmol), PPh3 (630 mg, 2.40 
mmol), DIAD (0.47 mL, 2.40 mmol) and BocNHOTs (690 mg, 2.40 mmol) in anhydrous THF 
(10 mL) were employed. Purification by flash column chromatography (10% EtOAc:hexane) 
afforded the title compound (940 mg, 83 %) as a colourless oil; Rf = 0.5 (20% EtOAc:hexane); 
νmax / cm
-1 (film) 2954 (m), 2930 (m), 2857 (m), 1720 (m), 1512 (s); 1H NMR (400 MHz, 
CDCl3) 7.84 (2H, d, J = 8.5 Hz, Ts ArCH), 7.32 (2H, d, J = 8.5 Hz, Ts ArCH), 6.74 (1H, d, J 
= 8.0 Hz, C6-H), 6.66 (1H, d, J = 2.0 Hz, C9-H), 6.59 (1H, dd, J = 8.0, 2.0 Hz, C5-H), 3.79 
(3H, s, C10-H3), 3.62 (2H, br s, C1-H2), 2.52 (2H, t, J = 8.0 Hz, C3-H2), 2.45 (3H, s, Ts CH3), 
1.98 – 1.87 (2H, m, C2-H2), 1.22 (9H, s, Boc (CH3)3), 0.99 (9H, s, TBS (CH3)3), 0.14 (6H, s, 
TBS Si(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 155.6 (Boc C=O), 150.9 (C8), 145.8 (Ts ArC), 
143.3 (C7), 134.7 (C4), 131.4 (Ts ArC), 129.8 (2 × Ts ArCH), 129.7 (2 × Ts ArCH), 120.8 
(C6), 120.5 (C5), 122.5 (C9) 83.3 (Boc C(CH3)3), 55.6 (C10), 52.8 (C1), 32.6 (C3), 27.8 (Boc 
(CH3)3), 27.6 (C2), 25.9 (TBS (CH3)3), 21.8 (Ts CH3), 18.6 (TBS SiC(CH3)3), -4.5 (TBS 
Si(CH3)2). HRMS (ESI










tert-Butyl (3-(4-hydroxy-3-methoxyphenyl)propyl)(tosyloxy)carbamate (186)  
 
General procedure H: tert-Butyl (3-(4-((tert-butyldimethylsilyl)oxy)-3-methoxyphenyl) 
propyl)(tosyloxy)carbamate (570 mg, 1.0 mmol), and 1:1 TBAF:AcOH solution (0.1 M in 
THF, 1.0 mmol) in THF (20 mL) were employed. Purification by flash column chromatography 
(20% EtOAc:hexane) afforded 186 (280 mg, 62%) as a colourless solid; m.p.: 82-84 oC 
(EtOAc:hexane); Rf = 0.4 (33% EtOAc:hexane); νmax / cm
-1 (solid) 3505 (m, br), 2989 (m), 
2964 (m), 2935 (m), 1749 (s), 1514 (m), 1153 (s); 1H NMR (400 MHz, CDCl3) δ 7.84 (2H, d, 
J = 8.0 Hz, Ts ArCH), 7.33 (2H, d, J = 8.0 Hz, Ts ArCH), 6.82 (1H, d, J = 8.0 Hz, C6-H), 6.69 
(1H, d, J = 2.0 Hz, C9-H), 6.64 (1H, dd, J = 8.0, 2.0 Hz, C5-H), 5.47 (1H, s, OH), 3.89 (3H, s, 
C10-H3), 3.60 (2H, br s, C1-H2), 2.53 (2H, t, J = 7.5 Hz, C3-H2), 2.45 (3H, s, Ts CH3), 1.97 – 
1.87 (2H, m, C2-H2), 1.22 (9H, s, Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) δ 155.6 (Boc 
C=O), 146.5 (C8) 145.8, (Ts ArC), 143.9 (C7), 133.1 (C4), 131.3 (Ts ArC), 129.8 (2 × Ts 
ArCH), 129.6 (2 × Ts ArCH), 120.9 (C5), 114.3 (C6), 110.9 (C9), 83.3 (Boc C(CH3)3), 56.1 
(C10), 52.6 (C1), 32.6 (C3), 27.7 (Boc (CH3)3), 27.7 (C2) 21.8 (Ts CH3); HRMS (ESI
+) 
Calculated for C22H29NNaO7S: 474.1557. Found [M+Na]
+: 474.1551. 
 
7-Methoxy-1-azaspiro[4.5]deca-6,9-dien-8-one trifluoroacetate (196) and 6-Methoxy-
1,2,3,4-tetrahydroquinolin-7-ol (197) 
 
General procedure I: The preceding N-tosyloxycarbamate 186 (67.7 mg, 0.15 mmol) and 
TFA (23 μL) in TFE (1.5 mL) were stirred at room temperature for 40 hours. Upon completion, 
the reaction mixture was concentrated in vacuo. An in situ yield was obtained by 1H NMR 
analysis versus 1,3,5-trimethoxybenzene as an internal standard; a 27 % yield of 196 and 62 % 




yield of 197 were observed. Purification by flash column chromatography (EtOAc) afforded 
197 (14.9 mg, 55%) as a yellow solid, however, 196 could not be isolated cleanly. 
Data for 196: from NMR analysis of crude material: 1H NMR (400 MHz, CD3OD) δ 7.11 (1H, 
dd, J = 10.0, 3.0 Hz, C5-H), 6.46 (1H, d, J = 10.0 Hz, C6-H), 6.03 (1H, d, J = 3.0 Hz, C10-H), 
3.75 (3H, s, C9-H3), 3.68 – 3.60 (2H, m, C1-H2), 2.46 – 2.43 (2H, m, C2-H2), 2.33 – 2.27 (2H, 
m, C3-H2); 
13C NMR (101 MHz, CD3OD) δ 180.8 (C7), 153.5 (C8), 144.8 (C5), 131.3 (C6), 
111.5 (C10), 66.6 (C4), 56.0 (C9) 46.1 (C1) 38.2 (C3), 24.7 (C2); 
Data for 197: m.p.: 76 - 78 oC (EtOAc:hexane); Rf = 0.7 (EtOAc); νmax / cm
-1 (solid) 3383 (br 
m), 3324 (br m), 2926 (m), 1508 (s), 1464 (m), 1443 (m); 1H NMR (400 MHz, CDCl3) δ 6.50 
(1H, s, C5-H), 6.14 (1H, s, C9-H), 3.79 (3H, s, C8-H3), 3.25 – 3.20 (2H, m, C1-H2), 2.68 (2H, 
t, J = 6.5 Hz, C3-H2), 1.94 – 1.88 (2H, m, C2-H2); 
13C NMR (101 MHz, CDCl3) δ 144.7 (C6), 
139.3 (C10), 139.1 (C7), 113.1 (C5), 112.7 (C4), 101.7 (C9), 57.0 (C8), 42.3 (C1), 26.7 (C3), 





A solution of bromine (0.25 mL, 4.75 mmol) in acetic acid (20 mL) was slowly added to a 
stirring solution of ethyl 3-(4-hydroxyphenyl)propionate (187) (1.84 g, 9.50 mmol) at room 
temperature. The reaction mixture was stirred for 6 hours then diluted with EtOAc (80 mL) 
and washed with brine (2 × 30 mL). The organic extracts were dried over anhydrous MgSO4, 
filtered and concentrated in vacuo. Purification by flash column chromatography (5% 
EtOAc:PhMe) afforded the title compound (1.14 g, 44%) as a pale yellow solid; Rf = 0.3 (5% 
EtOAc:PhMe); νmax / cm
-1 (solid) 3357 (br m), 2977 (m), 2936 (m), 1727 (s), 1704 (s), 1496 
(s), 1289 (s), 1254 (s), 1180 (s), 1156 (s), 1039 (s); 1H NMR (400 MHz, CDCl3) 7.29 (1H, d, J 
= 2.0 Hz), 7.03 (1H, dd, J = 8.0, 2.0 Hz), 6.91 (1H, d, J = 8.0 Hz), 4.11 (2H, q, J = 7.0 Hz), 
2.85 (2H, t, J = 8.5 Hz), 2.56 (2H, t, J = 7.5 Hz), 1.22 (3H, t, J = 7.0 Hz); 13C NMR (101 MHz, 
CDCl3) δ 172.7, 150.7, 134.2, 131.6, 129.1, 116.0, 110.0, 60.5, 36.0, 29.8, 14.2.  
The spectroscopic properties were consistent the data available in the literature.295 
 




Ethyl 3-(3-bromo-4-((tert-butyldimethylsilyl)oxy)phenyl)propanoate (188) 
 
To a solution of ethyl 3-(3-bromo-4-hydroxyphenyl)propanoate (1.08 g, 3.95 mmol) in DMF 
(5 mL) was added tert-butyldimethylsilyl chloride (710 mg, 4.74 mmol) and imidazole (670 
mg, 9.88 mmol) and the reaction was stirred at room temperature overnight. To the reaction 
was added water (25 mL) and the organic phase extracted with CH2Cl2 (2 × 20 mL). The 
combined organic extracts were washed with brine (20 mL), dried over MgSO4, filtered and 
concentrated in vacuo. Purification by flash column chromatography (5% EtOAc:hexane) 
afforded 188 (1.43 g, 93%) as a colourless oil; Rf  = 0.6 (5% EtOAc:hexane); νmax / cm
-1 (film) 
2956 (m), 2930 (m), 1734 (s), 1493 (s), 1287 (s), 1253 (s); 1H NMR (400 MHz, CDCl3) δ 7.35 
(1H, d, J = 2.0 Hz, C9-H), 6.98 (1H, dd, J = 8.5, 2.0 Hz, C5-H), 6.77 (1H, d, J = 8.5 Hz, C6-H), 
4.11 (2H, q, J = 7.0 Hz, OCH2), 2.84 (2H, t, J = 7.5 Hz, C3-H2), 2.56 (2H, t, J = 7.5 Hz, C2-H2), 
1.22 (3H, t, J = 7.0 Hz, CH2CH3), 1.03 (9H, s, TBS (CH3)3), 0.22 (6H, TBS (CH3)2); 
13C NMR 
(101 MHz, CDCl3) δ 172.8 (C1), 151.1 (C7), 134.9 (C4), 133.2 (C9), 128.2 (C5), 120.2 (C6), 
115.2 (C8), 60.6 (OCH2CH3), 36.1 (C2), 29.9 (C3), 25.9 (TBS (CH3)3), 18.5 (TBS SiC(CH3)3), 
14.4 (OCH2CH3), -4.11 (TBS Si(CH3)2); HRMS (ESI
+) Calculated for C17H27
79BrNaO3Si: 




To a solution of the preceding ester 188 (1.03 g, 2.66 mmol) in anhydrous THF (15 mL) at -15 
oC was added 0.75 equivalents of LiAlH4 (1M in THF) and the reaction was stirred at the same 
temperature for 25 minutes. Then to the reaction mixture was added water (0.5 mL), aqueous 
1 M NaOH (0.2 mL) and water (1 mL). The reaction mixture was warmed to room temperature, 
filtered through Celite® and washed with CH2Cl2. The filtrate was dried over Na2SO4, filtered 




and concentrated in vacuo. Purification by flash column chromatography (20% EtOAc:hexane) 
afforded 189 (800 mg, 87%) as a colourless oil; Rf = 0.2 (20% EtOAc:hexane); νmax / cm
-1 (film) 
3327 (br m), 2930 (m), 2858 (m), 1492 (s), 1280 (s), 1253 (s); 1H NMR (400 MHz, CDCl3) δ 
7.34 (1H, d, J = 2.0 Hz, C9-H), 6.97 (1H, dd, J = 8.0, 2.0 Hz, C5-H), 6.77 (1H, dd, J = 8.0, 1.0 
Hz, C6-H), 3.63 (2H, t, J = 6.5 Hz, C1-H2), 2.60 (2H, t, J = 7.5 Hz, C3-H2), 1.87 – 1.80 (2H, 
m, C2-H2), 1.51 (1H, br s, OH), 1.03 (9H, s, TBS (CH3)3), 0.22 (6H, s, TBS (CH3)2); 
13C NMR 
(101 MHz, CDCl3) δ 150.7 (C7), 136.1 (C4), 133.2 (C9), 128.3 (C5), 120.2 (C6), 115.2 (C8), 
62.1 (C1), 34.2 (C2), 31.0 (C3), 25.9 (TBS (CH3)3), 18.5 (TBS C(CH3)3), -4.1 (TBS Si(CH3)2); 
HRMS (ESI+) Calculated for C15H25
79BrNaO2Si: 367.0699. Found [M+Na]
+: 367.0701. 
 
tert-Butyl (3-(3-bromo-4-((tert-butyldimethylsilyl)oxy)phenyl)propyl) (tosyloxy) 
carbamate  
 
General procedure G: The preceding alcohol 189 (690 mg, 2.00 mmol), PPh3 (630 mg, 2.40 
mmol), DIAD (0.47 mL, 2.40 mmol) and BocNHOTs (690 mg, 2.40 mmol) in anhydrous THF 
were employed. Purification by flash column chromatography (gradient, eluent: 5% – 10% 
EtOAc:hexane) afforded the title compound (1.12 g, 91%) as a colourless oil; Rf = 0.6 (20% 
EtOAc:hexane); νmax / cm
-1 (film)  2955 (m), 2930 (m), 2858 (m), 1720 (s), 1493 (s), 1381 (s), 
1368 (s), 1288 (s), 1254 (s), 1178 (s); 1H NMR (400 MHz, CDCl3) δ 7.83 (2H, d, J = 8.0 Hz, 
Ts ArCH), 7.32 (2H, d, J = 8.0 Hz, Ts ArCH), 7.29 (1H, d, J = 2.0 Hz, C9-H), 6.94 (1H, dd, J 
= 8.5, 2.0 Hz, C5-H), 6.77 (1H, d, J = 8.5 Hz, C6-H), 3.58 (2H, br s, C1-H2), 2.49 (2H, t, J = 
8.0 Hz, C3-H2), 2.44 (3H, s, Ts CH3), 1.95 – 1.82 (2H, m, C2-H2), 1.22 (9H, s, Boc (CH3)3), 
1.03 (9H, s, TBS (CH3)3), 0.23 (6H, s, TBS Si(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 155.6 
(Boc C=O), 150.9 (C7), 145.8 (Ts ArC), 135.4 (C4), 133.1 (C9), 131.4 (Ts ArC), 129.8 (2 × 
Ts ArCH), 129.7 (2 × Ts ArCH), 128.2 (C5), 120.2 (C6), 115.2 (C8), 83.4 (Boc C(CH3)3), 52.6 
(C1), 31.8 (C3), 27.8 (Boc (CH3)3), 27.5 (C2), 25.9 (TBS (CH3)3), 21.8 (Ts CH3), 18.5 (TBS 
SiC(CH3)3), -4.1 (TBS Si(CH3)2); HRMS (ESI
+) Calculated for C27H40
79BrNNaO6SSi: 
636.1421. Found [M+Na]+: 636.1422. 
 




tert-Butyl (3-(3-bromo-4-hydroxyphenyl)propyl)(tosyloxy)carbamate (190) 
 
General procedure H: tert-Butyl (3-(3-bromo-4-((tert-butyldimethylsilyl)oxy)phenyl) 
propyl)(tosyloxy)carbamate (610 mg, 1.00 mmol) and 1:1 solution of TBAF:AcOH (0.1 M in 
THF, 1.00 mmol) in THF (20 mL) were employed. Purification by flash column 
chromatography (20% EtOAc:hexane) afforded 190 (480 mg, 96%) as a colourless solid; m.p.: 
93-95 oC (EtOAc:hexane); Rf = 0.25 (20% EtOAc:hexane); νmax / cm
-1 (solid) 3416 (br s), 2945 
(m), 1682 (s), 1371 (s), 1361 (s), 1180 (s), 1158 (s); 1H NMR (400 MHz, CDCl3) δ 7.83 (2H, 
d, J = 8.5 Hz, Ts ArCH), 7.32 (2H, d, J = 8.0 Hz, Ts ArCH), 7.25 (1H, d, J = 2.0 Hz, C9-H), 
7.00 (1H, dd, J = 8.5, 2.0 Hz, C5-H), 6.91 (1H, d, J = 8.5 Hz, C6-H), 5.43 (1H, s, OH), 3.59 
(2H, br s, C1-H2), 2.50 (2H, t, J = 8.0 Hz, C3-H2), 2.44 (3H, s, Ts CH3), 1.91 – 1.87 (2H, m, 
C2-H2), 1.21 (9H, s, Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) δ 155.6 (Boc C=O), 150.6 
(C7), 145.9 (Ts ArC), 134.9 (C4), 131.6 (C9), 131.3 (Ts ArC), 129.8 (2 × Ts ArCH), 129.7 (2 
× Ts ArCH), 129.2 (C5), 116.1 (C6), 110.1 (C8), 83.5 (Boc C(CH3)3), 52.5 (C1), 31.7 (C3), 
27.8 (Boc (CH3)3), 27.6 (C2), 21.8 (Ts CH3); HRMS (ESI
+) Calculated for C21H26
79BrNO6S: 
522.0556. Found [M+Na]+: 522.0555. 
 
7-B romo-1-azaspiro[4.5]deca-6,9-dien-8-one trifluoroacetate (198) and 6-Bromo-1,2,3,4-
tetrahydroquinolin-7-ol (199) 
 
General procedure I: The preceding N-tosyloxycarbamate 190 (75.06 mg, 0.15 mmol) and 
TFA (22.9 μL, 0.30 mmol) in TFE (1.5 mL) were employed. After stirring at room temperature 




for 45 hours, purification by flash column chromatography (EtOAc) afforded the title 
compounds 198 (22.0 mg, 43%) as a red/brown oil and 199 (8.8 mg, 19 %) as a brown oil. 
Data for 198; Rf = 0.1 (EtOAc); νmax / cm
-1 (film, CDCl3) 2924 (m), 1675 (s), 1407 (w), 1200 
(s), 1134 (m), 1066 (m); 1H NMR (400 MHz, CD3OD) δ 7.63 (1H, d, J = 3.0 Hz, C9-H), 7.14 
(1H, dd, J = 10.0, 3.0 Hz, C5-H), 6.55 (1H, d, J = 10.1 Hz, C6-H), 3.64 (2H, t, J = 7.0 Hz, 
C1-H2), 2.41 – 2.30 (4H, m, C2-H2, C3-H2). The signals corresponding to the NH2 were not 
observed.  13C NMR (101 MHz, CD3OD) δ 178.1 (C7), 144.7 (C9), 144.6 (C5), 130.3 (C6), 
128.3 (C8), 66.9 (C4), 46.7 (C1), 37.4 (C3), 24.8 (C2). The signals corresponding to the 
trifluoroacetate group could not be resolved due to their weak intensity. HRMS (ESI+) 
Calculated for C9H11
79BrNO: 228.0019. Found [M]+: 228.0019. 
Data for 199; Rf = 0.7 (EtOAc); νmax / cm
-1 (film) 3389 (m), 3197 (m), 2957 (m), 2918 (m), 
2850 (m); 1H NMR (400 MHz, CDCl3) δ 6.97 (1H, s, C5-H), 6.16 (1H, s, C8-H), 3.27 – 3.24 
(2H, m, C1-H2), 2.66 (2H, t, J = 6.5 Hz, C3-H2), 1.91 – 1.85 (2H, m, C2-H2); 
13C NMR (101 
MHz, CDCl3) δ 150.8 (C7), 145.1 (C9), 131.7 (C5), 115.8 (C4), 100.8 (C8), 96.6 (C6), 41.7 
(C1), 26.1 (C3), 21.9 (C2). HRMS (ESI+) Calculated for C9H11
79BrNO: 228.0018. Found [M]+: 
228.0029. 
 
Methyl 3-(3-bromo-4-hydroxyphenyl)propanoate  
 
To a solution of methyl 3-(4-hydroxyphenyl)propanoate (4.50 g, 25.0 mmol) in AcOH (20 mL) 
was slowly added a solution of Br2 (1.3 mL, 25.0 mmol) in AcOH (15 mL). The reaction was 
stirred at room temperature until completion by TLC analysis. The reaction was diluted with 
EtOAc (20 mL) and washed with brine (20 mL), dried over Na2SO4, filtered, and the solvent 
removed in vacuo. Purification by flash column chromatography (20% EtOAc:hexane) 
afforded the title compound (2.98 g, 46%) as a colourless solid; Rf = 0.2 (20% EtOAc:hexane); 
1H NMR (400 MHz, CDCl3) δ 7.30 (1H, d, J = 2.0 Hz), 7.05 (1H, dd, J = 8.5, 2.0 Hz), 6.93 
(1H, d, J = 8.5 Hz), 3.67 (3H, s), 2.86 (2H, t, J = 7.5 Hz), 2.59 (2H, dd, J = 8.5, 6.5 Hz); 
13C NMR (101 MHz, CDCl3) δ 173.2, 150.8, 134.3, 131.7, 129.2, 116.1, 110.1, 51.8, 35.8, 
29.7.  
The spectroscopic properties were consistent with the data available in the literature.296 




Methyl 3-(3-bromo-4-((tert-butyldimethylsilyl)oxy)phenyl)propanoate (191) 
 
To a solution of methyl 3-(3-bromo-4-hydroxyphenyl)propanoate (2.94 g, 11.3 mmol) in DMF 
(5 mL) was added tert-butyldimethylsilyl chloride (2.05 g, 13.6 mmol) and imidazole (1.93 g, 
28.4 mmol) and the reaction was stirred at room temperature overnight. To the reaction was 
added water (25 mL) and the organic phase was extracted with CH2Cl2 (2 × 20 mL). The 
combined organic phases were washed with brine (20 mL), dried over MgSO4, filtered and 
concentrated in vacuo. Purification by flash column chromatography (20% EtOAc:hexane) 
afforded 191 (3.53 g, 84%) as a colourless oil; Rf = 0.4 (20% EtOAc:hexane); νmax / cm
-1 (film) 
2952 (m), 2930 (m), 2858 (m), 1738 (s), 1492 (s), 1253 (s); 1H NMR (400 MHz, CDCl3) δ 7.35 
(1H, d, J = 2.0 Hz, C10-H), 7.04 – 6.93 (1H, m, C6-H), 6.78 (1H, d, J = 8.0 Hz, C7-H), 3.67 
(3H, s, C1-H3), 2.85 (2H, t, J = 8.0 Hz, C4-H2), 2.58 (2H, t, J = 8.0 Hz, C3-H2), 1.03 (9H, s, 
TBS (CH3)3), 0.23 (6H, s, TBS Si(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 173.3 (C2), 151.1 
(C8), 134.8 (C5), 133.2 (C10), 128.2 (C6), 120.2 (C7), 115.3 (C9), 51.8 (C1), 35.8 (C4), 29.9 
(C3), 25.9 (TBS (CH3)3), 18.5 (TBS C(CH3)3), -4.1 (TBS Si(CH3)2). HRMS (ESI
+) Calculated 
for C16H25
79BrNaO3Si: 395.0648. Found [M+Na]
+: 395.0647. 
 
Methyl 3-(6-((tert-butyldimethylsilyl)oxy)-[1,1'-biphenyl]-3-yl)propanoate (192) 
 
The preceding aryl bromide 191 (1.12 g, 3.00 mmol), phenylboronic acid (1.09 g, 9.00 mmol), 
K2CO3 (1.40 g, 10.2 mmol) and dichloro [1,1’-bis(di-tertbutylphosphino)ferrocene] 
palladium(II) (Pd(dtbpf)Cl2) (97.8 mg, 0.15 mmol) in 5:1 PhMe:MeOH (0.12 M) were heated 
at 110 oC overnight, under an atmosphere of N2, and monitored by GC-MS. Upon completion, 
the reaction was cooled to room temperature and filtered through Celite® washing with EtOAc. 




The crude reaction mixture was then washed with water and the organic layer dried over 
Na2SO4, filtered and concentrated in vacuo. Purification by flash column chromatography (5% 
EtOAc:hexane) afforded 192 (930 mg, 84%) as a pale yellow oil; Rf = 0.5 (20% 
EtOAc:hexane); νmax / cm
-1 (film) 2952 (m), 2929 (m), 2896 (m), 2857 (m), 1737 (s), 1486 (s), 
1253 (s); 1H NMR (440 MHz, CDCl3) δ 7.49 – 7.45 (2H, m, ArCH), 7.39 – 7.33 (2H, m, 
ArCH), 7.31 – 7.26 (1H, m, ArCH), 7.13 (1H, d, J = 2.5 Hz, C9-H), 7.03 (1H, dd, J = 8.5, 2.5 
Hz, C5-H), 6.82 (1H, d, J = 8.0 Hz, C6-H), 3.67 (3H, s, OCH3), 2.93 (2H, t, J = 8.0 Hz, C3-H2), 
2.63 (2H, t, J = 8.0 Hz, C2-H2), 0.81 (9H, s, TBS (CH3)3), -0.07 (6H, s, TBS Si(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 173.6 (C1), 151.1 (C7), 139.2 (C8), 133.6 (ArC), 133.5 (C4), 
130.8 (C9), 129.9 (2 × ArCH), 128.1 (C5), 127.9 (2 × ArCH), 126.9 (ArCH), 120.5 (C6), 51.7 
(OCH3), 36.1 (C2), 30.4 (C3), 25.7 (TBS (CH3)3), 18.2 (TBS SiC(CH3)3), -4.5 (TBS Si(CH3)2); 





General procedure B: Ester 192 (740 mg, 2.00 mmol) and 2.0 equivalents of LiAlH4 (1 M in 
THF) in anhydrous Et2O were employed. Purification by flash column chromatography (20% 
EtOAc:hexane) afforded the title compound (600 mg, 87%) as a colourless oil; Rf = 0.2 (20% 
EtOAc:hexane); νmax / cm
-1 (film) 3338 (m, br), 2929 (m), 2857 (m), 2884 (m), 1485 (s), 1256 
(s); 1H NMR (400 MHz, CDCl3) δ 7.52 – 7.47 (2H, m, ArCH), 7.40 – 7.34 (2H, m, ArCH), 
7.32 – 7.26 (1H, m, ArCH), 7.14 (1H, d, J = 2.5 Hz, C9-H), 7.04 (1H, dd, J = 8.0, 2.5 Hz, 
C5-H), 6.84 (1H, d, J = 8.0 Hz, C6-H), 3.69 (2H, t, J = 6.5 Hz, C1-H2), 2.69 (2H, t, J = 7.5 Hz, 
C3-H2), 1.94 – 1.87 (2H, m, C3-H2), 1.38 (1H, br s, OH), 0.82 (9H, s, TBS (CH3)3), -0.06 (6H, 
s, TBS Si(CH3)2). 
13C NMR (101 MHz, CDCl3) δ 150.8 (C7), 139.3 (C8), 134.9 (C4), 133.4 
(ArC), 130.9 (C9), 129.9 (2 × ArCH), 128.2 (C5), 127.9 (2 × ArCH), 126.8 (ArCH), 120.4 
(C6), 62.5 (C1), 34.5 (C2), 31.4 (C3), 25.7 (TBS (CH3)3), 18.2 (TBS SiC(CH3)3), -4.5 (TBS 
Si(CH3)2); HRMS (ESI
+) Calculated for C21H30NaO2Si: 365.1907. Found [M+Na]
+: 365.1924. 
 







General procedure G: 3-(6-((tert-Butyldimethylsilyl)oxy)-[1,1'-biphenyl]-3-yl)propan-1-ol 
(480 mg, 1.40 mmol), PPh3 (440 mg, 1.68 mmol), DIAD (0.33 ml, 1.68 mmol) and BocNHOTs 
(480 mg, 1.68 mmol) in anhydrous THF (6 mL) were employed. Purification by flash column 
chromatography (5% EtOAc:hexane) afforded the title compound (740 mg, 87%) as a 
colourless solid; m.p.: 95-96 oC (EtOAc:hexane); Rf = 0.5 (EtOAc:hexane); νmax / cm
-1 (solid) 
2985 (m), 2955 (m), 2937 (m), 1715 (s), 1365 (s); 1H NMR (400 MHz, CDCl3) δ 7.85 (2H, d, 
J = 8.0 Hz, Ts ArCH), 7.50 – 7.47 (2H, m, ArCH), 7.40 – 7.26 (5H, m, 3 × ArCH, 2 × Ts 
ArCH), 7.09 (1H, d, J = 2.5 Hz, C9-H), 7.01 (1H, dd, J = 8.0, 2.5 Hz, C5-H), 6.82 (1H, d, J = 
8.0 Hz, C6-H), 3.64 (2H, br s, C1-H2), 2.57 (2H, t, J = 8.0 Hz, C3-H2), 2.44 (3H, s, Ts CH3), 
2.01 – 1.88 (2H, m, C2-H2), 1.21 (9H, s, Boc (CH3)3), 0.81 (9H, s, TBS (CH3)3), -0.08 (6H, s, 
TBS Si(CH3)2). 
13C NMR (101 MHz, CDCl3) δ 155.5 (Boc C=O), 150.9 (C7), 145.8 (Ts ArC), 
139.3 (ArC), 134.2 (C4), 133.4 (C8), 131.4 (Ts ArC), 130.8 (C9), 129.9 (2 × ArCH), 129.8 (2 
× Ts ArCH), 129.6 (2 × Ts ArCH), 128.1 (C5), 127.9 (2 × ArCH), 126.8 (ArCH), 120.4 (C6), 
83.3 (Boc C(CH3)3), 52.8 (C1), 32.2 (C3), 27.8 (Boc (CH3)3), 27.7 (C2), 25.7 (TBS (CH3)3), 
21.8 (Ts CH3), 18.2 (TBS SiC(CH3)3), -4.5 (TBS Si(CH3)2); HRMS (ESI
+) Calculated for 
C33H45NNaO6SSi: 634.2629. Found [M+Na]
+: 634.2609. 
 
tert-Butyl (3-(6-hydroxy-[1,1'-biphenyl]-3-yl)propyl)(tosyloxy)carbamate (194) 
 
General procedure H: tert-Butyl(3-(6-((tert-butyldimethylsilyl)oxy)-[1,1'-biphenyl]-3-
yl)propyl) (tosyloxy)carbamate (610 mg, 1.00 mmol) and 1:1 TBAF:AcOH solution (0.1 M in 




THF, 1.00 mmol) in THF (20 mL) were employed. Purification by flash column 
chromatography (20% EtOAc:petroleum ether) afforded 194 (410 mg, 82%) as a colourless 
solid; m.p.: 108-110 oC (EtOAc:hexane); Rf = 0.2 (20% EtOAc:hexane); νmax / cm
-1 (film) 3467 
(m, br), 2980 (m), 2930 (m), 1719 (s), 1368 (s), 1176 (s), 1151 (s); 1H NMR (400 MHz, CDCl3) 
δ 7.84 (2H, d, J = 8.5 Hz, Ts ArCH), 7.51 – 7.46 (4H, m, ArCH), 7.42 – 7.36 (1H, m, ArCH), 
7.32 (2H, d, J = 8.0 Hz, Ts ArCH), 7.07 – 7.03 (2H, m C5, C9-H), 6.90 (1H, d, J = 8.0 Hz, 
C6-H), 5.17 (1H, s, OH), 3.65 (2H, br s, C1-H2), 2.57 (2H, t, J = 8.0 Hz, C3-H2), 2.44 (3H, s, 
Ts CH3), 2.01 – 1.87 (2H, m, C2-H2), 1.22 (9H, s, Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) 
δ 155.6 (Boc C=O), 150.8 (C7), 145.8 (Ts ArC), 137.3 (ArC), 133.5 (C4), 131.4 (Ts ArC), 
130.1 (C9), 129.8 (2 × ArCH), 129.7 (2 × Ts ArCH), 129.4 (2 × Ts ArCH), 129.2 (2 × ArCH), 
129.0 (C5), 128.1 (C8), 127.9 (ArCH), 115.9 (C6), 83.4 (Boc C(CH3)3), 52.7 (C1), 32.1 (C3), 
27.7 (Boc (CH3)3), 27.7 (C2), 21.8 (Ts CH3); HRMS (ESI
+) Calculated for C27H31NNaO6S: 
520.1764. Found [M+Na]+: 520.1766.  
 
7-Phenyl-1-azaspiro[4.5]deca-6,9-dien-8-one trifluoroacetate (200) and 6-Phenyl-1,2,3,4-
tetrahydroquinolin-7-ol (201) 
 
General procedure I: The preceding N-tosyloxycarbamate 194 (74.6 mg, 0.15 mmol) and 
TFA (23 μL, 0.30 mmol) in anhydrous TFE (1.5 mL) were employed. After stirring at room 
temperature for 46 hours, purification by flash column chromatography (EtOAc) afforded the 
title compounds 200 (26.0 mg, 51%) and 201 (11.7 mg, 35%) as yellow solids. 
Data for 200: m.p.: 136-138 oC (EtOAc:hexane); Rf = 0.1 (5% MeOH:CH2Cl2); νmax / cm
-1 
(film) 3374 (m, br), 2975 (m), 1665 (s), 1640 (s); 1H NMR (400 MHz, CD3OD) δ 7.46 – 7.37 
(5H, m, PhCH), 7.14 (1H, dd, J = 10.0, 3.5 Hz, C5-H), 7.09 (1H, d, J = 3.0 Hz, C9-H), 6.52 
(1H, d, J = 10.0 Hz, C6-H), 3.70 – 3.63 (2H, m, C1-H2), 2.45 – 2.30 (4H, m, C2-H2, C3-H2). 
The signals corresponding to the NH2 were not observed. 
13C NMR (101 MHz, CD3OD) δ 
184.4 (C7), 143.6 (C5), 142.1 (C8), 141.0 (C9), 135.6 (ArC), 132.2 (C6), 130.0 (2 × ArCH), 
129.9 (ArCH), 129.2 (2 × ArCH), 65.2 (C4), 46.5 (C1), 37.9 (C3), 24.9 (C2). The signals 




corresponding to the trifluoroacetate group could not be resolved due to their weak intensity. 
HRMS (ESI+) Calculated for C15H16NO: 226.1226. Found [M]
+: 226.1229. 
Data for 201: m.p.: 91-94 oC (EtOAc:hexane); Rf = 0.4 (5% MeOH:CH2Cl2); νmax / cm
-1 (solid) 
3405 (br m), 2925 (m), 2852 (m), 1622 (s), 1488 (s), 1160 (s); 1H NMR (400 MHz, CDCl3) δ 
7.46 – 7.40 (4H, m, ArCH), 7.33 – 7.28 (1H, m, ArCH), 6.84 (1H, s, C5-H), 6.11 (1H, s, C8-H), 
4.98 (1H, br s), 4.04 (1H, br s), 3.32 – 3.29 (2H, m, C1-H2), 2.73 (2H, t, J = 6.5 Hz, C3-H2), 
1.97 – 1.91 (2H, m, C2-H2); 
13C NMR (101 MHz, CDCl3) δ 151.3 (C7), 145.4 (C9), 137.7 
(ArC), 130.8 (C5), 129.1 (2 × ArCH), 128.9 (2 × ArCH), 126.8 (ArCH), 117.3 (C6), 114.2 
(C4), 100.5 (C8), 41.9 (C1), 26.2 (C3), 22.4 (C2); HRMS (ESI+) Calculated for C15H16NO: 
226.1226. Found [M+H]+: 226.1232. 
 
Methyl 3-(4-((tert-butyldimethylsilyl)oxy)-3-cyclopropylphenyl)propanoate (193) 
 
Aryl bromide 191 (1.12 g, 3.00 mmol), cyclopropylboronic acid (770 mg, 9.00 mmol), K3PO4 
(3.82 g, 18.0 mmol) and tetrakis(triphenylphosphine)palladium (0) (Pd(PPh3)4) (346 mg, 0.30 
mmol) in 20:1 toluene:H2O (0.1 M) were heated at 95 
oC overnight, under an atmosphere of 
N2, and monitored by GC-MS. Upon completion, the reaction was cooled to room temperature 
and filtered through Celite® washing with EtOAc. The crude reaction mixture was then washed 
with water and the organic layer was dried over Na2SO4, filtered and concentrated in vacuo. 
Purification by flash column chromatography (5% EtOAc:hexane) afforded 193 (810 mg, 80%) 
as a pale yellow oil; Rf = 0.5 (20% EtOAc:hexane); νmax / cm
-1 (film) 2953 (m), 2930 (m), 2897 
(m), 2858 (m), 1739 (s), 1498 (s), 1255 (s); 1H NMR (400 MHz, CDCl3) δ 6.85 (1H, dd, J = 
8.0, 2.3 Hz, C6-H), 6.70 (1H, d, J = 8.0 Hz, C7-H), 6.62 (1H, d, J = 2.0 Hz, C10-H), 3.67 (3H, 
s, C1-H3), 2.84 (2H, t, J = 8.0 Hz, C4-H2), 2.57 (2H, t, J = 8.0 Hz, C3-H2), 2.13 (1H, tt, J = 8.5, 
5.4 Hz, C11-H), 1.03, (9H, s, TBS (CH3)3), 0.93 – 0.87 (2H, m, C12/13-H2), 0.64 – 0.60 (2H, 
m, C12/C13-H2), 0.23 (6H, s, TBS Si(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 173.6 (C2), 152.9 
(C8), 134.2 (C9) , 133.2 (C5), 125.7 (C6), 124.8 (C10), 118.7 (C7), 51.7 (C1), 36.2 (C3), 30.6 
(C4), 25.9 (TBS (CH3)3), 18.4 (TBS C(CH3)3), 10.1 (C11), 8.2 (C12,C13), -4.1 (TBS Si(CH3)2). 
HRMS (ESI+) Calculated for C19H30NaO3Si: 357.1856. Found [M+Na]
+: 357.1862. 






General procedure B: Ester 193 (670 mg, 2.00 mmol) and 2.0 equivalents of LiAlH4 (1 M in 
THF) in anhydrous Et2O were employed. Purification by flash column chromatography (20% 
EtOAc:hexane) afforded the title compound (480 mg, 78%) as a colourless oil; Rf = 0.2 (20% 
EtOAc:hexane); νmax / cm
-1 (film) 3334 (m, br), 2953 (m), 2929 (m), 2885 (m), 2857 (m), 1496 
(s), 1254 (s); 1H NMR (400 MHz, CDCl3) δ 6.84 (1H, dd, J = 8.0, 2.5 Hz, C5-H), 6.70 (1H, d, 
J = 8.0 Hz, C6-H), 6.61 (1H, d, J = 2.0 Hz, C9-H), 3.65 (2H, t, J = 6.5 Hz, C1-H2), 2.59 (2H, 
dd, J = 8.5, 7.0 Hz, C3-H2), 2.12 (1H, tt, J = 8.5, 5.5 Hz, C10-H), 1.88 – 1.79 (2H, m, C2-H2), 
1.40 (1H, br s, OH), 1.03 (9H, s, TBS (CH3)3), 0.92 – 0.88 (2H, m, C11/C12-H2), 0.64 – 0.60 
(2H, m, C11/C12-H2), 0.23 (6H, s, TBS Si(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 152.6 (C7), 
134.4 (C4), 134.1 (C8), 125.8 (C5), 124.9 (C9), 118.6 (C6), 62.5 (C1), 34.6 (C2), 31.6 (C3), 
26.0 (TBS (CH3)3), 18.4 (TBS C(CH3)3), 10.1 (C10), 8.2 (C11, C12), -4.1 (TBS Si(CH3)2). 






General procedure G: 3-(4-((tert-Butyldimethylsilyl)oxy)-3-cyclopropylphenyl)propan-1-ol 
(430 mg, 1.40 mmol), PPh3 (440 mg, 1.68 mmol), DIAD (0.33 mL, 1.68 mmol) and 
BocNHOTs (480 mg, 1.68 mmol) in anhydrous THF (6 mL) were employed. Purification by 
flash column chromatography (5% EtOAc:hexane) afforded the title compound (770 mg, 96%) 
as a colourless solid; Rf = 0.5 (20% EtOAc:hexane); νmax / cm
-1 (solid) 2949 (m), 2928 (m), 
2883 (m), 2857 (m), 1712 (s), 1504 (m); 1H NMR (400 MHz, CDCl3) δ 7.84 (2H, d, J = 8.5 
Hz, Ts ArCH), 7.33 (2H, d, J = 8.0 H, Ts ArCH), 6.80 (1H, dd, J = 8.0, 2.0 Hz, C5-H), 6.68 




(1H, d, J = 8.0 Hz, C6-H), 6.57 (1H, d, J = 2.0 Hz, C9-H), 3.60 (2H, br s, C1-H2), 2.49 – 2.44 
(5H, m, C3-H2 and Ts CH3), 2.15 – 2.08 (1H, m, C10-H), 1.94 – 1.83 (2H, m, C2-H2), 1.22 
(9H, s, Boc (CH3)3), 1.03 (9H, s, TBS (CH3)3), 0.92 – 0.86 (2H, m, C11/C12-H2), 0.64 – 0.60 
(2H, m, C11/C12-H2), 0.22 (6H, s, TBS Si(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 155.6 (Boc 
C=O), 152.7 (C7), 145.7 (Ts ArC), 134.1 (C8), 133.7 (C4), 131.4 (Ts ArC), 129.8 (2 × Ts CH), 
129.6 (2 × Ts CH), 125.7 (C5), 124.8 (C9), 118.6 (C6), 83.2 (Boc C(CH3)3), 52.8 (C1), 32.3 
(C3), 27.7 (C2), 27.7 (Boc (CH3)3) 26.0 (TBS (CH3)3), 21.8 (Ts CH3), 18.4 (TBS C(CH3)3), 
10.1 (C10), 8.2 (C11, C12), -4.1 (TBS Si(CH3)2). HRMS (ESI
+) Calculated for 
C30H45NNaO6SSi: 598.2629. Found [M+Na]
+: 598.2615. 
 
tert-Butyl (3-(3-cyclopropyl-4-hydroxyphenyl)propyl)(tosyloxy)carbamate (195) 
 
General procedure H: tert-Butyl (3-(4-((tert-butyldimethylsilyl)oxy)-3-cyclopropylphenyl) 
propyl)(tosyloxy)carbamate (580 mg, 1.00 mmol) and 1:1 TBAF:AcOH solution (0.1 M in 
THF, 1.00 mmol) in THF (20 mL) were employed. Purification by flash column 
chromatography (20% EtOAc:hexane) afforded 195 (370 mg, 81% yield) as a colourless solid; 
m.p.: 82-83 oC (EtOAc:hexane); Rf = 0.2 (20% EtOAc:hexane); νmax / cm
-1 (solid) 3472 (m, 
br), 2988 (m), 2930 (m), 1693 (s); 1H NMR (400 MHz, CDCl3) δ 7.84 (2H, d, J = 8.0 Hz, Ts 
ArCH), 7.33 (2H, d, J = 8.0 Hz, Ts ArCH), 6.90 (1H, dd, J = 8.0, 2.0 Hz, C5-H), 6.86 (1H, d, 
J = 2.0 Hz, C9-H), 6.76 (1H, d, J = 8.0 Hz, C6-H), 5.35 (1H, s, OH), 3.61 (2H, br s, C1-H2), 
2.48 (2H, t, J = 8.0 Hz, C3-H2), 2.45 (3H, s, Ts CH3), 1.95 – 1.84 (2H, m, C2-H2), 1.83 – 1.76 
(1H, m, C10-H), 1.21 (9H, s, Boc (CH3)3), 0.98 – 0.93 (2H, m, C11/C12-H2), 0.66 – 0.63 (2H, 
m, C11/C12-H2); 
13C NMR (101 MHz, CDCl3) δ 155.6 (Boc C=O), 153.7 (C7), 145.8 (Ts 
ArC), 132.9 (C4), 131.4 (Ts, ArC), 129.8 (2 × Ts, ArCH), 129.6 (2 × Ts, ArCH), 128.5 (C9), 
127.5 (C5), 127.5 (C8), 114.6 (C6), 83.3 (Boc C(CH3)3), 52.8 (C1), 32.2 (C3), 27.8 (C2), 27.7 
(Boc (CH3)3), 21.8 (Ts CH3), 9.5 (C10), 5.6 (C11, C12). HRMS (ESI
+) Calculated for 
C24H31NNaO6S: 484.1764. Found [M+Na]
+: 484.1750. 




7-Cyclopropyl-1-azaspiro[4.5]deca-6,9-dien-8-one trifluoroacetate (202) and 
6-Cyclopropyl- 1,2,3,4-tetrahydroquinolin-7-ol (203) 
 
General procedure I: The preceding N-tosyloxycarbamate 195 (92.3 mg, 0.20 mmol) and 
TFA (31.0 μL, 0.40 mmol) in TFE (2 mL) were employed. After stirring at room temperature 
for 24 hours, purification by flash column chromatography (EtOAc) afforded the title 
compounds 202 (32.1 mg, 53%) and 203 (12.8 mg, 34%) as yellow solids. 
Data for 202: m.p.: 99-101 oC (EtOAc:hexane); Rf = 0.1 (EtOAc); νmax / cm
-1 (solid) 2962 (m), 
1667 (s), 1643 (s); 1H NMR (400 MHz, CD3OD) δ 7.07 (1H, dd, J = 10.0, 3.0 Hz, C5-H), 6.49 
(1H, d, J = 3.0 Hz, C9-H), 6.43 (1H, dd, J = 10.0, 1.5 Hz, C6-H), 3.66 – 3.56 (2H, m, C1-H2), 
2.38 – 2.31 (2H, m, C2-H2), 2.23 – 2.19 (2H, m, C3-H2), 1.94 – 1.88 (1H, m, C10-H), 0.91 – 
0.87 (2H, m, C11/C12-H2), 0.65 – 0.62 (2H, m, C11/C12-H2). The signals corresponding to 
the NH2 were not observed.  
13C NMR (101 MHz, CD3OD) δ 185.4 (C7), 144.5 (C8), 143.9 
(C5), 134.6 (C9), 131.7 (C6), 64.9 (C4), 46.3 (C1), 37.8 (C3), 24.8 (C2), 10.0 (C10), 8.0 
(C11/C12), 7.9 (C11/C12). The signals corresponding to the trifluoroacetate group could not 
be resolved due to their weak intensity. HRMS (ESI+) Calculated for C12H16NO: 190.1226. 
Found [M]+ 190.1230. 
Data for 203: m.p.: 108-110 oC (EtOAc:hexane); Rf = 0.4 (EtOAc); νmax / cm
-1 (solid) 3306 
(m), 2932 (m), 1614 (m); 1H NMR (400 MHz, CDCl3) δ 6.68 (1H, s, C5-H), 6.04 (1H, s, C8-H), 
5.10 (1H, br s, OH), 3.27 – 3.22 (2H, m, C1-H2), 2.66 (2H, t, J = 6.5 Hz, C3-H2), 1.93 – 1.87 
(2H, m, C2-H2), 1.69 – 1.62 (1H, m, C10-H), 0.89 – 0.84 (2H, m, C11/C12-H2), 0.57 – 0.53 
(2H, m, C11/C12-H2); 
13C NMR (101 MHz, CDCl3) 154.4 (C7), 144.5 (C9), 130.1 (C5), 116.3 
(C6), 113.4 (C4), 100.1 (C8), 42.1 (C1), 26.4 (C3), 22.7 (C2), 8.7 (C10), 5.2 (C11,C12); HRMS 










Ethyl (E)-3-(4-hydroxy-2-methoxyphenyl)acrylate  
 
General procedure J: 4-Hydroxy-2-methoxybenzaldehyde (3.04 g, 20.0 mmol) and ethyl 
2-(triphenyl-phosphaneylidene) acetate (10.5 g, 30.0 mmol) in CH2Cl2 (20 mL) were 
employed. Purification by flash column chromatography (20% EtOAc:pentane) afforded the 
title compound (3.54 g, 80%) as a colourless solid; m.p.: 144-146 oC (EtOAc:hexane); Rf = 0.2 
(20% EtOAc:hexane); νmax / cm
-1 (solid) 3322 (br m), 1675 (s); 1H NMR (400 MHz, (CD3)2CO) 
δ 7.88 (1H, d, J = 16.0 Hz, C3-H), 7.50 (1H, d, J = 8.5 Hz, C10-H), 6.53 (1H, d, J = 2.5 Hz, 
C7-H), 6.49 (1H, dd, J = 8.5, 2.5 Hz, C9-H), 6.39 (1H, d, J = 16.0 Hz, C2-H) 4.18 (2H, q, J = 
7.0 Hz, OCH2), 3.88 (3H, s, C6), 1.27 (3H, t, J = 7.0 Hz, CH2CH3); 
13C NMR (101 MHz, 
(CD3)2CO) δ 168.0 (C1), 162.1 (C8), 161.0 (C5), 140.5 (C3), 131.2 (C10), 115.8 (C4), 115.8 
(C2), 108.9 (C9), 100.0 (C7), 60.4 (OCH3), 56.0 (C6), 14.8 (CH2CH3); HRMS (ESI
+) 





General procedure E: Ethyl (E)-3-(4-hydroxy-2-methoxyphenyl)acrylate (2.22 g, 10.0 mmol) 
and 10 wt.% Pd/C (5 mol%) in EtOH (30 mL) were employed. Purification by flash column 
chromatography (20% EtOAc:hexane) afforded the title compound (1.80 g, 80%) as a 
colourless solid; Rf = 0.2 (20% EtOAc:hexane); 
1H NMR (400 MHz, CDCl3) δ 6.94 (1H, d, J 
= 8.0 Hz), 6.38 (1H, d, J = 2.5 Hz), 6.31 (1H, dd, J = 8.0, 2.5 Hz), 4.13 (2H, q, J = 7.0 Hz), 
3.74 (3H, s), 2.85 (2H, t, J = 8.0 Hz), 2.57 (2H, t, J = 8.0 Hz), 1.24 (3H, t, J = 7.0 Hz); 13C NMR 
(101 MHz, CDCl3) δ 174.3, 158.6, 155.8, 130.4, 120.7, 106.7, 99.0, 60.6, 55.3, 34.8, 25.6, 
14.30.  
The spectroscopic properties were consistent with the data available in the literature.297 




Ethyl 3-(4-((tert-butyldimethylsilyl)oxy)-2-methoxyphenyl)propanoate  
 
To a solution of ethyl 3-(4-hydroxy-2-methoxyphenyl)propanoate (1.68 g, 7.50 mmol) in DMF 
(15 mL) was added tert-butyldimethylsilyl chloride (1.36 g, 9.00 mmol), and imidazole (1.28 
g, 18.75 mmol) and the reaction was stirred at room temperature overnight. To the reaction was 
added water (25 mL) and the organic phases were extracted with CH2Cl2 (2 × 20 mL). The 
combined organic extracts were washed with brine (20 mL), dried over MgSO4, filtered and 
concentrated in vacuo. Purification by flash column chromatography (20% EtOAc:pentane) 
afforded the title compound (1.31 g, 52%) as a colourless oil; Rf = 0.4 (20% EtOAc:hexane); 
1H NMR (400 MHz, CDCl3) δ 6.95 (1H, d, J = 8.5 Hz, C10-H), 6.36 – 6.32 (2H, m, C7-H, 
C9-H), 4.11 (2H, q, J = 7.0 Hz, OCH2), 3.77 (3H, s, C6-H3), 2.85 (2H, t, J = 8.0 Hz, C3-H2), 
2.55 (2H, t, J = 8.0 Hz, C2-H2), 1.23 (3H, t, J = 8.0 Hz, CH2CH3), 0.98 (9H, s, TBS (CH3)3), 
0.20 (6H, s, TBS Si(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 173.6 (C1), 158.3 (C5), 155.4 (C8), 
130.1 (C10), 121.8 (C4), 111.3 (C9), 103.4 (C7), 60.3 (OCH2), 55.3 (C6), 34.7 (C2), 25.9 (TBS 
(CH3)3), 25.7 (C3), 18.3 (TBS C(CH3)3), 14.4 (OCH2CH3), -4.3 (TBS Si(CH3)2); HRMS (ESI
+) 





General procedure B: Ethyl 3-(4-((tert-butyldimethylsilyl)oxy)-2-methoxyphenyl) 
propanoate (1.01 g, 3.00 mmol) and 1.5 equivalents of LiAlH4 (1M in THF) in anhydrous Et2O 
(15 mL) were employed. Purification by flash column chromatography (33% EtOAc:hexane) 
afforded the title compound (650 mg, 73%) as a colourless oil; Rf = 0.3 (33% EtOAc:hexane); 
νmax / cm
-1 (film) 3351 (br m), 2952 (m), 2930 (m), 2857 (m), 1607 (m), 1503 (s); 1H NMR (400 
MHz, CDCl3) δ 6.95 (1H, d, J = 8.5 Hz, C10-H), 6.40 – 6.36 (2H, m, C7-H, C9-H), 3.79 (3H, 




s, C6-H3), 3.58 (2H, t, J = 6.0 Hz, C1-H2), 2.64 (2H, t, J = 7.5 Hz, C3-H2), 1.84 – 1.74 (3H, m, 
C2-H2, OH), 0.99 (9H, s, TBS (CH3)3), 0.20 (6H, s, TBS Si(CH3)2); 
13C NMR (101 MHz, 
CDCl3) δ 158.2 (C5), 155.1 (C8), 130.3 (C10), 122.8 (C4), 111.8 (C9), 103.5 (C7), 62.1 (C1), 
55.5 (C6), 33.2 (C2), 25.8, (TBS (CH3)3)  25.4 (C3), 18.3 (TBS C(CH3)3) , -4.3 (TBS Si(CH3)2); 






General procedure G: 3-(4-((tert-Butyldimethylsilyl)oxy)-2-methoxyphenyl)propan-1-ol 
(530 mg, 1.80 mmol), PPh3 (560 mg, 2.16 mmol), DIAD (0.42 mL, 2.16 mmol) and 
BocNHOTs (620 mg, 2.16 mmol) in anhydrous THF (10 mL) were employed. Purification by 
flash column chromatography afforded the title compound (940 mg, 92%) as a colourless oil; 
Rf = 0.5 (33% EtOAc:hexane); νmax / cm
-1 (film) 2955 (m), 2930 (m), 1721 (s), 1504 (s), 1158 
(s); 1H NMR (400 MHz, CDCl3) δ 7.84 (2H, d, J = 8.5 Hz, Ts ArCH), 7.32 (2H, d, J = 8.5 Hz, 
Ts ArCH), 6.90 (1H, d, J = 8.0 Hz, C10-H), 6.36 – 6.33 (2H, m, C7, C9-H), 3.75 (3H, s, C6-H3), 
3.69 – 3.48 (2H, m, C1-H2), 2.49 (2H, t, J = 8.0 Hz, C3-H2), 2.44 (3H, s, Ts CH3), 1.94 – 1.78 
(2H, m, C2-H2), 1.22 (9H, s, Boc (CH3)3), 0.99 (9H, s, TBS (CH3)3), 0.20 (6H, s, TBS 
Si(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 158.2 (C5), 155.6 (Boc C=O), 155.2 (C8), 145.7 (Ts 
ArC), 131.5 (Ts ArC), 129.8 (2 × Ts ArCH), 129.6 (2 × Ts ArCH), 122.4 (C4), 11.4 (C9), 103.5 
(C7), 83.2 (Boc C(CH3)3), 55.3 (C6), 53.1 (C1), 27.8 (Boc (CH3)3), 26.7 (C3), 26.1 (C2), 25.9 
(TBS (CH3)3), 21.8 (Ts CH3), 18.4 (TBS C(CH3)3), -4.2 (TBS Si(CH3)2); HRMS (ESI
+) 












tert-Butyl (3-(4-hydroxy-2-methoxyphenyl)propyl)(tosyloxy)carbamate (204) 
 
General procedure H: tert-Butyl (3-(4-((tert-butyldimethylsilyl)oxy)-2-methoxyphenyl) 
propyl)(tosyloxy)carbamate (560 mg, 1.00 mmol) and 1:1 TBAF:AcOH solution (0.1 M in 
THF, 1.00 mmol) in THF (20 mL) were employed. Purification by flash column 
chromatography (33% EtOAc:hexane) afforded 204 (380 mg, 84%) as a colourless viscous oil; 
Rf = 0.25 (33% EtOAc:hexane); νmax / cm
-1 (film) 3422 (br), 2936 (m), 1720 (m), 1368 (s); 
1H NMR (400 MHz, CDCl3) δ 7.84 (2H, d, J = 8.5 Hz, Ts ArCH), 7.32 (2H, d, J = 8.5 Hz, Ts 
ArCH), 6.90 (1H, d, J = 8.0 Hz, C10-H), 6.38 (1H, d, J = 2.5 Hz, C7-H), 6.32 (1H, dd, J =8.0, 
2.5 Hz, C9-H), 4.67 (1H, br s, OH), 3.76 (3H, s, C6-H3), 3.70 – 3.48 (2H, m, C1-H2), 2.48 (2H, 
t, J = 7.5 Hz, C3-H2), 2.43 (3H, s, Ts CH3), 1.94 – 1.78 (2H, m, C2-H2), 1.22 (9H, s, Boc 
(CH3)3); 
13C NMR (101 MHz, CDCl3) δ 158.5 (C5), 155.7 (Boc C=O), 155.3 (C8), 145.7 (Ts 
ArC), 131.4 (Ts ArC), 130.1 (C10), 129.8 (2 × Ts ArCH), 129.6 (2 × Ts ArCH), 121.7 (C4), 
106.6 (C9), 98.9 (C7), 83.3 (Boc C(CH3)3), 55.4 (C6), 53.1 (C1), 27.8 (Boc (CH3)3), 26.7 (C3), 
26.1 (C2), 21.8 (Ts CH3); HRMS (ESI
+) Calculated for C22H29NNaO7S: 474.1557. Found 
[M+Na]+: 474.1566. 
 
6-Methoxy-1-azaspiro[4.5]deca-6,9-dien-8-one trifluoroacetate (205) 
 
General procedure I: The preceding N-tosyloxycarbamate 204 (67.7 mg, 0.15 mmol) and 
TFA (23 μL) in TFE (1.5 mL) were stirred at room temperature for 39 hours until completion 
by TLC analysis. Purification by flash column chromatography (EtOAc) afforded 205 (32.6 
mg, 74%) as a viscous yellow oil; Rf = 0.1 (5% MeOH:CH2Cl2); νmax / cm
-1 (film) 2987 (m), 
2901 (m), 1665 (s), 1636 (m), 1602 (s); 1H NMR (400 MHz, CD3OD) δ 6.93 (1H, d, J = 10.0 
Hz, C10-H), 6.29 (1H, dd, J = 10.0, 1.5 Hz, C9-H) 5.79 (1H, d, J = 1.5 Hz, C7-H), 3.89 (3H, 




s, C6-H3), 3.66 – 3.54 (2H, m, C1-H2), 2.53 – 2.46 (1H, m, C3-H), 2.40 – 2.22 (3H, m, C3-H’, 
C2-H2). The signals corresponding to the NH2 were not observed. 
13C NMR (400 MHz, 
CD3OD) δ 187.4 (C8), 171.2 (C5), 141.4 (C10), 130.0 (C9), 104.2 (C7), 65.6 (C4), 57.6 (C6), 
48.7 (C1), 38.0 (C3), 26.0 (C2). The signals corresponding to the trifluoroacetate group could 
not be resolved due to their weak intensity. HRMS (ESI+) Calculated for C10H14NO2: 180.1019. 




General procedure K: Carboxylic acid 206 (2.40 g, 8.57 mmol), N,O-dimethylhydroxylamine 
hydrochloride (1.17 g, 12.0 mmol), Et3N (1.67 mL, 12.0 mmol), 4-dimethylaminopyridine 
(1.46 g, 12.0 mmol), and N,N’-dicyclohexylcarbodiimide (2.48 g, 12.0 mmol) were employed. 
Purification by flash column chromatography (20% EtOAc:hexane) afforded 207 (1.97 g, 71%) 
as a colourless oil; Rf = 0.2 (33% EtOAc:hexane); νmax / cm
-1 (film) 2955 (m), 2930 (m), 2857 
(m), 1665 (s), 1509 (s), 1250 (s), 1169 (m); 1H NMR (400 MHz, CDCl3) δ 7.06 (2H, d, J = 8.0 
Hz), 6.75 (2H, d, J = 8.0 Hz), 3.57 (3H, s), 3.16 (3H, s), 2.88 (2H, t, J = 7.5 Hz), 2.71 – 2.67 
(2H, m), 0.97 (9H, s), 0.17 (6H, s); 13C NMR (101 MHz, CDCl3) δ 173.7, 153.8, 133.9, 129.2, 
119.9, 61.1, 33.9, 32.1, 29.9, 25.6, 18.1, -4.4.  




To a solution of the preceding N-methoxyamide 207 (690 mg, 2.15 mmol) in anhydrous THF 
(5 mL) at 0 oC was added methyl magnesium bromide (3 M in Et2O, 1.43 mL, 4.30 mmol) 
dropwise over 5 minutes. The reaction mixture was stirred at room temperature for 1.5 hours 




and then saturated aqueous NH4Cl (5 mL) was added. The aqueous phase was extracted with 
EtOAc (3 × 5mL) and the combined organic layers were washed with brine (10 mL), dried over 
Na2SO4 and concentrated in vacuo to afford the title compound (600 mg, 99%) as a colourless 
oil, which was used without further purification; Rf = 0.6 (33% EtOAc:hexane); νmax / cm
-1 
(film) 2955 (m), 2929 (m), 2888 (m), 2857 (m), 1716 (s), 1610 (m), 1509 (s), 1361 (m), 1251 
(s), 1159 (m), 1168 (m); 1H NMR (400 MHz, CDCl3) δ 7.02 (2H, d, J = 8.0 Hz), 6.75 (2H, d, 
J = 8.0 Hz), 2.85 – 2.68 (4H, m), 2.12 (3H, s), 0.98 (9H, s), 0.18 (6H, s); 13C NMR (101 MHz, 
CDCl3) δ 208.2, 153.9, 133.6, 129.2, 120.1, 45.5, 30.2, 29.1, 25.8, 18.2, -4.3.  




To a solution of 4-(4-((tert-butyldimethylsilyl)oxy)phenyl)butan-2-one (560 mg, 2.14 mmol) 
in MeOH (10 mL) was slowly added NaBH4 (160 mg, 4.28 mmol) at 0 
o C. After stirring for 
45 minutes at this temperature the reaction was quenched by addition of water (10 mL) and 
extracted with Et2O (3 × 10 mL). The combined organic extracts were washed with brine (10 
mL), dried over MgSO4, filtered and concentrated in vacuo to afford 208 (550 mg, 92%) as a 
colourless oil which was used without further purification; Rf = 0.5 (33% EtOAc:hexane); νmax / 
cm-1 (film) 3339 (m, br), 2957 (m), 2929 (m), 2857 (m), 1609 (m), 1508 (s), 1250 (s), 1168 
(m); 1H NMR (400 MHz, CDCl3) δ 7.05 (2H, d, J = 8.5 Hz), 6.76 (2H, d, J = 8.5 Hz), 3.86 – 
3.77 (1H, m), 2.72 – 2.57 (2H, m), 1.80 – 1.69 (2H, m), 1.65 – 1.54 (1H, br s), 1.22 (3H, d, J 
= 6.0 Hz), 0.99 (9H, s), 0.19 (6H, s); 13C NMR (101 MHz, CDCl3) δ 153.6, 134.7, 129.2, 119.9, 
67.5, 41.0, 31.3, 25.7, 23.6, 18.2, -4.4.  











General procedure G: The preceding alcohol 208 (220 mg, 0.77 mmol), PPh3 (240 mg, 0.92 
mmol), DIAD (0.18 mL, 0.92 mmol) and BocNHOTs (260 mg, 0.92 mmol) in anhydrous THF 
(3 mL) were employed. Purification by flash column chromatography (10% EtOAc:hexane) 
afforded the title compound (340 mg, 75%) as a colourless oil; Rf = 0.6 (20% EtOAc:hexane); 
νmax / cm
-1 (film) 2954 (m), 2930 (m), 2857 (m), 1721 (m), 1509 (s), 1368 (m), 1251 (s); 
1H NMR (400 MHz, CDCl3) δ 7.86 (2H, d, J = 8.5 Hz, Ts ArCH), 7.32 (2H, d, J = 8.5 Hz, Ts 
ArCH), 7.01 (2H, d, J = 8.5 Hz, C6-H), 6.73 (2H, d, J = 8.5 Hz, C7-H), 3.97 (1H, app. sextet, 
J = 7.0 Hz, C2-H), 2.61 – 2.57 (2H, m, C4-H2), 2.43 (3H, s, Ts CH3), 2.06 – 1.97 (1H, m, 
C3-H), 1.74 – 1.66 (1H, m, C3-H’), 1.27 (9H, s, Boc (CH3)3), 1.21 (3H, d, J = 7.0 Hz, C1-H3), 
0.97 (9H, s, TBS (CH3)3), 0.17 (6H, s, TBS Si(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 156.4 
(Boc C=O), 153.8 (C8), 145.6 (Ts ArC), 134.4 (C5), 131.9 (Ts ArC), 129.7 (2 × Ts ArCH), 
129.6 (2 × Ts ArCH), 129.3 (C6), 119.9 (C7), 83.4 (Boc C(CH3)3, 60.8 (C2), 32.2 (C3), 29.8 
(C4), 27.8 (Boc (CH3)3), 25.8 (TBS (CH3)3), 21.8 (Ts CH3), 18.3 (TBS SiC(CH3)3), 17.4 (C1), 
-4.4 (TBS Si(CH3)2); HRMS (ESI
+) Calculated for C28H43NNaO6SSi: 572.2473. Found 
[M+Na]+: 572.2465. 
 
tert-Butyl (4-(4-hydroxyphenyl)butan-2-yl)(tosyloxy)carbamate (209) 
 
General procedure H: tert-Butyl (4-(4-((tert-butyldimethylsilyl)oxy)phenyl)butan-2-yl) 
(tosyloxy) carbamate (320 mg, 0.58 mmol) and 1:1 TBAF:HOAc solution (0.1 M in THF, 0.58 
mmol) in THF (20 mL) were employed. Purification by flash column chromatography (20% 
EtOAc:hexane) afforded 209 (190 mg, 75%) as a colourless oil; Rf = 0.2 (20% EtOAc:hexane); 
νmax / cm
-1 (film) 3477 (br m), 2979 (m), 1721 (s), 1515 (s), 1369 (s), 1191 (s), 1177 (s), 1156 




(s); 1H NMR (400 MHz, CDCl3) δ 7.85 (2H, d, J = 8.5 Hz, Ts ArCH), 7.31 (2H, d, J = 8.5 Hz, 
Ts ArCH), 7.01 (2H, d, J = 8.0 Hz, C6-H), 6.74 (2H, d, J = 8.5 Hz, C7-H), 5.14 (1H, br s, OH), 
3.97 (1H, app. sextet, J = 7.0 Hz, C2-H), 2.58 (2H, t, J = 7.5 Hz, C4-H2), 2.42 (3H, s, Ts CH3), 
2.05 – 1.95 (1H, m, C3-H), 1.73 – 1.60 (1H, m, C3-H’), 1.27 (9H, s, Boc (CH3)3), 1.20 (3H, d, 
J = 7.0 Hz, C1-H3); 
13C NMR (101 MHz, CDCl3) δ 156.5 (Boc C=O) 153.9 (C8), 145.7 (Ts 
ArC), 133.7 (C5), 131.8 (Ts ArC), 129.7 (2 × Ts ArCH), 129.6 (2 × Ts ArCH), 129.5 (C6), 
115.3 (C7), 83.6 (Boc C(CH3)3), 60.8 (C2), 36.0 (C3) 32.1 (C4), 27.8 (Boc C(CH3)3), 21.8 (Ts 
CH3), 17.4 (C1); HRMS (ESI




2-Methyl-1-azaspiro[4.5]deca-6,9-dien-8-one trifluoroacetate (210) 
 
General procedure I: The preceding N-tosyloxycarbamate 209 (93.0 mg, 0.21 mmol) and 
TFA (32 μL, 0.42 mmol) in TFE (2.1 mL) were stirred at room temperature for 24 hours. 
Purification by flash column chromatography (EtOAc) afforded 210 (34.0 mg, 58%) as a 
yellow/brown oil; Rf = 0.1 (5% MeOH:CH2Cl2); νmax / cm
-1 (film, CDCl3) 2922 (m), 1667 (s), 
1635 (m), 1393 (m), 1173 (s), 1133 (s); 1H NMR (400 MHz, CDCl3) δ 9.80 (2H, br s, NH2), 
7.04 (1H, dd, J = 10.0, 3.0 Hz, C5-H), 6.95 (1H, dd, J = 10.0, 3.0 Hz, C5-H’), 6.33 – 6.32 (1H, 
m, C6-H), 6.31 – 6.29 (1H, m, C6-H’), 4.05 – 3.96 (1H, m, C1-H), 2.47 – 2.39 (1H, m, C2-H), 
2.36 – 2.29 (1H, m, C3-H), 2.24 – 2.17 (1H, m, C3-H’), 2.08 – 1.98 (1H, m, C2-H’), 1.46 (3H, 
d, J = 6.5 Hz, C8-H3); 
13C NMR (101 MHz, CDCl3) δ 183.6 (C7), 143.6 (C5), 143.0 (C5), 
130.5 (C6), 130.4 (C6), 63.2 (C4), 57.2 (C1), 37.1 (C3), 32.0 (C2), 17.5 (C8); HRMS (ESI+) 














General procedure J: 4-Hydroxybenzaldehyde (4.88 g, 40.0 mmol) and ethyl 
(triphenylphosphoranylidene)acetate (20.9 g, 60.0 mmol) in CH2Cl2 (40 mL) were employed. 
Purification by flash column chromatography (20% EtOAc:hexane) afforded the title 
compound (6.56 g, 85%) as a colourless solid; Rf = 0.5 (33% EtOAc:hexane); 
1H NMR 
(400 MHz, CDCl3) δ 7.64 (1H, d, J = 16.0 Hz), 7.42 (2H, d, J = 8.5 Hz), 6.86 (2H, d, J = 8.5 
Hz), 6.30 (1H, d, J = 16.0 Hz), 6.14 (1H, br s), 4.27 (2H, q, J = 7.0 Hz), 1.34 (3H, t, J = 7.0 
Hz); 13C NMR (101 MHz) δ 168.1, 158.1, 144.9, 132.4, 130.1, 127.2, 116.1, 115.5, 115.1, 60.8, 
14.5.  
The spectroscopic properties were consistent with the data available in the literature.301  
 
Ethyl (E)-3-(4-((tert-butyldimethylsilyl)oxy)phenyl)acrylate (211) 
 
To a solution of Ethyl (E)-3-(4-hydroxyphenyl)acrylate (3.84 g, 20.0 mmol) in DMF (20 mL) 
were added tert-butyldimethylsilyl chloride (3.60 g, 24.0 mmol) and imidazole (3.40 g, 50.0 
mmol) and the reaction was stirred overnight at room temperature until completion by TLC 
analysis. Purification by flash column chromatography (20% EtOAc:hexane) afforded 211 
(5.13 g, 84%) as a colourless oil; Rf = 0.4 (10% EtOAc:hexane); 
1H NMR (400 MHz, CDCl3) 
δ 7.63 (1H, d, J = 16.0 Hz), 7.41 (2H, d, J = 8.5 Hz), 6.83 (2H, d, J =8.5 Hz), 6.30 (1H, d, J = 
16.0 Hz), 4.25 (2H, q, J = 7.5 Hz), 1.33 (3H, t, J = 7.5 Hz), 0.98 (9H, s, TBS (CH3)3), 0.22 (6H, 
s, TBS Si(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 167.5, 157.9, 144.4, 129.8, 127.9, 120.6, 
116.1, 60.4, 25.8, 18.4, 14.5, -4.2.  
The spectroscopic properties were consistent with the data available in the literature. 302 
 
 




Ethyl 3-(4-((tert-butyldimethylsilyl)oxy)phenyl)pentanoate (212)  
 
CuI (2.86 g, 15.0 mmol) in anhydrous Et2O (60 mL) was stirred under nitrogen at room 
temperature until a suspension was observed. The mixture was cooled to -20 oC and EtMgBr 
(3.0 M solution in Et2O, 37.5 mmol) was added. After stirring for 5 minutes, a solution of the 
preceding α,β-unsaturated ester 211 (4.6 g, 15.0 mmol) in anhydrous Et2O (15 mL) was added 
dropwise over 1 hour. After stirring at -20 oC for 4 hours, MeOH (15 mL) and saturated aqueous 
NH4Cl (60 mL) were sequentially added and the mixture was warmed to room temperature. 
After extracting with Et2O (3 × 20 mL), the combined organic extracts were dried over Na2SO4, 
filtered and concentrated in vacuo. Purification by flash column chromatography (20% 
EtOAc:hexane) afforded 212 (4.36 g, 86%) as a pale yellow oil; Rf = 0.5 (10% EtOAc:hexane); 
νmax / cm
-1 (film) 2958 (m), 2930 (m), 2858 (m), 1735 (s), 1509 (s), 1252 (s), 1165 (m); 1H NMR 
(400 MHz, CDCl3) δ 7.02 (2H, d, J = 8.5 Hz, C7-H), 6.75 (2H, d, J = 8.5 Hz, C8-H), 4.02 (2H, 
q, J = 7.0 Hz, OCH2CH3), 2.97 – 2.89 (1H, m, C3-H), 2.59 (1H, dd, J = 15.0, 7.0 Hz, C2-H), 
2.50 (1H, dd, J = 15.0, 8.5 Hz, C2-H’), 1.73 – 1.61 (1H, m, C4-H), 1.59 – 1.49 (1H, m, C4-H’), 
1.12 (3H, t, J = 7.0 Hz, OCH2CH3), 0.97 (9H, s, TBS (CH3)3), 0.77 (3H, t J = 7.3 Hz, C5-H3), 
0.18 (6H, s, TBS Si(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 172.7 (C1), 154.1 (C9), 136.6 (C6), 
128.5 (C7), 119.9 (C8), 60.2 (OCH2CH3), 43.4 (C3), 41.9 (C2) 29.4 (C4), 25.8 (TBS (CH3)3), 
18.3 (TBS SiC(CH3)3), 14.3 (OCH2CH3), 12.0 (C5), -4.4 (TBS Si(CH3)2); HRMS (ESI
+) 





General procedure B: The preceding ester 212 (4.10 g, 12.2 mmol), 1.0 equivalent of LiAlH4 
(1M in THF) and anhydrous Et2O were employed. The title compound (3.03 g, 84%) was 




obtained as a colourless oil which was used without further purification; Rf = 0.3 (20% 
EtOAc:hexane); νmax / cm
-1 (film) 3354 (br m), 2956 (m), 2929 (m), 2858 (m), 1607 (m), 1508 
(s), 1253 (s); 1H NMR (400 MHz, CDCl3) δ 7.00 (2H, d, J = 8.5 Hz, C7-H), 6.76 (2H, d, J = 
8.5 Hz, C8-H), 3.55 – 3.43 (2H, m, C1-H2), 2.55 – 2.47 (1H, m, C3-H), 1.94 – 1.87 (1H, m, 
C2-H), 1.79 – 1.72 (1H, m, C2-H’), 1.70 – 1.61 (1H, m, C4-H), 1.57 – 1.49 (1H, m, C4-H’), 
0.98 (9H, s, TBS (CH3)3), 0.77 (3H, t, J = 7.4 Hz, C5-H3), 0.19 (6H, s, TBS Si(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 154.0 (C9), 137.6 (C6), 128.6 (C7), 120.0 (C8), 61.5 (C1), 43.7 
(C3), 39.6 (C2), 30.1 (C4), 25.8 (TBS C(CH3)3), 18.3 (TBS C(CH3)3), 12.2 (C5), -4.3 (TBS 
Si(CH3)2); HRMS (ESI




General procedure G: 3-(4-((tert-Butyldimethylsilyl)oxy)phenyl)pentan-1-ol (2.94 g, 10.0 
mmol), PPh3 (3.15 g, 12.0 mmol mmol), DIAD (2.36 mL, 12.0 mmol) and BocNHOTs (3.44 g, 
12.0 mmol) in anhydrous THF (40 mL) were employed. Purification by flash column 
chromatography (5% EtOAc:hexane) afforded the title compound (5.35 g, 95%) as a colourless 
oil; Rf = 0.6 (20% EtOAc:hexane); νmax / cm
-1 (film) 2962 (m), 2931 (m), 1721 (s), 1509 (s), 
1382 (s), 1369 (s), 1253 (s), 1191 (s), 1155 (s); 1H NMR (400 MHz, CDCl3) δ 7.78 (2H, d, J = 
8.0 Hz, Ts ArCH), 7.28 (2H, d, J = 8.0 Hz, Ts ArCH), 6.93 (2H, d, J = 8.5 Hz, C7-H), 6.74 
(2H, d, J = 8.5 Hz, C8-H), 3.48 – 3.19 (2H, m, C1-H2), 2.42 (3H, s, Ts CH3), 2.33 – 2.26 (1H, 
m, C3-H), 1.94 (1H, br s, C2-H), 1.76 (1H, br s, C2-H’), 1.66 – 1.57 (1H, m, C4-H), 1.53 – 
1.43 (1H, m, C4-H’), 1.22 (9H, s, Boc (CH3)3), 0.98 (9H, s, TBS (CH3)3), 0.73 (3H, t, J = 
7.3 Hz, C5-H3), 0.18 (6H, s, TBS Si(CH3)2); 
13C NMR (101 MHz, CDCl3) 155.5 (Boc C=O), 
154.0 (C9), 145.7 (Ts ArC), 136.9 (C6), 131.4 (Ts ArC), 129.7 (2 × Ts ArCH), 129.6 (2 × Ts 
ArCH), 128.4 (C7), 120.0 (C8) 83.2 (Boc C(CH3)3), 52.0 (C1), 44.6 (C3), 32.0 (C2), 30.1 (C4), 
27.8 (Boc (CH3)3), 25.8 (TBS C(CH3)3), 21.8 (Ts CH3), 18.3 (TBS C(CH3)3), 12.1 (C5) , -4.3 
(TBS Si(CH3)2); HRMS (ESI








tert-Butyl (3-(4-hydroxyphenyl)pentyl)(tosyloxy)carbamate (213) 
 
General procedure H: tert-Butyl (3-(4-((tert-butyldimethylsilyl)oxy)phenyl)pentyl) 
(tosyloxy)carbamate (2.82 g, 5.0 mmol) and 1:1 TBAF:HOAc (0.1 M in THF, 5.0 mmol) in 
THF (50 mL) were employed. Purification by flash column chromatography (20% 
EtOAc:hexane) afforded 213 (1.80 g, 80%) as a colourless solid; m.p.: 93-95 oC 
(EtOAc:hexane); Rf = 0.4 (33% EtOAc:hexane); νmax / cm
-1 (film) 3436 (br m), 2965 (m), 2930 
(m), 1720 (s), 1514 (s), 1368 (s), 1191 (s), 1177 (s), 1153 (s); 1H NMR (400 MHz, CDCl3) 
δ 7.77 (2H, d, J = 8.0 Hz, Ts ArCH), 7.28 (2H, d, J = 8.0 Hz, Ts ArCH), 6.95 (2H, d, J = 8.5 
Hz C7-H), 6.74 (2H, d, J = 8.5 Hz, C8-H), 4.93 (1H, br s, OH), 3.51 – 3.16 (2H, br s, C1-H2), 
2.42 (3H, s, Ts CH3), 2.34 – 2.27 (1H, m, C3-H), 1.95 (1H, br s, C2-H), 1.77 (1H, br s, C2-H’), 
1.66 – 1.54 (1H, m, C4-H), 1.52 – 1.43 (1H, m, C4-H’), 1.22 (9H, s, Boc (CH3)3), 0.73 (3H, t, 
J = 7.3 Hz, C5-H3); 
13C NMR (101 MHz, CDCl3) δ 155.6 (Boc C=O), 154.1 (C9), 145.8 (Ts 
ArC), 136.3 (C6), 131.3 (Ts ArC), 129.7 (2 × Ts ArCH), 129.6 (2 × Ts ArCH), 128.7 (C7), 
115.4 (C8), 83.4 (Boc C(CH3)3), 51.9 (C1), 44.5 (C3), 32.0 (C2), 30.1 (C4), 27.8 (Boc (CH3)3), 
21.8 (Ts CH3), 12.05 (C5); HRMS (ESI
+) Calculated for C23H31NNaO6S: 472.1764. Found 
[M+H]+: 472.1763. 
 
4-Ethyl-1-azaspiro[4.5]deca-6,9-dien-8-one trifluoroacetate (214) 
 
General procedure I: The preceding N-tosyloxycarbamate 213 (89.9 mg, 0.20 mmol) and 
TFA (31 μL, 0.40 mmol) in anhydrous TFE (2 mL) were employed. Purification by flash 
column chromatography (EtOAc) afforded 214 (40.0 mg, 69%) as a red/brown oil; Rf = 0.1 
(5% MeOH:CH2Cl2); νmax / cm
-1 (film) 2966 (m), 1673 (s), 1636 (m), 1404 (m), 1201 (s), 1134 




(s); 1H NMR (400 MHz, CDCl3) δ 6.93 (1H, dd, J = 10.5, 3.0 Hz, C7-H), 6.78 (1H, dd, J = 
10.5, 3.0 Hz, C7-H’), 6.43 - 6.36 (2H, m, C8-H2), 3.62 – 3.45 (2H, m, C1-H2), 2.53 – 2.44 (1H, 
m, C3-H), 2.40 – 2.31 (1H, m, C2-H), 1.93 – 1.81 (1H, m, C2-H’), 1.31 – 1.23 (1H, m, C4-H), 
1.14 – 1.05 (1H, m, C4-H’), 0.91 (3H, J = 7.5 Hz, C5-H3); The signals corresponding to the 
NH2 were not observed. 
13C NMR (101 MHz, CDCl3) δ 183.5 (C9), 143.7 (C7), 139.6 (C7’), 
132.4 (C8), 132.0 (C8’), 65.5 (C6), 50.8 (C3), 43.4 (C1), 29.3 (C2), 21.5 (C4), 12.5 (C5); The 
signals corresponding to the trifluoroacetate group could not be resolved due to their weak 
intensity. HRMS (ESI+) Calculated for C11H16NO
+: 178.1226. Found [M+H]+: 178.1225. 
 
3-(2-((tert-Butyldimethylsilyl)oxy)phenyl)propanoic acid  
 
General procedure A: Carboxylic acid 215 (4.15 g, 25.0 mmol), tert-butyldimethylsilyl 
chloride (8.28 g, 55.0 mmol) and imidazole (5.62 g, 82.5 mmol) in DMF (50 mL) were 
employed. Purification by flash column chromatography (20% EtOAc:hexane) afforded the 
title compound (4.40 g, 63%) as a pale yellow oil; νmax / cm
-1 (film) 2954 (m), 2930 (m), 2896 
(m), 2858 (m), 1706 (s), 1490 (s), 1453 (m), 1250 (s), 1106 (m); 1H NMR (400 MHz, CDCl3) 
δ 7.18 (1H, dd, J = 7.5, 2.0 Hz, ArCH), 7.12 (1H, td, J = 7.5, 2.0 Hz, ArCH), 6.90 (1H, td, J = 
7.5, 1.0 Hz, ArCH), 6.81 (1H, dd, J = 8.0, 1.0 Hz, ArCH), 2.94 (2H, t, J = 8.0 Hz, C2 or C3), 
2.67 (2H, t, J = 8.0 Hz, C2 or C3), 1.04 (9H, s, TBS (CH3)3), 0.27 (6H, s, TBS Si(CH3)2); 
13C NMR (101 MHz, CDCl3) δ179.6 (C1), 153.7 (ArC), 130.7 (ArC), 130.2 (ArCH), 127.5 
(ArCH), 121.1 (ArCH), 118.4 (ArCH), 31.2 (C2 or C3), 26.0 (C2 or C3), 25.8 (TBS (CH3)3), 
18.2 (TBS C(CH3)3), -4.1 (TBS Si(CH3)2). 
3-(2-((tert-Butyldimethylsilyl)oxy)phenyl)propan-1-ol (216) 
 
General procedure F: 3-(2-((tert-Butyldimethylsilyl)oxy)phenyl)propanoic acid (1.40 g, 5.00 
mmol), Et3N (0.69 mL, 5.00 mmol), ethyl chloroformate (0.48 mL, 5.00 mmol) and NaBH4 
(470 mg, 12.5 mmol) in THF (50 mL) and H2O (20 mL) were employed. Purification by flash 
column chromatography (15% EtOAc:hexane) afforded 216 (850 mg, 64%) as a colourless oil; 





-1 (film) 3334 (m, br), 2953 (m), 2930 (m), 2884 (m), 2858 (m), 1489 (s), 1249 (s); 
1H NMR (400MHz, CDCl3) δ 7.14 (1H, dd, J = 7.5, 2.0 Hz, ArCH), 7.08 (1H, td, J = 7.5, 2.0 
Hz, ArCH), 6.89 (1H, td, J = 7.5, 1.0 Hz, ArCH), 6.80 (1H, dd, J = 8.0, 1.0 Hz, ArCH), 3.63 
(2H, t, J = 6.5 Hz, C1-H2), 2.69 (2H, t, J = 7.5 Hz, C3-H2), 1.89 – 1.82 (2H, m, C2-H2), 1.59 
(1H, s, OH), 1.02 (9H, s, TBS (CH3)3), 0.24 (6H, s, TBS Si(CH3)2); 
13C NMR (101 MHz, 
CDCl3) δ 153.7 (ArC), 132.4 (ArC), 130.5 (ArCH), 127.0 (ArCH), 121.4 (ArCH), 118.7 
(ArCH), 62.5 (C1), 33.2 (C3), 26.6 (C2), 25.9 (TBS (CH3)3), 18.4 (TBS C(CH3)3), -4.0 (TBS 
Si(CH3)2). 
The spectroscopic properties were consistent with the data available in the literature.303  
 
tert-Butyl (3-(2-((tert-butyldimethylsilyl)oxy)phenyl)propyl)(tosyloxy)carbamate  
 
General procedure G: The preceding alcohol 216 (370 mg, 1.40 mmol), PPh3 (440 mg, 1.66 
mmol), DIAD (0.32 mL, 1.66 mmol) and BocNHOTs (470 mg, 1.66 mmol) in anhydrous THF 
(8 mL) were employed. Purification by flash column chromatography (10% EtOAc:hexane) 
afforded the title compound (550 mg, 73%) as a colourless oil; νmax / cm
-1 (film) 2954 (m), 2928 
(m), 1724 (s), 1490 (s), 1366 (s), 1251 (s); 1H NMR (400 MHz, CDCl3) δ 7.84 (2H, d, J = 8.5 
Hz, Ts ArCH), 7.32 (2H, d, J = 8.5 Hz, Ts ArCH), 7.12 – 7.04 (2H, m, ArCH), 6.87 (1H, td, J 
= 7.5, 1.2 Hz, ArCH), 6.77 (1H, dd, J = 8.0, 1.0 Hz, ArCH), 3.55 (2H, br s, C1-H2), 2.55 (2H, 
t, J = 8.0 Hz, C3-H2), 2.44 (3H, s, Ts CH3), 1.97 – 1.84 (2H, m, C2-H2), 1.20 (9H, s, Boc 
(CH3)3), 1.01 (9H, s, TBS (CH3)3), 0.23 (6H, s, TBS Si(CH3)2); 
13C NMR (101 MHz, CDCl3) 
δ 155.4 (Boc C=O), 153.5 (ArC), 145.5 (Ts ArC), 131.6 (ArC), 131.3 (ArC), 130.0 (ArCH), 
129.7 (2 × Ts ArCH), 129.5 (2 × Ts ArCH), 127.0 (ArCH), 121.0 (ArCH), 118.4 (ArCH), 83.1 
(Boc C(CH3)3), 52.8 (C1), 27.6 (Boc (CH3)3, 27.5 (C3), 25.9 (C2), 25.8 (TBS (CH3)3), 21.7 (Ts 
CH3), 18.2 (TBS C(CH3)3), -4.1 (TBS Si(CH3)2). HRMS (ESI
+) Calculated for 










tert-Butyl (3-(2-hydroxyphenyl)propyl)(tosyloxy)carbamate (217) 
 
General procedure H: tert-Butyl (3-(2-((tert-butyldimethylsilyl)oxy)phenyl)propyl) 
(tosyloxy)carbamate (530 mg, 1.00 mmol) and 1.0 equivalent of 1:1 TBAF:AcOH solution 
(0.1 M in THF, 10 mL, 1.00 mmol) in THF (20 mL) were employed. Purification by flash 
column chromatography (20% EtOAc:hexane) afforded 217 (350 mg, 83%) as a colourless 
solid; νmax / cm
-1 (solid) 3462 (m, br), 2970 (m), 2929 (m), 1723 (s); 1H NMR (400 MHz, 
CDCl3) δ 7.85 (2H, d, J = 8.5 Hz, Ts ArCH), 7.33 (2H, d, J = 8.5 Hz, Ts ArCH), 7.10 – 7.05 
(2H, m, ArCH), 6.85 (1H, td, J = 7.5, 1.0 Hz, ArCH), 6.75 (1H, dt, J = 7.5, 1.0 Hz, ArCH), 
5.29 (1H, br s, OH), 3.65 (2H, br s, C1-H2), 2.61 (2H, t, J = 7.5 Hz, C3-H2), 2.45 (3H, s, Ts 
CH3), 2.01 – 1.92 (2H, m, C2-H2), 1.23 (9H, s, Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) 
δ 155.8 (Boc C=O), 153.7 (ArC), 145.7 (ArC), 131.2 (ArC), 130.1 (ArC), 129.6 (2 × Ts ArCH), 
129.5 (2 × Ts ArCH)), 127.4 (ArCH), 127.2 (ArCH), 120.7 (ArCH), 115.5 (ArCH), 83.5 (Boc 
C(CH3)3), 52.9 (C1), 27.6 (Boc (CH3)3), 27.1 (C3), 26.1 (C2), 21.7 (Ts CH3); HRMS (ESI
+) 




General procedure I: The preceding N-tosyloxycarbamate 217 (105.4 mg, 0.25 mmol) and 
TFA (38.0 μL, 0.50 mmol) in anhydrous TFE (2.5 mL) were employed. The reaction mixture 
was concentrated in vacuo and to the crude mixture in anhydrous CH2Cl2 (10 mL) was added 
acetyl chloride (21 μL, 0.3 mmol) and pyridine (0.10 mL, 1.25 mmol) at 0 oC. The reaction 
was stirred at room temperature until completion by TLC analysis. The reaction was quenched 
with saturated aqueous NaHCO3 (5 mL) and the organic phase extracted with EtOAc (2 × 20 
mL), washed with 1 M HCl (5 mL) and water (5 mL), dried over MgSO4, filtered and 
concentrated in vacuo. Purification by flash column chromatography (100 % EtOAc) afforded 
219 (6.6 mg, 14%) as a yellow solid; νmax / cm
-1 (solid) 2925 (m), 1669 (s), 1633 (s), 1413 (m); 
1H NMR (400 MHz, CDCl3) δ 7.01 – 6.96 (1H, m, C7-H), 6.24 (1H, d, J = 1.0 Hz, C5-H), 6.23 
(1H, t, J = 1.0 Hz, C6-H), 6.16 (1H, dt, J = 10.0, 1.5 Hz, C8-H), 3.83 – 3.78 (1H, m, C1-H), 




3.73 – 3.67 (1H, m, C1-H’), 2.29 – 2.21 (1H, m, C2-H), 2.12 – 2.07 (1H, m, C3-H), 2.06 (3H, 
s, C11-H3), 2.05 – 1.99 (1H, m, C2-H’), 1.93 – 1.88 (1H, m, C3-H); 
13C NMR (101 MHz, 
CDCl3) δ 200.6 (C9), 168.5 (C10), 143.5 (C5), 140.7 (C7), 126.3 (C8), 120.8 (C6), 69.7 (C4), 
49.2 (C1) 37.1 (C3), 23.8 (C2), 22.5 (C11); HRMS (ESI+) Calculated for C11H13NNaO2: 




General procedure E: 6-Methylcoumarin (4.80 g, 30.0 mmol) and 5 mol% Pd/C (10 wt. %, 
1.50 mmol), in EtOAc (30 mL) were employed. Purification by flash column chromatography 
afforded the title compound (3.40 g, 70%) as a colourless solid; Rf = 0.4 (20% EtOAc:hexane); 
1H NMR (400 MHz, CDCl3) δ 7.04 (1H, dd, J = 8.0, 2.0 Hz), 6.99 (1H, s), 6.93 (1H, d, J = 8.0 
Hz), 2.98 – 2.93 (2H, m), 2.79 – 2.73 (2H, m), 2.31 (3H, s); 13C NMR (101 MHz, CDCl3) 
δ 168.9, 149.9, 134.0, 128.8, 128.5, 122.4, 116.7, 29.4, 23.8, 20.8.  
The spectroscopic properties were consistent with the data available in the literature.95 
 
3-(2-((tert-Butyldimethylsilyl)oxy)-5-methylphenyl)propanoic acid (220) 
 
To a solution of 6-methylchroman-2-one (1.74 g, 10.0 mmol) in THF (50 mL) was added a 
1 M solution of aqueous LiOH (33.0 mmol, 58 mL). After stirring at room temperature 
overnight the pH was acidified to approx. 3 with 1 M HCl. The product was extracted with 
EtOAc (2 × 20 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude product 
was dissolved in DMF (20 mL) and cooled to 0 oC before tert-butyldimethylsilyl chloride 
(3.32 g, 22.0 mmol) and imidazole (2.24 g, 33.0 mmol) were added. After being stirred at room 
temperature overnight the reaction was quenched by addition of H2O (50 mL) and the product 
was extracted with hexane (3 × 20 mL), dried over MgSO4, filtered and concentrated in vacuo. 
To the crude product in MeOH (10 mL) and THF (10 mL) was added aqueous K2CO3 (20.0 
mmol, 2.76 g in 30 mL H2O). After stirring at room temperature overnight the reaction was 
cooled to 0 oC and quenched with 1 M HCl (30 mL). The mixture was extracted with Et2O (3 




× 20 mL), dried over Na2SO4, filtered and concentrated in vacuo. Purification by flash column 
chromatography (20% EtOAc:hexane) afforded 220 (1.60 g, 54%) as a colourless solid; m.p.: 
49-51 oC (EtOAc:hexane); Rf = 0.4 (20% EtOAc:hexane); νmax / cm
-1 (solid) 2961 (m), 2948 
(m), 2927 (m), 2900 (m), 1702 (s), 1499 (m), 1252 (s); 1H NMR (400 MHz, CDCl3) δ 6.97 
(1H, d, J = 2.5 Hz, C5-H), 6.89 (1H, dd, J = 8.5, 2.5 Hz, C8-H), 6.69 (1H, d, J = 8.5 Hz, C9-H), 
2.89 (2H, t, J = 8.0 Hz, C3-H2), 2.65 (2H, t, J = 8.0 Hz, C2-H2), 2.26 (3H, s, C7-H3), 1.01 (9H, 
s, TBS (CH3)3), 0.23 (6H, s, TBS Si(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 179.3 (C1), 151.5 
(C10), 130.9 (C5), 130.5 (C4), 130.4 (C6), 128.0, (C8) 118.3 (C9), 34.3 (C2), 26.2 (C3), 25.9 
(TBS (CH3)3), 20.7 (C7), 18.4 (TBS C(CH3)3), -4.0 (TBS Si(CH3)2); HRMS (ESI
+) Calculated 




General procedure F: The preceding carboxylic acid 220 (1.25 g, 4.26 mmol), Et3N (0.59 
mL, 4.26 mmol), ethyl chloroformate (0.41 mL, 4.26 mmol) and NaBH4 (400 mg, 10.60 mmol) 
in THF (30 mL) and H2O (15 mL) were employed. Purification by flash column 
chromatography (20% EtOAc:hexane) afforded the title compound (830 mg, 60%) as a 
colourless oil; Rf = 0.35 (20% EtOAc:hexane); νmax / cm
-1 (film) 3334 (br), 2953 (m), 2929 (m), 
2885  (m), 2858 (m), 1498 (s), 1253 (s); 1H NMR (400 MHz, CDCl3) δ 6.94 (1H, d, J = 2.5 
Hz, C5-H), 6.86 (1H, dd, J = 8.0, 2.5 Hz, C8-H), 6.68 (1H, d, J = 8.0 Hz, C9-H), 3.61 (2H, t, J 
= 6.5 Hz, C1-H2), 2.65 (2H, t, J = 7.5 Hz, C3-H2), 2.25 (3H, s, C7-H3), 1.99 – 1.70 (2H, m, 
C2-H2), 1.01 (9H, s, TBS (CH3)3), 0.22 (6H, s, TBS Si(CH3)2); 
13C NMR (400 MHz, CDCl3) 
δ 151.3 (C10), 131.9 (C4), 131.1 (C5), 130.6 (C6), 127.4 (C8), 118.5 (C9), 62.4 (C1), 33.3 
(C2), 26.6 (C3), 26.0 (TBS (CH3)3), 20.7 (C7), 18.4 (TBS C(CH3)3, -4.0 (TBS Si(CH3)2).  














General procedure G: 3-(2-((tert-Butyldimethylsilyl)oxy)-5-methylphenyl)propan-1-ol (870 
mg, 1.58 mmol), PPh3 (500 mg, 1.90 mmol), DIAD (0.37 mL, 1.90 mmol) and BocNHOTs 
(540 mg, 1.90 mmol) were employed. Purification by flash column chromatography (10% 
EtOAc:hexane) afforded the title compound (710 mg, 65%) as a colourless oil; Rf = 0.6 (20% 
EtOAc:hexane); νmax / cm
-1 (film) 2957 (m), 2929 (m), 2901 (m), 2859 (m), 1721 (m), 1499 
(m); 1H NMR (400 MHz, CDCl3) δ 7.84 (2H, d, J = 8.5 Hz, Ts ArCH), 7.31 (2H, d, J = 8.5 Hz, 
Ts ArCH), 6.92 (1H, d, J = 2.5 Hz, C5-H), 6.85 (1H, dd, J = 8.0, 2.5 Hz, C8-H), 6.66 (1H, d, J 
= 8.0 Hz, C9-H), 3.62 (2H, br s, C1-H2), 2.51 (2H, t, J = 8.0 Hz, C3-H2), 2.43 (3H, s, Ts CH3), 
2.25 (3H, s, C7-H3), 1.96 – 1.84 (2H, m, C2-H2), 1.20 (9H, s, Boc (CH3)3), 1.01 (9H, s, TBS 
(CH3)3), 0.21 (6H, s, TBS Si(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 155.5 (Boc C=O), 151.3 
(C10), 145.6 (Ts ArC), 131.5 (Ts ArC), 131.4 (C4), 130.8 (C5), 130.2 (C6), 129.8 (2 × Ts 
ArCH), 129.6 (2 × Ts ArCH), 127.5 (C8), 118.3 (C9), 83.1 (Boc C(CH3)3), 52.9 (C1), 27.7 
(C3), 27.7 (Boc (CH3)3), 26.1 (C2), 25.9 (TBS (CH3)3), 21.8 (Ts CH3), 20.6 (C7), 18.3 (TBS 
SiC(CH3)3), -4.1 (TBS Si(CH3)2); HRMS (ESI
+) Calculated for C28H43NNaO6SSi: 572.2473. 
Found [M+Na]+: 572.2477. 
 
tert-Butyl (3-(2-hydroxy-5-methylphenyl)propyl)(tosyloxy)carbamate (221) 
 
General procedure H: tert-Butyl (3-(2-((tert-butyldimethylsilyl)oxy)-5-methylphenyl) 
propyl)(tosyloxy)carbamate (440 mg, 0.80 mmol) and 1:1 TBAF:AcOH solution (0.1 M in 
THF, 0.80 mmol) in THF (16 mL) were employed. Purification by flash column 
chromatography (gradient, eluent 20 – 33% EtOAc:hexane) afforded 221 (270 mg, 77%) as a 
colourless solid; m.p.: 107-108 oC (EtOAc:hexane); Rf = 0.2 (20% EtOAc:hexane); νmax / cm
-1 
(solid) 3447 (m), 2986 (m), 1685 (s), 1509 (m), 1382 (s); 1H NMR (400 MHz, CDCl3) δ 7.85 
(2H, d, J = 8.5 Hz, Ts ArCH), 7.33 (2H, d, J = 8.0 Hz, Ts ArCH), 7.03 – 6.81 (2H, m, C8-H, 
C9-H), 6.64 (1H, d, J = 8.0 Hz, C5-H), 4.99 (1H, s, OH), 3.65 (2H, br s, C1-H2), 2.56 (2H, t, J 




= 8.0 Hz, C3-H2), 2.44 (3H, s, Ts CH3), 2.24 (3H, s, C7-H3), 2.00 – 1.89 (2H, m, C2-H2), 1.21 
(9H, s, Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) δ 155.8 (Boc C=O), 151.4 (C10), 145.7 (Ts 
ArC), 131.3 (Ts ArC), 130.8 (C5), 129.9 (C6) 129.8 (2 × Ts ArCH), 129.6 (2 × Ts ArCH), 
127.8 (C8), 127.0 (C4), 115.4 (C9), 83.5 (Boc C(CH3)3), 53.0 (C1), 27.7 (Boc (CH3)3), 27.2 
(C3), 26.3 (C2), 21.8 (Ts CH3), 20.6 (C7); HRMS (ESI
+) Calculated for C22H29NNaO6S: 
458.1608. Found [M+Na]+: 458.1608. 
9-Methyl-1-azaspiro[4.5]deca-7,9-dien-6-one tosylate (222) 
 
General procedure I: The preceding N-tosyloxycarbamate 221 (25.2 mg, 0.06 mmol) and 
TFA (8.9 μL, 0.12 mmol) in anhydrous TFE (0.57 mL) were employed. Upon completion, the 
reaction mixture was concentrated in vacuo to afford 222 as a brown solid. An in situ yield was 
obtained by 1H NMR versus 1,4-dinitrobenzene as an internal standard; a yield of 91% was 
obtained. Rf = 0.1 (5% MeOH:CH2Cl2); νmax / cm
-1 (solid) 3447 (m, br), 2970 (m), 2923 (m), 
1673 (m), 1655 (m), 1606 (m); 1H NMR (400 MHz, CDCl3) δ 9.31 (1H, br s, NH), 8.16 (1H, 
br s, NH), 7.71 (2H, d, J = 8.0 Hz, Ts ArCH), 7.18 (2H, d, J = 8.0 Hz, Ts ArCH), 6.83 (1H, dd, 
J = 10.0, 2.0 Hz, C8-H), 6.34 (1H, br s, C5-H), 6.07 (1H, d, J = 10.0 Hz, C9-H), 3.72 (2H, br 
s, C1-H2), 2.36 (3H, s, Ts CH3), 2.24 – 2.05 (4H, m, C2-H2, C3-H2), 1.83 (3H, s, C7-H3); 
13C NMR (101 MHz, CDCl3) δ 197.6 (C10), 147.1 (C8), 141.3 (Ts ArC), 140.4 (Ts ArC), 132.6 
(C6), 131.4 (C5), 129.2 (2 × Ts ArCH), 126.0 (2 × Ts ArCH), 123.9 (C9), 72.5 (C4), 48.2 (C1), 
37.2 (C2/C3), 22.6 (C2/C3), 21.5 (Ts CH3), 20.9 (C7); HRMS (ESI
+) Calculated for C10H14NO: 





General procedure J: 2-Hydroxy-4-methoxybenzaldehyde (1.80 g, 12.0 mmol) and ethyl 
2-(triphenyl-phosphaneylidene) acetate (6.27 g, 18.0 mmol) in CH2Cl2 (15 mL) were 
employed. Purification by flash column chromatography (20% EtOAc:hexane) afforded the 
title compound (2.73 g, quantitative) as a colourless solid; Rf = 0.3 (20% EtOAc:hexane); 




1H NMR (400 MHz, (CD3)2CO) δ 9.13 (1H, s), 7.93 (1H, d, J = 16.0 Hz), 7.54 (1H, d, J = 8.5 
Hz), 6.53 - 6.50 (2H, m), 6.48 (1H, d, J = 16.0 Hz), 4.18 (2H, q, J = 7.0 Hz), 3.79 (3H, s), 1.27 
(3H, t, J = 7.0 Hz); 13C NMR (101 MHz, CDCl3) δ 170.0, 163.6, 158.9, 140.7, 131.2, 116.1, 
115.6, 107.2, 102.3, 60.4, 55.7, 14.8.  




General procedure E: Ethyl (E)-3-(2-hydroxy-4-methoxyphenyl)acrylate (2.22 g, 10.0 mmol) 
and 10 wt.% Pd/C (5 mol%) in EtOH (30 mL) were employed to afford the title compound 
(2.21 g, 99%) as an off-white solid; Rf = 0.2 (20% EtOAc:hexane); 
1H NMR (400 MHz, CDCl3) 
δ 7.50 (1H, s), 6.97 (1H, d, J = 8.5 Hz), 6.48 - 6.40 (2H, m), 4.14 (2H, q, J = 7.0 Hz), 3.75 (3H, 
s), 2.79 – 2.89 (2H, m), 2.63 – 2.73 (2H, m), 1.24 (3H, t, J = 7.0 Hz); 13C NMR (101 MHz, 
CDCl3) δ 176.1, 159.7, 155.4, 131.1, 119.7, 106.9, 102.9, 61.5, 55.4, 35.6, 24.1, 14.2.  
The spectroscopic properties were consistent with the data available in the literature.306  
 
Ethyl 3-(2-((tert-butyldimethylsilyl)oxy)-4-methoxyphenyl)propanoate  
 
To a solution of ethyl 3-(2-hydroxy-4-methoxyphenyl)propanoate (1.68 g, 7.50 mmol) in DMF 
(15 mL) were added tert-butyldimethylsilyl chloride (1.36 g, 9.00 mmol), and imidazole 
(1.28 g, 18.75 mmol) and the reaction was stirred at room temperature overnight. To the 
reaction was added water (25 mL) and the organic phase was extracted with CH2Cl2 (2 × 20 
mL). The combined organic phases were washed with brine (20 mL), dried over MgSO4, 
filtered and concentrated in vacuo. Purification by flash column chromatography (20% 
EtOAc:pentane) afforded the title compound (1.59 g, 63%) as a colourless oil; Rf = 0.5 (20% 
EtOAc:hexane); νmax / cm
-1 (film) 2955 (m), 2931 (m), 2858 (m), 1733 (s), 1611 (s), 1505 (s); 
1H NMR (400 MHz, CDCl3) δ 7.04 (1H, d, J = 8.5 Hz, C5-H), 6.44 (1H, dd, J = 8.5, 2.5 Hz, 
C6-H), 6.38 (1H, d, J = 2.5 Hz, C9-H), 4.12 (2H, q, J = 7.0 Hz, OCH2), 3.75 (3H, s, C8-H3), 




2.84 (2H, dd, J = 9.0, 7.0 Hz, C3-H2), 2.54 (2H, dd, J = 9.0, 7.0 Hz, C2-H2), 1.23 (3H, t, J = 
7.0 Hz, CH2CH3), 1.02 (9H, s, TBS (CH3)3), 0.25 (6H, s, TBS Si(CH3)2); 
13C NMR (101 MHz, 
CDCl3) δ 173.4 (C1), 159.1 (C7), 154.5 (C10), 130.4 (C5), 123.7 (C4), 105.7 (C6/C9), 105.6 
(C6/C9), 60.3 (OCH2), 55.4 (C8), 34.9 (C2), 25.9 (TBS (CH3)3), 25.8 (C3), 18.3 (TBS 
SiC(CH3)3), 14.4 (CH2CH3), -4.0 (TBS Si(CH3)2); HRMS (ESI
+) Calculated for C18H30NaO4Si: 




A solution of ethyl 3-(2-((tert-butyldimethylsilyl)oxy)-4-methoxyphenyl)propanoate (1.01 g, 
3.0 mmol) in anhydrous THF (15 mL) was cooled to -78 oC before 2.0 equivalents of DIBALH 
(1 M in CH2Cl2) was added dropwise to maintain the temperature of the reaction mixture below 
-75 oC. The reaction was stirred at this temperature for 4 hours and then warmed to 0 oC and 
stirred for an additional 2 hours. The reaction mixture was diluted with EtOAc (10 mL) and 
quenched with Rochelle’s salt (10 mL). The mixture was filtered through Celite® and washed 
with EtOAc. The phases were separated, and the aqueous phase extracted with EtOAc (10 mL). 
The combined organic extracts were dried over Na2SO4, filtered and concentrated in vacuo. 
Purification by flash column chromatography (33% EtOAc:hexane) afforded the title 
compound (440 mg, 50%) as a colourless oil; Rf = 0.3 (33% EtOAc:hexane); 
1H NMR (400 
MHz, CDCl3) δ 7.03 (1H, d, J = 8.5 Hz), 6.47 (1H, dd, J = 8.5, 2.5 Hz), 6.39 (1H, d, J = 2.5 Hz), 
3.76 (3H, s), 3.61 (2H, t, J = 6.5 Hz), 2.62 (2H, t, J = 7.0 Hz), 1.85 – 1.77 (2H, m), 1.64 (1H, 
br s), 1.01 (9H, s), 0.25 (6H, s); 13C NMR (101 MHz, CDCl3) δ 158.8, 154.4, 130.6, 124.7, 
106.1, 105.7, 62.4, 55.4, 33.4, 25.9, 25.8, 18.4, -4.0.  














General procedure G: 3-(2-((tert-Butyldimethylsilyl)oxy)-4-methoxyphenyl)propan-1-ol 
(440 mg, 1.50 mmol), PPh3 (470 mg, 1.80 mmol), DIAD (0.35 mL, 1.80 mmol) and 
BocNHOTs (520 mg, 1.80 mmol) in anhydrous THF (6 mL) were employed. Purification by 
flash column chromatography (10% EtOAc:hexane) afforded the title compound (820 mg, 
96 %) as a colourless oil; Rf = 0.5 (33% EtOAc:hexane); νmax / cm
-1 (film) 2955 (m), 2931 (m), 
1720 (s), 1504 (s), 1160 (s); 1H NMR (400 MHz, CDCl3) δ 7.84 (2H, d, J = 8.5 Hz, Ts ArCH), 
7.31 (2H, d, J = 8.5 Hz, Ts ArCH), 7.00 (1H, d, J = 8.5 Hz, C5-H), 6.44 (1H, dd, J = 8.5, 
2.5 Hz, C6-H), 6.36 (1H, d, J = 2.5 Hz, C9-H), 3.75 (3H, s, C8-H3), 3.71 – 3.49 (2H, m, C1-H2), 
2.49 (2H, t, J = 7.5 Hz, C3-H2), 2.43 (3H, s, Ts CH3), 1.95 – 1.81 (2H, m, C2-H2), 1.21 (9H, s, 
Boc (CH3)3), 1.01 (9H, s, TBS (CH3)3), 0.24 (6H, s, TBS Si(CH3)2); 
13C NMR (101 MHz, 
CDCl3) δ 158.8 (C7), 155.5 (Boc C=O), 154.3 (C10), 145.6 (Ts ArC), 131.4 (Ts ArC), 130.3 
(C5), 129.7 (2 × Ts ArCH), 129.6 (2 × Ts ArCH), 124.1 (C4), 105.7 (C6), 105.5 (C9), 83.1 
(Boc C(CH3)3), 55.3 (C8), 52.8 (C1), 27.7 (Boc (CH3)3), 27.0 (C3), 26.2 (C2), 25.9 (TBS 
(CH3)3), 21.8 (Ts CH3), 18.3 (TBS SiC(CH3)3), -4.1 (TBS Si(CH3)2); HRMS (ESI
+) Calculated 
for C28H43NNaO7SSi: 588.2422. Found [M+Na]
+: 588.2426. 
 
tert-Butyl (3-(2-hydroxy-4-methoxyphenyl)propyl)(tosyloxy)carbamate (223) 
 
General procedure H: tert-Butyl (3-(2-((tert-butyldimethylsilyl)oxy)-4-methoxyphenyl) 
propyl)(tosyloxy)carbamate (560 mg, 1.00 mmol) and 1:1 TBAF:AcOH solution (0.1 M in 
THF, 0.1 mmol) in THF (20 mL) were employed. Purification by flash column chromatography 
(33% EtOAc:hexane) afforded 223 (300 mg, 68%) as a colourless, viscous oil; Rf = 0.2 (33% 
EtOAc:hexane); νmax / cm
-1 (film) 3422 (br s), 2936 (m), 1720 (m), 1508 (m), 1368 (s); 1H NMR 
(400 MHz, CDCl3) δ 7.85 (2H, d, J = 8.0 Hz, Ts ArCH), 7.33 (2H, d, J = 8.0 Hz, Ts ArCH), 
6.98 (1H, d, J =8.5 Hz, C5-H), 6.42 (1H, dd, J = 8.5, 2.5 Hz, C6-H), 6.36 (1H, d, J = 2.5 Hz, 
C9-H), 5.37 (1H, br s, OH), 3.75 (3H, s, C8-H3), 3.72 – 3.53 (2H, m, C1-H2), 2.54 (2H, t, J = 




7.5 Hz, C3-H2), 2.44 (3H, s, Ts CH3), 1.98 – 1.85 (2H, m, C2-H2), 1.22 (9H, s, Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) δ 159.3 (C7), 156.0 (Boc C=O), 154.6 (C10), 145.9 (Ts ArC), 
131.4 (Ts ArC), 130.7 (C5), 130.0 (2 × Ts ArCH), 129.7 (2 × Ts ArCH), 119.6 (C4), 106.1 
(C6), 102.1 (C9), 83.6 (Boc C(CH3)3), 55.5 (C8), 53.0 (C1), 27.8 (Boc (CH3)3), 26.6 (C2/C3), 
26.5 (C2/C3), 21.8 (Ts CH3); HRMS (ESI
+) Calculated for C22H29NNaO7S: 474.1557. Found 
[M+Na]+: 474.1560. 
 
8-Methoxy-1-azaspiro[4.5]deca-7,9-dien-6-one trifluoroacetate (224) 
 
General procedure I: The preceding N-tosyloxycarbamate 223 (67.7 mg, 0.15 mmol) and 
TFA (23 μL, 0.30 mmol) in TFE (1.5 mL) were stirred at room temperature for 25 hours. 
Purification by flash column chromatography (EtOAc) afforded 224 (34.1 mg, 78%) as a 
yellow oil; Rf = 0.1 (5% MeOH:CH2Cl2); νmax / cm
-1 (film) 2987 (m), 2901 (m), 1672 (s), 1634 
(m); 1H NMR (400 MHz, CD3OD) δ 6.69 (1H, d, J = 10.0 Hz, C5-H), 6.36 (1H, dd, J = 10.0, 
2.0 Hz, C6-H), 5.63 (1H, d, J = 2.0 Hz, C9-H), 3.88 (3H, s, C8-H3), 3.69 – 3.54 (2H, m, C1-H2), 
2.32 – 2.16 (4H, m, C2-H2, C3-H2). The signals corresponding to the NH2 were not observed. 
13C NMR (101 MHz, CD3OD) δ 196.9 (C10), 173.1 (C7), 138.5 (C5), 125.5 (C6), 98.8 (C9), 
71.4 (C4), 57.5 (C8), 48.5 (C1), 39.4 (C3), 24.2 (C2). The signals corresponding to the 
trifluoroacetate group could not be resolved due to their weak intensity. HRMS (ESI+) 
Calculated for C10H14NO2: 180.1019. Found [M+H]
+: 180.1011. 
 
4H-Spiro[naphthalene-1,2'-pyrrolidin]-4-one trifluoroacetate (226) 
 
General procedure I: N-Tosyloxycarbamate 225 (70.7 mg, 0.150 mmol) and TFA (23 μL, 
0.30 mmol) in anhydrous TFE (1.5 mL) were stirred at room temperature for 22 hours. 
Purification by flash column chromatography (EtOAc) afforded 226 (14.3 mg, 30%) as a 




yellow/brown solid; Rf = 0.1 (5% MeOH:CH2Cl2); νmax / cm
-1 (solid) 2987 (m), 2971 (m), 1665 
(s), 1601 (m); 1H NMR (400 MHz, CD3OD) δ 8.19 (1H, d, J = 7.5 Hz, C9-H), 7.88 – 7.82 (2H, 
m, C11-H, C12-H), 7.67 (1H, ddd, J = 8.0, 6.0, 2.5 Hz, C10-H), 7.25 (1H, d, J = 10.5 Hz, 
C5-H), 6.61 (1H, d, J = 10.5 Hz, C6-H), 3.84 – 3.72 (2H, m, C1-H2), 2.71 – 2.62 (1H, m, 
C3-H), 2.57 – 2.48 (3H, m, C3-H’, C2-H2). The signals corresponding to the NH2 were not 
observed. 13C NMR (101 MHz, CDCl3) δ 184.0 (C7), 144.5 (C5), 140.5 (C13), 135.4 (C11), 
132.1 (C8), 131.1 (C10), 130.7 (C6), 128.1 (C9), 127.7 (C12), 65.9 (C4), 47.7 (C1), 41.2 (C3), 
25.8 (C2). The signals corresponding to the trifluoroacetate group could not be resolved due 







To a solution of alcohol 168 (630 mg, 2.00 mmol), BocNHOTs (560 mg, 3.00 mmol) and PPh3 
(1.05 g, 4.00 mmol) in anhydrous PhMe:THF (3:1, 8 mL/mmol) at 0 o C was added a solution 
of DIAD (0.78 mL, 4.00 mmol) in anhydrous PhMe (2 mL/mmol) dropwise. The reaction was 
stirred at room temperature until completion by TLC analysis (4 hours). The reaction mixture 
was concentrated in vacuo and purification by flash column chromatography (gradient 20 – 
25% EtOAc:hexane) afforded the title compound (740 mg, 63%) as a colourless solid; m.p.: 
79-80 oC (EtOAc:hexane); Rf  = 0.7 (33% EtOAc:hexane); νmax / cm
-1 (solid) 2961 (m), 2927 
(m), 2857 (m), 1709 (s), 1596 (m), 1466 (m), 1368 (s), 1240 (s), 1174 (s), 1164 (s), 1153 (s), 
1087 (m); 1H NMR (400 MHz, CDCl3) δ 7.86 (1H, d, J = 8.5 Hz, ArCH), 7.82 (2H, d, J = 8.5 
Hz, ArCH), 7.75 (1H, d, J = 8.0 Hz, ArCH), 7.59 (1H, d, J = 9.0 Hz, ArCH), 7.47 – 7.43 (1H, 
m, ArCH), 7.33 (1H, ddd, J = 8.0, 7.0, 1.0 Hz, ArCH), 7.27 (2H, d, J = 8.0 Hz, ArCH), 7.05 
(1H, d, J = 9.0 Hz, ArCH), 3.71 (2H, br s, C1-H2), 3.02 (2H, t, J = 8.0 Hz, C3-H2), 2.42 (3H, 
s, Ts CH3), 1.98 – 1.89 (2H, m, C2-H2), 1.16 (9H, s, Boc (CH3)3), 1.07 (9H, s, TBS (CH3)3), 
0.27 (6H, s, Si(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 155.5 (Boc C=O), 150.6 (ArC), 145.6 
(Ts ArC), 133.3 (ArC), 131.5 (Ts ArC), 129.7 (2 × Ts ArCH), 129.6 (ArC), 129.5 (2 × Ts 
ArCH), 128.6 (ArCH), 127.5 (ArCH), 126.4 (ArCH), 124.2 (ArC), 123.3 (ArCH), 123.2 




(ArCH), 120.3 (ArCH), 83.1 (Boc C(CH3)3), 53.1 (C1), 27.6 (Boc (CH3)3), 26.1 (C2), 26.0 
(TBS (CH3)3), 22.7 (C3), 21.8 (Ts CH3), 18.4 (TBS C(CH3)3), -3.8 (TBS Si(CH3)2); HRMS 
(ESI+) Calculated for C31H43NNaO6SSi: 608.2473. Found [M+Na]
+: 608.2456. 
 
tert-Butyl (3-(2-hydroxynaphthalen-1-yl)propyl)(tosyloxy)carbamate (227) 
 
General procedure H: tert-Butyl (3-(2-((tert-butyldimethylsilyl)oxy)naphthalen-1-
yl)propyl)(tosyloxy) carbamate (160 mg, 0.28 mmol) and 1:1 TBAF:AcOH solution (0.1 M in 
THF, 0.28 mmol) in THF were employed. Purification by flash column chromatography (33% 
EtOAc:hexane) afforded 227 (110 mg, 84%)  as a pale yellow solid; m.p.: 55-57 oC 
(EtOAc:hexane); Rf = 0.35 (33% EtOAc:hexane); νmax / cm
-1 (solid) 3359 (m, br), 2931 (m), 
1721 (s), 1369 (s), 1191 (s), 1178 (s), 1154 (s); 1H NMR (400 MHz, CDCl3) δ 7.88 – 7.83 (3H, 
m, Ts ArCH, ArCH), 7.77 (1H, d, J = 8.0 Hz, ArCH), 7.62 (1H, d, J = 9.0 Hz, ArCH), 7.47 
(1H, ddd, J = 8.5, 7.0, 1.5 Hz, ArCH), 7.35 – 7.29 (3H, m, Ts ArCH, ArCH), 7.07 (1H, d, J = 
9.0 Hz, ArCH), 5.60 (1H, br s, OH), 3.79 – 3.70 (2H, m, C1-H2), 3.07 (2H, t, J = 8.0 Hz, 
C3-H2), 2.44 (3H, s, Ts CH3), 2.08 – 1.97 (2H, m, C2-H2), 1.20 (9H, s, Boc (CH3)3); 
13C NMR 
(101 MHz, CDCl3) δ 156.1 (Boc C=O), 151.1 (ArC), 145.9 (Ts ArC), 133.2 (ArC), 131.3 (Ts 
ArC), 129.7 (2 × Ts ArCH), 129.7 (2 × Ts ArCH), 129.5 (ArC), 128.8 (ArCH), 128.1 (ArCH), 
126.6 (ArCH), 123.1 (ArCH), 122.8 (ArCH), 118.8 (ArC), 118.1 (ArCH), 83.6 (Boc C(CH3)3), 
53.2 (C1), 27.7 (Boc (CH3)3), 26.4 (C2), 22.2 (C3) 21.8 (Ts CH3); HRMS (ESI
+) Calculated 
for C25H29NNaO6S: 494.1608. Found [M+Na]
+: 494.1598. 
 
2H-Spiro[naphthalene-1,2'-pyrrolidin]-2-one (228)  
 
General procedure I: The preceding N-tosyloxycarbamate 227 (117.9 mg, 0.25 mmol), TFA 
(38 μL, 0.50 mmol) and TFE (2.5 mL) were employed. After stirring at room temperature for 




38 hours, purification by flash column chromatography (50% EtOAc:hexane) afforded 228 
(38.8 mg, 78%) as a viscous yellow oil; Rf = 0.25 (33% EtOAc:hexane); νmax/ cm
-1 (film) 3339 
(m), 2965 (m), 2866 (m), 1671 (s); 1H NMR (400 MHz, CDCl3) δ 7.66 (1H, dd, J = 7.5, 1.0 
Hz, C6-H), 7.41 – 7.34 (2H, m, C11-H and C7-H), 7.29 – 7.21 (2H, m, C8-H and C9-H), 6.17 
(1H, d, J = 10.0 Hz, C12-H), 3.45 (1H, dt, J = 10.5, 6.5 Hz, C1-H), 3.28 (1H, dt, J = 10.0, 6.5 
Hz, C1-H’), 2.34  – 2.22 (1H, m, C3-H), 1.96 – 1.69 (3H, m, C2-H2, C3-H’); 
13C NMR (101 
MHz, CDCl3) δ 205.1, (C=O), 148.8 (C5), 144.8 (C11), 130.1 (C7), 129.2 (C8), 129.1 (C10), 
127.0 (C9), 126.0 (C6), 123.6 (C12), 73.9 (C4), 49.9 (C1), 42.9 (C3), 25.6 (C2); HRMS (ESI+) 




The title compound was prepared according to a literature procedure.91 
To a solution of 1-naphthol (5.05 g, 35.0 mmol) and K2CO3 (5.40 g, 39.0 mmol) in acetone 
(40 mL) was added allyl bromide (3.3 mL, 39.0 mmol) dropwise over 20 minutes. The reaction 
was stirred at room temperature for 15 minutes before heating at reflux overnight. The reaction 
was cooled to room temperature and the concentrated in vacuo. To the crude residue was added 
H2O (20 mL) and the organic phase was extracted with Et2O (3 × 15 mL). The combined 
organic extracts were washed with brine (15 mL), dried over Na2SO4 and concentrated in 
vacuo. 229 (6.4 g, 99%) was obtained as an orange/brown oil and was used without 
purification; 1H NMR (400 MHz, CDCl3) δ 8.37 – 8.28 (1H, m, C12-H), 7.85 – 7.78 (1H, m, 
C9-H), 7.54 – 7.47 (2H, m, C10-H, C11-H), 7.47 – 7.35 (2H, m, C6-H, C7-H), 6.83 (1H, dd, J 
= 7.5, 1.0 Hz, C5-H), 6.20 (1H, ddt, J = 17.5, 10.5, 5.0 Hz, C2-H), 5.55 (1H, dq, J = 17.5, 1.5 
Hz, C1-H), 5.36 (1H, dq, J = 10.5, 1.5 Hz, C1-H’), 4.80 – 4.64 (2H, m, C3-H2); 
13C NMR (101 
MHz, CDCl3) δ 154.5, 134.7, 133.5, 127.6 , 126.5, 125.9, 125.9 125.3, 122.2, 120.5, 117.5, 
105.2, 69.1. 










The title compound was prepared according to a literature procedure.91  
A solution of the preceding allyl ether 229 (6.4 g, 35.0 mmol) in N,N-diethylaniline (36 mL) 
was heated at reflux overnight. The solution was cooled to room temperature, diluted with 
EtOAc (25 mL) and washed with 2M HCl (4 × 15 mL) followed by brine (15 mL). The 
combined organic extracts were dried over Na2SO4 and concentrated in vacuo to afford the title 
compound (6.44 g, quantitative) which was used without further purification; 1H NMR 
(400 MHz, CDCl3) δ 8.23 – 8.12 (1H, m), 7.79 (1H, dd, J = 7.5, 2.0 Hz), 7.50 – 7.45 (2H, m), 
7.42 (1H, d, J = 8.5 Hz), 7.23 (1H, d, J = 8.5 Hz), 6.09 (1H, ddt, J = 16.5, 10.0, 6.5 Hz), 5.60 
(1H, s), 5.30 – 5.23 (2H, m), 3.59 (2H, dd, J = 6.5, 1.5 Hz); 13C NMR (101 MHz, CDCl3) δ 
149.7, 136.3, 133.9, 128.6, 127.7, 125.9, 125.4, 125.0, 121.5, 120.5, 118.0, 35.9. 




The title compound 230 was prepared according to a literature procedure.91  
To a solution of 2-allylnaphthalen-1-ol (6.44 g, 35.0 mmol) in CH2Cl2 (55 mL) were added 
imidazole (3.1 g, 46.0 mmol) and TBSCl (6.3 g, 42.0 mmol) and the reaction was stirred at 
room temperature overnight. The reaction was quenched with H2O (20 mL) and extracted with 
CH2Cl2 (3 × 15 mL). The combined organic extracts were washed with brine (15 mL), dried 
over Na2SO4 and concentrated in vacuo. Purification by flash column chromatography afforded 
230 (7.6 g, 73%) as a yellow oil; 1H NMR (400 MHz, CDCl3) δ 8.13 – 8.08 (1H, m), 7.83 – 
7.77 (1H, m), 7.49 (1H, d, J = 8.5 Hz), 7.47 – 7.40 (2H, m), 7.33 (1H, d, J = 8.5 Hz), 6.05 – 
5.94 (1H, m), 5.19 – 5.10 (2H, m), 3.59 (2H, dd, J = 6.5, 1.5 Hz), 1.17 (9H, s), 0.22 (6H, s). 
The spectroscopic properties were consistent with the data available in the literature.309 
 
 






The title compound 231 was prepared according to a literature procedure.91 
To a solution of the preceding alkene 230 (1.5 g, 5.0 mmol) in THF (10 mL) at 0 oC was added 
borane-dimethyl sulfide (0.94 mL, 10.0 mmol) and the reaction was stirred at this temperature 
for 3 hours. Aqueous 30% H2O2 (1.6 mL) and NaHCO3 (1.25 mL) were added and the reaction 
was warmed to room temperature overnight. The reaction was quenched with aqueous saturated 
NH4Cl (15 mL) and extracted with EtOAc (3 × 15 mL). The combined organic extracts were 
washed with brine (15 mL), dried over Na2SO4 and concentrated in vacuo. Purification by flash 
column chromatography afforded 231 (650 mg, 41%) as a colourless solid; 1H NMR (400 
MHz, CDCl3) δ 8.07 – 8.02 (1H, m), 7.78 – 7.73 (1H, m), 7.46 (1H, d, J = 8.5 Hz), 7.44 – 7.37 
(2H, m), 7.28 (1H, d, J = 8.5 Hz), 3.56 (2H, t, J = 6.5 Hz), 2.87 (2H, t, J = 7.5 Hz), 1.92 – 1.85 
(2H, m), 1.59 (1H, br s), 1.11 (9H, s), 0.17 (6H, s); 13C NMR (101 MHz, CDCl3) δ 148.3, 
133.8, 128.4, 128.2, 127.8, 126.8, 125.4, 125.0, 123.0, 122.1, 62.2, 33.3, 26.6, 26.3, 18.8, -3.1. 





General procedure G: The preceding alcohol 231 (470 mg, 1.50 mmol), PPh3 (470 mg, 1.80 
mmol), DIAD (0.35 mL, 1.80 mmol) and BocNHOTs (520 mg, 1.80 mmol) in anhydrous THF 
(8 mL) were employed. Purification by flash column chromatography (10% EtOAc:hexane) 
afforded the title compound as a colourless, viscous oil (670 mg, 76%); Rf = 0.4 (20% 
EtOAc:hexane); νmax / cm
-1 (film) 2955 (m), 2930 (m), 2895 (m), 2858 (m), 1720 (s), 1382 (s), 
1369 (s); 1H NMR (400 MHz, CDCl3) δ 8.06 – 8.02 (1H, m, ArCH), 7.80 (2H, d, J = 8.5 Hz, 
Ts ArCH), 7.78 – 7.74 (1H, m, ArCH), 7.46 – 7.37 (3H, m, ArCH), 7.28 – 7.22 (3H, m, Ts 
ArCH, ArCH), 3.71 – 3.43 (2H, m, C1-H2), 2.73 (2H, t, J = 7.5 Hz, C3-H2), 2.39 (3H, s, Ts 
CH3), 1.99 – 1.88 (2H, m, C2-H2), 1.19 (9H, s, Boc (CH3)3), 1.11 (9H, s, TBS (CH3)3), 0.17 
(6H, s, TBS Si(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 155.6 (Boc C=O), 148.3 (C5), 145.7 




(Ts ArC), 133.8 (ArC), 131.4 (Ts ArC), 129.7 (2 × Ts ArCH) 129.6 (2 × Ts ArCH), 128.2 
(ArC), 128.1 (ArCH), 127.7 (ArCH), 126.2 (C4), 125.4 (ArCH), 124.9 (ArCH), 123.2 (ArCH), 
121.8 (ArCH), 83.3 (Boc C(CH3)3), 52.8 (C1), 27.7 (Boc (CH3)3), 27.6 (C3), 26.4 (C2), 26.3 
(TBS (CH3)3), 21.8 (Ts CH3), 18.9 (TBS SiC(CH3)3), -3.0 (TBS Si(CH3)2); HRMS (ESI
+) 
Calculated for C31H43NNaO6SSi: 608.2472. Found [M+Na]
+: 608.2466. 
 
tert-Butyl (3-(1-hydroxynaphthalen-2-yl)propyl)(tosyloxy)carbamate (232) 
 
General procedure H: tert-Butyl (3-(1-((tert-butyldimethylsilyl)oxy)naphthalen-2-yl)propyl) 
(tosyloxy)carbamate (560 mg, 0.97 mmol) and 1:1 TBAF:AcOH solution (0.1 M in THF, 0.97 
mmol) in THF (20 mL) were employed. Purification by flash column chromatography (20% 
EtOAc:hexane) afforded 232 (310 mg, 68%) as a pale yellow solid; m.p.: 107-109 oC 
(EtOAc:hexane); Rf = 0.2 (20% EtOAc:hexane); νmax / cm
-1 (solid) 3485 (m), 2970 (m), 2942 
(m), 2882 (m), 1729 (s), 1385 (s); 1H NMR (400 MHz, CDCl3) δ 8.18 – 8.15 (1H, m, ArCH), 
7.85 (2H, d, J = 8.5 Hz, Ts ArCH), 7.77 (1H, dd, J = 8.0, 1.5 Hz, ArCH), 7.49 – 7.41 (2H, m, 
ArCH), 7.39 (1H, d, J = 8.5 Hz, ArCH), 7.30 (2H, d, J = 8.5 Hz, Ts ArCH), 7.22 (1H, d, J = 
8.5 Hz, ArCH), 6.07 (1H, br s, OH), 3.69 (2H, t, J = 6.5 Hz, C1-H2), 2.81 (2H, t, J = 7.5 Hz, 
C3-H2), 2.43 (3H, s, Ts CH3), 2.10 – 2.00 (2H, m, C2-H2), 1.24 (9H, s, Boc (CH3)3); 
13C NMR 
(101 MHz, CDCl3) δ 156.4 (Boc C=O), 148.8 (C5), 146.0 (Ts ArC), 133.6 (ArC), 131.3 (Ts 
ArC), 129.8 ( 2 × Ts ArCH), 129.7 (2 × Ts ArCH), 128.8 (ArCH), 127.7 (ArCH), 125.7 
(ArCH), 125.4 (ArCH), 125.0 (ArC), 121.5 (ArCH), 120.5 (ArCH), 120.3 (ArC), 84.0 (Boc 
C(CH3)3), 52.9 (C1), 27.7 (Boc (CH3)3), 27.3 (C3), 27.2 (C2), 21.8 (Ts CH3); HRMS (ESI
+) 
Calculated for C25H29NNaO6S: 494.1607. Found [M+Na]
+: 494.1614. 
 
1H-Spiro[naphthalene-2,2'-pyrrolidin]-1-one (233)  
 
General procedure I: The preceding N-tosyloxycarbamate 232 (70.7 mg, 0.15 mmol) and 
TFA (23 μL, 0.3 mmol) in 30:1 anhydrous TFE:CH2Cl2 (1.5 mL) were stirred at room 




temperature for 26 hours. Purification by flash column chromatography (gradient, eluent: 50% 
EtOAc:hexane – 100% EtOAc) afforded 233 (11.4 mg, 38%) as a yellow/brown solid; m.p.: 
57-60 oC (EtOAc:hexane); Rf = 0.1 (EtOAc); νmax / cm
-1 (solid) 2920 (m), 2851 (m), 1674 (s), 
1595 (s), 1371 (s); 1H NMR (400 MHz, CDCl3) δ 7.94 (1H, d, J = 7.5 Hz, C7-H), 7.56 – 7.51 
(1H, m, C9-H), 7.34 – 7.29 (1H, m, C8-H), 7.17 (1H, d, J = 7.5 Hz, C10-H), 6.43 (1H, d, J = 
10.0 Hz, C12-H), 6.25 (1H, d, J = 10.0 Hz, C13-H), 3.41 – 3.33 (1H, m, C1-H), 3.13 – 3.05 
(1H, m, C1-H’), 2.40 (1H, br s, NH), 2.11 – 2.06 (1H, m, C3-H), 1.92 – 1.78 (3H, m, C3-H’, 
C2-H2); 
13C NMR (101 MHz, CDCl3) δ 203.7 (C5), 139.8 (C13), 138.2 (C11), 134.7 (C9), 
129.0 (C6), 127.9 (C8), 127.3 (C7), 127.2 (C10), 123.3 (C12), 70.2 (C4), 48.4 (C1), 38.9 (C3), 





The title compound was prepared according to a literature procedure.287 
To a solution of 7-methoxy-2-naphthol (3.48 g, 20.0 mmol) and Amberlyst 15® (2.0 g) in 
PhMe (50 mL) was added acrylic acid (2.88 g, 40.0 mmol) and the solution was heated at reflux 
for 22 hours. After cooling to room temperature, the reaction mixture was filtered over Celite® 
and the filtrate was concentrated in vacuo. Purification by flash column chromatography 
(gradient, eluent: 20 – 25% EtOAc:hexane) afforded the title compound (2.05 g, 44%) as a 
pale-yellow solid; 1H NMR (400 MHz, CDCl3) δ 7.75 (1H, d, J = 9.5 Hz), 7.69 (1H, d, J = 9.0 
Hz), 7.15 – 7.13 (2H, m), 7.09 (1H, d, J = 9.0 Hz), 3.95 (3H, s), 3.31 (2H, t, J = 7.5 Hz), 2.92 
(2H, t, J = 7.5 Hz); 13C NMR (101 MHz, CDCl3) δ 168.5, 158.9, 150.4, 132.6, 130.4, 128.7, 
126.2, 117.4, 115.0, 114.4, 102.0, 55.4, 28.7, 20.2. 












3-(2-((tert-Butyldimethylsilyl) oxy)-7-methoxynaphthalen-1-yl)propanoic acid  
 
To a solution of 9-methoxy-1,2-dihydro-3H-naphtho[f]chromen-3-one (1.71 g, 7.50 mmol) in 
THF (75 mL) was added aqueous 1 M LiOH (44.0 mL, 24.8 mmol). After stirring at room 
temperature overnight the pH was acidified to approx. 3 with 1 M HCl. The product was 
extracted with EtOAc (50 mL), dried over Na2SO4, filtered and concentrated in vacuo. The 
crude product was dissolved in DMF (15 mL) and tert-butyldimethylsilyl chloride (2.50 g, 16.5 
mmol) and imidazole (1.68 g, 24.8 mmol) were added at 0 o C. After being stirred at room 
temperature overnight the reaction was quenched by addition of H2O and the product was 
extracted with hexane, dried over MgSO4, filtered and concentrated in vacuo. To the crude 
product in MeOH (7.5 mL) and THF (7.5 mL) was added aqueous K2CO3 (22 mL, 15.0 mmol). 
After stirring overnight at room temperature, the reaction was quenched with 1 M HCl (20 mL) 
at 0 oC. The organic phase was extracted with Et2O (3 × 10 mL), dried over Na2SO4, filtered 
and concentrated in vacuo. Purification by flash column chromatography (20% EtOAc:hexane) 
afforded the title compound (1.77 g, 65%) as a yellow solid; m.p.: 113-115 oC (EtOAc:hexane); 
Rf = 0.5 (33% EtOAc:hexane); νmax / cm
-1 (solid) 3675 (w), 2958 (m), 2927 (m), 1703 (s), 1627 
(m), 1514 (s), 1264 (s), 1231 (s), 1037 (s); 1H NMR (CDCl3) δ 7.68 (1H, d, J = 9.0 Hz, ArCH), 
7.56 (1H, d, J = 9.0 Hz, ArCH), 7.24 (1H, d, J = 2.5 Hz, ArCH), 7.02 (1H, dd, J = 9.0, 2.5 Hz, 
ArCH), 6.95 (1H, d, J = 9.0 Hz, ArCH), 3.95 (3H, s, OCH3), 3.43 – 3.26 (2H, m, C3-H2), 2.76 
– 2.56 (2H, m, C2-H2), 1.97 (9H, s, TBS (CH3)3), 0.29 (6H, s, TBS (Si(CH3)2); 
13C NMR 
(101 MHz, CDCl3) δ 178.9 (C1), 158.3 (ArC), 151.4 (ArC), 134.3 (ArC), 130.1 (ArCH), 127.6 
(ArCH), 124.8 (ArC), 122.1 (ArC), 117.6 (ArCH), 115.7 (ArCH), 101.7 (ArCH), 55.3 (OCH3), 
33.5 (C2), 25.8 (TBS (CH3)3), 21.1 (C3), 18.3 (TBS SiC(CH3)3), -3.9 (TBS Si(CH3)2); HRMS 













General procedure F: 3-(2-((tert-Butyldimethylsilyl)oxy)-7-methoxynaphthalen-1-yl) 
propanoic acid (1.08 g, 3.00 mmol), ethyl chloroformate (0.29 mL, 3.00 mmol), Et3N (0.42 
mL, 3.00 mmol), and NaBH4 (280 mg, 7.50 mmol) were employed. Purification by flash 
column chromatography (20% EtOAc:hexane) afforded the title compound (680 mg, 65%) as 
a pale yellow oil; Rf = 0.25 (20% EtOAc:hexane); νmax / cm
-1 (film) 3370 (br), 2953 (m), 2930 
(m), 2884 (m), 2857 (m), 1624 (s), 1513 (s), 1461 (s), 1230 (s); 1H NMR (400 MHz, CDCl3) 
δ 7.67 (1H, d, J = 9.0 Hz), 7.53 (1H, d, J = 9.0 Hz), 7.27 (1H, s), 7.02 (1H, dd, J = 9.0, 2.5 Hz), 
6.94 (1H, d, J = 9.0 Hz), 3.93 (3H, s), 3.59 (2H, t, J = 6.0 Hz), 3.14 (2H, t, J = 7.0 Hz), 2.06 – 
1.77 (3H, m), 1.05 (9H, s), 0.27 (6H, s); 13C NMR (101 MHz, CDCl3) δ 158.0, 151.2, 134.5, 
130.0, 127.0, 125.1, 123.4, 117.9, 115.6, 102.5, 62.0, 55.3, 31.9, 25.9, 21.5, 18.4, -3.9; HRMS 
(ESI+) Calculated for C20H30NaO3Si: 369.1856. Found [M+Na]
+: 369.1855.  





General procedure G: 3-(2-((tert-Butyldimethylsilyl)oxy)-7-methoxynaphthalen-1-yl) 
propan-1-ol (400 mg, 1.15 mmol), PPh3 (360 mg, 1.38 mmol), DIAD (0.27 mL, 1.38 mmol) 
and BocNHOTs (400 mg, 1.38 mmol) in anhydrous THF (5 mL) were employed. Purification 
by flash column chromatography (10% EtOAc:hexane) afforded the title compound (480 mg, 
68%)  as a colourless oil; Rf = 0.5 (20% EtOAc:hexane); νmax / cm
-1 (film) 2956 (m), 2930 (m), 
2900 (m), 2859 (m), 1721 (s), 1623 (s), 1513 (s), 1381 (s), 1368 (s), 1231 (s), 1178 (s), 1152 
(s); 1H NMR (400 MHz, CDCl3) δ 7.82 (2H, d, J = 8.0 Hz, Ts ArCH), 7.65 (1H, d, J = 9.0 Hz, 
ArCH), 7.51 (1H, d, J = 9.0 Hz, ArCH), 7.30 (2H, d, J = 8.0 Hz, Ts ArCH), 7.16 (1H, d, J = 
2.5 Hz, ArCH), 7.00 (1H, dd, J = 9.0, 2.5 Hz, ArCH), 6.90 (1H, d, J = 9.0 Hz, ArCH), 3.96 
(3H, s, OCH3), 3.73 (2H, br s, C1-H2), 2.96 (2H, t, J = 8.0 Hz, C3-H2), 2.42 (3H, s, Ts, CH3), 




1.96 (2H, app. qn, J = 7.5 Hz, C2-H2), 1.16 (9H, s, Boc (CH3)3), 1.05 (9H, s, TBS (CH3)3), 0.25 
(6H, s, TBS (Si(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 158.2 (ArC), 155.4 (Boc C=O), 151.2 
(ArC), 145.7 (Ts ArC), 134.5 (ArC), 131.4 (Ts ArC), 13.0 (ArCH), 129.7 (2 × Ts ArCH), 129.6 
(2 × Ts ArCH), 127.2 (ArCH), 124.9 (ArC), 123.2 (ArC), 117.7 (ArCH), 116.0 (ArCH), 101.9 
(ArCH), 83.2 (Boc C(CH3)3), 55.5 (OCH3), 52.9 (C1), 27.6 (Boc (CH3)3), 26.0 (TBS (CH3)3), 
25.8 (C2), 22.9 (C3), 21.8 (Ts CH3), 18.4 (TBS C(CH3)3), -3.8 (TBS Si(CH3)2); HRMS (ESI
+) 
Calculate for C32H45NNaO7SSi: 638.2578. Found [M+Na]
+: 638.2560. 
 
tert-Butyl (3-(2-hydroxy-7-methoxynaphthalen-1-yl)propyl)(tosyloxy)carbamate (234) 
 
General procedure H: tert-Butyl (3-(2-((tert-butyldimethylsilyl)oxy)-7-methoxynaphthalen-
1yl)propyl) (tosyloxy)carbamate (300 mg, 0.50 mmol) and 1:1 TBAF:AcOH solution (0.1 M 
in THF, 0.50 mmol) in THF (10 mL) were employed. Purification by flash column 
chromatography (gradient, eluent 20 – 33% EtOAc:hexane) afforded 234 (130 mg, 51%) as a 
pale yellow solid; Rf = 0.2 (20% EtOAc:hexane); 
1H NMR (400 MHz, CDCl3) δ 7.84 (2H, d, 
J = 8.0 Hz, Ts ArCH), 7.65 (1H, d, J = 9.0 Hz, ArCH), 7.54 (1H, d, J = 8.5 Hz, ArCH), 7.32 
(2H, d, J = 8.0 Hz, Ts ArCH), 7.14 (1H, d, J = 2.5 Hz, ArCH), 6.99 (1H, dd, J = 9.0, 2.5 Hz, 
ArCH), 6.89 (1H, d, J = 8.5 Hz, ArCH), 5.34 (1H, br s, OH), 3.95 (3H, s, OCH3), 3.76 (2H, br 
s, C1-H2), 3.00 (2H, t, J = 8.0 Hz, C3-H2), 2.43 (3H, s, Ts CH3), 2.07 – 2.00 (2H, m, C2-H2), 
1.19 (9H, s, Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) δ 158.4 (ArC), 155.9 (Boc C=O), 151.3 
(ArC), 145.7 (Ts ArC), 134.3 (ArC), 131.2 (Ts ArC), 130.1 (ArCH) 129.6 (2 × Ts ArCH), 
129.5 (2 × Ts ArCH), 127.7 (ArCH), 124.7 (ArC), 117.7 (ArCH), 115.4 (ArC), 115.3 (ArCH), 
101.7 (ArCH), 83.5 (Boc C(CH3)3), 55.3 (OCH3), 52.9 (C1), 27.5 (Boc (CH3)3), 25.8 (C2), 22.2 
(C3), 21.7 (Ts CH3); HRMS (ESI














General procedure I: The preceding N-tosyloxycarbamate 234 (50.2 mg, 0.10 mmol), TFA 
(15 μL, 0.20 mmol) and TFE (1 mL) were employed. After stirring at room temperature for 48 
hours, purification by flash column chromatography (gradient, eluent 50% EtOAc:hexane – 
EtOAc) afforded 235 (17.4 mg, 76%) as a yellow oil; Rf = 0.2 (EtOAc); νmax / cm
-1 (film) 3340 
(m), 2963 (m), 2942 (m), 2865 (m), 1666 (s), 1601 (s), 1555 (m), 1279 (s), 1224 (s); 1H NMR 
(400 MHz, CDCl3) δ 7.32 (1H, d, J = 10.0 Hz, C11-H), 7.23 (1H, d, J = 2.5 Hz, C6-H), 7.19 
(1H, d, J = 8.5 Hz, C9-H), 6.75 (1H, dd, J = 8.5, 2.5 Hz, C8-H), 6.03 (1H, d, J = 10.0 Hz, 
C12-H), 3.85 (3H, s, OCH3), 3.44 (1H, dt, J = 10.0, 6.5 Hz, C1-H), 3.27 (1H, dt, J = 10.0, 6.5 
Hz, C1-H’), 2.92 (1H, br s, NH), 2.30 – 2.23 (1H, m, C3-H), 1.93 – 1.72 (3H, m, C3-H’ and 
C2-H2); 
13C NMR (101 MHz, CDCl3) δ 204.9 (C13), 161.5 (C7), 151.2 (C5), 144.7 (C11), 
130.9 (C9), 122.4 (C10), 120.8 (C12), 112.2 (C6), 112.0 (C8), 74.1 (C4), 55.4 (OCH3), 49.9 





General procedure K: Carboxylic acid 167 (2.64 g, 8.00 mmol), N,O-dimethylhydroxylamine 
hydrochloride (1.09 g, 11.2 mmol), Et3N (1.56 mL, 11.2 mmol), 4-dimethylaminopyridine 
(1.37 g, 11.2 mmol), and N,N’-dicyclohexylcarbodiimide (2.31 g, 11.2 mmol) were employed. 
Purification by flash column chromatography (20% EtOAc:hexane) afforded the title 
compound (2.20 g, 74%) as a pale yellow oil; Rf = 0.7 (33% EtOAc:hexane); νmax / cm
-1 (film) 
2954 (m), 2930 (m), 2857 (m), 1664 (s), 1594 (m), 1466 (s), 1379 (m), 1242 (s), 1072 (m); 
1H NMR (400 MHz, CDCl3) 8.02 (1H, d, J = 8.5 Hz, ArCH) δ 7.78 (1H, d, J = 8.5 Hz, ArCH), 
7.64 (1H, d, J = 9.0 Hz, ArCH), 7.51 – 7.47 (1H, m, ArCH), 7.37 – 7.32 (1H, m, ArCH), 7.11 




(1H, d, J = 9.0 Hz, ArCH), 3.59 (3H, s, C2-H3), 3.41 (2H, t, J = 8.0 Hz, C5-H2), 3.21 (3H, s, 
C1-H3), 2.73 (2H, t, J = 8.0 Hz, C4-H2), 1.07 (9H, s, TBS (CH3)3), 0.30 (6H, s, TBS Si(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 174.2 (C3) 150.7 (ArC), 133.2 (ArC), 129.5 (ArC), 128.5 
(ArCH), 127.5 (ArCH), 126.3 (ArCH), 124.3 (ArC), 123.3 (ArCH), 123.1 (ArCH), 120.3 
(ArCH), 61.2 (C2), 32.3 (C4), 31.9 (C1), 25.8 (TBS (CH3)3), 20.7 (C5), 18.3 (TBS C(CH3)3), 
-3.9 (TBS Si(CH3)2); HRMS (ESI





To a solution of 3-(2-((tert-butyldimethylsilyl)oxy)naphthalen-1-yl)-N-methoxy-N-methyl 
propanamide (940 mg, 2.50 mmol) in anhydrous THF (6 mL) at 0 o C was added 
methylmagnesium bromide (3 M in Et2O, 1.6 mL, 5.0 mmol) dropwise over 5 minutes. The 
reaction mixture was stirred at room temperature for 1 hour until completion by TLC analysis. 
The reaction mixture was quenched by addition of saturated aqueous NH4Cl (5 mL) and the 
aqueous phase was extracted with EtOAc (3 × 5mL). The combined organic extracts were 
washed with brine (10 mL), dried over Na2SO4 and concentrated in vacuo to afford the title 
compound (610 mg, 74%) as a pale yellow oil which was used without further purification; 
Rf = 0.8 (33% EtOAc:hexane); νmax / cm
-1 (film) 2954 (m), 2929 (m), 2893 (m), 2857 (m), 1713 
(s), 1622 (m), 1594 (m), 1466 (s), 1360 (m), 1242 (s), 1161 (m), 1075 (m); 1H NMR (400 MHz, 
CDCl3) δ 7.91 (1H, d, J = 8.5 Hz, ArCH), 7.79 (1H, d, J = 8.5 Hz, ArCH), 7.64 (1H, d, J = 9.0 
Hz, ArCH), 7.49 (1H, ddd, J = 8.5, 7.0, 1.5 Hz, ArCH), 7.35 (1H, ddd, J = 8.0, 7.0, 1.0 Hz, 
ArCH), 7.10 (1H, d, J = 9.0 Hz, ArCH), 3.33 (2H, t, J = 8.0 Hz, C4-H2), 2.74 (2H, t, J = 8.0 Hz, 
C3-H2), 2.18 (3H, s, C1-H3), 1.06 (9H, s, TBS (CH3)3), 0.29 (6H, s, TBS Si(CH3)2); 
13C NMR 
(101 MHz, CDCl3) δ 208.5 (C2), 150.6 (ArC), 133.0 (ArC), 129.5 (ArC), 128.6 (ArCH), 127.5 
(ArCH), 126.4 (ArCH), 123.9 (ArC), 123.4 (ArCH), 122.9 (ArCH), 120.2 (ArCH), 43.5 (C3), 
29.9 (C1), 25.8 (TBS (CH3)3), 19.9 (C4), 18.3 (TBS C(CH3)3), -3.9 (TBS Si(CH3)2); HRMS 
(ESI+) Calculated for C20H28NaO2Si: 351.1750. Found [M+Na]
+: 351.1753. 
 






To a solution of 4-(2-((tert-butyldimethylsilyl)oxy)naphthalen-1-yl)butan-2-one (560 mg, 1.70 
mmol) in MeOH (10 mL) was slowly added NaBH4 (130 mg, 3.40 mmol) at 0 
oC. The reaction 
was stirred at this temperature for 1.5 hours until complete by TLC analysis. The reaction was 
quenched by addition of water (10 mL) and extracted with Et2O (3 × 10 mL). The combined 
organic extracts were washed with brine (10 mL), dried over MgSO4, filtered and the solvent 
removed in vacuo to afford the title compound (490 mg, 87%) as a pale yellow oil which was 
used without further purification; Rf = 0.6 (33% EtOAc:hexane); νmax / cm
-1 (film) 3360 (br), 
2957 (m), 2928 (m), 2884 (m), 2857 (m), 1622 (m), 1594 (m), 1465 (m), 1241 (s); 1H NMR 
(400 MHz, CDCl3) δ 7.97 (1H, d, J = 8.5 Hz, ArCH), 7.78 (2H, d, J = 8.5 Hz, ArCH), 7.62 
(1H, d, J = 9.0 Hz, ArCH), 7.48 (1H, ddd, J = 8.5, 7.0, 1.5 Hz, ArCH), 7.35 (1H, ddd, J = 8.0, 
7.0, 1.0 Hz, ArCH), 7.10 (1H, d, J = 9.0 Hz, ArCH), 3.73 – 3.65 (1H, m, C2-H), 3.27 – 3.13 
(2H, m, C4-H2), 2.29 (1H, br s, OH), 1.87 – 1.74 (2H, m, C3-H2), 1.19 (3H, d, J = 6.0 Hz, 
C1-H3), 1.06 (9H, s, TBS (CH3)3), 0.29 (6H, s, TBS Si(CH3)2); 
13C NMR (101 MHz, CDCl3) 
δ 150.3 (ArC), 133.2 (ArC), 129.8 (ArC), 128.5 (ArCH), 127.3 (ArCH), 126.2 (ArCH), 124.8 
(ArCH), 123.5 (ArC), 123.4 (ArCH), 120.5 (ArCH), 67.1 (C2), 38.9 (C3), 25.9 (TBS (CH3)3), 
23.1 (C4), 21.6 (C1), 18.4 (TBS SiC(CH3)3), -3.9 (TBS Si(CH3)2); HRMS (ESI
+) Calculated 
for C20H30NaO2Si: 353.1907. Found [M+Na]
+: 353.1894. 
 
tert-Butyl (4-(2-hydroxynaphthalen-1-yl)butan-2-yl)(tosyloxy)carbamate (236) 
 
General procedures G and H: 4-(2-((tert-Butyldimethylsilyl)oxy)naphthalen-1-yl)butan-2-ol 
(220 mg, 0.77 mmol), PPh3 (240 mg, 0.92 mmol), DIAD (0.18 mL, 0.92 mmol) and 
BocNHOTs (260 mg, 0.92 mmol) in anhydrous THF (3 mL) were employed. The desired 




product could not be obtained pure so to the crude product in THF (5 mL) was added a solution 
of TBAF (1M in THF, 1.06 mL, 1.06 mmol) at 0 oC. The reaction mixture was stirred at this 
temperature for 1.5 hours until complete by TLC. The reaction mixture was quenched with 
saturated aqueous NH4Cl (5 mL) and extracted with EtOAc (3 × 5 mL). The combined organic 
extracts were washed with brine (10 mL), dried over MgSO4, filtered and concentrated in 
vacuo. Purification by flash column chromatography (gradient 20 – 33% EtOAc:hexane) 
afforded 236 (320 mg, 69%) as a colourless solid; Rf = 0.4 (33% EtOAc:hexane); νmax / cm
-1 
(solid) 3461 (m, br) 2975 (m), 1688 (s), 1386 (s); 1H NMR (400 MHz, CD3OD) δ 7.83 (3H, d, 
J = 8.5, Ts ArCH, ArCH), 7.72 (1H, d, J = 8.0 Hz, ArCH), 7.58 (1H, d, J = 9.0 Hz, ArCH), 
7.42 – 7.33 (3H, m, ArCH), 7.24 (1H, t, J = 7.5 Hz, ArCH), 7.09 (1H, d, J = 9.0 Hz, ArCH), 
4.00 (1H, sextet, J = 7.0 Hz, C2-H), 3.03 (2H, dd, J = 9.5, 6.5 Hz, C4-H2), 2.38 (3H, s, Ts CH3), 
1.94 – 1.83 (1H, m, C3-H), 1.77 – 1.66 (1H, m, C3-H’), 1.27 (3H, d, J = 6.5 Hz, C1-H3), 1.20 
(9H, s, Boc (CH3)3); 
13C NMR (101 MHz, CD3OD) δ 157.9 (Boc C=O), 153.3 (ArC), 147.4 
(Ts ArC), 134.7 (ArC), 132.9 (ArC), 130.8 (2 × Ts ArCH), 130.7 (2 × Ts ArCH), 130.4 (ArC), 
129.5 (ArCH), 128.5 (ArCH), 127.1 (ArCH), 123.7 (ArCH), 123.4 (ArCH), 120.3 (ArC), 118.6 
(ArCH), 84.7 (Boc C(CH3)3, 62.8 (C2), 35.2 (C3), 27.9 (Boc (CH3)3), 22.8 (C4), 21.6 (Ts CH3), 






General procedure I: The preceding N-tosyloxycarbamate 236 (97.1 mg, 0.20 mmol) and 
TFA (30 μL, 0.4 mmol) in 5:1 TFE:CH2Cl2 (3 mL) were stirred at room temperature for 48 
hours. Purification by flash column chromatography (20 – 33% EtOAc:hexane – 100% EtOAc) 
afforded 237 (23.0 mg, 54%) as a 1.5:1 mixture of diastereomers and as a yellow solid; Rf = 
0.5 (2:1 EtOAc:hexane); νmax / cm
-1 (solid) 3337 (s), 2963 (s), 2916 (s), 2850 (s), 1668 (s), 1084 
(s). 




Data for the major diastereomer 237a: m.p.: 89-90 oC (EtOAc:hexane); 1H NMR (400 MHz, 
CDCl3) δ 7.67 (1H, d, J = 8.0 Hz, C7-H), 7.41 – 7.35 (2H, m, C8-H, C12-H), 7.26 – 7.24 (2H, 
m, C9-H, C10-H), 6.18 (1H, d, J = 10.0 Hz, C13-H), 3.63 – 3.55 (1H, m, C2-H), 2.42 (1H , br 
s, NH) overlapping 2.45 – 2.39 (1H, ddd, J = 13.0, 7.0, 3.0 Hz, C4-H), 1.92 – 1.86 (1H, dddd, 
J = 11.5, 6.5, 5.0, 3.0 Hz, C3-H), 1.82 – 1.74 (1H, ddd, J = 13.0, 11.0, 6.0Hz, C4-H’), 1.42 – 
1.35 (1H, m, C3-H’) overlapping 1.39 (3H, d, J = 6.0 Hz, C1-H3); 
13C NMR (101 MHz, CDCl3) 
δ 204.3 (C14), 149.1 (C6), 144.6 (C12), 130.4 (C8), 129.1 (C10), 128.9 (C11), 126.9 (C9), 
125.8 (C7), 123.4 (C13), 74.8 (C5), 58.2 (C2), 42.9 (C4), 33.3 (C3), 20.2 (C1). 
Data for the minor diastereomer 237b:1H NMR (400 MHz, CDCl3) δ 7.85 (1H, dd, J = 8.0, 
1.0 Hz, C7-H), 7.42 – 7.32 (2H, m, C8-H, C12-H), 7.28 – 7.22 (2H, m, C9-H, C10-H), 6.15 
(1H, d, J = 10.0 Hz, C13-H), 3.76 – 3.67 (1H, m, C2-H), 2.72 (1H, br s, NH), 2.25 (1H, ddd, J 
= 12.5, 10.0, 7.0 Hz, C4-H), 1.90 (1H, dddd, J = 12.5, 7.0, 5.5, 3.5 Hz, C3-H), 1.81 (1H, ddd, 
J = 12.5, 7.0, 3.5 Hz, C4-H’), 1.53 (1H, dddd, J = 12.0, 10.0, 9.0, 7.0 Hz, C3-H’), 1.33 (3H, d, 
J = 6.0 Hz, C1-H3); 
13C NMR (101 MHz, CDCl3) δ 206.5 (C14), 149.2 (C6), 144.4 (C12) 130.0 
(C8), 129.5 (C10), 129.2 (C11), 127.1 (C9), 126.6 (C7), 124.0 (C13), 74.0 (C5), 55.9 (C2), 
42.7 (C4), 32.6 (C3), 22.3 (C1). 
HRMS (ESI+) Calculated for C14H15NNaO: 236.1046. Found [M+Na]
+: 236.1046. 
The stereochemistry of the major diastereomer was determined by X-ray crystallography. 
 
X-ray crystal structure of 237a. 
 
 






The title compound 238 was prepared according to a literature procedure.311 
To a solution of 2-naphthol (3.6 g, 25 mmol) and K2CO3 (10.4 g, 75 mmol) in acetone (80 mL) 
was added cinnamyl bromide (3.95 g, 30 mmol) and the reaction was heated at 60 oC overnight. 
After cooling to room temperature, the reaction mixture was diluted with ethyl acetate and 
water. The organic layer was washed with brine, dried over MgSO4 and concentrated in vacuo. 
Purification by flash column chromatography (5% EtOAc:hexane) afforded 238 (4.2 g, 81%) 
as a colourless solid; 1H NMR (400 MHz, CDCl3) δ 7.80 – 7.73 (3H, m), 7.48 – 7.42 (3H, m), 
7.38 – 7.31 (3H, m), 7.29 – 7.25 (1H, m), 7.24 – 7.19 (2H, m), 6.80 (1H, dt, J = 16.0, 1.5 Hz), 
6.53 – 6.44 (1H, m), 4.82 (2H, dd, J = 6.0, 1.5 Hz). 




The title compound was prepared according to a literature procedure.311 
A solution of the preceding allyl ether 238 (3.9 g, 15.0 mmol) in 2-methoxyethanol (60 mL) 
was heated at 120 oC for 48 hours. The reaction was diluted with water and extracted with ethyl 
acetate. The combined organic extracts were washed with brine, dried over MgSO4 and 
concentrated in vacuo. Purification by flash column chromatography (10% EtOAc:hexane) 
afforded the title compound (1.8 g, 46%) as a yellow oil. 











To a solution of 1-(1-phenylallyl)naphthalen-2-ol (1.40 g, 5.30 mmol), in DMF (10 mL) was 
added tert-butyldimethylsilyl chloride (970 mg, 6.45 mmol) and imidazole (910 mg, 13.4 
mmol) and the reaction mixture was stirred at room temperature overnight until completion by 
TLC analysis. The reaction was quenched with water (50 mL) and extracted with CH2Cl2 (3 × 
20 mL). The organic phase was washed with brine (20 mL), dried over Na2SO4, filtered and 
concentrated in vacuo. Purification by flash column chromatography (4% EtOAc:hexane) 
afforded 239 (1.37 g, 69%) as a pale-yellow oil; Rf = 0.4 (20% EtOAc:hexane); νmax / cm
-1 
(film) 2955 (m), 2928 (m), 1622 (m), 1586 (m), 1463 (m), 1253 (m), 1236 (m); 1H NMR 
(400 MHz, CDCl3) δ 7.75 (1H, d, J = 8.0 Hz, ArCH), 7.70 - 7.63 (2H, m, ArCH), 7.25 - 7.13 
(8H, m, ArCH), 6.64 (1H, ddd, J = 17.5, 10.0, 7.5 Hz, C2-H), 5.91 (1H, d, J = 7.5 Hz, C3-H) 
5.28 – 5.16 (2H, m, C1-H2), 0.99 (9H, s, TBS (CH3)3), 0.23 (6H, d, J = 7.5 Hz, TBS Si(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 151.4 (ArC), 143.7 (ArC), 138.9 (C2), 132.9 (ArC), 130.4 
(ArC), 128.7 (ArCH), 128.6 (ArCH), 128.3 (2 × ArCH), 127.6 (2 × ArCH), 126.0 (ArC), 125.7 
(2 × ArCH), 125.5 (ArCH), 123.2 (ArCH), 120.6 (ArCH), 117.5 (C1), 45.4 (C3), 26.0 (TBS 
(CH3)3), 18.5 (TBS SiC(CH3)3), -3.6 (TBS Si(CH3)2); HRMS (ESI
+) Calculated for 




This compound 240 was prepared according to a literature procedure.91 
To a solution of the preceding alkene 239 (790 mg, 2.0 mmol) in THF (4 mL) at 0 oC was 
added borane-dimethyl sulfide (0. 4 mL, 4.0 mmol) and the reaction was stirred at this 
temperature for 5 hours. Aqueous 30% H2O2 (0.6 mL) and NaHCO3 (0.5 mL) were added and 
the reaction was warmed to room temperature overnight. The reaction was quenched with 
aqueous saturated NH4Cl (15 mL) and extracted with EtOAc (3 × 15 mL). The combined 




organic extracts were washed with brine (15 mL), dried over Na2SO4 and concentrated in 
vacuo. Purification by flash column chromatography afforded 240 (230 mg, 29%) as a yellow 
oil; νmax / cm
-1 (film) 3447 (m, br), 2952 (m), 2929 (m), 2857 (m), 1595 (m), 1463 (m), 1237 
(m); 1H NMR (400 MHz, CDCl3) δ 7.78 – 7.74 (1H, m, ArCH), 7.76 – 7.68 (1H, m, ArCH), 
7.66 – 7.57 (1H, m, ArCH), 7.32 – 7.24 (5H, m, ArCH), 7.21 – 7.15 (3H, m, ArCH), 5.37 (1H, 
dd, J = 11.5, 4.5 Hz, C3-H), 3.62 – 3.53 (1H, m, C1-H), 3.37 – 3.27 (1H, m, C1-H’), 2.87 – 
2.79 (1H, m, C2-H), 2.55 – 2.46 (1H, m, C2-H’), 2.28 (1H, br s, OH), 1.03 (9H, s, TBS (CH3)3), 
0.37 (3H, s, TBS Si(CH3)), 0.25 (3H, s, TBS Si(CH3)); 
13C NMR (101 MHz, CDCl3) δ 151.6 
(ArC), 144.6 (ArC), 132.8 (ArC), 130.8 (ArC), 128.5 (ArC), 128.8 (ArCH), 128.7 (ArCH), 
128.3 (2 × ArCH), 127.1 (2 × ArCH), 125.7 (ArCH), 125.7 (ArCH), 125.5 (ArCH), 123.5 
(ArCH), 120.2 (ArCH) 61.5 (C1), 36.4 (C3), 34.9 (C2) 25.9 (TBS (CH3)3), 18.4 (TBS 
SiC(CH3)3), -3.44 (TBS Si(CH3)), -3.83 (TBS Si(CH3)); HRMS (ESI
+) Calculated for 
C25H33NaO2Si: 415.2064. Found [M+Na]
+: 415.2061. 
 
tert-Butyl (3-(2-hydroxynaphthalen-1-yl)-3-phenylpropyl)(tosyloxy)carbamate (241) 
 
General procedures G and H: The preceding alcohol 240 (270 mg, 0.69 mmol), PPh3 (220 
mg, 0.832 mmol), DIAD (0.16 mL, 0.83 mmol) and BocNHOTs (240 mg, 0.83 mmol) in 
anhydrous THF (4 mL) were employed. The product was purified by flash column 
chromatography (10% EtOAc:hexane) to afford the desired product (400 mg) which could not 
be obtained cleanly so was used crude in the next step using 1:1 TBAF:AcOH solution (0.1 M 
in THF, 0.60 mmol) in THF (12 mL). Purification by flash column chromatography (33% 
EtOAc:hexane) afforded 241 (260 mg, 71% over two steps) as an off-white solid; m.p.: 75-78 
oC (EtOAc:hexane); Rf = 0.1 (20% EtOAc:hexane); νmax / cm
-1 (film) 3410 (m, br), 2978 (m), 
1721 (m), 1373 (s); 1H NMR (400 MHz, CDCl3) δ 7.79 – 7.70 (3H, m, ArCH), 7.66 (1H, d, J 
= 9.0 Hz, ArCH), 7.46 – 7.37 (1H, m, ArCH), 7.35 – 7.26 (9H, m, ArCH), 7.00 (1H, d, J  = 9.0 
Hz, ArCH), 5.11 (1H, br s, OH), 4.99 (1H, t, J = 8.0 Hz, C3-H), 3.73 – 3.61 (1H, m, C1-H), 
3.42 – 3.15 (1H, m, C1-H’), 2.84 – 2.51 (2H, m, C2-H2), 2.37 (3H, s, Ts CH3), 1.15 (9H, s, Boc 
(CH3)3); 
13C NMR (101 MHz, CDCl3) δ 155.6 (Boc C=O), 151.9 (ArC), 145.7 (Ts ArC), 142.9 
(ArC), 133.2 (ArC), 131.3 (Ts ArC), 129.8 (ArC), 129.7 (2 × Ts ArCH), 129.6 (2 × Ts ArCH), 




129.2 (ArCH), 129.0 (ArCH), 128.9 (ArCH), 129.2 (ArCH), 127.5 (ArCH), 126.8 (ArCH), 
126.6 (ArCH), 123.3 (ArCH), 121.3 (ArC), 119.2 (ArCH), 83.6 (Boc C(CH3)3), 52.3 (C1), 38.4 
(C3), 28.0 (C2), 27.7 (Boc (CH3)3), 21.8 (Ts CH3)3; HRMS (ESI
+) Calculated for 





General procedure I: The preceding N-tosyloxycarbamate 241 (53.2 mg, 0.097 mmol) and 
TFA (15.0 μL, 0.19 mmol) in anhydrous TFE (1 mL) were employed. After stirring at room 
temperature for 22 hours and purification by flash column chromatography (20% 
EtOAc:hexane) 242 (19.2 mg, 72 %) was obtained as a 1:1 mixture of diastereomers A and B 
and as a pale-yellow solid. The diastereomers could not be separated by column 
chromatography. 
Data for mixture of diastereomers A + B: Rf = 0.5 (50% EtOAc:hexane); νmax / cm
-1 (solid) 
2961 (m), 2864 (m), 1650 (s); 1H NMR (400 MHz, CDCl3) δ 7.85 (1H, d, J = 8.0 Hz, C6-H, 
B), 7.68 (1H, d, J = 8.0 Hz, C6-H, A), 7.47 (1H, td, J = 7.5, 1.5 Hz, C7-H, B), 7.38 (1H, td, J = 
7.5, 1.5 Hz, C7-H, A), 7.30 – 7.25 (1H, m, C8-H, B), 7.18 – 7.09 (5H, m, 3 × ArCH, B, C8-H, 
A, C9-H, B), 7.05 – 7.00 (1H, m, ArCH, A), 6.93 – 6.90 (2H, m, 2 × ArCH, A), 6.85 – 6.81 
(2H, m, C9-H, A, C11-H, A), 6.77 (1H, d, J = 10.0 Hz, C11-H, B), 6.71 – 6.68 (2H, m, 2 × 
ArCH, B), 6.52 – 6.48 (2H, m, 2 × ArCH, A), 6.03 (1H, d, J = 10.0 Hz, C12-H, A), 5.44 (1H, 
d, J = 10.0 Hz, C12-H, B), 3.69 (1H, ddd, J = 10.5, 8.0 Hz, C1-H, B), 3.56 – 3.49 (2H, m, 
C1-H2, A), 3.40 – 3.25 (3H, m, C3-H, A+B, C1-H’, B), 2.69 (2H, br s, NH, A+B), 2.57 – 2.46 
(1H, m, C2-H, B), 2.44 – 2.33 (1H, m, C2-H, A), 2.22 – 1.26 (1H, m, C2-H’, A), 2.04 – 1.98 
(1H, m, C2-H’, B); 13C NMR (101 MHz, CDCl3) δ 205.8 (C13, B), 205.2 (C13, A), 147.7 (C5, 
B) , 145.9 (C11, A), 145.0 (C5, A), 143.8 (C11, B), 137.1 (ArC, B), 136.9 (ArC, A), 130.9 (C10, 
A), 130.5 (C10, B), 130.5 (C7, B), 129.3 (C7, A), 129.2 (2 × ArCH A), 128.7 (C9, A), 128.6 (2 
× ArCH, B), 128.1 (ArCH, B), 128.0 (C6, A),  127.6 (2 × ArCH, B), 127.3 (C8, B), 127.4 (C8, 
A/C9, B), 127.3 (C8, A/C9, B),  127.0 (ArCH, A), 126.9 (2 × ArCH, A), 126.8 (C6, B), 124.9 
(C12, B), 124.1 (C12, A), 78.1 (C4, A), 77.2 (C4, B), 64.5 (C3, A/B), 61.8 (C3, A/B), 48.3 (C1, 




B), 47.3 (C1, A), 32.0 (C2, A), 30.0 (C2, B); HRMS (ESI+) Calculated for C19H17NNaO: 
298.1202. Found [M+Na]+: 298.1200. 
 
2-(4-((tert-Butyldimethylsilyl)oxy)phenyl)acetic acid  
 
General procedure A: Carboxylic acid 243 (1.52 g, 10.0 mmol), tert-butyldimethylsilyl 
chloride (3.30 g, 22.0 mmol) and imidazole (2.25 g, 33.0 mmol) in DMF (20 mL) were 
employed. The title compound was obtained (1.45 g, 54%) as a colourless solid which was 
used without further purification; 1H NMR (400 MHz, CDCl3) δ 7.15 – 7.10 (2H, m), 6.78 – 
6.76 (2H, m), 3.55 (2H, s), 0.98 (9H, s), 0.19 (6H, s); 13C NMR (101 MHz, CDCl3) δ 177.8, 
155.1, 130.5, 126.2, 120.3, 40.4, 25.8, 18.3, -4.3.  




General procedure B: 2-(4-((tert-Butyldimethylsilyl)oxy)phenyl)acetic acid (1.33 g, 5.00 
mmol) and 2.0 equivalents of LiAlH4 (1.0 M in THF, 10 mL, 10.0 mmol) in anhydrous Et2O 
(25 mL) were employed. The title compound was obtained (988 mg, 78%) as a colourless oil 
which was used without further purification; 1H NMR (400 MHz, CDCl3) δ 7.10 – 7.06 (2H, 
m), 6.80 – 6.77 (2H, m), 3.79 (2H, t, J = 6.5 Hz), 2.79 (2H, t, J = 6.5 Hz), 0.99 (9H, s), 0.20 
(6H, s); 13C NMR (101 MHz, CDCl3) δ 154.3, 131.1, 130.0, 120.2, 63.9, 38.5, 25.8, 18.3, -4.3.  








tert-Butyl (4-((tert-butyldimethylsilyl)oxy)phenethyl)(tosyloxy)carbamate  
 
General procedure G: 2-(4-((tert-Butyldimethylsilyl)oxy)phenyl)ethan-1-ol (370 mg, 1.40 
mmol), PPh3 (440 mg, 1.66 mmol), DIAD (0.32 mL, 1.66 mmol) and BocNHOTs (470 mg, 
1.66 mmol) in anhydrous THF (8 mL) were employed. Purification by flash column 
chromatography (10% EtOAc:hexane) afforded the title compound (549 mg, 73%) as a 
colourless oil; νmax/cm
-1 (film) 2955 (m), 2930 (m), 1721 (s), 1509 (s), 1367 (s), 1252 (s); 
1H NMR (400 MHz, CDCl3) δ 7.86 (2H, d, J = 8.5 Hz, Ts ArCH), 7.34 (2H, d, J = 8.5 Hz, Ts 
ArCH), 7.03 (2H, d, J = 8.5 Hz, C4-H), 6.73 (2H, d, J = 8.5 Hz, C5-H), 3.81 (2H, br s, C1-H2), 
2.85 (2H, t, J = 7.5 Hz, C2-H2), 2.45 (3H, s, Ts CH3), 1.16 (9H, s, Boc (CH3)3), 0.97 (9H, s, 
TBS (CH3)3), 0.17 (6H, s, TBS Si(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 155.2 (Boc C=O), 
154.4 (C6), 145.8 (Ts ArC), 131.4 (Ts ArC), 130.6 (C3), 130.1 (2 × Ts ArCH), 129.9 (2 × Ts 
ArCH), 129.6 (C4), 120.2 (C5), 83.2 (Boc C(CH3)3), 54.4 (C1), 31.5 (C2), 27.7 (Boc (CH3)3), 
25.8 (TBS (CH3)3), 21.8 (Ts CH3), 18.3 (TBS C(CH3)3), -4.30 (TBS Si(CH3)2). HRMS (ESI
+) 
Calculated for C26H39NNaO6SSi: 544.2160. Found [M+Na]
+: 544.2164. 
tert-Butyl (4-hydroxyphenethyl)(tosyloxy)carbamate (244) 
 
General procedure H: tert-Butyl (4-((tert-butyldimethylsilyl)oxy)phenethyl)(tosyloxy) 
carbamate (828 mg, 1.59 mmol) and 1.0 equivalent of 1:1 TBAF:AcOH solution (0.1 M in 
THF, 15.9 mL, 1.59 mmol) in THF (20 mL) were employed. Purification by flash column 
chromatography (33% EtOAc:hexane) afforded 244 (470 mg, 73%) as a colourless solid; 
1H NMR (400 MHz, CDCl3) δ 7.86 (2H, d, J = 8.5 Hz, Ts ArCH), 7.34 (2H, d, J = 8.5 Hz, Ts 
ArCH), 7.05 (2H, d, J = 8.5 Hz, C4-H), 6.73 (2H, d, J = 8.5 Hz, C5-H), 3.82 (2H, br s, C1-H2), 
2.86 (2H, t, J = 7.5 Hz, C2-H2), 2.45 (3H, s, Ts CH3), 1.13 (9H, s, Boc (CH3)3); 
13C NMR (101 
MHz, CDCl3) δ 155.2 (Boc C=O), 154.4 (C6), 145.9 (Ts ArC), 131.3 (Ts ArC), 130.4 (C3), 




130.0 (C4), 129.9 (2 × Ts ArCH), 129.7 (2 × Ts ArCH), 115.5 (C5), 83.3 (Boc C(CH3)3), 54.2 
(C1), 31.4 (C2), 27.7 (Boc (CH3)3), 21.9 (Ts CH3); HRMS (ESI
+) Calculated for: 
C20H25NNaO6S: 430.1295. Found [M+Na]
+: 430.1291. 
 
4-(4-Hydroxyphenyl)butanoic acid  
 
To a solution of 4-(4-methoxyphenyl)butanoic acid (1.94 g, 10.0 mmol) in anhydrous CH2Cl2 
(100 mL) at 0 oC was added boron tribromide (1.0 M in CH2Cl2, 30 mL, 30.0 mmol) and the 
reaction was stirred at room temperature until completion by TLC analysis. The reaction was 
quenched by addition to water (200 mL) at 0 oC and the phases were separated. The aqueous 
phase was washed with CH2Cl2 (50 mL) and the combined organic extracts were dried over 
Na2SO4, filtered and concentrated in vacuo. Purification by flash column chromatography 
(33% EtOAc:hexane) afforded the title compound (590 mg, 33%) as a pale yellow solid; 
1H NMR (400 MHz, acetone-D6) δ 10.36 (1H, br s), 8.20 (1H, br s), 7.08 – 7.00 (2H, m), 6.78 
– 6.73 (2H, m), 2.59 – 2.53 (2H, m), 2.29 (2H, t, J = 7.5 Hz), 1.90 – 1.80 (2H, m).  
The spectroscopic properties were consistent with the data available in the literature.315  
 
4-(4-((tert-Butyldimethylsilyl)oxy)phenyl)butanoic acid  
 
General procedure A: 4-(4-Hydroxyphenyl)butanoic acid (500 mg, 2.77 mmol), 
tert-butyldimethylsilyl chloride (910 mg, 6.10 mmol) and imidazole (620 mg, 9.16 mmol) in 
DMF (6 mL) were employed to afford the title compound (695 mg, 85%) as a yellow oil which 
was used without further purification; 1H NMR (400 MHz, CDCl3) δ 7.03 (2H, d, J = 8.5 Hz), 
6.76 (2H, d, J = 8.5 Hz), 2.60 (2H, t, J = 7.5 Hz), 2.36 (2H, t, J = 7.5 Hz), 1.93 (2H, app. qn, J 




= 7.5 Hz), 0.98 (9H, s), 0.19 (6H, s); 13C NMR (101 MHz, CDCl3) δ 179.8, 153.8, 133.8, 129.3, 
119.9, 34.2, 33.3, 26.4, 25.7, 18.2, -4.4.  




General procedure B: 4-(4-((tert-Butyldimethylsilyl)oxy)phenyl)butanoic acid (640 mg, 2.17 
mmol) and 2.0 equivalents of LiAlH4 (1.0 M in THF, 4.34 mL, 4.34 mmol) in anhydrous Et2O 
(10 mL) were employed to afford the title compound (450 mg, 74%) as a colourless oil which 
was used without further purification; 1H NMR (400 MHz, CDCl3) δ 7.03 (2H, d, J = 8.5 Hz), 
6.75 (2H, d, J = 8.5 Hz), 3.64 (2H, t, J = 6.5 Hz), 2.57 (2H, t, J = 7.5 Hz), 1.70 – 1.54 (4H, m), 
0.99 (9H, s), 0.19 (6H, s); 13C NMR (101 MHz, CDCl3) δ 153.5, 134.9, 129.1, 119.8, 62.8, 
34.8, 32.2, 27.7, 25.7, 18.2, -4.4.  
The spectroscopic properties were consistent with the data available in the literature.316  
 
tert-Butyl (4-(4-((tert-butyldimethylsilyl)oxy)phenyl)butyl)(tosyloxy)carbamate  
 
General procedure G: 4-(4-((tert-Butyldimethylsilyl)oxy)phenyl)butan-1-ol (350 mg, 1.25 
mmol), PPh3 (390 mg, 1.50 mmol), DIAD (0.29 mL, 1.50 mmol) and BocNHOTs (430 mg, 1.5 
mmol) in anhydrous THF (5 mL) were employed. Purification by flash column 
chromatography (10% EtOAc:hexane) afforded the title compound (480 mg, 70%) as a 
colourless viscous oil containing a small impurity that was carried through to the next step; 
νmax /cm
-1 (film) 2954 (m), 2930 (m), 2858 (m), 1720 (s), 1509 (s), 1251 (s); 1H NMR (400 




MHz, CDCl3) δ 7.85 (2H, d, J = 8.5 Hz, Ts ArCH), 7.34 (2H, d, J = 8.5 Hz, Ts ArCH), 7.00 
(2H, d, J = 8.5 Hz, C6-H), 6.74 (2H, d, J = 8.5 Hz, C7-H), 3.64 (2H, br s, C1-H2), 2.53 (2H, t, 
J = 7.5 Hz, C4-H2), 2.44 (3H, s, Ts CH3), 1.69 – 1.49 (4H, m, C2-H2, C3-H2), 1.20 (9H, s, Boc 
(CH3)3), 0.98 (9H, s, TBS (CH3)3), 0.18 (6H, s, TBS Si(CH3)2); 
13C NMR (101 MHz, CDCl3) 
δ 155.6 (Boc C=O), 153.7 (C8), 145.7 (Ts ArC), 134.7 (C5), 131.4 (Ts ArC), 129.8 (2 × Ts 
ArCH), 129.6 (2 × Ts ArCH), 129.2 (C6), 119.9 (C7), 83.2 (Boc C(CH3)3, 52.8 (C1), 34.6 (C4), 
28.6 (C3), 27.7 (Boc (CH3)3), 25.8 (TBS (CH3)3), 25.5 (C2), 21.8 (Ts CH3), 18.3 (TBS 
SiC(CH3)3), -4.4 (TBS Si(CH3)2); HRMS (ESI
+) Calculated for C28H43NNaO6SSi: 572.2473. 
Found [M+Na]+: 572.2480. 
 
tert-Butyl (4-(4-hydroxyphenyl)butyl)(tosyloxy)carbamate (246) 
 
General procedure H: tert-Butyl (4-(4-((tert-butyldimethylsilyl)oxy)phenyl)butyl)(tosyloxy) 
carbamate (470 mg, 0.86 mmol) and 1.0 equivalent of 1:1 solution of TBAF:AcOH (0.1 M in 
THF, 8.6 mL, 0.86 mmol) in THF (20 mL) were employed. Purification by flash column 
chromatography (20% EtOAc:hexane) afforded 246 (275 mg, 73%) as a colourless oil; 
1H NMR (400 MHz, CDCl3) δ 7.85 (2H, d, J = 8.5 Hz, Ts ArCH), 7.33 (2H, d, J = 8.5 Hz, Ts 
ArCH), 6.99 (2H, d, J = 8.5 Hz, C6-H), 6.74 (2H, d, J = 8.5 Hz, C7-H), 5.38 (1H, br s, OH), 
3.63 (2H, br s, C1-H2), 2.51 (2H, t, J = 7.5 Hz, C4-H2), 2.44 (3H, s, Ts CH3), 1.70 – 1.59 (2H, 
m, C2-H2), 1.56 – 1.48 (2H, m, C3-H2), 1.21 (9H, s, Boc (CH3)3); 
13C NMR (101 MHz, CDC3) 
δ 155.6 (Boc C=O), 153.8 (C8), 145.7 (Ts ArC), 133.9 (C5), 131.1 (Ts ArC), 129.7 (2 × Ts 
ArCH), 129.6 (2 × Ts ArCH), 129.4 (C6), 115.2 (C7), 83.4 (Boc C(CH3)3), 52.7 (C1), 34.5 
(C4), 28.6 (C3), 27.6 (Boc (CH3)3), 25.4 (C2), 21.7 (Ts CH3); HRMS (ESI
+) Calculated for 









Methyl (3-(4-((tert-butyldimethylsilyl)oxy)phenyl)propyl)(tosyloxy)carbamate  
 
General procedure G: Alcohol 146 (530 mg, 2.00 mmol), PPh3 (630 mg, 2.40 mmol), DIAD 
(0.47 mL, 2.40 mmol) and methyl (tosyloxy)carbamate (590 mg, 2.40 mmol) in anhydrous 
THF (8 mL) were employed. Purification by flash column chromatography (10% 
EtOAc:hexane) afforded the title compound (930 mg, 94%) as a colourless oil; Rf = 0.4 (20% 
EtOAc:hexane); νmax / cm
-1 (film) 2955 (m), 2930 (m), 2858 (m), 1728 (s), 1509 (s), 1253 (s); 
1H NMR (400 MHz, CDCl3) δ 7.83 (2H, d, J = 8.0 Hz, Ts ArCH), 7.33 (2H, d, J = 8.0 Hz, Ts 
ArCH), 6.99 (2H, d, J = 8.0 Hz, C5-H), 6.74 (2H, d, J = 8.0 Hz, C6-H), 3.58 (2H, br s, C1-H2), 
3.47 (3H, s, OCH3), 2.51 (2H, t, J = 8.0 Hz, C3-H2), 2.45 (3H, s, Ts CH3), 1.94 – 1.85 (2H, m, 
C2-H2), 0.98 (9H, s, TBS (CH3)3), 0.18 (6H, s, TBS Si(CH3)2); 
13C NMR (101 MHz, CDCl3) 
δ 157.2 (C=O), 153.9 (C7), 146.0 (Ts ArC), 133.6 (C4), 131.2 (Ts ArC), 129.7 (2 × Ts ArCH), 
129.6 (2 × Ts ArCH), 129.2 (C5), 120.1 (C6), 53.7 (OCH3), 52.7 (C1), 32.0 (C3), 27.7 (C2), 
25.8 (TBS (CH3)3), 21.9 (Ts CH3), 18.3 (TBS C(CH3)3), -4.3 (TBS Si(CH3)2); HRMS (ESI
+) 
Calculated for C24H35NNaO6SSi: 516.1847. Found [M+Na]
+: 516.1851. 
 
Methyl (3-(4-hydroxyphenyl)propyl)(tosyloxy)carbamate (251) 
 
General procedure H: Methyl (3-(4-((tert-butyldimethylsilyl)oxy)phenyl)propyl)(tosyloxy) 
carbamate (490 mg, 1.00 mmol) and 1.1 equivalents of 1:1 TBAF:AcOH solution (0.1 M in 
THF, 11 mL, 1.1 mmol) in THF (20 mL) were employed. Purification by flash column 
chromatography (gradient 20 – 33% EtOAc:hexane) afforded 251 (289 mg, 76%) as a viscous, 
colourless oil; Rf = 0.1 (20% EtOAc:hexane); νmax / cm
-1 (film) 3431 (m, br), 3023 (m), 2956 




(m), 1726 (m), 1514 (m), 1175 (s); 1H NMR (400 MHz, CDCl3) δ 7.82 (2H, d, J = 8.0 Hz, Ts 
ArCH), 7.33 (2H, d, J = 8.0 Hz, Ts ArCH), 6.99 (2H, d, J  = 8.0 Hz, C5-H), 6.74 (2H, d, J = 
8.0 Hz, C6-H), 4.88 (1H, s, OH), 3.59 (2H, br s, C1-H2), 2.51 (2H, t, J = 8.0 Hz, C3-H2), 2.45 
(3H, s, OCH3), 1.95 – 1.85 (2H, m, C2-H2); 
13C NMR (101 MHz, CDCl3) δ 157.3 (C=O), 154.0 
(C7), 146.1 (Ts ArC), 133.0 (C4), 131.1 (Ts ArC), 129.7 (2 × Ts ArCH), 129.6 (2 × Ts ArCH), 
129.5 (C5), 115.4 (C6), 53.8 (OCH3), 52.7 (C1), 31.9 (C3), 27.8 (C2), 21.9 (Ts CH3); HRMS 
(ESI+) Calculated for C18H21NNaO6S: 402.0982. Found [M+Na]
+: 402.0984.  
 
tert-Butyl pent-4-en-1-yl(tosyloxy)carbamate (255) 
 
General procedure G: 4-Penten-1-ol (170 mg, 2.00 mmol), PPh3 (630 mg, 2.40 mmol), DIAD 
(0.47 mL, 2.40 mmol) and BocNHOTs (690 mg, 2.40 mmol) in anhydrous THF (15 mL) were 
employed. Purification by flash column chromatography (10% EtOAc:hexane) afforded 255 
(470 mg, 66%) as a colourless crystalline solid; m.p.: 47-50 oC (EtOAc:hexane); Rf = 0.5 (33% 
EtOAc:hexane); νmax / cm
-1 (solid) 2977 (m), 1715 (s), 1365 (s), 1355 (s), 1177 (s), 1154 (s); 
1H NMR (400 MHz, CDCl3) δ 7.85 (2H, d, J = 8.5 Hz, Ts ArCH), 7.34 (2H, d, J = 8.0 Hz, Ts 
ArCH), 5.81 – 5.71 (1H, m, C4-H), 5.05 – 4.93 (2H, m, C5-H2), 3.62 (2H, br s, C1-H2), 2.45 
(3H, s, Ts CH3), 2.07 – 2.00 (2H, m, C3-H2), 1.77 – 1.66 (2H, m, C2-H2), 1.22 (9H, s, Boc 
(CH3)3); 
13C NMR (101 MHz, CDCl3) δ 155.6 (Boc C=O), 145.8 (Ts ArC), 137.4 (C4), 131.4 
(Ts ArC) 129.8 (2 × Ts ArCH), 129.7 (2 × Ts ArCH), 115.4 (C5), 83.42 (Boc C(CH3)3), 52.6 
(C1), 30.7 (C3), 27.7 (Boc (CH3)3), 25.0 (C2), 21.8 (Ts CH3); HRMS (ESI
+) Calculated for 





To a solution of N-tosyloxycarbamate 213 (67.4 mg, 0.15 mmol) in anhydrous TFE (2.3 mL, 
0.07 M) at room temperature was added TFA (1.7 μL, 0.022 mmol). The reaction was heated 
to 60 oC and stirred overnight monitoring by TLC analysis. Purification by flash column 




chromatography (gradient, eluent 33% EtOAc:hexane – 100% EtOAc (a small amount < 1% 
Et3N was added to the eluent)) afforded 257 (20.4 mg, 77%) as a yellow oil; Rf = 0.5 (EtOAc); 
νmax / cm
-1 (film) 3145 (m, br), 2971 (m), 1618 (m), 1467 (m), 1238 (m); 1H NMR (400 MHz, 
CDCl3) δ 6.55 (1H, s, C10-H), 6.49 (1H, d, J = 8.0 Hz, C8-H), 6.41 (1H, d, J = 8.5 Hz, C7-H), 
4.20 (2H, br s, OH, NH), 3.28 – 3.16 (2H, m, C5-H2), 2.62 – 2.56 (1H, m, C3-H), 1.95 – 1.87 
(1H, m, C4-H), 1.80 – 1.67 (2H, m, C4-H’, C2-H), 1.56 – 1.45 (1H, m, C2-H’), 0.96 (3H, t, J 
= 7.5 Hz, C1-H3); 
13C NMR (101 MHz, CDCl3) δ 147.7 (C9), 138.1 (C6), 127.9 (C11), 116.0 
(C7), 115.9 (C10), 114.2 (C8), 39.3 (C5), 37.2 (C3), 29.4 (C2), 26.2 (C4), 11.7 (C1). HRMS 
(ESI+) Calculated for C11H16NO: 178.1226. Found [M+H]
+: 178.1227. 
The regiochemistry of the compound was confirmed by nOe analysis as shown on the 




General procedure L: Spirocycle 214 (23.4 mg, 0.08 mmol), phenylacetyl chloride (22 μL, 
0.16 mmol) and K3PO4 (67.9 mg, 0.32 mmol) in anhydrous THF (0.4 mL) were employed. 
Purification by flash column chromatography (gradient, eluent: 50% EtOAc:pentane – 100% 
EtOAc) afforded 261 (18.7 mg, 79%) as a 2.3:1 mixture of rotamers A:B and a colourless oil; 
Rf = 0.3 (3 % MeOH:CH2Cl2); νmax / cm
-1 (film) 2962 (m), 2930 (m), 2876 (m), 1660 (s), 1623 
(s), 1454 (m), 1397 (s), 1384 (s), 719 (m); 1H NMR (400 MHz, CDCl3) δ 7.33 – 7.17 (4.40 H, 
m, ArCH, A+B), 7.13 – 7.10 (0.60 H, m, 2 × ArCH, B), 6.82 – 6.70 (0.60 H, m, 0.60 × C7-H, 
B), 6.67 (0.70 H, dd, J = 10.0, 3.0 Hz, 0.70 × C7-H, A), 6.57 (0.70 H, dd, J = 10.0, 3.0 Hz, 0.70 
× C7-H’, A), 6.40 – 6.34 (0.60 H, m, 0.60 × C8-H, B), 6.34 – 6.26 (1.40 H, m, 1.40 × C8-H, 
A), 4.09 (0.3 H, dd, J = 12.5, 8.0 Hz, 0.3 × C1-H), 3.82 (0.7 H, t, J = 9.0 Hz, 0.7 × C1-H), 3.65 
– 3.52 (2.40 H, m, 1 × C1-H’, 1.4 × A+B, C11-H2, A), 3.43 (0.6 H, d, J = 4.5 Hz, 0.6 × C11-H2, 
B), 2.31 – 2.25 (1H, m, C2-H, A+B), 2.23 – 2.14 (0.30 H, m, 0.30 × C3-H, B), 2.02 – 1.95 (0.70 
H, m, 0.70 × C3-H, A), 1.76 – 1.64 (0.70 H, m, 0.70 × C2-H’, A), 1.63 – 1.55 (0.3 H, m, 0.30 
× C2-H’, B), 1.27 – 1.17 (1H, m, C4-H, A+B), 1.06 – 0.95 (1H, m, C4-H’, A+B), 0.93 – 0.84 
(3H, m, C5-H3, A+B); 
13C NMR (101 MHz, CDCl3) δ 185.8 (C9, A), 184.7 (C9, B), 170.6 
(C10, B), 169.5 (C10, A), 152.1 (C7, A), 152.0 (C7, B), 147.8 (C7’, B), 146.4 (C7’, A), 134.8 




(ArC, B), 134.1 (ArC, A), 130.4 (C8, A), 129.9 (C8, B), 129.6 (C8’, B), 129.3 (ArCH, B), 128.9 
(ArCH, A + B), 128.7 (ArCH, A + B), 128.3 (ArCH, A + B), 128.2 (C8’, A), 126.9 (ArCH, A 
+ B), 126.7 (ArCH), 65.7 (C6, A), 65.5 (C6, B), 53.5 (C3, B), 50.6 (C3, A), 47.4 (C1, B), 47.3 
(C1, A), 42.5 (C11, A), 40.1 (C11, B), 29.9 (C2, A), 27.8 (C2, B), 21.3 (C4, A + B), 12.5 (C5, 
A + B); HRMS (ESI+) Calculated for C19H21NNaO2: 318.1464. Found [M+Na]
+: 318.1472. 
 
(1R*, 6R*, 6aS*, 10aS*) and (1S*, 6R*, 6aS*, 10aS*)-1-Ethyl-6-phenyl-2,3,6a,7-
tetrahydro-1H,5H-pyrrolo[2,1-i]indole-5,8(6H)-dione (262a) and (1S*,6R*,6aS*,10aS*)-
1-Ethyl-6-phenyl-2,3,6a,7-tetrahydro-1H,5H-pyrrolo[2,1-i]indole-5,8(6H)-dione (262b) 
 
General procedure M: The preceding amide 261 (29.5 mg, 0.100 mmol) and 1.5 equivalents 
of lithium bis(trimethylsilyl)amide (1 M in THF) in anhydrous THF (1 mL) were employed. 
The reaction was stirred at this temperature for 2 hours. Purification by flash column 
chromatography (50% EtOAc:hexane) afforded 262 (16.6 mg, 56%) as a 3:1 mixture of 
diastereomers 262a and 262b and as a colourless solid; Rf = 0.6 (3% MeOH:CH2Cl2); νmax / 
cm 1 (solid) 2963 (m), 2929 (m), 2877 (m), 1693 (s), 1675 (s), 1394 (s). 
Spectroscopic data for the major diastereomer 262a: m.p.: 194 oC (EtOAc:hexane); 1H NMR 
(400 MHz, CDCl3) δ 7.36 – 7.32 (2H, m, ArCH), 7.30 – 7.24 (1H, m, ArCH), 7.15 – 7.12 (2H, 
m, ArCH), 6.62 (1H, dd, J = 10.5, 1.5 Hz, C10-H), 6.22 (1H, d, J = 10.5 Hz, C11-H), 3.77 – 
3.71 (1H, m, C4-H), 3.68 (1H, d, J = 12.0 Hz, C3-H), 3.43 (1H, t, J = 10.5 Hz, C4-H’), 2.71 
(1H, dd, J = 12.5, 6.0 Hz, C2-H), 2.65 – 2.53 (2H, m, C1-H, C5-H), 2.50 – 2.43 (1H, m, C1-H’), 
2.10 – 1.91 (2H, m, C6-H, C5-H’), 1.62 – 1.52 (1H, m, C7-H), 1.37 – 1.23 (1H, m, C7-H’), 
0.99 (3H, t, J = 7.5 Hz, C8-H3); 
13C NMR (101 MHz, CDCl3) δ 196.3 (C=O), 171.8 (NC=O), 
144.1 (C10), 135.8 (ArC), 129.8 (C11), 129.3 (2 × ArCH), 128.9 (2 × ArCH), 127.8 (ArCH), 
67.7 (C9), 57.8 (C3), 51.7 (C2), 51.4 (C6), 40.5 (C4), 36.8 (C1), 32.3 (C5), 23.7 (C7), 13.0 
(C8). 
Spectroscopic data for the minor 262b: 1H NMR (400 MHz, CDCl3) δ 7.38 – 7.32 (2H, m, 
ArCH), 7.32 – 7.28 (1H, m, ArCH), 7.14 – 7.10 (2H, m, ArCH), 6.58 (1H, dd, J = 10.0, 2.0 




Hz, C10-H), 6.16 (1H, dd, J = 10.0, 1.0 Hz, C11-H), 4.05 (1H, ddd, J = 11.0, 7.5, 2.5 Hz, 
C4-H), 3.62 (1H, d, J = 12.5 Hz, C3-H), 3.14 – 3.06 (1H, m, C4-H’), 2.76 (1H, dd, J = 12.5, 
5.5 Hz, C2-H), 2.56 – 2.41 (2H, m, C1-H2), 2.33 – 2.25 (1H, m, C5-H), 2.17 – 2.08 (1H, m, 
C6-H), 1.78 – 1.68 (1H, m, C7-H), 1.64 – 1.55 (1H, m, C5-H’), 1.47 – 1.35 (1H, m, C7-H’), 
1.03 (3H, t, J =7.5 Hz, C8-H3); 
13C NMR (101 MHz, CDCl3) δ 196.1 (C=O), 174.6 (NC=O), 
148.8 (C10), 135.8 (ArC), 129.4 (2 × ArCH), 129.0 (2 × ArCH), 128.2 (C11), 127.9 (ArCH), 
66.4 (C9), 55.6 (C3), 48.9 (C6), 46.3 (C2), 42.9 (C4), 36.2 (C1), 31.9 (C5), 22.4 (C7), 13.2 
(C8). 
HRMS (ESI+) Calculated for C19H21NNaO2: 318.1464. Found [M+Na]
+: 318.1469. 
The relative stereochemistry of the minor diastereomer was determined by nOe experiments as 
indicated on the compound structure; nOes were observed between C2-H and C7-H2 and 
between C6-H and C10-H. The major diastereomer was determined unambiguously by X-ray 
crystallography. 
  













General procedure L: Spirocycle 178 (19.2 mg, 0.073 mmol), phenylacetyl chloride (19.4 
μL, 0.147 mmol) and K3PO4 (62.2 mg, 0.293 mmol) in anhydrous THF (0.36 mL) were 
employed. Purification by flash column chromatography (gradient, eluent: 50% 
EtOAc:pentane – 100% EtOAc) afforded 263 (12.2 mg, 63%) as a 3:1 mixture of rotamers A+B 
and as a colourless, viscous oil; Rf = 0.3 (3% MeOH:CH2Cl2); νmax / cm
-1 (film) 3029 (m), 2972 
(m), 2881 (m), 1659 (s), 1622 (s), 1395 (s); 1H NMR (400 MHz, CDCl3) δ 7.35 – 7.10 (5H, m, 
5 × ArCH, A + B), 6.95 (0.50 H, d, J = 10.0 Hz, 0.50 × C5-H, B), 6.76 (1.50 H, d, J = 10.0 Hz, 
1.50 × C5-H, A), 6.32 (0.50 H, d, J = 10.0 Hz, 0.50 H × C6-H, B), 6.25 (1.50 H, d, J = 10.0 Hz, 
1.5 × C6-H, A), 3.86 (0.5 H, t, J = 7.0 Hz, 0.50 × C1-H2, B), 3.71 (1.50 H, t, J = 7.0 Hz, 1.50 × 
C1-H2, A), 3.65 (1.50 H, s, 1.50 × C9-H2, A), 3.43 (0.50 H, s, 0.50 × C9-H2, B), 2.25 (0.50 H, 
t, J = 7.0 Hz, 0.50 × C3-H2, B), 2.12 – 1.99 (3.5 H, m, 3.5 H × C2 + C3-H2, A + B); 
13C NMR 
(101 MHz, CDCl3) δ 185.4 (C7, A), 184.4 (C7, B), 170.7 (C8, B), 169.5 (C8, A), 151.2 (C5, B) 
150.7 (C5, A), 134.8 (ArC, B), 134.2 (ArC, A), 129.4 (2 × ArCH, B), 129.0 (2 × ArCH, A), 
128.9 (2 × ArCH, A), 128.7 (2 × ArCH, B), 128.5 (C6, B), 128.3 (C6, A), 127.1 (ArCH, A), 
126.9 (ArCH, B), 62.7 (C4, A), 62.0 (C4, B),  49.0 (C1, B), 48.5 (C1, A), 42.8 (C9, A), 42.0 
(C3, B), 39.9 (C9, B), 38.9 (C3, A), 24.5 (C2, A), 22.6 (C2, B); HRMS (ESI+) Calculated for 






General procedure M: The preceding amide 263 (26.7 mg, 0.10 mmol) and 1.5 equivalents 
of lithium bis(trimethylsilyl)amide (1.0 M in THF, 0.15 mL, 0.15 mmol) in anhydrous THF (1 
mL) were employed. The reaction was stirred at this temperature for 2 hours. Purification by 




flash column chromatography (EtOAc) afforded 264 (17.9 mg, 67%, >20:1 d.r.) as a colourless 
oil; Rf = 0.4 (3% MeOH:CH2Cl2); νmax / cm
-1 (film) 2920 (m), 1677 (br s), 1395 (s); 1H NMR 
(400 MHz, CDCl3) δ 7.39 – 7.27 (3H, m, ArCH), 7.15 – 7.11 (2H, m, ArCH), 6.64 (1H, dd, J 
= 10.5, 2.0 Hz, C9-H), 6.13 (1H, dd, J = 10.5, 1.0 Hz, C10-H), 3.97 (1H, ddd, J = 12.5, 7.5, 
5.0 Hz, C5-H), 3.68 (1H, d, J =12.0 Hz, C3-H), 3.28 – 3.20 (1H, m, C5-H’), 2.71 – 2.62 (2H, 
m, C2-H, C1-H), 2.49 – 2.43 (1H, m, C1-H’), 2.32 – 2.21 (1H, m, C6-H), 2.19 – 2.11 (1H, m, 
C6-H’), 2.10 – 2.02 (2H, m, C7-H2); 
13C NMR (101 MHz, CDCl3) δ 196.0 (C11), 173.5 (C4), 
146.9 (C9), 135.7 (ArC), 129.2 (2 × ArCH), 129.0 (2 × ArCH), 128.0 (C10), 127.8 (ArCH), 
65.3 (C8), 56.3 (C3), 51.5 (C2), 42.7 (C5), 36.3 (C1), 35.6 (C7), 26.3 (C6). HRMS (ESI+) 
Calculated for C17H17NNaO2: 290.1151. Found [M+Na]
+: 290.1155. 
The relative stereochemistry of this compound was determined by nOe experiments as 




To a solution of spirocycle 214 (43.7 mg, 0.15 mmol) in anhydrous CH2Cl2 (1 mL) at 0 
oC and 
under an atmosphere of nitrogen were added benzyl isocyanate (37.0 μL, 0.30 mmol) and Et3N 
(84.0 μL, 0.60 mmol). The reaction mixture was stirred at 0 oC for 3 hours and then overnight 
at room temperature until completion by TLC analysis. The reaction mixture was quenched 
with saturated aqueous NH4Cl (1 mL) and extracted with EtOAc (3 × 5 mL). The combined 
organic extracts were washed with brine (5 mL), dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo. Purification by flash column chromatography (1% MeOH:CH2Cl2) 
afforded 265 (27.7 mg, 59%) as a colourless solid; νmax/cm
-1 (solid) 3316 (m), 2968 (m), 2929 
(m), 2871 (m), 1660 (s), 1638 (s), 1528 (s), 1376 (m), 1337 (m); 1H NMR (400 MHz, CDCl3) 
δ 7.30 – 7.18 (5H, m, ArCH), 6.77 (1H, dd, J = 10.0, 3.0 Hz, C7/C12-H), 6.70 (1H, dd, J = 
10.5, 3.0 Hz, C7/C12-H), 6.30 (2H, ddd, J = 10.5, 4.5, 2.0 Hz, C8-H, C11-H), 4.65 – 4.59 (1H, 
br s, NH), 4.38 – 4.28 (2H, m, C13-H2), 3.80 (1H, t, J = 9.0 Hz, C1-H), 3.58 – 3.51 (1H, m, 
C1-H’), 2.27 (1H, dt, J = 12.5, 6.5 Hz, C2-H), 2.15 – 2.06 (1H, m, C3-H), 1.72 – 1.60 (1H, m, 
C2-H’), 1.26 – 1.16 (1H, m, C4-H), 1.07 – 0.95 (1H, m, C4-H’), 0.88 (3H, t, J = 7.5 Hz, C5-H3); 
13C NMR (101 MHz, CDCl3) δ 185.1 (C9), 155.7 (NC=O), 153.2 (C7/12), 148.5 (C7/C12), 




139.1 (ArC), 130.2 (C8/C11), 129.3 (C8/C11), 128.7 (2 × ArCH), 127.6 (2 × ArCH), 127.4 
(ArCH), 64.8 (C6), 52.5 (C3), 46.5 (C1), 44.6 (C13), 29.2 (C2) , 21.9 (C4), 12.6 (C5); HRMS 





General procedure M: The preceding urea 265 (31.2 mg, 0.10 mmol) and lithium 
bis(trimethylsilyl)amide (1.0 M in THF, 0.15 mL, 0.15 mmol) in anhydrous THF (1 mL) were 
employed. The reaction was stirred at this temperature overnight until completion by TLC 
analysis. The reaction was warmed to 0 oC and quenched with saturated aqueous NH4Cl (0.3 
mL) and extracted with EtOAc (3 × 1 mL). The combined organic extracts were washed with 
brine (5 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. Purification by 
flash column chromatography (1% MeOH:CH2Cl2) afforded 266 (29.0 mg, 93%) as a 3:1 
mixture of diastereomers and as a colourless solid; νmax/cm
-1 (solid) 2963 (m), 2926 (m), 2901 
(m), 2878 (m), 1683 (s, br), 1405 (m). 
Spectroscopic data for the major diastereomer 266a: 1H NMR (400 MHz, CDCl3) δ 7.32 – 
7.20 (5H, m, ArCH), 6.49 (1H, d, J = 10.5 Hz, C7-H), 6.13 (1H, d, J = 10.5 Hz, C8-H), 4.80 
(1H, d, J = 15.0 Hz, C13-H), 4.00 (1H, d, J = 15.0 Hz, C13-H’), 3.79 – 3.71 (1H, m, C1-H), 
3.66 (1H, t, J = 6.5 Hz, C12-H), 3.34 (1H, ddd, J = 11.5, 8.5, 3.0 Hz, C1-H’), 2.67 (1H, dd, J 
= 16.0, 5.5 Hz, C11-H), 2.57 (1H, dd, J = 16.0, 7.0 Hz, C11-H’), 2.38 – 2.30 (1H, m, C2-H), 
1.79 – 1.70 (2H, m, C2-H’, C3-H), 1.33 – 1.16 (2H, m, C4-H2), 0.83 (3H, t, J = 7.0 Hz, C5-H3); 
13C NMR (101 MHz, CDCl3) δ 195.7 (C9), 161.6 (C14), 142.8 (C7), 136.4 (ArC), 129.4 (C8), 
128.9 (2 × ArCH), 128.3 (2 × ArCH), 127.9 (ArCH), 65.3 (C6), 57.0 (C12), 49.6 (C3), 45.4 
(C13), 44.1 (C1), 39.6 (C11), 31.2 (C2), 22.5 (C4), 13.2 (C5). 
Spectroscopic data for the minor diastereomer 266b: 1H NMR (400 MHz, CDCl3) δ 7.34 – 
7.19 (5H, m, ArCH), 6.39 (1H, d, J = 10.0 Hz, C7-H), 6.08 (1H, d, J = 10.0 Hz, C8-H), 4.76 
(1H, d, J = 15.5 Hz, C13-H), 4.01 (1H, d, J = 15.5 Hz, C13-H’), 3.87 (1H, dd, J = 12.0, 7.0 Hz, 
C1-H), 3.70 (1H, s, C12-H), 3.14 (1H, td, J = 12.0, 5.0 Hz, C1-H’), 2.68 (1H, dd, J = 17.5, 2.5 
Hz, C11-H’), 2.43 (1H, dd, J = 17.5, 4.5 Hz, C11-H’), 2.13 – 2.00 (2H, m, C2-H, C3-H), 1.55 




– 1.45 (1H, m, C4-H), 1.32 – 1.16 (2H, m, C2-H’, C4-H’), 0.95 (3H, t, J = 7.5 Hz, C5-H3); 
13C NMR (101 MHz, CDCl3) δ 194.6 (C9), 162.7 (C14), 149.5 (C7), 136.1 (ArC), 128.8 (2 × 
ArCH), 128.0 (C8), 128.0 (2 × ArCH), 127.7 (ArCH), 64.0 (C6), 56.0 (C12), 50.1 (C3) 47.5 
(C1), 45.3 (C13), 36.6 (C11), 32.5 (C2), 20.9 (C4), 13.2 (C5). 
HRMS (ESI+) Calculated for C19H23N2O2: 311.1754. Found [M+H]
+: 311.1753. 
 
(1R*, 6aR*, 10aS*) and (1S*, 6aR*, 10aS*)-1-Ethyl-6-phenyl-2,3,6a,7-tetrahydro-1H,5H-




General procedure N: Spirocycle 214 (45.0 mg, 0.154 mmol), phenyl isocyanate (34.0 μL, 
0.308 mmol) and Et3N (86.0 μL, 0.618 mmol) in anhydrous CH2Cl2 (0.77 mL, 0.2 M) were 
employed. The reaction was stirred at this temperature for 2 hours before warming to room 
temperature and stirring overnight. Purification by flash column chromatography (33% 
EtOAc:hexane) afforded 267 (34.1 mg, 75%) as a colourless solid. A mixture of diastereomers 
267a and 267b were obtained in a 4:1 ratio; Rf = 0.6 (3% MeOH:CH2Cl2); νmax / cm
-1 (solid) 
2965 (m), 2926 (m), 2885 (m), 1692 (s), 1683 (s), 1380 (s), 1309 (s). 
Data for the major diastereomer 267a: m.p.: 148-151 oC (EtOAc:hexane); 1H NMR (400 MHz, 
CDCl3) δ 7.37 – 7.30 (4H, m, ArCH), 7.17 – 7.11 (1H, m, ArCH), 6.57 (1H, d, J = 10.5 Hz, 
C7-H), 6.21 (1H, d, J = 10.5 Hz, C8-H), 4.57 (1H, app. t, J = 6.0 Hz, C11-H), 3.87 – 3.78 (1H, 
m, C1-H), 3.43 – 3.35 (1H, m, C1-H’), 2.84 (1H, dd, J = 16.5, 6.0 Hz, C10-H), 2.66 (1H, dd, J 
= 16.5, 7.0 Hz, C10-H’), 2.45 – 2.36 (1H, m, C2-H), 2.08 – 1.98 (1H, m, C3-H), 1.88 – 1.76 
(1H, m, C2-H’), 1.54 – 1.44 (1H, m, C4-H), 1.39 – 1.28 (1H, m, C4-H’), 0.99 (3H, t, J = 7.5 
Hz, C5-H3); 
13C NMR (101 MHz, CDCl3) δ 195.6 (C9), 159.4 (C12), 142.4 (C7), 137.3 (ArC), 
129.6 (C8), 129.3 (2 × ArCH), 125.1 (2 × ArCH), 122.2 (ArCH), 64.8 (C6), 58.6 (C11), 50.1 
(C3), 43.9 (C1), 39.6 (C10), 30.9 (C2), 25.6 (C4), 13.2 (C5).  
The minor diastereomer could not be isolated in a pure form. 




Spectroscopic data for the minor diastereomer 267b: Characteristic peaks only: 1H NMR (400 
MHz, CDCl3) δ 6.48 (1H, d, J = 10.0 Hz, C7-H), 6.14 (1H, d, J = 10.0 Hz, C8-H), 4.51 – 4.48 
(1H, m, C11-H), 3.94 – 3.87 (1H, m, C1-H), 3.20 (1H, td, J = 11.5, 5.0 Hz, C1-H’), 2.78 (1H, 
dd, J = 17.5, 3.0 Hz, C10-H), 2.57 (1H, dd, J = 17.5, 5.0 Hz, C10-H’), 1.05 (3H, t, J = 7.5 Hz, 
C5-H3). 
HRMS (ESI+) Calculated for C18H20N2NaO2: 319.1417. Found [M+Na]
+: 319.1426. 
The relative stereochemistry of the major diastereomer of this compound was determined by 
nOe experiments as indicated on the compound structure. nOes were observed between C3-H 




General procedure L: Spirocyclic amine 222 (0.150 mmol), phenylacetyl chloride (40.0 μL, 
0.300 mmol) and K3PO4 (127.4 mg, 0.600 mmol) in anhydrous THF (0.75 mL) were employed. 
Purification by flash column chromatography (EtOAc) afforded 268 (34.0 mg, 81%) as a 9:1 
mixture of rotamers A:B and as a yellow oil; Rf = 0.4 (3% MeOH:CH2Cl2); νmax / cm
-1 (film) 
2972 (m), 2878 (m), 1675 (s), 1642 (s), 1406 (s); 1H NMR (400 MHz, CDCl3) δ 7.32 – 7.27 
(2H, m, ArCH, A+B), 7.25 – 7.20 (2.90H, m, ArCH, A+B), 7.13 – 7.09 (0.10H, m, 0.10 × 
ArCH, B), 6.93 (0.10H, dd, J = 10.0, 2.5 Hz, 0.10 × C8-H, B), 6.82 (0.90H, dd, J = 10.0, 2.5 
Hz, 0.90 × C8-H, A), 6.18 – 6.09 (1.10H, m, 1.00 × C9-H, A+B, 0.10 × C5-H, B), 5.90 – 5.87 
(0.90H, m, 0.90 × C5-H, A), 3.97 – 3.91 (0.10 H, m, 0.1 × C1-H, B), 3.78 – 3.69 (0.9H, m, 0.90 
× C1-H, A), 3.67 – 3.60 (2.8H, m, 1.00 × C1-H’, A+B, 1.80 × C12-H2, A), 3.12 (0.20H, m, 0.20 
× C12-H2, B), 2.28 – 2.22 (0.10H, m, 0.10 × C3-H, B), 2.21 – 2.12 (1H, m, 0.90 × C2-H, A, 
C3-H’, B), 2.10 – 1.95 (2.30 H, m, 1.00 × C3-H’, A+B, 1.00 × C2-H’, A+B, 0.30 × C7-H3, B), 
1.92 (2.70H, s, C7-H3, A), 1.89 – 1.82 (1H, m, 0.90 × C3-H, A, 0.10 × C2-H, B); 
13C NMR 
(101 MHz, CDCl3) δ 208. 6 (C10, B), 200.1 (C10, A), 170.3 (C11, B), 168.6 (C11, A), 145.5 
(C8, B), 145.0 (C8, A), 140.3 (C5, B), 137.5 (C5, A), 134.5 (ArC, A+B), 129.6 (2 × ArCH, B), 
129.2 (2 × ArCH, A), 128.7 (C6, A + B) 128.6 (2 × ArCH, A), 128.3 (2 × ArCH, B), 126.8 
(ArCH, A), 126.6 (ArCH, B), 125.8 (C9), 125.1 (C9, B), 70.1 (C4, B), 69.3 (C4, A), 49.0 (C1, 
B), 48.8 (C1, A), 41.9 (C12, A), 40.7 (C12, B), 37.6 (C2 or C3, A + B), 24.0 (C2 or C3 A + B), 









General procedure M: The preceding spirocyclic amide 268 (28.1 mg, 0.10 mmol) and 1.5 
equivalents of lithium bis(trimethylsilyl)amide (1.0 M in THF) in anhydrous THF (1 mL) were 
employed. Purification by flash column chromatography (1% MeOH:CH2Cl2) afforded 269 
(18.9 mg, 67%, > 15:1 d.r.) as a colourless solid; m.p.: 150-152 oC (EtOAc:hexane); Rf = 0.5 
(3% MeOH:CH2Cl2); νmax / cm
-1 (solid) 3356 (br m), 2969 (m), 2942 (m), 2880 (m), 1673 (s), 
1402 (s); 1H NMR (400 MHz, CDCl3) δ 7.38 – 7.31 (3H, m, ArCH), 7.28 – 7.24 (2H, m, 
ArCH), 5.78 (1H, dd, J = 10.0, 1.5 Hz, C8-H), 5.53 (1H, m, C5-H), 5.38 (1H, d, J = 10.0 Hz, 
C9-H), 4.27 (1H, s, C11-H), 3.89 (1H, ddd, J = 12.0, 7.5, 4.5 Hz, C1-H), 3.16 (1H, ddd, J = 
12.0, 7.5, 1.5 Hz, C1-H’), 2.54 (1H, ddd, J = 13.0, 8.5, 6.0 Hz, C3-H), 2.07 – 1.97 (1H, m, 
C2-H), 1.95 – 1.87 (1H, m, C2-H’), 1.85 (1H, d, J = 1.5 Hz, C7-H3), 1.44 (1H, dt, J = 13.0, 7.5 
Hz, C3-H’); 13C NMR (101 MHz, CDCl3) δ 172.8 (C12), 134.2 (2 × ArCH), 131.3 (C9), 131.2 
(ArC), 128.6 (2 × ArCH), 128.6 (C6), 128.0 (ArCH), 127.0 (C5), 126.7 (C8), 79.1 (C10), 72.7 
(C4), 61.6 (C11), 42.9 (C1), 30.6 (C3), 26.2 (C2), 21.2 (C7); HRMS (ESI+) Calculated for 
C18H19NNaO2: 304.1308. Found [M+Na]
+: 304.1322. 
The relative stereochemistry of this compound was determined unambiguously using X-ray 
crystallography. 









General procedure N: Spirocyclic amine 222 (0.15 mmol), 1.1 equivalents of phenyl 
isocyanate (18 μL, 0.17 mmol) and Et3N (84 μL, 0.60 mmol) in anhydrous CH2Cl2 (0.2 M) 
were employed. The reaction was stirred at this temperature for 3 hours then heated to 40 oC 
and stirred overnight, monitoring by TLC analysis. Purification by flash column 
chromatography (1% MeOH:CH2Cl2) afforded 270 (28.9 mg, 68%) as a colourless solid; m.p.: 
110-113 oC (EtOAc:hexane); Rf = 0.6 (3% MeOH:CH2Cl2); νmax / cm
-1 (solid) 2987 (m), 2953 
(m), 2923 (m), 1726 (s), 1693 (s); 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.35 (4H, m, ArCH), 
7.21 – 7.16 (1H, m, ArCH), 5.59 – 5.55 (1H, m, C8-H), 4.74 (1H, s, C5-H), 3.94 – 3.87 (1H, 
m, C1-H), 3.68 – 3.60 (1H, m, C9-H), 2.88 (1H, ddd, J = 12.0, 9.0, 6.5 Hz, C1-H’), 2.79 – 2.70 
(2H, m, C9-H’, C3-H), 2.00 – 1.85 (2H, m, C2-H2), 1.55 – 1.46 (1H, m, C3-H’), 1.41 (3H, s, 
C7-H3); 
13C NMR (101 MHz, CDCl3) δ 204.6 (C10), 161.5 (C11), 138.9 (ArC), 134.4 (C6), 
129.3 (2 × ArCH), 125.8 (ArCH), 123.9 (2 × ArCH), 121.6 (C8), 70.9 (C4), 66.5 (C5), 45.9 
(C1), 36.5 (C9), 29.4 (C3), 23.7 (C2), 22.6 (C7); HRMS (ESI+) Calculated for C17H18N2NaO2: 
305.1260. Found [M+Na]+: 305.1273. 




The relative stereochemistry was determined using nOe analysis as indicated on the compound 
structure. An nOe was observed between C5-H and C3-H2. 
 
tert-Butyl 2-oxo-2H-spiro[naphthalene-1,2'-pyrrolidine]-1'-carboxylate (277b) 
 
General procedure O: N-Tosyloxycarbamate 227 (47.2 mg, 0.1 mmol), 9-Hydroxy-1-
(phenylmethyl)cinchonanium chloride 295 (4.2 mg, 10 mol%), Cs2CO3 (65.2 mg, 200 mol%) 
in anhydrous PhMe (0.1 M) were employed. The reaction was stirred at 30 oC for 48 hours. 
Purification by flash column chromatography (20% EtOAc:hexane) afforded 277b (8.4 mg, 
28%, 22% e.e.) as a colourless solid. This compound exists as an approximately 7:2 mixture of 
rotamers A and B.  SFC conditions: column: CHIRALPACK IA, elute: 3.0% MeOH/CO2, 
detector: 250 nm, flow rate: 2.0 mL/min, retention times: (major enantiomer) t1 = 6.3 min, 
(minor enantiomer) t2 = 7.2 min; 
1H NMR (400 MHz, CDCl3) δ 7.43 – 7.34 (3H, m), 7.32 – 
7.24 (2H, m), 6.18 (1H, d, J = 10.0 Hz), 4.00 – 3.88 (1H, m), 3.84 – 3.75 (1H, m), 2.36 – 2.25 
(1H, m), 2.17 – 2.07 (1H, m), 2.01 – 1.85 (2H, m), 1.39 (2H, s), 1.00 (7H, s); 13C NMR (101 
MHz, CDCl3) δ 
13C NMR (101 MHz, CDCl3) δ 200.8, 153.3, 147.4, 146.5, 145.1, 144.9, 130.4, 
129.7, 129.3, 129.1, 127.3, 124.9, 124.5, 124.4, 124.2, 80.2, 79.9, 71.9, 49.4, 48.9, 42.2, 41.8, 
28.6, 27.9, 22.6, 21.7. 
The spectroscopic properties were consistent with the data available in the literature.97 
 
Benzyl (3-(2-((tert-butyldimethylsilyl)oxy)naphthalen-1-yl)propyl)(tosyloxy)carbamate  
  
General procedure G: Alcohol 168 (1.58 g, 5.0 mmol), PPh3 (1.57 g, 6.0 mmol), DIAD (1.18 
mL, 6.0 mmol) and CbzNHOTs (1.93 g, 6.0 mmol) in anhydrous THF (20 mL) were employed. 
Purification by flash column chromatography (gradient, eluent: 5 – 10% EtOAc:hexane) 
afforded the title compound (1.64 g, 53%) as a viscous, colourless oil; νmax / cm
-1 (film) 2954 
(m), 2929 (m), 1724 (s), 1381 (s), 1177 (s); 1H NMR (400 MHz, CDCl3) δ 7.84 (1H, d, J = 8.5 




Hz, ArCH), 7.76 (1H, dd, J = 8.0, 1.5 Hz, ArCH), 7.72 (2H, d, J = 8.5 Hz, ArCH), 7.60 (1H, 
d, J = 9.0 Hz, ArCH), 7.45 (1H, ddd, J = 8.5, 6.5, 1.5 Hz, ArCH), 7.35 – 7.25 (4H, m, ArCH), 
7.13 – 7.08 (4H, m, ArCH), 7.05 (1H, d, J = 9.0 Hz, ArCH), 4.87 (2H, s, Cbz CH2), 3.75 (2H, 
br s, C1-H2), 3.00 (2H, t, J = 8.0 Hz, C3-H2), 2.35 (3H, s, Ts CH3), 2.00 – 1.89 (2H, m, C2-H2), 
1.04 (9H, s, TBS (CH3)3), 0.25 (6H, s, Si(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 156.7 (Cbz 
C=O), 150.7 (ArC), 145.7 (ArC), 135.0 (ArC), 133.3 (ArC), 131.1 (ArC), 129.6 (ArCH), 129.5 
(ArCH), 128.6 (ArC), 128.6 (ArCH), 128.5 (ArCH), 128.2 (ArCH), 127.6 (ArCH), 126.4 
(ArCH), 124.1 (ArC), 123.4 (ArCH), 123.2 (ArCH), 120.4 (ArCH), 68.7 (Cbz CH2), 53.3 (C1), 
26.2 (C2) 26.0 (TBS C(CH3)3), 22.7 (C3), 21.9 (Ts CH3), 18.4 (TBS C(CH3)3), -3.7 (TBS 
Si(CH3)2); HRMS (ESI
+) Calculated for C34H41NNaO6SSi: 642.2316. Found [M+Na]
+: 
642.2279. 
Benzyl (3-(2-hydroxynaphthalen-1-yl)propyl)(tosyloxy)carbamate (299) 
 
General procedure H: Benzyl (3-(2-((tert-butyldimethylsilyl)oxy)naphthalen-1-
yl)propyl)(tosyloxy)carbamate (1.24 g, 2.0 mmol), and 1:1 TBAF:HOAc solution (0.1 M in 
THF, 2.0 mmol) in THF (30 mL) were employed. Purification by flash column chromatography 
(20% EtOA:hexane) afforded 299 (740 mg, 73%) as a pale-orange, viscous oil; νmax / cm
-1 
(film) 3406 (br), 1722 (s), 1379 (s), 1190 (s), 1176 (s); 1H NMR (400 MHz, CDCl3) δ 7.83 (1H, 
d, J = 8.5 Hz, ArCH), 7.79 – 7.70 (3H, m, ArCH), 7.61 (1H, d, J = 9.0 Hz, ArCH), 7.46 (1H, 
ddd, J = 8.5, 7.0, 1.5 Hz, ArCH), 7.34 – 7.26 (4H, m, ArCH), 7.16 – 7.09 (4H, m, ArCH), 7.03 
(1H, d, J = 9.0 Hz, ArCH), 4.90 (s, 2H, Cbz CH2), 3.78 (2H, t, J = 7.0 Hz, C1-H2), 3.04 (2H, t, 
J = 8.0 Hz, C3-H2), 2.36 (s, 3H, Ts CH3); 2.07 – 1.98 (2H, m, C2-H2); 
13C NMR (101 MHz, 
CDCl3) δ 157.2 (Cbz C=O), 150.9 (ArC), 145.9 (ArC), 134.9 (ArC), 133.2 (ArC), 130.9 (ArC), 
129.7 (2 × ArCH), 129.5 (2 × ArCH), 128.8 (ArC), 128.6 (2 × ArCH), 128.3 (2 × ArCH), 128.1 
(ArCH), 126.7 (ArCH), 123.2 (ArCH), 122.8 (ArCH), 118.7 (ArC), 118.1 (ArCH), 68.9 
(OCH2), 53.4 (C1), 26.3 (C2), 22.2 (C3), 21.9 (Ts CH3); HRMS (ESI
+) Calculated for 








Benzyl 2-oxo-2H-spiro[naphthalene-1,2'-pyrrolidine]-1'-carboxylate (170) 
 
General procedure O: The preceding N-tosyloxycarbamate 299 (50.6 mg, 0.1 mmol), 
(8a,9R)-Cinchonanium,9-hydroxy-6'-methoxy-1-(phenylmethyl) chloride 298 (4.5 mg, 10 
mol%), Cs2CO3 (65.2 mg, 200 mol%) in anhydrous PhMe (0.1 M) were employed. The reaction 
was stirred at 30 oC for 48 hours. Purification by flash column chromatography (20% 
EtOAc:hexane) afforded 170 (20.7 mg, 62%, 54% e.e.) as a colourless oil. This compound 
exists as an approximately 3:2 mixture of rotamers A and B. SFC conditions: column: 
CHIRALPACK IA, elute: 10.0% MeOH/CO2, detector: 250 nm, flow rate: 2.0 mL/min, 
retention times: (major enantiomer) t1 = 8.4 min, (minor enantiomer) t2 = 7.5 min. 
Characteristic data for 170 has been provided earlier (section 6.3). 
  




6.4 Experimental procedure for the studies in Chapter 3 
(E)-5-Phenylpent-4-enoic acid (343) 
 
The title compound 343 was prepared according to a literature procedure.317 




General procedure B: The preceding carboxylic acid 343 (930 mg, 5.26 mmol), and 2.0 
equivalents of LiAlH4 (10.5 mL, 10.5 mmol, 1M in THF) in anhydrous THF (25 mL) were 
employed. Purification by flash column chromatography (gradient, eluent 20 – 33% EtOAc: 
petroleum ether) afforded 344 (710 mg, 83%) as a colourless oil; 1H NMR (400 MHz, CDCl3) 
δ 7.43 – 7.27 (4H, m), 7.23 – 7.18 (1H, m), 6.42 (1H, d, J = 16.0 Hz), 6.23 (1H, dt, J = 16.0, 
7.0 Hz), 3.72 – 3.66 (2H, m), 2.34 – 2.26 (2H, m), 1.80 – 1.71 (2H, m); 13C NMR (101 MHz, 
CDCl3) δ 137.7, 130.5, 130.2, 128.6, 127.1, 126.1, 62.5, 32.3, 29.4. 
The Spectroscopic properties were consistent with the data available in the literature.318 
 
tert-Butyl (E)-(5-phenylpent-4-en-1-yl)(tosyloxy)carbamate (345) 
 
General procedure G: The preceding alcohol 344 (550 mg, 3.39 mmol), PPh3 (1.07 g, 4.07 
mmol), DIAD (0.79 mL, 4.07 mmol) and BocNHOTs (1.17 g, 4.07 mmol) in anhydrous THF 
(13 mL) were employed. Purification by flash column chromatography (5% EtOAc: petroleum 
ether) afforded 345 (1.36 g, 93%) as a colourless solid; Rf = 0.55 (33% EtOAc:hexane); m.p.: 
61-63 oC (Et2O:hexane); νmax / cm
-1 (film) 2980 (m), 2933 (m), 1749 (m), 1718 (s), 1597 (m), 
1368 (s), 1177 (s), 1152 (s); 1H NMR (400 MHz, CDCl3) δ 7.86 (2H, d, J = 8.5 Hz, Ts ArCH), 
7.33 – 7.25 (6H, m, ArCH, Ts ArCH), 7.21 – 7.16 (1H, m, ArCH), 6.38 (1H, d, J = 16.0 




Hz, C5-H), 6.18 – 6.10 (1H, m, C4-H), 3.65 (2H, br s, C1-H2), 2.43 (3H, Ts CH3), 2.22 – 2.15 
(2H, m, C3-H2), 1.85 – 1.75 (2H, m, C2-H2), 1.24 (9H, s, Boc (CH3)3); 
13C NMR (101 MHz, 
CDCl3) δ 155.6 (Boc C=O), 145.8 (Ts ArC), 137.7 (ArC), 131.4 (Ts ArC), 130.9 (C5), 129.8 
(2 × Ts ArCH), 129.7 (2 × Ts ArCH), 129.3 (C4), 128.6 (2 × ArCH), 127.1 (2 × ArCH), 126.1 
(ArCH), 83.4 (Boc C(CH3)3), 52.6 (C1), 30.1 (C3), 27.8 (Boc (CH3)3), 25.6 (C2), 21.8 (Ts 
CH3); HRMS (ESI
+) Calculated for C23H29NNaO5S: 454.1659. Found [M+Na]
+: 454.1652. 
(5S*,6S*)-6-Phenyl-1-azabicyclo[3.1.0]hexane (346)  
 
General procedure P: The preceding N-tosyloxycarbamate 345 (48.8 mg, 0.11 mmol) and 
TFA (17 μL, 0.23 mmol) in anhydrous TFE (1.1 mL) were employed. The reaction was stirred 
at room temperature for 24 hours. Purification by flash column chromatography (~0.1% Et3N 
in 33% Et2O:pentane) afforded 346 (13.7 mg, 76%) as a colourless oil; νmax / cm
-1 (film) 2953 
(m), 2972 (m), 1605 (m), 1452 (m), 1078 (m); 
1H NMR (400 MHz, CDCl3) δ 7.30 – 7.18 (5H, 
m, ArCH), 3.21 (1H, ddd, J = 12.0, 8.5, 1.5 Hz, C1-H), 3.06 (1H, td, J = 11.5, 7.5 Hz, C1-H’), 
2.44 (1H, dd, J = 5.0, 2.5 Hz, C4-H), 2.36 (1H, d, J = 2.5 Hz, C5-H), 2.24 (1H, ddd, J = 13.5, 
8.5, 1.0 Hz, C3-H), 2.03 –  1.94 (1H, m, C3-H’), 1.78 – 1.70 (1H, m, C2-H), 1.67 – 1.56 (1H, 
m, C2-H’); 13C NMR (101 MHz, CDCl3) δ 140.4 (ArC), 128.4 (ArCH), 126.8 (ArCH), 126.2 
(ArCH), 53.3 (C1), 50.9 (C4), 39.8 (C5), 26.8 (C3), 20.8 (C2); HRMS (ESI
+) Calculated for 
C11H14N: 160.1121. Found [M+H]
+: 160.1126.  
The spectroscopic properties were consistent with the data available in the literature.319 
 
tert-Butyl (E)-(benzoyloxy)(5-phenylpent-4-en-1-yl)carbamate (347) 
 
General procedure G: Alcohol 344 (162 mg, 1.0 mmol), PPh3 (315 mg, 1.2 mmol), DIAD 
(0.24 mL, 1.2 mmol) and BocNHOBz (285 mg, 1.2 mmol) in anhydrous THF (4 mL) were 
employed. Purification by flash column chromatography (5% EtOAc:petroleum ether) afforded 
347 (300 mg, 79%) as a pale-yellow oil; νmax / cm
-1 (film) 2977 (m), 2934 (m), 1763 (s), 1711 




(s), 1242 (s), 1155 (s); 1H NMR (400 MHz, CDCl3) δ 8.10 – 8.06 (2H, m, ArCH), 7.62 (1H, 
td, J = 7.3, 1.3 Hz, ArCH), 7.48 (2H, t, J = 7.8 Hz, ArCH), 7.33 – 7.25 (4H, m, ArCH), 7.21 – 
7.16 (1H, m, ArCH), 6.41 (1H, d, J = 16.0 Hz, C5-H), 6.21 (1H, dt, J = 16.0, 6.5 Hz, C4-H), 
3.76 (2H, t, J = 7.0 Hz, C1-H2), 2.33 (2H, td, J = 8.0, 7.5, 6.5 Hz, C3-H2), 1.84 (1H, app. qn, J 
= 7.4 Hz, C2-H2), 1.47 (9H, s, Boc (CH3)3).; 
13C NMR (101 MHz, CDCl3) δ 164.8 (Bz, C=O), 
155.0 (Boc C=O), 137.7 (ArC), 133.9 (ArCH), 130.8 (C5), 130.0 (ArCH), 129.6 (C4), 128.8 
(ArCH), 128.6 (ArCH), 127.8 (ArC), 127.1 (ArCH), 126.1 (ArCH), 82.5 (Boc C(CH3)3), 50.3 
(C1), 30.2 (C3), 28.3 (Boc (CH3)3), 27.2 (C2). 
 
tert-Butyl (E)-((methylsulfonyl)oxy)(5-phenylpent-4-en-1-yl)carbamate (348) 
 
General procedure G: Alcohol 344 (162 mg, 1.0 mmol), PPh3 (315 mg, 1.2 mmol), DIAD 
(0.24 mL, 1.2 mmol) and BocNHOMs (253 mg, 1.2 mmol) in anhydrous THF (4 mL) were 
employed. Purification by flash column chromatography (5% EtOAc:petroleum ether) afforded 
348 (330 mg, 93%) as a colourless solid; νmax / cm
-1 (solid) 2939 (m), 1726 (s), 1361 (s), 1337 
(s), 1178 (s), 1150 (s); 1H NMR (400 MHz, CDCl3) δ 7.35 – 7.26 (4H, m, ArCH), 7.22 – 7.17 
(1H, m, ArCH), 6.41 (1H, d, J = 16.0 Hz, C5-H), 6.18 (1H, dt, J = 16.0, 7.0 Hz, C4-H), 3.74 
(2H, br s, C1-H2), 3.14 (3H, s, Ms CH3), 2.28 – 2.21 (2H, m, C3-H2), 1.92 – 1.82 (2H, m, 
C2-H2), 1.52 (9H, s, Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) δ 155.7 (Boc C=O), 137.6 
(ArC), 131.0 (C5), 129.1 (C4), 128.6 (ArCH), 127.2 (ArCH), 126.1 (ArCH), 84.3 (Boc 
C(CH3)3), 53.1 (C1), 37.1 (Ms CH3), 30.1 (C3), 28.2 (Boc (CH3)3), 25.6 (C2); HRMS (ESI
+) 





CuI (32.4 mg, 0.17 mmol) and Pd(PPh3)4 (97.1 mg, 84 μmol) were added to a solution of 
4-pentyn-1-ol (0.93 mL, 10.0 mmol) and iodobenzene (2.24 mL, 20.0 mmol) in triethylamine 
(8 mL) and THF (20 mL) under an atmosphere of N2. The reaction was stirred at room 
temperature overnight and monitored by TLC. Upon completion, the reaction mixture was 




filtered through Celite® and the filtrate concentrated in vacuo. Purification by flash column 
chromatography (20% EtOAc:hexane) afforded 349 (1.38 g, 86%) as a colourless oil; 1H NMR 
(400 MHz, CDCl3) δ 7.41 – 7.37 (2H, m), 7.30 – 7.25 (3H, m), 3.79 (2H, t, J = 6.0 Hz), 2.52 
(2H, t, J = 7.0 Hz), 2.34 (1H, br s), 1.88 – 1.81 (2H, m); 13C NMR (101 MHz, CDCl3) δ 131.6, 
128.3, 127.7, 123.8, 89.5, 81.1, 61.7, 31.4, 16.0. 




To a solution of the preceding alkyne 349 (928 mg, 5.79 mmol) and quinoline (0.20 mL, 1.73 
mmol) in EtOAc (15 mL) was added 5% Lindlar catalyst (153.5 mg). The reaction flask was 
fitted with a balloon of hydrogen and stirred at room temperature, monitoring by TLC analysis. 
Upon completion (~1 hour), the reaction was filtered through Celite® and concentrated in 
vacuo. Purification by flash column chromatography (CH2Cl2) afforded (Z)-344 (895 mg, 95%) 
as a colourless oil; 1H NMR (400 MHz, CDCl3) δ 7.37 – 7.21 (5H, m), 6.46 (1H, d, J = 11.5 
Hz), 5.68 (1H, dt, J = 11.5, 7.5 Hz), 3.65 (2H, t, J = 6.5 Hz), 2.46 – 2.39 (2H, m), 1.76 – 1.69 
(2H, m); 13C NMR (101 MHz, CDCl3) δ 137.6, 132.2, 129.5, 128.8, 128.3, 126.7, 62.4, 32.9, 
25.0.  
The spectroscopic properties were consistent with the data available in the literature.321 
 
tert-Butyl (Z)-(5-phenylpent-4-en-1-yl)(tosyloxy)carbamate ((Z)-345)  
 
General procedure G: The preceding alcohol (Z)-344 (687 mg, 4.24 mmol), PPh3 (1.34 g, 
5.09 mmol), DIAD (0.99 mL, 5.09 mmol) and BocNHOTs (1.46 g, 5.09 mmol) in anhydrous 
THF (17 mL) were employed. Purification by flash column chromatography  (5% 
EtOAc:hexane) afforded (Z)-345 (1.81 g, 99%) as a colourless solid; Rf = 0.50 (20% 
EtOAc:hexane); m.p.: 45-47 oC (CH2Cl2:hexane); νmax / cm
-1 (solid) 2988 (m), 2939 (m), 1714 
(s), 1369 (s), 1176 (s), 1152 (s); 1H NMR (400 MHz, CDCl3) δ 7.85 (2H, d, J = 8.5 Hz, Ts 




ArCH), 7.35 – 7.29 (4H, m, Ts ArCH, ArCH), 7.25 – 7.19 (3H, m, ArCH), 6.44 (1H, d, J = 
11.5 Hz, C5-H), 5.60 (1H, dt, J = 11.5, 7.0 Hz, C4-H), 3.63 (2H, br s, C1-H2), 2.44 (3H, s, Ts 
CH3), 2.34 – 2.27 (2H, m, C3-H2), 1.83 – 1.73 (2H, m, C2-H2), 1.21 (9H, s, Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) δ 155.6 (Boc C=O), 145.8 (Ts ArC), 137.5 (ArC), 131.4 (Ts 
ArC), 131.3 (C4), 129.9 (C5), 129.8 (2 × Ts ArCH), 129.7 (2 × Ts ArCH), 128.8 (ArCH), 128.3 
(ArCH), 126.8 (ArCH), 83.4 (Boc C(CH3)3), 52.6 (C1), 27.7 (Boc (CH3)3), 26.2 (C2), 25.7 
(C3), 21.8 (Ts CH3); HRMS (ESI




(5R*,6S*)-6-Phenyl-1-azabicyclo[3.1.0]hexane TsOH salt (350) 
 
General procedure P: The preceding N-tosyloxycarbamate (Z)-345 (43.2 mg, 0.1 mmol) and 
TFA (15 μL, 0.2 mmol) in anhydrous TFE (1.0 mL, 0.1 M) were employed. The free base of 
the title compound was unstable to column chromatography and so upon completion (24 hours) 
the reaction mixture was concentrated in vacuo to afford 350 (78% yield as determined by 
analysis of 1H NMR with addition of 1,3,5-trimethoxybenzene as an internal standard); νmax / 
cm-1 (film) 3411 (br), 1771 (m), 1150 (s), 1121 (s); 1H NMR (400 MHz, CD3OD) δ 7.72 (2H, 
d, J = 8.0 Hz, Ts ArCH), 7.53 – 7.39 (5H, m, ArCH), 7.23 (2H, d, J = 8.0 Hz, Ts ArCH), 4.39 
(1H, d, J = 8.0 Hz, C5-H), 4.08 – 4.04 (1H, m, C4-H), 3.60 – 3.50 (1H, m, C1-H), 3.43 – 3.35 
(1H, m, C1-H’), 2.47 – 2.32 (5H, m, C3-H2, Ts CH3), 1.83 – 1.73 (1H, m, C2-H), 0.60 – 0.46 
(1H, m, C2-H’); 13C NMR (101 MHz, CDCl3) δ 143.4 (Ts ArC), 141.8 (Ts ArC), 130.9 (ArCH), 
130.7 (ArCH), 129.9 (2 × Ts ArCH), 128.7 (ArCH), 128.4 (ArC), 126.9 (2 × Ts ArCH), 51.1 
(C4), 46.9 (C5), 46.7 (C1), 23.4 (2C, C2 and C3), 21.3 (Ts CH3); HRMS (ESI
+) Calculated for 
C11H14N: 160.1121. Found [M]
+: 160.1125. 
 
(E)-5-(p-Tolyl)pent-4-enoic acid (351a) 
 
The title compound 351a was prepared according to a literature procedure.317  




m.p. 135-137 oC (Et2O:petroleum ether) [lit: 142-143 (EtOAc:hexane)
317]; 1H NMR (400 MHz, 
CDCl3) δ 7.24 (2H, d, J = 8.0 Hz), 7.10 (2H, d, J = 8.0 Hz), 6.42 (1H, d, J = 16.0 Hz), 6.18 – 
6.13 (1H, m), 2.54 (4H, d, J = 3.0 Hz), 2.33 (3H, s); 13C NMR (101 MHz, CDCl3) δ 179.0, 
137.1, 134.6, 131.2, 129.4, 127.1, 126.1, 33.9, 28.1, 21.3. 




General procedure B: The preceding carboxylic acid 351a (761 mg, 4.0 mmol) and 2.0 
equivalents of LiAlH4 (8.0 mmol, 2 M in THF) in anhydrous Et2O (20 mL) were employed. 
Purification by flash column chromatography (33% EtOAc:petroleum ether) afforded 352a 
(680 mg, 96%) as a colourless solid; m.p. 35-37 oC (EtOAc:petroleum ether) [lit: 42-43 oC 
(EtOAc:hexane)322]; 1H NMR (400 MHz, CDCl3) δ 7.25 – 7.22 (2H, m), 7.11 (2H, d, J = 8.0 
Hz), 6.39 (1H, d, J = 16.0 Hz), 6.22 – 6.14 (1H, m), 3.70 (2H, t, J = 6.5 Hz), 2.34 – 2.27 (5H, 
m), 1.78 – 1.71 (2H, m), 1.53 (1H, br s); 13C NMR (101 MHz, CDCl3) δ 136.8, 135.0, 130.4, 
129.3, 129.1, 126.0, 62.6, 32.4, 29.4, 21.3. 
The spectroscopic properties were consistent with the data available in the literature.323 
 
tert-Butyl (E)-(5-(p-tolyl)pent-4-en-1-yl)(tosyloxy)carbamate (353a) 
 
General procedure G: The preceding alcohol 352a (352 mg, 2.0 mmol), PPh3 (629 mg, 2.4 
mmol), DIAD (0.47 mL, 2.4 mmol) and BocNHOTs (689 mg, 2.4 mmol) in anhydrous THF (8 
mL) were employed. Purification by flash column chromatography (gradient, eluent: 5 – 20% 
EtOAc:petroleum ether) afforded 353a (699 mg, 78%) as a viscous, colourless oil; Rf = 0.67 
(2:1 hexane:EtOAc); νmax / cm
-1 (film) 3023 (m), 2981 (m), 2932 (m), 1719 (s), 1368 (s), 1191 
(s), 1177 (s), 1158 (s); 1H NMR (400 MHz, CDCl3) δ 7.86 (2H, d, J = 8.5 Hz, Ts ArCH), 7.32 
(2H, d, J = 8.5 Hz, Ts ArCH), 7.22 (2H, d, J = 8.0 Hz, ArCH), 7.10 (2H, d, J = 8.0 Hz, ArCH), 
6.35 (1H, d, J = 16.0 Hz, C5-H), 6.09 (1H, dt, J = 16.0, 7.0 Hz, C4-H), 3.64 (2H, br s, C1-H2), 
2.43 (3H, s, Ts CH3), 2.32 (3H, s, CH3), 2.21 – 2.14 (2H, m, C3-H2), 1.85 – 1.75 (2H, m, 




C2-H2), 1.23 (9H, s, Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) δ 155.6 (Boc C=O), 145.8 (Ts 
ArC), 136.8 (ArC), 134.9 (ArC), 131.4 (Ts ArC), 130.7 (C5), 129.8 (2 × Ts ArCH), 129.7 (2 × 
Ts ArCH), 129.3 (ArCH), 128.2 (C4), 126.0 (ArCH), 83.3 (Boc C(CH3)3), 52.7 (C1), 30.1 (C3), 
27.8 (Boc (CH3)3), 25.7 (C2), 21.8 (Ts CH3), 21.3 (CH3); HRMS (ESI
+) Calculated for 





General procedure P: The preceding N-tosyloxycarbamate 353a (89.1 mg, 0.20 mmol) and 
TFA (31 μL, 0.40 mmol) in anhydrous TFE (2.0 mL) were employed. The reaction was stirred 
at room temperature for 24 hours. Purification by flash column chromatography (~0.1% Et3N 
in EtOAc) afforded 354a (21.1 mg, 61%) as a colourless oil; Rf = 0.20 (EtOAc); νmax / cm
-1 
(film) 2946 (m), 2871 (m), 1517 (m), 1453 (m), 1078 (m); 1H NMR (400 MHz, CDCl3) δ 7.12 
– 7.07 (4H, m, C7 and C8), 3.19 (1H, ddd, J = 12.0, 8.5, 1.5 Hz, C1-H), 3.04 (1H, td, J = 12.0, 
7.5 Hz, C1-H’), 2.42 (1H, dd, J = 5.0, 2.5 Hz, C4-H), 2.33 (1H, d, J = 2.5 Hz, C5-H), 2.31 (3H, 
s, C10-H3), 2.23 (1H, dd, J = 13.5, 8.5 Hz, C3-H), 1.97 (1H, dddd, J = 13.5, 11.0, 8.5, 5.0 Hz, 
C3-H’), 1.77 –  1.68 (1H, m, C2-H), 1.67 – 1.56 (1H, m, C2-H’); 13C NMR (101 MHz, CDCl3) 
δ 137.3 (C6), 136.4 (C9), 129.0 (C8), 126.0 (C7), 53.3 (C1), 50.6 (C4), 39.6 (C5), 26.7 (C3), 




 (E)-5-(4-Fluorophenyl)pent-4-enoic acid (351b) 
  
The title compound 351b was prepared according to a literature procedure.317  
1H NMR (400 MHz, CDCl3) δ 7.32 – 7.27 (2H, m), 7.01 – 6.95 (2H, m), 6.41 (1H, d, J = 16.0 
Hz), 6.18 – 6.08 (1H, m), 2.55 – 2.53 (4H, m); 13C NMR (101 MHz, CDCl3) δ 179.0, 162.2 (d, 




1JC,F = 246.5 Hz), 133.5 (d, 
4JC,F = 3.5 Hz), 130.2, 127.8, 127.6 (d, 
3JC,F = 8.0 Hz), 115.5 (d, 
2JC,F = 21.5 Hz), 33.8, 28.0. 




General procedure B: The preceding carboxylic acid 351b (777 mg, 4.0 mmol) and 2.0 
equivalents of. LiAlH4 (8.0 mmol, 2 M in THF) in anhydrous Et2O (20 mL) were employed. 
Purification by flash column chromatography (33% EtOAc:petroleum ether) afforded 352b 
(396 mg, 55%) as a colourless oil; 1H NMR (400 MHz, CDCl3) δ 7.30 – 7.25 (2H, m), 7.00 – 
6.93 (2H, m), 6.36 (1H, d, J = 16.0 Hz), 6.12 (1H, dt, J = 16.0, 7.0 Hz), 3.68 (2H, t, J = 7.0 
Hz), 2.31 – 2.25 (2H, m), 1.80 (1H, br s), 1.76 – 1.69 (2H, m); 13 C NMR (101 MHz, CDCl3) 
δ 162.0 (d, 1JC-F = 246.0 Hz), 133.8 (d, 
4JC-F = 3.0 Hz), 129.9, 129.3, 127.4 (d, 
3JC-F = 8.0 Hz), 
115.4 (d, 2JC-F = 22.0 Hz), 62.4, 32.3, 29.3; 
19F (377 MHz, CDCl3) δ -115.5 (1F, m). 
The spectroscopic properties were consistent with the data available in the literature.322 
 
tert-Butyl (E)-(5-(4-fluorophenyl)pent-4-en-1-yl)(tosyloxy)carbamate (353b) 
 
General procedure G: The preceding alcohol 352b (342 mg, 1.89 mmol), PPh3 (598 mg, 2.28 
mmol), DIAD (0.45 mL, 2.28 mmol) and BocNHOTs (655 mg, 2.28 mmol) in anhydrous THF 
(8 mL) were employed. Purification by flash column chromatography (10% EtOAc:petroleum 
ether) afforded 353b (530 mg, 62%) as a colourless solid; Rf = 0.65 (33% EtOAc:hexane); 
m.p.: 52-54 oC (Et2O:petroleum ether); νmax / cm
-1 (solid) 2978 (m), 2940 (m), 2983 (m), 1718 
(s), 1507 (s), 1368 (s), 1178 (s), 1155 (s); 1H NMR (400 MHz, CDCl3) δ 7.85 (2H, d, J = 8.5 
Hz, Ts ArCH), 7.34 – 7.26 (4H, m, Ts ArCH, ArCH), 7.00 – 6.94 (2H, m, ArCH), 6.35 (1H, d, 
J = 16.0 Hz, C5-H), 6.06 (1H, dt, J = 16.0, 7.0 Hz, C4-H), 3.65 (2H, br s, C1-H2), 2.43 (3H, s, 
Ts CH3), 2.22 – 2.15 (2H, m, C3-H2), 1.85 – 1.76 (2H, m, C2-H2), 1.22 (9H, s, Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) δ 162.1 (d, 
1JC-F = 245.8 Hz, ArC), 155.6 (Boc C=O), 145.8 (Ts 
ArC), 133.8 (d, 4JC-F = 3.4, ArC), 131.4 (Ts ArC), 129.8 (2 × Ts ArCH), 129.7 (C5), 129.7 (2 




× Ts ArCH), 129.0 (C4), 127.6 (d, 3JC-F = 7.9 Hz, ArCH), 115.5 (d, 
2JC-F = 21.4 Hz, ArCH), 
83.4 (Boc C(CH3)3), 52.6 (C1), 30.0 (C3), 27.8 (Boc (CH3)3, 25.6 (C2), 21.8 (Ts CH3); 
19F (377 
MHz, CDCl3) δ -115.4; HRMS (ESI




General procedure P: The preceding N-tosyloxycarbamate 353b (89.9 mg, 0.20 mmol) and 
TFA (31 μL, 0.40 mmol) in anhydrous TFE (2.0 mL) were employed. The reaction was stirred 
at room temperature for 24 hours. Purification by flash column chromatography (0.1% Et3N in 
EtOAc) afforded 354b (23.9 mg, 67%) as a colourless oil; Rf = 0.25 (EtOAc); νmax / cm
-1 (film) 
2963 (m), 2874 (m), 1604 (m), 1509 (s), 1226 (s), 1212 (s); 1H NMR (400 MHz, CDCl3) δ 7.20 
– 7.14 (2H, m, C7-H), 6.99 – 6.92 (2H, m, C8-H), 3.19 (1H, ddd, J = 12.0, 8.5, 1.5 Hz, C1-H), 
3.03 (1H, td, J = 12.0, 7.5 Hz, C1-H’), 2.39 (1H, dd, J = 5.0, 3.0 Hz, C4-H), 2.34 (1H, d, J = 
3.0 Hz, C5-H), 2.23 (1H, dd, J = 13.5, 8.5 Hz, C3-H), 1.97 (1H, dddd, J = 13.5, 11.0, 8.5, 5.0 
Hz, C3-H’), 1.78 – 1.69 (1H, m, C2-H), 1.66 – 1.54 ( 1H, m, C2-H’); 13C NMR (101 MHz, 
CDCl3) δ 161.8 (d, 
1JC,F = 244.0 Hz, C9), 135.8 (d, 
4JC,F = 3.0 Hz, C6), 127.4 (d, 
3JC,F = 8.0 
Hz, C7), 115.0 (d, 2JC,F = 21.4 Hz, C8), 53.1 (C1), 50.5 (C4), 39.0 (C5), 26.5 (C3), 20.7 (C2); 
19F NMR (377 MHz, CDCl3) δ -116.4; HRMS (ESI
+) Calculated for C11H13FN: 178.1026. 
Found [M+H]+: 178.1026. 
 
(E)-5-(4-Chlorophenyl)pent-4-enoic acid (351c) 
 
The title compound 351c was prepared according to a literature procedure.317  
m.p. 121-124 oC (Et2O:petroleum ether); 
1H NMR (400 MHz, CDCl3) δ 7.26 (4H, s), 6.40 (1H, 
d, J = 16.0 Hz), 6.22 – 6.16 (1H, m), 2.56 – 2.52 (4H, m); 13C NMR (101 MHz, CDCl3) δ 
178.7, 135.9, 133.0, 130.2, 128.9, 128.8, 127.4, 33.7, 28.0. 
The spectroscopic properties were consistent with the data available in the literature.317  






General procedure B: The preceding carboxylic acid 351c (1.05 g, 5.0 mmol) and 1.1 
equivalents of LiAlH4 (5.5 mmol, 2 M in THF) in anhydrous THF (25 mL) were employed. 
Purification by flash column chromatography (gradient, eluent: 20% – 33% EtOAc:petroleum 
ether) afforded 352c (724 mg, 74%) as a colourless solid; 1H NMR (400 MHz, CDCl3) δ 7.26 
(4H, s), 6.36 (1H, d, J = 16.0 Hz), 6.21 (1H, dt, J = 16.0, 7.0 Hz), 3.71 (2H, t, J = 6.5 Hz), 2.31 
(2H, q, J = 7.0 Hz), 1.76 (2H, app. qn, J = 6.5 Hz), 1.43 (1H, br s); 13C NMR (101 MHz, CDCl3) 
δ 136.3, 132.6, 130.9, 129.4, 128.8, 127.3, 62.5, 32.3, 29.5. 
The spectroscopic properties were consistent with the data available in the literature.324 
 
tert-Butyl (E)-(5-(4-chlorophenyl)pent-4-en-1-yl)(tosyloxy)carbamate (353c) 
 
General procedure G: The preceding alcohol 352c (295 mg, 1.50 mmol), PPh3 (470 mg, 1.80 
mmol), DIAD (0.35 mL, 1.80 mmol) and BocNHOTs (517 mg, 1.80 mmol) in anhydrous THF 
(6 mL) were employed. Purification by flash column chromatography (10% EtOAc:petroleum 
ether) afforded 353c (643 mg, 92%) as a colourless oil; Rf = 0.6 (33% EtOAc:hexane); νmax / 
cm-1 (film) 2981 (m), 2933 (m), 1718 (s), 1368 (s), 1191 (s), 1177 (s), 1153 (s); 1H NMR (400 
MHz, CDCl3) δ 7.85 (2H, d, J = 8.0 Hz, Ts ArCH), 7.32 (2H, d, J = 8.0 Hz, Ts ArCH), 7.24 
(4H, s, ArCH), 6.34 (1H, d, J = 16.0 Hz, C5-H), 6.17 – 6.08 (1H, m, C4-H), 3.65 (2H, br s, 
C1-H2), 2.43 (3H, s, Ts CH3), 2.23 – 2.15 (2H, m, C3-H2), 1.87 – 1.75 (2H, m, C2-H2), 1.22 
(9H, Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) δ 155.5 (Boc C=O), 145.8 (Ts ArC), 136.1 
(ArC), 132.6 (ArC), 131.3 (Ts ArC), 130.0 (C4), 129.8 (2 × Ts ArCH), 129.7 (C5) 129.6 (2 × 
Ts ArCH), 128.7 (ArCH), 127.3 (ArCH), 83.4 (Boc C(CH3)3), 52.5 (C1), 30.0 (C3), 27.7 (Boc 
(CH3)3), 25.5 (C2), 21.8 (Ts CH3); HRMS (ESI
+) Calculated for C23H28
35ClNNaO5S: 488.1269. 
Found [M+Na]+: 488.1275. 
 
 






General procedure P: The preceding N-tosyloxycarbamate 353c (93.2 mg, 0.2 mmol) and 
TFA (31 μL, 0.4 mmol) in anhydrous TFE (2.0 mL) were employed. The reaction time was 24 
hours. Purification by flash column chromatography (0.1% Et3N in EtOAc) afforded 354c (25.7 
mg, 66%) as a colourless solid; Rf = 0.35 (EtOAc); m.p.: 43-45 
oC (EtOAc:hexane); νmax / cm
-1 
(solid) 2973 (m), 2948 (m), 2922 (m), 2856 (m), 1490 (s), 1190 (m), 785 (s); 1H NMR (400 
MHz, CDCl3) δ 7.24 (2H, d, J = 8.5 Hz, C7-H), 7.14 (2H, d, J = 8.5 Hz, C8-H), 3.20 (1H, ddd, 
J = 12.0, 8.5, 1.5 Hz, C1-H), 3.04 (1H, td, J = 12.0, 7.5 Hz, C1-H’), 2.39 (1H, dd, 5.0, 2.5 Hz, 
C4-H), 2.33 (1H, d, J = 2.5 Hz, C5-H), 2.24 (1H, dd, J = 13.5, 8.5 Hz, C3-H), 2.03 – 1.93 (1H, 
m, C3-H’), 1.78 – 1.71 (1H, m, C2-H), 1.66 – 1.52 (1H, m, C2-H’); 13C NMR (101 MHz, 
CDCl3) δ 139.0 (C6), 132.4 (C9), 128.5 (C7), 127.5 (C8), 53.3 (C1), 51.0 (C4), 39.2 (C5), 26.7 
(C3), 20.8 (C2); HRMS (ESI+) Calculated for C11H13
35ClN: 194.0731. Found [M+H]+: 
194.0732. 
The structure and relative stereochemistry of 354c were confirmed by X-ray crystallography 
after recrystallization (EtOAc:hexane). 
 
 









(E)-5-(Naphthalen-2-yl)pent-4-enoic acid (351d) 
 
The title compound 351d was prepared according to a literature procedure.317 
m.p. 168-170 oC (Et2O:petroleum ether); [lit: 173-175 
oC (MeOH)325]; 1H NMR (400 MHz, 
DMSO-d6) δ 12.15 (1H, br s), 7.88 – 7.82 (3H, m), 7.78 (1H, s), 7.66 – 7.62 (1H, m), 7.51 – 
7.42 (2H, m), 6.60 (1H, d, J = 16.0 Hz), 6.48 – 6.40 (1H, m), 2.49 - 2.41 (4H, m); 13C NMR 
(101 MHz, DMSO-d6) δ 173.8, 134.7, 133.3, 132.3, 130.1, 129.9, 128.0, 127.7, 127.5, 126.3, 
125.7, 125.2, 123.5, 33.4, 28.0. 




General procedure B: The preceding carboxylic acid 351d (910 mg, 4.00 mmol) and 2.0 
equivalents of LiAlH4 (8.0 mmol, 2M in THF) in anhydrous THF (20 mL) were employed. 
Purification by flash column chromatography (33% EtOAc:hexane) afforded 352d (510 mg, 
60 %) as a colourless solid; m.p.: 89-91 oC (E2O:petroleum ether); 
1H NMR (400 MHz, CDCl3) 
δ 7.79 – 7.74 (3H, m), 7.67 (1H, d, J = 1.0 Hz), 7.56 (1H, dd, J = 8.5, 1.5 Hz), 7.45 – 7.38 (2H, 
m), 6.58 (1H, d, J = 16.0 Hz), 6.36 (1H, dt, J = 16.0, 7.0 Hz), 3.72 (2H, t, J = 6.5 Hz), 2.40 – 
2.34 (2H, m), 1.83 – 1.76 (2H, m), 1.49 (1H, br s); 13C NMR (101 MHz, CDCl3) δ 135.2, 133.8. 
132.8, 130.6, 128.2, 127.9, 127.7, 126.3, 125.6, 124.5, 123.7, 62.6, 32.4, 29.6. 
The spectroscopic properties were consistent with the data available in the literature.322 
 
tert-Butyl (E)-(5-(naphthalen-2-yl)pent-4-en-1-yl)(tosyloxy)carbamate (353d) 
 
General procedure G: The preceding alcohol 352d (320 mg, 1.50 mmol), PPh3 (470 mg, 1.80 
mmol), DIAD (0.35 mL, 1.80 mmol) and BocNHOTs (517 mg, 1.80 mmol) in anhydrous THF 
(6 mL) were employed. Purification by flash column chromatography (10% EtOAc:petroleum 
ether) afforded 353d (640 mg, 88%) as a colourless solid; Rf = 0.75 (33% EtOAc:hexane); 




m.p.: 67-69 oC (CH2Cl2:hexane); νmax / cm
-1 (solid) 2982 (m), 2954 (m), 2932 (m), 1711 (s), 
1383 (s), 1368 (s), 1191 (s), 1178 (s), 1154 (s); 1H NMR (400 MHz, CDCl3) δ 7.87 (2H, d, J = 
8.5 Hz, Ts ArCH), 7.80 – 7.75 (3H, m, ArCH), 7.68 – 7.66 (1H, m, ArCH), 7.56 (1H, dd, J = 
8.6, 1.7 Hz, ArCH), 7.47 – 7.39 (2H, m, ArCH), 7.32 (2H, d, J = 8.5 Hz, Ts ArCH), 6.55 (1H, 
d, J = 16.0 Hz, C5-H), 6.29 (1H, dt, J = 16.0, 7.0 Hz, C4-H), 3.67 (2H, br s, C1-H2), 2.42 (3H, 
s, TsCH3), 2.29 – 2.22 (2H, m, C3-H2), 1.91 – 1.81 (2H, m, C2-H2), 1.24 (9H, s, Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) δ 155.6 (Boc C=O), 145.8 (Ts ArC), 135.1 (ArC), 133.8 (ArC), 
132.9 (ArC), 131.4 (Ts ArC), 131.0 (C5), 129.8 (2 × Ts ArCH), 129.8 (C4), 129.7 (2 × Ts 
ArCH), 128.2 (ArCH), 128.0 (ArCH), 127.8 (ArCH), 126.3 (ArCH), 125.7 (ArCH), 123.7 
(ArCH), 83.4 (Boc C(CH3)3), 52.6 (C1), 30.2 (C3), 27.8 (Boc (CH3)3), 25.6 (C2), 21.8 (Ts 
CH3); HRMS (ESI
+) Calculated for C27H31NNaO5S: 504.1815. Found [M+Na]
+: 504.1794.  
 
(5S*,6S*)-6-(Naphthalen-2-yl)-1-azabicyclo[3.1.0]hexane (354d) and (S*)-2-((R*)-
Naphthalen-2-yl(2,2,2-trifluoroethoxy)methyl)pyrrolidine (355)
 
General procedure P: The preceding N-tosyloxycarbamate 353d (96.3 mg, 0.20 mmol) and 
TFA (31 μL, 0.20 mmol) in anhydrous TFE (2.0 mL) were employed. After stirring for 24 
hours purification by flash column chromatography (gradient, eluent 0.1% Et3N in 33% 
EtOAc:petroleum ether – EtOAc) afforded 354d (24.6 mg, 58%) as colourless solid; m.p.: 60-
62 oC (pentane:EtOAc); Rf = 0.35 (EtOAc) and 355 (12.3 mg, 20%) as a 15:1 mixture of 
diastereomers and as a yellow oil; Rf = 0.05 (EtOAc). 
Data for compound 354d: νmax / cm
-1 (film) 2920 (m), 1369 (m), 1191 (m), 1179 (m); 1H NMR 
(400 MHz, CDCl3) δ 7.81 – 7.76 (3H, m, ArCH), 7.71 – 7.69 (1H, m, ArCH), 7.46 – 7.38 (2H, 
m, ArCH), 7.34 (1H, dd, J = 8.5, 1.5 Hz, ArCH), 3.27 (1H, ddd, J = 12.0, 8.5, 1.5 Hz, C1-H), 
3.11 (1H, td, J = 12.0, 7.5 Hz, C1-H’), 2.55 – 2.52 (2H, m, C4-H, C5-H), 2.29 (1H, dd, J = 
13.5, 8.5 Hz, C3-H), 2.08 – 1.98 (1H, m, C3-H’), 1.83 – 1.74 (1H, m, C2-H), 1.71 – 1.62 (1H, 
m, C2-H’); 13C NMR (101 MHz, CDCl3) δ 137.9 (ArC), 133.5 (ArC), 132.7 (ArC), 128.0 
(ArCH), 127.8 (ArCH), 127.7 (ArCH), 126.1 (ArCH), 125.4 (ArCH), 124.7 (ArCH), 124.6 




(ArCH), 53.3 (C1), 51.1 (C4), 40.0 (C5), 26.8 (C3), 20.9 (C2); HRMS (ESI+) Calculated for 
C15H16N: 210.1277. Found [M+H]
+: 210.1280. 
Data for compound 355: νmax / cm
-1 (film) 2931 (m), 2873 (m), 1273 (s), 1155 (s), 1121 (s), 
1106 (s). 
The spectroscopic properties for the major diastereomer of 355:1H NMR (400 MHz, CDCl3) 
δ 7.89 – 7.81 (3H, m, ArCH), 7.75 (1H, d, J = 1.6 Hz, ArCH), 7.54 – 7.43 (3H, m, ArCH), 4.38 
(1H, d, J = 8.2 Hz, C5-H), 3.75 – 3.66 (2H, m, C6-H2), 3.45 (1H, app. q, J = 7.8 Hz, C4-H), 
3.15 – 3.09 (1H, m, C1-H), 2.96 (1H, td, J = 9.1, 7.2 Hz, C1-H’), 2.64 (1H, br s, NH), 1.86 – 
1.76 (1H, m, C2-H), 1.75 – 1.64 (1H, m, C2-H’), 1.44 – 1.38 (2H, m, C3-H2); 
13C NMR (101 
MHz, CDCl3) δ 135.8 (ArC), 133.6 (ArC), 133.2 (ArC), 128.9 (ArCH), 128.1 (ArCH), 127.9 
(ArCH), 127.3 (ArCH), 126.6 (ArCH), 126.5 (ArCH), 124.7 (ArCH), 124.2 (q, 1JC-F = 278.6 
Hz), 87.7 (C5), 66.0 (q, 2JC-F = 66 Hz, C6), 63.8 (C4), 46.1 (C1), 27.6 (C3), 24.3 (C2). 
Characteristic signals for the minor diastereomer of 355: 1H NMR (400 MHz, CDCl3) δ 4.48 
(1H, d, J = 7.0 Hz). 
HRMS (ESI+) Calculated for C17H19F3NO: 310.1413. Found [M+H]
+: 310.1416. 
 
tert-Butyl (E)-non-4-en-1-yl(tosyloxy)carbamate (357) 
 
General procedure G: Alcohol 356 (284 mg, 2.0 mmol), PPh3 (630 mg, 2.4 mmol), DIAD 
(0.47 mL, 2.4 mmol) and BocNHOTs (690 mg, 2.4 mmol) in anhydrous THF (8 mL) were 
employed. Purification by flash column chromatography (5% EtOAc:petroleum ether) afforded 
357 (694 mg, 84%) as a colourless, viscous oil; Rf = 0.80 (33% EtOAc:hexane); νmax / cm
-1 
(film) 2956 (m), 2929 (m), 2872 (m), 1720 (s), 1368 (s), 1191 (s), 1178 (s), 1154 (s); 1H NMR 
(400 MHz, CDCl3) δ 7.85 (2H, d, J = 8.0 Hz, Ts ArCH), 7.34 (2H, d, J = 8.0 Hz, Ts ArCH), 
5.45 – 5.29 (2H, m, C4-H and C5-H), 3.59 (2H, br s, C1-H2), 2.45 (3H, s, Ts CH3), 2.00 – 1.91 
(4H, m, C3-H2 and C6-H2), 1.72 – 1.62 (2H, m, C2-H2), 1.34 – 1.24 (4H, m, C7-H2 and C8-H2), 
1.22 (9H, s, Boc (CH3)3), 0.90 – 0.85 (3H, m, C9-H3); 
13C NMR (101 MHz, CDCl3) δ 155.6 
(Boc C=O), 145.7 (Ts ArC), 131.7 (C4 or C5), 131.4 (Ts ArC), 129.8 (2 × Ts ArCH), 129.6 (2 
× Ts ArCH), 128.6 (C4 or C5), 83.2 (Boc C(CH3)3), 52.8 (C1), 32.4 (C3 or C6), 31.8 (C7), 
29.7 (C3 or C6), 27.8 (Boc (CH3)3), 25.7 (C2), 22.3 (C8), 21.8 (Ts CH3), 14.1 (C9); HRMS 
(ESI+) Calculated for C21H33NNaO5S: 434.1972. Found [M+Na]
+: 434.1696. 






General procedure P: The preceding N-tosyloxycarbamate 357 (87.9 mg, 0.21 mmol) and 
TFA (31 μL, 0.4 mmol) in anhydrous TFE (2.0 mL) were employed. After stirring for 48 hours 
at room temperature purification by flash column chromatography (~0.1% Et3N in EtOAc) 
afforded 362 (16.1 mg, 55%) as a colourless oil; Rf = 0.1 (EtOAc); νmax / cm
-1 (film) 2926 (m), 
2859 (m), 1456 (m); 1H NMR (400 MHz, CDCl3) δ 2.95 (1H, ddd, J = 12.0, 8.5, 1.5 Hz, C1-H), 
2.85 (1H, td, J = 11.5, 7.5 Hz, C1-H’), 2.09 (1H, dd, J = 5.0, 2.5 Hz, C4-H), 2.06 – 1.99 (1H, 
m, C3-H), 1.87 – 1.76 (1H, m, C3-H’), 1.64 – 1.55 (1H, m, C2-H), 1.49 – 1.26 (8H, m, C2-H’, 
C5-H, C6-H2, C7-H2, C8-H2), 0.89 (3H, t, J = 7.0 Hz, C9-H3); 
13C NMR (101 MHz, CDCl3) δ 
52.8 (C1), 46.3 (C4), 38.0 (C5), 32.2 (C6), 29.8 (C7 or C8), 26.1 (C3), 22.7 (C7 or C8), 21.3 





The title compound was prepared according to a literature procedure.52 
To a solution of Hoveyda-Grubbs 2nd generation catalyst (109 mg, 0.174 mmol) in anhydrous, 
degassed CH2Cl2 (80 mL) was added 4-penten-1-ol (1.2 mL, 11.6 mmol) and allyl benzene 
(5.8 mL, 44 mmol). The reaction was heated at reflux for 2 days before being concentrated in 
vacuo and purified by flash column chromatography (20% EtOAc:PhMe) to afford 358 (900 
mg, 44%, 7:1 mixture of E and Z isomers) as a light brown oil (the colouration was due to the 
presence of trace amounts of Ru-impurities).  
Spectroscopic data for the major E isomer: 1H NMR (400 MHz, CDCl3) δ 7.35 – 7.28 (2H, 
m), 7.25 – 7.18 (3H, m), 5.64 (1H, dt, J = 15.0, 6.5 Hz), 5.54 (1H, dt, J = 15.0, 6.5 Hz), 3.66 
(2H, t, J = 6.5 Hz), 3.35 (2H, d, J = 6.5 Hz), 2.16 – 2.10 (2H, m), 1.71 – 1.63 (2H, m), 1.61 
(1H, br s); 13C NMR (101 MHz, CDCl3) δ 140.9, 131.2, 129.7, 128.6, 128.5, 126.0, 62.5, 39.1, 
32.4, 28.9. 




Characteristic signals for the minor Z isomer: 1H NMR (400 MHz, CDCl3) δ 3.44 (2H, d, J = 
7.0 Hz), 2.29 – 2.24 (2H, m). 
The spectroscopic properties were consistent with the data available in the literature.52  
 
tert-Butyl (E)-(6-phenylhex-4-en-1-yl)(tosyloxy)carbamate (360) 
 
General procedure G: The preceding alcohol 358 (350 mg, 2.0 mmol), PPh3 (630 mg, 2.4 
mmol), DIAD (0.47 mL, 2.4 mmol) and BocNHOTs (690 mg, 2.4 mmol) in anhydrous THF 
(8 mL) were employed. Purification by flash column chromatography (10% EtOAc:petroleum 
ether) afforded 360 (524 mg, 60%, 7:1 mixture of E and Z isomers) as a colourless oil; Rf = 
0.70 (33% EtOAc:hexane); νmax / cm
-1 (film) 2980 (m), 1719 (s), 1368 (s), 1191 (s), 1178 (s), 
1152 (s). 
Spectroscopic data for the major E isomer: 1H NMR (400 MHz, CDCl3) δ 7.85 (2H, d, J = 8.5 
Hz, Ts ArCH), 7.34 (2H, d, J = 8.5 Hz, Ts ArCH), 7.31 – 7.26 (2H, m, ArCH), 7.21 – 7.15 
(3H, m, ArCH), 5.59 (1H, dt, J = 15.0, 6.5 Hz, C5-H), 5.45 (1H, dt, J = 15.0, 6.5 Hz, C4-H), 
3.62 (2H, br s, C1-H2), 3.32 (2H, d, J = 6.5 Hz, C6-H2), 2.45 (3H, s, Ts CH3), 2.03 – 1.98 (2H, 
m, C3-H2), 1.78 – 1.66 (2H, m, C2-H2), 1.22 (9H, s, Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) 
δ 155.6 (Boc C=O), 145.8 (Ts ArC), 140.9 (ArC), 131.4 (Ts ArC), 130.4 (C4), 130.0 (C5), 
129.8 (2 × Ts ArCH), 129.6 (2 × Ts ArCH), 128.6 (ArCH), 128.5 (ArCH), 126.1 (ArCH), 83.3 
(Boc C(CH3)3), 52.7 (C1), 39.1 (C6), 29.6 (C3), 27.8 (Boc (CH3)3), 25.7 (C2), 21.8 (Ts CH3). 
Characteristic signals for the minor Z isomer: 1H NMR (400 MHz, CDCl3) δ 3.37 (2H, d, J = 
7.0 Hz), 2.13 (2H, q, J = 7.0 Hz); HRMS (ESI+) Calculated for C24H31NNaO5S: 468.1815. 













General procedure P: The preceding N-tosyloxycarbamate 360 (89.11 mg, 0.20 mmol) and 
TFA (31 μL, 0.40 mmol) in anhydrous TFE (2.0 mL) were employed. After stirring for 24 
hours, purification by flash column chromatography (~0.1% Et3N in EtOAc) afforded 363 
(21.6 mg, 62%) as a pale-yellow oil; Rf = 0.10 (EtOAc); νmax / cm
-1 (film) 3025 (m), 2937 (m), 
2871 (m), 1494 (m), 1453 (m); 1H NMR (400 MHz, CDCl3) δ 7.32 – 7.18 (5H, m, ArCH), 3.00 
(1H, ddd, J = 12.0, 8.5, 1.5 Hz, C1-H), 2.89 (1H, td, J = 11.5, 7.5 Hz, C1-H’), 2.77 (1H, dd, J 
= 14.5, 6.5 Hz, C6-H), 2.57 (1H, dd, J = 14.5, 6.0 Hz, C6-H’), 2.28 (1H, dd, J = 5.0, 3.0 Hz, 
C4-H), 2.06 (1H, dd, J = 13.0, 8.5 Hz, C3-H), 1.91 – 1.80 (1H, m, C3-H’), 1.66 – 1.57 (2H, m, 
C5-H, C2-H), 1.47 – 1.37 (1H, m, C2-H’); 13C NMR (101 MHz, CDCl3) δ 140.1 (ArC), 128.7 
(ArCH), 128.5 (ArCH), 126.3 (ArCH), 52.7 (C1), 46.3 (C4), 38.8 (C6), 38.7 (C5), 26.1 (C3), 
21.2 (C2); HRMS (ESI+) Calculated for C12H15NNa: 196.1097. Found [M+Na]
+: 196.1101. 
 
Methyl (E)-6-hydroxyhex-2-enoate (359) 
 
The title compound was prepared according to a literature procedure.52 
To a solution of Hoveyda-Grubbs 2nd generation catalyst (15.7 mg, 25.0 µmol) in anhydrous, 
degassed CH2Cl2 (40 mL) was added methyl acrylate (2.25 mL, 25.0 mmol) and pent-4-en-1-ol 
(0.26 mL, 2.5 mmol). The reaction was heated at reflux overnight and then concentrated in 
vacuo. Purification by flash column chromatography (33% EtOAc:hexane) afforded 359 (349 
mg, 97%) as a light brown oil (the colouration was due to the presence of trace amounts of 
Ru-impurities); 1H NMR (400 MHz, CDCl3) δ 6.97 (1H, dt, J = 15.5, 7.0 Hz), 5.84 (1H, dt, J 
= 15.5, 1.5 Hz), 3.70 (3H, s), 3.65 (2H, t, J = 6.5 Hz), 2.32 – 2.26 (2H, m), 1.83 (1H, br s), 1.75 
– 1.66 (2H, m); 13C NMR (101 MHz, CDCl3) δ 167.2, 148.9, 121.4, 62.0, 51.6, 31.0, 28.6. 
The spectroscopic properties were consistent with the data available in the literature.52  
 
 




Methyl (E)-6-((tert-butoxycarbonyl)(tosyloxy)amino)hex-2-enoate (361) 
 
General procedure G: The preceding alcohol 359 (288 mg, 2.0 mmol), PPh3 (629 mg, 2.4 
mmol), DIAD (0.47 mL, 2.4 mmol) and BocNHOTs (689 mg, 2.4 mmol) in anhydrous THF (8 
mL) were employed. Purification by flash column chromatography (9:1 petroleum 
ether:EtOAc) afforded 361 (755 mg, 91%) as a colourless solid; Rf = 0.60 (33% 
EtOAc:hexane); m.p.: 45-47 oC (CH2Cl2:hexane); νmax / cm
-1 (solid) 2981 (m), 2953 (m), 2934 
(m), 1717 (s), 1175 (s), 1159 (s); 1H NMR (400 MHz, CDCl3) δ 7.85 (2H, d, J = 8.5 Hz, Ts 
ArCH), 7.34 (2H, d, J = 8.5 Hz, Ts ArCH), 6.91 (1H, dt, J = 15.5, 7.0 Hz, C4-H), 5.83 (1H, dt, 
J = 15.5, 1.5 Hz, C5-H), 3.72 (3H, s, OCH3), 3.62 (2H, br s, C1-H2), 2.45 (3H, s, Ts CH3), 2.23 
– 2.15 (2H, m, C3-H2), 1.84 – 1.74 (2H, m, C2-H2), 1.22 (9H, s, Boc (CCH3)3); 
13C NMR (101 
MHz, CDCl3) δ 167.0 (C6), 155.5 (Boc C=O), 147.8 (C4), 145.9 (Ts ArC), 131.3 (Ts ArC), 
129.8 (2 × Ts ArCH), 129.7 (2 × Ts ArCH), 121.8 (C5), 83.6 (Boc C(CH3)3), 52.4 (C1), 51.6 
(OCH3), 29.3 (C3), 27.7 (Boc (CH3)3), 24.5 (C2), 21.9 (Ts CH3); HRMS (ESI
+) Calculated for 
C19H27NNaO7S: 436.1400. Found [M+Na]
+: 436.1417. 
tert-Butyl (E)-(9-hydroxynon-4-en-1-yl)(tosyloxy)carbamate (366) 
 
To a solution of TBDPS-protected alcohol 365 (133 mg, 0.20 mmol) in THF (2.0 mL) at 0 oC 
was added 1.0 equivalent of TBAF (1 M in THF, 0.20 mmol) dropwise. The reaction was 
warmed to room temperature and stirred overnight until completion. The reaction mixture was 
quenched with water (5 mL), extracted with EtOAc (2 × 5 mL), washed with saturated aqueous 
NaHCO3 (5 mL) and brine (5 mL), dried over Na2SO4, filtered and concentrated in vacuo. 
Purification by flash column chromatography (33% EtOAc:hexane) afforded 366 (65.8 mg, 
77%) as a colourless viscous oil; Rf = 0.01 (20% EtOAc:hexane); νmax / cm
-1 (film) 3392 (br 
m), 2983 (m), 2931 (m), 2860 (m), 1723 (s), 1368 (s), 1191 (s), 1178 (s), 1153 (s); 1H NMR 
(400 MHz, CDCl3) δ 7.85 (2H, d, J = 8.5 Hz, Ts ArCH), 7.34 (2H, d, J = 8.5 Hz, Ts ArCH), 
5.45 – 5.32 (2H, m, C4-H and C5-H), 3.72 – 3.52 (4H, m, C1-H2 and C9-H2), 2.45 (3H, s, Ts 
CH3), 2.04 – 1.94 (4H, m, C3-H2 and C6-H2), 1.74 – 1.64 (2H, m, C2-H2), 1.60 – 1.53 (2H, m, 
C8-H2), 1.45 – 1.36 (2H, m, C7-H2), 1.21 (9H, s, Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) δ 




155.6 (Boc C=O), 145.8 (Ts ArC), 131.4 (Ts ArC), 131.2 (C5), 129.8 (2 × Ts ArCH), 129.6 (2 
× Ts ArCH), 129.2 (C4), 83.3 (Boc C(CH3)3), 63.0 (C9), 52.6 (C1), 32.3 (C6), 32.3 (C8), 29.6 
(C3), 27.7 (Boc C(CH3)3), 25.6 (C7), 25.6 (C2) 21.8 (Ts CH3); HRMS (ESI
+) Calculated for 





General procedure P: TBDPS-Protected alcohol 365 (66.6 mg, 0.10 mmol) and TFA (23 μL, 
0.30 mmol) in TFE (1.0 mL) were employed. After stirring for 70 hours at room temperature 
purification by flash column chromatography (~0.1% Et3N in EtOAc) afforded 369 (9.4 mg, 
24%) as a yellow oil; Rf = 0.01 (EtOAc); νmax / cm
-1 (film) 2938 (m), 2864 (m), 1681 (m), 1426 
(m), 1108 (s), 1091 (s), 907 (s), 729 (s), 700 (s); 1H NMR (400 MHz, CDCl3) δ 7.67 – 7.65 
(4H, m, ArCH), 7.43 – 7.35 (6H, m, ArCH), 3.66 (2H, t, J = 6.5 Hz, C9-H2), 2.99 – 2.84 (2H, 
m, C1-H2), 2.16 – 2.11 (1H, m, C4-H), 2.06 – 2.00 (1H, m, C3-H’), 1.88 – 1.78 (1H, m, C3-H’), 
1.66 – 1.55 (3H, m, C2-H, C8-H2), 1.48 – 1.39 (3H, m, C2-H’, C7-H2), 1.36 – 1.25 (3H, m, 
C5-H, C6-H2), 1.04 (9H, s, SiC(CH3)3); 
13C NMR (101 MHz, CDCl3) δ 135.7 (ArCH), 134.3 
(ArC), 129.6 (ArCH), 127.7 (ArCH), 64.1 (C9), 52.5 (C1), 46.4 (C4), 38.2 (C5), 32.6 (C8), 
32.1 (C6), 27.0 (SiC(CH3)3), 26.0 (C3), 23.8 (C7), 21.2 (C2), 19.4 (SiC); HRMS (ESI
+) 
Calculated for C25H36NOSi: 394.2560. Found [M+H]
+: 394.2576. 
 
(E)-9-((tert-Butoxycarbonyl)(tosyloxy)amino)non-5-en-1-yl benzoate (367)  
 
To a solution of alcohol 366 (70.5 mg, 0.165 mmol) and pyridine (29 μL, 0.36 mmol) in 
anhydrous CH2Cl2 (1.0 mL) at 0 
oC was added benzoyl chloride (17 μL, 0.15 mmol). The 
reaction stirred at room temperature for 2 hours and quenched with H2O (1 mL). The aqueous 
layer was extracted with Et2O (3 × 5 mL) and the combined organic extracts were washed with 
saturated aqueous NH4Cl (1 mL), saturated aqueous NaHCO3 (1 mL) and brine (1 mL), filtered 
and concentrated in vacuo. Purification by flash column chromatography (gradient, eluent: 10 




– 20% EtOAc:hexane) afforded 367 (51.0 mg, 58%) as a colourless oil; Rf = 0.45 (33% 
EtOAc:hexane); νmax / cm
-1 (film) 2929 (m), 2852 (m), 1719 (s), 1382 (m), 1369 (m), 1274 (s), 
1191 (s), 1179 (s), 713 (m); 1H NMR (400 MHz, CDCl3) δ 8.06 – 8.02 (2H, m, ArCH), 7.85 
(2H, d, J = 8.5 Hz, Ts ArCH), 7.57 – 7.52 (1H, m, ArCH), 7.46 – 7.41 (2H, m, ArCH), 7.34 
(2H, d, J = 8.5 Hz, Ts ArCH), 5.47 – 5.34 (2H, m, C4-H and C5-H), 4.31 (2H, t, J = 6.5 Hz, 
C9-H2), 3.61 (2H, br s, C1-H2), 2.44 (3H, s, Ts CH3), 2.08 – 2.03 (2H, m, C6-H2), 1.99 – 1.94 
(2H, m, C3-H2), 1.80 – 1.64 (4H, m, C8-H2, C2-H2), 1.54 – 1.47 (2H, m, C7-H2), 1.20 (9H, s, 
Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) δ 166.8 (C10), 155.5 (Boc C=O), 145.7 (Ts ArC), 
132.9 (ArCH), 131.4 (Ts ArC), 130.9 (C5), 130.6 (ArC), 129.8 (2 × Ts ArCH), 129.7 (ArCH), 
129.6 (2 × Ts ArCH), 129.4 (C4), 128.4 (ArCH), 83.2 (Boc C(CH3)3), 65.1 (C9), 52.7 (C1), 
32.2 (C6), 29.6 (C3), 28.3 (C8), 27.7 (Boc (CH3)3), 26.0 (C7), 25.7 (C2), 21.8 (Ts CH3); HRMS 
(ESI+) Calculated for C28H37NNaO7S: 554.2183. Found [M+Na]
+: 554.2185. 
4-((5S*,6S*)-1-Azabicyclo[3.1.0]hexan-6-yl)butyl benzoate (370) 
 
General procedure P: The preceding N-tosyloxycarbamate 367 (48.8 mg, 0.092 mmol), and 
TFA (14 μL, 0.184 mmol) in anhydrous TFE (0.1 M) were employed. After stirring for 44 
hours purification by flash column chromatography (eluent: ~0.1% Et3N in EtOAc) afforded 
370 (18.5 mg, 78%) as a pale-yellow oil; Rf = 0.01 (EtOAc); νmax / cm
-1 (film) 2936 (m), 2870 
(m), 1715 (s), 1451 (m), 1270 (s), 1110 (s), 710 (s); 1H NMR (400 MHz, CDCl3) δ 8.06 – 8.02 
(2H, m, ArCH), 7.57 – 7.52 (1H, m, ArCH), 7.46 – 7.41 (2H, m, ArCH), 4.32 (2H, t, J = 6.5 
Hz, C9-H2), 2.97 (1H, ddd, J = 12.0, 8.5, 1.5 Hz, C1-H), 2.86 (1H, td, J = 11.5, 7.5 Hz, C1-H’), 
2.11 (1H, dd, J = 5.0, 3.0 Hz, C4-H), 2.04 (1H, dd, J = 13.0, 8.5 Hz, C3-H), 1.87 – 1.76 (3H, 
m, C3-H’, C8-H2), 1.64 – 1.38 (6H, m, C2-H2, C6-H2, C7-H2), 1.35 – 1.30 (1H, m, C5-H); 
13C NMR (101 MHz, CDCl3) δ 166.8 (C10), 132.9 (ArCH), 130.6 (ArC), 129.7 (ArCH), 128.5 
(ArCH), 65.2 (C9), 52.8 (C1), 46.2 (C4), 37.7 (C5), 32.2 (C6), 28.8 (C8), 26.1 (C3), 24.2 (C7), 








Methyl (E)-2-(cyclopropanecarbonyl)-5-phenylpent-4-enoate (372) 
 
The title compound was prepared following a literature procedure.52 
β-Ketoester 371 (1.70 g, 12.0 mmol) was added dropwise to a suspension of NaH (60% weight 
in mineral oil, 480 mg, 12.0 mmol) in anhydrous DMF (23 mL). The reaction mixture was 
stirred at room temperature for 1 hour before addition of 3-bromo-1-phenyl-1-propene (1.57 g, 
8.0 mmol) and heated at 80 oC overnight. The reaction mixture was cooled to room temperature 
before addition of saturated aqueous NH4Cl (30 mL) and extraction with Et2O (3 × 30 mL). 
The organic extracts were dried over Na2SO4 and concentrated in vacuo. The crude mixture 
was purified by flash column chromatography (gradient, eluent: 5 – 7% EtOAc:hexane) to 
afford 372 (1.39, 67%) as a pale yellow oil; Rf = 0.30 (20% EtOAc:hexane); νmax / cm
-1 (film) 
3025 (m), 2952 (m), 1738 (s), 1698 (s); 1H NMR (400 MHz, CDCl3) δ 7.30 – 7.23 (4H, m, 
ArCH), 7.20 – 7.16 (1H, ArCH), 6.44 (1H, d, J = 16.0 Hz, C8-H), 6.10 (1H, ddd, J = 16.0, 7.5, 
6.5 Hz, C7-H), 3.76 – 3.70 (4H, m, C4-H, OCH3), 2.79 – 2.74 (2H, m, C6-H2), 2.09 – 2.03 
(1H, m, C2-H), 1.11 – 1.03 (2H, m, C1-H2), 0.96 – 0.87 (2H, m, C1’-H2); 
13C NMR (101 MHz, 
CDCl3) δ 204.6 (C3), 169.9 (C5), 137.2 (ArC), 132.7 (C8), 128.6 (ArCH), 127.4 (ArCH), 126.3 
(ArCH), 126.0 (C7), 59.7 (C4), 52.6 (OCH3), 31.8 (C6), 20.2 (C2), 12.0 (C1), 11.9 (C1’); 





To a solution of the preceding β-ketoester 372 (1.03 g, 4.0 mmol), in MeOH:water (5:3, 16 
mL) was added KOH (898 mg, 16.0 mmol). The reaction mixture was stirred at room 
temperature for 45 minutes before addition of 2 M HCl (11 mL) and extraction with Et2O (3 × 
30 mL). The organic phases were dried over Na2SO4 and concentrated in vacuo. The crude 




mixture was dissolved in EtOAc (13 mL) and heated to reflux for 4 hours before being 
concentrated in vacuo. The resulting oil was dissolved in MeOH (10 mL) and cooled to 0 oC 
before addition of NaBH4 (151 mg, 4.0 mmol). The reaction mixture was stirred at this 
temperature for 90 minutes before addition of 1 M HCl (20 mL) and extraction with Et2O (3 × 
30 mL). The combined organic extracts were dried over Na2SO4 and concentrated in vacuo. 
Purification by flash column chromatography (20% EtOAc:petroleum ether) afforded 374 (508 
mg, 63%) as a colourless oil; Rf = 0.40 (20% EtOAc:hexane); νmax / cm
-1 (film) 3387 (br m), 
3001 (m), 2930 (m), 1447 (m), 963 (s), 692 (s); 1H NMR (400 MHz, CDCl3) δ 7.35 – 7.26 (4H, 
m, ArCH), 7.21 – 7.18 (1H, m, ArCH), 6.43 (1H, d, J = 16.0 Hz, C7-H), 6.25 (1H, dt, J = 16.0, 
7.0 Hz, C6-H), 2.93 (1H, dt, J = 8.5, 6.0 Hz, C3-H), 2.46 – 2.30 (2H, m, C5-H2), 1.83 – 1.77 
(2H, m, C4-H2), 1.62 (1H, br s, OH), 0.98 – 0.89 (1H, m, C2-H), 0.59 – 0.48 (2H, m, C1-H2), 
0.32 – 0.21 (2H, m, C1’-H2); 
13C NMR (101 MHz, CDCl3) δ 137.8 (ArC), 130.6 (C6), 130.2 
(C7), 128.6 (ArCH), 127.0 (ArCH), 126.0 (ArCH), 76.4 (C3), 36.8 (C4), 29.4 (C5), 18.1 (C2), 
2.9 (C1), 2.7 (C1’); HRMS (ESI+) Calculated for C14H18NaO: 225.1250. Found [M+Na]
+: 
225.1247. 
tert-Butyl (E)-(1-cyclopropyl-5-phenylpent-4-en-1-yl)(tosyloxy)carbamate (375) 
 
General procedure G: The preceding alcohol 374 (303 mg, 1.50 mmol), PPh3 (472 mg, 1.80 
mmol), DIAD (0.35 mL, 1.80 mmol) and BocNHOTs (517 mg, 1.80 mmol) in anhydrous THF 
(6.0 mL) were employed. Purification by flash column chromatography (gradient, eluent: 2 – 
5% EtOAc:hexane) afforded 375 (231 mg, 33%) as a colourless, viscous oil; Rf = 0.65 (20% 
EtOAc:hexane); νmax / cm
-1 (film) 2980 (m) 1721 (s), 1369 (s), 1191 (s), 1178 (s); 1H NMR 
(400 MHz, CDCl3) δ 7.87 (2H, d, J = 8.5 Hz, Ts ArCH), 7.34 – 7.25 (6H, m, Ts ArCH, ArCH), 
7.20 – 7.15 (1H, m, ArCH), 6.38 (1H, d, J = 16.0 Hz, C7-H), 6.18 (1H, dt, J = 16.0, 7.0 Hz, 
C6-H), 3.15 – 3.08 (1H, m, C3-H), 2.42 (3H, s, Ts CH3), 2.36 – 2.29 (2H, m, C5-H2), 2.10 – 
1.99 (1H, m, C4-H), 1.88 – 1.76 (1H, m, C4-H’), 1.25 (9H, s, Boc C(CH3)3), 1.17 – 1.09 (1H, 
m, C2-H), 0.63 – 0.55 (1H, m, C1-H), 0.50 – 0.40 (2H, m, C1-H2, C1’-H2), 0.25 – 0.18 (1H, 
m, C1-H’); 13C NMR (101 MHz, CDCl3) δ 156.6 (Boc C=O), 145.6 (Ts ArC), 137.9 (ArC), 
131.9 (Ts ArC), 130.5 (C7), 130.1 (C6), 129.8 (2 × Ts ArCH), 129.6 (2 × Ts ArCH), 128.6 
(ArCH) 127.0 (ArCH), 126.1 (ArCH), 83.4 (Boc C(CH3)3), 70.9 (C3), 32.8 (C4) 30.3 (C5), 




27.8 (Boc C(CH3)3), 21.8 (Ts CH3), 14.0 (C2), 5.3 (C1), 3.4 (C1’); HRMS (ESI
+) Calculated 





General procedure P: The preceding N-tosyloxycarbamate 375 (47.9 mg, 0.10 mmol) and 
TFA (15 μL, 0.2 mmol) in anhydrous TFE (1.0 mL) were employed. After stirring at room 
temperature for 72 hours, purification by flash column chromatography (~0.1% Et3N in 33% 
EtOAc:pentane) afforded 376 (11.4 mg, 57%) as a >20:1 mixture of diastereomers and as a 
pale-yellow oil; Rf = 0.20 (20% EtOAc:hexane); νmax / cm
-1 (film) 3002 (m), 2955 (m), 2879 
(m), 1453 (m), 1087 (m), 740 (s), 697 (s); 1H NMR (400 MHz, CDCl3) δ 7.31 – 7.18 (5H, m, 
ArCH), 2.75 – 2.69 (1H, m, C3-H), 2.61 (1H, d, J = 2.5 Hz, C7-H), 2.42 (1H, dd, J = 5.0, 2.5 
Hz, C6-H), 2.23 (1H, dd, J = 13.5, 8.0 Hz, C5-H), 2.03 – 1.98 (1H, m, C5-H’), 1.74 (1H, ddd, 
J = 13.5, 8.5, 7.0 Hz, C4-H), 1.38 (1H, dtd, J = 13.5, 11.0, 8.0 Hz, C4-H’), 0.88 – 0.78 (1H, m, 
C2-H), 0.51 – 0.41 (3H, m, 2 × C1-H, 1 × C1’-H), 0.22 – 0.14 (1H, m, C1’-H’); 13C NMR (101 
MHz, CDCl3) δ 140.6 (ArC), 128.3 (ArCH), 126.8 (ArCH), 126.6 (ArCH), 69.4 (C3), 49.7 
(C6), 36.2 (C7), 27.2 (C5), 26.1 (C4), 13.0 (C2), 4.1 (C1), 2.8 (C1’); HRMS (ESI+) Calculated 
for C14H18N: 200.1433. Found [M+H]
+: 200.1441. 
The relative stereochemistry was assigned by nOe experiments as indicated on the compound 
structure. nOe correlations were observed between C6-H and ArCH and between C7-H and 













To a solution of α,β-unsaturated aldehyde 377 (2.3 mL, 20.0 mmol) in anhydrous THF (40 mL) 
at – 78 oC was added PhMgCl (2M in THF, 16.0 mL, 32.0 mmol) dropwise. The reaction was 
warmed to room temperature and stirred for 2 hours before addition of a solution of saturated 
aqueous NH4Cl (20 mL) and extraction with EtOAc (2 × 10 mL). The combined organic 
extracts were washed with brine (10 mL), dried over Na2SO4 and concentrated in vacuo. 
Purification by flash column chromatography (20% EtOAc:hexane) afforded 378 (2.56 g, 73%) 
as a colourless oil; 1H NMR (400 MHz, CDCl3) δ 7.38 – 7.22 (5H, m), 5.79 – 5.70 (1H, m), 
5.69 – 5.60 (1H, m), 5.14 (1H, d, J = 6.5 Hz), 2.13 – 1.82 (3H, m), 1.45 – 1.35 (2H, m), 0.89 
(3H, t, J = 7.5 Hz); 13C NMR (101 MHz, CDCl3) δ 143.5, 132.7, 132.5, 128.6, 127.6, 126.3, 
75.3, 34.4, 22.4, 13.8. 
The spectroscopic properties were consistent with the data available in the literature.326 
 
Ethyl (E)-3-styrylhexanoate (379) 
 
General procedure Q: The preceding alcohol 378 (441 mg, 2.5 mmol), propionic acid (37 μL, 
0.5 mmol) and triethyl orthoacetate (4.6 mL, 25 mmol) were employed. The reaction time was 
16 hours. Purification by flash column chromatography (5% EtOAc:hexane) afforded 379 (379 
mg, 62%) as a colourless oil containing an unknown impurity which was used in the next step; 
Rf = 0.40 (10% EtOAc:hexane); νmax / cm
-1 (film) 2958 (m), 2929 (m), 1732 (s), 1235 (s), 1161 
(s), 965 (s); 1H NMR (400 MHz, CDCl3) δ 7.35 – 7.16 (5H, m, ArCH), 6.39 (1H, d, J = 16.0 
Hz, C5-H), 6.00 (1H, dd, J = 16.0 Hz, C4-H), 4.09 (2H, q, J = 7.0 Hz, OCH2CH3), 2.74 – 2.65 
(1H, m, C3-H), 2.46 – 2.32 (2H, m, C2-H2), 1.47 – 1.28 (4H, m, C6-H2, C7-H2), 1.20 (3H, t, J 
= 7.0 Hz, OCH2CH3), 0.89 (3H, t, J = 7.0 Hz, C8-H3); 
13C NMR (101 MHz, CDCl3) δ 172.6 
(C1), 137.6 (ArC), 133.1 (C4), 130.5 (C5), 128.6 (ArCH), 127.2 (ArCH), 126.2 (ArCH), 60.4 




(OCH2CH3), 40.7 (C2), 39.9 (C3), 37.3 (C6), 20.4 (C7), 14.4 (OCH2CH3), 14.2 (C8); HRMS 




General procedure B: The preceding ester 379 (325 mg, 1.32 mmol) and 0.8 equivalents 
LiAlH4 (1.06 mL, 1 M in THF) in anhydrous THF (5 mL) were employed. Purification by flash 
column chromatography (20% EtOAc:hexane) afforded 380 (95 mg, 35%); Rf = 0.2 (20% 
EtOAc:hexane);νmax / cm
-1 (film) 3332 (br m), 2955 (m), 2927 (m), 1449 (m), 965 (s), 747 (s), 
691 (s); 1H NMR (400 MHz, CDCl3) δ 7.38 – 7.29 (4H, m, ArCH), 7.23 – 7.19 (1H, m, ArCH), 
6.39 (1H, d, J = 16.0 Hz, C5-H), 5.98 (1H, dd, J = 16.0, 9.0 Hz, C4-H), 3.73 – 3.62 (2H, m, 
C1-H2), 2.38 – 2.28 (1H, m, C3-H), 1.80 – 1.72 (1H, m, C2-H), 1.63 – 1.51 (2H, m, OH, 
C2-H’), 1.49 – 1.27 (4H, m, C6-H2, C7-H2), 0.91 (3H, t, J = 7.0 Hz, C8-H3); 
13C NMR (101 
MHz, CDCl3) δ 137.6 (ArC), 134.9 (C4), 130.2 (C5), 128.6 (ArCH), 127.1 (ArCH), 126.1 
(ArCH), 61.4 (C1), 40.2 (C3), 38.4 (C2), 38.0 (C6), 20.5 (C7), 14.2 (C8); HRMS (ESI+) 
Calculated for C14H20NaO: 227.1406. Found [M+Na]
+: 227.1407. 
 
tert-Butyl (E)-(3-styrylhexyl)(tosyloxy)carbamate (381)  
 
General procedure G: The preceding alcohol 380 (307 mg, 1.50 mmol), PPh3 (472 mg, 1.80 
mmol), DIAD (0.35 mL, 1.80 mmol) and BocNHOTs (517 mg, 1.80 mmol) in anhydrous THF 
(6.0 mL) were employed. Purification by flash column chromatography (gradient, eluent: 5 –
10% EtOAc:hexane) afforded 381 (542 mg, 76%) as a pale yellow, viscous oil; Rf = 0.70 (20% 
EtOAc:hexane); νmax / cm
-1 (film) 2958 (m), 2930 (m), 1719 (s), 1368 (s), 1191 (s), 1178 (s), 
732 (s); 1H NMR (400 MHz, CDCl3) δ 7.81 (2H, d, J = 8.5 Hz, Ts ArCH), 7.34 – 7.24 (6H, m, 
ArCH, Ts ArCH), 7.22 – 7.17 (1H, m, ArCH), 6.31 (1H, d, J = 16.0 Hz, C5-H), 5.87 (1H, dd, 
J = 16.0, 9.0 Hz, C4-H), 3.53 (2H, br s, C1-H2), 2.38 (3H, s, Ts CH3), 2.15 – 2.06 (1H, m, 




C3-H), 1.85 – 1.71 (1H, m, C2-H), 1.65 – 1.52 (1H, m, C2-H’), 1.43 – 1.24 (4H, m, C6-H2 and 
C7-H2), 1.23 (9H, s, Boc (CH3)3), 0.87 (3H, t, J = 7.0 Hz, C8-H3); 
13C NMR (101 MHz, CDCl3) 
δ 155.6 (Boc C=O), 145.7 (Ts ArC), 137.6 (ArC), 133.8 (C4), 131.4 (Ts ArC), 130.7 (C5), 
129.8 (2 × Ts ArCH), 129.6 (2 × Ts ArCH), 128.6 (ArCH), 127.2 (ArCH), 126.2 (ArCH), 83.3 
(Boc C(CH3)3), 51.7 (C1), 40.9 (C3), 37.7 (C6), 31.0 (C2), 27.8 (Boc (CH3)3), 21.8 (Ts CH3), 




(4R*,5R*,6R*)-6-Phenyl-4-propyl-1-azabicyclo[3.1.0]hexane (382a) and (4S*,5R*,6R*)-
6-Phenyl-4-propyl-1-azabicyclo[3.1.0]hexane (382b) 
 
General procedure P: The preceding N-tosyloxycarbamate 381 (94.7 mg, 0.20 mmol) and 
TFA (31 μL, 0.40 mmol) in anhydrous TFE (2.0 mL) were employed. After stirring for 48 
hours purification by flash column chromatography (eluent: ~0.1% Et3N in 33% 
EtOAc:pentane) afforded 382 (27.9 mg, 69%) as a 10:1 mixture of diastereomers and as a pale-
yellow oil; Rf = 0.35 (20% EtOAc:hexane); νmax / cm
-1 (film) 2955 (m), 2925 (m), 2873 (m), 
1453 (m), 737 (s), 696 (s). 
Spectroscopic properties for the major diastereomer 382a: 1H NMR (400 MHz, CDCl3) δ 7.28 
– 7.23 (2H, m, ArCH), 7.21 – 7.16 (3H, m, ArCH), 3.14 – 3. 07 (2H, m, C1-H2), 2.47 – 2.40 
(1H, m, C3-H), 2.33 (1H, d, J = 2.5 Hz, C5-H), 2.25 (1H, d, J = 2.5 Hz, C4-H), 1.82 – 1.70 
(1H, m, C2-H), 1.50 –1.29 (5H, m, C2-H’, C6-H2, C7-H2), 0.92 (3H, t, J = 7.0 Hz, C8-H3); 
13C NMR (101 MHz, CDCl3) δ 140.4 (ArC), 128.3 (ArCH), 126.8 (ArCH), 126.1 (ArCH), 55.6 
(C4), 52.0 (C1), 41.0 (C5), 39.5 (C3), 37.0 (C6), 27.3 (C2), 21.0 (C7), 14.3 (C8). 
In CDCl3 the signals for the minor diastereomer were overlapped by the major diastereomer 
however in (CD3)2CO some of the minor peaks could be observed allowing for the d.r. to be 
determined. 
Characteristic signals for the minor diastereomer 382b: 1H NMR (400 MHz, (CD3)2CO) δ 
2.55 (1H, d, J = 2.5 Hz), 2.22 (1H, dd, J = 4.5, 2.5 Hz). 




HRMS (ESI+) Calculated for C14H20N: 202.1590. Found [M+H]
+: 202.1591. 
The relative stereochemistry was determined by nOe experiments as indicated on the 
compound structure. nOe correlations were observed between C4-H and ArCH and between 




This compound was prepared according to a literature procedure.327 
To a solution of 4-(dimethylamino)benzoic acid (830 mg, 5.0 mmol) and pyrrolidine (0.21 mL, 
2.5 mmol) in CH2Cl2 (25 mL) were added formaldehyde (37% solution in H2O, 2.0 mL, 25 
mmol) and 3-phenylpropanal (383) (3.35 mg, 25.0 mmol) at room temperature. The reaction 
was heated at 45 oC and stirred for 2 hours. The reaction mixture was added to saturated 
aqueous NaHCO3 (20 mL) and the resulting mixture was extracted with CH2Cl2 (3 × 20mL). 
The combined organic extracts were then washed with brine (20 mL), dried over Na2SO4 and 
concentrated in vacuo. Purification by flash column chromatography (20% EtOAc:hexane) 
afforded 384 (2.56 g, 70%) as a yellow oil; 1H NMR (400 MHz, CDCl3) δ 9.61 (1H, s), 7.33 – 
7.15 (5H, m), 6.11 (1H, s), 6.07 (1H, s), 3.57 (2H, s); 13C NMR (101 MHz, CDCl3) δ 193.9, 
149.9, 138.2, 135.3, 129.3, 128.7, 126.6, 34.3. 




The title compound was prepared according to a literature procedure.137 
To a solution of aldehyde 384 (2.50 g, 17.0 mmol) in MeOH (8.5 mL) at 0 oC was added NaBH4 
(680 mg, 17.85 mmol) portion wise and the reaction was stirred for 30 minutes. The reaction 
mixture was quenched with saturated aqueous NH4Cl (8.5 mL), diluted with H2O (17 mL) and 
extracted with Et2O (3 × 35 mL). The combined organic extracts were dried over Na2SO4 and 
concentrated in vacuo. Purification by flash column chromatography (gradient, eluent 10 – 
20% EtOAc:petroleum ether) afforded 385 (1.67 g, 66%) as a colourless oil; 1H NMR (400 




MHz, CDCl3) δ 7.32 – 7.17 (5H, m), 5.14 – 5.11 (1H, m), 4.93 – 4.89 (1H, m), 4.04 (2H, s), 
3.41 (2H, s), 1.73 (1H, br s); 13C NMR (101 MHz, CDCl3) δ 148.3, 139.2, 129.0, 128.5, 126.4, 
111.6, 65.4, 40.0. 
The spectroscopic properties were consistent with the data available in the literature.137 
 
Ethyl 4-benzylpent-4-enoate (386) 
 
General procedure Q: The preceding alcohol 385 (1.46 g, 10 mmol), propionic acid (0.15 
mL, 2.0 mmol) and triethyl orthoacetate (18.3 mL, 100 mmol) were employed. Purification by 
flash column chromatography (5% EtOAc:petroleum ether) afforded 386 (1.15 g, 53%) as a 
colourless oil; Rf = 0.70 (20% EtOAc:hexane); νmax / cm
-1 (film) 2980 (m), 2906 (m), 1732 (s), 
1155 (s), 698 (s); 1H NMR (400 MHz, CDCl3) δ 7.32 – 7.26 (2H, m, ArCH), 7.23 – 7.17 (3H, 
m, ArCH), 4.85 – 4.83 (1H, m, C5-H), 4.81 – 4.79 (1H, m, C5-H’), 4.12 (2H, q, J = 7.0 Hz, 
OCH2CH3), 3.37 (2H, s, C6-H2), 2.48 – 2.42 (2H, m, C2-H2), 2.34 – 2.28 (2H, m, C3-H2), 1.24 
(3H, t, J = 7.0 Hz, OCH2CH3); 
13C NMR (101 MHz, CDCl3) δ 173.3 (C1), 147.4 (C4), 139.4 
(ArC), 129.1 (ArCH), 128.5 (ArCH), 126.3 (ArCH), 111.7 (C5), 60.5 (OCH2CH3), 43.3 (C6), 
32.7 (C2), 30.4 (C3), 14.3 (OCH2CH3); HRMS (ESI
+) Calculated for C14H18NaO2: 241.1199. 




General procedure B: The preceding ester 386 (873 mg, 4.0 mmol) and 0.8 equivalents of 
LiAlH4 (121 mg, 3.2 mmol) in THF (20 mL) were employed. Purification by flash column 
chromatography (20% EtOAc:petroleum ether) afforded 387 (556 mg, 80%) as a colourless 
oil; Rf = 0.20 (20% EtOAc:hexane); νmax / cm
-1 (film) 3327 (br m), 2937 (m), 697 (s); 1H NMR 
(400 MHz, CDCl3) δ 7.31 – 7.26 (2H, m, ArCH), 7.22 – 7.16 (3H, m, ArCH), 4.87 – 4.85 (1H, 
m, C5-H), 4.79 – 4.77 (1H, m, C5-H’), 3.61 (2H, t, J = 6.5 Hz, C1-H2), 3.35 (2H, s, C6-H2), 
2.04 (2H, t, J = 7.5 Hz, C3-H2), 1.74 – 1.66 (2H, m, C2-H2), 1.50 (1H, br s, OH); 
13C NMR 




(101 MHz, CDCl3) δ 148.6 (C4), 139.7 (ArC), 129.1 (ArCH), 128.4 (ArCH), 126.3 (ArCH), 
111.6 (C5), 62.8 (C1), 43.2 (C6), 31.7 (C3), 30.7 (C2); HRMS (ESI+) Calculated for 
C12H16NaO: 199.1093. Found [M+Na]
+: 199.1098. 
 
tert-Butyl (4-benzylpent-4-en-1-yl)(tosyloxy)carbamate (388)  
 
General procedure G: The preceding alcohol 387 (441 mg, 2.5 mmol), PPh3 (787 mg, 3.0 
mmol), DIAD (0.59 mL, 3.0 mmol) and BocNHOTs (862 mg, 3.0 mmol) in anhydrous THF 
(10 mL) were employed. Purification by flash column chromatography (10% EtOAc:hexane) 
afforded 388 (895 mg, 80%) as a colourless solid; Rf = 0.4 (20% EtOAc:hexane); m.p.: 84-86 
oC (Et2O:pentane); νmax / cm
-1 (solid) 2980 (m), 1711 (s), 1370 (s), 1342 (s), 1176 (s), 1150 (s); 
1H NMR (400 MHz, CDCl3) δ 7.84 (2H, d, J = 8.5 Hz, Ts ArCH), 7.33 (2H, d, J = 8.0 Hz, Ts 
ArCH), 7.30 – 7.36 (2H, m, ArCH), 7.22 – 7.14 (3H, m, ArCH), 4.84 – 4.81 (1H, m, C5-H), 
4.78 – 4.76 (1H, m, C5-H’), 3.57 (2H, br s, C1-H2), 3.32 (2H, s, C6-H2), 2.45 (3H, s, Ts CH3), 
1.93 (2H, t, J = 7.5 Hz, C3-H2), 1.82 – 1.71 (2H, m, C2-H2), 1.21 (9H, s, Boc (CH3)3); 
13C NMR 
(101 MHz, CDCl3) δ 155.6 (Boc C=O), 147.6 (C4), 145.8 (Ts ArC), 139.6 (ArC), 131.4 (Ts 
ArC), 129.8 (2 × Ts ArCH), 129.7 (2 × Ts ArCH), 129.1 (ArCH), 128.5 (ArCH), 126.3 (ArCH), 
111.9 (C5), 83.3 (Boc C(CH3)3), 52.8 (C1), 43.1 (C6), 32.2 (C3), 27.7 (Boc C(CH3)3), 23.7 
(C2), 21.8 (Ts CH3); HRMS (ESI






General procedure P: The preceding N-tosyloxycarbamate 388 (89.1 mg, 0.2 mmol) and TFA 
(31 μL, 0.4 mmol) in anhydrous TFE (2.0 mL) were employed. After stirring for 42 hours at 
room temperature purification by flash column chromatography (~0.1% Et3N in EtOAc) 




afforded 389 (27.8 mg, 80%) as a yellow oil; Rf = 0.1 (EtOAc); νmax / cm
-1 (film) 2925 (m), 
1673 (m), 1453 (m), 700 (s); 1H NMR (400 MHz, CDCl3) δ 7.30 – 7.18 (5H, m, ArCH), 2.99 
– 2.89 (3H, m, C1-H2, C6-H), 2.80 (1H, d, J = 14.0 Hz, C6-H’), 1.96 (1H, dd, J = 12.5, 8.0 Hz, 
C3-H), 1.71 – 1.56 (3H, m, C2-H, C3-H’, C5-H), 1.54 – 1.43 (2H, m, C2-H’, C5-H’); 13C NMR 
(101 MHz, CDCl3) δ 139.2 (ArC), 129.4 (ArCH), 128.4 (ArCH), 126.3 (ArCH), 53.1 (C1), 
50.4 (C4), 41.9 (C6), 32.2 (C5), 29.2 (C3), 21.5 (C2); HRMS (ESI+) Calculated for C12H16N: 
174.1277. Found [M+H]+: 174.1283. 
2-Methyl-1-phenylprop-2-en-1-ol (391) 
 
This compound was prepared according to a literature procedure.328 
To a solution of methacrolein (390) (2.8 g, 40.0 mmol) in anhydrous THF (18 mL) at 0 oC was 
added PhMgBr (3.0 M in Et2O, 13.6 mL, 41.0 mmol) dropwise. The reaction was warmed to 
room temperature and stirred for 1.5 hours. The reaction was quenched with a solution of 
saturated aqueous NH4Cl (50 mL) and diluted with H2O (100 mL). The layers were separated, 
and the organic phase was extracted with Et2O (2 × 20 mL). The combined organic extracts 
were washed with brine (20 mL), dried over Na2SO4 and concentrated in vacuo. 391 was 
obtained as a yellow oil (5.02 g, 85%) and was used without further purification; 1H NMR (400 
MHz, CDCl3) δ 7.39 – 7.26 (5H, m), 5.22 – 5.20 (1H, m), 5.13 (1H, s), 4.97 – 4.95 (1H, m), 
2.19 (1H, br s), 1.62 (3H, s); 13C NMR (101 MHz, CDCl3) δ 146.9, 142.1, 128.5, 127.7, 126.6, 
111.3, 78.0, 18.4. 




General procedure Q: The preceding alcohol 391 (3.71 g, 25.0 mmol), propionic acid (0.37 
mL, 5.0 mmol) and triethyl orthoacetate (46 mL, 250 mmol) were employed. Purification by 
flash column chromatography (3% EtOAc:petroleum ether) afforded the title compound (3.38 
g, 62%) as a colourless oil; 1H NMR (400 MHz, CDCl3) δ 7.33 – 7.30 (2H, m), 7.24 – 7.18 
(3H, m), 6.31 (1H, s), 4.15 (2H, q, J = 7.0 Hz), 2.54 – 2.50 (4H, m), 1.87 (3H, s), 1.27 (3H, t, 




J = 7.0 Hz); 13C NMR (101 MHz, CDCl3) δ 173.3, 138.3, 137.2, 128.9, 128.2, 126.2, 125.7, 
60.5, 35.8, 33.3, 17.8, 14.4. 
The spectroscopic properties were consistent with the data available in the literature.322 
 
 (E)-4-Methyl-5-phenylpent-4-en-1-ol  
 
 
General procedure B: Ethyl (E)-4-methyl-5-phenylpent-4-enoate (3.30 g, 15.2 mmol) and 0.8 
equivalents of LiAlH4 (1M in THF) in anhydrous THF (50 mL) were employed. Purification 
by flash column chromatography (20% EtOAc:petroleum ether) afforded the title compound 
(1.88 g, 70%) as a colourless oil; 1H NMR (400 MHz, CDCl3) δ 7.35 – 7.29 (2H, m), 7.26 – 
7.16 (3H, m), 6.32 (1H, s), 3.71 (2H, t, J = 6.5 Hz), 2.27 (2H, t, J = 7.5 Hz), 1.88 (3H, s), 1.85 
– 1.77 (2H, m); 13C NMR (101 MHz, CDCl3) δ 138.6, 138.5, 128.9, 128.2, 126.1, 125.3, 62.8, 
37.1, 31.0, 17.9. 
The spectroscopic properties were consistent with the data available in the literature.322  
 
tert-Butyl (E)-(4-methyl-5-phenylpent-4-en-1-yl)(tosyloxy)carbamate (392)  
 
General procedure G: (E)-4-Methyl-5-phenylpent-4-en-1-ol (1.76 g, 10.0 mmol), PPh3 (3.15 
g, 12.0 mmol), DIAD (2.36 mL, 12.0 mmol) and BocNHOTs (3.40 g, 12.0 mmol) in anhydrous 
THF (40 mL) were employed. Purification by flash column chromatography (10% 
EtOAc:petroleum ether) afforded 392 (3.70 g, 83%) as a colourless solid; Rf = 0.7 (50% 
EtOAc:hexane); m.p.: 74-76 oC (CH2Cl2:hexane); νmax / cm
-1 (solid) 2980 (m), 2958 (m), 2948 
(m), 1709 (s), 1369 (s), 1348 (s), 1174 (s), 1151 (s); 1H NMR (400 MHz, CDCl3) δ 7.87 (2H, 
d, J = 8.5 Hz, Ts ArCH), 7.36 – 7.28 (4H, m, Ts ArCH and ArCH), 7.24 – 7.16 (3H, m, ArCH), 
6.26 (1H, s, C5-H), 3.64 (2H, br s, C1-H2), 2.44 (3H, s, Ts CH3), 2.18 – 2.12 (2H, m, C3-H2), 
1.90 – 1.79 (5H, m, C2-H2 and C6-H3), 1.24 (9H, s, Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) 
δ 155.6 (Boc C=O), 145.8 (Ts ArC), 138.4 (ArC), 137.6 (C4), 131.4 (Ts ArC), 129.9 (2 × Ts 
ArCH), 129.7 (2 × Ts ArCH), 129.0 (ArCH), 128.2 (ArCH), 126.1 (ArCH), 125.7 (C5), 83.4 




(Boc C(CH3)3), 52.8 (C1), 37.6 (C3), 27.8 (Boc (CH3)3), 24.1 (C2), 21.9 (Ts CH3), 17.7 (C6); 
HRMS (ESI+) Calculated for C24H31NNaO5S: 468.1815. Found [M+Na]+: 468.1814. 
 
(5S*,6S*)-5-Methyl-6-phenyl-1-azabicyclo[3.1.0]hexane (393)  
 
General procedure P: The preceding N-tosyloxycarbamate 392 (89.1 mg, 0.2 mmol) and TFA 
(31 μL, 0.4 mmol) in anhydrous TFE (2.0 mL) were employed. After stirring for 48 hours 
purification by flash column chromatography (0.1% Et3N in EtOAc) afforded 393 (28.1 mg, 
81%) as a yellow oil; Rf = 0.50 (EtOAc); νmax / cm
-1 (film) 2951 (m), 2925 (m), 2874 (m), 1498 
(m), 1449 (m), 1063 (m); 1H NMR (400 MHz, CDCl3) δ 7.31 – 7.26 (4H, m, ArCH), 7.23 – 
7.18 (1H, m, ArCH), 3.17 – 3.12 (2H, m, C1-H2), 2.65 (1H, s, C5-H), 2.27 – 2.21 (1H, m, 
C3-H), 1.88 – 1.81 (1H, m, C3-H’), 1.80 – 1.65 (2H, m, C2-H2), 1.06 (3H, s, C6-H3); 
13C NMR 
(101 MHz, CDCl3) δ 138.4 (ArC), 128.0 (ArCH), 127.8 (ArCH), 126.5 (ArCH), 53.7 (C1), 
53.3 (C4), 44.4 (C5), 33.4 (C3), 22.1 (C2), 16.3 (C6); HRMS (ESI+) Calculated for C12H16N: 




To a solution of MeMgBr (3.0 M in Et2O, 20 mL, 60 mmol) in anhydrous Et2O (50 mL) at 0 
oC was added 2-benzylacrylaldehyde (384) (5.85 g, 40 mmol) dropwise. The reaction mixture 
was stirred for 1 hour at room temperature before addition of saturated aqueous NH4Cl (50 
mL). The phases were separated, and the aqueous phase extracted with Et2O (2 × 50 mL). The 
combined organic extracts were dried over Na2SO4, filtered and concentrated in vacuo to afford 
the title compound (4.85 g, 75%) as a pale-yellow oil, which was used without further 
purification; 1H NMR (400 MHz, CDCl3) δ 7.33 – 7.27 (2H, m), 7.24 – 7.19 (3H, m), 5.16 – 
5.14 (1H, m), 4.76 – 4.74 (1H, m), 4.25 (1H, q, J = 6.5 Hz), 3.48 (1H, d, J = 15.5 Hz), 3.36 
(1H, d, J = 15.5 Hz), 1.67 (1H, br s), 1.31 (3H, d, J = 6.5 Hz); 13C NMR (101 MHz, CDCl3) δ 
152.7, 139.5, 129.3, 128.5, 126.3, 111.0, 70.3, 39.1, 22.3. 








General procedure Q: 3-Benzylbut-3-en-2-ol (4.06 g, 25.0 mmol), propionic acid (0.37 mL, 
5.0 mmol) and triethyl orthoacetate (46 mL, 250 mmol) were employed. Purification by flash 
column chromatography (10% EtOAc:petroleum ether) afforded the title compound (3.50 g, 
60%) as a colourless oil; 1H NMR (400 MHz, CDCl3) δ 7.30 – 7.24 (2H, m), 7.21 – 7.14 (3H, 
m), 5.45 (1H, q, J = 6.5 Hz), 4.09 (2H, q, J = 7.0 Hz), 3.42 (2H, s), 2.39 – 2.32 (2H, m), 2.29 
– 2.23 (2H, m), 1.72 (3H, d, J = 6.5 Hz), 1.23 (3H, t, J = 7.0 Hz); 13C NMR (101 MHz, CDCl3) 
δ 173.5, 140.0, 137.0, 128.6, 128.5, 126.1, 121.1, 60.3, 35.8, 33.2, 31.9, 14.4, 13.8. 




General procedure B: Ethyl (Z)-4-benzylhex-4-enoate (2.32 g, 10.0 mmol) and 0.8 
equivalents of LiAlH4 (304 mg) in anhydrous Et2O (50 mL) were employed. 394a (1.79 g, 
94%) was obtained as a colourless oil which was used without further purification; 1H NMR 
(400 MHz, CDCl3) δ 7.32 – 7.24 (2H, m), 7.22 – 7.15 (3H, m), 5.46 (1H, q, J = 7.0 Hz), 3.58 
(2H, t, J = 6.5 Hz), 3.42 (2H, s), 2.03 – 1.97 (2H, m), 1.74 (3H, d, J = 7.0 Hz), 1.67 – 1.60 (2H, 
m), 1.45 (1H, br s); 13C NMR (101 MHz, CDCl3) δ 140.3, 138.2, 128.6, 128.5, 126.0, 120.7, 
62.8, 35.7, 32.9, 31.0, 13.8. 









tert-Butyl (Z)-(4-benzylhex-4-en-1-yl)(tosyloxy)carbamate (395a)  
 
General procedure G: The preceding alcohol 394a (290 mg, 1.50 mmol), PPh3 (470 mg, 1.80 
mmol), DIAD (0.35 mL, 1.80 mmol) and BocNHOTs (520 mg, 1.80 mmol) in anhydrous THF 
(6 mL) were employed. Purification by flash column chromatography (10% EtOAc:petroleum 
ether) afforded 395a (630 mg, 92%) as a viscous, colourless oil; Rf = 0.80 (20% 
EtOAc:hexane); νmax / cm
-1 (film) 3027 (m), 2980 (m), 2932 (m), 1720 (s), 1380 (s), 1368 (s), 
1191 (s), 1178 (s), 1152 (s); 1H NMR (400 MHz, CDCl3) δ 7.84 (2H, d, J = 8.5 Hz, Ts ArCH), 
7.33 (2H, d, J = 8.0 Hz, Ts ArCH), 7.29 – 7. 24 (2H, m, ArCH), 7.20 – 7.12 (3H, m, ArCH), 
5.41 (1H, q, J = 6.5 Hz, C5-H), 3.53 (2H, br s, C1-H2), 3.38 (2H, s, C7-H2), 2.45 (3H, s, Ts 
CH3), 1.87 (2H, t, J = 7.5 Hz, C3-H2), 1.75 – 1.66 (5H, m, C2-H2, C6-H3), 1.20 (9H, s, Boc 
(CH3)3); 
13C NMR (101 MHz, CDCl3) δ 155.6 (Boc C=O), 145.7 (Ts ArC), 140.1 (ArC), 137.3 
(C4), 131.4 (Ts ArC), 129.8 (2 × Ts ArCH), 129.6 (2 × Ts ArCH), 128.6 (ArCH), 128.5 
(ArCH), 126.0 (ArCH), 120.9 (C5), 83.2 (Boc C(CH3)3), 52.9 (C1), 35.6 (C7), 33.4 (C3), 27.7 
(Boc (CH3)3), 24.0 (C2), 21.8 (Ts CH3), 13.8 (C6); HRMS (ESI
+) Calculated for 
C25H33NNaO5S: 482.1972. Found [M+Na]
+: 482.1974. 
(5R*,6S*)-5-Benzyl-6-methyl-1-azabicyclo[3.1.0]hexane (396a)  
 
General procedure P: The preceding N-tosyloxycarbamate 395a (91.9 mg, 0.20 mmol), and 
TFA (31 μL, 0.4 mmol) in anhydrous TFE (2.0 mL) were employed. After stirring at room 
temperature for 48 hours purification by flash column chromatography (~0.1% Et3N in EtOAc) 
afforded 396a (26.5 mg, 71%) as a colourless oil; Rf = 0.31 (EtOAc); νmax / cm
-1 (film) 2955 
(m), 2871 (m), 1495 (m), 1453 (m); 1H NMR (400 MHz, CDCl3) δ 7.30 – 7.18 (5H, m, ArCH), 
3.03 – 2.91 (2H, m, C1-H2), 2.89 (2H, s, C7-H2), 1.89 (1H, dd, J = 12.5, 8.5 Hz, C3-H), 1.71 – 
1.62 (2H, m, C5-H, C3-H’), 1.60 – 1.43 (2H, m, C2-H2) 1.28 (3H, d, J = 6.0 Hz, C6-H3); 
13C NMR (101 MHz, CDCl3) δ 139.7 (ArC), 129.3 (ArCH), 128.4 (ArCH), 126.2 (ArCH), 54.2 




(C4), 53.2 (C1), 37.3 (C7), 36.8 (C5), 30.5 (C2), 22.2 (C3), 14.4 (C6); HRMS (ESI+) Calculated 
for C13H18N: 188.1433. Found [M+H]
+: 188.1438. 
The relative stereochemistry of this compound was determined by nOe experiments as 
indicated on the compound structure. An nOe correlation was observed between C7-H2 and 




To a solution of 2-benzylacrylaldehyde (384) (1.17 g, 8.0 mmol) in anhydrous THF (26 mL) 
at -78 oC was added n-BuLi (2.5 M in hexanes, 3.84 mL, 9.6 mmol) dropwise. The reaction 
mixture was stirred at this temperature for 1 hour then warmed to 0 oC before addition of water 
(20 mL). The phases were separated, and the aqueous phase was extracted with Et2O (3 × 20 
mL) and the combined organic extracts were washed with brine (20 mL), dried over Na2SO4, 
filtered and concentrated in vacuo. Purification by flash column chromatography (20% 
EtOAc:petroleum ether) afforded the title compound (1.28 g, 78%) as a colourless oil; 1H NMR 
(400 MHz, CDCl3) δ 7.33 – 7.27 (2H, m), 7.24 – 7.18 (3H, m), 5.12 (1H, s), 4.75 (1H, t, J = 
1.5 Hz), 4.09 (1H, m), 3.47 (1H, d, J = 15.5 Hz), 3.32 (1H, d, J = 15.5 Hz), 1.67 – 1.50 (2H, 
m), 1.41 – 1.23 (4H, m), 0.90 (3H, t, J = 7.0 Hz); 13C NMR (101 MHz, CDCl3) δ 151.6, 139.6, 
129.4, 128.5, 126.3, 112.1, 74.9, 38.7, 35.3, 27.9, 22.8, 14.2. 




General procedure Q: 2-Benzylhept-1-en-3-ol (1.02 g, 5.0 mmol), propionic acid (75 μL, 1.0 
mmol) and triethyl orthoacetate (9.2 mL, 50 mmol) were employed. Purification by flash 
column chromatography (5% EtOAc:hexane) afforded the title compound (1.04 g, 76%) as a 
colourless oil.; Rf = 0.35 (5% EtOAc:hexane); νmax / cm
-1 (film) 2956 (m), 2927 (m), 1733 (s), 
1452 (m), 1164 (s); 1H NMR (400 MHz, CDCl3) δ 7.30 – 7.24 (2H, m, ArCH), 7.21 – 7.14 




(3H, m, ArCH), 5.36 (1H, t, J = 7.5 Hz, C5-H), 4.09 (2H, q, J = 7.0 Hz, OCH2CH3), 3.41 (2H, 
s, C10-H2), 2.40 – 2.33 (2H, m, C2-H2), 2.29 – 2.22 (2H, m, C3-H2), 2.17 – 2.10 (2H, m, 
C6-H2), 1.42 – 1.29 (4H, m, C7-H2, C8-H2), 1.23 (3H, t, J = 7.0 Hz, OCH2CH3), 0.91 (3H, t, J 
= 7.0 Hz, C9-H3); 
13C NMR (101 MHz, CDCl3) δ 173.5 (C1), 140.0 (ArC), 135.9 (C4), 128.6 
(ArCH), 128.5 (ArCH), 127.6 (C5), 126.1 (ArCH), 60.3 (OCH2CH3), 36.2 (C10), 33.3 (C2), 
32.3 (C7 or C8), 31.8 (C3), 27.9 (C6), 22.5 (C7 or C8), 14.4 (OCH2CH3), 14.2 (C9); HRMS 




General procedure B: Ethyl (Z)-4-benzylnon-4-enoate (960 mg, 3.5 mmol) and 0.8 
equivalents of LiAlH4 (2M in THF) in anhydrous Et2O (7 mL) were employed. Purification by 
flash column chromatography (20% EtOAc:hexane) afforded 394b (700 mg, 86%) as a 
colourless oil; Rf = 0.5 (20% EtOAc:hexane); νmax / cm
-1 (film) 3328 (br s), 2954 (m), 2927 
(m), 1494 (m), 1452 (m), 1055 (m), 1029 (m); 1H NMR (400 MHz, CDCl3) δ 7.29 – 7.23 (2H, 
m, ArCH), 7.20 – 7.14 (3H, m, ArCH), 5.37 (1H, t, J = 7.0 Hz, C5-H), 3.57 (2H, t, J = 6.5 Hz, 
C1-H2), 3.40 (2H, s, C10-H2), 2.19 – 2.12 (2H, m, C6-H2), 2.00 – 1.95 (2H, m, C3-H2), 1.67 – 
1.60 (2H, m, C2-H2), 1.54 – 1.29 (5H, m, OH, C7-H2, C8-H2), 0.91 (3H, t, J = 7.0 Hz, C9-H3); 
13C NMR (101 MHz, CDCl3) δ 140.3 (ArC), 137.0 (C4), 128.7 (ArCH), 128.4 (ArCH), 127.3 
(C5), 126.0 (ArCH), 62.9 (C1), 36.0 (C10), 32.8 (C3), 32.4 (C7 or C8), 31.0 (C2), 28.0 (C6), 
22.6 (C7 or C8), 14.2 (C9); HRMS (ESI+) Calculated for C16H24NaO: 255.1719. Found 
[M+Na]+: 255.1726. 
tert-Butyl (Z)-(4-benzylnon-4-en-1-yl)(tosyloxy)carbamate (395b) 
 
General procedure G: The preceding alcohol 394b (465 mg, 2.0 mmol), PPh3 (629 mg, 2.4 
mmol), DIAD (0.47 mL, 2.4 mmol), and BocNHOTs (689 mg, 2.4 mmol) in anhydrous THF 
(8.0 mL) were employed. Purification by flash column chromatography (gradient, eluent: 5 – 
20% EtOAc:petroleum ether) afforded 395b (911 mg, 91%) as a colourless solid; Rf = 0.55 




(20% EtOAc:hexane); m.p.: 36-38 oC (Et2O:petroleum ether); νmax / cm
-1 (solid) 2925 (m), 2855 
(m), 1719 (s), 1377 (s), 1176 (s); 1H NMR (400 MHz, CDCl3) δ 7.84 (2H, d, J = 8.5 Hz, Ts 
ArCH), 7.32 (2H, d, J = 8.0 Hz, Ts ArCH), 7.28 – 7.23 (2H, m, ArCH), 7.19 – 7.12 (3H, m, 
ArCH), 5.32 (1H, t, J = 7.0 Hz, C5-H), 3.52 (2H, br s, C1-H2), 3.37 (2H, s, C10-H2), 2.44 (3H, 
s, Ts CH3), 2.16 – 2.09 (2H, m, C6-H2), 1.85 (2H, t, J = 7.5 Hz, C3-H2), 1.75 – 1.64 (2H, m, 
C2-H2), 1.41 – 1.30 (4H, m, C7-H2, C8-H2), 1.20 (9H, s, Boc (CH3)3), 0.91 (3H, t, J = 7.0 Hz, 
C9-H3); 
13C NMR (101 MHz, CDCl3) δ 155.6 (Boc C=O), 145.7 (Ts ArC), 140.2 (ArC), 136.1 
(C4), 131.5 (Ts ArC), 129.8 (2 × Ts ArCH), 129.6 (2 × Ts ArCH), 128.6 (ArCH), 128.5 
(ArCH), 127.5 (C5), 126.0 (ArCH), 83.2 (Boc C(CH3)3), 53.0 (C1), 35.9 (C10), 33.4 (C3), 32.4 
(C7 or C8), 28.0 (C6), 27.7 (Boc (CH3)3), 24.0 (C2), 22.6 (C7 or C8), 21.8 (Ts CH3), 14.2 (C9); 




General procedure P: The preceding N-tosyloxycarbamate 395b (100.3 mg, 0.2 mmol), TFA 
(31 μL, 0.4 mmol) in anhydrous TFE (2.0 mL) were employed. The reaction was stirred at 
room temperature for 22 hours. Purification by flash column chromatography (~0.1% Et3N in 
EtOAc) afforded 396b (37.2 mg, 81%) as a colourless oil.; Rf = 0.30 (EtOAc); νmax / cm
-1 (film) 
2955 (m), 2931 (m), 2870 (m), 1687 (m), 1453 (m), 1180 (m), 701 (s); 1H NMR (400 MHz, 
CDCl3) δ 7.30 – 7.18 (5H, m, ArCH), 3.05 – 3.00 (2H, m, C1-H2), 2.98 (1H, d, J = 14.5 Hz, 
C10-H), 2.92 (1H, d, J = 14.5 Hz, C10-H’), 1.92 (1H, dd, J = 13.0, 8.0 Hz, C3-H), 1.75 – 1.33 
(10H, m, C2-H2, C3-H’, C5-H, C6-H2, C7-H2, C8-H2), 0.92 (3H, t, J = 7.0 Hz, C9-H3); 
13C NMR (101 MHz, CDCl3) δ 139.1 (ArC), 129.4 (ArCH), 128.5 (ArCH), 126.3 (ArCH), 54.9 
(C4), 52.9 (C1), 42.9 (C5), 37.0 (C10), 30.4 (C3), 30.3 (C7 or C8), 28.5 (C6), 22.8 (C7 or C8), 












To a solution of 2-benzylacrylaldehyde (384) (1.17 g, 8.0 mmol) in anhydrous THF (18 mL) 
at 0 oC was added i-PrMgCl (2 M in THF, 4.4 mL, 8.8 mmol) dropwise. After stirring at this 
temperature for 1 hour the reaction was quenched with a saturated aqueous Rochelle’s salt (3 
mL). The phases were separated, and the aqueous phase was extracted with Et2O (3 × 20 mL) 
and the combined organic extracts were washed with brine (20 mL), dried over Na2SO4, filtered 
and concentrated in vacuo. Purification by flash column chromatography (gradient, eluent: 10 
– 20% EtOAc:petroleum ether) afforded the title compound (335 mg, 22%) as a colourless oil; 
Rf = 0.60 (20% EtOAc:hexane); νmax / cm
-1 (film) 3427 (br), 2958 (m), 1453 (m), 1012 (m); 
1H NMR (400 MHz, CDCl3) δ 7.33 – 7.27 (2H, m, ArCH), 7.24 – 7.18 (3H, m, ArCH), 5.09 
(1H, t, J = 1.0 Hz, C3-H), 4.75 (1H, q, J = 1.5 Hz, C3-H’), 3.80 (1H, d, J = 6.5 Hz, C1-H), 3.46 
(1H, d, J = 15.5 Hz, C4-H), 3.29 (1H, d, J = 15.5 Hz, C4-H’), 1.93 – 1.83 (1H, m, C5-H), 1.59 
(1H, br s, OH), 0.96 (3H, d, J = 7.0 Hz, C6-H3), 0.91 (3H, d, J = 7.0 Hz, C6’-H3); 
13C NMR 
(101 MHz, CDCl3) δ 150.7 (C2), 139.5 (ArC), 129.5 (ArCH), 128.5 (ArCH), 126.3 (ArCH), 
113.1 (C3), 80.5 (C1), 38.7 (C4), 31.3 (C5), 19.8 (C6), 17.4 (C6’); HRMS (ESI+) Calculated 




General procedure Q: 2-Benzyl-4-methylpent-1-en-3-ol (287 mg, 1.51 mmol), propionic acid 
(22 μL, 0.30 mmol) and triethyl orthoacetate (2.77 mL, 15.1 mmol) were employed. 
Purification by flash column chromatography (2% EtOAc:petroleum ether) afforded the title 
compound (200 mg, 51%) as a pale-yellow oil; Rf = 0.70 (10% EtOAc:hexane); νmax / cm
-1 
(film) 2956 (m), 1733 (s), 1452 (m), 1154 (s); 1H NMR (400 MHz, CDCl3) δ 7.29 – 7.24 (2H, 
m, ArCH), 7.20 – 7.13 (3H, m, ArCH), 5.16 (1H, d, J = 9.5 Hz, C5-H), 4.08 (2H, q, J = 7.0 Hz, 
OCH2CH3), 3.40 (2H, s, C8-H2), 2.69 – 2.59 (1H, m, C6-H), 2.37 – 2.31 (2H, m, C2-H2), 2.22 
– 2.17 (2H, m, C3-H2), 1.22 (3H, t, J = 7.0 Hz, OCH2CH3), 0.97 (6H, d, J = 6.5 Hz, C7-H3); 




13C NMR (101 MHz, CDCl3) δ 173.5 (C1), 140.0 (ArC), 135.2 (C5), 133.4 (C4), 128.6 (ArCH), 
128.5 (ArCH), 126.1 (ArCH), 60.3 (OCH2CH3), 36.3 (C8), 33.4 (C2), 31.6 (C3), 27.4 (C6), 
23.5 (C7), 14.4 (OCH2CH3); HRMS (ESI




General procedure B: Ethyl (Z)-4-benzyl-6-methylhept-4-enoate (198 mg, 0.76 mmol) and 
0.8 equivalents of LiAlH4 (2M in THF) in anhydrous Et2O (2.0 mL) were employed. 
Purification by flash column chromatography (gradient, eluent: 10 – 25% EtOAc:petroleum 
ether) afforded 394c (127 mg, 77%) as a colourless oil; Rf = 0.4 (20% EtOAc:hexane); νmax / 
cm-1 (film) 3336 (br m), 2953 (m), 2856 (m), 1452 (m), 728 (m), 697 (m); 1H NMR (400 MHz, 
CDCl3) δ 7.31 – 7.26 (2H, m, ArCH), 7.22 – 7.16 (3H, m, ArCH), 5.20 (1H, d, J = 9.5 Hz, 
C5-H), 3.57 (2H, t, J = 6.5 Hz, C1-H2), 3.43 (2H, s, C8-H2), 2.74 – 2.64 (1H, m, C6-H), 1.98 
– 1.93 (2H, m, C3-H2), 1.82 – 1.60 (3H, m, C2-H2, OH), 1.02 (6H, d, J = 6.5 Hz, C7-H3); 
13C NMR (101 MHz, CDCl3) δ 140.2 (ArC), 134.8 (C5), 134.5 (C4), 128.6 (ArCH), 128.4 
(ArCH), 126.0 (ArCH), 63.8 (C1), 36.1 (C8), 32.6 (C3), 30.9 (C2), 27.3 (C6), 23.6 (C7); 
HRMS (ESI+) Calculated for C15H22NaO: 241.1563. Found [M+Na]
+: 241.1564. 
tert-Butyl (Z)-(4-benzyl-6-methylhept-4-en-1-yl)(tosyloxy)carbamate (395c)  
 
General procedure G: The preceding alcohol 394c (120 mg, 0.55 mmol), PPh3 (173 mg, 0.66 
mmol), DIAD (0.13 mL, 0.66 mmol) and BocNHOTs (189 mg, 0.66 mmol) in anhydrous THF 
(3.0 mL) were employed. Purification by flash column chromatography (5% EtOAc:hexane) 
afforded 395c (198 mg, 74%) as a colourless solid; m.p.: 64-66 oC (CH2Cl2:hexane); νmax / cm
 1 
(solid) 2964 (m), 2953 (m), 2934 (m), 1716 (s), 1365 (s), 1175 (s); 1H NMR (400 MHz, CDCl3) 
δ 7.84 (2H, d, J = 8.5 Hz, Ts ArCH), 7.32 (2H, d, J = 8.5 Hz, Ts ArCH), 7.29 – 7.24 (2H, m, 
ArCH), 7.20 – 7.12 (3H, m, ArCH), 5.14 (1H, d, J = 9.5 Hz, C5-H), 3.52 (2H, br s, C1-H2), 




3.38 (2H, s, C8-H2), 2.72 – 2.59 (1H, m, C6-H), 2.44 (3H, s, Ts CH3), 1.84 – 1.80 (2H, m, C3-
H2), 1.76 – 1.63 (2H, m, C2-H2), 1.21 (9H, s, Boc (CH3)3), 0.99 (6H, d, J = 6.5 Hz, C7-H3); 
13C NMR (101 MHz, CDCl3) δ 155.9 (Boc C=O), 145.7 (Ts ArC), 140.1 (ArC), 135.1 (C5), 
133.6 (C4), 131.4 (Ts ArC), 129.8 (2 × Ts ArCH), 129.6 (2 × Ts ArCH), 128.6 (ArCH), 128.5 
(ArCH), 126.0 (ArCH), 83.2 (Boc C(CH3)3), 52.9 (C1), 36.0 (C8), 33.2 (C3), 27.7 (Boc 
(CH3)3), 27.4 (C6), 23.9 (C2), 23.6 (C7), 21.8 (Ts CH3); HRMS (ESI
+) Calculated for 




General procedure P: The preceding N-tosyloxycarbamate 395c (97.5 mg, 0.2 mmol) and 
TFA (31 μL, 0.4 mmol) in anhydrous TFE (2.0 mL) were employed. After stirring for 46 hours 
purification by flash column chromatography (~0.1% Et3N in EtOAc) afforded 396c (34.6 mg, 
80%) as a colourless oil; νmax / cm
-1 (film) 2957 (m), 2868 (m), 1494 (m), 1453 (s), 1181 (m), 
1063 (m); 1H NMR (400 MHz, CDCl3) δ 7.32 – 7.25 (4H, m, ArCH), 7.22 – 7.17 (1H, m, 
ArCH), 2.99 – 2.87 (4H, m, C1-H2, C8-H2), 1.94 – 1.87 (1H, m, C3-H), 1.69 – 1.49 (4H, m, 
C2-H2, C3-H’, C6-H), 1.23 (1H, d, J = 9.5 Hz, C5-H), 1.10 (3H, d, J = 6.5 Hz, C7-H3), 0.93 
(3H, d, J = 6.5 Hz, C7’-H3); 
13C NMR (101 MHz, CDCl3) δ 139.6 (ArC), 129.7 (ArCH), 128.3 
(ArCH), 126.2 (ArCH), 54.6 (C4), 53.7 (C1), 49.6 (C5), 36.9 (C8), 30.1 (C3), 28.5 (C6), 22.3 





The title compound was prepared according to a literature procedure.331 
1H NMR (400 MHz, CDCl3) δ 9.82 (1H, t, J = 1.5 Hz), 7.30 (1H, dd, J = 2.0, 1.0 Hz), 6.28 
(1H, dd, J = 3.0, 2.0 Hz), 6.02 (1H, dd, J = 3.0, 1.0 Hz), 2.98 (2H, t, J = 7.5 Hz), 2.85 – 2.68 
(2H, m). 
 






The title compound was prepared according to a literature procedure.327 
To a solution of pyrrolidine (54 µL, 0.64 mmol) and 4-(dimethylamino)benzoic acid (213 mg, 
1.28 mmol) in dichloromethane (6.44 mL) were added formaldehyde (37% solution in H2O, 
0.51 mL, 6.44 mmol) and 3-(furan-2-yl)propanal (800 mg, 6.44 mmol) at room temperature. 
The reaction mixture was rapidly heated to 45 °C and stirred for 1 hour. The reaction mixture 
was then added to saturated aqueous NaHCO3 (10 mL) and the resulting mixture extracted with 
CH2Cl2 (3 × 10 mL). The combined organic extracts were then washed with brine (10 mL), 
dried over Na2SO4, and concentrated in vacuo to obtain the crude product (896 mg, 
quantitative), which was used for the next step without further purification; 1H NMR (400 
MHz, CDCl3) δ 9.58 (1H, s), 7.32 – 7.30 (1H, m), 6.30 – 6.28 (1H, m), 6.22 – 6.20 (1H, m), 
6.10 -6.09 (1H, m), 6.08 – 6.06 (1H, m), 3.59 – 3.56 (2H, m); 13C NMR (101 MHz, CDCl3) δ 




To a solution of MeMgBr (3.0 M in Et2O, 2.95 mL, 8.85 mmol) in anhydrous Et2O (10 mL) at 
0 oC was added 3-(furan-2-yl)but-3-enal (809 mg, 5.90 mmol) dropwise. The reaction mixture 
was stirred for 45 minutes at room temperature before addition of saturated aqueous NH4Cl (10 
mL). The phases were separated, and the aqueous phase extracted with Et2O (2 × 10 mL). The 
combined organic extracts were washed with brine (10 mL), dried over Na2SO4, filtered and 
concentrated in vacuo to afford the title compound (873 mg, 97%) as a pale-yellow oil, which 
was used without further purification; νmax / cm
-1 (film) 3357 (br m), 2975 (m), 2899 (m), 1505 
(m), 1071 (s), 1010 (s), 896 (s); 1H NMR (400 MHz, CDCl3) δ 7.31 (1H, dd, J = 2.0, 1.0 Hz, 
C9-H), 6.29 (1H, dd, J = 3.0, 2.0 Hz, C8-H), 6.08 – 6.06 (1H, m, C7-H), 5.14 – 5.12 (1H, m, 
C4-H’), 4.84 – 4.81 (1H, m, C4-H), 4.27 (1H, q, J = 6.5 Hz, C2-H), 3.43 (2H, q, J = 16.5 Hz, 
C5-H2), 2.12 (1H, br s, OH), 1.28 (3H, d, J = 6.5 Hz, C1-H3); 
13C NMR (101 MHz, CDCl3) δ 




153.2 (C6), 149.5 (C3), 141.2 (C9), 111.0 (C4), 110.2 (C8), 106.4 (C7), 70.0 (C2), 30.9 (C5), 
21.7 (C1); HRMS (APCI+) Calculated for C9H12O2: 153.0910. Found [M+H]
+: 153.0911. 
Ethyl (Z)-4-(furan-2-ylmethyl)hex-4-enoate  
 
General procedure Q: 4-(Furan-2-yl)pent-4-en-2-ol (873 mg, 5.70 mmol), propionic acid (86 
μL, 1.15 mmol) and triethyl orthoacetate (10.4 mL, 57.0 mmol) were employed. The title 
compound was obtained as an orange oil (983 mg, 76%) which was used without further 
purification; νmax / cm
-1 (film) 2980 (m), 2931 (m), 1732 (s), 1160 (s), 1148 (s);  1H NMR (400 
MHz, CDCl3) δ 7.29 (1H, dd, J = 2.0, 1.0 Hz, C11-H), 6.26 (1H, dd, J = 3.0, 2.0 Hz, C10-H), 
5.97 (1H, dd, J = 3.0, 1.0 Hz, C9-H), 5.45 – 5.38 (1H, m, C5-H), 4.10 (2H, q, J = 7.0 Hz, 
COCH2CH3), 3.37 (2H, s, C7-H2), 2.40 – 2.28 (4H, m, C2-H2 and C3-H2), 1.67 (3H, dd, J = 
6.5 Hz, C6-H3), 1.23 (3H, t, J = 7.0 Hz, COCH2CH3); 
13C NMR (101 MHz, CDCl3) δ 173.4 
(C1), 153.7 (C8), 141.2 (C11), 134.5 (C4), 122.0 (C5), 110.3 (C10), 105.8 (C9), 60.3 
(CH2CH3), 33.2 (C3), 32.2 (C2), 28.9 (C7), 14.3 (CH2CH3), 13.5 (C6); HRMS (APCI
+) 




General procedure B: Ethyl (Z)-4-(furan-2-ylmethyl)hex-4-enoate (983 mg, 4.42 mmol) and 
0.8 equivalents of LiAlH4 (3.54 mmol, 2 M in THF) in anhydrous Et2O (20 mL) were 
employed. 394d was obtained as a yellow oil (697 mg, 87%) which was used without further 
purification; Rf = 0.20 (20% EtOAc:hexane); νmax / cm
-1 (film) 3336 (br m), 2922 (m), 1505 
(m), 1147 (m), 1055 (s), 1009 (s), 725 (s); 1H NMR (400 MHz, CDCl3) δ 7.30 (1H, dd, J = 2.0, 
1.0 Hz, C11-H), 6.27 (1H, dd, J = 3.0, 2.0 Hz, C10-H), 5.98 (1H, dd, J = 3.0, 1.0 Hz, C9-H), 
5.46 – 5.41 (1H, m, C5-H), 3.60 (2H, t, J = 6.5 Hz, C1-H2), 3.38 (2H, s, C7-H2), 2.10 – 2.06 
(2H, m, C3-H2), 1.70 – 1.61 (5H, m, C2-H2, C6-H3), 1.26 (1H, br s, OH); 
13C NMR (101 MHz, 




CDCl3) δ 154.1 (C8), 141.2 (C11), 135.7 (C4), 121.6 (C5), 110.3 (C10), 105.8 (C9), 62.9 (C1), 
33.4 (C3), 31.1 (C2), 28.9 (C7), 13.6 (C6). 
tert-Butyl (Z)-(4-(furan-2-ylmethyl)hex-4-en-1-yl)(tosyloxy)carbamate (395d) 
 
General procedure G: The preceding alcohol 394d (697 mg, 3.87 mmol), PPh3 (1.22 g, 4.64 
mmol), DIAD (0.91 mL, 4.64 mmol) and BocNHOTs (1.33 g, 4.64 mmol) in anhydrous THF 
(15 mL) were employed. Purification by flash column chromatography (gradient, eluent: 5 – 
10% EtOAc:hexane) afforded 395d (1.07 g, 62%) as a viscous, colourless oil; Rf = 0.55 (20% 
EtOAc:hexane); νmax / cm
-1 (film) 2986 (m), 2931 (m), 1719 (s), 1379 (s), 1368 (s), 1191 (s), 
1178 (s), 1152 (s); 1H NMR (400 MHz, CDCl3) δ 7.85 (2H, d, J = 8.5 Hz, Ts ArCH), 7.34 (2H, 
d, J = 8.5 Hz, Ts ArCH), 7.29 (1H, dd, J = 2.0, 1.0 Hz, C11-H), 6.26 (1H, dd, J = 3.0, 2.0 Hz, 
C10-H), 5.96 (1H, dd, J = 3.0, 1.0 Hz, C9-H), 5.41 – 5.36 (1H, m, C5-H), 3.54 (2H, br s, 
C1-H2), 3.35 (2H, s, C7-H2), 2.45 (3H, s, Ts CH3), 1.97 – 1.92 (2H, m, C3-H2), 1.75 – 1.66 
(5H, m, C2-H2, C6-H3), 1.21 (9H, s, Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) δ 155.6 (Boc 
C=O), 153.9 (C8), 145.8 (Ts ArC), 141.2 (C11), 134.8 (C4), 131.4 (Ts ArC), 129.8 (2 × Ts 
ArCH), 129.6 (2 × Ts ArCH), 121.7 (C5), 110.3 (C10), 105.8 (C9), 83.3 (Boc C(CH3)3), 52.9 
(C1), 33.9 (C3), 28.8 (C7), 27.8 (Boc (CH3)3), 24.0 (C2), 21.8 (Ts CH3), 13.5 (C6); HRMS 




General procedure P: The preceding N-tosyloxycarbamate 395d (89.9 mg, 0.2 mmol), and 
TFA (31 μL, 0.4 mmol) in anhydrous TFE (0.1 M) were employed. After stirring for 48 hours 
purification by flash column chromatography (~0.1% Et3N in 33% EtOAc:hexane) afforded 
396d (17.1 mg, 48%) as a colourless oil; Rf = 0.01 (EtOAc); νmax / cm
-1 (film) 2958 (m), 2876 
(m), 1505 (m), 1146 (s), 1009 (s), 731 (s), 723 (s); 1H NMR (400 MHz, CDCl3) δ 7.32 (1H, 




dd, J = 2.0, 1.0 Hz, C11-H), 6.29 (1H, dd, J = 3.0, 2.0 Hz, C10-H), 6.06 (3.0, 1.0 Hz, C9-H), 
3.01 – 2.83 (4H, m, C1-H2, C7-H2), 2.02 (1H, dd, J = 13.0, 8.5 Hz, C3-H), 1.78 – 1.69 (1H, m, 
C3-H’), 1.68 – 1.59 (2H, m, C2-H, C5-H), 1.58 – 1.46 (1H, m, C2-H’), 1.21 (3H, d, J = 6.0 
Hz, C6-H3); 
13C NMR (101 MHz, CDCl3) δ 153.7 (C8), 141.2 (C11), 110.3 (C10), 106.3 (C9), 
53.2 (C1), 52.6 (C4), 36.7 (C5), 30.9 (C3), 30.5 (C7), 22.4 (C2), 14.1 (C6); HRMS (ESI+) 




General procedure P: N-Tosyloxycarbamate 397a (94.3 mg, 0.195 mmol) and TFA (31 μL, 
0.4 mmol) in anhydrous TFE (2.0 mL) were employed. After stirring at room temperature for 
41 hours purification by flash column chromatography (0.1% Et3N in EtOAc) afforded 398a 
(33.6 mg, 81%) as a colourless oil; Rf = 0.30 (EtOAc); νmax / cm
-1 (film) 2959 (m), 2935 (m), 
2871 (m), 1640 (m), 1494 (m), 1453 (m), 909 (s); 1H NMR (400 MHz, CDCl3) δ 7.33 – 7.26 
(4H, m ArCH), 7.25 – 7.19 (1H, m, ArCH), 5.95 (1H, ddt, J = 16.5, 10.0, 6.5 Hz, C7-H), 5.18 
– 5.06 (2H, m, C8-H2), 3.06 – 2.89 (4H, m, C1-H2, C9-H2), 2.38 – 2.32 (2H, m, C6-H2), 1.94 
(1H, dd, J = 12.5, 8.5 Hz, C3-H), 1.73 – 1.51 (4H, m, C2-H2, C3-H’, C5-H); 
13C NMR (101 
MHz, CDCl3) δ 139.4 (ArC), 136.3 (C7), 129.5 (ArCH), 128.4 (ArCH), 126.2 (ArCH), 115.9 
(C8), 54.2 (C4), 53.5 (C1), 41.2 (C5), 37.3 (C9), 33.6 (C6), 30.4 (C3), 22.2 (C2); HRMS (ESI+) 
Calculated for C15H19N: 214.1590. Found [M+H]
+: 214.1590. 
The relative stereochemistry of this compound was determined by nOe experiments as 













General procedure P: N-Tosyloxycarbamate 397b (91.9 mg, 0.2 mmol) and TFA (31 μL, 0.4 
mmol) in anhydrous TFE (2.0 mL) were employed. The reaction was stirred at room 
temperature for 24 hours. Purification by flash column chromatography (~0.1% Et3N in 
EtOAc) afforded 398b (27.3 mg, 73%) as a pale-yellow oil; Rf = 0.15 (EtOAc); νmax / cm
-1 
(film) 2950 (m), 2873 (m), 1493 (m), 1453 (m), 730 (s), 697 (s); 1H NMR (400 MHz, CDCl3) 
δ 7.32 – 7.24 (4H, m, ArCH), 7.23 – 7.18 (1H, m, ArCH), 3.04 – 2.95 (2H, m, C1-H2), 2.81 
(1H, dd, J = 15.0, 6.5 Hz, C6-H), 2.68 (1H, dd, 15.0, 6.0 Hz, C6-H’), 2.09 (1H, dd, J = 12.5, 
8.5 Hz, C3-H), 1.76 – 1.60 (3H, m, C3-H’, C5-H, C2-H), 1.58 – 1.48 (1H, m, C2-H’), 1.37 
(3H, s, C7-H3); 
13C NMR (101 MHz, CDCl3) δ 140.5 (ArC), 128.6 (ArCH), 128.5 (ArCH), 
126.2 (ArCH), 53.4 (C1), 50.1 (C4), 42.8 (C5), 35.4 (C6), 33.2 (C3), 22.4 (C2), 17.3 (C7); 
HRMS (ESI+) Calculated for C13H18N: 188.1434. Found [M+H]
+: 188.1439. 
The relative stereochemistry of this compound was determined by nOe experiments as 
indicated on the compound structure. nOe correlations were observed between C6-H2 and 





General procedure P: N-Tosyloxycarbamate 397c (66.2 mg, 0.1 mmol) and 3.0 equivalents 
of TFA (23 μL) in anhydrous TFE (1.0 mL) were employed. Purification by flash column 
chromatography (~0.1% Et3N in EtOAc) afforded 398c (26.3 mg, 67%) as a yellow oil; Rf = 
0.60 (EtOAc); νmax / cm
-1 (film) 2954 (m), 2929 (m), 1609 (m), 1504 (s), 1161 (s), 837 (s), 778 




(s); 1H NMR (400 MHz, CDCl3) δ 7.22 (1H, d, J = 8.5 Hz, C12-H), 6.48 (1H, dd, J = 8.5, 2.5 
Hz, C13-H), 6.37 (1H, d, J = 2.5 Hz, C15-H), 3.76 (3H, s, C17-H3), 2.98 – 2.74 (4H, m, C1-H2, 
C10-H2), 1.96 – 1.90 (1H, m, C3-H), 1.67 – 1.30 (10H, m, C3-H’, C2-H2, C6-H2, C7-H2, 
C8-H2, C5-H), 1.01 (9H, s, TBS SiC(CH3)3), 0.91 (3H, t, J = 7.0 Hz, C9-H3), 0.22 (3H, s, TBS 
SiCH3), 0.22 (3H, s, TBS SiCH3); 
13C NMR (101 MHz, CDCl3) δ 158.6 (C14), 154.6 (C16), 
130.7 (C12), 122.6 (C11), 106.0 (C13), 105.4 (C15), 55.4 (C17), 54.2 (C4), 53.5 (C1), 42.3 
(C5), 30.6 (C6 or C7 or C8), 30.6 (C3), 29.5 (C10), 28.9 (C6 or C7 or C8), 26.0 (TBS 
SiC(CH3)3), 22.9 (C6 or C7 or C8), 22.3 (C2), 18.4 (TBS SiC(CH3)3), 14.3 (C9), -3.9 (TBS 
SiCH3), -4.0 (TBS SiCH3); HRMS (ESI




General procedure P: N-Tosyloxycarbamate 397d (101.9 mg, 0.2 mmol), and TFA (31 μL, 
0.4 mmol) in anhydrous TFE (0.1 M) were employed. After stirring for 48 hours purification 
by flash column chromatography (~0.1% Et3N in 33% EtOAc:hexane) afforded 398d (33.5 
mg, 71%) as a yellow oil; Rf = 0.1 (EtOAc); νmax / cm
-1 (film) 2955 (m), 2929 (m), 2869 (m), 
791 (s), 778 (s); 1H NMR (400 MHz, CDCl3) δ 8.22 (1H, d, J = 8.5 Hz, ArCH), 7.85 (1H, dd, 
J = 8.0, 1.5 Hz, ArCH), 7.74 (1H, d, J = 8.0 Hz, ArCH), 7.56 – 7.40 (4H, m, ArCH), 3.46 (1H, 
d, J = 15.5 Hz, C7-H), 3.31 (1H, d, J = 15.5 Hz, C7-H’), 3.06 – 2.90 (2H, m, C1-H2), 1.99 – 
1.92 (1H, m, C3-H), 1.81 (1H, q, J = 6.0 Hz, C5-H), 1.58 – 1.46 (3H, m, C2-H2, C3-H’), 1.31 
(3H, d, J = 6.0 Hz, C6-H3); 
13C NMR (101 MHz, CDCl3) δ 135.9 (ArC), 133.8 (ArC), 132.7 
(ArC), 128.7 (ArCH), 126.9 (ArCH), 126.7 (ArCH), 126.0 (ArCH), 125.6 (ArCH), 125.5 
(ArCH), 124.7 (ArCH), 53.3 (C4), 52.8 (C1), 37.1 (C5), 34.2 (C7), 30.2 (C3), 22.3 (C2), 14.1 
(C6); HRMS (ESI+) Calculated for C17H20N: 238.1590. Found [M+H]
+: 238.1593. 
The relative stereochemistry of this compound was determined by nOe experiments as 











This compound was prepared according to a literature procedure.332 
To a solution of diethyl 2-benzylmalonate (12.5 g, 50.0 mmol) in EtOH (45 mL) was added a 
solution of KOH (2.80 g, 50.0 mmol) in EtOH (45 mL) and the reaction was stirred overnight. 
The reaction was concentrated in vacuo, diluted with ice-cold H2O and extracted with Et2O. 
The aqueous solution was acidified to pH 2 with concentrated HCl and extracted with Et2O, 
dried over Na2SO4, filtered and concentrated in vacuo to give the title compound (8.75 g, 79%) 
which was used without further purification; 1H NMR (400 MHz, CDCl3) δ 8.73 (1H, br s), 
7.31 – 7.19 (5H, m), 4.17 (2H, q, J = 7.0 Hz), 3.70 (1H, t, J = 7.5 Hz), 3.24 (2H, d, J = 7.5 Hz), 
1.20 (3H, t, J = 7.0 Hz). 




This compound was prepared based on a literature procedure.332 
To a solution of 2-benzyl-3-ethoxy-3-oxopropanoic acid (8.73 g, 39.3 mmol) in diethylamine 
(4.2 mL) and CH2Cl2 (5 mL) at 0 
oC was added formaldehyde (37% aqueous solution, 4.1 mL) 
and the reaction was stirred at room temperature overnight. The reaction was extracted with 
Et2O (3 × 50 mL) and washed with aqueous 2 M HCl (50 mL) and then a saturated aqueous 
solution of NaHCO3 (50 mL) and finally brine (50 mL). The combined organic extracts were 
dried over Na2SO4 and concentrated in vacuo. The title compound (7.14 g, 96%) was obtained 
as a colourless oil which was used without further purification; 1H NMR (400 MHz, CDCl3) δ 
7.33 – 7.28 (2H, m), 7.23 – 7.20 (3H, m), 6.25 – 6.24 (1H, m), 5.47 – 5.45 (1H, m), 4.19 (2H, 
q, J = 7.0 Hz), 3.65 (2H, s), 1.27 (3H, t, J = 7.0 Hz); 13C NMR (101 MHz, CDCl3) δ 167.0, 
140.5, 138.9, 129.2, 128.5, 126.4, 126.1, 60.8, 38.2, 14.3. 
The spectroscopic properties were consistent with the data available in the literature.334 
 
 







A solution of ethyl 2-benzylacrylate (3.80 g, 20.0 mmol) in anhydrous Et2O (25 mL) was 
cooled to 0 oC before addition of MeMgBr (3.0 M in Et2O, 14.6 mL, 44.0 mmol) dropwise over 
30 minutes. The reaction was stirred at room temperature for 1 hour then quenched with 
saturated aqueous NH4Cl (20 mL). The layers were separated, and the aqueous phase extracted 
with Et2O (3 × 50 mL) and the combined organic extracts were washed with brine (50 mL), 
dried over Na2SO4, filtered and concentrated in vacuo. Purification by flash column 
chromatography (20% EtOAc:petroleum ether) afforded 399 (1.54 g, 44%) as a colourless oil; 
Rf = 0.40 (20% EtOAc:hexane); νmax / cm
-1 (film) 3388 (br s), 2976 (m), 1128 (s), 904 (s); 
1H NMR (400 MHz, CDCl3) δ 7.32 – 7.28 (2H, m, ArCH), 7.23 – 7.18 (3H, m, ArCH), 5.21 – 
5.20 (1H, m, C4-H), 4.59 – 4.58 (1H, m, C4-H’), 3.47 (2H, s, C5-H2), 1.51 (1H, br s, OH), 1.39 
(6H, s, C1-H3); 
13C NMR (101 MHz, CDCl3) δ 155.7 (C3), 140.3 (ArC), 129.4 (ArCH), 128.5 
(ArCH), 126.2 (ArCH), 110.7 (C4), 73.6 (C2), 38.5 (C5), 29.7 (C1); HRMS (ESI+) Calculated 
for C12H15: 159.1168. Found [M+H-H2O]
+: 159.1170. 
 
Ethyl 4-benzyl-5-methylhex-4-enoate  
 
General procedure Q: The preceding allylic alcohol 399 (1.32 g, 7.5 mmol), propionic acid 
(0.11 mL, 1.50 mmol) and triethyl orthoacetate (13.7 mL, 75 mmol) were employed. 
Purification by flash column chromatography (5% EtOAc:petroleum ether) afforded the title 
compound (1.18 g, 64%) as a colourless oil; Rf = 0.70 (20% EtOAc:hexane); νmax / cm
-1 (film) 
2981 (m), 2927 (m), 1732 (s), 1162 (s); 1H NMR (400 MHz, CDCl3) δ 7.30 – 7.25 (2H, m, 
ArCH), 7.20 – 7.13 (3H, m, ArCH), 4.09 (2H, q, J = 7.0 Hz, CO2CH2CH3), 3.43 (2H, s, C7-H2), 
2.37 – 2.31 (2H, m, C3-H2), 2.30 – 2.25 (2H, m, C2-H2), 1.78 (6H, s, C6-H3), 1.23 (3H, t, J = 
7.0 Hz, CO2CH2CH3); 
13C NMR (101 MHz, CDCl3) δ 173.6 (C1), 140.7 (ArC), 129.2 (C4 or 
C5), 128.5 (ArCH), 128.4 (ArCH), 128.4 (C4 or C5), 125.9 (ArCH), 60.4 (CO2CH2CH3), 37.7 




(C7), 33.4 (C2), 27.7 (C3), 21.1 (C6), 20.5 (C6’), 14.3 (CO2CH2CH3); HRMS (ESI
+) 




General procedure B: Ethyl 4-benzyl-5-methylhex-4-enoate (932 mg, 3.78 mmol) and 0.8 
equivalents of LiAlH4 (1M in THF) in anhydrous Et2O (20 mL) were employed. Purification 
by flash column chromatography (20% EtOAc:petroleum ether) afforded 400 (584 mg, 76%) 
as a colourless oil; Rf = 0.20 (20% EtOAc:hexane); νmax / cm
-1 (film) 3330 (br s), 2918 (m), 
2853 (m), 1493 (m), 1451 (m), 1057 (m), 1030 (m); 1H NMR (400 MHz, CDCl3) δ 7.29 – 7.24 
(2H, m, ArCH), 7.20 – 7.13 (3H, m, ArCH), 3.56 (2H, t, J = 6.5 Hz, C1-H2), 3.44 (2H, s, 
C7-H2), 2.06 (2H, dd, J = 9.5, 6.5 Hz, C3-H2), 1.79 (3H, s, C6-H3), 1.77 (3H, s, C6’-H3), 1.63 
(1H, br s, OH), 1.62 – 1.54 (2H, m, C2-H2); 
13C NMR (101 MHz, CDCl3) δ 141.0 (ArC), 130.4 
(C4), 128.6 (ArCH), 128.4 (ArCH), 127.3 (C5), 125.9 (ArCH), 63.2 (C1), 37.9 (C7), 31.7 (C2), 
28.4 (C3), 21.0 (C6), 20.5 (C6’); HRMS (ESI+) Calculated for C14H20NaO: 227.1406. Found 
[M+Na]+: 227.1397. 
tert-Butyl (4-benzyl-5-methylhex-4-en-1-yl)(tosyloxy)carbamate (401) 
 
General procedure G: The preceding alcohol 400 (409 mg, 2.0 mmol), PPh3 (629 mg, 2.4 
mmol), DIAD (0.47 mL, 2.4 mmol) and BocNHOTs (689 mg, 2.4 mmol) in anhydrous THF (8 
mL) were employed. Purification by flash column chromatography (10% EtOAc:petroleum 
ether) afforded 401 (791 mg, 84%) as a colourless, viscous oil; Rf = 0.4 (4:1 hexane:EtOAc); 
νmax / cm
-1 (film) 2981 (m), 2929 (m), 1720 (s), 1379 (s), 1368 (s), 1191 (s), 1177 (s), 1156 (s); 
1H NMR (400 MHz, CDCl3) δ 7.84 (2H, d, J = 8.5 Hz, Ts ArCH), 7.32 (2H, d, J = 8.5 Hz, Ts 
ArCH), 7.28 – 7.22 (2H, m, ArCH), 7.18 – 7.10 (3H, m, ArCH), 3.52 (2H, br s, C1-H2), 3.39 
(2H, s, C7-H2), 2.44 (3H, s, Ts CH3), 1.92 (2H, t, J = 8.0 Hz, C3-H2), 1.76 (3H, s, C6-H3), 1.72 
(3H, s, C6’-H3), 1.68 – 1.59 (2H, m, C2-H2), 1.19 (9H, s, Boc (CH3)3); 
13C NMR (101 MHz, 




CDCl3) δ 155.6 (Boc C=O), 145.7 (Ts ArC), 140.9 (ArC), 131.5 (Ts ArC), 129.9 (C4 or C5), 
129.8 (2 × Ts ArCH), 129.6 (2 × Ts ArCH), 128.6 (ArCH), 128.4 (ArCH), 127.5 (C4 or C5), 
125.9 (ArCH), 83.2 (Boc C(CH3)3), 53.1 (C1), 37.6 (C7), 29.0 (C3), 27.7 (Boc (CH3)3), 24.8 
(C2), 21.8 (Ts CH3), 21.0 (C6), 20.6 (C6’); HRMS (ESI
+) Calculated for C26H35NNaO5S: 
496.2128. Found [M+Na]+: 496.2112. 
5-Benzyl-6,6-dimethyl-1-azabicyclo[3.1.0]hexane (402) 
  
General procedure P: The preceding N-tosyloxycarbamate 401 (94.7 mg, 0.2 mmol) and TFA 
(31 μL, 0.4 mmol) in anhydrous TFE (2 mL) were employed. After stirring for 48 hours 
purification by flash column chromatography (~0.1% Et3N in EtOAc) afforded 402 (36.2 mg, 
90%) as a colourless oil; Rf = 0.05 (EtOAc); νmax / cm
-1 (film) 2951 (m), 2924 (m), 2878 (m), 
1494 (m), 1452 (m), 1114 (m); 1H NMR (400 MHz, CDCl3) δ 7.30 – 7.17 (5H, m, ArCH), 3.23 
(1H, ddd, J = 13.0, 10.20, 6.0 Hz, C1-H), 2.97 (1H, d, J = 15.0 Hz, C7-H), 2.88 (1H, d, J = 
15.0 Hz, C7-H’), 2.70 (1H, ddd, J = 13.0, 9.5, 5.5 Hz, C1-H’), 1.97 – 1.85 (1H, m, C2-H), 1.83 
– 1.71 (2H, m, C3-H2), 1.68 – 1.57 (1H, m, C2-H’), 1.31 (3H, s, C6-H3), 1.09 (3H, s, C6’-H3); 
13C NMR (101 MHz, CDCl3) δ 140.1 (ArC), 129.0 (ArCH), 128.4 (ArCH), 126.0 (ArCH), 59.7 
(C4), 49.8 (C1), 44.3 (C5), 39.6 (C7), 30.0 (C2), 29.7 (C3), 24.6 (C6), 15.9 (C6’); HRMS 





The title compound was prepared according to a literature procedure.335  
To a stirred solution of iodobenzene (2.04 g, 10.0 mmol) in Et3N (20 mL) under an atmosphere 
of nitrogen were added Pd(PPh3)2Cl2 (105.3 mg, 0.15 mmol) and CuI (57.1 mg, 0.3 mmol). 
The reaction was stirred at room temperature for 10 minutes then 5-hexyn-1-ol (1.21 mL, 11.0 
mmol) was added and then reaction was stirred at room temperature overnight. The reaction 
mixture was poured into a saturated aqueous solution of NH4Cl (20 mL) and extracted with 




Et2O. The organic extracts were washed with brine, dried over Na2SO4 and concentrated in 
vacuo. Purification by flash column chromatography (gradient, eluent: 20 – 33% 
EtOAc:petroleum ether) afforded 403 (1.74 g, 99%) as a brown oil; 1H NMR (400 MHz, 
CDCl3) δ 7.41 – 7.36 (2H, m), 7.29 – 7.24 (3H, m), 3.70 (2H, t, J = 6.0 Hz), 2.45 (2H, t, J = 
6.5 Hz), 1.85 (1H, br s), 1.78 – 1.65 (4H, m); 13C NMR (101 MHz, CDCl3) δ 131.7, 128.3, 
127.7, 124.0, 90.0, 81.1, 62.6, 32.0, 25.1, 19.3. 
The spectroscopic properties were consistent with the data available in the literature.336  
 
 (E)-6-Phenylhex-5-en-1-ol (404) 
 
To a solution of the preceding alkyne 403 (1.59 g, 9.13 mmol) in THF (15 mL) at 0 oC was 
added 3.5 equivalents of LiAlH4 (16 mL, 2 M in THF). After stirring at 0 
oC for 20 minutes the 
reaction was heated to reflux and stirred overnight. Upon completion, the reaction mixture was 
cooled to 0 o C before addition of water (1 mL/g of LiAlH4), 15% aqueous NaOH (1 mL/g 
LiAlH4) and a final portion of water (3 mL/g of LiAlH4). The mixture was filtered through 
Celite® and washed with CH2Cl2. The phases were separated, and the aqueous phase extracted 
with CH2Cl2 (2 × 10 mL). The combined organic extracts were dried over Na2SO4, filtered and 
concentrated in vacuo. Purification by flash column chromatography (gradient, eluent: 20 – 
33% EtOAc:petroleum ether) afforded 404 (920 mg, 57%, 10:1 mixture of E and Z isomers) as 
a colourless oil.  
Spectroscopic data for the major E isomer: 1H NMR (400 MHz, CDCl3) δ 7.36 – 7.17 (5H, 
m), 6.40 (1H, dt, J = 16.0, 1.5 Hz), 6.22 (1H, dt, J = 16.0, 7.0 Hz), 3.68 (2H, t, J = 6.5 Hz), 
2.25 (2H, qd, J = 7.0, 1.5 Hz), 1.66 - 1.53 (4H, m), 1.49 (1H, br s); 13C NMR (101 MHz, CDCl3) 
δ 137.9, 130.7 , 130.3, 128.6, 127.0, 126.1, 63.0, 32.9, 32.4, 25.6. 
Characteristic signals for the minor Z isomer: 1H NMR (400 MHz, CDCl3) δ 5.66 (1H, dt, J 
= 11.5, 7.0 Hz), 3.63 (2H, t, J = 6.5 Hz), 2.37 (2H, qd, J = 7.5, 2.0 Hz).  








tert-Butyl (E)-(6-phenylhex-5-en-1-yl)(tosyloxy)carbamate (405) 
 
General procedure G: The preceding alcohol 404 (260 mg, 1.50 mmol), PPh3 (470 mg, 1.80 
mmol), DIAD (0.35 mL, 1.80 mmol) and BocNHOTs (520 mg, 1.80 mmol) in anhydrous THF 
(6 mL) were employed. Purification by flash column chromatography (5% EtOAc:petroleum 
ether) afforded 405 (560 mg, 84%) as a viscous, colourless oil; Rf = 0.40 (20% EtOAc:hexane); 
νmax / cm
-1 (film) 2933 (m), 1719 (s), 1368 (s), 1191 (s), 1177 (s), 1152 (s); 1H NMR (400 MHz, 
CDCl3) δ 7.86 (2H, d, J = 8.5 Hz, Ts ArCH), 7.36 – 7.27 (6H, m, ArCH, Ts ArCH), 7.21 – 7.16 
(1H, m, ArCH), 6.37 (1H, d, J = 16.0 Hz, C6-H), 6.17 (1H, dt, J = 16.0, 7.0 Hz, C5-H), 3.64 
(2H, br s, C1-H2), 2.45 (3H, s, Ts CH3), 2.24 – 2.17 (2H, m, C4-H2), 1.74 – 1.63 (2H, m, 
C2-H2), 1.49 – 1.40 (2H, m, C3-H2), 1.22 (9H, s, Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) δ 
155.7 (Boc C=O), 145.8 (Ts ArC), 137.8 (ArC), 131.4 (Ts ArC), 130.5 (C6), 130.3 (C5), 129.8 
(2 × Ts ArCH), 129.7 (2 × Ts ArCH), 128.6 (ArCH), 127.0 (ArCH), 126.1 (ArCH), 83.3 (Boc 
C(CH3)), 52.8 (C1), 32.7 (C4), 27.8 (Boc (CH3)), 26.4 (C3), 25.5 (C2), 21.8 (Ts CH3); HRMS 




General procedure P: The preceding N-tosyloxycarbamate 405 (66.8 mg, 0.15 mmol) and 2.0 
equivalents of TFA (23 μL, 0.3 mmol) in anhydrous TFE (1.5 mL) were employed. After 
stirring for 48 hours purification by flash column chromatography (~0.1% Et3N in EtOAc) 
afforded 406 (11.5 mg, 44%) as a pale-yellow oil; Rf = 0.30 (EtOAc); νmax / cm
-1 (film) 2932 
(m), 2852 (m), 1602 (m), 1498 (m), 1450 (m), 1161 (m); 1H NMR (400 MHz, CDCl3) δ 7.31 
– 7.25 (2H, m, ArCH), 7.22 – 7.16 (3H, m, ArCH), 3.49 – 3.41 (1H, m, C1-H), 2.96 – 2.88 
(1H, m, C1-H’), 2.56 (1H, d, J = 3.0 Hz, C6-H), 2.20 – 2.16 (1H, m, C5-H), 2.08 – 2.00 (2H, 
m, C4-H2), 1.54 – 1.39 (4H, m, C2-H2, C3-H2); 
13C NMR (101 MHz, CDCl3) δ 141.4 (ArC), 
128.4 (ArCH), 126.8 (ArCH), 125.9 (ArCH), 48.7 (C1), 45.6 (C6), 42.1 (C5), 22.1 (C4), 21.4 
(C2), 18.4 (C3); HRMS (ESI+) Calculated for C12H16N: 174.1277. Found [M+H]
+: 174.1279. 




tert-Butyl (E)-(2-(but-2-en-1-yl)benzyl)(tosyloxy)carbamate (408) 
 
General procedure G: Alcohol 407 (243 mg, 1.50 mmol), PPh3 (472 mg, 1.80 mmol), DIAD 
(0.35 mL, 1.80 mmol) and BocNHOTs (517 mg, 1.80 mmol) in anhydrous THF (6 mL) were 
employed. Purification by flash column chromatography (10% EtOAc:petroleum ether) 
afforded 408 (499 mg, 77%) as colourless solid; Rf = 0.36 (10% EtOAc:petroleum ether); m.p.: 
77-78 oC (CH2Cl2:hexane); νmax / cm
-1 (solid) 2977 (m), 1723 (s), 1368 (s), 1175 (s), 1191 (s), 
1152 (s); 1H NMR (400 MHz, CDCl3) δ 7.84 (2H, d, J = 8.5 Hz, Ts ArCH), 7.32 (2H, d, J = 
8.5 Hz, Ts ArCH), 7.23 – 7.18 (2H, m, ArCH), 7.16 – 7.11 (2H, m, ArCH), 5.56 – 5.48 (1H, 
m, C3-H), 5.44 – 5.34 (1H, m, C4-H), 4.86 (2H, br s, C1-H2), 3.33 (2H, d, J = 6.0 Hz, C2-H2), 
2.45 (3H, s, Ts CH3), 1.66 (3H, dd, J = 6.0, 1.5 Hz, C5-H3), 1.22 (9H, s, Boc (CH3)3); 
13C NMR 
(101 MHz, CDCl3) δ 155.5 (Boc C=O), 145.8 (Ts ArC), 139.2 (ArC), 133.4 (ArC), 131.5 (Ts 
ArC), 129.9 (ArCH), 129.8 (2 × Ts ArCH), 129.7 (2 × Ts ArCH), 129.3 (C3) 128.4 (ArCH), 
128.0 (ArCH), 126.7 (C4), 126.5 (ArCH), 83.6 (Boc C(CH3)3), 53.0 (C1) 36.0 (C2), 27.7 (Boc 
(CH3)3), 21.9 (Ts CH3), 18.1 (C5); HRMS (ESI
+) Calculated for C23H29NNaO5S: 454.1659. 
Found [M+Na]+: 454.1660. 
(1S*,8aS*)-1-Methyl-1,3,8,8a-tetrahydroazirino[1,2-b]isoquinoline (409) 
 
General procedure P: The preceding N-tosyloxycarbamate 408 (86.3 mg, 0.20 mmol) and 
TFA (31 μL, 0.40 mmol) in anhydrous TFE (2.0 mL) were employed. After stirring for 24 
hours, purification by flash column chromatography (gradient, eluent: ~ 0.1% Et3N in 33% 
EtOAc:petroleum ether  –  ~ 0.1% Et3N in EtOAc) afforded 409 (8.3 mg, 26%) as a colourless 
oil; Rf = 0.1 (EtOAc); νmax / cm
-1 (film) 2956 (m), 2923 (m), 2849 (m), 1494 (m), 1456 (m); 
1H NMR (400 MHz, CDCl3) δ 7.21 – 7.14 (2H, m, ArCH), 7.05 – 7.01 (1H, m, ArCH), 6.99 – 
6.95 (1H, m, ArCH), 4.17 (1H, d, J = 16.0 Hz, C1-H), 4.04 (1H, d, J = 16.0 Hz, C1-H’), 3.11 
– 3.08 (2H, m, C4-H2), 2.18 – 2.14 (1H, m, C3-H), 1.59 – 1.53 (1H, m, C2-H), 1.13 (3H, d, J 




= 5.5 Hz, C5-H3); 
13C NMR (101 MHz, CDCl3) δ 133.0 (ArC), 132.9 (ArC), 128.1 (ArCH), 
127.3 (ArCH), 127.2 (ArCH), 127.0 (ArCH), 50.9 (C1), 38.6 (C3), 29.0 (C2), 27.3 (C4), 17.2 




To a solution of alcohol 410 (2.01 g, 10.0 mmol) in Et3N (20 mL) under an atmosphere of N2 
was added CuI (114.3 mg, 0.6 mmol), Pd(OAc)2 (134.7 mg, 0.6 mmol), PPh3 (262.3 mg, 1.0 
mmol) and hex-1-yne (1.26 mL, 11.0 mmol). The reaction mixture was heated to 90 oC and 
stirred for 48 hours. The reaction was poured into a saturated aqueous solution of NH4Cl (20 
mL) and extracted with Et2O (2 × 20 mL). The combined organic extracts were washed with 
brine (20 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude product was 
purified by flash column chromatography (20% EtOAc:petroleum ether) to afford 411 (358 
mg, 18%) as a light brown oil; Rf = 0.3 (33% EtOAc:petroleum ether); νmax / cm
-1 (film) 3337 
(br m), 2956 (m), 2930 (m), 2871 (m), 1484 (m), 1447 (m), 1041 (s); 1H NMR (400 MHz, 
CDCl3) δ 7.40 (1H, dd, J = 7.5, 1.5 Hz, ArCH), 7.23 – 7.13 (3H, m, ArCH), 3.92 – 3.84 (2H, 
m, C1-H2), 3.04 (2H, t, J = 7.0 Hz, C2-H2), 2.44 (2H, t, J = 7.0 Hz, C5-H2), 1.68 – 1.55 (3H, 
m, OH, C6-H2), 1.54 – 1.44 (2H, m, C7-H2), 0.96 (3H, t, J = 7.5 Hz, C8-H3); 
13C NMR (101 
MHz, CDCl3) δ 140.2 (ArC), 132.6 (ArCH), 129.7 (ArCH), 127.8 (ArCH), 126.5 (ArCH), 
124.0 (ArC), 94.5 (C4), 79.2 (C3), 63.1 (C1), 38.1 (C2), 31.0 (C6), 22.2 (C7), 19.3 (C5), 13.8 





A solution of the preceding alkyne 411 (506 mg, 2.5 mmol) in diglyme (15 mL) under an 
atmosphere of nitrogen was cooled to 0 oC before addition of LiAlH4 (569 mg, 15 mmol). The 
solution was then heated to reflux until completion by TLC analysis (1 hour). Upon completion 
the reaction was cooled to room temperature before addition of water (1 mL), 15% aqueous 
NaOH (1 mL) and a final portion of water (3 mL). The resulting mixture was filtered through 




Celite® and washed with Et2O. The phases were separated, and the aqueous phase extracted 
with Et2O. The organic phase was dried over Na2SO4 and concentrated in vacuo. The crude 
product was dissolved in pentane and washed with water to remove diglyme before purification 
by flash column chromatography (20% EtOAc:petroleum ether) to afford 412 (337 mg, 66% 
as an 8:1 mixture of E and Z isomers) as a pale-yellow oil; Rf = 0.60 (33% EtOAc:hexane) 
νmax / cm
-1 (film) 3416 (br m), 2928 (m), 1718 (s), 1028 (s).  
Spectroscopic data for the major E isomer: 1H NMR (400 MHz, CDCl3) δ 7.46 – 7.43 (1H, m, 
ArCH), 7.22 – 7.15 (3H, m, ArCH), 6.64 (1H, dt, J = 15.5, 1.5 Hz, C3-H), 6.10 (1H, dt, J = 
15.5, 7.0 Hz, C4-H), 3.82 (2H, t, J = 7.0 Hz, C1-H2), 2.96 (2H, t, J = 7.0 Hz, C2-H2), 2.27 – 
2.21 (2H, m, C5-H2), 1.51 – 1.35 (5H, m, C6-H2, C7-H2, OH), 0.94 (3H, t, J = 7.0 Hz, C8-H3); 
13C NMR (101 MHz, CDCl3) δ 137.5 (ArC), 135.1 (ArC), 133.6 (C4), 130.4 (ArCH), 127.2 
(C3), 127.1 (ArCH), 127.0 (ArCH), 126.4 (ArCH), 63.2 (C1), 36.7 (C2), 33.1 (C5), 31.7 (C6 
or C7), 22.4 (C6 or C7), 14.1 (C8). 
Characteristic signals for the minor Z isomer: 1H NMR (400 MHz, CDCl3) δ 6.51 (1H, dt, J = 
11.5, 1.5 Hz), 5.74 (1H, dt, J = 11.5, 7.5 Hz), 3.79 (2H, t, J = 7.0 Hz), 2.89 (2H, t, J = 7.0 Hz), 
2.13 (2H, qd, J = 7.5, 1.5 Hz); HRMS (ESI+) Calculated for C14H20NaO: 227.1406. Found 
[M+Na]+: 227.1411. 
 
tert-Butyl (E)-(2-(hex-1-en-1-yl)phenethyl)(tosyloxy)carbamate (413) 
 
General procedure G: The preceding alcohol 412 (245 mg, 1.2 mmol), PPh3 (377 mg, 1.44 
mmol), DIAD (0.28 mL, 1.44 mmol) and BocNHOTs (413 mg, 1.44 mmol) in anhydrous THF 
(5.0 mL) were employed. Purification by flash column chromatography (5% EtOAc:petroleum 
ether) afforded 413 (445 mg, 78%) as a colourless, viscous oil; Rf = 0.70 (20% EtOAc:hexane); 
νmax / cm
-1 (film) 2957 (m), 2930 (m), 1720 (s), 1368 (s), 1178 (s); 1H NMR (400 MHz, CDCl3) 
δ 7.87 (2H, d, J = 8.5 Hz, Ts ArCH), 7.43 – 7.40 (1H, m, ArCH), 7.34 (2H, d, J = 8.5 Hz, Ts 
ArCH), 7.18 – 7.10 (3H, m, ArCH), 6.64 (1H, d, J = 15.5 Hz, C3-H), 6.12 (1H, dt, J = 15.5, 
7.0 Hz, C4-H), 3.79 (2H, br s, C1-H2), 3.04 – 2.96 (2H, m, C2-H2), 2.44 (3H, s, Ts CH3), 2.29 
– 2.22 (2H, m, C5-H2), 1.52 – 1.44 (2H, m, C6-H2), 1.43 – 1.34 (2H, m, C7-H2), 1.16 (9H, s, 
Boc (CH3)3), 0.94 (3H, t, J = 7.0 Hz, C8-H3); 
13C NMR (101 MHz, CDCl3) δ 155.1 (Boc C=O), 
145.8 (Ts ArC), 137.5 (ArC), 134.6 (ArC), 133.8 (C4), 131.4 (Ts ArC), 130.4 (ArCH), 129.9 




(ArCH), 129.9 (2 × Ts ArCH), 129.6 (2 × Ts ArCH), 127.1 (ArCH), 126.7 (C3), 126.1 (ArCH), 
83.2 (Boc C(CH3)3), 53.4 (C1), 33.1 (C5), 31.7 (C6), 29.8 (C2), 27.7 (Boc (CH3)3), 22.5 (C7), 
21.8 (Ts CH3), 14.1 (C8); HRMS (ESI




General procedure P: The preceding N-tosyloxycarbamate 413 (47.4 mg, 0.1 mmol) and 2.0 
equivalents of TFA (15 μL, 0.2 mmol) in anhydrous TFE (1.0 mL) were employed. After 
stirring for 48 hours purification by flash column chromatography (~0.1% Et3N in EtOAc) 
afforded 414 (12.0 mg, 60%) as a pale-yellow oil; Rf = 0.40 (EtOAc); νmax / cm
-1 (film) 2954 
(m), 2927 (s), 2858 (m), 1494 (m), 1463 (m), 752 (s), 736 (s); 1H NMR (400 MHz, CDCl3) δ 
7.32 (1H, dd, J = 7.5, 1.5 Hz, C7-H), 7.23 – 7.18 (1H, m, C6-H), 7.15 (1H, td, J = 7.5, 1.5 Hz, 
C5-H), 7.05 (1H, d, J = 7.5 Hz, C4-H), 3.43 (1H, ddd, J = 13.0, 6.0, 2.0 Hz, C1-H), 2.89 – 2.81 
(1H, m, C1-H’), 2.70 (1H, d, J = 2.5 Hz, C9-H), 2.65 – 2.50 (2H, m, C2-H2), 2.10 (1H, td, J = 
6.0, 2.5 Hz, C10-H), 1.57 – 1.48 (2H, m, C11-H2), 1.46 – 1.31 (4H, m, C12-H2, C13-H2), 0.91 
(3H, t, J = 7.0 Hz, C14-H3); 
13C NMR (101 MHz, CDCl3) δ 134.9 (C8), 131.9 (C3), 128.5 (C4), 
128.1 (C7), 126.5 (C6), 125.9 (C5), 42.9 (C1), 40.8 (C9), 38.7 (C10), 32.9 (C11), 29.6 (C12 or 
C13), 24.5 (C2), 22.7 (C12 or C13), 14.3 (C14); HRMS (ESI+) Calculated for C14H20N: 
202.1590. Found [M+H]+: 202.1589. 
The relative stereochemistry of this compound was determined by nOe experiments as 
indicated on the compound structure. An nOe correlation was observed between C9-H and 




The title compound was prepared according to a literature procedure.49 
The spectroscopic properties were consistent with the data available in the literature.49 
 






General procedure R: N-(2-Hydroxyethyl)-4-methylbenzenesulfonamide 415 (2.15 g, 10.0 
mmol), K2CO3 (2.07 g, 15.0 mmol) and (E)-1-bromo-2-methylbut-2-ene (1.72 mL, 15.0 mmol) 
in acetone (20 mL) were employed. Purification by flash column chromatography (gradient, 
eluent: 33 – 50% EtOAc:petroleum ether) afforded 416 (1.40 g, 49%) as a colourless oil; 
1H NMR (400 MHz, CDCl3) δ 7.69 (2H, d, J = 8.0 Hz), 7.31 (2H, d, J = 8.0 Hz), 5.38 (1H, q, 
J = 6.5 Hz), 3.70 – 3.60 (4H, m), 3.14 (2H, t, J = 5.5 Hz), 2.42 (3H, s), 2.37 (1H, br s), 1.63 – 
1.56 (6H, m); 13C NMR (101 MHz, CDCl3) δ 143.6, 136.1, 131.4, 129.9, 127.4, 124.7, 61.4, 
58.3, 50.2, 21.6, 13.8, 13.6. 





General procedure G: The preceding alcohol 416 (708 mg, 2.5 mmol), PPh3 (789 mg, 3.0 
mmol), DIAD (0.59 mL, 3.0 mmol) and BocNHOTs (860 mg, 3.0 mmol) in anhydrous THF 
(10 mL) were employed. Purification by flash column chromatography (10% EtOAc:petroleum 
ether) followed by (gradient, eluent: 50% CH2Cl2:PhMe – CH2Cl2) afforded 418 (373 mg, 
27%) as a pale-yellow, viscous oil; Rf = 0.70 (33% EtOAc:hexane); νmax / cm
-1 (film) 3029 (m), 
2981 (m), 2925 (m), 2862 (m), 1723 (m), 1370 (s), 1339 (s), 1192 (s), 1178 (s), 1155 (s); 
1H NMR (400 MHz, CDCl3) δ 7.82 (2H, d, J = 8.5 Hz, Ts ArCH), 7.68 (2H, d, J = 8.5 Hz, Ts 
ArCH), 7.34 (2H, d, J = 8.5 Hz, Ts ArCH), 7.30 (2H, d, J = 8.5 Hz, Ts ArCH), 5.47 – 5.40 
(1H, m, C5-H), 3.71 (2H, br s, C1-H2), 3.60 (2H, s, C3-H2), 3.25 – 3.19 (2H, m, C2-H2), 2.45 
(3H, s, Ts CH3), 2.42 (3H, s, Ts CH3), 1.60 (3H, d, J = 6.5 Hz, C7-H3), 1.56 (3H, s, C6-H3), 
1.23 (9H, s, Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) δ 154.7 (Boc C=O), 145.9 (Ts ArC), 
143.4 (Ts ArC), 136.3 (Ts ArC), 131.0 (Ts ArC), 130.3 (C4), 129.8 (2 ×Ts ArCH), 129.7 (2 
×Ts ArCH), 129.6 (2 ×Ts ArCH), 127.3 (2 × Ts ArCH), 125.7 (C5), 83.7 (Boc C(CH3)3), 57.5 
(C3), 51.3 (C1), 42.8 (C2), 27.6 (Boc (CH3)3), 21.8 (Ts CH3), 21.6 (Ts CH3), 13.7 (C6), 13.6 
(C7); HRMS (ESI+) Calculated for C26H36N2NaO7S2: 575.1856. Found [M+Na]
+: 575.1872. 






General procedure P: The preceding N-tosyloxycarbamate 418 (55.3 mg, 0.1 mmol) and 2.0 
equivalents of TFA (15 μL, 0.2 mmol) in anhydrous TFE (1.0 mL) were employed. After 
stirring for 48 hours purification by flash column chromatography (~0.1% Et3N in EtOAc) 
afforded 420 (18.0 mg, 64%) as a colourless oil; Rf = 0.10 (EtOAc); νmax / cm
-1 (film) 2926 (m), 
2871 (m), 1597 (m), 1457 (m), 1340 (s), 1162 (s); 1H NMR (400 MHz, CDCl3) δ 7.62 (2H, d, 
J = 8.5 Hz, Ts ArCH), 7.33 (2H, d, J = 8.0 Hz, Ts ArCH), 3.77 (1H, dd, J = 12.0, 1.5 Hz, 
C3-H), 3.41 (1H, dddd, J = 12.0, 6.0, 2.5, 1.5 Hz, C2-H), 3.31 (1H, ddd, J = 13.0, 5.0, 3.0 Hz, 
C1-H), 2.88 (1H, ddd, J = 13.0, 11.0, 6.0 Hz, C1-H’), 2.66 (1H, d, J = 12.0 Hz, C3-H’), 2.48 – 
2.40 (4H, m, C2-H’ and Ts CH3), 2.05 (1H, q, J = 5.5 Hz, C6-H), 1.10 (3H, d, J = 5.5 Hz, 
C7-H3), 1.05 (3H, s, C5-H3); 
13C NMR (101 MHz, CDCl3) δ 143.9 (Ts ArC), 133.3 (Ts ArC), 
129.9 (2 × Ts ArCH), 127.7 (2 × Ts ArCH), 48.5 (C3), 48.1 (C1), 42.7 (C2), 42.3 (C6), 39.3 
(C4), 21.7 (Ts CH3), 18.6 (C5), 14.0 (C7); HRMS (ESI
+) Calculated for C14H20N2NaO2S: 
303.1138. Found [M+Na]+: 303.1141. 
The relative stereochemistry of this compound was determined by nOe experiments as 





To a solution of cyclohex-1-en-1-ylmethanol (550 mg, 4.9 mmol) in Et2O (25 mL) at 0 
oC was 
added PBr3 (667 mg, 2.5 mmol) and the reaction was warmed to room temperature and 
monitored by TLC. Upon completion of the reaction, the solution was poured into an ice-cold 
solution of K2CO3 (677 mg, 4.9 mmol) and the phases were separated. The aqueous phase was 
extracted with Et2O (2 × 10 mL) and the combined organic phases were dried over Na2SO4, 
filtered and concentrated in vacuo to afford the title compound (650 mg, 76%) as a colourless 
oil which was used without further purification. 








General procedure R: N-(2-Hydroxyethyl)-4-methylbenzenesulfonamide 415 (540 mg, 2.50 
mmol), K2CO3 (520 mg, 3.77 mmol) and 1-(bromomethyl)cyclohex-1-ene (660 mg, 3.77 
mmol) in acetone (5 mL) were employed. Purification by flash column chromatography (33% 
EtOAc:petroleum ether) afforded 417 (719 mg, 93%) as a colourless oil; Rf = 0.40 (50% 
petroleum ether:EtOAc);  νmax / cm
-1 (film) 3438 (br m), 2926 (m), 1328 (s), 1154 (s); 1H NMR 
(400 MHz, CDCl3) δ 7.69 (2H, d, J = 8.0 Hz, Ts ArCH), 7.30 (2H, d, J = 8.0 Hz, Ts ArCH), 
5.60 – 5.56 (1H, m, C5-H), 3.68 – 3.62 (4H, m, C1-H2, C3-H2), 3.16 (3H, t, J = 5.5 Hz, C2-H2), 
2.42 (3H, s, Ts CH3), 2.32 (1H, br s, OH), 2.01 – 1.91 (4H, m, C6-H2, C9-H2), 1.63 – 1.49 (4H, 
m, C7-H2, C8-H2); 
13C NMR (101 MHz, CDCl3) δ 143.6 (Ts ArC), 136.1 (Ts ArC), 133.3 (C4), 
129.8 (2 × Ts ArCH), 127.4 (2 × Ts ArCH), 127.2 (C5), 61.4 (C1), 56.9 (C3), 50.4 (C2), 26.1 
(C6 or C9), 25.3 (C6 or C9), 22.5 (C7 or C8), 22.3 (C7 or C8), 21.6 (Ts CH3); HRMS (ESI
+) 





General procedure G: The preceding alcohol 417 (619 mg, 2.0 mmol), PPh3 (629 mg, 2.4 
mmol), DIAD (0.47 mL, 2.4 mmol) and BocNHOTs (689 mg, 2.4 mmol) in anhydrous THF (8 
mL) were employed. Purification by flash column chromatography (gradient, eluent: 10 – 20% 
EtOAc:petroleum ether, then 4% EtOAc:toluene) afforded 419 (121 mg, 10%) as a viscous, 
colourless oil; Rf = 0.40 (4% EtOAc:toluene); νmax / cm
-1 (film) 2929 (m), 2837 (m), 1722 (m), 
1369 (s), 1340 (s), 1192 (s), 1178 (s), 1156 (s); 1H NMR (400 MHz, CDCl3) δ 7.82 (2H, d, J = 
8.5 Hz, Ts ArCH), 7.67 (2H, d, J = 8.5 Hz, Ts ArCH), 7.33 (2H, d, J = 8.5 Hz, Ts ArCH), 7.29 
(2H, d, J = 8.5 Hz, Ts ArCH), 5.65 – 5.61 (1H, m, C5-H), 3.74 (2H, br s, C1-H2), 3.59 (2H, s, 
C3-H2), 3.22 (2H, t, J = 7.5 Hz, C2-H2), 2.44 (3H, s, Ts CH3), 2.42 (3H, s, Ts CH3), 2.06 – 2.00 




(2H, m, C6-H2), 1.92 – 1.86 (2H, m, C9-H2), 1.63 – 1.51 (4H, m, C7-H2 and C8-H2), 1.24 (9H, 
s, Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) δ 154.8 (Boc C=O), 145.9 (Ts ArC), 143.4 (Ts 
ArC), 136.4 (Ts ArC), 132.4 (C4), 131.1 (Ts ArC), 129.8 (4 × Ts ArCH), 129.7 (Ts ArCH), 
128.2 (C5), 127.3 (Ts ArCH), 83.8 (Boc C(CH3)3), 56.2 (C3), 51.6 (C1), 43.1 (C2), 27.7 (Boc 
(CH3)3), 26.1 (C9), 25.3 (C6), 22.5 (C7 or C8), 22.2 (C7 or C8), 21.8 (Ts CH3), 21.6 (Ts CH3); 




General procedure P: The preceding N-tosyloxycarbamate 419 (57.9 mg, 0.1 mmol) and 2.0 
equivalents of TFA (15 μL, 0.2 mmol) in anhydrous TFE (1.0 mL) were employed. After 
stirring for 48 hours purification by flash column chromatography (0.1% Et3N in EtOAc) 
afforded 421 (15.5 mg, 51%) as a yellow oil; Rf = 0.30 (EtOAc); νmax / cm
-1 (film) 2929 (m), 
2855 (m), 1339 (m), 1159 (s); 1H NMR (400 MHz, CDCl3) δ 7.63 (2H, d, J = 8.0 Hz, Ts ArCH), 
7.33 (2H, d, J = 8.0 Hz, Ts ArCH), 3.84 (1H, dd, J = 12.0, 1.5 Hz, C3-H), 3.43 (1H, dddd, J = 
12.0, 6.0, 3.0, 1.5 Hz, C2-H), 3.32 (1H, ddd, J = 13.0, 5.0, 3.0 Hz, C1-H), 2.89 (1H, ddd, J = 
13.0, 11.0, 6.0 Hz, C1-H’), 2.60 (1H, d, J = 13.0 Hz, C3-H’), 2.45 – 2.34 (4H, m, C2-H’ and 
Ts CH3), 2.15 (1H, dd, J = 4.5, 2.0 Hz, C9-H), 1.77 – 1.70 (2H, m, C8-H2), 1.67 – 1.59 (1H, 
m, C5-H), 1.45 – 1.08 (5H, m, C5-H’, C6-H2 and C7-H2); 
13C NMR (101 MHz, CDCl3) δ 143.9 
(Ts ArC), 133.2 (Ts ArC), 129.9 (2 × Ts ArCH), 127.7 (2 × Ts ArCH), 48.4 (C1), 47.9 (C3), 
42.8 (C2), 42.7 (C9), 38.9 (C4), 29.5 (C5), 24.4 (C8), 21.7 (Ts CH3), 20.7 (C7), 20.4 (C6); 
HRMS (ESI+) Calculated for C16H23N2O2S: 307.1475. Found [M+H]
+: 307.1490. 
tert-Butyl (E)-(2-(but-2-en-1-yloxy)ethyl)(tosyloxy)carbamate (422) 
 
General procedure G: (E)-2-(But-2-en-1-yloxy)ethan-1-ol (188 mg, 1.62 mmol), PPh3 (509 
mg, 1.94 mmol), DIAD (0.38 mL, 1.94 mmol), and BocNHOTs (558 mg, 1.94 mmol) in 
anhydrous THF (6.5 mL) were employed. Purification by flash column chromatography (5% 
EtOAc:petroleum ether) afforded 422 (365 mg, 58%) as a viscous, colourless oil; 1H NMR 




(400 MHz, CDCl3) δ 7.85 (2H, d, J = 8.0 Hz, Ts ArCH), 7.33 (2H, d, J = 8.0 Hz, Ts ArCH), 
5.71 – 5.61 (1H, m, C5-H), 5.53 – 5.45 (1H, m, C4-H), 4.16 – 3.44 (4H, m, C1-H2 and C2-H2), 
3.86 (2H, dd, J = 6.0, 1.0 Hz, C3-H2), 2.44 (3H, s, Ts CH3), 1.66 (3H, d, J = 6.5 Hz, C6-H3), 
1.19 (9H, s, Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) δ 155.8 (Boc C=O), 145.8 (Ts ArC), 
131.2 (Ts ArC), 129.9 (2 × Ts ArCH), 129.6 (C5), 129.6 (2 × Ts ArCH), 127.5 (C4), 83.1 (Boc 
C(CH3)3), 71.8 (C3), 64.5 (C2), 52.0 (C1), 27.7 (Boc (CH3)3), 21.8 (Ts CH3), 17.8 (C6). 
(6S*,7S*)-6-Methyl-7-phenethyl-1-azabicyclo[4.1.0]heptane (426) 
 
General procedure P: N-Tosyloxycarbamate 424 (48.8 mg, 0.1 mmol), TFA (15 μL, 0.2 
mmol) in anhydrous TFE (1.0 mL) were employed. After stirring for 48 hours, purification by 
flash column chromatography (~0.1% Et3N in EtOAc) afforded 426 (11.3 mg, 52%) as a 
colourless oil; Rf = 0.05 (EtOAc); νmax / cm
-1 (film) 2928 (m), 2856 (m), 1452 (m), 749 (s), 697 
(s); 1H NMR (400 MHz, CDCl3) δ 7.30 – 7.25 (2H, m, ArCH), 7.22 – 7.15 (3H, m, ArCH), 
3.35 – 3.29 (1H, m, C1-H), 2.79 (1H, dt, J = 14.5, 7.5 Hz, C8-H), 2.72 – 2.58 (2H, m, C1-H’, 
C8-H’), 1.84 (1H, dt, J = 11.5, 5.5 Hz, C4-H), 1.76 – 1.56 (3H, m, C4-H’, C7-H2), 1.46 – 1.38 
(1H, m, C3-H), 1.38 – 1.24 (3H, m, C2-H2, C3-H’), 1.03 (3H, s, C9-H3); 
13C NMR (101 MHz, 
CDCl3) δ 142.3 (ArC), 128.7 (ArCH), 128.4 (ArCH), 125.9 (ArCH), 49.1 (C1), 47.8 (C6), 38.9 
(C5), 34.3 (C8), 31.6 (C7), 29.4 (C4), 21.9 (C9), 21.1 (C2), 18.1 (C3); HRMS (ESI+) Calculated 




General procedure P: N-Tosyloxycarbamate 425 (51.8 mg, 0.1 mmol) and TFA (15 μL, 0.2 
mmol) in anhydrous TFE (1.0 mL) were employed. The reaction was stirred at room 
temperature for 48 hours. Purification by flash column chromatography (~0.1% Et3N in 




EtOAc) afforded 427 (9.9 mg, 40%) as a pale-yellow oil; Rf = 0.05 (EtOAc); νmax / cm
-1 (film) 
2928 (m), 2856 (m), 1611 (m), 1511 (s), 1244 (s), 1036 (m); 1H NMR (440 MHz, CDCl3) δ 
7.12 (2H, d, J = 8.5 Hz, C11-H), 6.82 (2H, d, J = 8.5 Hz, C12-H), 3.78 (3H, s, C14-H3), 3.34 
– 3.27 (1H, m, C1-H), 2.73 (1H, ddd, J = 14.5, 8.5, 6.5 Hz, C9-H), 2.66 – 2.57 (2H, m, C1-H’, 
C9-H’), 1.87 – 1.81 (1H, m, C4-H), 1.70 – 1.54 (4H, m, C4-H’, C6-H, C8-H2), 1.46 – 1.24 
(4H, m, C2-H2, C3-H2), 1.03 (3H, s, C7-H3); 
13C NMR (101 MHz, CDCl3) δ 157.8 (C13), 134.4 
(C10), 129.5 (C11), 113.8 (C12), 55.4 (C14), 49.1 (C1), 47.8 (C6), 38.7 (C5), 33.4 (C9), 31.9 
(C8), 29.4 (C4), 22.0 (C7), 21.2 (C2 or C3), 18.1 (C2 or C3); HRMS (ESI+) Calculated for 




The title compound was prepared according to a literature procedure.317 
m.p. 137-139 oC (Et2O:petroleum ether); [lit: 144-145 
oC (EtOAc:hexane)317]; 1H NMR (400 
MHz, CDCl3) δ 7.27 (2H, d, J = 9.0 Hz), 6.84 (2H, d, J = 8.5 Hz), 6.39 (1H, d, J = 16.0 Hz), 
6.12 – 6.02 (1H, m), 3.80 (3H, s), 2.54 – 2.50 (4H, m); 13C NMR (101 MHz, CDCl3) δ 178.6, 
159.1, 130.7, 130.2, 127.3, 126.0, 114.1, 55.4, 34.0, 28.1. 




General procedure B: (E)-5-(4-Methoxyphenyl)pent-4-enoic acid (820 mg, 4.00 mmol) and 
2.0 equivalents of LiAlH4 (8.0 mmol, 2M in THF) in anhydrous THF (20 mL) were employed. 
Purification by flash column chromatography (50% petroleum ether:EtOAc) afforded the title 
compound (520 mg, 67%) as a colourless solid; m.p.: 69-72 oC (Et2O:petroleum ether) [lit: 71-
73 oC (EtOAc:hexane)322]; 1H NMR (400 MHz, CDCl3) δ 7.26 (2H, d, J = 9.0 Hz), 6.82 (2H, 
d, J = 9.0 Hz), 6.35 (1H, d, J = 15.5 Hz), 6.11 – 6.04 (1H, m), 3.79 (3H, s), 3.69 (2H, t, J = 6.5 
Hz), 2.31 – 2.25 (2H, m), 1.77 – 1.70 (2H, m); 13C NMR (101 MHz, CDCl3) δ 158.9, 130.6, 
129.9, 128.0, 127.2, 114.1, 62.6, 55.4, 32.5, 29.4. 
The spectroscopic properties were consistent with the data available in the literature.323 




tert-Butyl (E)-(5-(4-methoxyphenyl)pent-4-en-1-yl)(tosyloxy)carbamate (434) 
 
General procedure G: (E)-5-(4-Methoxyphenyl)pent-4-en-1-ol (290 mg, 1.50 mmol), PPh3 
(470 mg, 1.80 mmol), DIAD (0.35 mL, 1.80 mmol) and BocNHOTs (517 mg, 1.80 mmol) in 
anhydrous THF (6 mL) were employed. Purification by flash column chromatography 
(gradient, eluent: 10 – 20% EtOAc:petroleum ether) afforded 434 (680 mg, 99 %) as a 
colourless solid; Rf = 0.60 (33% EtOAc:hexane); m.p. 57-59 
oC (EtOAc:hexane); νmax / cm
-1 
(solid) 2995 (m), 2977 (m), 2961 (m), 2935 (m), 2865 (m), 1711 (s), 1367 (s), 1173 (s), 1152 
(s); 1H NMR (400 MHz, CDCl3) δ 7.85 (2H, d, J = 8.5 Hz, Ts ArCH), 7.32 (2H, d, J = 8.5 Hz, 
Ts ArCH), 7.26 (2H, d, J = 8.5 Hz, ArCH), 6.83 (2H, d, J = 8.5 Hz, ArCH), 6.32 (1H, d, J = 
16.0 Hz, C5-H), 6.00 (1H, dt, J = 16.0, 7.0 Hz, C4-H), 3.79 (3H, s, OCH3), 3.63 (2H, br s, 
C1-H2), 2.43 (3H, s, Ts CH3), 2.20 – 2.13 (2H, m, C3-H2), 1.83 – 1.75 (2H, m, C2-H2), 1.23 
(9H, s, Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) δ 158.9 (ArC), 155.6 (Boc C=O), 145.8 (Ts 
ArC), 131.4 (Ts ArC), 130.5 (ArC), 130.2 (C5), 129.8 (2 × Ts ArCH), 129.6 (2 × Ts ArCH), 
127.2 (ArCH), 127.1 (C4), 114.0 (ArCH), 83.3 (Boc C(CH3)3), 55.4 (OCH3), 52.6 (C1), 30.0 
(C3), 27.7 (Boc (CH3)3), 25.7 (C2), 21.8 (Ts CH3); HRMS (ESI
+) Calculated for 




To a solution of the preceding N-tosyloxycarbamate 434 (92.3 mg, 0.2 mmol) in anhydrous 
TFE (2.0 mL) was added TFA (31 μL, 0.4 mmol). After stirring overnight at room temperature, 
the reaction mixture was concentrated in vacuo. To the crude reaction mixture was added 
EtOAc (5 mL) and saturated aqueous NaHCO3 (5 mL) and the phases were separated. The 
aqueous phase was extracted with EtOAc (3 × 2 mL) and the combined organic phases were 
washed with brine (5 mL), dried over Na2SO4, filtered and concentrated in vacuo. Purification 
by flash column chromatography (eluent: EtOAc) afforded 436 (32.9 mg, 57%) as a 12:1 




mixture of diastereomers 436a and 436b and as a yellow oil; Rf = 0.05 (EtOAc); νmax / cm
-1 
(film) 3417 (br w), 2943 (m), 1671 (s), 1168 (s), 1123 (s).  
Spectroscopic properties for the major diastereomer 436a: 1H NMR (400 MHz, CDCl3) δ 7.23 
(2H, d, J = 8.5 Hz, ArCH), 6.89 (2H, d, J = 8.5 Hz, ArCH), 4.13 (1H, d, J = 8.5 Hz, C5-H), 
3.81 (3H, s, OCH3), 3.63 (2H, q, J = 8.8 Hz, C6-H2), 3.29 (1H, q, J = 8.2 Hz, C4-H), 3.10 – 
3.03 (1H, m, C1-H), 2.95 – 2.88 (1H, m, C1-H’), 2.63 (1H, br s, NH) 1.81 – 1.62 (2H, m, 
C2-H2), 1.44 – 1.25 (2H, m, C3-H2); 
13C NMR (101 MHz, CDCl3) δ 159.9 (ArC), 130.5 (ArC), 
128.8 (ArCH), 124.2 (q, 1JC-F = 278.5 Hz, C7), 114.2 (ArCH), 87.2 (C5), 65.7 (q, 
2JC-F = 34.0 
Hz, C6), 63.9 (C4), 55.4 (OCH3), 46.0 (C1), 27.6 (C3), 24.3 (C2). 
Characteristic signals for the minor diastereomer 436b: 1H NMR (400 MHz, CDCl3) δ 4.23 
(1H, d, J = 7.0 Hz). 






To a solution of pyrrolidine 436 (65.2 mg, 0.225 mmol) and Et3N (47 μL, 0.338 mmol) in 
CH2Cl2 (0.9 mL) at 0 
oC was added 4-nitrobenzenesulfonyl chloride (49.9 mg, 0.225 mmol). 
The reaction was warmed to room temperature and stirred overnight. To the reaction was added 
CH2Cl2 (5 mL) and aqueous 1 M HCl (1 mL) and the layers were separated. The aqueous layer 
was extracted with CH2Cl2 (3 × 5 mL) and the combined organic extracts were washed with 
water (5 mL), dried over Na2SO4 and concentrated in vacuo. Purification by flash column 
chromatography (20% EtOAc:petroleum ether) afforded 440 (84.9 mg, 80%)  as a colourless 
solid; Rf = 0.80 (EtOAc); m.p. 83-85 
oC (CH2Cl2:hexane); νmax / cm
-1 (solid) 2883 (m), 2953 
(m)1607 (m), 1533 (s), 1350 (s), 1164 (s), 1145 (s); 1H NMR (400 MHz, CDCl3) δ 8.39 (2H, 
d, J = 8.5 Hz, ArCH), 8.06 (2H, d, J = 8.5 Hz, ArCH), 7.34 (2H, d, J = 8.5 Hz, ArCH), 6.92 
(2H, d, J = 8.5 Hz, ArCH), 4.92 (1H, d, J = 4.5 Hz, C5-H), 4.04 – 3.99 (1H, m, C4-H), 3.90 – 
3.80 (4H, m, OCH3, C6-H), 3.78 – 3.69 (1H, m, C6-H’), 3.06 – 2.96 (2H, m, C1-H2), 1.94 – 
1.86 (1H, m, C3-H), 1.56 – 1.46 (1H, m, C3-H’), 1.31 – 1.21 (1H, m, C2-H), 0.91 – 0.80 (1H, 
m, C2-H’); 13C NMR (101 MHz, CDCl3) δ 160.0 (ArC), 150.3 (ArC), 143.1 (ArC), 129.0 




(ArCH), 128.9 (ArCH), 127.2 (ArC), 124.5 (ArCH) 123.5 (q, 1JC-F = 279.5 Hz, C7), 114.1 
(ArCH), 83.3 (C5), 66.6 (q, 2JC-F = 34.2 Hz, C6), 63.2 (C4), 55.4 (OCH3), 49.5 (C1), 26.2 (C3), 
23.9 (C2); HRMS (ESI+) Calculated for C20H21F3N2NaO6S: 497.0965. Found [M+Na]
+: 
497.0970. 
The structure and relative stereochemistry of this compound was confirmed by X-ray 
crystallography after recrystallization (Et2O:hexane). 
 




The title compound was prepared according to a literature procedure.317  
1H NMR (400 MHz, CDCl3) δ 7.11 (1H, d, J = 5.0 Hz), 6.96 – 6.89 (2H, m), 6.58 (1H, d, J = 
15.5 Hz), 6.10 – 6.01 (1H, m), 2.54 – 2.51 (4H, m); 13C NMR (101 MHz, CDCl3) δ 178.9, 
142.5, 128.0, 127.4, 125.0, 124.6, 123.8, 33.7, 27.9. 












General procedure B: (E)-5-(Thiophen-2-yl)pent-4-enoic acid (910 mg, 5.0 mmol) and 2.0 
equivalents of LiAlH4 (10.0 mmol, 2M in THF) in anhydrous THF (25 mL) were employed. 
Purification by flash column chromatography (33% EtOAc:hexane) afforded the title 
compound (580 mg, 69 %) as a pale-yellow oil; Rf = 0.50 (33% EtOAc:hexane); νmax / cm
-1 
(film) 3373 (br), 2935 (m), 1037 (m); 1H NMR (400 MHz, CDCl3) δ 7.09 (1H, d, J = 5.0 Hz, 
C9-H), 6.94 – 6.92 (1H, m, C8-H), 6.87 (1H, d, J = 2.4 Hz, C7-H), 6.55 (1H, d, J = 15.6 Hz, 
C5-H), 6.07 (1H, dt, J = 15.6, 7.0 Hz, C4-H), 3.70 (2H, t, J = 6.5 Hz, C1-H2), 2.31 – 2.25 (2H, 
m, C3-H2), 1.77 – 1.70 (2H, m, C2-H2), 1.59 (1H, br s, OH); 
13C NMR (101 MHz, CDCl3) δ 
142.9 (C6), 130.1 (C4), 127.3 (C8), 124.5 (C7), 123.8 (C5), 123.4 (C9), 62.4 (C1), 32.2 (C2), 
29.2 (C3). 
tert-Butyl (E)-(5-(thiophen-2-yl)pent-4-en-1-yl)(tosyloxy)carbamate (437) 
 
General procedure G: (E)-5-(Thiophen-2-yl)pent-4-enoic acid (252 mg, 1.50 mmol), PPh3 
(470 mg, 1.80 mmol), DIAD (0.35 mL, 1.80 mmol) and BocNHOTs (517 mg, 1.80 mmol) in 
anhydrous THF (6 mL) were employed. Purification by flash column chromatography (10% 
EtOAc:petroleum ether) afforded 437 (505 mg, 77%) as a pale-yellow oil; Rf = 0.80 (33% 
EtOAc:hexane); νmax / cm
-1 (film) 2981 (m), 2933 (m), 1718 (s), 1368 (s), 1191 (s), 1177 (s), 
1152 (s); 1H NMR (400 MHz, CDCl3) δ 7.85 (2H, d, J = 8.5 Hz, Ts ArCH), 7.33 (2H, d, J = 
8.5 Hz, Ts ArCH), 7.09 (1H, dd, J = 5.0, 1.0 Hz, C9-H), 6.93 (1H, dd, J = 5.0, 3.5 Hz, C8-H), 
6.87 (1H, d, J = 3.5 Hz, C7-H), 6.51 (1H, d, J = 15.5 Hz, C5-H), 5.99 (1H, dt, J = 15.5, 7.0 Hz, 
C4-H), 3.62 (2H, br s, C1-H2), 2.43 (3H, s, Ts CH3), 2.19 – 2.12 (2H, m, C3-H2), 1.86 – 1.73 
(2H, m, C2-H2), 1.24 (9H, s, Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) δ 155.6 (Boc C=O), 
145.8 (Ts ArC), 142.8 (C6), 131.4 (Ts ArC), 129.8 (2 × Ts ArCH), 129.7 (2 × Ts ArCH), 129.1 
(C4), 127.3 (C8), 124.7 (C7), 124.1 (C5), 123.5 (C9), 83.4 (Boc C(CH3)3), 52.5 (C1), 29.9 
(C3), 27.8 (Boc (CH3)3), 25.5 (C2), 21.8 (Ts CH3); HRMS (ESI
+) Calculated for 
C21H27NNaO5S2: 460.1223. Found [M+Na]
+: 460.1232. 






To a solution of the preceding N-tosyloxycarbamate 437 (87.5 mg, 0.2 mmol) in anhydrous 
TFE (2.0 mL, 0.1 M) was added TFA (31 μL, 0.4 mmol). After stirring for 24 hours at room 
temperature, the reaction mixture was concentrated in vacuo. To the crude reaction mixture 
was added EtOAc (5 mL) and saturate aqueous NaHCO3 (5 mL) and the phases were separated. 
The aqueous phase was extracted with EtOAc (3 × 2 mL) and the combined organic phases 
were washed with brine (5 mL), dried over Na2SO4, filtered and concentrated in vacuo. 
Purification by flash column chromatography (5% MeOH: CH2Cl2) afforded 439 (16.3 mg, 
31%) as a 12:1 mixture of diastereomers 439a and 439b and as a yellow oil; Rf = 0.1 (EtOAc); 
νmax / cm
-1 (film) 3362 (br), 2936 (m), 1276 (s), 1158 (s). 
Spectroscopic data for the major diastereomer 439a: 1H NMR (400 MHz, CDCl3) δ 7.37 (1H, 
dd, J = 5.0, 1.0 Hz, C9-H), 7.09 (1H, dd, J = 3.5, 1.5 Hz, C7-H), 7.01 (1H, dd, J = 5.0, 3.5 Hz, 
C8-H), 4.69 (1H, d, J = 9.0 Hz, C5-H), 4.41 (1H, br s, NH), 3.87 (1H, dq, J = 11.5, 8.5 Hz, 
C10-H), 3.73 (1H, dq, J = 11.5, 8.5 Hz, C10-H’), 3.61 – 3.55 (1H, m, C4-H), 3.24 – 3.09 (2H, 
m, C1-H2), 1.93 – 1.75 (2H, m, C2-H2), 1.69 – 1.62 (1H, m, C3-H), 1.51 – 1.42 (1H, m, C3-H’); 
13C NMR (101 MHz, CDCl3) δ 140.5 (C6), 127.6 (C7), 127.0 (C9), 126.9 (C8), 123.9 (q, 
1JC-F 
= 278.3 Hz, C11) 81.2 (C5), 65.6 (q, 2JC-F = 34.6 Hz, C10) 64.1 (C4), 46.2 (C1), 28.0 (C3), 
24.3 (C2); 19F NMR (377 MHz, CDCl3) δ -73.6 (3H, t, J = 8.5 Hz). 
Characteristic signals for the minor diastereomer 439b: 1H NMR (400 MHz, CDCl3) δ 4.84 
(1H, d, J = 6.0 Hz). 













To a solution of 4-iodotolune (2.18 g, 10.0 mmol) in Et3N (20 mL) under an atmosphere of N2 
was added Pd(PPh3)2Cl2 (105 mg, 0.15 mmol) and CuI (57 mg, 0.3 mmol). The reaction was 
stirred at room temperature for 10 minutes and 5-hexyn-1-ol (1.21 mL, 11.0 mmol) was added. 
The reaction was stirred at room temperature overnight then poured into saturated aqueous 
NH4Cl (20 mL) and extracted with Et2O (3 × 20 mL). The combined organic extracts were 
washed with brine (20 mL), dried over Na2SO4 and concentrated in vacuo. Purification by flash 
column chromatography (33% EtOAc:petroleum ether) afforded the title compound (1.95 g, 
quantitative) as a colourless oil; 1H NMR (400 MHz, CDCl3) δ 7.28 (2H, d, J = 8.0 Hz), 7.08 
(2H, d, J = 8.0 Hz), 3.73 – 3.68 (2H, m), 2.45 (2H, td, J = 7.0, 1.0 Hz), 2.33 (3H, s), 1.79 – 
1.65 (4H, m), 1.60 (1H, br s); 13C NMR (101 MHz, CDCl3) δ 137.7, 131.5, 129.1, 121.0, 89.2, 
81.1, 62.6, 32.1, 25.2, 21.5, 19.3. 




To a solution of 6-(p-tolyl)hex-5-yn-1-ol (508 mg, 2.70 mmol) in diglyme (15 mL) at 0 oC was 
added 3.5 equivalents of LiAlH4 (610 mg, 16.1 mmol). After stirring at 0 
oC for 20 minutes the 
reaction was heated to reflux and stirred for 1 hour. Upon completion, the reaction mixture was 
cooled to 0 o C before addition of water (1 mL/g of LiAlH4), 15% aqueous NaOH (1 mL/g 
LiAlH4) and a final portion of water (3 mL/g of LiAlH4). The mixture was filtered through 
Celite® and washed with CH2Cl2. The phases were separated, and the aqueous phase extracted 
with CH2Cl2 (2 × 10 mL). The combined organic extracts were dried over Na2SO4, filtered and 
concentrated in vacuo. Purification by flash column chromatography (20% EtOAc:petroleum 
ether) afforded the title compound (281 mg, 55%) as a pale-yellow oil; νmax / cm
-1 (film) 3335 
(br m), 2930 (m), 2858 (m), 1512 (m), 964 (s); 1H NMR (400 MHz, CDCl3) δ 7.24 (2H, d, J = 
8.0 Hz, ArCH), 7.10 (2H, d, J = 8.0 Hz, ArCH), 6.36 (1H, d, J = 16.0 Hz, C6-H), 6.16 (1H, dt, 




J = 16.0, 7.0 Hz, C5-H), 3.67 (2H, t, J = 6.5 Hz, C1-H2), 2.32 (3H, s, CH3), 2.28 – 2.20 (2H, 
m, C4-H2), 1.67 – 1.51 (4H, m, C2-H2, C3-H2), 1.31 (1H, br s, OH); 
13C NMR (101 MHz, 
CDCl3) δ 136.4 (ArC), 134.8 (ArC), 129.8 (C6), 129.3 (C5), 129.0 (ArCH), 125.6 (ArCH), 
62.7 (C1), 32.5 (C4), 32.1 (C2), 25.4 (C3), 20.9 (CH3); HRMS (ESI
+) Calculated for 
C13H18NaO: 213.1250. Found [M+Na]
+: 213.1250. 
tert-Butyl (E)-(6-(p-tolyl)hex-5-en-1-yl)(tosyloxy)carbamate (442) 
 
General procedure G: (E)-6-(p-Tolyl)hex-5-en-1-ol (228 mg, 1.2 mmol), PPh3 (377 mg, 1.44 
mmol), DIAD (0.28 mL, 1.44 mmol) and BocNHOTs (413 mg, 1.44 mmol) in anhydrous THF 
(5 mL) were employed. Purification by flash column chromatography (gradient, eluent: 10-
20% EtOAc:petroleum ether) afforded 442 (508 mg, 92%) as a colourless, crystalline solid; Rf 
= 0.50 (20% EtOAc:hexane); m.p.: 54-57 oC (EtOAc:petroleum ether)  νmax / cm
-1 (film) 2932 
(m), 1716 (s), 1366 (s), 1351 (s), 1177 (s), 1155 (s); 1H NMR (400 MHz, CDCl3) δ 7.86 (2H, 
d, J = 8.0 Hz, Ts ArCH), 7.34 (2H, d, J = 8.0 Hz, Ts ArCH), 7.22 (2H, d, J = 8.0 Hz, ArCH), 
7.09 (2H, J = 8.0 Hz, ArCH), 6.34 (1H, d, J = 16.0 Hz, C6-H), 6.11 (1H, dt, J = 16.0, 7.0 Hz, 
C5-H), 3.64 (2H, br s, C1-H2), 2.45 (3H, s, Ts CH3), 2.32 (3H, s, CH3), 2.22 – 2.17 (2H, m, 
C4-H2), 1.73 – 1.63 (2H, m, C2-H2), 1.47 – 1.39 (2H, m, C3-H2), 1.22 (9H, s, Boc C(CH3)3); 
13C NMR (101 MHz, CDCl3) δ 155.7 (Boc C=O), 145.8 (ArC), 136.7 (ArC), 135.1 (ArC), 
131.4 (ArC), 130.3 (C6), 129.8 (ArCH), 129.7 (ArCH), 129.3 (ArCH), 129.2 (C5), 126.0 
(ArCH), 83.3 (Boc C(CH3)3), 52.8 (C1), 32.7 (C4), 27.8 (Boc C(CH3)3), 26.5 (C3), 25.5 (C2), 
21.9 (Ts CH3), 21.3 (CH3); HRMS (ESI




An oven dried re-sealable tube, fitted with a magnetic stirrer, was charged with the preceding 
N-tosyloxycarbamate 442 (45.9 mg, 0.1 mmol). The tube was fitted with a rubber septum and 




purged with nitrogen before addition of BnOH (0.25 mL), HFIP (0.75 mL) and TFA (15 μL). 
The tube was sealed and stirred at room temperature for 45 hours. The solvent was removed in 
vacuo and purification by flash column chromatography (~0.1% Et3N in EtOAc) afforded 443 
(12.5 mg, 42%) as a 14:1 mixture of diastereomers 443a and 443b and as a yellow oil; Rf = 
0.05 (EtOAc); νmax / cm
-1 (film) 3345 (m), 2928 (m), 2855 (m), 1065 (s), 812 (s). 
Spectroscopic data for the major diastereomer 443a: 1H NMR (400 MHz, CDCl3) δ 7.34 – 
7.16 (9H, m, ArCH), 4.33 (1H, d, J = 11.0 Hz, C7-H), 4.24 (1H, d, J = 11.0 Hz, C7-H’), 4.12 
(1H, d, J = 8.5 Hz, C6-H), 3.12 – 3.05 (1H, m, C1-H), 2.72 – 2.65 (1H, m, C5-H), 2.60 (1H, 
td, J = 12.0, 3.0 Hz, C1-H’), 2.37 (3H, s, CH3), 1.70 – 1.63 (1H, m, C3-H), 1.60 – 1.52 (1H, 
m, C2-H), 1.51 – 1.38 (1H, m, C2-H’), 1.18 – 1.04 (3H, m, C3-H’, C4-H2); 
13C NMR (101 
MHz, CDCl3) δ 138.5 (ArC), 137.8 (ArC), 136.5 (ArC), 129.2 (ArCH), 128.5 (ArCH), 128.3 
(ArCH), 128.0 (ArCH), 127.8 (ArCH), 86.7 (C6), 70.9 (C7), 62.1 (C5), 46.8 (C1), 28.5 (C4), 
26.1 (C2), 24.6 (C3), 21.4 (CH3). 
Characteristic signals for the minor diastereomer 443b: 1H NMR (400 MHz, CDCl3) δ 4.43 
(1H, d, J = 11.5 Hz) 





To a solution of piperidine 443 (29.8 mg, 0.1 mmol) and Et3N (21 μL, 0.15 mmol) in CH2Cl2 
(0.4 mL) at 0 oC was added 2,4-dinitrobenzenesulfonyl chloride (24.0 mg, 0.09 mmol) and the 
reaction was stirred at room temperature overnight. To the reaction mixture was added CH2Cl2 
(5 mL) and 1 M HCl (1 mL) and the layers were separated. The aqueous layer was extracted 
with CH2Cl2 (3 × 2 mL) and the combined organic extracts were washed with water (2 mL), 
dried over Na2SO4 and concentrated in vacuo. Purification by flash column chromatography 
(10% EtOAc:pentane) afforded 444 (25.5 mg, 54%) as a yellow solid; Rf = 0.50 (20% 
EtOAc:hexane); m.p.: 137-140 oC (CH2Cl2:Et2O); νmax / cm
-1 (solid) 2926 (m), 2855 (m), 1548 
(s), 1535 (s), 1344 (s), 1161 (s), 750 (s); 1H NMR (400 MHz, CDCl3) δ 8.17 (1H, d, J = 8.5 




Hz, ArCH), 8.02 (1H, dd, J = 8.5, 2.5 Hz, ArCH), 7.86 (1H, d, J = 2.5 Hz, ArCH), 7.24 – 7.18 
(4H, m, ArCH), 7.15 – 7.06 (3H, m, ArCH), 6.83 – 6.77 (2H, m, ArCH), 4.63 (1H, d, J = 10.5 
Hz, C6-H), 4.25 – 4.19 (1H, m, C5-H), 4.11 – 4.05 (1H, m, C1-H), 3.97 (1H, d, J = 10.5 Hz, 
C7-H), 3.89 (1H, d, J = 10.5 Hz, C7-H’), 3.35 – 3.26 (1H, m, C1-H’), 2.38 (3H, s, CH3), 1.86 
– 1.78 (1H, m, C2-H), 1.68 – 1.55 (4H, m, C2-H’, C3-H2, C4-H), 1.35 – 1.22 (1H, m, C4-H’); 
13C NMR (101 MHz, CDCl3) δ 148.5 (ArC), 147.2 (ArC), 140.9 (ArC), 138.9 (ArC), 137.2 
(ArC), 135.6 (ArC), 132.8 (ArCH), 129.8 (ArCH), 128.4 (ArCH), 128.1 (ArCH), 127.6 
(ArCH), 125.3 (ArCH), 119.4 (ArCH), 78.5 (C6), 71.0 (C7), 59.2 (C5), 42.6 (C1), 26.6 (C2), 
26.2 (C4), 21.4 (CH3), 19.4 (C3); HRMS (ESI
+) Calculated for C26H27N3NaO7S: 548.1462. 
Found [M+Na]+: 548.1454. 
The structure and relative stereochemistry of this compound was confirmed by X-ray 
crystallography after recrystallization (CH2Cl2:hexane). 
  
Crystal structure of 444. 
 (R*)-2-((R*)-Phenyl(2,4,6-trimethoxyphenyl)methyl)pyrrolidine (445) 
 
To a re-sealable tube was added N-tosyloxycarbamate 345 (43.2 mg, 0.10 mmol) and 1,3,5-
trimethoxybenzene (33.6 mg, 0.20 mmol). The tube was fitted with a rubber septum and purged 
with nitrogen before addition of TFE (0.1 mL) and TFA (15 μL, 0.20 mmol). The tube was 




sealed and stirred at room temperature for 42 hours before being concentrated in vacuo. The 
crude reaction mixture was purified by flash column chromatography (~0.1% Et3N in EtOAc) 
to afford 445 (16.5 mg, 50%) as a >20:1 mixture of diastereomers and as a yellow oil; Rf = 
0.05 (EtOAc); νmax / cm
-1 (film) 2937 (m), 2836 (m), 1602 (s), 1589 (s), 1452 (s), 1202 (s), 1148 
(s), 1115 (s), 730 (s), 698 (s); 1H NMR (400 MHz, CDCl3) δ 7.48 – 7.44 (2H, m, ArCH), 7.24 
– 7.18 (2H, m, ArCH), 7.12 – 7.07 (1H, m, ArCH), 6.08 (2H, s, C9-H), 4.44 (1H, d, J = 10.5 
Hz, C5-H), 4.32 (1H, ddd, J = 10.5, 7.6, 6.1 Hz, C4-H), 3.76 (9H, s, C8-H3, and C11-H3), 3.03 
(1H, ddd, J = 10.0, 7.5, 5.2 Hz, C1-H), 2.89 (1H, dt, J = 10.1, 7.4 Hz, C1-H’), 2.39 (1H, br s, 
NH), 1.83 – 1.64 (3H, m, C2-H2, C3-H), 1.34 – 1.25 (1H, m, C3-H’); 
13C NMR (101 MHz, 
CDCl3) δ 159.6 (C10), 159.0 (C7), 144.3 (ArC), 128.9 (ArCH), 128.0 (ArCH), 125.7 (ArCH), 
113.6 (C6), 91.2 (C9), 59.6 (C4), 55.8 (C8), 55.3 (C11), 46.8 (C5), 46.5 (C1), 30.4 (C3), 25.1 





To a solution of pyrrolidine 445 (16.5 mg, 0.05 mmol) and Et3N (10.5 μL, 0.075 mmol) in 
CH2Cl2 (0.2 mL) at 0 
oC was added 4-nitrobenzenesulfonyl chloride (11.1 mg, 0.05 mmol). 
The reaction was warmed to room temperature and stirred overnight. The reaction was diluted 
with CH2Cl2 (5 mL) and 1 M HCl (1 mL) was added. The phases were separated, and the 
aqueous layer extracted with CH2Cl2 (3 × 5 mL). The combined organic extracts were washed 
with H2O, dried over Na2SO4, filtered and concentrated in vacuo. The crude product was 
purified by flash column chromatography (20% EtOAc:petroleum ether) to afford 446 (13.9 
mg, 54%) as a yellow solid; Rf = 0.75 (EtOAc); m.p.: 201-203 
oC (EtOAc); νmax / cm
-1 (solid) 
2940 (m), 2839 (m), 1604 (s), 1587 (s), 1526 (s), 1348 (s), 1149 (s), 1121 (s), 734 (s); 1H NMR 
(400 MHz, CDCl3) δ 8.08 – 8.03 (2H, m, Ns ArCH), 7.44 – 7.37 (4H, m, Ns ArCH, ArCH), 
7.14 – 7.09 (3H, m, ArCH), 6.08 (2H, s, C9-H), 5.58 (1H, ddd, J = 11.0, 7.0, 2.0 Hz, C4-H), 
4.35 (1H, d, J = 11.0 Hz, C5-H), 3.93 – 3.67 (10H, m, C1-H, C8-H3, C8-H3’, C11-H3), 3.30 
(1H, ddd, J = 11.5, 8.5, 5.5 Hz, C1-H’), 1.97 – 1.80 (2H, m, C2-H2), 1.76 – 1.65 (1H, m, C3-H), 
1.64 – 1.57 (1H, m, C3-H’); 13C NMR (101 MHz, CDCl3) δ 160.1 (C10), 158.8 (C7), 149.4 




(Ns ArC), 146.6 (Ns ArC), 143.0 (ArC), 129.6 (ArCH), 128.2 (2 × Ns ArCH), 128.0 (ArCH), 
126.2 (ArCH), 123.8 (2 × Ns ArCH), 111.5 (C6), 91.2 (C9), 63.6 (C4), 55.4 (C8, C11), 47.1 
(C1), 45.3 (C5), 30.1 (C3), 24.6 (C2); HRMS (ESI+) Calculated for C26H28N2NaO7S: 535.1509. 
Found [M+Na]+: 535.1503. 
The structure and relative stereochemistry were confirmed by single crystal X-ray diffraction 
after recrystallisation (CHCl3:hexane).  
  
X-ray crystal structure of 446. 
(S*)-2-((S*)-Azido(phenyl)methyl)pyrrolidine (447) 
 
To a solution of 1-azabicyclo[3.1.0]hexane 346 (23.9 mg, 0.15 mmol) and TMSN3 (39.8 μL, 
0.30 mmol) in HFIP (75 μL, 2 M) was added TfOH (1.3 μL, 10 mol%) and the reaction was 
stirred at room temperature for 3 hours. After completion the crude mixture was concentrated 
in vacuo and purified by flash column chromatography (EtOAc) to afford 447 (20.0 mg, 66%) 
as a >15:1 mixture of diastereomers and as a pale-yellow oil; νmax / cm
-1 (film) 2964 (m), 2870 
(m), 2093 (s), 1452 (m), 1243 (m); 1H NMR (400 MHz, CDCl3) δ 7.46 – 7.27 (5H, m), 4.39 
(1H, d, J = 7.5 Hz), 3.35 (1H, q, J = 7.2 Hz), 2.98 (1H, ddd, J = 10.0, 7.2, 5.2 Hz), 2.84 (1H, 
ddd, J = 9.9, 7.5, 6.5 Hz), 2.02 (1H, br s), 1.96 – 1.63 (4H, m); 13C NMR (101 MHz, CDCl3) δ 
138.2, 128.8, 128.4, 127.4, 70.1, 62.9, 46.5, 28.2, 25.0; HRMS (ESI+) Calculated for C11H15N4: 
203.1299. Found [M+H]+: 203.1297. 




The spectroscopic properties were consistent with the data available in the literature.340 




To solution of 1-azabicyclo[3.1.0]hexane 393 (16.9 mg, 0.098 mmol) in MeOH (1 mL) was 
added 5 % Pd/C (1.69 mg, 10 wt.%). The reaction flask was fitted with a hydrogen balloon and 
stirred overnight at room temperature. Upon completion the reaction mixture was filtered 
through Celite® and concentrated in vacuo to afford 448 (16.8 mg, 98%) as a colourless oil; 
Rf = 0.01 (5% MeOH:CH2Cl2); νmax / cm
-1 (film) 3328 (br m), 2959 (m), 699 (s); 1H NMR (400 
MHz, CDCl3) δ 7.31 – 7.17 (5H, m, ArCH), 3.00 (2H, t, J = 7.0 Hz, C1-H2), 2.73 (2H, q, J = 
13.0 Hz, C5-H2), 2.03 (1H, br s, NH), 1.87 – 1.67 (3H, m, C2-H2, C3-H), 1.49 (1H, ddd, J = 
12.5, 8.5, 5.5 Hz, C3-H’), 1.08 (3H, s, C6-H3); 
13C NMR (101 MHz, CDCl3) δ 138.9 (ArC), 
130.4 (ArCH), 128.2 (ArCH), 126.3 (ArCH), 62.3 (C4), 46.9 (C5), 45.4 (C1), 37.4 (C3), 26.3 





The title compound was prepared according to a literature procedure.341  














General procedure S: 1-Azabicyclo[3.1.0]hexane 389 (27.9 mg, 0.16 mmol) and 
2-phenylacetyl fluoride (33.2 mg, 0.24 mmol) in anhydrous THF (0.16 mL) were employed. 
The reaction was stirred at 0 oC for 3 h before being concentrated in vacuo. The crude product 
was purified twice by flash column chromatography (20% EtOAc:PhMe then gradient, eluent: 
20 – 33% EtOAc:pentane) to afford 457 (29.2 mg, 59%) as a colourless oil; Rf = 0.25 (33% 
EtOAc:hexane); νmax / cm
-1 (film) 3029 (m), 2929 (m), 1638 (s), 1454 (s), 1438 (s), 1159 (m); 
HRMS (ESI+) Calculated for C20H22FNNaO: 334.1578. Found [M+Na]
+: 334.1584. 
The complex exists as an approximately 3:2 mixture of rotamers. The amide of 457 was reduced 




General procedure B: The preceding piperidine 457 (49.9 mg, 0.17 mmol) and 2.0 equivalents 
of LiAlH4 (0.34 mmol, 0.34 mL, 1M in THF) in anhydrous THF (1 mL) were employed. 
Purification by flash column chromatography (20% EtOAc:pentane) afforded the title 
compound (20.6 mg, 41%) as a colourless oil; Rf = 0.60 (33% EtOAc:hexane); νmax / cm
-1 (film) 
2942 (m), 2802 (m), 1495 (m), 1453 (m), 1115 (m); 1H NMR (400 MHz, CD3CN) δ 7.31 – 
7.14 (10H, m, ArCH), 3.04 – 2.86 (2H, m, C8-H2), 2.80 – 2.68 (2H, m, C1-H2), 2.60 – 2.33 
(6H, m, C2-H2, C3-H2, C7-H2), 1.76 – 1.51 (4H, m, C4-H2, C5-H2);
 13C NMR (101 MHz, 
CD3CN) δ 141.9 (ArC), 137.5 (ArC), 131.5 (ArCH), 129.8 (ArCH), 129.2 (ArCH), 128.9 




(ArCH), 127.4 (ArCH), 126.8 (ArCH), 94.8 (d, 1JC-F = 174.5 Hz, C6), 61.4 (d, 
2JC-F = 23.5 Hz, 
C7), 60.9 (C2), 53.6 (C3), 44.1 (d, 3JC-F = 21.0 Hz, C8), 34.3 (d, 
2JC-F = 21.5 Hz, C5), 33.8 
(C1), 23.0 (d, 3JC-F = 6.0 Hz, C4); 
19F NMR (377 MHz, CD3CN) δ -151.9; HRMS (ESI
+) 
Calculated for C20H25FN: 298.1966. Found [M+H]
+: 298.1979. 
Ethyl 3-benzyl-3-chloropiperidine-1-carboxylate (459) 
 
General procedure S: 1-Azabicyclo[3.1.0]hexane 389 (17.3 mg, 0.1 mmol) and ethyl 
chloroformate (10.5 μL, 0.11 mmol) in anhydrous THF (0.1 mL) were employed. The reaction 
time was 18 hours. Purification by flash column chromatography (33% EtOAc:hexane) 
afforded 459 (22.0 mg, 78%) as a colourless solid; Rf = 0.60 (33% EtOAc:hexane); m.p. 100-
103 oC; νmax / cm
-1 (solid) 2983 (m), 2932 (m), 2954 (m), 1679 (s), 1439 (s), 1244 (s); 1H NMR 
(400 MHz, CDCl3) δ 7.35 – 7.25 (5H, m, ArCH), 4.15 (2H, q, J = 7.0 Hz, CH2CH3), 4.12 – 
3.93 (1H, m, C5-H), 3.89 (1H, dt, J = 13.5, 4.0 Hz, C1-H), 3.32 – 3.18 (1H, m, C5-H’), 3.13 
(1H, d, J = 14.0 Hz, C6-H), 3.08 (1H, d, J = 14.0 Hz, C6-H’), 3.04 – 2.92 (1H, m, C1-H’), 1.96 
– 1.85 (2H, m, C2-H, C3-H), 1.82 – 1.72 (1H, m, C3-H’), 1.63 – 1.55 (1H, m, C2-H’), 1.26 
(3H, t, J = 7.0 Hz, CH2CH3); 
13C NMR (101 MHz, CDCl3) δ 155.8 (C=O), 135.4 (ArC), 131.1 
(ArCH), 128.2 (ArCH), 127.2 (ArCH), 70.7 (C4), 61.6 (CH2CH3), 55.0 (C5), 47.3 (C6), 43.7 
(C1), 37.4 (C3), 21.9 (C2), 14.8 (CH2CH3); HRMS (ESI
+) Calculated for C15H20
35ClNNaO2: 
304.1074. Found [M+Na]+: 304.1083. 
The structure of 459 was confirmed by X-ray crystallography after recrystallisation 
(CH2Cl2:hexane). 





X-ray crystal structure of 459. 
 
1-Acetyl-3-benzylpiperidin-3-yl acetate (460) 
 
General procedure S: 1-Azabicyclo[3.1.0]hexane (389) (17.6 mg, 0.10 mmol) and acetic 
anhydride (10.4 μL, 0.11 mmol) in anhydrous THF (0.1 mL) were employed. The reaction time 
was 18 hours. Purification by flash column chromatography (gradient, eluent: 33% 
EtOAc:hexane – EtOAc) afforded 460 (19.8 mg, 72%) as a colourless oil. This compound exists 
as an approximately 3:1 mixture of rotamers A and B.  Rf = 0.10 (33% EtOAc:hexane); νmax / 
cm-1 (film) 2931 (m), 2850 (m), 1728 (s), 1631 (s), 1438 (s), 1236 (s); 1H NMR (400 MHz, 
CDCl3) δ 7.32 – 7.05 (5H, m, A and B: ArCH), 4.58 (0.25H, d, J = 14.0 Hz, B: C7-H), 4.45 – 
4.38 (0.75H, m, A: C3-H), 4.27 (0.75H, d, J = 13.5 Hz, A: C7-H), 3.61 – 3.54 (0.25H, m, B: 
C3-H), 3.34 (0.25H, d, J = 14.0 Hz, B: C8-H), 3.27 (0.75H, d, J = 14.0 Hz, A: C8-H), 3.16 – 
3.02 (2H, m, B: C3-H’, A: C7-H’, A + B: C8-H’), 2.95 (0.25H, d, J = 13.5 Hz, B: C7-H’), 2.61 
– 2.52 (0.75H, m, A: C3-H’), 2.36 – 2.25 (1H, m, A + B: C5-H), 2.06 (0.75H, s, B: C1-H3), 2.00 
– 1.94 (4.50H, m, A: C1-H3 + C10-H3), 1.91 (0.75H, s, B: C10-H3), 1.63 – 1.41 (3H, m, A + B: 
C4-H2 + C5-H’); 
13C NMR (101 MHz, CDCl3) δ 171.3 (A: C9), 170.8 (B: C9), 170.1 (A: C2), 
169.5 (B: C2), 135.9 (B: ArC), 135.5 (A: ArC), 130.5 (B: ArCH), 130.3 (A: ArCH), 128.5 (A: 
ArCH), 128.4 (B: ArCH), 127.1 (A: ArCH), 126.8 (B: ArCH), 80.7 (A: C6), 80.6 (B: C6), 53.2 




(A: C7), 48.3 (B: C7), 46.5 (B: C3), 41.7 (A: C3), 41.1 (B: C8), 41.0 (A: C8), 33.1 (A: C5), 32.6 
(B: C5), 22.4 (A: C10), 22.0 (B: C10), 21.7 (B: C1), 21.3 (A: C1), 20.8 (A + B: C4); HRMS 




The title compound was prepared according to a literature procedure.342 
1H NMR (400 MHz, CDCl3) δ 7.73 (1H, s), 3.10 (3H, s), 1.43 (9H, s); 
13C NMR (101 MHz, 
CDCl3) δ 157.7, 81.6, 38.0, 28.3. 
The spectroscopic properties were consistent with the data available in the literature.342  
 
tert-Butyl methyl(tosyloxy)carbamate (463) 
 
General procedure T: tert-Butyl hydroxy(methyl)carbamate (8.97 g, 61.0 mmol), 
4-toluenesulfonyl chloride (12.2 g, 64.0 mmol) and Et3N (8.9 mL, 64.0 mmol) in Et2O (250 
mL) were employed. Purification by flash column chromatography (10% EtOAc:petroleum 
ether) afforded 463 (9.02 g, 49%) as a colourless solid; 1H NMR (400 MHz, CDCl3) δ 7.86 
(2H, d, J = 8.5 Hz), 7.35 (2H, d, J = 8.5 Hz), 3.24 (3H, s), 2.45 (3H, s), 1.21 (9H, s); 13C NMR 
(101 MHz, CDCl3) δ 156.2, 145.8, 131.2, 129.8, 129.7, 83.4, 40.3, 27.7, 21.8; HRMS (ESI
+) 
Calculated for C13H19NNaO5S: 324.0876. Found [M+Na]
+: 324.0875. 
The spectroscopic properties were consistent with the data available in the literature.343 
 
tert-Butyl methyl((methylsulfonyl)oxy)carbamate (465a) 
 
General procedure T: tert-Butyl hydroxy(methyl)carbamate (736 mg, 5.0 mmol), 
methanesulfonylchloride (0.41 mL, 5.25 mmol) and Et3N (0.73 mL, 5.25 mmol) in Et2O (20 
mL) were employed. Purification by flash column chromatography (10% EtOAc:petroleum 
ether) afforded 465a (680 mg, 60%)  as a colourless oil; νmax / cm
-1 (film) 2981 (m), 1726 (s), 




1367 (s), 1322 (s), 1181 (s), 1145 (s); 1H NMR (400 MHz, CDCl3) δ 3.31 (3H, s, NCH3), 3.13 
(3H, s, Ms CH3), 1.51 (9H, s, Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) δ 156.2 (Boc C=O), 
84.5 (Boc C(CH3)3), 40.7 (NCH3), 36.8 (Ms CH3), 28.2 (Boc (CH3)3); HRMS (ESI
+) Calculated 
for C7H15NNaO5S: 248.0563. Found [M+Na]
+: 248.0567. 
 
tert-Butyl ((mesitylsulfonyl)oxy)(methyl)carbamate (465b) 
 
General procedure T: tert-Butyl hydroxy(methyl)carbamate (1.47 g, 10.0 mmol), 
2-mesitylenesulfonyl chloride (2.30 g, 10.5 mmol) and Et3N (1.46 mL, 10.5 mmol) in Et2O (40 
mL) were employed. Purification by flash column chromatography (10% EtOAc:petroleum 
ether) followed by recrystallisation (from hexane) afforded 465b (645 mg, 20%)  as a 
colourless solid; m.p. 69-70 oC (CH2Cl2:hexane) [lit: 67-69 
oC (hexane)344]; 1H NMR (400 
MHz, CDCl3) δ 6.97 (2H, s), 3.22 (3H, s), 2.64 (6H, s), 2.30 (3H, s), 1.25 (9H, s); 
13C NMR 
(101 MHz, CDCl3) δ 156.4, 144.3, 142.1, 131.8, 129.6, 83.5, 40.4, 27.8, 23.5, 21.2; HRMS 
(ESI+) Calculated for C15H23NNaO5S: 352.1189. Found [M+Na]
+: 352.1191. 
The spectroscopic properties were consistent with the data available in the literature.344 
 
tert-Butyl methyl(((4-nitrophenyl)sulfonyl)oxy)carbamate (465c) 
 
General procedure T: tert-Butyl hydroxy(methyl)carbamate (1.47 g, 10.0 mmol), 
4-nitrobenzenesulfonyl chloride (2.33 g, 10.5 mmol) and Et3N (1.46 mL, 10.5 mmol) in Et2O 
(40 mL) were employed. Purification by flash column chromatography (10% EtOAc:petroleum 
ether) afforded 465c (1.44 g, 43%)  as a pale-yellow solid; m.p.: 98-99 oC (CH2Cl2/hexane); 
νmax / cm
-1 (solid) 3115 (m), 2984 (m), 2934 (m), 1736 (s), 1535 (s), 1383 (s), 1371 (s), 1133 
(s); 1H NMR (400 MHz, CDCl3) δ 8.39 (2H, d, J = 8.7 Hz, ArCH), 8.20 (2H, d, J = 8.7 Hz, 
ArCH), 3.29 (3H, s, NCH3), 1.23 (9H, s, Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) δ 155.7 
(Boc C=O), 151.3 (ArC), 140.0 (ArC), 131.3 (ArCH), 124.0 (ArCH), 84.3 (Boc C(CH3)3), 40.9 




(NCH3), 27.8 (Boc (CH3)3); HRMS (ESI
+) Calculated for C12H16N2NaO7S: 355.0570. Found 
[M+Na]+: 355.0573. 
tert-Butyl (((2,4-dinitrophenyl)sulfonyl)oxy)(methyl)carbamate (465d) 
 
General procedure T: tert-Butyl hydroxy(methyl)carbamate (1.47 g, 10.0 mmol), 
2,4-dinitrobenzenesulfonyl chloride (2.79 g, 10.5 mmol) and Et3N (1.46 mL, 10.5 mmol) in 
Et2O (40 mL) were employed. Purification by flash column chromatography (20% 
EtOAc:petroleum ether) afforded 465d (335 mg, 9%) as a colourless solid; 1H NMR (400 MHz, 
CDCl3) δ 8.61 (1H, d, J = 2.0 Hz), 8.54 (1H, dd, J = 8.5, 2.0 Hz), 8.41 (1H, d, J = 8.5 Hz), 3.32 
(3H, s), 1.30 (9H, s); 13C NMR (101 MHz, CDCl3) δ 155.5, 150.1, 149.4, 134.7, 133.1, 126.0, 
120.1, 84.9, 41.2, 27.9. 
The spectroscopic properties were consistent with the data available in the literature.342 
 
tert-Butyl (((chloromethyl)sulfonyl)oxy)(methyl)carbamate (465e) 
 
General procedure T: tert-Butyl hydroxy(methyl)carbamate (1.47 g, 10.0 mmol), 
chloromethane sulfonyl chloride (0.95 mL, 10.5 mmol) and Et3N (1.46 mL, 10.5 mmol) in 
Et2O (40 mL) were employed. Purification by flash column chromatography (10% EtOAc: 
petroleum ether) afforded 465e (1.27 g, 49%) as an off-white solid; m.p.: 49-51 oC 
(CH2Cl2:hexane); νmax / cm
-1 (solid) 3030 (m), 2978 (m), 2963 (m), 1722 (s), 1384 (s), 1371 
(s), 1147 (s); 1H NMR (400 MHz, CDCl3) δ 4.79 (2H, s, CH2Cl), 3.34 (3H, s, NCH3), 1.53 (9H, 
s, Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) δ 156.1 (Boc C=O), 85.2 (Boc C(CH3)3), 53.7 
(CH2Cl), 41.1 (NCH3), 28.2 (Boc C(CH3)3); HRMS (ESI
+) Calculated for C7H14Cl35NNaO5S: 










General procedure U: tert-Butyl (((chloromethyl)sulfonyl)oxy)(methyl)carbamate 465e 
(155.8 mg, 0.6 mmol),  cis-β-methylstyrene (65 μL, 0.5 mmol) and TFA (77 μL, 2.0 mmol) in 
TFE (1.0 mL, 0.5 M) were employed. The reaction was stirred at room temperature for 48 
hours. After completion the solvent was removed in vacuo and purification by flash column 
chromatography (~0.1% Et3N in 10% EtOAc:pentane) afforded 464 (31.0 mg, 42%) as a 
colourless oil; Rf = 0.40 (20% EtOAc:hexane); 
1H NMR (400 MHz, CDCl3) δ 7.31 – 7.27 (4H, 
m), 7.24 – 7.19 (1H, m), 2.51 (3H, s), 2.45 (1H, d, J = 6.5 Hz), 1.70 (1H, dq, J = 6.5, 5.5 Hz), 
0.93 (3H, d, J = 5.5 Hz); 13C NMR (101 MHz, CDCl3) δ 137.7, 128.0, 127.9, 126.6, 47.8, 47.7, 
43.1, 12.8. 




General procedure U: tert-Butyl (((chloromethyl)sulfonyl)oxy)(methyl)carbamate 465e 
(155.8 mg, 0.6 mmol), trans-β-methylstyrene (65 μL, 0.5 mmol) and TFA (77 μL, 2.0 mmol) 
in TFE (1.0 mL, 0.5 M) were employed. The reaction was stirred at room temperature for 48 
hours and concentrated in vacuo. Purification by flash column chromatography (~0.1% Et3N 
in 20% EtOAc:pentane) afforded 466 (23.7 mg, 32%) as an approximately 3:1 mixture of 
invertomers (at 298 K) and as a pale-yellow oil.  
Spectroscopic data for the major invertomer: 1H NMR (400 MHz, CDCl3) δ 7.36 – 7.19 (5H, 
m), 2.55 (3H, s), 2.15 – 2.10 (1H, m), 2.09 – 2.07 (1H, m), 1.37 (3H, d, J = 6.0 Hz); 13C NMR 
(101 MHz, CDCl3) δ 140.9, 128.4, 126.8, 126.0, 49.7, 42.7, 38.4, 10.9. 
Characteristic signals for the minor invertomer: 1H NMR (400 MHz, CDCl3) δ 2.86 (1H, d, J 
= 3.5 Hz), 2.05 (3H, s), 1.99 – 1.93 (1H, m), 1.32 (3H, d, J = 5.5 Hz); 13C NMR (101 MHz), δ 
134.4, 130.3, 128.0, 127.5, 47.2, 39.8, 39.0, 18.3. 
The spectroscopic properties were consistent with the data available in the literature.346  
 






To N-methylhydroxylamine hydrochloride (169 mg, 2.02 mmol)  in MeOH (20 mL) was added 
a solution of KOH (20 mL, 0.1 M in MeOH) and N-[2-(trimethylsilyl)ethoxy 
carbonyloxy]succinimide (500 mg, 1.93 mmol) and the reaction was stirred at room 
temperature overnight. The solvent was removed in vacuo and the residue was dissolved in 
EtOAc (30 mL) and washed with saturated aqueous NaHCO3 (3 × 15 mL) and brine (15 mL), 
dried over Na2SO4, filtered and concentrated in vacuo. The resulting colourless oil (318 mg, 
86%) was used without further purification; 1H NMR (400 MHz, CDCl3) δ 4.27 – 4.22 (2H, 
m), 3.20 (3H, s), 1.59 (1H, br s), 1.06 – 1.01 (2H, m), 0.05 (9H, s); 13C NMR (101 MHz, CDCl3) 
δ 158.2, 65.2, 37.7, 17.9, -1.4. 
The spectroscopic properties were consistent with the data available in the literature.347  
 
2-(Trimethylsilyl)ethyl methyl(tosyloxy)carbamate (467) 
 
To a solution of 2-(trimethylsilyl)ethyl hydroxy(methyl)carbamate (318 mg, 1.66 mmol) in 
CH2Cl2 (5 mL) cooled to 0 
oC were added Et3N (0.25 mL) and TsCl (349 mg, 1.83 mmol). The 
reaction was warmed to room temperature and stirred overnight. The reaction was quenched 
with 1M aqueous HCl (5 mL) and the layers were separated. The aqueous phase was extracted 
with CH2Cl2 (5 mL) and the combined organic phases were washed with brine, dried over 
Na2SO4, filtered and concentrated in vacuo. Purification by flash column chromatography 
(10% EtOAc:hexane) afforded 467 (480 mg, 84%) as a colourless solid; m.p.: 68-70 oC 
(CH2Cl2); νmax / cm
-1 (solid) 2960 (m), 1722 (s), 1375 (s), 1172 (s); 1H NMR (400 MHz, CDCl3) 
δ 7.86 (2H, d, J = 8.5 Hz, Ts ArCH), 7.34 (2H, d, J = 8.5 Hz, Ts ArCH), 3.98 – 3.92 (2H, m, 
C2-H2), 3.24 (3H, s, NCH3), 2.45 (3H, s, Ts CH3), 0.75 – 0.68 (2H, m, C1-H2), -0.01 (9H, s, 
Si(CH3)3); 
13C NMR (101 MHz, CDCl3) δ 157.6 (C=O), 145.9 (Ts ArC), 131.3 (Ts ArC), 129.8 
(2 × Ts ArCH), 129.7 (2 × Ts ArCH), 65.9 (C2), 40.3 (NCH3), 21.9 (Ts CH3), 17.5 (C1), -1.51 
(Si(CH3)3); HRMS (ESI
+) Calculated for C14H23NNaO5SSi: 368.0958. Found [M+Na]
+: 
368.0966. 




tert-Butyl cinnamyl(tosyloxy)carbamate (476) 
 
General procedure G: Cinnamyl alcohol (671 mg, 5.0 mmol), PPh3 (1.57 g, 6.0 mmol), DIAD 
(1.17 mL, 6.0 mmol) and BocNHOTs (1.72 g, 6.0 mmol) in anhydrous THF (20 mL) were 
employed. Purification by flash column chromatography (gradient, eluent: 5 – 10% 
EtOAc:hexane) afforded 476 (1.28 g, 63%) as a colourless solid; m.p.: 77-79 oC 
(CH2Cl2/hexane); νmax/cm
-1 (solid) 1715 (s), 1379 (s), 1344 (s), 1190 (s); 1H NMR (400 MHz, 
CDCl3) δ 7.86 (2H, d, J = 8.0 Hz, Ts ArCH), 7.38 – 7.13 (7H, m, Ts ArCH, ArCH), 6.54 (1H, 
d, J = 16.0 Hz, C3-H), 6.17 (1H, dt, J = 16.0, 6.5 Hz, C2-H), 4.31 (2H, br s, C1-H2), 2.42 (3H, 
s, Ts CH3), 1.23 (9H, s, Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) δ 155.6 (Boc C=O), 145.9 
(Ts ArC), 136.4 (ArC), 135.3 (C3), 131.4 (Ts ArC), 129.8 (Ts ArCH), 129.7 (Ts ArCH), 128.7 
(ArCH), 128.1 (ArCH), 126.7 (ArCH), 121.4 (C2) 83.7 (Boc C(CH3)3), 55.4 (C1), 27.8 (Boc 
(CH3)3), 21.8 (Ts CH3); HRMS (ESI




To a solution of the preceding N-tosyloxycarbamate 476 (202 mg, 0.5 mmol) in anhydrous 
TFE (0.1 M) under an atmosphere of nitrogen was added TFA (77 µL, 1.0 mmol). The reaction 
was stirred at room temperature for 26 h and concentrated in vacuo. The crude reaction mixture 
was dissolved in anhydrous CH2Cl2 (5 mL) and cooled to 0 
oC. To the reaction was added 
methanesulfonyl chloride (77 µL, 1.0 mmol) and Et3N (0.28 mL, 2.0 mmol). The reaction was 
allowed to warm to room temperature and stirred overnight before being quenched with 
saturated aqueous NH4Cl (5 mL). The phases were separated, and the aqueous phase extracted 
with CH2Cl2 (3 × 5 mL). The combined organic extracts were washed with brine (5 mL), dried 
over Na2SO4, filtered and concentrated in vacuo. Purification by flash column chromatography 
(gradient, eluent: 20% – 33% hexane:EtOAc) afforded 477 (52.4 mg, 34 %) as a 9:1 mixture 
of diastereomers and as a yellow oil. 




Spectroscopic properties for the major diastereomer 477a: 1H NMR (400 MHz, CDCl3) δ 7.46 
– 7.32 (5H, m, ArCH), 4.17 (1H, d, J = 7.5 Hz, C3-H), 3.87 – 3.67 (2H, m, C4-H2), 3.05 (3H, 
s, Ms CH3), 2.98 (1H, td, J = 7.5, 4.5 Hz, C2-H), 2.66 (1H, dd, J = 7.5, 1.0 Hz, C1-H), 2.31 
(1H, dd, J = 4.5, 1.0 Hz, C1-H’); 13C NMR (101 MHz, CDCl3) δ 136.1 (ArC), 129.6 (ArCH), 
129.4 (ArCH), 127.1 (ArCH), 123.9 (q, J = 278.5 Hz, C5), 83.2 (C3), 66.1 (q, J = 34.5 Hz, C4) 
44.3 (C2), 39.4 (Ms CH3), 29.1 (C1). 
Characteristic signals for the minor diastereomer 477b: 1H NMR (400 MHz, CDCl3) δ 4.35 
(1H, d, J = 6.0 Hz), 2.72 (1H, d, J = 7.0 Hz). 
HRMS (MALDI+) Calculated for: C12H14NaNO3F3S: 332.0539. Found [M+Na]
+: 332.0548. 
 
Ethyl (E)-3-phenylbut-2-enoate (478) 
 
General procedure V: Acetophenone (2.40 g, 20 mmol), triethyl phosponoacetate (6.73 g, 30 
mmol) and NaH (60 w.t.% in mineral oil, 1.22 g, 30 mmol) in anhydrous THF (100 mL) were 
employed. The title compound was obtained as a 5:1 mixture of E:Z alkene isomers which 
were separated by flash column chromatography (5% EtOAc:hexane) to obtain (E)-478 (1.99 
g, 52%) as a colourless oil and (Z)-478 (430 mg, 11%) as a colourless oil. 
Spectroscopic properties for (E)-478: 1H NMR (400 MHz, CDCl3) δ 7.50 – 7.45 (2H, m), 7.40 
– 7.35 (3H, m), 6.14 (1H, q, J = 1.5 Hz), 4.22 (2H, q, J = 7.0 Hz), 2.58 (3H, d, J = 1.5 Hz), 
1.32 (3H, t, J = 7.0 Hz); 13C NMR (101 MHz, CDCl3) δ 167.0, 155.7, 142.4, 129.1, 128.6, 
126.4, 117.3, 59.9, 18.1, 14.5. 
The spectroscopic properties were consistent with the data available in the literature.348 
 
(E)-3-Phenylbut-2-en-1-ol (479)  
 
To a solution of the preceding ester (E)-478 (1.54 g, 8.0 mmol) in anhydrous Et2O (18 mL) at 
0 oC was added DIBAL-H (1M in hexanes, 17.6 mL) dropwise over 15 min. The reaction was 
stirred at room temperature until completion by TLC analysis (2.5 hours). Upon completion 




the reaction was cooled to 0 oC and water (10 mL) was added then brine (10 mL). The white 
solid formed was partially dissolved by the addition of aqueous HCl (1 M) and the layers were 
separated. The aqueous layer was extracted with Et2O and the combined organic extracts were 
dried, filtered and concentrated under reduced pressure. Purification by flash column 
chromatography (33% EtOAc:hexane) afforded 479 (873 mg, 74%) as a colourless oil; 
1H NMR (400 MHz, CDCl3) δ 7.43 – 7.38 (2H, m), 7.35 – 7.30 (2H, m), 7.28 – 7.23 (1H, m), 
6.00 – 5.95 (1H, m), 4.36 (2H, d, J = 6.5 Hz), 2.08 (3H, s), 1.72 (1H, br s); 13C NMR (101 MHz, 
CDCl3) δ 142.8, 137.2, 128.4, 127.3, 126.4, 125.9, 60.1, 16.2. 
The spectroscopic properties were consistent with the data available in the literature.349 
 
tert-Butyl (E)-(3-phenylbut-2-en-1-yl)(tosyloxy)carbamate (480)  
 
General procedure G: The preceding alcohol 479 (445 mg, 3.0 mmol), PPh3 (940 mg, 3.6 
mmol), DIAD (0.71 mL, 3.6 mmol) and BocNHOTs (1.03 g, 3.6 mmol) in anhydrous THF (12 
mL) were employed. Purification by flash column chromatography (gradient 5 – 10% 
EtOAc:hexane) afforded 480 (985 mg, 79%) as an off-white solid; νmax/cm
-1 (solid) 2985 (m), 
1746 (s), 1721 (s), 1365 (s), 1147 (s); 1H NMR (400 MHz, CDCl3) δ 7.94 – 7.84 (2H, m, Ts 
ArCH), 7.37 – 7.22 (7H, m, ArCH, Ts ArCH), 5.79 (1H, td, J = 7.0, 1.5 Hz, C2-H), 4.39 (2H, 
s, C1-H2), 2.43 (3H, s, Ts CH3), 2.08 (3H, d, J = 1.5 Hz, C4-H3), 1.22 (9H, s, Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) δ 155.8 (Boc C=O), 145.8 (Ts ArC), 143.0 (C3), 140.7 (ArC), 
131.4 (Ts ArC), 129.8 (2 × Ts ArCH), 129.7 (2 × Ts ArCH), 128.4 (ArCH), 127.5 (ArCH), 
126.1 (ArCH), 119.6 (C2), 83.6 (Boc C(CH3)3), 51.5 (C1), 27.7 (Boc (CH3)3), 21.8 (Ts CH3), 
















General procedure W: The preceding N-tosyloxycarbamate 480 (125 mg, 0.3 mmol) and TFA 
(46 µL, 0.6 mmol) in anhydrous TFE (3 mL, 0.1 M) were employed. The reaction was stirred 
at room temperature for 24 hours. Purification by flash column chromatography with ~0.1 % 
Et3N added to the eluent (33% EtOAc:hexane) afforded 481 (37.4 mg, 51%) as an 8:1 mixture 
of diastereomers and as a colourless oil; νmax / cm
-1 (film) 2936 (m), 1275 (s), 1150 (s), 1109 
(s). 
Spectroscopic properties for the major diastereomer 481a:1H NMR (400 MHz, CDCl3) δ 7.45 
– 7.29 (5H, m), 3.82 – 3.63 (2H, m, C5-H2), 2.32 (1H, dd, J = 6.0, 3.5 Hz, C2-H), 1.74 (1H, d, 
J = 6.0 Hz, C1-H), 1.60 (1H, d, J = 3.5 Hz, C1-H’), 1.53 (3H, s, C4-H3); 
13C NMR (101 MHz, 
CDCl3) δ 142.1 (ArC), 128.7 (ArCH), 128.1 (ArCH), 126.3 (ArCH), 124.3 (q, J = 277.6 Hz, 
C6), 78.9 (C3), 61.6 (q, J = 34.5 Hz, C5), 38.5 (C2), 22.1 (C1), 20.8 (C4); 19F NMR (377 MHz, 
CDCl3) δ -74.00 (t, J = 8.5 Hz). 
Characteristic signals for the minor diastereomer 481b: 1H NMR (400 MHz, CDCl3) δ 2.19 
(1H, dd, J = 6.0, 3.5 Hz), 1.84 (1H, d, J = 3.5 Hz). 
HRMS (ESI+) Calculated for C12H15NOF3: 246.1100. Found [M+H]
+: 246.1093. 
 
Ethyl (E)-3-(4-bromophenyl)but-2-enoate  
 
General procedure V: 4-Bromoacetophenone (3.00 g, 20 mmol), triethyl phosphonoacetate 
(6.73 g, 30 mmol) and NaH (60 w.t.% in mineral oil, 1.22 g, 30 mmol) in anhydrous THF (100 
mL) were employed. The title compound was obtained as a 3:1 mixture of E:Z alkene isomers 
which was purified by flash column chromatography (5% EtOAc:hexane) to obtain the title 
compound (4.55 g, 56%, 3:1 E:Z) as a colourless oil. 
Spectroscopic properties of the major E isomer: 1H NMR (400 MHz, CDCl3) δ 7.51 – 7.47 
(2H, m), 7.36 – 7.31 (2H, m), 6.12 – 6.10 (1H, m), 4.21 (2H, q, J = 7.0 Hz), 2.54 (3H, d, J = 




1.5 Hz), 1.31 (3H, t, J = 7.0 Hz); 13C NMR (101 MHz, CDCl3) δ 166.7, 154.2, 141.2, 131.8, 
128.0, 123.3, 117.7, 60.1, 17.9, 14.4. 
The spectroscopic properties were consistent with the data available in the literature.350 
 
(E)-3-(4-Bromophenyl)but-2-en-1-ol (482)  
 
To a solution of the proceeding compound (2.15 g, 8.0 mmol, 3:1 E:Z) in Et2O (18 mL) at 0 
oC 
was added DIBAL-H (17.6 mL, 1 M in hexanes) dropwise. The reaction was stirred at room 
temperature overnight. The reaction was cooled to 0 oC and quenched with H2O (0.04 
mL/mmol DIBAL-H), 2M NaOH (0.04 mL/mmol DIBAL-H) and H2O (0.1 mL/mmol 
DIBAL-H). The reaction mixture was warmed to room temperature and stirred for 15 minutes 
before being dried over Na2SO4 and stirred for a further 30 minutes. The resulting solid was 
filtered, and the filtrate concentrated in vacuo. Purification by flash column chromatography 
(33% EtOAc:hexane) afforded 482 (968 mg, 53%, 3:1 mixture of E:Z isomers) as a colourless 
oil. 
Spectroscopic data for the major E isomer: 1H NMR (400 MHz, CDCl3) δ 7.43 (2H, d, J = 8.5 
Hz), 7.26 (2H, d, J = 9.0 Hz), 5.98 – 5.92 (1H, m), 4.35 (2H, d, J = 6.5 Hz), 2.04 (3H, d, J = 
1.0 Hz), 1.38 (1H, br s); 13C NMR (101 MHz, CDCl3) δ 141.8, 136.8, 131.4, 127.5, 127.2, 
121.3, 60.0, 16.0.   
The spectroscopic properties were consistent with the data available in the literature.351  
Spectroscopic data for the minor Z isomer: 1H NMR (400 MHz, CDCl3) δ 7.45 (2H, d, J = 8.5 
Hz), 7.04 (1H, d, J = 8.5 Hz), 5.71 (1H, tq, J = 7.0, 1.5 Hz), 4.03 (1H, d, J = 7.0 Hz), 2.05 (2H, 
d, J = 1.5 Hz). 
 
tert-Butyl (E)-(3-(4-bromophenyl)but-2-en-1-yl)(tosyloxy)carbamate (483)  
 
General procedure G: The preceding alcohol 482 (3:1 E:Z, 681 mg, 3.0 mmol), PPh3 (940 
mg, 3.6 mmol), DIAD (0.71 mL, 3.6 mmol) and BocNHOTs (1.03 g, 3.6 mmol) in anhydrous 




THF (12 mL) were employed. Purification by flash column chromatography (5% 
EtOAc:hexane) afforded 483 (3:1 E:Z, 989 mg, 66%) as a pale-yellow solid; mp. 90-92 oC 
(CH2Cl2/hexane); νmax / cm
-1 (solid) 2981 (m), 1746 (s), 1370 (s), 1180 (s), 1152 (s). 
Spectroscopic data for the major E isomer: 1H NMR (400 MHz, CDCl3) δ 7.87 (2H, d, J = 8.0 
Hz, Ts ArCH), 7.43 (2H, d, J = 8.5 Hz, ArCH), 7.34 (2H, d, J = 8.0 Hz, Ts ArCH), 7.22 (2H, 
d, J = 8.5 Hz, ArCH), 5.79 (1H, td, J = 7.0, 1.5 Hz, C2-H), 4.39 (2H, br s, C1-H2), 2.45 (3H, s, 
Ts CH3), 2.07 (3H, s, C4-H3), 1.22 (9H, s, Boc C(CH3)3), 
13C NMR (101 MHz, CDCl3) δ 155.8 
(Boc C=O), 145.9 (Ts ArC), 141.8 (ArC), 139.6 (C3), 131.5 (ArCH), 131.4 (Ts ArC), 129.9 (2 
× Ts ArCH), 129.7 (2 × Ts ArCH), 127.7 (ArCH), 121.5 (ArC), 120.2 (C2), 83.7 (Boc 
C(CH3)3), 51.4 (C1), 27.7 (Boc C(CH3)3), 21.8 (Ts CH3), 16.3 (C4); HRMS (ESI
+) Calculated 





General procedure W: The proceeding compound 483 (3:1 E:Z, 149 mg, 0.3 mmol) and TFA 
(46 µL, 0.6 mmol) in anhydrous TFE (3 mL) were employed. The reaction was stirred at room 
temperature for 24 hours. Purification by flash column chromatography with the addition of 
~0.1% Et3N to the eluent (33% EtOAc:hexane) afforded 488 (44 mg, 45 %, 6:1 mixture of 
diastereomers) as a colourless oil; νmax / cm
-1 (film) 2938 (m), 1487 (m), 1277 (s), 1153 (s). 
Spectroscopic data for the major diastereomer 488a: 1H NMR (400 MHz, CDCl3) δ 7.49 (2H, 
d, J = 8.5 Hz, C9-H), 7.31 (2H, d, J = 8.5 Hz, C8-H), 3.87 – 3.61 (2H, m, C5-H2), 2.28 (1H, 
m, C2-H), 1.76 (1H, d, J = 6.0 Hz, C1-H), 1.59 – 1.54 (1H, m, C1-H’), 1.48 (3H, s, C4-H3); 
13C NMR (101 MHz, CDCl3) δ 141.4 (C7), 131.8 (C9), 128.1 (C8), 124.1 (d, J = 277.5 Hz, 
C6), 122.2 (C10), 78.7 (C3) 61.6 (q, J = 34.5 Hz, C5-H2), 38.0 (C2), 22.0 (C1), 20.6 (C4); 
19F NMR (377 MHz, CDCl3) δ -74.02 (t, J = 8.5 Hz). 
Characteristic signals for the minor isomer 488b: 1H NMR (400 MHz, CDCl3) δ 2.20 – 2.14 
(1H, m). 
HRMS (ESI+) Calculated for C12H14BrF3NO: 324.0205. Found [M+H]
+: 324.0201. 
 




Ethyl (E)-3-(p-tolyl)but-2-enoate  
 
General procedure V: 4-Methylacetophenone (2.99 g, 22.3 mmol), triethyl phosphonoacetate 
(4.8 mL, 26.8 mmol) and NaH (60 w.t.% in mineral oil, 1.06 g, 26.8 mmol) in anhydrous THF 
(25 mL) were employed. Purification by flash column chromatography afforded the title 
compound (2.93 g, 5:1 E:Z) as a colourless oil. 
Spectroscopic data for the major E isomer: 1H NMR (400 MHz, CDCl3) δ 7.38 (2H, d, J = 8.0 
Hz), 7.17 (2H, d, J = 8.0 Hz), 6.14 – 6.11 (1H, m), 4.20 (2H, q, J = 7.0), 2.56 (3H, s), 2.36 (3H, 
s), 1.30 (3H, t, J = 7.0 Hz); 13C NMR (101 MHz, CDCl3) δ 167.2, 155.6, 139.4, 139.3, 129.3, 
126.4, 116.4, 59.9, 21.3, 17.9, 14.5. 
Spectroscopic data for the minor Z isomer: 1H NMR (400 MHz, CDCl3) δ 7.16 – 7.09 (4H, m), 
5.87 (1H, q, J = 1.5 Hz), 4.01 (2H, q, J = 7.0 Hz), 2.34 (3H, s), 2.15 (3H, d, J = 1.5 Hz), 1.11 
(3H, t, J = 7.0 Hz); 13C NMR (101 MHz, CDCl3) δ 166.2, 155.7, 137.9, 137.8, 128.7, 127.0, 
117.5, 59.9, 27.3, 21.4, 14.2. 




To a solution of the proceeding compound (5:1 E:Z, 1.63 g, 8.0 mmol) in anhydrous Et2O (18 
mL) at 0 oC was added DIBAL-H (17.6 mL, 1M in THF) dropwise. The reaction was warmed 
to room temperature and stirred for 2 hours until completion. The reaction was cooled to 0 oC 
and quenched with H2O (0.04 mL/mmol DIBAL-H), 2M NaOH (0.04 mL/mmol DIBAL-H) 
and H2O (0.1 mL/mmol DIABL-H). To the crude reaction mixture was then added Rochelle’s 
salt (20 mL) and the reaction was stirred overnight. Et2O (20 mL) was added and the layers 
were separated. The aqueous phase was extracted with Et2O (20 mL) and the combined organic 
phases were dried over Na2SO4, filtered and concentrated in vacuo. Purification by flash 
column chromatography (2:1 hexane:EtOAc) afforded 484 (1.16 g, 89%, 5:1 mixture of E:Z 
isomer) as a colourless oil. 




Spectroscopic data for the major E isomer: 1H NMR (400 MHz, CDCl3) δ 7.30 (2H, d, J = 8.0 
Hz), 7.13 (2H, d, J = 8.0 Hz), 5.95 (1H, t, J = 6.5, Hz), 4.34 (2H, t, J = 6.0 Hz), 2.33 (3H, s), 
2.06 (3H, s). 
The spectroscopic properties were consistent with the data available in the literature.353  
 
tert-Butyl (E)-(3-(p-tolyl)but-2-en-1-yl)(tosyloxy)carbamate (485) 
 
General procedure G: The proceeding compound 484 (5:1 E:Z, 487 mg, 3.0 mmol), PPh3 
(940 mg, 3.6 mmol), DIAD (0.71 mL, 3.6 mmol) and BocNHOTs (1.03 g, 3.6 mmol) in 
anhydrous THF (12 mL) were employed. Purification by flash column chromatography (5% 
EtOAc:hexane) afforded 485 (633 mg, 49%, 5:1 mixture of E:Z) as a pale yellow oil; νmax / 
cm 1 (solid) 2977 (s), 1746 (s), 1370 (s), 1179 (s), 1153 (s). 
Spectroscopic data for major E isomer: 1H NMR (400 MHz, CDCl3) δ 7.87 (2H, d, J = 8.5 Hz, 
Ts ArCH), 7.32 (2H, d, J = 8.0 Hz, Ts ArCH), 7.25 (2H, d, J = 8.0 Hz, ArCH) 7.11 (2H, d, J = 
8.0 Hz, ArCH), 5.80 – 5.74 (1H, m, C2-H), 4.38 (2H, br s, C1-H2), 2.43 (3H, s, Ts CH3), 2.32 
(3H, s, CH3), 2.06 (3H, s, C4-H3), 1.22 (9H, s, Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) δ 
155.8 (Boc, C=O), 145.7 (Ts ArC), 140.4 (ArC), 140.0 (C3), 137.2 (ArC), 131.4 (Ts ArC), 
129.8 (2 × Ts ArCH), 129.6 (2 × Ts ArCH), 129.0 (ArCH), 125.9 (ArCH), 118.7 (C2), 83.5 
(Boc C(CH3)3), 51.5 (C1), 27.7 (Boc (CH3)3), 21.8 (Ts CH3), 21.2 (CH3), 16.4 (C4). 
Spectroscopic data for minor Z isomer: 1H NMR (400 MHz, Chloroform-d) δ 7.72 (d, J = 8.0 
Hz, 2H), 7.01 (d, J = 8.0 Hz, 2H), 5.47 – 5.42 (m, 2H), 2.40 (s, 3H), 2.35 (s, 3H), 1.99 (s, 3H), 
1.24 (s, 9H). 














General procedure W: The proceeding compound 485 (130 mg, 0.3 mmol) and TFA (46 µL, 
0.6 mmol) in anhydrous TFE (3 mL) were employed. The reaction was stirred for 23 hours. 
Purification by flash column chromatography with the addition of ~0.1 % Et3N to the eluent 
(33% EtOAc: hexane) afforded 489 (26.2 mg, 34 %, 5:1 mixture of diastereomers) as a 
colourless oil; νmax / cm
-1: (film) 2927 (m), 1275 (s), 1153 (s). 
Spectroscopic data for the major diastereomer 489a: 1H NMR (400 MHz, CDCl3) δ 7.31 (2H, 
d, J = 8.0 Hz, C8-H), 7.18 (2H, d, J = 8.0 Hz, C9-H), 3.79 – 3.58 (2H, m, C5-H2), 2.34 (3H, s, 
C11-H3), 2.32 – 2.27 (1H, m, C2-H), 1.72 (1H, d, J = 6.0 Hz, C1-H), 1.62 – 1.55 (1H, m, 
C1-H’), 1.52 (3H, s, C4-H3); 
13C NMR (101 MHz, CDCl3) δ 138.8 (C7), 137.9 (C10), 129.3 
(C9), 126.4 (C8), 124.3 (q, J = 277.4 Hz, C6), 78.8 (C3), 61.5 (q, J = 34.0 Hz, C5-H2), 38.6 
(C2), 22.1 (C1), 21.2 (C11), 20.9 (C4); 19F NMR (377 MHz, CDCl3) -73.97 (t, J = 8.5 Hz). 
Characteristic signals for the minor isomer 489b: 1H NMR (400 MHz, CDCl3) δ 3.55 – 3.45 
(1H, m), 2.20 – 1.25 (1H, m), 1.82 (1H, d, J = 4.0 Hz), 1.63 (3H, s). 





General procedure V: 4-Methoxyacetophenone (3.0 g, 20.0 mmol), triethyl phosphonoacetate 
(6.73 g, 30.0 mmol) and NaH (60 w.t.% in mineral oil, 1.22 g, 30.0 mmol) in anhydrous THF 
(100 mL) were employed. The title compound was obtained as a 4:1 mixture of (E:Z) alkene 
isomers which were separated by flash column chromatography (5% EtOAc:hexane) to obtain 
ethyl (E)-3-(4-methoxyphenyl)but-2-enoate (1.95 g, 30%) and ethyl (Z)-3-(4-
methoxyphenyl)but-2-enoate (609 mg, 9%) as colourless oils. 




Spectroscopic properties for the major E isomer: 1H NMR (400 MHz, CDCl3) δ 7.45 (2H, d, 
J = 9.0 Hz), 6.89 (2H, d, J = 9.0 Hz), 6.12 – 6.09 (1H, m), 4.20 (2H, q, J = 7.0 Hz), 3.83 (3H, 
s), 2.56 (3H, d, J = 1.5 Hz), 1.31 (3H, t, J = 7.0 Hz); 13C NMR (101 MHz, CDCl3) δ 167.2, 
160.5, 155.0, 134.4, 127.8, 115.4, 113.9, 59.8, 55.5, 17.8, 14.5. 




To a solution of ethyl (E)-3-(4-methoxyphenyl)but-2-enoate (1.39  g, 6.30 mmol) in anhydrous 
Et2O (14 mL) at 0 
oC was added a solution of DIBAL-H (13.9 mL, 1M in hexanes) dropwise. 
The reaction was stirred at room temperature overnight. The reaction was cooled to 0 oC and 
quenched with H2O (0.04 mL/mmol DIBAL-H), 2M NaOH (0.04 mL/mmol DIBAL-H) and 
H2O (0.1 mL/mmol DIBAL-H). The reaction mixture was warmed to room temperature and 
stirred for 15 minutes before being dried over Na2SO4 and stirred for a further 30 minutes. The 
resulting solid was filtered, and the filtrate concentrated in vacuo. Purification by flash column 
chromatography (gradient, eluent: 33 – 50 % EtOAc:hexane) afforded 486 (839 mg, 75%) as 
a colourless solid; 1H NMR (101 MHz, CDCl3) δ 7.36 (2H, d, J = 8.5 Hz), 6.87 (2H, d, J = 8.5 
Hz), 5.92 (1H, dt, J = 7.0, 1.0 Hz), 4.35 (2H, d, J = 7.0 Hz), 3.81 (3H, s), 2.06 (3H, s); 13C NMR 
(101 MHz, CDCl3) δ 159.1, 137.5, 135.4, 127.0, 125.0, 113.7, 60.1, 55.4, 16.1. 
The spectroscopic properties were consistent with the data available in the literature.354 
 
Ethyl (Z)-3-phenylbut-2-enoate  
 
The title compound was prepared following a literature procedure.355 
CuI (85.7 mg, 5 mol%) and LiCl (38.2 mg, 10 mol%) were suspended in anhydrous THF (60 
mL) in a flame-dried flask under nitrogen and stirred for 1.5 hours until completely dissolved. 
The flask was then cooled to -78 oC before addition of ethyl but-2-ynoate (1.00 g, 9.0 mmol) 
and TMSOTf (2.1 g, 9.45 mmol). The reaction was stirred at this temperature for 5 minutes 
and then PhMgBr (10.8 mL, 1M in THF) was added dropwise. The reaction was then stirred at 




-78 oC for 1 hour at which point TFA (0.83 mL, 10.8 mmol) was added and the reaction was 
warmed to room temperature and stirred for 1 hour. The reaction was quenched by addition of 
a saturated aqueous solution of NaHCO3 (80 mL) and extracted with Et2O (3 × 25 mL). The 
combined organic extracts were washed sequentially with H2O (25 mL) and a saturated 
aqueous solution of NH4Cl (25 mL), dried over Na2SO4, filtered and concentrated in vacuo. 
The title compound was obtained as a 5:1 mixture of Z:E alkene which was purified by flash 
column chromatography (5% EtOAc:hexane) to afford the title compound (1.10 g, >99:1 Z:E) 
as a pale yellow oil; 1H NMR (400 MHz, CDCl3) δ 7.38 – 7.26 (3H, m), 7.22 – 7.16 (2H, m), 
5.90 (1H, q, J = 1.5 Hz), 3.99 (2H, q, J = 7.0 Hz), 2.17 (3H, d, J = 1.5 Hz), 1.07 (3H, t, J = 7.0 
Hz); 13C NMR (101 MHz, CDCl3) δ 166.1, 155.5, 141.0, 128.0, 127.9, 126.9, 117.9, 59.9, 27.3, 
14.1. 




To a solution of ethyl (Z)-3-phenylbut-2-enoate (951 mg, 5.0 mmol) in anhydrous Et2O (11 
mL) at 0 oC was added DIBAL-H (11.0 mL, 1M in THF) dropwise. The reaction was warmed 
to room temperature and stirred for 3.5 h until completion. The reaction was cooled to 0 oC and 
quenched with H2O (0.04 mL/mmol DIBAL-H), 2M NaOH (0.04 mL/mmol DIBAL-H) and 
H2O (0.1 mL/mmol DIABL-H). The reaction was warmed to room temperature and stirred for 
15 minutes. The reaction was dried over Na2SO4 and stirred for 30 minutes then filtered and 
concentrated in vacuo. Purification by flash column chromatography (20% EtOAc:hexane) 
afforded the title compound (597 mg, 81%) as a colourless oil; 1H NMR (400 MHz, CDCl3 δ 
7.37 – 7.29 (2H, m), 7.29 – 7.23 (1H, m), 7.20 – 7.12 (2H, m), 5.73 – 5.68 (1H, m), 4.10 – 4.02 
(2H, m), 2.08 (3H, d, J = 1.5 Hz); 13C NMR (101 MHz, CDCl3) δ 140.9, 140.5, 128.3, 127.9, 
127.4, 126.2, 60.0, 25.0. 








tert-Butyl (Z)-(3-phenylbut-2-en-1-yl)(tosyloxy)carbamate ((Z)-480)  
 
General procedure G: (Z)-3-Phenylbut-2-en-1-ol (445 mg, 3.0 mmol), PPh3 (944 mg, 3.6 
mmol), DIAD (0.70 mL, 3.6 mmol) and BocNHOTs (1.03 g, 3.6 mmol) in anhydrous THF (12 
mL) were employed. Purification by flash column chromatography (10% EtOAc:hexane) 
afforded (Z)-480 (704 mg, 56%) as a colourless solid; νmax / cm
-1 (solid) 2977 (m), 1748 (s), 
1374 (s), 1367 (s), 1179 (s), 1150 (s); 1H NMR (400 MHz, CDCl3) δ 7.72 (2H, d, J = 8.5 Hz, 
Ts ArCH), 7.36 – 7.30 (2H, m, Ts ArCH), 7.29 – 7.20 (3H, m, ArCH), 7.20 – 7.07 (2H, m, 
ArCH), 5.48 (1H, m, C2-H), 3.98 (2H, br s, C1-H2), 2.40 (3H, s, Ts CH3), 2.02 (3H, s, C4-H3), 
1.24 (9H, s, Boc (CH3)3); 
13C NMR (101 MHz, CDCl3) δ 155.9 (Boc C=O), 145.5 (Ts ArC), 
142.4 (ArC), 140.7 (C3), 131.5 (Ts ArC), 129.6 (2 × Ts ArCH), 129.6 (2 × Ts ArCH), 128.4 
(ArCH), 127.9 (ArCH), 127.3 (ArCH), 119.3 (C2), 83.6 (Boc C(CH3)3), 51.9 (C1), 27.8 (Boc 
(CH3)3), 25.8 (C4), 21.8 (Ts CH3); HRMS (ESI
+) Calculated for C22H27NaNO5S: 440.1502. 
Found [M+Na]+: 440.1495. 
1-Cyclopropyl-1-phenylethan-1-ol (495) 
 
The title compound was prepared based on a literature procedure.353 
To a solution of PhMgBr (1 M in THF, 12 mmol, 12 mL) in anhydrous Et2O at 0 
oC under 
nitrogen was added a solution of ketone (494) (0.99 mL, 10 mmol) in anhydrous Et2O (10 mL) 
dropwise maintaining the temperature at 0 oC. The reaction was warmed to room temperature 
and stirred overnight. The reaction was cooled to 0 oC and diluted with tert-butyl methyl ether 
(15 mL) and H2O (15 mL) and stirred for 15 minutes. The resulting precipitate which was 
formed was removed by filtration and the layers were separated. The aqueous layer was 
extracted with Et2O (20 mL), dried over Na2SO4, filtered and concentrated in vacuo. 
Purification by flash column chromatography (20% EtOAc:hexane) afforded 495 (1.33 g, 82%) 
as a colourless oil; 1H NMR (400 MHz, CDCl3) δ 7.56 – 7.50 (2H, m), 7.34 (2H, dd, J = 8.5, 
7.0 Hz), 7.28 – 7.21 (1H, m), 1.66 (1H, br s), 1.49 (3H, s), 1.26 (1H, tt, J = 8.0, 5.5 Hz), 0.56 




– 0.36 (4H, m); 13C NMR (101 MHz, CDCl3) δ 148.2, 128.2, 126.9, 125.3, 73.3, 28.6, 22.9, 
2.1, 1.2. 




The title compound was prepared following a literature procedure.353  
A solution of the preceding alcohol 495 (811 mg, 5.0 mmol) in dioxane was cooled to 0 oC (the 
reaction was required to warm slightly as the dioxane had frozen). A solution of 20% aqueous 
HClO4 (3 mL) was added dropwise over 15 minutes and the reaction was warmed to room 
temperature and stirred overnight. Upon completion the reaction was diluted with H2O (15 mL) 
and extracted with EtOAc (4 × 20 mL). The combined organic extracts were washed 
sequentially with saturated aqueous NaHCO3 (3 × 15 mL) and brine (15 mL), dried over 
Na2SO4, filtered and concentrated in vacuo. Purification by flash column chromatography 
(gradient, eluent: 20 – 33% EtOAc:hexane) afforded 496 (519 mg, 64%) as a colourless oil; 
1H NMR (400 MHz, CDCl3) δ 7.43 – 7.35 (2H, m), 7.33 – 7.27 (2H, m), 7.27 – 7.18 (1H, m), 
5.80 – 5.75 (1H, m), 3.74 (2H, q, J = 6.0 Hz), 2.53 – 2.46 (2H, m), 2.07 (3H, s), 1.43 (1H, br 
s); 13C NMR (101 MHz, CDCl3) δ 143.6, 137.8, 128.3, 126.9, 125.7, 123.9, 62.4, 32.4, 16.1. 
The spectroscopic properties were consistent with the data available in the literature.353 
 
tert-Butyl (E)-(4-phenylpent-3-en-1-yl)(tosyloxy)carbamate (497) 
 
General procedure G: The preceding alcohol 496 (325 mg, 2.0 mmol), PPh3 (629 mg, 2.4 
mmol), DIAD (0.47 mL) and BocNHOTs (690 mg, 3,6 mmol) in anhydrous THF (8 mL) were 
employed. Purification by flash column chromatography (10% EtOAc:hexane) afforded 497 
(431 mg, 50%) as a viscous, colourless oil; 1H NMR (400 MHz, CDCl3) δ 7.86 (2H, d, J = 8.5 
Hz, Ts ArCH), 7.37 – 7.31 (4H, m, ArCH, Ts ArCH), 7.30 – 7.23 (2H, m, ArCH), 7.22 – 7.16 
(1H, m, ArCH), 5.69 – 5.62 (1H, m, C3-H), 3.73 (2H, br s, C1-H2), 2.54 (2H, q, J = 7.5 Hz, 
C2-H2), 2.44 (3H, s, Ts CH3), 2.03 (3H, s, C5-H3), 1.14 (9H, s, Boc (CH3)3); 
13C NMR (101 




MHz, CDCl3) δ 155.5 (Boc C=O), 145.8 (Ts ArC), 143.5 (ArC), 137.9 (C4), 131.3 (Ts ArC), 
129.9 (2 × Ts ArCH), 129.7 (2 × Ts ArCH), 128.3 (ArCH), 127.0 (ArCH), 125.8 (ArCH), 123.2 
(C3), 83.3 (Boc C(CH3)3), 52.1 (C1), 27.7 (Boc C(CH3)3), 25.7 (C2), 21.9 (Ts CH3), 15.9 (C5); 




General procedure W: The proceeding N-tosyloxycarbamate 497 (64.7 mg, 0.15 mmol) and 
TFA (23 µL, 0.3 mmol) in anhydrous TFE (1.5 mL) were employed. The reaction was stirred 
at room temperature for 18 hours. Purification by flash column chromatography with the 
addition of 0.1 % Et3N to the eluent (EtOAc) afforded 500 (11.7 mg, 44 %) as a unstable 
colourless oil; νmax / cm
-1: (film) 3394 (br), 2929 (m), 1709 (s), 1602 (s), 1506 (s); 1H NMR 
(400 MHz, CDCl3) δ 7.16 (2H, dd, J = 8.5, 7.0 Hz, ArCH), 6.68 (1H, t, J = 7.0 Hz, ArCH), 
6.58 (2H, d, J = 8.0 Hz, ArCH), 3.12 (2H, t, J = 7.0 Hz, C1-H2), 2.56 (2H, t, J = 7.0 Hz, C3-H2), 
2.14 (3H, s, C5-H3), 1.89 (2H, app. qn, J = 7.0 Hz,C2-H2); 
13C NMR (101 MHz, CDCl3) δ 
208.8 (C4), 148.4 (ArC), 129.4 (ArCH), 117.5 (ArCH), 112.8 (ArCH), 43.5 (C1), 41.3 (C3), 
30.2 (C5), 23.5 (C2); HRMS (ESI+) Calculated for C11H16NO: 178.1226. Found [M+H]
+: 
178.1225. 




6.5 Experimental procedures for Chapter 4 
 
tert-Butyl (3-phenylpropyl)(tosyloxy)carbamate (517a) 
 
General procedure G: Alcohol 516a (200 mg, 1.50 mmol), PPh3 (470 mg, 1.80 mmol), DIAD 
(0.36 mL, 1.80 mmol) and BocNHOTs (520 mg, 1.80 mmol) in anhydrous THF (6 mL) were 
employed. Purification by flash column chromatography (10% EtOAc:hexane) afforded 517a 
(520 mg, 85%) as a viscous colourless oil; Rf = 0.7 (33% EtOAc:hexane); νmax / cm
-1 (film) 
2981 (m), 2932 (m), 2865 (m), 1718 (s), 1598 (m), 1454 (m), 1368 (s), 1294 (m), 1191 (s), 
1151 (s), 1177 (s), 1089 (m); 1H NMR (400 MHz, CDCl3) δ 7.85 (2H, d, J = 8.5 Hz), 7.35 – 
7.31 (2H, m), 7.31 – 7.26 (2H, m), 7.22 – 7.15 (3H, m), 3.63 (2H, br s), 2.60 (2H, t, J = 8.0 
Hz), 2.45 (3H, s), 2.02 – 1.91 (2H, m), 1.23 (9H, s); 13C NMR (101 MHz, CDCl3) δ 155.4, 
145.7, 141.1, 131.2, 129.7, 129.5, 128.4, 128.3, 126.0, 83.2, 52.6, 32.8, 27.6, 27.4, 21.7.  




General procedure X: The preceding N-tosyloxycarbamate 517a (120 mg, 0.30 mmol) and 
TFA (46.0 μL, 0.60 mmol) in TFE (3 mL) were employed. After stirring at room temperature 
for 24 hours, purification by flash column chromatography (33% Et2O:hexane) afforded 518a 
(26.0 mg, 65%) as a yellow oil; Rf = 0.7 (33% EtOAc:hexane); νmax / cm
-1 (film); 1H NMR (400 
MHz, CDCl3) δ 6.99 – 6.95 (2H, m), 6.62 (1H, t, J = 7.5 Hz), 6.48 (1H, d, J = 8.0 Hz), 3.80 
(1H, br s), 3.31 (2H, t, J = 5.5 Hz), 2.78 (2H, t, J = 6.5 Hz), 2.01 – 1.90 (2H, m); 13C NMR 
(101 MHz, CDCl3) δ 144.8, 129.5, 126.7, 121.4, 116.9, 114.2, 41.9, 26.9, 22.2.  













General procedure B: 3-(3-Methoxyphenyl)propanoic acid (540 mg, 3.00 mmol) and 2.0 
equivalents of LiAlH4 (1 M in THF) in anhydrous Et2O were employed to afford 516b (340 
mg, 68%) as a pale yellow oil which was used without further purification; 1H NMR (400 MHz, 
CDCl3) δ 7.23 – 7.19 (1H, m), 6.82 – 6.79 (1H, m), 6.77 – 6.73 (2H, m), 3.80 (3H, s), 3.66 (2H, 
t, J = 6.5 Hz), 2.71 – 2.67 (2H, m), 2.14 (1H, br s), 1.92 – 1.85 (2H, m).  
The spectroscopic properties were consistent with the data available in the literature.33 
 




General procedure G: The preceding alcohol 516b (240 mg, 1.50 mmol), PPh3 (470 mg, 1.80 
mmol), DIAD (0.35 mL, 1.80 mmol) and BocNHOTs (517 mg, 1.80 mmol) in anhydrous THF 
(8 mL) were employed. Purification by flash column chromatography (gradient, eluent: 5  – 
10% EtOAc:hexane) afforded 517b (530 mg, 81%) as a colourless, viscous oil; Rf = 0.5 (33% 
EtOAc:hexane); 1H NMR (400 MHz, CDCl3) δ 7.83 (2H, d, J = 8.5 Hz), 7.32 (2H, d, J = 8.5 
Hz), 7.19 (1H, t, J = 8.0 Hz), 6.80 – 6.69 (3H, m), 3.79 (3H, s), 3.62 (2H, br s), 2.57 (2H, t, J 
= 8.0 Hz), 2.44 (3H, s), 1.95 (2H, br s), 1.21 (9H, s); 13C NMR (101 MHz, CDCl3) δ 159.7, 
155.4, 145.7, 142.7, 131.2, 129.7, 129.5, 129.4, 120.7, 113.9, 111.4, 83.2, 55.1, 52.6, 32.8, 
27.6, 27.3, 21.7.  














General procedure X: The preceding N-tosyloxycarbamate (517b) (87.1 mg, 0.20 mmol), 
TFA (31.0 μL, 0.40 mmol) in TFE (2 mL) were employed. After stirring at room temperature 
for 40 hours, purification by flash column chromatography (gradient, eluent: 10 – 25% 
EtOAc:hexane) afforded 518b (26.0 mg, 80%) as a pale yellow oil; Rf = 0.45 (33% 
EtOAc:hexane); 1H NMR (400 MHz, CDCl3) δ 6.63 – 6.54 (2H, m), 6.46 (1H, d, J = 8.5 Hz), 
3.73 (3H, s), 3.37 (1H, br s), 3.27 – 3.24 (2H, m), 2.76 (2H, t, J = 6.5 Hz), 1.97 – 1.89 (2H, m); 
13C NMR (101 MHz, CDCl3) δ 151.9, 138.8, 122.9, 115.6, 114.9, 112.9, 55.8, 42.3, 27.2, 22.4.  




To a solution of ethyl 3-(2-bromophenyl)propanoic acid (920 mg, 4.00 mmol) in anhydrous 
THF (20 mL) at -10 oC was added 0.75 equivalents of LiAlH4 (1 M in THF) and the reaction 
was stirred at the same temperature for 30 minutes. To the reaction mixture was added water 
(0.5 mL), aqueous 1 M NaOH (0.2 mL) and a further portion of water (1 mL). The reaction 
mixture was warmed to room temperature, filtered through Celite® and washed with CH2Cl2. 
The phases were separated, and the aqueous phase washed with CH2Cl2. The combined organic 
extracts were dried over Na2SO4, filtered and concentrated in vacuo to afford 516c as a 
colourless oil (160 mg, 19%) which was used without further purification; 1H NMR (400 MHz, 
CDCl3) δ 7.53 (1H, d, J = 8.0 Hz), 7.26 – 7.21 (2H, m), 7.09 – 7.02 (1H, m), 3.70 (2H, t, J = 
6.5 Hz), 2.83 (2H, t, J = 8.0 Hz), 1.94 – 1.85 (2H, m), 1.54 (1H, br s); 13C NMR (101 MHz, 
CDCl3) δ 141.1, 132.8, 130.4, 127.6, 127.5, 124.4, 62.1, 32.7, 32.4.  










General procedure G: The preceding alcohol 516c (160 mg, 0.74 mmol), PPh3 (230 mg, 0.88 
mmol), DIAD (0.17 mL, 0.88 mmol) and BocNHOTs (250 mg, 0.88 mmol) in anhydrous THF 
(4 mL) were employed. Purification by flash column chromatography (10 % EtOAc:hexane) 
afforded 517c (260 mg, 72%) as a colourless solid; Rf = 0.6 (20 % EtOAc); 
1H NMR (400 
MHz, CDCl3) δ 7.86 (2H, d, J  = 8.5 Hz), 7.52 (1H, dd, J = 8.0, 1.0 Hz), 7.33 (2H, d, J = 8.0 
Hz), 7.24 – 7.19 (2H, m), 7.06 (1H, ddd, J = 8.0, 6.5, 2.5 Hz), 3.66 (2H, br s), 2.71 (2H, t, J = 
8.0 Hz), 2.45 (3H, s), 1.99 – 1.90 (2H, m), 1.23 (9H, s); 13C NMR (101 MHz, CDCl3) δ 155.5, 
145.8, 140.6, 132.9, 131.4, 130.3, 129.8, 129.7, 127.9, 127.6, 124.5, 83.4, 52.7, 33.3, 27.8, 
26.2, 21.9.  




General procedure B: 3-(2-(Trifluoromethyl)phenyl)propanoic acid (550 mg, 2.50 mmol) and 
1.0 equivalents of LiAlH4 (1.0 M in THF) in anhydrous THF were employed to afford 516d 
(380 mg, 75%) as a colourless oil which was used without further purification; 1H NMR (400 
MHz, CDCl3) δ 7.61 (1H, d, J = 8.0 Hz), 7.45 (1H, t, J = 7.5 Hz), 7.34 (1H, d, J = 7.5 Hz), 7.27 
(1H, t, J = 7.5 Hz), 3.71 (2H, t, J = 6.5 Hz), 2.87 (2H, t, J = 8.0 Hz), 1.93 (1H, br s), 1.92 – 
1.85 (2H, m); 13C NMR (101 MHz, CDCl3) δ 140.7, 131.7, 131.0, 128.5, 125.9, 123.3, 120.6, 
62.2, 34.5, 28.9.  










tert-Butyl (tosyloxy)(3-(2-(trifluoromethyl)phenyl)propyl)carbamate (517d) 
 
General procedure G: The preceding alcohol 516d (200 mg, 1.00 mmol), PPh3 (320 mg, 1.20 
mmol), DIAD (0.24 mL, 1.20 mmol) and BocNHOTs (350 mg, 1.20 mmol) in anhydrous THF 
(5 mL) were employed. Purification by flash column chromatography (10% EtOAc:hexane) 
afforded 517d (450 mg, 95%) as a colourless oil; Rf = 0.5 (20% EtOAc:hexane); 
1H NMR (400 
MHz, CDCl3) δ 7.85 (2H, d, J = 8.5 Hz), 7.60 (1H, d, J = 8.0 Hz), 7.47 (1H, t, J = 7.5 Hz), 7.33 
(2H, d, J = 8.5 Hz), 7.31 – 7.27 (2H, m), 3.67 (2H, br s), 2.75 (2H, t, J = 8.0 Hz), 2.44 (3H, s), 
2.01 – 1.90 (2H, m), 1.23 (9H, s); 13C NMR (101 MHz, CDCl2) δ 155.5, 145.8, 140.1, 132.0, 
131.3, 130.9, 129.8, 129.7, 128.5, 126.3, 126.1, 124.6, 83.5, 52.9, 29.7, 27.9, 27.7, 27.5, 21.8.  
The spectroscopic properties were consistent with the data available in the literature.33 
 
Imino(methyl)(phenyl)- λ6-sulfanone (535a) 
 
General procedure Y: Sulfoxide 534a (21.03 mg, 0.15 mmol), TFA (23 µL, 0.30 mmol), 
BocNHOTs (64.6 mg, 0.225 mmol) in PhMe (0.15 mL, 1.0 M) were employed. The reaction 
was heated at 30 oC for 22 hours. Purification by flash column chromatography (gradient, 
eluent: 50% hexane:EtOAc - EtOAc) afforded 535a (17.4 mg, 75%) as a pale-yellow oil; 
1H NMR (400 MHz, CDCl3) δ 8.02 – 8.00 (2H, m, ArCH), 7.64 – 7.53 (3H, m, ArCH), 3.10 
(3H, s, SCH3); 
13CNMR (101 MHz, CDCl3) δ 143.6, 133.2, 129.4, 127.8, 46.3. 
The spectroscopic properties were consistent with the data available in the literature.357  














General procedure Z: Dibenzyl sulphide (1.07 g, 5.0 mmol), FeCl3 (24.3 mg, 0.15 mmol) and 
H5IO6 (1.25 g, 5.5 mmol) in MeCN (5 mL, 1.0 M) were employed. The reaction time was 10 
minutes. Purification by flash column chromatography (gradient, eluent: 50% hexane:EtOAc 
– 100% EtOAc) afforded 534b (647 mg, 56%) as a colourless solid; m.p.: 131-132 oC 
(EtOAc:hexane) [lit: 130-132 oC (no recrystallisation solvent given)358]; 1H NMR (400 MHz, 
CDCl3) δ 7.41 – 7.27 (10H, m), 3.93 (2H, d, J = 13.0 Hz), 3.87 (2H, d, J = 13.0 Hz); 
13C NMR 
(101 MHz, CDCl3) δ 130.3, 129.1, 128.5, 57.4. 




General procedure Y: The preceding sulfoxide 534b (34.5 mg, 0.15 mmol), TFA (23 µL, 
0.30 mmol) and BocNHOTs (64.6 mg, 0.225 mmol) in PhMe (0.15 mL, 1.0 M) were employed. 
The reaction was stirred at 30 oC for 23 hours. Purification by flash column chromatography 
(gradient, eluent: 33% hexane:EtOAc – EtOAc) afforded 535b (20.8 mg, 57%) as a colourless 
solid; m.p.: 167-168 oC (EtOAc:hexane) [lit 167-168 oC (EtOH:H2O)
360]; 1H NMR (400 MHz, 
CDCl3) δ 7.39 (10H, s, ArCH), 4.27 (2H, d, J = 13.0 Hz, SCH2), 4.15 (2H, d, J = 13.0 Hz, 
SCH2); 
13C NMR (101 MHz, CDCl3) δ 131.3, 129.2, 129.1, 128.0, 60.7. 
The spectroscopic properties were consistent with the data available in the literature.277 











General procedure Z: 4-Methoxythioanisole (770 mg, 5.0 mmol), FeCl3 (24.3 mg, 0.15 
mmol) and H5IO6 (1.25 g, 5.5 mmol) in MeCN (5 mL, 1.0 M) were employed. The reaction 
time was 5 minutes. Purification by flash column chromatography (gradient, eluent: 50% 
hexane:EtOAc – 100% EtOAc) afforded 534c (716 mg 84%) as a yellow oil; 1H NMR (400 
MHz, CDCl3) δ 7.59 – 7.55 (2H, m), 7.02 – 6.98 (2H, m), 3.83 (3H, s), 2.67 (3H, s); 
13C NMR 
(101 MHz, CDCl3) δ 162.1, 136.7, 125.5, 114.9, 55.6, 44.1. 




General procedure Y: The preceding sulfoxide 534c (25.5 mg, 0.15 mmol), TFA (23 µL, 0.30 
mmol) and BocNHOTs (64.6 mg, 0.225 mol) in PhMe (0.15 mL, 1.0 M) were employed. The 
reaction was stirred at 30 oC for 23 hours. Purification by flash column chromatography 
(gradient, eluent: 50% hexane:EtOAc – 100% EtOAc) afforded 535c (18.9 mg, 68%) as a 
colourless oil; 1H NMR (400 MHz, CDCl3) δ 7.92 (2H, d, J = 9.0 Hz), 7.00 (2H, d, J = 9.0 Hz), 
3.87 (3H, s), 3.08 (3H, s), 2.41 (1H, br s); 13C NMR (101 MHz, CDCl3) δ 163.5, 135.2, 129.9, 
114.5, 55.8, 46.7. 
The spectroscopic properties were consistent with the data available in the literature.362  













General procedure Z: Chloromethyl phenyl sulfide (670 mg, 5.0 mmol), FeCl3 (24.3 mg, 0.15 
mmol) and H5IO6 (1.25 g, 5.5 mmol) in MeCN (5 mL, 1.0 M) were employed. The reaction 
time was 30 minutes. Purification by flash column chromatography (gradient, eluent: 50% 
hexane:EtOAc – 100% EtOAc) afforded 534d (530 mg, 61%) as a colourless oil; 1H NMR 
(400 MHz, CDCl3) δ 7.73 – 7.69 (2H, m), 7.59 – 7.55 (3H, m), 4.39 (2H, d, J = 2.5 Hz); 
13C NMR (101 MHz, CDCl3) δ 141.1, 132.3, 129.5, 125.0, 61.4. 




General procedure Y: The preceding sulfoxide 534d (26.2 mg, 0.15 mmol), TFA (26 µL, 
0.30 mmol) and BocNHOTs (64.6 mg, 0.225 mmol) in TFE (0.15 mL, 1.0 M) were employed. 
The reaction was stirred at room temperature for 23 hours. Purification by flash column 
chromatography (33% EtOAc:hexane) afforded 535d (5.4 mg, 19%) as a colourless oil; 
1H NMR (400 MHz, CDCl3) δ 8.08 – 8.03 (2H, m, ArCH), 7.72 – 7.67 (1H, m, ArCH), 7.63 – 
7.57 (2H, m, ArCH), 4.57 (2H, s, SCH2), 3.11 (1H, s, NH); 
13C NMR (101 MHz, CDCl3) δ 
137.7, 134.2, 129.5, 129.4, 61.4. 
The spectroscopic properties were consistent with the data available in the literature.364  
Using the other optimised conditions: PhMe (1.0 M) at 30 oC a yield of 16% was obtained. 
 
Methyl 2-(phenylsulfinyl)acetate (354e) 
 
The title compound was prepared according to a literature procedure.365 




To a solution of 1-(phenylthio)propan-2-one (365 mg, 2.0 mmol) in CH3CN (10 mL) was added 
30% aq. H2O2 (0.4 mL, 4.0 mmol) and TMSCl (0.25 mL, 2.0 mmol). The reaction was stirred 
at room temperature for 3 hours, quenched with H2O (10 mL) and extracted with EtOAc (4 × 
5 mL). The combined organic extracts were dried over Na2SO4, filtered and concentrated in 
vacuo. Purification by flash column chromatography (33% EtOAc:hexane) afforded 354e (203 
mg, 56%) as a colourless oil; 1H NMR (400 MHz, CDCl3) δ 7.70  – 7.64 (2H, m), 7.55 – 7.50 
(3H, m), 3.83 (1H, d, J = 13.5 Hz), 3.69 (3H, s), 3.66 (1H, d, J = 13.5 Hz).  
The spectroscopic properties were consistent with the data available in the literature.365 
 
Methyl 2-(phenylsulfonimidoyl)acetate (535e)  
 
General procedure Y: The preceding sulfoxide 354e (29.7 mg, 0.15 mmol), TFA (23 µL, 0.30 
mmol) and BocNHOTs (67.8 mg, 0.225 mmol) in TFE (0.15 mL, 1.0 M) were employed. The 
reaction was stirred at room temperature for 22 hours. Purification by flash column 
chromatography (50% PhMe:EtOAc) afforded a mixture of the title compound 535e and the 
starting sulfoxide 534e (11.1 mg) as a colourless oil. The yield of the title compound was 
obtained as 38% as determined by 1H NMR analysis with the addition of 1,4-dinitrobenzene as 
internal standard; 1H NMR (400 MHz, CDCl3) δ 8.05 – 7.99 (2H, m), 7.67 – 7.62 (1H, m), 7.58 
– 7.51 (2H, m) 4.16 – 4.08 (2H, m), 3.72 (3H, s), 3.29 (1H, s); 13C NMR (101 MHz, CDCl3) δ 
163.6, 140.5, 133.9, 129.3, 128.8, 63.2, 53.2. 




General procedure Y: Diphenyl sulfoxide (30.3 mg, 0.15 mmol), TFA (23 µL, 0.30 mmol) 
and BocNHOTs (64.6 mg, 0.225 mmol) in TFE (0.15 mL, 1.0 M) were employed. The reaction 
was stirred at room temperature for 22 hours. Purification by flash column chromatography 
(33% EtOAc:hexane) afforded 535f (18.7 mg, 58%) as a colourless solid; mp: 97-98 oC 
(EtOAc:hexane) [lit: 102-104 oC (no recrystallisation solvent given)367]; 1H NMR (400 MHz, 




CDCl3) δ 8.06 – 8.03 (4H, m, ArCH), 7.54 – 7.45 (6H, m, ArCH), 3.04 (1H, br s, NH); 
13C NMR (101 MHz, CDCl3) δ 143.6, 132.7, 129.3, 128.1. 
The spectroscopic properties were consistent with the data available in the literature.366  








Table 17 Attempted dearomatising amination using bidentate ligands.  
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